PT J
AU Palecek, T
   Tesarova, M
   Kuchynka, P
   Dytrych, V
   Elleder, M
   Hulkova, H
   Hansikova, H
   Honzik, T
   Zeman, J
   Linhart, A
AF Palecek, Tomas
   Tesarova, Marketa
   Kuchynka, Petr
   Dytrych, Vladimir
   Elleder, Milan
   Hulkova, Helena
   Hansikova, Hana
   Honzik, Tomas
   Zeman, Jiri
   Linhart, Ales
TI Hypertrophic Cardiomyopathy Due to the Mitochondrial DNA Mutation m.3303C&gt;T Diagnosed in an Adult Male
SO INTERNATIONAL HEART JOURNAL
LA English
DT Article
DE Mitochondrial disease; Short PR interval
ID maternally inherited cardiomyopathy; point mutation; trna(leu(uur)) gene; disease; patient; myopathy; defects; tissue; brain; onset
AB Mitochondrial disorders comprise a heterogeneous group of diseases with multisystem involvement including myocardium. Most cases of mitochondrial cardiomyopathy are associated with myopathy and encephalopathy and are generally present in infancy or childhood. The disease often exhibits a rapid downward course with death frequently occuring within the first year of life. We describe a unique case of hypertrophic cardiomyopathy due to mitochondrial DNA mutation m.3303C>T in the MT-TL1 gene, diagnosed accidentally in a 35-year-old male. The patient initially presented with stroke of assumed cardioembolic origin due to the presence of two interatrial communications associated with mobile aneurysm of the interatrial septum. No other extracardiac manifestations of mitochondrial disorder were observed. (Int Heart J 2012; 53: 383-387)
C1 [Palecek, Tomas; Kuchynka, Petr; Dytrych, Vladimir; Linhart, Ales] Charles Univ Prague, Fac Med 1, Dept Med 2, Dept Cardiovasc Med,Gen Univ Hosp Prague, Prague 12808 2, Czech Republic.
   [Palecek, Tomas] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic.
   [Tesarova, Marketa; Hansikova, Hana; Honzik, Tomas; Zeman, Jiri] Charles Univ Prague, Fac Med 1, Gen Univ Hosp Prague, Dept Pediat & Adolescent Med, Prague 12808 2, Czech Republic.
   [Elleder, Milan; Hulkova, Helena] Charles Univ Prague, Fac Med 1, Gen Univ Hosp Prague, Inst Inherited Metab Disorders, Prague 12808 2, Czech Republic.
C3 Charles University Prague; General University Hospital Prague; University Hospital Hradec Kralove; St Anne's University Hospital Brno (FNUSA); St Anne's University Hospital Brno (FNUSA-ICRC); Charles University Prague; General University Hospital Prague; General University Hospital Prague; Charles University Prague
RP Palecek, T (corresponding author), Charles Univ Prague, Fac Med 1, Dept Med 2, Dept Cardiovasc Med,Gen Univ Hosp Prague, U Nemocnice 2, Prague 12808 2, Czech Republic.
FU European Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123];  [PRVOUK-P35/LF1/5];  [PRVOUK-P24/LF1/3];  [RVO-VFN64165/2012]
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Arad M, 2005, NEW ENGL J MED, V352, P362, DOI 10.1056/NEJMoa033349
   Bruno C, 1999, J PEDIATR-US, V135, P197, DOI 10.1016/S0022-3476(99)70022-3
   CASALI C, 1995, BIOCHEM BIOPH RES CO, V213, P588, DOI 10.1006/bbrc.1995.2172
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Fornuskova D, 2008, BBA-MOL BASIS DIS, V1782, P317, DOI 10.1016/j.bbadis.2008.02.001
   FUJII T, 1990, PEDIATR NEUROL, V6, P253, DOI 10.1016/0887-8994(90)90116-I
   Goldstein JD, 1999, PEDIATR DEVEL PATHOL, V2, P78, DOI 10.1007/s100249900094
   GUENTHARD J, 1995, ARCH DIS CHILD, V72, P223, DOI 10.1136/adc.72.3.223
   Honzík T, 2010, ARCH DIS CHILD, V95, P296, DOI 10.1136/adc.2009.168096
   Hsu PC, 2008, INT J CARDIOL, V129, P441, DOI 10.1016/j.ijcard.2007.06.098
   HUANG CC, 1995, EUR NEUROL, V35, P199, DOI 10.1159/000117128
   HUG G, 1970, LAB INVEST, V22, P541
   Hulková H, 2009, J INHERIT METAB DIS, V32, P551, DOI 10.1007/s10545-009-1178-9
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Lindberg C, 2008, ACTA NEUROL SCAND, V117, P128, DOI 10.1111/j.1600-0404.2007.00913.x
   MARON BJ, 1975, J MOL CELL CARDIOL, V7, P697, DOI 10.1016/0022-2828(75)90146-7
   Palecek T, 2006, HEART VESSELS, V21, P13, DOI 10.1007/s00380-005-0852-6
   Santorelli FM, 1996, AM J HUM GENET, V58, P933
   Schiff M, 2011, SEMIN FETAL NEONAT M, V16, P216, DOI 10.1016/j.siny.2011.04.002
   Schwartz ML, 1996, CIRCULATION, V94, P2021, DOI 10.1161/01.CIR.94.8.2021
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Vesela K, 2008, APMIS, V116, P41, DOI 10.1111/j.1600-0463.2008.00772.x
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Yokoyama U, 2002, JPN HEART J, V43, P61, DOI 10.1536/jhj.43.61
   ZEVIANI M, 1989, NEUROL CLIN, V7, P123, DOI 10.1016/S0733-8619(18)30832-6
NR 29
TC 16
Z9 16
U1 0
U2 3
PU INT HEART JOURNAL ASSOC
PI TOKYO
PA UNIV TOKYO, GRADUATE SCHOOL MEDICINE, DEPT CARDIOVASCULAR MEDICINE, HONGO 7-3-1, BUNKYO-KU, TOKYO, 113-8655, JAPAN
SN 1349-2365
EI 
J9 INT HEART J
JI Int. Heart J.
PD NOV 15
PY 2012
VL 53
IS 6
BP 383
EP 387
DI 10.1536/ihj.53.383
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 218SC
UT WOS:000324451800009
PM 23258140
DA 2024-11-01
ER

PT J
AU Martín-Jiménez, R
   Martín-Hernández, E
   Cabello, A
   García-Silva, MT
   Arenas, J
   Campos, Y
AF Martin-Jimenez, Rebeca
   Martin-Hernandez, Elena
   Cabello, Ana
   Teresa Garcia-Silva, Maria
   Arenas, Joaquin
   Campos, Yolanda
TI Clinical and cellular consequences of the mutation m.12300G&gt;A in the mitochondrial tRNA<SUP>Leu(CUN)</SUP> gene
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial disease; Mitochondrial DNA tRNA(Leu(CUN)) gene; Cybrid; ATP; Mitochondrial membrane potential; Reactive oxygen species
ID mtdna; melas; encephalomyopathy; fibroblasts; disease; cells; patient; muscle; merrf; lines
AB We report, for the first time, a patient with an overlap MERRF-NARP syndrome who carries the mutation m.12300G>A in the mitochondrial tRNA(Leu(CUN)) gene. The mutation was heteroplamic and more abundant in her muscle and fibroblast than in blood from her oligosymptomatic mother. Single muscle fiber analysis revealed that the proportion of mutant mtDNA in ragged red fibers was higher than that in normal fibers. Combined defects of mitochondrial respiratory chain complexes were detected in muscle, fibroblasts and transmitochondrial hybrid cells. Significant reduction of total ATP and mitochondrial membrane potential and an increased production of reactive oxygen species were observed. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Martin-Jimenez, Rebeca; Campos, Yolanda] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Patol Mitocondrial, Madrid 28220, Spain.
   [Martin-Hernandez, Elena; Teresa Garcia-Silva, Maria] Hosp Univ 12 Octubre, Dept Pediat, Unidad Enfermedades Metabol Hereditarias & Mitoco, Madrid, Spain.
   [Cabello, Ana] Hosp Univ 12 Octubre, Dept Neuropatol, Madrid, Spain.
   [Arenas, Joaquin] Inst Salud Carlos III, Subdirecc Gen Evaluac & Promoc Invest, Madrid 28220, Spain.
C3 Instituto de Salud Carlos III; Centro Nacional de Microbiologia (CNM); Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Instituto de Salud Carlos III
RP Campos, Y (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Patol Mitocondrial, Ctra Majadahonda Pozuelo Km 2, Madrid 28220, Spain.
EM rmartin@isciii.es; emartinh.hdoc@salud.madrid.org; acabello.hdoc@salud.madrid.org; mgarcias.hdoc@salud.madrid.org; jarenas@isciii.es; ycampos@isciii.es
FU Fondo de Investigacion Sanitaria (FIS) [PI 06/1030, PS09/2341]; Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation [UIPY 07/1464]
CR Antonická H, 1999, BIOCHEM J, V342, P537, DOI 10.1042/0264-6021:3420537
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Campos Y, 1996, NEUROLOGY, V47, P1012, DOI 10.1212/WNL.47.4.1012
   Chalmers-Redman RME, 1999, BIOCHEM BIOPH RES CO, V257, P440, DOI 10.1006/bbrc.1999.0487
   del Hoyo P, 2006, NEUROCHEM RES, V31, P1103, DOI 10.1007/s11064-006-9110-2
   DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2
   El Meziane A, 1998, NAT GENET, V18, P350
   El Meziane A, 1998, HUM MOL GENET, V7, P2141, DOI 10.1093/hmg/7.13.2141
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirino Y, 2006, HUM MOL GENET, V15, P897, DOI 10.1093/hmg/ddl007
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Maneiro E, 2005, ANN RHEUM DIS, V64, P388, DOI 10.1136/ard.2004.022152
   McKenzie M, 2007, J BIOL CHEM, V282, P36845, DOI 10.1074/jbc.M704158200
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Navarro-Sastre A, 2008, MOL GENET METAB, V94, P234, DOI 10.1016/j.ymgme.2008.01.012
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   Schon EA, 2010, TRENDS MOL MED, V16, P268, DOI 10.1016/j.molmed.2010.04.007
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Seibel P, 2008, NUCLEIC ACIDS RES, V36, P5872, DOI 10.1093/nar/gkn592
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Vergani L, 1999, HUM MOL GENET, V8, P1751, DOI 10.1093/hmg/8.9.1751
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
NR 27
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAR 15
PY 2012
VL 12
IS 2
BP 288
EP 293
DI 10.1016/j.mito.2011.10.004
PG 6
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 913VX
UT WOS:000301906600015
PM 22094595
DA 2024-11-01
ER

PT J
AU Lee, HC
   Wei, YH
AF Lee, Hsin-Chen
   Wei, Yau-Huei
TI Mitochondria and Aging
SO ADVANCES IN MITOCHONDRIAL MEDICINE
LA English
DT Article; Book Chapter
DE Aging; mtDNA; Mitochondria; ROS; Oxidative damage; Caloric restriction
ID human skeletal-muscle; dna-deletion mutations; electron-transport chain; heart submitochondrial particles; manganese superoxide-dismutase; hydrogen-peroxide production; substantia-nigra neurons; chronic iron overload; age-related decline; human lung tissue
AB Aging is a degenerative process that is associated with progressive accumulation of deleterious changes with time, reduction of physiological function and increase in the chance of disease and death. Studies in several species reveal a wide spectrum of alterations in mitochondria and mitochondrial DNA (mtDNA) with aging, including (1) increased disorganization of mitochondrial structure, (2) decline in mitochondrial oxidative phosphorylation (OXPHOS) function, (3) accumulation of mtDNA mutation, (4) increased mitochondrial production of reactive oxygen species (ROS) and (5) increased extent of oxidative damage to DNA, proteins, and lipids. In this chapter, we outline the common alterations in mitochondria of the aging tissues and recent advances in understanding the role of mitochondrial H2O2 production and mtDNA mutation in the aging process and lifespan determination. In addition, we discuss the effect of caloric restriction on age-associated mitochondrial changes and its role in longevity. Taking these findings together, we suggest that decline in mitochondrial energy metabolism, enhanced mitochondrial oxidative stress, and accumulation of mtDNA mutations are important contributors to human aging.
C1 [Lee, Hsin-Chen] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan.
   [Wei, Yau-Huei] Natl Yang Ming Univ, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
   [Wei, Yau-Huei] Mackay Med Coll, Dept Med, Danshui, Taipei County, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Mackay Medical College
RP Lee, HC (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Pharmacol, 155,Sec 2,Li Nong St, Taipei 112, Taiwan.
EM hclee2@ym.edu.tw
CR Agarwal S, 1995, MECH AGEING DEV, V85, P55, DOI 10.1016/0047-6374(95)01655-4
   ALBANO E, 1991, BIOCHIM BIOPHYS ACTA, V1091, P310, DOI 10.1016/0167-4889(91)90194-3
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   BACON BR, 1993, GASTROENTEROLOGY, V105, P1134, DOI 10.1016/0016-5085(93)90959-G
   Bailey LJ, 2009, NUCLEIC ACIDS RES, V37, P2327, DOI 10.1093/nar/gkp091
   BAILEY PJ, 1984, MECH AGEING DEV, V24, P233, DOI 10.1016/0047-6374(84)90074-5
   Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312
   Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7
   Barrientos A, 1997, BIOCHEM MOL MED, V62, P165, DOI 10.1006/bmme.1997.2647
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345
   BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616
   BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x
   BRITTON RS, 1990, HEPATOLOGY, V11, P93, DOI 10.1002/hep.1840110116
   Bua EA, 2004, FASEB J, V18, P582, DOI 10.1096/fj.03-0668fje
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   BULOS B, 1972, ARCH BIOCHEM BIOPHYS, V149, P461, DOI 10.1016/0003-9861(72)90345-1
   BULOS BA, 1975, ARCH BIOCHEM BIOPHYS, V166, P639, DOI 10.1016/0003-9861(75)90430-0
   CALLEJA M, 1993, J BIOL CHEM, V268, P18891
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chen HC, 2009, HUM MOL GENET, V18, PR169, DOI 10.1093/hmg/ddp326
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   de Magalhaes JP, 2009, BIOINFORMATICS, V25, P875, DOI 10.1093/bioinformatics/btp073
   DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567
   DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194
   Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Fahn HJ, 1998, AM J RESP CELL MOL, V19, P901, DOI 10.1165/ajrcmb.19.6.3130
   Fernandez-Silva SP, 1991, BIOCHEM BIOPH RES CO, V176, P645
   GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x
   GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248
   Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392
   Greco M, 2003, FASEB J, V17, P1706, DOI 10.1096/fj.02-1009fje
   Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378
   Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje
   Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064
   Hagopian K, 2005, AM J PHYSIOL-ENDOC M, V288, PE674, DOI 10.1152/ajpendo.00382.2004
   Hamilton ML, 2001, NUCLEIC ACIDS RES, V29, P2117, DOI 10.1093/nar/29.10.2117
   Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698
   Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harper ME, 1998, AM J PHYSIOL-ENDOC M, V275, PE197, DOI 10.1152/ajpendo.1998.275.2.E197
   HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X
   HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235
   HRUSZKEWYCZ AM, 1992, MUTAT RES, V275, P243, DOI 10.1016/0921-8734(92)90028-N
   HSIEH RH, 1994, BIOCHEM MOL BIOL INT, V32, P1009
   Iñarrea P, 2007, BIOCHEM J, V405, P173, DOI 10.1042/BJ20061809
   Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1
   Khrapko K, 2009, TRENDS GENET, V25, P91, DOI 10.1016/j.tig.2008.11.007
   Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098
   Kopsidas G, 1998, MUTAT RES-FUND MOL M, V421, P27, DOI 10.1016/S0027-5107(98)00150-X
   Kovalenko SA, 1997, BIOCHEM BIOPH RES CO, V232, P147, DOI 10.1006/bbrc.1997.6251
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0
   Lee CM, 1998, ANN NY ACAD SCI, V854, P182, DOI 10.1111/j.1749-6632.1998.tb09901.x
   Lee HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P309, DOI 10.1006/abbi.1998.1036
   Lee HC, 2001, MUTAT RES-GEN TOX EN, V493, P67, DOI 10.1016/S1383-5718(01)00160-7
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   LEE HC, 1994, FEBS LETT, V354, P79, DOI 10.1016/0014-5793(94)01063-3
   Lee HC, 2007, EXP BIOL MED, V232, P592
   Lee S, 2007, J BIOL CHEM, V282, P22977, DOI 10.1074/jbc.M700679200
   Lesnefsky EJ, 2006, AGEING RES REV, V5, P402, DOI 10.1016/j.arr.2006.04.001
   LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Lin PH, 2003, FREE RADICAL BIO MED, V35, P1310, DOI 10.1016/j.freeradbiomed.2003.07.002
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   López-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6
   Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6
   Mansouri A, 2006, MECH AGEING DEV, V127, P298, DOI 10.1016/j.mad.2005.11.004
   MARCUS DL, 1982, EXP GERONTOL, V17, P333, DOI 10.1016/0531-5565(82)90033-X
   MARTINEZ AO, 1979, EXP GERONTOL, V14, P231, DOI 10.1016/0531-5565(79)90034-2
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   Miyoshi N, 2006, P NATL ACAD SCI USA, V103, P1727, DOI 10.1073/pnas.0510346103
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127
   MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H
   MURFITT RR, 1978, MECH AGEING DEV, V8, P197, DOI 10.1016/0047-6374(78)90018-0
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   OBrien KM, 2004, J BIOL CHEM, V279, P51817, DOI 10.1074/jbc.M405958200
   Ojaimi J, 1999, MECH AGEING DEV, V111, P39, DOI 10.1016/S0047-6374(99)00071-8
   Ojaimi J, 1999, ANN NEUROL, V46, P656, DOI 10.1002/1531-8249(199910)46:4<656::AID-ANA16>3.3.CO;2-H
   Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200
   PANG CY, 1994, ARCH BIOCHEM BIOPHYS, V312, P534, DOI 10.1006/abbi.1994.1342
   Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6
   Park SK, 2005, AGEING RES REV, V4, P55, DOI 10.1016/j.arr.2004.09.003
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9
   PIERI C, 1993, MECH AGEING DEV, V70, P201, DOI 10.1016/0047-6374(93)90048-V
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364
   Roth GS, 2004, SCIENCE, V305, P1423, DOI 10.1126/science.1102541
   Sanz A, 2005, J BIOENERG BIOMEMBR, V37, P83, DOI 10.1007/s10863-005-4131-0
   SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P291, DOI 10.1007/BF00763100
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X
   Sohal RS, 2002, FREE RADICAL BIO MED, V33, P37, DOI 10.1016/S0891-5849(02)00856-0
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   SOHAL RS, 1995, FREE RADICAL BIO MED, V19, P499, DOI 10.1016/0891-5849(95)00037-X
   SUGIYAMA S, 1993, BIOCHEM MOL BIOL INT, V30, P937
   TAKASAWA M, 1993, EXP GERONTOL, V28, P269, DOI 10.1016/0531-5565(93)90034-B
   TORII K, 1992, AM J RESP CELL MOL, V6, P543, DOI 10.1165/ajrcmb/6.5.543
   TORII K, 1992, AM J RESP CELL MOL, V6, P88, DOI 10.1165/ajrcmb/6.1.88
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Wei YH, 1996, ANN NY ACAD SCI, V786, P82, DOI 10.1111/j.1749-6632.1996.tb39054.x
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   WEI YH, 1992, MUTAT RES, V275, P145, DOI 10.1016/0921-8734(92)90019-L
   WEI YH, 1981, BIOCHEM BIOPH RES CO, V99, P1411, DOI 10.1016/0006-291X(81)90776-2
   Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168
   Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896
   YANG JH, 1995, ARCH DERMATOL RES, V287, P641
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
   Zahn JM, 2007, PLOS GENET, V3, P2326, DOI 10.1371/journal.pgen.0030201
   ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7
   ZHANG CF, 1993, BIOCHEM BIOPH RES CO, V195, P1104, DOI 10.1006/bbrc.1993.2158
NR 141
TC 177
Z9 210
U1 2
U2 46
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PD JUN 15
PY 2012
VL 942
IS 
BP 311
EP 327
DI 10.1007/978-94-007-2869-1_14
PG 17
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA BA2RR
UT WOS:000333840200015
PM 22399429
DA 2024-11-01
ER

PT J
AU Habek, M
   Barun, B
   Adamec, I
   Mitrovic, Z
   Ozretic, D
   Brinar, VV
AF Habek, Mario
   Barun, Barbara
   Adamec, Ivan
   Mitrovic, Zoran
   Ozretic, David
   Brinar, Vesna V.
TI Early-onset Ataxia With Progressive External Ophthalmoplegia Associated With POLG Mutation <i>Autosomal Recessive Mitochondrial Ataxic</i> <i>Syndrome or SANDO</i>?
SO NEUROLOGIST
LA English
DT Article
DE ataxia; autosomal recessive; MRI; POLG; choreoathetotic movements; dysphonia
ID diffuse cerebral degeneration; dna-polymerase; neuropathy; disease
AB Autosomal recessive ataxias caused by mutations of the polymerase gamma (POLG) gene make an important group of progressive ataxias accompanied by a diverse spectrum of neurological disorders. Because the clinical picture can be quite miscellaneous, it is challenging to assort patients to any of the currently described syndromes; therefore, to provide such a patient with a conclusive diagnosis can be challenging for the neurologist. A typical magnetic resonance imaging finding is probably the most useful landmark in the diagnostic process, which will steer the clinician toward POLG gene testing. To illustrate this, we present a case of progressive ataxia caused by A467T and W748S mutations of POLG gene, who presented with overlapping symptoms of autosomal recessive mitochondrial ataxic syndrome and SANDO, as well as choreoathetotic movements and dysphonia. After lengthy investigations, magnetic resonance imaging showed T2 and FLAIR hyperintensities in the thalamus, inferior olives, and cerebellum, which led us to the analysis of POLG mutations.
C1 [Habek, Mario] Zagreb Univ Hosp Ctr, Zagreb Sch Med, Univ Dept Neurol, Referral Ctr Demyelinating Dis Cent Nervous Syst, HR-10000 Zagreb, Croatia.
   [Habek, Mario; Barun, Barbara; Adamec, Ivan; Mitrovic, Zoran; Brinar, Vesna V.] Univ Zagreb, Dept Neurol, Sch Med, Zagreb 41000, Croatia.
   [Ozretic, David] Zagreb Univ Hosp Ctr, Univ Dept Radiol, Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb; University of Zagreb
RP Habek, M (corresponding author), Zagreb Univ Hosp Ctr, Zagreb Sch Med, Univ Dept Neurol, Referral Ctr Demyelinating Dis Cent Nervous Syst, Kispaticeva 12, HR-10000 Zagreb, Croatia.
EM mhabek@mef.hr
CR BLACKWOOD W, 1963, ARCH DIS CHILD, V38, P193, DOI 10.1136/adc.38.199.193
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Fogel BL, 2007, LANCET NEUROL, V6, P245, DOI 10.1016/S1474-4422(07)70054-6
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Rantamäki M, 2001, NEUROLOGY, V57, P1043, DOI 10.1212/WNL.57.6.1043
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
NR 24
TC 6
Z9 6
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1074-7931
EI 
J9 NEUROLOGIST
JI Neurologist
PD SEP 15
PY 2012
VL 18
IS 5
BP 287
EP 289
DI 10.1097/NRL.0b013e318266f5a6
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 002VA
UT WOS:000308563400008
PM 22931735
DA 2024-11-01
ER

PT J
AU Dillon, LM
   Hida, A
   Garcia, S
   Prolla, TA
   Moraes, CT
AF Dillon, Lloye M.
   Hida, Aline
   Garcia, Sofia
   Prolla, Tomas A.
   Moraes, Carlos T.
TI Long-Term Bezafibrate Treatment Improves Skin and Spleen Phenotypes of the mtDNA Mutator Mouse
SO PLOS ONE
LA English
DT Article
ID proliferator-activated receptors; mitochondrial biogenesis; skeletal-muscle; mice; myopathy
AB Pharmacological agents, such as bezafibrate, that activate peroxisome proliferator-activated receptors (PPARs) and PPAR gamma coactivator-1 alpha (PGC-1 alpha) pathways have been shown to improve mitochondrial function and energy metabolism. The mitochondrial DNA (mtDNA) mutator mouse is a mouse model of aging that harbors a proofreading-deficient mtDNA polymerase gamma. These mice develop many features of premature aging including hair loss, anemia, osteoporosis, sarcopenia and decreased lifespan. They also have increased mtDNA mutations and marked mitochondrial dysfunction. We found that mutator mice treated with bezafibrate for 8-months had delayed hair loss and improved skin and spleen aging-like phenotypes. Although we observed an increase in markers of fatty acid oxidation in these tissues, we did not detect a generalized increase in mitochondrial markers. On the other hand, there were no improvements in muscle function or lifespan of the mutator mouse, which we attributed to the rodent-specific hepatomegaly associated with fibrate treatment. These results showed that despite its secondary effects in rodent's liver, bezafibrate was able to improve some of the aging phenotypes in the mutator mouse. Because the associated hepatomegaly is not observed in primates, long-term bezafibrate treatment in humans could have beneficial effects on tissues undergoing chronic bioenergetic-related degeneration.
C1 [Dillon, Lloye M.; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   [Hida, Aline; Garcia, Sofia; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Prolla, Tomas A.] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.
C3 University of Miami; University of Miami; University of Wisconsin System; University of Wisconsin Madison
RP Dillon, LM (corresponding author), Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU U.S. Public Health Service (PHS) [AG036871, EY010804, NS079965]; Muscular Dystrophy Association; Florida Biomedical Research Foundation
CR Ahlqvist KJ, 2012, CELL METAB, V15, P100, DOI 10.1016/j.cmet.2011.11.012
   Cesta MF, 2006, TOXICOL PATHOL, V34, P455, DOI 10.1080/01926230600867743
   Cheung MC, 2009, J SURG RES, V153, P326, DOI 10.1016/j.jss.2008.05.002
   De Souza AT, 2006, TOXICOL SCI, V92, P578, DOI 10.1093/toxsci/kfl019
   Dillon LM, 2012, HUM MOL GENET, V21, P2288, DOI 10.1093/hmg/dds049
   Dillon LM, 2012, IUBMB LIFE, V64, P231, DOI 10.1002/iub.608
   Djouadi F, 2011, CELL METAB, V14, P715, DOI 10.1016/j.cmet.2011.11.003
   Ham SA, 2010, J CELL MOL MED, V14, P1747, DOI 10.1111/j.1582-4934.2009.00816.x
   Harries MJ, 2009, J INVEST DERMATOL, V129, P1066, DOI 10.1038/jid.2008.425
   Hiona A, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0011468
   Johri A, 2012, HUM MOL GENET, V21, P1124, DOI 10.1093/hmg/ddr541
   Kuenzli S, 2003, BRIT J DERMATOL, V149, P229, DOI 10.1046/j.1365-2133.2003.05532.x
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   OIKARINEN A, 1994, PHOTODERMATOL PHOTO, V10, P47
   Pickrell AM, 2011, J NEUROSCI, V31, P9895, DOI 10.1523/JNEUROSCI.6223-10.2011
   Smaldone S, 2011, FIBROGENESIS TISSUE, V4, P0, DOI 10.1186/1755-1536-4-8
   Tenenbaum A, 2005, CARDIOVASC DIABETOL, V4, P0, DOI 10.1186/1475-2840-4-14
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200
   Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011
   Wang YX, 2010, CELL RES, V20, P124, DOI 10.1038/cr.2010.13
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Yatsuga S, 2012, HUM MOL GENET, V21, P526, DOI 10.1093/hmg/ddr482
NR 23
TC 38
Z9 41
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD SEP 4
PY 2012
VL 7
IS 9
BP 
EP 
DI 10.1371/journal.pone.0044335
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 002ZJ
UT WOS:000308577600038
PM 22962610
DA 2024-11-01
ER

PT J
AU Gómez-Durán, A
   Pacheu-Grau, D
   Martínez-Romero, I
   López-Gallardo, E
   López-Pérez, MJ
   Montoya, J
   Ruiz-Pesini, E
AF Gomez-Duran, Aurora
   Pacheu-Grau, David
   Martinez-Romero, Inigo
   Lopez-Gallardo, Ester
   Lopez-Perez, Manuel J.
   Montoya, Julio
   Ruiz-Pesini, Eduardo
TI Oxidative phosphorylation differences between mitochondrial DNA haplogroups modify the risk of Leber's hereditary optic neuropathy
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Leber's hereditary optic neuropathy; Oxidative phosphorylation; Mitochondrial DNA; Haplogroup; Cybrid
ID gene-expression; messenger-rna; copy number; cell-lines; mtdna; transcription; mutations; muscle; encephalomyopathy; replication
AB Leber's hereditary optic neuropathy is a maternally inherited optic atrophy caused by mitochondrial DNA point mutations. Previous epidemiological studies have shown that individuals from mitochondrial genetic backgrounds (haplogroups) J/Uk and H have a higher and a lower risk, respectively, of suffering this disorder. To analyze the bases of these associations at cellular and molecular levels, functional studies with cybrids provide high quality evidence. Cybrids from haplogroup J contain less mitochondrial deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) and synthesize a smaller amount of mitochondrial DNA-encoded polypeptides than those from haplogroup H. Haplogroup J cybrids also display lower oxygen consumption, mitochondrial inner membrane potential and total adenosine-5'-triphosphate (ATP) levels. Moreover, mitochondrial DNA levels correlate with many parameters of the oxidative phosphorylation system. These results suggest that the mitochondria! DNA amount determines oxidative phosphorylation capacity and, along with other recently published observations, support the possibility that mitochondrial DNA levels may be responsible for the bias of the disorder toward males, for the incomplete penetrance of mutations causing Leber's hereditary optic neuropathy and for the association of the disease with particular mitochondria! DNA haplogroups. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Gomez-Duran, Aurora; Pacheu-Grau, David; Martinez-Romero, Inigo; Lopez-Gallardo, Ester; Lopez-Perez, Manuel J.; Montoya, Julio; Ruiz-Pesini, Eduardo] Univ Zaragoza, Dept Bioquim Biol Mol & Celular, CIBERER, E-50013 Zaragoza, Spain.
   [Ruiz-Pesini, Eduardo] Univ Zaragoza, Fdn ARAID, E-50013 Zaragoza, Spain.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Zaragoza; University of Zaragoza
RP Ruiz-Pesini, E (corresponding author), Univ Zaragoza, Dept Bioquim Biol Mol & Celular, CIBERER, C Miguel Servet 177, E-50013 Zaragoza, Spain.
EM eduruiz@unizar.es
FU Instituto de Salud Carlos III [FIS-PI10/00662, PI08/0264, PI11/01301]; Departamento de Ciencia, Tecnologia y Universidad del Gobierno de Aragon y Fondo Social Europeo [B33]; Instituto Aragones de Ciencias de la Salud [PIPAMER10-010]; Fundacion ARAID; Asociacion de Enfermos de Patologia Mitocondrial (AEPMI)
CR Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819
   Arning L, 2010, J MOL MED, V88, P431, DOI 10.1007/s00109-010-0589-2
   Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188
   Beckstead WA, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0005836
   Bellizzi D, 2009, CELL STRESS CHAPERON, V14, P265, DOI 10.1007/s12192-008-0081-x
   Bellizzi D, 2006, GENES CELLS, V11, P883, DOI 10.1111/j.1365-2443.2006.00986.x
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   Bouhours-Nouet N, 2005, AM J PHYSIOL-ENDOC M, V288, PE171, DOI 10.1152/ajpendo.00260.2003
   Brown MD, 1997, AM J HUM GENET, V60, P381
   Bruni F, 2010, J BIOL CHEM, V285, P3939, DOI 10.1074/jbc.M109.044305
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Carelli V, 2006, AM J HUM GENET, V78, P564, DOI 10.1086/501236
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Cotney J, 2007, NUCLEIC ACIDS RES, V35, P4042, DOI 10.1093/nar/gkm424
   Desquiret V, 2006, BBA-BIOENERGETICS, V1757, P21, DOI 10.1016/j.bbabio.2005.11.005
   Fernández-Vizarra E, 2011, MITOCHONDRION, V11, P207, DOI 10.1016/j.mito.2010.09.011
   Finley LWS, 2009, AGEING RES REV, V8, P173, DOI 10.1016/j.arr.2009.03.003
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Hinttala R, 2010, MITOCHONDRION, V10, P358, DOI 10.1016/j.mito.2010.02.002
   Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474
   Houshmand M, 2004, ANN NY ACAD SCI, V1011, P345, DOI 10.1196/annals.1293.035
   Howell N, 2003, AM J MED GENET A, V119A, P147, DOI 10.1002/ajmg.a.20135
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Hwang S, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0022116
   Kaaman M, 2007, DIABETOLOGIA, V50, P2526, DOI 10.1007/s00125-007-0818-6
   Karamanlidis G, 2010, CIRC RES, V106, P1541, DOI 10.1161/CIRCRESAHA.109.212753
   Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Kulawiec M, 2009, J HUM GENET, V54, P647, DOI 10.1038/jhg.2009.89
   Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891
   Lamminen T, 1997, EUR J HUM GENET, V5, P271, DOI 10.1159/000484777
   Li YF, 2010, NUCLEIC ACIDS RES, V38, P1913, DOI 10.1093/nar/gkp1162
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Marcuello A, 2009, MITOCHONDRION, V9, P27, DOI 10.1016/j.mito.2008.10.002
   Martínez-Redondo D, 2010, MITOCHONDRION, V10, P102, DOI 10.1016/j.mito.2009.11.005
   McKenzie M, 2007, J BIOL CHEM, V282, P36845, DOI 10.1074/jbc.M704158200
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Nishioka T, 2004, J HUM GENET, V49, P701, DOI 10.1007/s10038-004-0209-5
   Parasassi T, 2010, THESCIENTIFICWORLDJO, V10, P1192, DOI 10.1100/tsw.2010.104
   Pello R, 2008, HUM MOL GENET, V17, P4001, DOI 10.1093/hmg/ddn303
   Quintana-Murci L, 2004, AM J HUM GENET, V74, P827, DOI 10.1086/383236
   Rocher C, 2008, J BIOENERG BIOMEMBR, V40, P59, DOI 10.1007/s10863-008-9130-5
   SHIBANUMA M, 1994, FEBS LETT, V353, P62, DOI 10.1016/0014-5793(94)01014-5
   Suissa S, 2009, PLOS GENET, V5, P0, DOI 10.1371/journal.pgen.1000474
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Welle S, 2003, J APPL PHYSIOL, V94, P1479, DOI 10.1152/japplphysiol.01061.2002
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
NR 50
TC 81
Z9 86
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD AUG 15
PY 2012
VL 1822
IS 8
BP 1216
EP 1222
DI 10.1016/j.bbadis.2012.04.014
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 969CH
UT WOS:000306032800005
PM 22561905
DA 2024-11-01
ER

PT J
AU Newsholme, P
   Gaudel, C
   Krause, M
AF Newsholme, Philip
   Gaudel, Celine
   Krause, Maurico
TI Mitochondria and Diabetes. An Intriguing Pathogenetic Role
SO ADVANCES IN MITOCHONDRIAL MEDICINE
LA English
DT Article; Book Chapter
DE Insulin resistance and diabetes; Mitochondrial DNA; Mitochondrial dysfunction; Muscle dysfunction in aging; Reactive Oxygen Species (ROS)
ID human skeletal-muscle; pancreatic beta-cells; substantia-nigra neurons; enzyme gene-expression; cytochrome-c-oxidase; oxidative stress; insulin-secretion; dna deletions; pyruvate-carboxylase; hydrogen-peroxide
AB Mitochondria play a key role in energy metabolism and ATP production in many tissues, including skeletal muscle, cardiac muscle, brain and liver. Inherent disorders of mitochondria such as mDNA deletions cause major disruption of metabolism and can result in severe disease phenotypes. However, the incidence of such mDNA based disorders is extremely rare and cannot account for the dramatic rise in human metabolic diseases, which are characterised by defects in energy metabolism. Mitochondrial dysfunction characterized by reduced ATP generation and reduced mitochondrial number in skeletal muscle or reduced ATP generation and mitochondrial stimulus-secretion coupling in the pancreatic beta cell has been implicated in the pathology of chronic metabolic disease associated with type 2 diabetes mellitus and also with aging. Additionally the generation of ROS from mitochondria and other cellular sources may interfere in insulin signaling in muscle, contributing to insulin resistance. Reduced mitochondrial oxidative capacity coupled with increased ROS generation underlies the accumulation of intramuscular fat, insulin resistance and muscle dysfunction in aging. We will review the molecular basis for optimal mitochondrial function or mechanisms of dysfunction and correlate with pathology of identified diseases and aging.
C1 [Newsholme, Philip; Gaudel, Celine; Krause, Maurico] UCD Dublin, UCD Sch Biomol & Biomed Sci, Belfield Dublin 4, Ireland.
   [Newsholme, Philip; Gaudel, Celine; Krause, Maurico] UCD Dublin, UCD Inst Sport & Hlth, Belfield Dublin 4, Ireland.
   [Newsholme, Philip; Gaudel, Celine] Curtin Univ, Sch Biochem Sci, Perth, WA 6845, Australia.
   [Krause, Maurico] Inst Technol Tallaght, Dept Sci, Biomed Res Grp BMRG, Dublin 24, Ireland.
C3 Curtin University; Technological University Dublin
RP Newsholme, P (corresponding author), UCD Dublin, UCD Sch Biomol & Biomed Sci, Belfield Dublin 4, Ireland.
EM philip.newsholme@ucd.ie
CR Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Befroy DE, 2007, DIABETES, V56, P1376, DOI 10.2337/db06-0783
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bender K, 2006, BIOCHEM SOC T, V34, P811, DOI 10.1042/BST0340811
   Boushel R, 2007, DIABETOLOGIA, V50, P790, DOI 10.1007/s00125-007-0594-3
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S
   Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302
   Conley KE, 2000, J PHYSIOL-LONDON, V526, P203, DOI 10.1111/j.1469-7793.2000.t01-1-00203.x
   Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981
   Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Fridlyand LE, 2005, ANN NY ACAD SCI, V1066, P136, DOI 10.1196/annals.1363.019
   Goffart S, 2003, EXP PHYSIOL, V88, P33, DOI 10.1113/eph8802500
   Harper ME, 2004, ACTA PHYSIOL SCAND, V182, P321, DOI 10.1111/j.1365-201X.2004.01370.x
   Heilbronn LK, 2007, J CLIN ENDOCR METAB, V92, P1467, DOI 10.1210/jc.2006-2210
   Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235
   Hütter E, 2007, AGING CELL, V6, P245, DOI 10.1111/j.1474-9726.2007.00282.x
   Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649
   Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179
   Jackman MR, 2008, OBESITY, V16, P363, DOI 10.1038/oby.2007.40
   Jensen MV, 2008, AM J PHYSIOL-ENDOC M, V295, PE1287, DOI 10.1152/ajpendo.90604.2008
   Katakam AK, 2005, J ENDOCRINOL, V187, P237, DOI 10.1677/joe.1.06411
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   LEE CM, 1993, J GERONTOL, V48, PB201, DOI 10.1093/geronj/48.6.B201
   Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5
   Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703
   LU D, 1993, AM J PHYSIOL, V264, PC715, DOI 10.1152/ajpcell.1993.264.3.C715
   MacDonald MJ, 1996, DIABETES, V45, P1626, DOI 10.2337/diabetes.45.11.1626
   Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905
   Maiese K, 2007, CURR NEUROVASC RES, V4, P63, DOI 10.2174/156720207779940653
   Mármol P, 2009, J BIOL CHEM, V284, P515, DOI 10.1074/jbc.M806729200
   Menshikova EV, 2006, J GERONTOL A-BIOL, V61, P534, DOI 10.1093/gerona/61.6.534
   Michalska M, 2010, BIOSCIENCE REP, V30, P445, DOI 10.1042/BSR20090138
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151
   MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I
   Newsholme P, 2007, J PHYSIOL-LONDON, V583, P9, DOI 10.1113/jphysiol.2007.135871
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Rachek LI, 2007, ENDOCRINOLOGY, V148, P293, DOI 10.1210/en.2006-0998
   Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8
   Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581
   Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003
   Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364
   Rubi B, 2004, J BIOL CHEM, V279, P55659, DOI 10.1074/jbc.M409303200
   Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3
   Schrauwen-Hinderling VB, 2007, DIABETOLOGIA, V50, P113, DOI 10.1007/s00125-006-0475-1
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Szendroedi J, 2008, DIABETOLOGIA, V51, P2155, DOI 10.1007/s00125-008-1153-2
   Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199
   Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733
   Tonkonogi M, 2003, PFLUG ARCH EUR J PHY, V446, P261, DOI 10.1007/s00424-003-1044-9
   Troen BR, 2003, MT SINAI J MED, V70, P3
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Viña J, 2009, ADV DRUG DELIVER REV, V61, P1369, DOI 10.1016/j.addr.2009.06.006
   Vincent AM, 2005, ANTIOXID REDOX SIGN, V7, P1494, DOI 10.1089/ars.2005.7.1494
   Xu J, 2008, DIABETOLOGIA, V51, P2022, DOI 10.1007/s00125-008-1130-9
   Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6
NR 68
TC 76
Z9 86
U1 0
U2 12
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PD JUN 15
PY 2012
VL 942
IS 
BP 235
EP 247
DI 10.1007/978-94-007-2869-1_10
PG 13
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA BA2RR
UT WOS:000333840200011
PM 22399425
DA 2024-11-01
ER

PT J
AU Vantyghem, MC
   Balavoine, AS
   Douillard, C
   Defrance, F
   Dieudonne, L
   Mouton, F
   Lemaire, C
   Bertrand-Escouflaire, N
   Bourdelle-Hego, MF
   Devemy, F
   Evrard, A
   Gheerbrand, D
   Girardoth, C
   Gumuche, S
   Hober, C
   Topolinski, H
   Lamblin, B
   Mycinski, B
   Ryndak, A
   Karrouz, W
   Duvivier, E
   Merlen, E
   Cortet, C
   Weill, J
   Lacroix, D
   Wémeau, JL
AF Vantyghem, Marie-Christine
   Balavoine, Anne-Sophie
   Douillard, Claire
   Defrance, Frederique
   Dieudonne, Lucile
   Mouton, Fanny
   Lemaire, Christine
   Bertrand-Escouflaire, Nicole
   Bourdelle-Hego, Marie-Francoise
   Devemy, Fabrice
   Evrard, Anne
   Gheerbrand, Dominique
   Girardoth, Caroline
   Gumuche, Sophie
   Hober, Christine
   Topolinski, Helene
   Lamblin, Blandine
   Mycinski, Benedicte
   Ryndak, Amelie
   Karrouz, Wassila
   Duvivier, Etienne
   Merlen, Emilie
   Cortet, Christine
   Weill, Jacques
   Lacroix, Dominique
   Wemeau, Jean-Louis
TI How to diagnose a lipodystrophy syndrome
SO ANNALES D ENDOCRINOLOGIE
LA English
DT Review
ID familial partial lipodystrophy; acquired generalized lipodystrophy; lmna r482w mutation; insulin-resistance; adipose-tissue; skeletal-muscle; dunnigan-type; hiv-1-infected patients; metabolic phenotypes; madelungs disease
AB The spectrum of adipose tissue diseases ranges from obesity to lipodystrophy, and is accompanied by insulin resistance syndrome, which promotes the occurrence of type 2 diabetes, dyslipidemia and cardiovascular complications. Lipodystrophy refers to a group of rare diseases characterized by the generalized or partial absence of adipose tissue, and occurs with or without hypertrophy of adipose tissue in other sites. They are classified as being familial or acquired, and generalized or partial. The genetically determined partial forms usually occur as Dunnigan syndrome, which is a type of laminopathy that can also manifest as muscle, cardiac, neuropathic or progeroid involvement. Gene mutations encoding for PPAR-gamma, Akt2, CIDEC, perilipin and the ZMPSTE 24 enzyme are much more rare. The genetically determined generalized forms are also very rare and are linked to mutations of seipin AGPAT2, FBN1, which is accompanied by Marfan syndrome, or of BANF1, which is characterized by a progeroid syndrome without insulin resistance and with early bone complications. Glycosylation disorders are sometimes involved. Some genetically determined forms have recently been found to be due to autoinflammatory syndromes linked to a proteasome anomaly (PSMB8). They result in a lipodystrophy syndrome that occurs secondarily with fever, dermatosis and panniculitis. Then there are forms that are considered to be acquired. They may be iatrogenic (protease inhibitors in HIV patients, glucocorticosteroids, insulin, graft-versus-host disease, etc.), related to an immune system disease (sequelae of dermatopolymyositis, autoimmune polyendocrine syndromes, particularly associated with type I diabetes, Barraquer-Simons and Lawrence syndromes), which are promoted by anomalies of the complement system. Finally, lipomatosis is currently classified as a painful form (adiposis dolorosa or Dercum's disease) or benign symmetric multiple form, also known as Launois-Bensaude syndrome or Madelung's disease, which are sometimes related to mitochondrial DNA mutations, but are usually promoted by alcohol. In addition to the medical management of metabolic syndrome and the sometimes surgical treatment of lipodystrophy, recombinant leptin provides hope for genetically determined lipodystrophy syndromes, whereas modifications in antiretroviral treatment and tesamorelin, a GHRH analog, is effective in the metabolic syndrome of HIV patients. Other therapeutic options will undoubtedly be developed, dependent on pathophysiological advances, which today tend to classify genetically determined lipodystrophy as being related to laminopathy or to lipid droplet disorders. (C) 2012 Published by Elsevier Masson SAS.
C1 [Vantyghem, Marie-Christine; Balavoine, Anne-Sophie; Douillard, Claire; Defrance, Frederique; Mouton, Fanny; Bertrand-Escouflaire, Nicole; Bourdelle-Hego, Marie-Francoise; Gumuche, Sophie; Ryndak, Amelie; Karrouz, Wassila; Merlen, Emilie; Cortet, Christine; Wemeau, Jean-Louis] CHRU Lille, Hop Huriez, Serv Endocrinol & Malad Metab, Inserm U859, F-59000 Lille, France.
   [Defrance, Frederique; Lemaire, Christine] Ctr Hosp Bethune, F-62660 Beuvry, France.
   [Dieudonne, Lucile; Hober, Christine; Topolinski, Helene] Ctr Hosp Henin Beaumont, F-62251 Henin Beaumont, France.
   [Mouton, Fanny] Ctr Hosp Douai, F-59507 Douai, France.
   [Devemy, Fabrice] Ctr Hosp Lens, F-62307 Lens, France.
   [Evrard, Anne] Polyclin Riaumont, F-62806 Lievin, France.
   [Gheerbrand, Dominique] Polyclin Bois Bernard, F-62320 Bois Bernard, France.
   [Girardoth, Caroline] Clin Louviere, F-59800 Lille, France.
   [Lamblin, Blandine] Clin Parc, F-59170 Croix, France.
   [Mycinski, Benedicte] Ctr Hosp Calais, F-62107 Calais, France.
   [Duvivier, Etienne] Grand Hop Charleroi, Serv Med Interne, B-6061 Montignies Sur Sambre, Belgium.
   [Weill, Jacques] CHRU, Hop Jeanne de Flandre, F-59037 Lille, France.
   [Lacroix, Dominique] Univ Lille 2, CHRU Lille, Clin Cardiol, F-59000 Lille, France.
   [Lacroix, Dominique] Univ Lille 2, Fac Med, F-59000 Lille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille; CHU Lille; Grand Hopital De Charleroi; Universite de Lille; CHU Lille; Universite de Lille; CHU Lille; Universite de Lille
RP Vantyghem, MC (corresponding author), CHRU Lille, Hop Huriez, Serv Endocrinol & Malad Metab, Inserm U859, 1 Rue Polonovski, F-59000 Lille, France.
EM mc-vantyghem@chru-lille.fr
CR Al-Attar Salam A, 2006, BMC MED IMAGING, V6, P11, DOI 10.1186/1471-2342-6-11
   Amati F, 2011, DIABETES, V60, P2588, DOI 10.2337/db10-1221
   Ampollini L, 2011, NEW ENGL J MED, V364, P465, DOI 10.1056/NEJMicm1003531
   Barroso E, 2011, ENDOCRINOLOGY, V152, P1848, DOI 10.1210/en.2010-1468
   Barrowman J, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032120
   Ben Yaou R, 2011, EUR J HUM GENET, V19, P647, DOI 10.1038/ejhg.2010.256
   Béréziat V, 2011, AM J PATHOL, V179, P2443, DOI 10.1016/j.ajpath.2011.07.049
   Bingham A, 2008, MEDICINE, V87, P70, DOI 10.1097/MD.0b013e31816bc604
   Boufassa F, 2012, ANTIVIR THER, V17, P91, DOI 10.3851/IMP1916
   Bouloumié A, 2008, ARTERIOSCL THROM VAS, V28, P1211, DOI 10.1161/ATVBAHA.108.168229
   Briand N, 2011, DIABETES, V60, P448, DOI 10.2337/db10-0856
   Cabanillas R, 2011, AM J MED GENET A, V155A, P2617, DOI 10.1002/ajmg.a.34249
   Capeau J, 2012, AIDS, V26, P303, DOI 10.1097/QAD.0b013e32834e8776
   Casado M, 2012, CEREBELLUM, V11, P557, DOI 10.1007/s12311-011-0313-y
   Caux F, 2003, J CLIN ENDOCR METAB, V88, P1006, DOI 10.1210/jc.2002-021506
   Cenni V, 2011, EUR J HISTOCHEM, V55, P200, DOI 10.4081/ejh.2011.e36
   Chan JL, 2011, ENDOCR PRACT, V17, P922, DOI 10.4158/EP11229.OR
   Chen WQ, 2012, MOL CELL BIOL, V32, P1099, DOI 10.1128/MCB.06465-11
   Couturier J, 2012, OBESITY, V20, P253, DOI 10.1038/oby.2011.275
   Decaudain A, 2007, J CLIN ENDOCR METAB, V92, P4835, DOI 10.1210/jc.2007-0654
   Duband-Goulet I, 2011, EXP CELL RES, V317, P2800, DOI 10.1016/j.yexcr.2011.09.012
   Dwianingsih EK, 2010, MOL GENET METAB, V101, P233, DOI 10.1016/j.ymgme.2010.06.016
   Fardet L, 2012, CLIN ENDOCRINOL OXF, V0, P0
   Fiorenza CG, 2011, NAT REV ENDOCRINOL, V7, P137, DOI 10.1038/nrendo.2010.199
   Gandotra S, 2011, NEW ENGL J MED, V364, P740, DOI 10.1056/NEJMoa1007487
   Garg A, 2011, J CLIN ENDOCR METAB, V96, P3313, DOI 10.1210/jc.2011-1159
   Goldbach-Mansky R, 2012, CLIN EXP IMMUNOL, V167, P391, DOI 10.1111/j.1365-2249.2011.04533.x
   Hamilton G, 2011, J MAGN RESON IMAGING, V34, P468, DOI 10.1002/jmri.22623
   Hegele RA, 2006, AM J HUM GENET, V79, P383, DOI 10.1086/505885
   Herbst KL, 2009, INT J OBESITY, V33, P1031, DOI 10.1038/ijo.2009.119
   Herbst KL, 2003, DIABETES CARE, V26, P1819, DOI 10.2337/diacare.26.6.1819
   Herrero L, 2010, P NATL ACAD SCI USA, V107, P240, DOI 10.1073/pnas.0905310107
   Horn D, 2011, AM J MED GENET A, V155A, P721, DOI 10.1002/ajmg.a.33905
   Hu M, 2012, HEPATOLOGY, V55, P437, DOI 10.1002/hep.24708
   Ito D, 2009, BRAIN, V132, P8, DOI 10.1093/brain/awn216
   Jing EX, 2011, P NATL ACAD SCI USA, V108, P14608, DOI 10.1073/pnas.1111308108
   Kitamura A, 2011, J CLIN INVEST, V121, P4150, DOI 10.1172/JCI58414
   Kobayashi J, 2010, INTERNAL MED, V49, P479, DOI 10.2169/internalmedicine.49.2996
   Kulkarni SS, 2011, J BIOL CHEM, V286, P34567, DOI 10.1074/jbc.M111.268292
   Le Dour C, 2011, J CLIN ENDOCR METAB, V96, PE856, DOI 10.1210/jc.2010-2234
   Lee P, 2011, ENDOCRINOLOGY, V152, P3597, DOI 10.1210/en.2011-1349
   Livadas S, 2011, PEDIAT TRANSPLANT, V0, P0
   Llamas-Velasco M, 2011, ACTAS DERMOSIFILIOGR, V0, P0
   Luedtke A, 2012, HORM METAB RES, V44, P306, DOI 10.1055/s-0031-1301284
   Lungu AO, 2012, J CLIN ENDOCR METAB, V97, P563, DOI 10.1210/jc.2011-1896
   Lupsa BC, 2010, MEDICINE, V89, P245, DOI 10.1097/MD.0b013e3181e9442f
   Madej-Pilarczyk A, 2009, AM J MED GENET A, V149A, P2387, DOI 10.1002/ajmg.a.33018
   Mathiesen P, 2012, SCAND J RHEUMATOL, V41, P50, DOI 10.3109/03009742.2011.608376
   MCKEON FD, 1983, P NATL ACAD SCI-BIOL, V80, P4374, DOI 10.1073/pnas.80.14.4374
   Milan G, 2010, J CLIN ENDOCR METAB, V95, P3126, DOI 10.1210/jc.2009-2773
   Misra A, 2003, MEDICINE, V82, P129, DOI 10.1097/00005792-200303000-00007
   Moreau F, 2007, DIABETES METAB, V33, P385, DOI 10.1016/j.diabet.2007.04.005
   Oriot P, 2011, ANN ENDOCRINOL-PARIS, V72, P244, DOI 10.1016/j.ando.2011.04.003
   Park JY, 2008, J CLIN ENDOCR METAB, V93, P26, DOI 10.1210/jc.2007-1856
   Pelosini C, 2011, ACTA DIABETOL, V48, P243, DOI 10.1007/s00592-011-0308-7
   Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034
   Rubio-Cabezas O, 2009, EMBO MOL MED, V1, P280, DOI 10.1002/emmm.200900037
   Rzymski P, 2011, ARCH MED SCI, V7, P1017, DOI 10.5114/aoms.2011.26614
   Sagelius H, 2008, J CELL SCI, V121, P969, DOI 10.1242/jcs.022913
   Saini-Chohan HK, 2012, J LIPID RES, V53, P4, DOI 10.1194/jlr.R012120
   Sankar J, 2012, INDIAN J PEDIAT, V0, P0
   Savage DB, 2009, J CLIN ENDOCR METAB, V94, P10, DOI 10.1210/jc.2008-1703
   Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271
   Simha V, 2012, J CLIN ENDOCR METAB, V97, P785, DOI 10.1210/jc.2011-2229
   Sokolov M, 2010, ISR MED ASSOC J, V12, P253
   Spite M, 2011, J IMMUNOL, V187, P1942, DOI 10.4049/jimmunol.1100196
   Spooner LM, 2012, ANN PHARMACOTHER, V46, P240, DOI 10.1345/aph.1Q629
   Spuler S, 2007, NEUROLOGY, V68, P677, DOI 10.1212/01.wnl.0000255939.73424.f8
   Sysi-Aho M, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0015744
   Tan K, 2007, DIABETES, V56, P714, DOI 10.2337/db06-0921
   Vantyghem MC, 2008, J CLIN ENDOCR METAB, V93, P2223, DOI 10.1210/jc.2007-2521
   Vantyghem MC, 2007, CLIN ENDOCRINOL, V67, P247, DOI 10.1111/j.1365-2265.2007.02870.x
   Vantyghem MC, 1999, DIABETES CARE, V22, P1374, DOI 10.2337/diacare.22.8.1374
   Vantyghem MC, 2004, J CLIN ENDOCR METAB, V89, P5337, DOI 10.1210/jc.2003-031658
   Vantyghem MC, 2011, ANN ENDOCRINOL, V5, P347
   Veloso S, 2012, CYTOKINE, V58, P253, DOI 10.1016/j.cyto.2012.01.013
   Vigouroux C, 2000, DIABETES, V49, P1958, DOI 10.2337/diabetes.49.11.1958
   Visser ME, 2011, DIABETOLOGIA, V54, P1639, DOI 10.1007/s00125-011-2142-4
   Wong SPY, 2005, DIABETOLOGIA, V48, P2641, DOI 10.1007/s00125-005-0038-x
   Xia GX, 2012, MOL CELL ENDOCRINOL, V358, P46, DOI 10.1016/j.mce.2012.02.017
   Yee JK, 2012, LIPIDS HEALTH DIS, V11, P0, DOI 10.1186/1476-511X-11-19
   Yin HQ, 2012, J BIOL CHEM, V287, P9817, DOI 10.1074/jbc.M111.333534
NR 82
TC 51
Z9 59
U1 4
U2 33
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003-4266
EI 2213-3941
J9 ANN ENDOCRINOL-PARIS
JI Ann Endocrinol.
PD JUN 15
PY 2012
VL 73
IS 3
BP 170
EP 189
DI 10.1016/j.ando.2012.04.010
PG 20
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 992AM
UT WOS:000307747100003
PM 22748602
DA 2024-11-01
ER

PT J
AU Joshi, AS
   Thompson, MN
   Fei, N
   Hüttemann, M
   Greenberg, ML
AF Joshi, Amit S.
   Thompson, Morgan N.
   Fei, Naomi
   Huettemann, Maik
   Greenberg, Miriam L.
TI Cardiolipin and Mitochondrial Phosphatidylethanolamine Have Overlapping Functions in Mitochondrial Fusion in <i>Saccharomyces cerevisiae</i>
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID dynamin-related gtpase; linked cardioskeletal myopathy; wd repeat protein; barth-syndrome; phosphatidylserine decarboxylase; lymphoblast mitochondria; temperature sensitivity; carrier protein; yeast requires; inner membrane
AB The two non-bilayer forming mitochondrial phospholipids cardiolipin (CL) and phosphatidylethanolamine (PE) play crucial roles in maintaining mitochondrial morphology. We have shown previously that CL and PE have overlapping functions, and the loss of both is synthetically lethal. Because the lack of CL does not lead to defects in the mitochondrial network in Saccharomyces cerevisiae, we hypothesized that PE may compensate for CL in the maintenance of mitochondrial tubular morphology and fusion. To test this hypothesis, we constructed a conditional mutant crd1 Delta psd1 Delta containing null alleles of CRD1 (CL synthase) and PSD1 (mitochondrial phosphatidylserine decarboxylase), in which the wild type CRD1 gene is expressed on a plasmid under control of the TETOFF promoter. In the presence of tetracycline, the mutant exhibited highly fragmented mitochondria, loss of mitochondrial DNA, and reduced membrane potential, characteristic of fusion mutants. Deletion of DNM1, required for mitochondrial fission, restored the tubular mitochondrial morphology. Loss of CL and mitochondrial PE led to reduced levels of small and large isoforms of the fusion protein Mgm1p, possibly accounting for the fusion defect. Taken together, these data demonstrate for the first time in vivo that CL and mitochondrial PE are required to maintain tubular mitochondrial morphology and have overlapping functions in mitochondrial fusion.
C1 [Joshi, Amit S.; Thompson, Morgan N.; Fei, Naomi; Greenberg, Miriam L.] Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.
   [Huettemann, Maik] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA.
C3 Wayne State University; Wayne State University
RP Greenberg, ML (corresponding author), 5047 Gullen Mall Biol Sci Bldg, Detroit, MI 48202 USA.
EM mlgreen@sun.science.wayne.edu
FU National Institutes of Health [R21 HL 084218]; Barth Syndrome Foundation; Wayne State University Graduate Enhancement Research Fellowship; Graduate Enhancement Research Funds
CR Acehan D, 2007, LAB INVEST, V87, P40, DOI 10.1038/labinvest.3700480
   Acehan D, 2011, J BIOL CHEM, V286, P899, DOI 10.1074/jbc.M110.171439
   ARDAIL D, 1990, J BIOL CHEM, V265, P18797
   Ban T, 2010, HUM MOL GENET, V19, P2113, DOI 10.1093/hmg/ddq088
   Barth PG, 1996, J INHERIT METAB DIS, V19, P157, DOI 10.1007/BF01799418
   Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014
   BOLHUIS PA, 1991, AM J HUM GENET, V48, P481
   Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010
   Bürgermeister M, 2004, BBA-MOL CELL BIOL L, V1686, P161, DOI 10.1016/j.bbalip.2004.09.007
   CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Chen L, 2009, CARDIOVASC RES, V84, P91, DOI 10.1093/cvr/cvp181
   Chen SL, 2010, J BIOL CHEM, V285, P10397, DOI 10.1074/jbc.M110.100784
   Chen S, 2008, MOL BIOL CELL, V19, P5047, DOI 10.1091/mbc.E08-05-0486
   Claypool SM, 2008, J CELL BIOL, V182, P937, DOI 10.1083/jcb.200801152
   CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1
   DeVay RM, 2009, J CELL BIOL, V186, P793, DOI 10.1083/jcb.200906098
   Dorn GW, 2011, CIRC RES, V108, P12, DOI 10.1161/CIRCRESAHA.110.236745
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Furt F, 2009, INT J BIOCHEM CELL B, V41, P1828, DOI 10.1016/j.biocel.2009.02.005
   Gebert N, 2009, CURR BIOL, V19, P2133, DOI 10.1016/j.cub.2009.10.074
   Gohil VM, 2009, J CELL BIOL, V184, P468, DOI 10.1083/jcb.200901127
   Gohil VM, 2005, J BIOL CHEM, V280, P35410, DOI 10.1074/jbc.M505478200
   Gonzalvez F, 2007, APOPTOSIS, V12, P877, DOI 10.1007/s10495-007-0718-8
   GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678
   Herlan M, 2004, J CELL BIOL, V165, P167, DOI 10.1083/jcb.200403022
   Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200
   Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359
   Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048
   Hoppins S, 2009, J CELL BIOL, V184, P569, DOI 10.1083/jcb.200809099
   Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199
   Kuroda T, 2011, MOL MICROBIOL, V80, P248, DOI 10.1111/j.1365-2958.2011.07569.x
   Ludovico P, 2001, MICROBIOL-SGM, V147, P3335, DOI 10.1099/00221287-147-12-3335
   Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612
   Mitra K, 2009, P NATL ACAD SCI USA, V106, P11960, DOI 10.1073/pnas.0904875106
   Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367
   Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233
   Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610
   Osman C, 2011, J CELL BIOL, V192, P7, DOI 10.1083/jcb.201006159
   Osman C, 2009, J CELL BIOL, V184, P583, DOI 10.1083/jcb.200810189
   RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6
   Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150
   Rujiviphat J, 2009, J BIOL CHEM, V284, P28682, DOI 10.1074/jbc.M109.044933
   Schlame M, 2009, BBA-BIOMEMBRANES, V1788, P2080, DOI 10.1016/j.bbamem.2009.04.019
   SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x
   Sesaki H, 2004, J BIOL CHEM, V279, P28298, DOI 10.1074/jbc.M401363200
   Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699
   Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123
   Tamura Y, 2009, J CELL BIOL, V185, P1029, DOI 10.1083/jcb.200812018
   Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353
   Tieu Q, 2002, J CELL BIOL, V158, P445, DOI 10.1083/jcb.200205031
   TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071
   TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062
   TROTTER PJ, 1993, J BIOL CHEM, V268, P21416
   Vaden DL, 2005, ANAL BIOCHEM, V338, P162, DOI 10.1016/j.ab.2004.11.020
   Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L
   WILLINGHAM MC, 1984, J HISTOCHEM CYTOCHEM, V32, P455, DOI 10.1177/32.4.6323574
   Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015
   Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341
   Xu Y, 2005, LAB INVEST, V85, P823, DOI 10.1038/labinvest.3700274
   Zhong Q, 2004, J BIOL CHEM, V279, P32294, DOI 10.1074/jbc.M403275200
   Zhong Q, 2007, J BIOL CHEM, V282, P15946, DOI 10.1074/jbc.M701055200
   Zhou JM, 2009, J BIOL CHEM, V284, P18106, DOI 10.1074/jbc.M109.003236
   Zick M, 2009, FEBS LETT, V583, P2237, DOI 10.1016/j.febslet.2009.05.053
NR 64
TC 147
Z9 169
U1 1
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 18
PY 2012
VL 287
IS 21
BP 17589
EP 17597
DI 10.1074/jbc.M111.330167
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 973PU
UT WOS:000306373000057
PM 22433850
DA 2024-11-01
ER

PT J
AU Yatsuga, S
   Suomalainen, A
AF Yatsuga, Shuichi
   Suomalainen, Anu
TI Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID cytochrome-c-oxidase; ppar-alpha; coactivator-1-alpha pgc-1-alpha; lipid-metabolism; receptor-alpha; cox deficiency; activation; multiple; disease; gamma
AB Mitochondrial dysfunction is an important cause of metabolic disorders of children and adults, with no effective therapy options. Recently, induction of mitochondrial biogenesis, by transgenic overexpression of PGC1alpha [peroxisome proliferator-activated receptor (PPAR)-gamma coactivator 1-alpha], was reported to delay progression of early-onset cytochrome-c-oxidase (COX) deficiency in skeletal muscle of two mouse models: a muscle-specific knock-out of COX10 (COX10-mKO) and a constitutive knock-out of Surf1 (Surf1-KO). A panPPAR agonist, bezafibrate, could similarly delay myopathy progression in COX10-mKOs, but not in SURF1KOs. We asked whether bezafibrate affected disease progression in late-onset adult-type mitochondrial myopathy mice. These ` Deletor mice' express a dominant patient mutation in Twinkle-helicase, leading to accumulation of multiple mtDNA deletions and subsequent progressive respiratory chain (RC) deficiency with COX-negative muscle fibers at 12 months of age. The primary and secondary molecular findings in Deletor mice mimic closely those in patients with Twinkle myopathy. We applied 0.5% bezafibrate diet to Deletors for 22 weeks, starting at disease manifestation, mimicking patient treatment after diagnosis. Bezafibrate delayed significantly the accumulation of COX-negative fibers and multiple mtDNA deletions. However, mitochondrial biogenesis was not induced: mitochondrial DNA copy number, transcript and RC protein amounts decreased in both Deletors and wild-type mice. Furthermore, bezafibrate induced severe lipid oxidation effects, with hepatomegaly and loss of adipose tissue, the mechanism involving lipid mobilization by high hepatic expression of FGF21 cytokine. However, as bezafibrate has been tolerated well by humans, the beneficial muscle findings in Deletor mice support consideration of bezafibrate trials on adult patients with mitochondrial myopathy.
C1 [Yatsuga, Shuichi; Suomalainen, Anu] Univ Helsinki, Res Programs Unit, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland.
   [Suomalainen, Anu] Inst Mol Med Finland, Helsinki 00290, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Res Programs Unit, Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
FU Sigrid Juselius foundation; Jane and Aatos Erkko Foundation; University of Helsinki; Academy of Finland's Centre of Excellence program; Finland-Japan program; CIMO organization
CR Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002
   CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302
   DellAgnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795
   Domouzoglou EM, 2011, AM J CLIN NUTR, V93, P901S, DOI 10.3945/ajcn.110.001941
   Goldenberg I, 2008, VASC HEALTH RISK MAN, V4, P131, DOI 10.2147/vhrm.2008.04.01.131
   Goto T, 2011, J LIPID RES, V52, P873, DOI 10.1194/jlr.M011320
   Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200
   Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   MINCHOM PE, 1983, J NEUROL SCI, V60, P453, DOI 10.1016/0022-510X(83)90156-9
   Mori Yutaka, 2004, J ATHEROSCLER THROMB, V11, P224
   Nakajima T, 2009, MOL PHARMACOL, V75, P782, DOI 10.1124/mol.108.052928
   Oishi K, 2008, FEBS LETT, V582, P3639, DOI 10.1016/j.febslet.2008.09.046
   Potthoff MJ, 2009, P NATL ACAD SCI USA, V106, P10853, DOI 10.1073/pnas.0904187106
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Pyper Sean R, 2010, NUCL RECEPT SIGNAL, V8, Pe002, DOI 10.1621/nrs.08002
   Siersbæk R, 2010, FEBS LETT, V584, P3242, DOI 10.1016/j.febslet.2010.06.010
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Suomalainen A, 2011, SEMIN FETAL NEONAT M, V16, P236, DOI 10.1016/j.siny.2011.05.003
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310
   Tyynismaa H, 2009, EMBO REP, V10, P137, DOI 10.1038/embor.2008.242
   Varga T, 2011, BBA-MOL BASIS DIS, V1812, P1007, DOI 10.1016/j.bbadis.2011.02.014
   Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011
   Wagner KD, 2010, PHARMACOL THERAPEUT, V125, P423, DOI 10.1016/j.pharmthera.2009.12.001
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Zhang Y, 2004, J BIOL CHEM, V279, P53963, DOI 10.1074/jbc.M406028200
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 36
TC 103
Z9 112
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD FEB 1
PY 2012
VL 21
IS 3
BP 526
EP 535
DI 10.1093/hmg/ddr482
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 879RX
UT WOS:000299351000005
PM 22012983
DA 2024-11-01
ER

PT J
AU Du, ZD
   Hu, YJ
   Yang, Y
   Sun, Y
   Zhang, SL
   Zhou, T
   Zeng, LL
   Zhang, WJ
   Huang, X
   Kong, WJ
   Zhang, HL
AF Du, Zhengde
   Hu, Yujuan
   Yang, Yang
   Sun, Yu
   Zhang, Sulin
   Zhou, Tao
   Zeng, Lingling
   Zhang, Wenjuan
   Huang, Xiang
   Kong, Weijia
   Zhang, Honglian
TI NADPH oxidase-dependent oxidative stress and mitochondrial damage in hippocampus of D-galactose-induced aging rats
SO JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES
LA English
DT Article
DE D-galactose; common deletion; oxidative stress; NADPH oxidase; uncoupling protein 2
ID dna deletions; energy-metabolism; bp deletion; memory loss; neuro degeneration; common deletion; skeletal-muscle; inner-ear; mice; brain
AB Mitochondrial DNA (mtDNA) common deletion (CD) plays a significant role in aging and age-related diseases. In this study, we used D-galactose (D-gal) to generate an animal model of aging and the involvement and causative mechanisms of mitochondrial damage in such a model were investigated. Twenty 5-week-old male Sprague-Dawley rats were randomly divided into two groups: D-gal group (n=10) and control group (n=10). The quantity of the mtDNA CD in the hippocampus was determined using a TaqMan real-time PCR assay. Transmission electron microscopy was used to observe the mitochondrial ultrastructure in the hippocampus. Western blot was used to detect the protein levels of NADPH oxidase (NOX) and uncoupling protein 2 (UCP2). We found that the level of mtDNA CD was significantly higher in the hippocampus of D-gal-induced aging rats than in control rats. In comparison with the control group, the mitochondrial ultrastructure in the hippocampus of D-gal-treated rats was damaged, and the protein levels of NOX and UCP2 were significantly increased in the hippocampus of D-gal-induced aging rats. This study demonstrated that the levels of mtDNA CD and NOX protein expression were significantly increased in the hippocampus of D-gal-induced aging rats. These findings indicate that NOX-dependent reactive oxygen species generation may contribute to D-gal-induced mitochondrial damage.
C1 [Du, Zhengde; Hu, Yujuan; Yang, Yang; Sun, Yu; Zhang, Sulin; Zhou, Tao; Zeng, Lingling; Zhang, Wenjuan; Huang, Xiang; Kong, Weijia] Huazhong Univ Sci & Technol, Dept Otorhinolaryngol, Tongji Med Coll, Union Hosp, Wuhan 430022, Peoples R China.
   [Zhang, Honglian] Huazhong Univ Sci & Technol, Dept Publ Hlth, Tongji Med Coll, Union Hosp, Wuhan 430022, Peoples R China.
   [Du, Zhengde] Huazhong Univ Sci & Technol, Dept Otorhinolaryngol, Shenzhen Peoples Hosp 6, Nanshan Hosp, Shenzhen 518052, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology
RP Kong, WJ (corresponding author), Huazhong Univ Sci & Technol, Dept Otorhinolaryngol, Tongji Med Coll, Union Hosp, Wuhan 430022, Peoples R China.
EM duzhengde@gmail.com; safiner@gmail.com; entwjkong@yahoo.com.cn; zhl_bjk@whuh.com
FU Natural Science Foundation of Hubei province [2010CDB08005]; National Natural Science Foundation of China [30730094, 81000409]; Special Funds for State Key Development Program for Basic Research of China (973 Program) [2011CB504504]
CR Amaral S, 2008, FEBS LETT, V582, P4191, DOI 10.1016/j.febslet.2008.11.020
   Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2
   Barazzoni R, 2001, AM J PHYSIOL-ENDOC M, V280, PE413, DOI 10.1152/ajpendo.2001.280.3.E413
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002
   Bruce-Keller AJ, 2011, NEUROBIOL DIS, V44, P317, DOI 10.1016/j.nbd.2011.07.012
   Chen B, 2011, MOL BIOL REP, V38, P3635, DOI 10.1007/s11033-010-0476-5
   Chen B, 2010, BRAIN RES, V1344, P43, DOI 10.1016/j.brainres.2010.04.082
   Chen CF, 2006, PSYCHONEUROENDOCRINO, V31, P805, DOI 10.1016/j.psyneuen.2006.03.004
   Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576
   Chen TF, 2011, BRIT J NUTR, V105, P1294, DOI 10.1017/S0007114510005052
   Choi Jung Hoon, 2011, LAB ANIM RES, V27, P181, DOI 10.5625/lar.2011.27.3.181
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   Cui X, 2006, J NEUROSCI RES, V84, P647, DOI 10.1002/jnr.20899
   Cui X, 2006, J NEUROSCI RES, V83, P1584, DOI 10.1002/jnr.20845
   Deng SM, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0030714
   Filburn CR, 1996, MECH AGEING DEV, V87, P35, DOI 10.1016/0047-6374(96)01696-X
   Frisard M, 2006, ENDOCRINE, V29, P27, DOI 10.1385/ENDO:29:1:27
   Fukui H, 2009, HUM MOL GENET, V18, P1028, DOI 10.1093/hmg/ddn437
   Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698
   Harman D, 2001, ANN NY ACAD SCI, V928, P1, DOI 10.1111/j.1749-6632.2001.tb05631.x
   Hiona A, 2008, EXP GERONTOL, V43, P24, DOI 10.1016/j.exger.2007.10.001
   Ho SC, 2003, BIOGERONTOLOGY, V4, P15, DOI 10.1023/A:1022417102206
   Hsieh HM, 2009, FOOD CHEM TOXICOL, V47, P625, DOI 10.1016/j.fct.2008.12.026
   Hua XD, 2007, LIFE SCI, V80, P1897, DOI 10.1016/j.lfs.2007.02.030
   Kleinschnitz C, 2010, PLOS BIOL, V8, P0, DOI 10.1371/journal.pbio.1000479
   Kong WJ, 2006, EXP GERONTOL, V41, P628, DOI 10.1016/j.exger.2006.04.008
   Kong WJ, 2006, BIOCHEM BIOPH RES CO, V344, P425, DOI 10.1016/j.bbrc.2006.03.060
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Kumar A, 2010, FOOD CHEM TOXICOL, V48, P626, DOI 10.1016/j.fct.2009.11.043
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Lu J, 2010, BRAIN PATHOL, V20, P598, DOI 10.1111/j.1750-3639.2009.00339.x
   Markaryan A, 2009, LARYNGOSCOPE, V119, P1184, DOI 10.1002/lary.20218
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   Mizuno T, 2000, BIOCHEM BIOPH RES CO, V278, P691, DOI 10.1006/bbrc.2000.3859
   Mohamed SA, 2006, EXP GERONTOL, V41, P508, DOI 10.1016/j.exger.2006.03.014
   Nair D, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0019847
   Nicklas JA, 2004, ENVIRON MOL MUTAGEN, V44, P313, DOI 10.1002/em.20050
   Nicolle MM, 2001, NEUROSCIENCE, V107, P415, DOI 10.1016/S0306-4522(01)00374-8
   Pamenter ME, 2012, BRAIN RES, V1452, P165, DOI 10.1016/j.brainres.2012.03.004
   Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1
   Raz L, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0012606
   Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2
   SOONG NW, 1992, NAT GENET, V2, P318
   Tian Y, 2011, FOOD CHEM TOXICOL, V49, P1728, DOI 10.1016/j.fct.2011.04.018
   Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252
   Wei HF, 2005, BEHAV BRAIN RES, V157, P245, DOI 10.1016/j.bbr.2004.07.003
   Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6
   Zhang D, 2006, J ETHNOPHARMACOL, V104, P250, DOI 10.1016/j.jep.2005.09.010
   Zhang XL, 2008, FOOD CHEM TOXICOL, V46, P2888, DOI 10.1016/j.fct.2008.05.032
   Zhong Y, 2011, FEBS J, V278, P2500, DOI 10.1111/j.1742-4658.2011.08176.x
   Zhong Y, 2011, MUTAT RES-FUND MOL M, V712, P11, DOI 10.1016/j.mrfmmm.2011.03.013
NR 56
TC 15
Z9 18
U1 1
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0733
EI 1993-1352
J9 J HUAZHONG U SCI-MED
JI J. Huazhong Univ. Sci. Tech.-Med.
PD AUG 15
PY 2012
VL 32
IS 4
BP 466
EP 472
DI 10.1007/s11596-012-0081-z
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 988SW
UT WOS:000307512000002
PM 22886955
DA 2024-11-01
ER

PT J
AU Sasarman, F
   Nishimura, T
   Thiffault, I
   Shoubridge, EA
AF Sasarman, Florin
   Nishimura, Tamiko
   Thiffault, Isabelle
   Shoubridge, Eric A.
TI A novel mutation in YARS2 causes myopathy with lactic acidosis and sideroblastic anemia
SO HUMAN MUTATION
LA English
DT Article
DE mitochondrial aminoacyl-tRNA synthetase; YARS2; MLASA; TRMU; MTU1; mitochondrial translation
ID transfer-rna-synthetase; mitochondrial-dna mutations; translation; gene; deficiency; complexes
AB Mutations in the mitochondrial aminoacyl-tRNA synthetases (ARSs) are associated with a strikingly broad range of clinical phenotypes, the molecular basis for which remains obscure. Here, we report a novel missense mutation (c.137G>A, p.Gly46Asp) in the catalytic domain of YARS2, which codes for the mitochondrial tyrosyl-tRNA synthetase, in a subject with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). YARS2 was undetectable by immunoblot analysis in subject myoblasts, resulting in a generalized mitochondrial translation defect. Retroviral expression of a wild-type YARS2 complementary DNA completely rescued the translation defect. We previously demonstrated that the respiratory chain defect in this subject was only present in fully differentiated muscle, and we show here that this likely reflects an increased requirement for YARS2 as muscle cells differentiate. An additional, heterozygous mutation was detected in TRMU/MTU1, a gene encoding the mitochondrial 2-thiouridylase. Although subject myoblasts and myotubes contained half the normal levels of TRMU, thiolation of mitochondrial tRNAs was normal. YARS2 eluted as part of high-molecular-weight complexes of similar to 250 kDa and 1 MDa by gel filtration. This study confirms mutations in YARS2 as a cause of MLASA and shows that, like some of the cytoplasmic ARSs, mitochondrial ARSs occur in high-molecular-weight complexes. Hum Mutat 33:12011206, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Sasarman, Florin; Nishimura, Tamiko; Thiffault, Isabelle; Shoubridge, Eric A.] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada.
   [Sasarman, Florin; Nishimura, Tamiko; Thiffault, Isabelle; Shoubridge, Eric A.] McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada.
C3 McGill University; McGill University
RP Shoubridge, EA (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.
EM eric@ericpc.mni.mcgill.ca
FU CIHR [Mt-15460]
CR Antonellis A, 2003, AM J HUM GENET, V72, P1293, DOI 10.1086/375039
   Antonicka H, 2010, AM J HUM GENET, V87, P115, DOI 10.1016/j.ajhg.2010.06.004
   Belostotsky R, 2011, AM J HUM GENET, V88, P193, DOI 10.1016/j.ajhg.2010.12.010
   Bonnefond L, 2007, STRUCTURE, V15, P1505, DOI 10.1016/j.str.2007.09.018
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Galmiche L, 2011, HUM MUTAT, V32, P1225, DOI 10.1002/humu.21562
   Götz A, 2011, AM J HUM GENET, V88, P635, DOI 10.1016/j.ajhg.2011.04.006
   Hausmann CD, 2008, FEMS MICROBIOL REV, V32, P705, DOI 10.1111/j.1574-6976.2008.00119.x
   Jordanova A, 2006, NAT GENET, V38, P197, DOI 10.1038/ng1727
   Kaufman BA, 2007, MOL BIOL CELL, V18, P3225, DOI 10.1091/mbc.E07-05-0404
   Kemp JP, 2011, BRAIN, V134, P183, DOI 10.1093/brain/awq320
   Latour P, 2010, AM J HUM GENET, V86, P77, DOI 10.1016/j.ajhg.2009.12.005
   Lee SW, 2004, J CELL SCI, V117, P3725, DOI 10.1242/jcs.01342
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Park SG, 2008, P NATL ACAD SCI USA, V105, P11043, DOI 10.1073/pnas.0802862105
   Pierce SB, 2011, P NATL ACAD SCI USA, V108, P6543, DOI 10.1073/pnas.1103471108
   Pulkes T, 2000, NEUROLOGY, V55, P1210, DOI 10.1212/WNL.55.8.1210
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Sahashi K, 2001, J MED GENET, V38, P703, DOI 10.1136/jmg.38.10.703
   Sasarman F, 2002, HUM MOL GENET, V11, P1669, DOI 10.1093/hmg/11.14.1669
   Sasarman F, 2012, METHODS MOL BIOL, V837, P207, DOI 10.1007/978-1-61779-504-6_14
   Sasarman F, 2011, HUM MOL GENET, V20, P4634, DOI 10.1093/hmg/ddr397
   Scaglia F, 2003, AM J MED GENET A, V123A, P172, DOI 10.1002/ajmg.a.20315
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Steenweg ME, 2012, BRAIN 0404, V0, P0
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   WALKER EJ, 1983, BIOCHEMISTRY-US, V22, P1934, DOI 10.1021/bi00277a030
   Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
NR 36
TC 47
Z9 52
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD AUG 15
PY 2012
VL 33
IS 8
BP 1201
EP 1206
DI 10.1002/humu.22098
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 973QV
UT WOS:000306375800011
PM 22504945
DA 2024-11-01
ER

PT J
AU Liu, CH
   Chang, CH
   Kuo, HC
   Ro, LS
   Liou, CW
   Wei, YH
   Huang, CC
AF Liu, Chi-Hung
   Chang, Chien-Hung
   Kuo, Hung-Chou
   Ro, Long-Sun
   Liou, Chia-Wei
   Wei, Yau-Huei
   Huang, Chin-Chang
TI Prognosis of symptomatic patients with the A3243G mutation of mitochondrial DNA
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Article
DE A3243G mutation; MELAS; mitochondrial disease; mitochondrial DNA; prognosis; seizures; Taiwanese
ID stroke-like-episodes; melas-syndrome; pediatric-patients; clinical spectrum; lactic-acidosis; gene mutation; follow-up; disorders; 3243a-greater-than-g; manifestations
AB Background/Purpose: The clinical analyses and prognoses of mitochondrial diseases with A3243G mutation are rarely documented in Taiwan. Our study investigated the clinical phenotypes and the outcomes of patients with mitochondrial disease and the A3243G mutation of mtDNA in a Taiwanese population, and compared these with previous reports. Methods: We retrospectively studied 22 consecutive patients with mitochondrial disease and the A3243G mutation of mtDNA in Chang Gung Memorial Hospital between 1988 and 2009. All patients underwent a detailed demographic registration, neurological examinations, a muscle biopsy, and mitochondrial DNA analysis. Modified Rankin scale, the presence of recurrent strokes or seizures, critical medical complications, and death were monitored during the follow-up period. Results: Of the 22 patients, seizures and stroke-like episodes were found in 12 (55%). Visceral involvement, including cardiomyopathy, nephropathy, and pulmonary hypertension, were noted in five patients (23%). Patients with seizures had a high frequency of status epilepticus (92%) and a younger age of onset (21.3 +/- 7.2 years). Both the Kaplan-Meier survival analysis and the Cox-regression model showed a marked deterioration in patients with seizures after 7 years of follow-up. Conclusion: Our study found that seizures and status epilepticus are the most important predictive values for a poor outcome in patients with the mtA3243G mutation of mtDNA. Age of onset and visceral organ involvement had no prominent influence on the prognosis. Some medical complications could be well controlled or even reversed after management. Copyright (C) 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
C1 [Liu, Chi-Hung; Chang, Chien-Hung; Kuo, Hung-Chou; Ro, Long-Sun; Huang, Chin-Chang] Chang Gung Mem Hosp, Dept Neurol, Linkou branch, Tao Yuan, Taiwan.
   [Liou, Chia-Wei] Chang Gung Mem Hosp, Dept Neurol, Kaohsiung branch, Kaohsiung, Taiwan.
   [Wei, Yau-Huei] Mackay Med Coll, Dept Med, Taipei, Taiwan.
   [Wei, Yau-Huei] Natl Yang Ming Univ, Sch Life Sci, Dept Biochem, Taipei 112, Taiwan.
   [Huang, Chin-Chang] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Mackay Medical College; National Yang Ming Chiao Tung University; Chang Gung University
RP Huang, CC (corresponding author), Chang Gung Mem Hosp, Dept Neurol, Chang Gung Mem Hosp, 199 Tung Hua N Rd, Taipei, Taiwan.
EM cch0537@adm.cgmh.org.tw
FU National Science Council [NSC 95-2314-B-184A-067]
CR Barclay AR, 2005, J INHERIT METAB DIS, V28, P1081, DOI 10.1007/s10545-005-4484-x
   Bourgeois JM, 2004, MITOCHONDRION, V4, P441, DOI 10.1016/j.mito.2004.07.036
   Debray FG, 2007, PEDIATRICS, V119, P722, DOI 10.1542/peds.2006-1866
   El Sabbagh S, 2010, EPILEPSIA, V51, P1225, DOI 10.1111/j.1528-1167.2009.02504.x
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   Finsterer J, 2011, EUR J NEUROL, V18, P28, DOI 10.1111/j.1468-1331.2010.03086.x
   Finsterer J, 2009, EUR J NEUROL, V16, P1178, DOI 10.1111/j.1468-1331.2009.02789.x
   Finsterer J, 2010, EPILEPTIC DISORD, V12, P330, DOI 10.1684/epd.2010.0338
   García-Cazorla A, 2005, PEDIATRICS, V116, P1170, DOI 10.1542/peds.2004-2407
   Huang CC, 1996, ACTA NEUROL SCAND, V93, P198
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   Huang CC, 2002, J BIOMED SCI, V9, P527, DOI 10.1007/BF02254979
   Krähenbühl S, 2000, LIVER, V20, P346, DOI 10.1034/j.1600-0676.2000.020004346.x
   Lam CW, 1997, EUR J PEDIATR, V156, P562, DOI 10.1007/s004310050663
   Lin CM, 2007, METAB BRAIN DIS, V22, P105, DOI 10.1007/s11011-006-9039-9
   Majamaa-Voltti K, 2008, J NEUROL NEUROSUR PS, V79, P0, DOI 10.1136/jnnp.2007.122648
   Majamaa-Voltti KAM, 2006, NEUROLOGY, V66, P1470, DOI 10.1212/01.wnl.0000216136.61640.79
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Sproule DM, 2007, ARCH NEUROL-CHICAGO, V64, P1625, DOI 10.1001/archneur.64.11.1625
   Sunada Y, 2001, INTERNAL MED, V40, P561, DOI 10.2169/internalmedicine.40.561
   Tay SHK, 2006, ARCH NEUROL-CHICAGO, V63, P281, DOI 10.1001/archneur.63.2.281
   Vydt TCG, 2007, AM J CARDIOL, V99, P264, DOI 10.1016/j.amjcard.2006.07.089
   Wallace DC, 2008, GENETICS, V179, P727, DOI 10.1534/genetics.104.91769
   Wang W, 2008, AM J EMERG MED, V26, P0, DOI 10.1016/j.ajem.2007.05.027
   Yu Q, 2007, MITOCHONDRION, V7, P147, DOI 10.1016/j.mito.2006.11.019
NR 25
TC 14
Z9 15
U1 1
U2 4
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN
SN 0929-6646
EI 1876-0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD SEP 15
PY 2012
VL 111
IS 9
BP 489
EP 494
DI 10.1016/j.jfma.2011.06.014
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 032LD
UT WOS:000310719200005
PM 23021505
DA 2024-11-01
ER

PT J
AU Bonomi, M
   Somigliana, E
   Cacciatore, C
   Busnelli, M
   Rossetti, R
   Bonetti, S
   Paffoni, A
   Mari, D
   Ragni, G
   Persani, L
AF Bonomi, Marco
   Somigliana, Edgardo
   Cacciatore, Chiara
   Busnelli, Marta
   Rossetti, Raffaella
   Bonetti, Silvia
   Paffoni, Alessio
   Mari, Daniela
   Ragni, Guido
   Persani, Luca
TI Blood Cell Mitochondrial DNA Content and Premature Ovarian Aging
SO PLOS ONE
LA English
DT Article
ID progressive external ophthalmoplegia; copy number; polymerase-gamma; skeletal-muscle; poor response; x-chromosome; in-vitro; failure; oocyte; insufficiency
AB Primary ovarian insufficiency (POI) is a critical fertility defect characterized by an anticipated and silent impairment of the follicular reserve, but its pathogenesis is largely unexplained. The frequent maternal inheritance of POI together with a remarkable dependence of ovarian folliculogenesis upon mitochondrial biogenesis and bioenergetics suggested the possible involvement of a generalized mitochondrial defect. Here, we verified the existence of a significant correlation between blood and ovarian mitochondrial DNA (mtDNA) content in a group of women undergoing ovarian hyperstimulation (OH), and then aimed to verify whether mtDNA content was significantly altered in the blood cells of POI women. We recruited 101 women with an impaired ovarian reserve: 59 women with premature ovarian failure (POF) and 42 poor responders (PR) to OH. A Taqman copy number assay revealed a significant mtDNA depletion (P<0.001) in both POF and PR women in comparison with 43 women of similar age and intact ovarian reserve, or 53 very old women with a previous physiological menopause. No pathogenic variations in the mitochondrial DNA polymerase gamma (POLG) gene were detected in 57 POF or PR women with low blood mtDNA content. In conclusion, blood cell mtDNA depletion is a frequent finding among women with premature ovarian aging, suggesting that a still undetermined but generalized mitochondrial defect may frequently predispose to POI which could then be considered a form of anticipated aging in which the ovarian defect may represent the first manifestation. The determination of mtDNA content in blood may become an useful tool for the POI risk prediction.
C1 [Bonomi, Marco; Busnelli, Marta; Persani, Luca] Fdn Ist Ricovero & Cura Carattere Sci Ist Auxol I, Lab Ric Endocrinometab E, Milan, Italy.
   [Cacciatore, Chiara; Persani, Luca] Fdn Ist Ricovero & Cura Carattere Sci Ist Auxol I, UO Med Gen Indirizzo Endocrinometab, Milan, Italy.
   [Somigliana, Edgardo; Bonetti, Silvia; Paffoni, Alessio; Ragni, Guido] Fdn Ist Ricovero & Cura Carattere Sci Ca Granda O, Ctr Sterilita, Milan, Italy.
   [Cacciatore, Chiara; Rossetti, Raffaella; Mari, Daniela; Persani, Luca] Univ Milan, Dipartimento Sci Clin & Comunita, Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan
RP Bonomi, M (corresponding author), Fdn Ist Ricovero & Cura Carattere Sci Ist Auxol I, Lab Ric Endocrinometab E, Milan, Italy.
EM luca.persani@unimi.it
FU Telethon Foundation - Italy [GGP09126A]; Istituto Auxologico Italiano, Italy [05C501]
CR BOLAND NI, 1993, BIOL REPROD, V48, P798, DOI 10.1095/biolreprod48.4.798
   Broekmans FJ, 2006, HUM REPROD UPDATE, V12, P685, DOI 10.1093/humupd/dml034
   Cree LM, 2008, DIABETOLOGIA, V51, P1440, DOI 10.1007/s00125-008-1054-4
   Davis CJ, 2000, HUM REPROD, V15, P2418, DOI 10.1093/humrep/15.11.2418
   de Boer EJ, 2003, HUM REPROD, V18, P1544, DOI 10.1093/humrep/deg278
   Dumollard R, 2007, CURR TOP DEV BIOL, V77, P21, DOI 10.1016/S0070-2153(06)77002-8
   Farhi J, 1997, HUM REPROD, V12, P241, DOI 10.1093/humrep/12.2.241
   Gagnon A, 2009, AM J HUM BIOL, V21, P533, DOI 10.1002/ajhb.20893
   Harris SE, 2009, MOL REPROD DEV, V76, P231, DOI 10.1002/mrd.20945
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   HUTCHINSON EW, 1991, GENETICS, V127, P729
   Jansen RPS, 1998, MOL CELL ENDOCRINOL, V145, P81, DOI 10.1016/S0303-7207(98)00173-7
   Johannsen DL, 2009, CURR OPIN PHARMACOL, V9, P780, DOI 10.1016/j.coph.2009.09.002
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lawson R, 2003, HUM REPROD, V18, P527, DOI 10.1093/humrep/deg101
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   May-Panloup P, 2005, HUM REPROD, V20, P593, DOI 10.1093/humrep/deh667
   May-Panloup P, 2007, CURR TOP DEV BIOL, V77, P51, DOI 10.1016/S0070-2153(06)77003-X
   Menshikova EV, 2006, J GERONTOL A-BIOL, V61, P534, DOI 10.1093/gerona/61.6.534
   Nelson LM, 2009, NEW ENGL J MED, V360, P606, DOI 10.1056/NEJMcp0808697
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Pang CY, 2008, FRONT BIOSCI-LANDMRK, V13, P3661, DOI 10.2741/2957
   Perls TT, 1997, NATURE, V389, P133, DOI 10.1038/38148
   Persani L, 2010, J MOL ENDOCRINOL, V45, P257, DOI 10.1677/JME-10-0070
   Persani L, 2009, J AUTOIMMUN, V33, P35, DOI 10.1016/j.jaut.2009.03.004
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.9.e45
   Rizzolio F, 2009, J MED GENET, V46, P585, DOI 10.1136/jmg.2007.056093
   Rossetti R, 2009, HUM MUTAT, V30, P804, DOI 10.1002/humu.20961
   Santos TA, 2006, FERTIL STERIL, V85, P584, DOI 10.1016/j.fertnstert.2005.09.017
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Shoubridge EA, 2007, CURR TOP DEV BIOL, V77, P87, DOI 10.1016/S0070-2153(06)77004-1
   Simpson JL, 2008, ANN NY ACAD SCI, V1135, P146, DOI 10.1196/annals.1429.019
   Smith KR, 2009, J GERONTOL A-BIOL, V64, P740, DOI 10.1093/gerona/glp055
   Spikings EC, 2007, BIOL REPROD, V76, P327, DOI 10.1095/biolreprod.106.054536
   Tatone C, 2006, MOL HUM REPROD, V12, P655, DOI 10.1093/molehr/gal080
   Tong ZB, 2010, FERTIL STERIL, V94, P2932, DOI 10.1016/j.fertnstert.2010.06.049
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trinei M, 2006, BBA-BIOENERGETICS, V1757, P624, DOI 10.1016/j.bbabio.2006.05.029
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VANBLERKOM J, 1995, HUM REPROD, V10, P415, DOI 10.1093/oxfordjournals.humrep.a135954
   Vegetti W, 2000, MOL CELL ENDOCRINOL, V161, P53, DOI 10.1016/S0303-7207(99)00224-5
   Wai T, 2010, BIOL REPROD, V83, P52, DOI 10.1095/biolreprod.109.080887
   Welt CK, 2008, CLIN ENDOCRINOL, V68, P499, DOI 10.1111/j.1365-2265.2007.03073.x
   Wycherley G, 2005, HUM REPROD, V20, P2757, DOI 10.1093/humrep/dei132
NR 45
TC 39
Z9 46
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD AUG 3
PY 2012
VL 7
IS 8
BP 
EP 
DI 10.1371/journal.pone.0042423
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 985QT
UT WOS:000307284100086
PM 22879975
DA 2024-11-01
ER

PT J
AU Li, J
   Liu, XL
   Wang, HY
   Zhang, WP
   Chan, DC
   Shi, YG
AF Li, Jia
   Liu, Xiaolei
   Wang, Huayan
   Zhang, Weiping
   Chan, David C.
   Shi, Yuguang
TI Lysocardiolipin acyltransferase 1 (ALCAT1) controls mitochondrial DNA fidelity and biogenesis through modulation of MFN2 expression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
ID human skeletal-muscle; endoplasmic-reticulum; oxidative stress; cardiolipin; fusion; obesity; dysfunction; lipidomics; mitofusins; fission
AB Oxidative stress causes mitochondrial fragmentation and dysfunction in age-related diseases through unknown mechanisms. Cardiolipin (CL) is a phospholipid required for mitochondrial oxidative phosphorylation. The function of CL is determined by its acyl composition, which is significantly altered by the onset of age-related diseases. Here, we examine a role of acyl-CoA: lysocardiolipin acyltransferase lysocardiolipin acyltransferase 1 (ALCAT1), a lysocardiolipin acyltransferase that catalyzes pathological CL remodeling, in mitochondrial biogenesis. We show that overexpression of ALCAT1 causes mitochondrial fragmentation through oxidative stress and depletion of mitofusin mitofusin 2 (MFN2) expression. Strikingly, ALCAT1 overexpression also leads to mtDNA instability and depletion that are reminiscent of MFN2 deficiency. Accordingly, expression of MFN2 completely rescues mitochondrial fusion defect and respiratory dysfunction. Furthermore, ablation of ALCAT1 prevents mitochondrial fragmentation from oxidative stress by up-regulating MFN2 expression, mtDNA copy number, and mtDNA fidelity. Together, these findings reveal an unexpected role of CL remodeling in mitochondrial biogenesis, linking oxidative stress by ALCAT1 to mitochondrial fusion defect.
C1 [Li, Jia; Wang, Huayan] NW A&F Univ, Shaanxi Ctr Stem Cell Engn & Technol, Yangling 712100, Shaanxi, Peoples R China.
   [Li, Jia; Liu, Xiaolei; Shi, Yuguang] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.
   [Liu, Xiaolei] Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410078, Hunan, Peoples R China.
   [Zhang, Weiping] Second Mil Med Univ, Dept Pathophysiol, Shanghai 200433, Peoples R China.
   [Chan, David C.] CALTECH, Howard Hughes Med Inst, Div Biol, Pasadena, CA 91125 USA.
C3 Northwest A&F University - China; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Central South University; Naval Medical University; Howard Hughes Medical Institute; California Institute of Technology
RP Shi, YG (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.
EM yus11@psu.edu
FU National Institutes of Health [DK076685, GM062967]; Chinese National Scholarship Council
CR Bach D, 2005, DIABETES, V54, P2685, DOI 10.2337/diabetes.54.9.2685
   Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200
   Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253
   Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168
   Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200
   Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200
   Cartoni R, 2005, J PHYSIOL-LONDON, V567, P349, DOI 10.1113/jphysiol.2005.092031
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Choi SY, 2006, NAT CELL BIOL, V8, P1255, DOI 10.1038/ncb1487
   Claypool SM, 2012, TRENDS BIOCHEM SCI, V37, P32, DOI 10.1016/j.tibs.2011.09.003
   de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534
   Edwards JL, 2010, DIABETOLOGIA, V53, P160, DOI 10.1007/s00125-009-1553-y
   Gebert N, 2009, CURR BIOL, V19, P2133, DOI 10.1016/j.cub.2009.10.074
   Haigis MC, 2010, MOL CELL, V40, P333, DOI 10.1016/j.molcel.2010.10.002
   Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200
   Han XL, 2007, BIOCHEMISTRY-US, V46, P6417, DOI 10.1021/bi7004015
   Hulbert AJ, 2007, PHYSIOL REV, V87, P1175, DOI 10.1152/physrev.00047.2006
   Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Lee HJ, 2006, LIPIDS HEALTH DIS, V5, P0, DOI 10.1186/1476-511X-5-2
   Li J, 2010, CELL METAB, V12, P154, DOI 10.1016/j.cmet.2010.07.003
   Molina AJA, 2009, DIABETES, V58, P2303, DOI 10.2337/db07-1781
   National Institute of Health, 1985, NIH PUBL, V8623, P0
   Paradies G, 2010, FREE RADICAL BIO MED, V48, P1286, DOI 10.1016/j.freeradbiomed.2010.02.020
   Peng TI, 2004, ANN NY ACAD SCI, V1011, P112, DOI 10.1196/annals.1293.012
   Sandra F, 2005, CANCER RES, V65, P8286, DOI 10.1158/0008-5472.CAN-04-1913
   Shenouda SM, 2011, CIRCULATION, V124, P444, DOI 10.1161/CIRCULATIONAHA.110.014506
   Shi YG, 2010, J BIOMED RES, V24, P6, DOI 10.1016/S1674-8301(10)60003-6
   Song ZY, 2009, MOL BIOL CELL, V20, P3525, DOI 10.1091/mbc.E09-03-0252
   Sparagna GC, 2009, J CARDIOVASC PHARM, V53, P290, DOI 10.1097/FJC.0b013e31819b5461
   Watkins SM, 1998, J LIPID RES, V39, P1583
   Yu TZ, 2008, CARDIOVASC RES, V79, P341, DOI 10.1093/cvr/cvn104
   Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103
NR 35
TC 75
Z9 79
U1 2
U2 23
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 1
PY 2012
VL 109
IS 18
BP 6975
EP 6980
DI 10.1073/pnas.1120043109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 936PI
UT WOS:000303602100047
PM 22509026
DA 2024-11-01
ER

PT J
AU Tonska, K
   Piekutowska-Abramczuk, D
   Kaliszewska, M
   Kowalski, P
   Tanska, A
   Bartnik, E
   Pronicka, E
   Krajewska-Walasek, M
AF Tonska, Katarzyna
   Piekutowska-Abramczuk, Dorota
   Kaliszewska, Magdalena
   Kowalski, Pawel
   Tanska, Anna
   Bartnik, Ewa
   Pronicka, Ewa
   Krajewska-Walasek, Malgorzata
TI Molecular investigations of mitochondrial deletions: Evaluating the usefulness of different genetic tests
SO GENE
LA English
DT Article
DE mtDNA deletions; MLPA; Mitochondrial diseases
ID multiple deletions; dna deletion; epidemiology; single
AB Deletions in mitochondrial DNA are a common cause of mitochondrial disorders. The molecular diagnosis of mtDNA deletions for years was based on Southern hybridization later replaced by PCR methods such as PCR with primers specific for a particular deletion (mainly the so-called common deletion of 4977 bp) and long PCR. In order to evaluate the usefulness of MLPA (Multiplex Ligation-dependent Probe Amplification) in molecular diagnosis of large scale mtDNA deletions we compare four diagnostic methods: Southern hybridization, PCR, long-PCR and MLPA in a group of 16 patients with suspected deletions. Analysis was performed on blood, muscle and in one case hepatic tissue DNA. The MLPA was not able to confirm all the deletions detected by PCR methods, but due to its relative ease of processing, minimal equipment, low costs and the additional possibility to detect frequent point mtDNA mutations in one assay it is worth considering as a screening method. We recommend to always confirm MLPA results by PCR methods. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Tonska, Katarzyna; Kaliszewska, Magdalena; Bartnik, Ewa] Univ Warsaw, Fac Biol, Inst Genet & Biotechnol, PL-02106 Warsaw, Poland.
   [Piekutowska-Abramczuk, Dorota; Kowalski, Pawel; Tanska, Anna; Krajewska-Walasek, Malgorzata] Childrens Mem Hlth Inst, Dept Med Genet, PL-04730 Warsaw, Poland.
   [Bartnik, Ewa] Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland.
   [Pronicka, Ewa] Childrens Mem Hlth Inst, Dept Metab Dis, PL-04730 Warsaw, Poland.
C3 University of Warsaw; Children's Memorial Health Institute; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; Children's Memorial Health Institute
RP Tonska, K (corresponding author), Univ Warsaw, Fac Biol, Inst Genet & Biotechnol, Ul Pawinskiego 5A, PL-02106 Warsaw, Poland.
EM kaska@igib.uw.edu.pl
FU CMHI [S111/2009]; National Science Centre [NN407285739, NN401049238]
CR Bank C, 2000, BIOCHEM BIOPH RES CO, V279, P595, DOI 10.1006/bbrc.2000.3951
   Carrozzo R, 1999, J NEUROL SCI, V170, P24, DOI 10.1016/S0022-510X(99)00193-8
   Chen T, 2011, J HUM GENET, V56, P689, DOI 10.1038/jhg.2011.97
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Deschauer M, 2004, GENET TEST, V8, P395, DOI 10.1089/gte.2004.8.395
   Ferreira M, 2011, NEUROMUSCULAR DISORD, V21, P483, DOI 10.1016/j.nmd.2011.03.011
   Kierdaszuk B, 2009, NEUROL NEUROCHIR POL, V43, P216
   Kleinle S, 1997, HUM GENET, V100, P643, DOI 10.1007/s004390050567
   Kozlowski P, 2008, ELECTROPHORESIS, V29, P4627, DOI 10.1002/elps.200800126
   Kwon MJ, 2011, ANN CLIN LAB SCI, V41, P385
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Mierzewska H, 2010, ANN DIGAN PAEDIAT PA, V14, P11
   MITOMAP, 2011, HUM MIT GEN DAT, V0, P0
   Sadikovic B, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0015687
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Soong N W, 1996, METHODS ENZYMOL, V264, P421, DOI 10.1016/S0076-6879(96)64038-5
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   van Veghel-Plandsoen MM, 2011, EUR J HUM GENET, V19, P1009, DOI 10.1038/ejhg.2011.60
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
NR 20
TC 8
Z9 8
U1 0
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD SEP 10
PY 2012
VL 506
IS 1
BP 161
EP 165
DI 10.1016/j.gene.2012.06.081
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 998SJ
UT WOS:000308260400024
PM 22766397
DA 2024-11-01
ER

PT J
AU Götz, A
   Isohanni, P
   Liljeström, B
   Rummukainen, J
   Nikolajev, K
   Herrgård, E
   Marjavaara, S
   Suomalainen, A
AF Gotz, Alexandra
   Isohanni, Pirjo
   Liljestrom, Brita
   Rummukainen, Jaana
   Nikolajev, Kari
   Herrgard, Eila
   Marjavaara, Sanna
   Suomalainen, Anu
TI Fatal neonatal lactic acidosis caused by a novel <i>de novo</i> mitochondrial G7453A tRNA-Serine<SUP>(UCN)</SUP> mutation
SO PEDIATRIC RESEARCH
LA English
DT Article
ID trna(ser(ucn)) gene; point mutation; transfer-rnas; purifying selection; leigh-syndrome; dna mutations; disease; mtdna; prevalence; defects
AB INTRODUCTION: Heteroplasmic mitochondrial DNA (mtDNA) mutations are an important cause of childhood disorders, but the role of homoplasmic mtDNA mutations in severe neonatal manifestations is not well understood. METHODS: The following were performed: full mtDNA sequencing for mutation detection, blue-native protein analysis of autopsy-derived tissues to detect respiratory chain (RC) deficiency, light and electron microscopy for morphologic analysis, and northern blot and computational modeling to study the effect of mtDNA mutations on transfer RNA (tRNA) stability. RESULTS: We describe data from a patient with fatal neonatal lactic acidosis caused by a novel homoplasmic mutation at a highly conserved nucleotide G7453A within the tRNA(ser (UCN)) in mtDNA. The patient's heart, skeletal muscle, brain, and liver showed severe combined complex I and IV (Cl and CIV) deficiencies, accompanied by severe depletion of mature tRNA(ser (UCN)). The mutation was absent in the patient's mother and in a placental sample from a subsequent pregnancy of the mother, suggesting a de novo mutation. DISCUSSION: We conclude that the G7453A mutation of mtDNA manifests with exceptional severity as compared with other tRNA(ser (UCN)) mutations, typically associated with sensorineural deafness. De novo homoplasmic mtDNA tRNA-mutations should be considered as a cause of fatal neonatal lactic acidosis.
C1 [Gotz, Alexandra; Isohanni, Pirjo; Marjavaara, Sanna; Suomalainen, Anu] Univ Helsinki, Res Programs Unit, Biomedicum Helsinki, Helsinki, Finland.
   [Isohanni, Pirjo] Univ Helsinki, Cent Hosp, Dept Gynaecol & Pediat, Hosp Children & Adolescents, Helsinki, Finland.
   [Liljestrom, Brita] Kuopio Univ Hosp, Dept Clin Genet, SF-70210 Kuopio, Finland.
   [Rummukainen, Jaana] Kuopio Univ Hosp, Dept Pathol, SF-70210 Kuopio, Finland.
   [Nikolajev, Kari; Herrgard, Eila] Kuopio Univ Hosp, Dept Pediat, SF-70210 Kuopio, Finland.
   [Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Eastern Finland; Kuopio University Hospital; Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Res Programs Unit, Biomedicum Helsinki, Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
FU Sigrid Juselius Foundation; Jane and Aatos Erkko Foundation; Academy of Finland; University of Helsinki; Helsinki University Central Hospital; Graduate School of Biotechnology and Molecular Biology; Finnish Cultural Foundation; Maud Kuistila Memorial Foundation
CR Bidooki S, 2004, NEUROMUSCULAR DISORD, V14, P417, DOI 10.1016/j.nmd.2004.03.004
   Degoul F, 1995, J INHERIT METAB DIS, V18, P682, DOI 10.1007/BF02436757
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5
   Nagao Asuteka, 2007, NUCLEIC ACIDS SYMP SER (OXF), V0, P41
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   Ohtsuki T, 2007, IUBMB LIFE, V59, P68, DOI 10.1080/15216540701218722
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Stewart JB, 2008, NAT REV GENET, V9, P657, DOI 10.1038/nrg2396
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   TULINIUS MH, 1995, HUM GENET, V96, P290
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62
NR 24
TC 14
Z9 15
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 
J9 PEDIATR RES
JI Pediatr. Res.
PD JUL 15
PY 2012
VL 72
IS 1
BP 90
EP 94
DI 10.1038/pr.2012.43
PG 5
WC Pediatrics
SC Pediatrics
GA 961BY
UT WOS:000305440100014
PM 22453297
DA 2024-11-01
ER

PT J
AU Bekheirnia, MR
   Zhang, W
   Eble, T
   Willis, A
   Shaibani, A
   Wong, LJC
   Scaglia, F
   Dhar, SU
AF Bekheirnia, Mir Reza
   Zhang, Wei
   Eble, Tanya
   Willis, Alecia
   Shaibani, Aziz
   Wong, Lee-Jun C.
   Scaglia, Fernando
   Dhar, Shweta U.
TI <i>POLG</i> mutation in a patient with cataracts, early-onset distal muscle weakness and atrophy, ovarian dysgenesis and 3-methylglutaconic aciduria
SO GENE
LA English
DT Article
DE POLG; 3-Methylglutaconic aciduria; Muscle weakness; Cataracts; Ovarian dysgenesis
ID mitochondrial-dna polymerase; depletion; spectrum
AB Mutations in POLG account for one of the most frequent nuclear encoded causes of mitochondrial disorders to date. Individuals harboring POLG mutations exhibit fairly heterogeneous clinical presentations leading to increasing difficulties in classifying these patients into defined clinical phenotypes. This study aims to investigate the molecular basis of a mitochondrial cytopathy in a patient with 3-methylglutaconic aciduria and to expand the clinical phenotype associated with POLG mutations. Clinical, molecular and genetic analyses as well as neurophysiological examinations were carried out for a 23-year-old woman of mixed Caucasian and Latin American ancestry with a history of cataracts diagnosed at age 1year, she had onset of distal muscle weakness at age 2years progressing to atrophy and ovarian dysgenesis at puberty. The patient was found to have 3-methylglutaconic acid with normal 3 hydroxyisovaleric acid on urine organic acid analysis. POLG sequencing was done and a heterozygous variant, c.2851T>A (p.Y951N) was found which is predicted to be deleterious. There are limited reports of POLG mutations in individuals with 3-methylglutaconic aciduria. This case report of a young woman with a heterozygous mutation in POLG, presenting with muscle weakness and atrophy at a young age aims to aid clinicians in similar challenging diagnostic situations as well as enhances our understanding of POLG-related disease phenotypes. Published by Elsevier B.V.
C1 [Bekheirnia, Mir Reza; Zhang, Wei; Eble, Tanya; Willis, Alecia; Wong, Lee-Jun C.; Scaglia, Fernando; Dhar, Shweta U.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Shaibani, Aziz; Dhar, Shweta U.] Nerve & Muscle Ctr Texas, Houston, TX USA.
   [Shaibani, Aziz] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine
RP Dhar, SU (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1709 Dryden Rd,Rm 17-20, Houston, TX 77030 USA.
EM dhar@bcm.edu
CR Atiq M, 2004, INDIAN JOURNAL OF PEDIATRICS, V71, P437, DOI 10.1007/BF02725636
   Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Giordano C, 2010, ARCH NEUROL-CHICAGO, V67, P1144, DOI 10.1001/archneurol.2010.200
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Gunay-Aygun M, 2005, MOL GENET METAB, V84, P1, DOI 10.1016/j.ymgme.2004.12.003
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Ledig S, 2010, SEX DEV, V4, P225, DOI 10.1159/000314958
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   REDDY VN, 1988, OPHTHALMIC RES, V20, P191, DOI 10.1159/000266585
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tong ZB, 2010, FERTIL STERIL, V94, P2932, DOI 10.1016/j.fertnstert.2010.06.049
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Wortmann SB, 2009, BRAIN, V132, P136, DOI 10.1093/brain/awn296
NR 24
TC 15
Z9 16
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAY 10
PY 2012
VL 499
IS 1
BP 209
EP 212
DI 10.1016/j.gene.2012.02.034
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA 936WT
UT WOS:000303621400032
PM 22405928
DA 2024-11-01
ER

PT J
AU Phadke, M
   Lokeshwar, MR
   Bhutada, S
   Tampi, C
   Saxena, R
   Kohli, S
   Shah, KN
AF Phadke, Meghana
   Lokeshwar, M. R.
   Bhutada, Shraddha
   Tampi, Chandralekha
   Saxena, Renu
   Kohli, Sudha
   Shah, K. N.
TI RETRACTED: Kearns Sayre Syndrome-Case Report with Review of Literature (Retracted article. See vol. 80, pg. 982, 2013)
SO INDIAN JOURNAL OF PEDIATRICS
LA English
DT Article; Retracted Publication
DE Kearns-Sayre's syndrome; CPEO (Chronic progressive external ophthalmoplegia with myopathy); Chronic progressive external ophthalmoplegia with ragged red fibers; Oculo cranio somatic neuromuscular disease with ragged red fibers
ID mitochondrial-dna; heart block; ophthalmoplegia; deletion
AB Kearns-Sayre Syndrome is form of rare mitochondrial cytopathy, first described by Thomas P. Kearns and George Pomeroy Sayre in 1958 and is characterized by progressive external opthalmoplegia, cardiac conduction block, pigmentary retinal degeneration, variable number of red ragged fibers on muscle biopsy. It presents before the child reaches the age of twenty. Kearns-Sayre syndrome may affect many organ systems and additional features may include myopathy, dystonia, bulbar symptoms in the form of dysarthria and nasal regurgitation and bilateral facial weakness. Endocrine abnormalities (e.g., diabetes, growth retardation/short stature, and hypoparathyroidism), bilateral sensorineural deafness, dementia, cataracts, and proximal renal tubular acidosis, skeletal muscle weakness (proximal more than distal) and exercise intolerance are additional features. Kearns Sayre Syndrome occurs as a result of large-scale single deletions (or rearrangements) of mitochondrial DNA (mtDNA), which is usually not inherited but occurs spontaneously, probably at the germ-cell level or very early in embryonic development. No disease-modifying therapy is available for Kearns-Sayre syndrome (KSS). Management is supportive vigilance for detection of associated problems. In the future, potential treatment in patients with Kearns-Sayre syndrome may attempt to inhibit mutant mtDNA replication or encourage replication of wild-type mtDNA.
C1 [Phadke, Meghana; Lokeshwar, M. R.; Bhutada, Shraddha; Shah, K. N.] Lilavati Hosp & Res Ctr, Dept Pediat, Mumbai, Maharashtra, India.
   [Saxena, Renu; Kohli, Sudha] Sir Gangaram Hosp, Ctr Med Genet, New Delhi, India.
   [Tampi, Chandralekha] Lilavati Hosp & Res Ctr, Dept Pathol, Mumbai, Maharashtra, India.
RP Lokeshwar, MR (corresponding author), 19A Shree Dattaguru Soc, Mumbai 400088, Maharashtra, India.
EM mrlokeshwar@gmail.com
CR Barragan-Campos Hector Manuel, 1999, ARCHIVOS DEL INSTITUTO DE CARDIOLOGIA DE MEXICO, V69, P559
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Carod-Artal FJ, 2006, NEUROLOGIA, V21, P357
   Chu BC, 1999, NEURORADIOLOGY, V41, P759, DOI 10.1007/s002340050838
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   FISCHELGHODSIAN N, 1992, PEDIATR RES, V31, P557, DOI 10.1203/00006450-199206000-00004
   Franco E, 1999, NEUROLOGIA, V9, P463
   Gregoratos Gabriel, 2002, CIRCULATION, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   JAGER BV, 1960, AM J MED, V29, P888, DOI 10.1016/0002-9343(60)90122-4
   Katsanos KH, 2001, AM J NEPHROL, V21, P150, DOI 10.1159/000046239
   KEARNS THOMAS P, 1965, TRANS AMER OPHTHALMOL SOC, V63, P559
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Lee K T, 2001, KAOHSIUNG J MED SCI, V17, P336
   Lertrit P, 1999, HUM GENET, V105, P127, DOI 10.1007/s004390051074
   LESTIENNE P, 1988, LANCET, V1, P885
   Mehndiratta MM, 2002, NEUROL INDIA, V50, P162
   OGASAHARA S, 1985, NEUROLOGY, V35, P372, DOI 10.1212/WNL.35.3.372
   Rajakannan, 2000, INDIAN J OPHTHALMOL, V48, P54
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   Usui M, 2002, KYOBU GEKA, V55, P1112
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 23
TC 15
Z9 15
U1 0
U2 23
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
SN 0019-5456
EI 0973-7693
J9 INDIAN J PEDIATR
JI Indian J. Pediatr.
PD MAY 15
PY 2012
VL 79
IS 5
BP 650
EP 654
DI 10.1007/s12098-011-0618-3
PG 5
WC Pediatrics
SC Pediatrics
GA 934XX
UT WOS:000303481200009
PM 22231766
DA 2024-11-01
ER

PT J
AU Leung, GPH
AF Leung, George P. H.
TI Iatrogenic Mitochondriopathies: A Recent Lesson from Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
SO ADVANCES IN MITOCHONDRIAL MEDICINE
LA English
DT Article; Book Chapter
DE NRTIs; Mitochondrial toxicity; Polymerase-gamma; DNA depletion; Reactive oxygen species
ID human-immunodeficiency-virus; hiv-infected patients; dna-polymerase-gamma; active antiretroviral therapy; chronic hepatitis-b; equilibrative nucleoside transporters; stimulated human-lymphocytes; rat-liver mitochondria; severe lactic-acidosis; tumor-necrosis-factor
AB The use of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has revolutionized the treatment of infection by human immunodeficiency virus (HIV) and hepatitis-B virus. NRTIs can suppress viral replication in the long-term, but possess significant toxicity that can seriously compromise treatment effectiveness. The major toxicity of NRTIs is mitochondrial toxicity. This manifests as serious side effects such as myopathy, peripheral neuropathy and lactic acidosis. In general, it is believed that the mitochondrial pathogenesis is closely related to the effect of NRTIs on mitochondrial DNA polymerase-g. Depletion and mutation of mitochondrial DNA during chronic NRTI therapy may lead to cellular respiratory dysfunction and release of reactive oxidative species, resulting in cellular damage. It is now apparent that the etiology is far more complex than originally thought. It appears to involve multiple mechanisms as well as host factors such as HIV per se, inborn mitochondrial mutation, and sex. Management of mitochondrial toxicity during NRTI therapy remains a challenge. Interruption of NRTI therapy and substitution of the causative agents with alternative better-tolerated NRTIs represents the mainstay of management for mitochondrial toxicity and its clinical manifestations. A range of pharmacological approaches has been proposed as treatments and prophylaxes.
C1 Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong
RP Leung, GPH (corresponding author), Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China.
EM gphleung@hkucc.hku.hk
CR Adani GL, 2005, AM J TRANSPLANT, V5, P634, DOI 10.1111/j.1600-6143.2005.00691.x
   Affandi JS, 2008, AIDS RES HUM RETROV, V24, P1281, DOI 10.1089/aid.2008.0045
   Al-Madhoun AS, 2004, MINI-REV MED CHEM, V4, P341
   Allaouchiche B, 1999, J ANTIMICROB CHEMOTH, V44, P137, DOI 10.1093/jac/44.1.137
   Amacher DE, 2005, CURR MED CHEM, V12, P1829, DOI 10.2174/0929867054546663
   Amarapurkar DN, 2007, WORLD J GASTROENTERO, V13, P6150, DOI 10.3748/wjg.13.6150
   Anderson PL, 2004, CLIN INFECT DIS, V38, P743, DOI 10.1086/381678
   Anderson PL, 2003, AIDS, V17, P2159, DOI 10.1097/00002030-200310170-00003
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Bailey CM, 2009, ANTIMICROB AGENTS CH, V53, P2610, DOI 10.1128/AAC.01659-08
   Baldwin SA, 2005, J BIOL CHEM, V280, P15880, DOI 10.1074/jbc.M414337200
   BALZARINI J, 1994, PHARM WORLD SCI, V16, P113, DOI 10.1007/BF01880662
   BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   Bani-Sadr F, 2005, JAIDS-J ACQ IMM DEF, V40, P47, DOI 10.1097/01.qai.0000174649.51084.46
   BARILE M, 1994, BIOCHEM PHARMACOL, V48, P1405, DOI 10.1016/0006-2952(94)90564-9
   Barile M, 1997, BIOCHEM PHARMACOL, V53, P913, DOI 10.1016/S0006-2952(96)00831-3
   BARRY M, 1994, AIDS, V8, PF1, DOI 10.1097/00002030-199408000-00002
   Behbahani H, 2000, J ACQ IMMUN DEF SYND, V25, P150, DOI 10.1097/00126334-200010010-00009
   Benbrik E, 1997, J NEUROL SCI, V149, P19, DOI 10.1016/S0022-510X(97)05376-8
   Birkus G, 2003, J VIRAL HEPATITIS, V10, P50, DOI 10.1046/j.1365-2893.2003.00399.x
   Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P1610, DOI 10.1128/AAC.46.5.1610-1613.2002
   BISSUEL F, 1994, J INTERN MED, V235, P367, DOI 10.1111/j.1365-2796.1994.tb01088.x
   Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0
   Bolhaar MG, 2007, CLIN INFECT DIS, V45, P254, DOI 10.1086/518976
   Bourdais J, 1996, J BIOL CHEM, V271, P7887, DOI 10.1074/jbc.271.14.7887
   BREMER J, 1990, J CLIN CHEM CLIN BIO, V28, P297
   Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620
   BRINKMAN K, 1999, AIDS REV, V1, P141
   Butt Adeel A, 2003, AIDS READ, V13, P344
   Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207
   Casademont J, 1996, BRAIN, V119, P1357, DOI 10.1093/brain/119.4.1357
   Cepeda JA, 2000, AIDS, V14, P332, DOI 10.1097/00002030-200002180-00022
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Chen R, 2000, BIOCHEM PHARMACOL, V60, P215, DOI 10.1016/S0006-2952(00)00334-8
   Cherry CL, 2006, JAIDS-J ACQ IMM DEF, V42, P435, DOI 10.1097/01.qai.0000224974.67962.ce
   Cherry CL, 2003, J CLIN VIROL, V26, P195, DOI 10.1016/S1386-6532(02)00118-X
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI 10.1097/00126334-200207010-00002
   Cihlar T, 2008, ANTIMICROB AGENTS CH, V52, P655, DOI 10.1128/AAC.01215-07
   Collier AC, 2003, TOXICOL APPL PHARM, V192, P164, DOI 10.1016/S0041-008X(03)00274-6
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Currier JS, 2007, CLIN INFECT DIS, V45, P261, DOI 10.1086/518977
   Dabis F, 2002, LANCET, V359, P2097, DOI 10.1016/S0140-6736(02)08909-2
   Dagan T, 2002, MITOCHONDRION, V1, P397, DOI 10.1016/S1567-7249(02)00003-X
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Dambrova M, 2002, TRENDS CARDIOVAS MED, V12, P275, DOI 10.1016/S1050-1738(02)00175-5
   De Clercq E, 2004, BIOCHEM PHARMACOL, V68, P2301, DOI 10.1016/j.bep.2004.07.039
   de la Asunción JG, 1998, J CLIN INVEST, V102, P4, DOI 10.1172/JCI1418
   Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998
   DOLIN R, 1995, ARCH INTERN MED, V155, P961, DOI 10.1001/archinte.155.9.961
   DOMANSKI MJ, 1995, J PEDIATR-US, V127, P137, DOI 10.1016/S0022-3476(95)70275-X
   Elimadi A, 1997, BRIT J PHARMACOL, V121, P1295, DOI 10.1038/sj.bjp.0701276
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099, DOI 10.1128/AAC.41.5.1099
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Famularo G, 1997, AIDS, V11, P185, DOI 10.1097/00002030-199702000-00008
   FICHTENBAUM CJ, 1995, J ACQ IMMUN DEF SYND, V10, P169, DOI 10.1097/00042560-199510020-00009
   Fleischer RD, 2009, J HEPATOL, V51, P787, DOI 10.1016/j.jhep.2009.06.011
   Fodale V, 2005, ANAESTHESIA, V60, P806, DOI 10.1111/j.1365-2044.2005.04208.x
   Foli A, 2001, AIDS, V15, P1687, DOI 10.1097/00002030-200109070-00012
   Fouty B, 1998, LANCET, V352, P291, DOI 10.1016/S0140-6736(05)60266-8
   Frank I, 2004, AIDS RES HUM RETROV, V20, P916, DOI 10.1089/aid.2004.20.916
   FRICK LW, 1988, BIOCHEM BIOPH RES CO, V154, P124, DOI 10.1016/0006-291X(88)90659-6
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   GAO WY, 1993, J CLIN INVEST, V91, P2326, DOI 10.1172/JCI116463
   GAO WY, 1994, J BIOL CHEM, V269, P12633
   Gattermann N, 2004, NUCLEOS NUCLEOT NUCL, V23, P1275, DOI 10.1081/NCN-200027545
   Gerschenson M, 2000, ANN NY ACAD SCI, V918, P269
   GERTNER E, 1989, AM J MED, V86, P814, DOI 10.1016/0002-9343(89)90478-6
   GODFRIED MH, 1993, AIDS, V7, P33, DOI 10.1097/00002030-199301000-00005
   Govindarajan R, 2009, AM J PHYSIOL-GASTR L, V296, PG910, DOI 10.1152/ajpgi.90672.2008
   GRAY NM, 1995, BIOCHEM PHARMACOL, V50, P1043, DOI 10.1016/0006-2952(95)96620-A
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Han HK, 1998, PHARMACEUT RES, V15, P1154, DOI 10.1023/A:1011919319810
   Hanes JW, 2008, ANTIMICROB AGENTS CH, V52, P253, DOI 10.1128/AAC.00778-07
   Hart AM, 2004, AIDS, V18, P1549, DOI 10.1097/01.aids.0000131354.14408.fb
   Hashimoto K, 1997, AIDS RES HUM RETROV, V13, P193, DOI 10.1089/aid.1997.13.193
   Hendrickson SL, 2009, JAIDS-J ACQ IMM DEF, V51, P111, DOI 10.1097/QAI.0b013e3181a324d6
   Hervey PS, 2000, DRUGS, V60, P447, DOI 10.2165/00003495-200060020-00015
   Hestdal K, 1997, BLOOD, V90, P2670, DOI 10.1182/blood.V90.7.2670.2670_2670_2679
   Hill A, 2007, EXPERT OPIN PHARMACO, V8, P679, DOI 10.1517/14656566.8.5.679
   Hoggard PG, 2002, AIDS, V16, P2439, DOI 10.1097/00002030-200212060-00009
   Hsu CH, 2007, ANTIMICROB AGENTS CH, V51, P1687, DOI 10.1128/AAC.01432-06
   Hulgan T, 2005, AIDS, V19, P1341, DOI 10.1097/01.aids.0000180786.02930.a1
   Hulgan T, 2008, J INFECT DIS, V197, P858, DOI 10.1086/528697
   Imaoka T, 2007, MOL PHARMACOL, V71, P619, DOI 10.1124/mol.106.028233
   Izzedine H, 2004, KIDNEY INT, V66, P1153, DOI 10.1111/j.1523-1755.2004.00866.x
   Izzedine H, 2009, NAT REV NEPHROL, V5, P564, DOI 10.1038/nrneph.2009.142
   JOHNSON MA, 1989, MOL PHARMACOL, V36, P291
   Jüllig M, 2000, EUR J BIOCHEM, V267, P5466, DOI 10.1046/j.1432-1327.2000.01607.x
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   KESTENS L, 1994, CLIN EXP IMMUNOL, V95, P436, DOI 10.1111/j.1365-2249.1994.tb07015.x
   Kewn S, 2000, BRIT J CLIN PHARMACO, V50, P597
   Klusa V, 2006, BASIC CLIN PHARMACOL, V99, P323, DOI 10.1111/j.1742-7843.2006.pto_543.x
   KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011
   Lai YR, 2004, J BIOL CHEM, V279, P4490, DOI 10.1074/jbc.M307938200
   Lam W, 2005, MOL PHARMACOL, V67, P408, DOI 10.1124/mol.104.007120
   Lebrecht D, 2008, ARTHRITIS RHEUM-US, V58, P318, DOI 10.1002/art.23235
   Lenzo NP, 1997, AIDS, V11, P1294, DOI 10.1097/00002030-199710001-00003
   Leung GPH, 2007, EXPERT OPIN DRUG MET, V3, P705, DOI 10.1517/17425225.3.5.705
   Leung S, 1999, CAN J PHYSIOL PHARM, V77, P625, DOI 10.1139/cjpp-77-8-625
   Lewis W, 2006, AIDS, V20, P675, DOI 10.1097/01.aids.0000216367.23325.58
   Lewis W, 2005, LAB INVEST, V85, P972, DOI 10.1038/labinvest.3700301
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Lichtenstein KA, 2005, CLIN INFECT DIS, V40, P148, DOI 10.1086/426076
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lipshultz SE, 2000, NEW ENGL J MED, V343, P759, DOI 10.1056/NEJM200009143431102
   Lonergan JT, 2004, JAIDS-J ACQ IMM DEF, V36, P935, DOI 10.1097/00126334-200408010-00007
   Lund KC, 2008, TOXICOL APPL PHARM, V226, P94, DOI 10.1016/j.taap.2007.08.015
   Lund Kaleb C, 2004, CARDIOVASC TOXICOL, V4, P217, DOI 10.1385/CT:4:3:217
   Lynx MD, 2009, ANTIMICROB AGENTS CH, V53, P1252, DOI 10.1128/AAC.01115-08
   Martin AM, 2003, AM J HUM GENET, V72, P549, DOI 10.1086/367849
   MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743
   Mazzucco CE, 2008, ANTIMICROB AGENTS CH, V52, P598, DOI 10.1128/AAC.01122-07
   McComsey G, 2005, JAIDS-J ACQ IMM DEF, V39, P181
   McComsey G, 2003, JAIDS-J ACQ IMM DEF, V33, P605, DOI 10.1097/00126334-200308150-00009
   McComsey G, 2002, AIDS, V16, P513, DOI 10.1097/00002030-200203080-00001
   McComsey GA, 2004, CLIN INFECT DIS, V38, P263, DOI 10.1086/380790
   McComsey GA, 2003, JAIDS-J ACQ IMM DEF, V34, P45, DOI 10.1097/00126334-200309010-00006
   McKee Edward E, 2004, CARDIOVASC TOXICOL, V4, P155, DOI 10.1385/CT:4:2:155
   MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702
   Meng QX, 2000, MUTAGENESIS, V15, P405, DOI 10.1093/mutage/15.5.405
   MERTA A, 1992, BIOCHEM PHARMACOL, V44, P2067, DOI 10.1016/0006-2952(92)90110-5
   Miller KD, 2000, ANN INTERN MED, V133, P192, DOI 10.7326/0003-4819-133-3-200008010-00010
   Miró O, 2004, JAIDS-J ACQ IMM DEF, V37, P1550, DOI 10.1097/00126334-200412150-00002
   MODICANAPOLITANO JS, 1993, BIOCHEM BIOPH RES CO, V194, P170, DOI 10.1006/bbrc.1993.1800
   Modrzejewski KA, 2004, ANN PHARMACOTHER, V38, P1006, DOI 10.1345/aph.1D302
   Mokrzycki MH, 2000, CLIN INFECT DIS, V30, P198, DOI 10.1086/313594
   Moore RD, 2000, AIDS, V14, P273, DOI 10.1097/00002030-200002180-00009
   Moreno A, 2004, ANTIVIR THER, V9, P133
   Moretti S, 2002, ANTIOXID REDOX SIGN, V4, P391, DOI 10.1089/15230860260196191
   Morris GW, 2009, BIOCHEM J, V422, P513, DOI 10.1042/BJ20082427
   Moyle G, 2005, ANTIVIR THER, V10, P0
   Moyle G, 2000, CLIN THER, V22, P911, DOI 10.1016/S0149-2918(00)80064-8
   Moyle GJ, 2002, AIDS, V16, P1341, DOI 10.1097/00002030-200207050-00005
   MUNCHPETERSEN B, 1984, MOL CELL BIOCHEM, V64, P173
   MUNCHPETERSEN B, 1977, BIOCHIM BIOPHYS ACTA, V478, P364, DOI 10.1016/0005-2787(77)90152-6
   Negredo E, 2009, CLIN INFECT DIS, V49, P892, DOI 10.1086/605440
   Opii WO, 2007, EXP NEUROL, V204, P29, DOI 10.1016/j.expneurol.2006.09.010
   Pan-Zhou XR, 2000, ANTIMICROB AGENTS CH, V44, P496, DOI 10.1128/AAC.44.3.496-503.2000
   Panel on Antiretroviral Guidelines for Adults and Adolescents, 2008, GUID US ANT AG HIV 1, V0, P139
   Peltier AC, 2006, DRUG SAFETY, V29, P23, DOI 10.2165/00002018-200629010-00002
   PERNO CF, 1992, BLOOD, V80, P995
   Ronan A, 2000, AIDS, V14, P615
   Rossi L, 1999, BIOCHEM J, V344, P915, DOI 10.1042/0264-6021:3440915
   Rylova SN, 2005, BIOCHEM PHARMACOL, V69, P951, DOI 10.1016/j.bcp.2004.12.010
   Rylova SN, 2007, BIOCHEM PHARMACOL, V74, P169, DOI 10.1016/j.bcp.2007.03.029
   SAKAMOTO S, 1984, CARCINOGENESIS, V5, P183, DOI 10.1093/carcin/5.2.183
   Sales SD, 2001, TOXICOL APPL PHARM, V177, P54, DOI 10.1006/taap.2001.9288
   Scadden DT, 1996, AIDS RES HUM RETROV, V12, P1151, DOI 10.1089/aid.1996.12.1151
   Schramm C, 1999, EUR J ANAESTH, V16, P733
   SEMINOMORA MC, 1994, LAB INVEST, V71, P773
   Setzer B, 2008, AM J PATHOL, V172, P681, DOI 10.2353/ajpath.2008.070613
   Shaer AJ, 2000, AM J NEPHROL, V20, P332, DOI 10.1159/000013610
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   Shiramizu B, 2003, JAIDS-J ACQ IMM DEF, V32, P370, DOI 10.1097/00126334-200304010-00004
   Skuta G, 1999, BIOCHEM PHARMACOL, V58, P1915, DOI 10.1016/S0006-2952(99)00282-8
   Smyth K, 2007, HIV MED, V8, P367, DOI 10.1111/j.1468-1293.2007.00478.x
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Sussman HE, 1999, MUTAT RES-FUND MOL M, V429, P249, DOI 10.1016/S0027-5107(99)00111-6
   Szabados E, 1999, FREE RADICAL BIO MED, V26, P309, DOI 10.1016/S0891-5849(98)00199-3
   Tanji N, 2001, HUM PATHOL, V32, P734, DOI 10.1053/hupa.2001.25586
   TESCO G, 1992, DEMENTIA, V3, P58, DOI 10.1159/000106995
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   TSAI CH, 1994, BIOCHEM PHARMACOL, V48, P1477, DOI 10.1016/0006-2952(94)90573-8
   Tuon FF, 2008, BRAZ J INFECT DIS, V12, P263, DOI 10.1590/S1413-86702008000400001
   Turriziani O, 2005, AIDS, V19, P473, DOI 10.1097/01.aids.0000162335.12815.12
   Uwai Y, 2007, PHARM RES, V24, P811, DOI 10.1007/s11095-006-9196-x
   Valenti D, 1999, FEBS LETT, V444, P291, DOI 10.1016/S0014-5793(99)00071-X
   Valenti D, 2002, BIOCHEM PHARMACOL, V64, P201, DOI 10.1016/S0006-2952(02)01065-1
   Van Huyen JPD, 2006, MODERN PATHOL, V19, P1277, DOI 10.1038/modpathol.3800652
   Velsor LW, 2004, TOXICOL APPL PHARM, V199, P10, DOI 10.1016/j.taap.2004.03.005
   Venhoff N, 2007, ANTIVIR THER, V12, P1075
   Vrouenraets SME, 2002, ANTIVIR THER, V7, P239
   Wada S, 2000, J PHARMACOL EXP THER, V294, P844
   Walker UA, 2005, ANTIVIR THER, V10, P0
   Walker UA, 2002, AIDS, V16, P2165, DOI 10.1097/00002030-200211080-00009
   Walker UA, 2004, HEPATOLOGY, V39, P311, DOI 10.1002/hep.20074
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375
   WIESNER RJ, 1992, BIOCHEM BIOPH RES CO, V183, P553, DOI 10.1016/0006-291X(92)90517-O
   Wu YS, 2009, MUTAT RES-FUND MOL M, V664, P28, DOI 10.1016/j.mrfmmm.2009.02.006
   Yamanaka G, 1999, ANTIMICROB AGENTS CH, V43, P190, DOI 10.1128/AAC.43.1.190
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zhang XS, 2008, WORLD J GASTROENTERO, V14, P3549, DOI 10.3748/wjg.14.3549
NR 189
TC 13
Z9 14
U1 0
U2 3
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PD JUN 15
PY 2012
VL 942
IS 
BP 347
EP 369
DI 10.1007/978-94-007-2869-1_16
PG 23
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA BA2RR
UT WOS:000333840200017
PM 22399431
DA 2024-11-01
ER

PT J
AU O'Callaghan, MD
   Emperador, S
   López-Gallardo, E
   Jou, C
   Buján, N
   Montero, R
   Garcia-Cazorla, A
   Gonzaga, D
   Ferrer, I
   Briones, P
   Ruiz-Pesini, E
   Pineda, M
   Artuch, R
   Montoya, J
AF del Mar O'Callaghan, Maria
   Emperador, Sonia
   Lopez-Gallardo, Ester
   Jou, Cristina
   Bujan, Nuria
   Montero, Raquel
   Garcia-Cazorla, Angels
   Gonzaga, Diana
   Ferrer, Isidre
   Briones, Paz
   Ruiz-Pesini, Eduardo
   Pineda, Merce
   Artuch, Rafael
   Montoya, Julio
TI New mitochondrial DNA mutations in tRNA associated with three severe encephalopamyopathic phenotypes: neonatal, infantile, and childhood onset
SO NEUROGENETICS
LA English
DT Article
DE Mitochondrial DNA; tRNA mutations; Homoplasmic mutations; Mitochondrial respiratory chain; Encephalopamyopathic phenotypes
ID respiratory-chain disorders; hypertrophic cardiomyopathy; disease; pathogenicity; penetrance; synthetase; deficiency; diagnosis; children; criteria
AB The reported cases showed clinical, biochemical, histopathological, and molecular features lending support to the hypothesis of a pathogenic effect of the detected mutations. Case 1 was a neonatal presentation who showed multiple mitochondrial respiratory chain enzyme defects in muscle associated with a new homoplasmic m.5514A > G transition in the tRNA(Trp) gene. Case 2 was a late infantile presentation who also showed mitochondrial respiratory chain enzyme deficiencies in muscle together with a new m.1643A > G tRNA(Val) mutation in homoplasmy. Case 3 showed a MERRF phenotype presented in childhood associated with the once previously reported m.15923A > G mutation in heteroplasmy in all the tissues studied.
C1 [del Mar O'Callaghan, Maria; Jou, Cristina; Montero, Raquel; Garcia-Cazorla, Angels; Gonzaga, Diana; Pineda, Merce; Artuch, Rafael] Hosp St Joan de Deu, Dept Pediat Neurol, Barcelona 08950, Spain.
   [del Mar O'Callaghan, Maria; Jou, Cristina; Montero, Raquel; Garcia-Cazorla, Angels; Gonzaga, Diana; Pineda, Merce; Artuch, Rafael] Hosp St Joan de Deu, Dept Pathol, Barcelona 08950, Spain.
   [del Mar O'Callaghan, Maria; Jou, Cristina; Montero, Raquel; Garcia-Cazorla, Angels; Gonzaga, Diana; Pineda, Merce; Artuch, Rafael] Hosp St Joan de Deu, Dept Clin Biochem, Barcelona 08950, Spain.
   [Emperador, Sonia; Lopez-Gallardo, Ester; Ruiz-Pesini, Eduardo; Montoya, Julio] Univ Zaragoza, Dept Bioquim Biol Mol & Celular, Inst Aragones Ciencias Salud, Zaragoza, Spain.
   [Ferrer, Isidre] Hosp Univ Bellvitge, Inst Neuropatol, Hosp Llobregat, Barcelona, Spain.
   [Bujan, Nuria; Briones, Paz] Corporacio Sanitaria Clin CSIC, Inst Bioquim Clin, Barcelona, Spain.
   [del Mar O'Callaghan, Maria; Emperador, Sonia; Lopez-Gallardo, Ester; Bujan, Nuria; Montero, Raquel; Garcia-Cazorla, Angels; Briones, Paz; Ruiz-Pesini, Eduardo; Pineda, Merce; Artuch, Rafael; Montoya, Julio] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain.
   [Briones, Paz] CSIC, Barcelona, Spain.
C3 University of Barcelona; University of Barcelona; University of Zaragoza; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III; Consejo Superior de Investigaciones Cientificas (CSIC)
RP O'Callaghan, MD (corresponding author), Hosp St Joan de Deu, Dept Pediat Neurol, Passeig St Joan de Deu 2, Barcelona 08950, Spain.
EM mocallaghan@hsjdbcn.org
FU Instituto de Salud Carlos III (ISCIII), Ministry of Science and Innovation (MICIN), Spain [PI080663, PI080264, PI1000662]; CIBERER; program Intensificacion de la Actividad Investigadora, of the ISCIII-MICIN
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   CASALI C, 1995, BIOCHEM BIOPH RES CO, V213, P588, DOI 10.1006/bbrc.1995.2172
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Diogo L, 2010, PEDIATR NEUROL, V42, P196, DOI 10.1016/j.pediatrneurol.2009.09.010
   Gibson K, 2008, PEDIATRICS, V122, P1003, DOI 10.1542/peds.2007-3502
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Montero R, 2008, CLIN BIOCHEM, V41, P697, DOI 10.1016/j.clinbiochem.2008.03.007
   Morava E, 2006, NEUROLOGY, V67, P1823, DOI 10.1212/01.wnl.0000244435.27645.54
   Naviaux RK, 2004, MITOCHONDRION, V4, P351, DOI 10.1016/j.mito.2004.07.002
   Perli E, 2012, HUM MOL GENET, V21, P85, DOI 10.1093/hmg/ddr440
   Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P3065, DOI 10.1093/nar/gkn147
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Saneto RP, 2008, MITOCHONDRION, V8, P396, DOI 10.1016/j.mito.2008.05.003
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Stickler DE, 2006, PEDIATR NEUROL, V34, P127, DOI 10.1016/j.pediatrneurol.2005.08.006
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   YOON KL, 1991, BIOCHEM BIOPH RES CO, V176, P1112, DOI 10.1016/0006-291X(91)90399-R
   YOON KL, 1993, PEDIATR RES, V33, P433, DOI 10.1203/00006450-199305000-00002
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 24
TC 18
Z9 18
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1364-6745
EI 1364-6753
J9 NEUROGENETICS
JI Neurogenetics
PD AUG 15
PY 2012
VL 13
IS 3
BP 245
EP 250
DI 10.1007/s10048-012-0322-0
PG 6
WC Genetics & Heredity; Clinical Neurology
SC Genetics & Heredity; Neurosciences & Neurology
GA 988WC
UT WOS:000307520500007
PM 22638997
DA 2024-11-01
ER

PT J
AU Catania, C
   Spitaleri, G
   Delmonte, A
   Giovannini, M
   Toffalorio, F
   Noberasco, C
   Bresolin, N
   Comi, G
   De Pas, T
AF Catania, Chiara
   Spitaleri, Gianluca
   Delmonte, Angelo
   Giovannini, Monica
   Toffalorio, Francesca
   Noberasco, Cristina
   Bresolin, Nereo
   Comi, Giacomo
   De Pas, Tommaso
TI Safety of Systemic Chemotherapy in a Patient With Mitochondrial Myopathy and Non-Small-Cell Lung Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID dna mutations; somatic mutations; breast-cancer; tumors; genome; prevention; carcinomas; cisplatin; variants; sequence
C1 [Catania, Chiara; Spitaleri, Gianluca; Delmonte, Angelo; Giovannini, Monica; Toffalorio, Francesca; Noberasco, Cristina; De Pas, Tommaso] European Inst Oncol, Milan, Italy.
   [Bresolin, Nereo; Comi, Giacomo] Univ Milan, Dino Ferrari Ctr, Ist Ric & Cura Carettere, Fdn Ca Granda,Sci Osped Maggiore Policlin, Milan, Italy.
C3 IRCCS European Institute of Oncology (IEO); University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Catania, C (corresponding author), European Inst Oncol, Milan, Italy.
CR Aleisa AM, 2007, CLIN EXP PHARMACOL P, V34, P1252, DOI 10.1111/j.1440-1681.2007.04714.x
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Carew Jennifer S, 2002, MOL CANCER, V1, P9, DOI 10.1186/1476-4598-1-9
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   GRIVELL LA, 1983, SCI AM, V248, P78, DOI 10.1038/scientificamerican0383-78
   dos Santos NAG, 2007, CHEM-BIOL INTERACT, V170, P177, DOI 10.1016/j.cbi.2007.07.014
   Langsjoen PH, 1997, MOL ASPECTS MED, V18, P0
   Liu VWS, 2001, CANCER RES, V61, P5998
   Máximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7
   Mythili Y, 2005, TOXICOLOGY, V215, P108, DOI 10.1016/j.tox.2005.07.001
   Nissim I, 2006, CANCER RES, V66, P7824, DOI 10.1158/0008-5472.CAN-06-1043
   Parrella P, 2001, CANCER RES, V61, P7623
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Sanchez-Cespedes M, 2001, CANCER RES, V61, P7015
   Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012
   Tan DJ, 2002, CANCER RES, V62, P972
   Walker UA, 2000, MED KLIN, V95, P689, DOI 10.1007/PL00002087
   Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537
NR 18
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 20
PY 2012
VL 30
IS 24
BP E226
EP E228
DI 10.1200/JCO.2011.40.1828
PG 3
WC Oncology
SC Oncology
GA 996JR
UT WOS:000308082300003
PM 22711848
DA 2024-11-01
ER

PT J
AU Taivassalo, T
   Ayyad, K
   Haller, RG
AF Taivassalo, Tanja
   Ayyad, Karen
   Haller, Ronald G.
TI Increased capillaries in mitochondrial myopathy: implications for the regulation of oxygen delivery
SO BRAIN
LA English
DT Article
DE mitochondrial DNA defects; skeletal muscle; angiogenesis; regulation of oxygen delivery; oxidative metabolism
ID quadriceps femoris muscle; human skeletal-muscle; exercise intolerance; metabolic myopathy; oxidative defect; angiogenesis; mutations; capacity; system; transcription
AB Human skeletal muscle respiratory chain defects restrict the ability of working muscle to extract oxygen from blood, and result in a hyperkinetic circulation during exercise in which oxygen delivery is excessive relative to oxygen uptake and oxygen levels within contracting muscle are abnormally high. To investigate the role of the muscle microcirculation in this anomalous circulatory response and possible implications for the regulation of muscle angiogenesis, we assessed muscle oxidative capacity during cycle exercise and determined capillary levels and distribution and vascular endothelial growth factor expression in quadriceps muscle biopsies in patients with mitochondrial myopathy attributable to heteroplasmic mitochondrial DNA mutations. We found that in patients with mitochondrial myopathy, muscle capillary levels were twice that of sedentary healthy subjects (3.0 +/- 0.9% compared with 1.4 +/- 0.3%, P < 0.001) despite the fact that oxygen utilization during peak cycle exercise was half that of control subjects (11.1 +/- 4.0 ml/kg/min compared with 20.7 +/- 7.9 ml/kg/min, P < 0.01); that capillary area was greatest in patients with the most severe muscle oxidative defects and was more than two times higher around muscle fibre segments with defective (i.e. cytochrome oxidase negative/succinic dehydrogenase-positive or 'ragged-red' fibres) compared with more preserved respiratory chain function; and that vascular endothelial growth factor expression paralleled capillary distribution. The increased muscle capillary levels in patients correlated directly (r(2) = 0.68, P < 0.05) with the severity of the mismatch between systemic oxygen delivery (cardiac output) and oxygen utilization during cycle exercise. Our results suggest that capillary growth is increased as a result of impaired muscle oxidative phosphorylation in mitochondrial myopathy, thus promoting increased blood flow to respiration-incompetent muscle fibres and a mismatch between oxygen delivery and utilization during exercise. Furthermore, the finding of high capillary levels despite elevated tissue oxygen levels during exercise in respiration-deficient muscle fibres implies that mitochondrial metabolism activates angiogenesis in skeletal muscle by a mechanism that is independent of hypoxia.
C1 [Taivassalo, Tanja; Ayyad, Karen; Haller, Ronald G.] Texas Hlth Presbyterian Hosp, Inst Exercise & Environm Med, Neuromuscular Ctr, Dallas, TX 75231 USA.
   [Taivassalo, Tanja] McGill Univ, Dept Kinesiol, Montreal, PQ H2W 1S4, Canada.
   [Haller, Ronald G.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA.
   [Ayyad, Karen; Haller, Ronald G.] N Texas VA Med Ctr, Div Neurol, Dallas, TX 75216 USA.
C3 McGill University; University of Texas System; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System
RP Haller, RG (corresponding author), Texas Hlth Presbyterian Hosp, Inst Exercise & Environm Med, Neuromuscular Ctr, 7232 Greenville Ave, Dallas, TX 75231 USA.
EM Ronald.Haller@UTSouthwestern.edu
FU National Institutes of Health [National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS)] [RO1-AR050597]; Muscular Dystrophy Association USA; Natural Sciences and Engineering Council of Canada (NSERC); Canadian Institutes of Health Research
CR ADAIR TH, 1990, AM J PHYSIOL, V259, PR393, DOI 10.1152/ajpregu.1990.259.3.R393
   Adhihetty PJ, 2007, AM J PHYSIOL-ENDOC M, V293, PE672, DOI 10.1152/ajpendo.00043.2007
   ANDERSEN P, 1977, J PHYSIOL-LONDON, V270, P677, DOI 10.1113/jphysiol.1977.sp011975
   Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   BANK W, 1994, ANN NEUROL, V36, P830, DOI 10.1002/ana.410360606
   Breen EC, 1996, J APPL PHYSIOL, V81, P355, DOI 10.1152/jappl.1996.81.1.355
   Brown GK, 1996, J INHERIT METAB DIS, V19, P553, DOI 10.1007/BF01799116
   CARPENTER S, 1978, NEUROLOGY, V28, P8, DOI 10.1212/WNL.28.1.8
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Grassi B, 2007, MUSCLE NERVE, V35, P510, DOI 10.1002/mus.20708
   GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x
   Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, PH679, DOI 10.1152/ajpheart.1999.276.2.H679
   HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135
   HALLER RG, 1991, J CLIN INVEST, V88, P1197, DOI 10.1172/JCI115422
   Hedges LV, 1985, PROCEDURE IDENTIFY O, V0, P0
   Hepple RT, 2000, MED SCI SPORT EXER, V32, P117
   Hepple RT, 1997, J APPL PHYSIOL, V82, P1305, DOI 10.1152/jappl.1997.82.4.1305
   INGJER F, 1978, ACTA PHYSIOL SCAND, V104, P238, DOI 10.1111/j.1748-1716.1978.tb06273.x
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   KLAUSEN K, 1981, ACTA PHYSIOL SCAND, V113, P9, DOI 10.1111/j.1748-1716.1981.tb06854.x
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Mathieu-Costello O, 2002, EXERC SPORT SCI REV, V30, P80, DOI 10.1097/00003677-200204000-00007
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Richardson RS, 2006, J PHYSIOL-LONDON, V571, P415, DOI 10.1113/jphysiol.2005.102327
   Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6
   STADHOUDERS AM, 1987, J INHERIT METAB DIS, V10, P62, DOI 10.1007/BF01812848
   Swalwell H, 2008, EUR J HUM GENET, V16, P1265, DOI 10.1038/ejhg.2008.65
   Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Tang K, 2004, PHYSIOL GENOMICS, V18, P63, DOI 10.1152/physiolgenomics.00023.2004
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
NR 34
TC 25
Z9 26
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD JAN 15
PY 2012
VL 135
IS 
BP 53
EP 61
DI 10.1093/brain/awr293
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 888ZX
UT WOS:000300044400014
PM 22232594
DA 2024-11-01
ER

PT J
AU Schrier, SA
   Wong, LJ
   Place, E
   Ji, JQ
   Pierce, EA
   Golden, J
   Santi, M
   Anninger, W
   Falk, MJ
AF Schrier, Samantha A.
   Wong, Lee-Jun
   Place, Emily
   Ji, Jack Q.
   Pierce, Eric A.
   Golden, Jeffrey
   Santi, Mariarita
   Anninger, William
   Falk, Marni J.
TI Mitochondrial tRNA-Serine (AGY) m. C12264T Mutation Causes Severe Multisystem Disease with Cataracts
SO DISCOVERY MEDICINE
LA English
DT Article
ID pearson-syndrome; lactic-acidosis; hearing-loss; complex-i; myopathy; gene; deficiency; eye
AB Progressive multisystem disease should invoke consideration of potential mitochondrial etiologies. Mitochondrial disease can affect any organ system at any time, particularly involving neurologic, cardiac, muscular, gastroenterologic, and/or ophthalmologic manifestations. We report here a 19-year-old Caucasian man who was followed since birth in multiple pediatric subspecialty clinics for myelomeningocele complications. However, he progressively developed a host of additional problems that were not readily attributable to his neural tube defect involving developmental, ophthalmologic, cardiac, muscular, endocrine, and intermediary metabolic manifestations. Clinical diagnostic testing limited to analysis for common point mutations and deletions in his blood mitochondrial DNA (mtDNA) was not revealing. Skeletal muscle biopsy revealed abnormal mitochondrial morphology and immunostaining, mitochondrial proliferation, and mildly reduced respiratory chain complex I-III activity. Whole mitochondrial genome sequencing analysis in muscle identified an apparently homoplasmic, novel, m. 12264C>T transition in the tRNA serine (AGY) gene. The pathogenicity of this mutation was supported by identification of it being present at low heteroplasmy load in his blood (34%) as well as in blood from his maternal grandmother (1%). The proband developed severe nuclear cataracts that proved to be homoplasmic for the pathogenic mtDNA m. 12264C>T mutation. This case highlights the value of pursuing whole mitochondrial genome sequencing in symptomatic tissues in the diagnostic evaluation of suspected mitochondrial disease. Furthermore, it is the first report to directly implicate a single mtDNA mutation in the pathogenesis of ocular cataracts and clearly illustrates the important contribution of normal metabolic activity to the function of the ocular lens. [Discovery Medicine 13(69):143-150, February 2012]
C1 [Schrier, Samantha A.; Place, Emily; Falk, Marni J.] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA.
   [Schrier, Samantha A.; Place, Emily; Pierce, Eric A.; Golden, Jeffrey; Santi, Mariarita; Anninger, William; Falk, Marni J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Wong, Lee-Jun; Ji, Jack Q.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Pierce, Eric A.] Massachusetts Eye & Ear Infirm, Ocular Genom Inst, Boston, MA 02114 USA.
   [Pierce, Eric A.; Anninger, William] Childrens Hosp Philadelphia, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Golden, Jeffrey; Santi, Mariarita] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Baylor College of Medicine; Harvard University; Massachusetts Eye & Ear Infirmary; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia
RP Falk, MJ (corresponding author), Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA.
EM falkm@email.chop.edu
FU National Institutes of Health [R03-DK082446]
CR Almousa R, 2009, OPHTHAL PLAST RECONS, V25, P366, DOI 10.1097/IOP.0b013e3181b2fd06
   Babizhayev MA, 2010, AM J THER, V0, P0
   Babizhayev MA, 2011, CELL BIOCHEM FUNCT, V29, P183, DOI 10.1002/cbf.1737
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   Cardaioli E, 2011, J NEUROL SCI, V303, P142, DOI 10.1016/j.jns.2010.12.020
   Churchill A, 2011, PHILOS T R SOC B, V366, P1234, DOI 10.1098/rstb.2010.0227
   CIULLA TA, 1995, J PEDIATR OPHTHALMOL, V32, P378
   Cursiefen C, 1998, AM J OPHTHALMOL, V125, P260, DOI 10.1016/S0002-9394(99)80105-6
   Di Rosa G, 2006, J INHERIT METAB DIS, V29, P546, DOI 10.1007/s10545-006-0279-y
   Fernandes J, 2006, INBORN METABOLIC DIS, VFourth, P0
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Graw J, 2009, MOL VIS, V15, P1881
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Ji Q, 2003, PROSTATE, V54, P275, DOI 10.1002/pros.10192
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Leveque M, 2007, EUR J HUM GENET, V15, P1145, DOI 10.1038/sj.ejhg.5201891
   Lou MF, 2003, PROG RETIN EYE RES, V22, P657, DOI 10.1016/S1350-9462(03)00050-8
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Mansergh FC, 1999, AM J HUM GENET, V64, P971, DOI 10.1086/302344
   Nicklas JA, 2006, J FORENSIC SCI, V51, P1005, DOI 10.1111/j.1556-4029.2006.00211.x
   Reddy MA, 2004, HUM MOL GENET, V13, P945, DOI 10.1093/hmg/ddh110
   RIBES A, 1993, J INHERIT METAB DIS, V16, P537, DOI 10.1007/BF00711675
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Schmidt W, 2008, MOL VIS, V14, P851
   Schrier SA, 2011, CURR OPIN OPHTHALMOL, V22, P325, DOI 10.1097/ICU.0b013e328349419d
   SENGERS RCA, 1975, J PEDIATR-US, V86, P873, DOI 10.1016/S0022-3476(75)80217-4
   Shutt TE, 2010, ENVIRON MOL MUTAGEN, V51, P360, DOI 10.1002/em.20571
   Tang XW, 2010, MOL GENET METAB, V100, P57, DOI 10.1016/j.ymgme.2010.01.008
   Vinson Joe A, 2006, PATHOPHYSIOLOGY, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   Wong LJC, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.040626
   Yarham K, 2010, WILEY INTERDISCIP RE, V1, P304
   Zaragoza MV, 2011, EUR J HUM GENET, V19, P200, DOI 10.1038/ejhg.2010.169
NR 34
TC 4
Z9 4
U1 0
U2 1
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD FEB 15
PY 2012
VL 13
IS 69
BP 143
EP 150
DI 
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 094PH
UT WOS:000315275800005
PM 22369973
DA 2024-11-01
ER

PT J
AU Escames, G
   López, LC
   García, JA
   García-Corzo, L
   Ortiz, F
   Acuña-Castroviejo, D
AF Escames, Germaine
   Carlos Lopez, Luis
   Antonio Garcia, Jose
   Garcia-Corzo, Laura
   Ortiz, Francisco
   Acuna-Castroviejo, Dario
TI Mitochondrial DNA and inflammatory diseases
SO HUMAN GENETICS
LA English
DT Review
ID nitric-oxide synthase; nonsteroidal antiinflammatory drugs; thioredoxin-interacting protein; embryonic stem-cells; nf-kappa-b; oxidative stress; amyloid-beta; parkinsons-disease; reactive oxygen; skeletal-muscle
AB Increasing experimental evidence supports a connection between inflammation and mitochondrial dysfunction. Both acute and chronic inflammatory diseases course with elevated free radicals production that may affect mitochondrial proteins, lipids, and mtDNA. The subsequent mitochondrial impairment produces more reactive oxygen species that further reduce the ATP generation, increasing the probability of cell death. Mitochondrial impairment in now considered a key factor in inflammation because (1) there are specific pathologies directly derived from mtDNA mutations, causing chronic inflammatory diseases such as neuromuscular and neurodegenerative disorders, (2) there are neurodegenerative, metabolic, and other inflammatory diseases in which their progression is accompanied by mitochondrial dysfunction, which is directly involved in the cell death. Recently, a direct implication of mitochondrial reactive oxygen species and, particularly, mtDNA in the innate immune response has been reported. Thus, the mitochondria should be considered targets for new therapies related to the treatment of acute and chronic inflammatory diseases, including the auto-inflammatory ones.
C1 [Escames, Germaine; Carlos Lopez, Luis; Antonio Garcia, Jose; Garcia-Corzo, Laura; Ortiz, Francisco; Acuna-Castroviejo, Dario] Univ Granada, Inst Biotecnol, Ctr Invest Biomed, Granada 18100, Spain.
   [Escames, Germaine; Carlos Lopez, Luis; Antonio Garcia, Jose; Garcia-Corzo, Laura; Ortiz, Francisco; Acuna-Castroviejo, Dario] Univ Granada, Dept Fisiol, Fac Med, Granada 18100, Spain.
C3 University of Granada; University of Granada
RP Acuña-Castroviejo, D (corresponding author), Univ Granada, Inst Biotecnol, Ctr Invest Biomed, Parque Tecnol Ciencias Salud,Ave Conocimiento S-N, Granada 18100, Spain.
EM dacuna@ugr.es
FU European Community [COQMITMEL-266691]; Ministerio de Ciencia e Innovacion, Spain [SAF200908315]; Consejeria de Economia, Innovacion y Ciencia, Junta de Andalucia [P10-CTS-6133, P07-CTS-03135, CTS-101]; Instituto de Salud Carlos III, Spain [RD06/0013/0008, PI08-1664]
CR Castroviejo DA, 2011, CURR TOP MED CHEM, V11, P221
   Acuña-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x
   Acuna-Castroviejo D, 2007, FRONT BIOSCI-LANDMRK, V12, P947, DOI 10.2741/2116
   Aganna E, 2002, ARTHRITIS RHEUM-US, V46, P2445, DOI 10.1002/art.10509
   Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9
   Aliev G, 2008, VASC HEALTH RISK MAN, V4, P721, DOI 10.2147/VHRM.S2608
   ALVAREZBUYLLA A, 1995, STEM CELLS, V13, P263, DOI 10.1002/stem.5530130307
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Angus DC, 2001, CRIT CARE MED, V29, PS109, DOI 10.1097/00003246-200107001-00035
   Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522
   Baharvand Hossein, 2003, REPROD BIOMED ONLINE, V7, P330
   Bartz RR, 2011, AM J RESP CRIT CARE, V183, P226, DOI 10.1164/rccm.200911-1709OC
   Biolo G, 2007, CRIT CARE MED, V35, PS591, DOI 10.1097/01.CCM.0000278913.19123.13
   Bogenhagen DF, 2010, EXP GERONTOL, V45, P473, DOI 10.1016/j.exger.2009.12.002
   Bolaños JP, 2006, ANTIOXID REDOX SIGN, V8, P955, DOI 10.1089/ars.2006.8.955
   Brealey David, 2002, LANCET (NORTH AMERICAN EDITION), V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3
   Brown TA, 2005, GENE DEV, V19, P2466, DOI 10.1101/gad.1352105
   Callahan LA, 2005, AM J RESP CRIT CARE, V172, P861, DOI 10.1164/rccm.200410-1344OC
   Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040
   Cardinali DP, 2010, CURR NEUROPHARMACOL, V8, P218, DOI 10.2174/157015910792246209
   Cardinali DR, 2011, NEUROENDOCRINOLOGY, V93, P133, DOI 10.1159/000324699
   Carretero M, 2009, J PINEAL RES, V47, P192, DOI 10.1111/j.1600-079X.2009.00700.x
   Caspersen C, 2005, FASEB J, V19, P2040, DOI 10.1096/fj.05-3735fje
   Cassel SL, 2009, SEMIN IMMUNOL, V21, P194, DOI 10.1016/j.smim.2009.05.002
   Castroviejo Dario Acuna, 2002, CURRENT TOPICS IN MEDICINAL CHEMISTRY, V2, P133, DOI 10.2174/1568026023394344
   Chahbouni M, 2010, J PINEAL RES, V48, P282, DOI 10.1111/j.1600-079X.2010.00752.x
   Chen DX, 2000, J NEUROSCI RES, V61, P225, DOI 10.1002/1097-4547(20000715)61:2<225::AID-JNR13>3.0.CO;2-0
   Chen JX, 2010, J ALZHEIMERS DIS, V20, PS569, DOI 10.3233/JAD-2010-100357
   Chen J, 2008, DIABETES, V57, P938, DOI 10.2337/db07-0715
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708
   Cho YM, 2006, BIOCHEM BIOPH RES CO, V348, P1472, DOI 10.1016/j.bbrc.2006.08.020
   Coto-Montes A, 2006, AUTOPHAGY, V2, P126, DOI 10.4161/auto.2.2.2351
   Crespo E, 1999, FASEB J, V13, P1537, DOI 10.1096/fasebj.13.12.1537
   Crimi E, 2006, FREE RADICAL BIO MED, V40, P398, DOI 10.1016/j.freeradbiomed.2005.10.054
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007
   Devi L, 2006, J NEUROSCI, V26, P9057, DOI 10.1523/JNEUROSCI.1469-06.2006
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   DiMauro S, 2010, ACTA MYOL, V29, P333
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Driver JA, 2011, BMJ-BRIT MED J, V342, P0, DOI 10.1136/bmj.d198
   Dunne A, 2011, BIOCHEM SOC T, V39, P669, DOI 10.1042/BST0390669
   Escames G, 2006, J PINEAL RES, V40, P71, DOI 10.1111/j.1600-079X.2005.00281.x
   Escames G, 2003, FASEB J, V17, P932, DOI 10.1096/fj.02-0692fje
   Escames G, 2007, FEBS J, V274, P2135, DOI 10.1111/j.1742-4658.2007.05755.x
   Escames G, 2006, J PHARM PHARMACOL, V58, P1153, DOI 10.1211/jpp.58.9.0001
   Escames G, 2010, CURR NEUROPHARMACOL, V8, P182, DOI 10.2174/157015910792246245
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Fike JR, 2009, SEMIN RADIAT ONCOL, V19, P122, DOI 10.1016/j.semradonc.2008.12.003
   Frazier AE, 2006, BIOL CHEM, V387, P1551, DOI 10.1515/BC.2006.193
   Fröjdö S, 2009, BBA-MOL BASIS DIS, V1792, P83, DOI 10.1016/j.bbadis.2008.10.019
   Fukui H, 2008, TRENDS NEUROSCI, V31, P251, DOI 10.1016/j.tins.2008.02.008
   Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   Galley HF, 2010, CRIT CARE, V14, P0, DOI 10.1186/cc9098
   Garcia JJ, 2010, NEUROBIOL A IN PRESS, V0, P0
   Goldstein BJ, 2005, DIABETES, V54, P311, DOI 10.2337/diabetes.54.2.311
   Haden DW, 2007, AM J RESP CRIT CARE, V176, P768, DOI 10.1164/rccm.200701-161OC
   Halberg F, 2005, BIOMED PHARMACOTHER, V59, PS192, DOI 10.1016/S0753-3322(05)80031-9
   Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785
   Hardeland R, 2009, J PINEAL RES, V47, P109, DOI 10.1111/j.1600-079X.2009.00701.x
   Hardy J, 2006, ANN NEUROL, V60, P389, DOI 10.1002/ana.21022
   HARRIS ED, 1992, FASEB J, V6, P2675, DOI 10.1096/fasebj.6.9.1612291
   Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756
   Holt IJ, 2007, MITOCHONDRION, V7, P311, DOI 10.1016/j.mito.2007.06.004
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Howell N, 2005, TRENDS GENET, V21, P583, DOI 10.1016/j.tig.2005.08.012
   Iborra FJ, 2004, BMC BIOL, V2, P0, DOI 10.1186/1741-7007-2-9
   Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5
   Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3
   Jou MJ, 2010, J PINEAL RES, V48, P20, DOI 10.1111/j.1600-079X.2009.00721.x
   Kennaway David J, 2002, CURRENT TOPICS IN MEDICINAL CHEMISTRY, V2, P199, DOI 10.2174/1568026023394380
   Khaldy H, 2003, NEUROBIOL AGING, V24, P491, DOI 10.1016/S0197-4580(02)00133-1
   Kienhöfer J, 2009, FASEB J, V23, P2034, DOI 10.1096/fj.08-113571
   Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900
   Kirby DM, 2009, CELL PROLIFERAT, V42, P413, DOI 10.1111/j.1365-2184.2009.00612.x
   Koziróg M, 2011, J PINEAL RES, V50, P261, DOI 10.1111/j.1600-079X.2010.00835.x
   Kubota T, 2010, MOD RHEUMATOL, V20, P213, DOI 10.1007/s10165-009-0271-0
   Lee HK, 1998, DIABETES RES CLIN PR, V42, P161, DOI 10.1016/S0168-8227(98)00110-7
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Liberatore GT, 1999, NAT MED, V5, P1403
   Lim S, 2010, ANN NY ACAD SCI, V1201, P166, DOI 10.1111/j.1749-6632.2010.05622.x
   Lonergan T, 2007, MITOCHONDRION, V7, P289, DOI 10.1016/j.mito.2007.05.002
   Lonergan T, 2006, J CELL PHYSIOL, V208, P149, DOI 10.1002/jcp.20641
   López A, 2009, J PINEAL RES, V46, P188, DOI 10.1111/j.1600-079X.2008.00647.x
   López LC, 2006, INT J BIOCHEM CELL B, V38, P267, DOI 10.1016/j.biocel.2005.09.008
   López LC, 2006, NEUROENDOCRINOL LETT, V27, P623
   Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066
   Manczak M, 2011, HUM MOL GENET, V20, P2495, DOI 10.1093/hmg/ddr139
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Mariathasan S, 2007, MICROBES INFECT, V9, P664, DOI 10.1016/j.micinf.2007.01.017
   Martí R, 2003, CLIN CHEM LAB MED, V41, P845, DOI 10.1515/CCLM.2003.128
   Martín M, 2002, INT J BIOCHEM CELL B, V34, P348, DOI 10.1016/S1357-2725(01)00138-8
   Martín M, 2000, FASEB J, V14, P1677
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Masters SL, 2009, ANNU REV IMMUNOL, V27, P621, DOI 10.1146/annurev.immunol.25.022106.141627
   McMorrow JP, 2011, BIOCHEM SOC T, V39, P688, DOI 10.1042/BST0390688
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151
   Müller WE, 2010, MOL NEUROBIOL, V41, P159, DOI 10.1007/s12035-010-8141-5
   Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423
   Neven B, 2008, NAT CLIN PRACT RHEUM, V4, P481, DOI 10.1038/ncprheum0874
   Nishikawa T, 2007, ANTIOXID REDOX SIGN, V9, P343, DOI 10.1089/ars.2006.1458
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Olcese JM, 2009, J PINEAL RES, V47, P82, DOI 10.1111/j.1600-079X.2009.00692.x
   Paradies G, 2010, J PINEAL RES, V48, P297, DOI 10.1111/j.1600-079X.2010.00759.x
   Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146
   Reddy PH, 2008, TRENDS MOL MED, V14, P45, DOI 10.1016/j.molmed.2007.12.002
   Reddy PH, 2008, NEUROMOL MED, V10, P291, DOI 10.1007/s12017-008-8044-z
   REITER RJ, 1980, INT J BIOMETEOROL, V24, P57, DOI 10.1007/BF02245542
   Rensing L, 2002, CHRONOBIOL INT, V19, P807, DOI 10.1081/CBI-120014569
   Roifman I, 2011, CAN J CARDIOL, V27, P174, DOI 10.1016/j.cjca.2010.12.040
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9
   Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003
   Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482
   SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X
   Siggins RW, 2008, INT J CLIN EXP MED, V1, P2
   Sonnen JA, 2010, NEUROLOGY, V75, P1203, DOI 10.1212/WNL.0b013e3181f52db1
   St John JC, 2005, CLONING STEM CELLS, V7, P141, DOI 10.1089/clo.2005.7.141
   Stienstra R, 2010, CELL METAB, V12, P593, DOI 10.1016/j.cmet.2010.11.011
   Stuart JA, 2005, FREE RADICAL BIO MED, V38, P737, DOI 10.1016/j.freeradbiomed.2004.12.003
   Suliman HB, 2005, FASEB J, V19, P1531, DOI 10.1096/fj.04-3500fje
   Suliman HB, 2004, CARDIOVASC RES, V64, P279, DOI 10.1016/j.cardiores.2004.07.005
   Suliman HB, 2003, AM J RESP CRIT CARE, V167, P570, DOI 10.1164/rccm.200206-518OC
   Svistunenko DA, 2006, BBA-BIOENERGETICS, V1757, P262, DOI 10.1016/j.bbabio.2006.03.007
   Sweeney E, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0009518
   Swerdlow RH, 2010, J ALZHEIMERS DIS, V20, PS265, DOI 10.3233/JAD-2010-100339
   Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x
   Tan DX, 2010, BIOL REV, V85, P607, DOI 10.1111/j.1469-185X.2009.00118.x
   Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje
   Tan DX, 1998, BIOCHEM BIOPH RES CO, V253, P614, DOI 10.1006/bbrc.1998.9826
   TAN DX, 1993, CANCER LETT, V70, P65, DOI 10.1016/0304-3835(93)90076-L
   Tang L, 1998, MOL CELL BIOCHEM, V178, P299, DOI 10.1023/A:1006815530519
   Tapias V, 2009, J NEUROSCI RES, V87, P3002, DOI 10.1002/jnr.22123
   Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788
   Tschopp J, 2011, EUR J IMMUNOL, V41, P1196, DOI 10.1002/eji.201141436
   Tsutsui H, 2010, GASTROENT RES PRACT, V2010, P0, DOI 10.1155/2010/641865
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Van Blerkom J, 2004, REPRODUCTION, V128, P269, DOI 10.1530/rep.1.00240
   Voloboueva LA, 2010, J NEUROSCI, V30, P12242, DOI 10.1523/JNEUROSCI.1752-10.2010
   Wang W, 2010, STEM CELLS, V28, P2195, DOI 10.1002/stem.542
   Wang XL, 2009, J NEUROCHEM, V109, P153, DOI 10.1111/j.1471-4159.2009.05867.x
   Wang XL, 2008, P NATL ACAD SCI USA, V105, P19318, DOI 10.1073/pnas.0804871105
   Wang YS, 2006, J BIOL CHEM, V281, P25791, DOI 10.1074/jbc.M604501200
   Yoo YM, 2010, J PINEAL RES, V48, P204, DOI 10.1111/j.1600-079X.2010.00744.x
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
   Zingarelli B, 2005, CRIT CARE MED, V33, PS414, DOI 10.1097/01.CCM.0000186079.88909.94
   Zingarelli B, 2003, CRIT CARE MED, V31, PS105, DOI 10.1097/00003246-200301001-00015
NR 158
TC 82
Z9 89
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD FEB 15
PY 2012
VL 131
IS 2
BP 161
EP 173
DI 10.1007/s00439-011-1057-y
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 876QQ
UT WOS:000299123000001
PM 21735170
DA 2024-11-01
ER

PT J
AU Cox, R
   Platt, J
   Chen, LC
   Tang, S
   Wong, LJ
   Enns, GM
AF Cox, Rachel
   Platt, Julia
   Chen, Li Chieh
   Tang, Sha
   Wong, Lee-Jun
   Enns, Gregory M.
TI Leigh syndrome caused by a novel m.4296G&gt;A mutation in mitochondrial tRNA isoleucine
SO MITOCHONDRION
LA English
DT Article
DE Leigh syndrome; tRNA isoleucine; Mitochondrial DNA mutation; Heteroplasmy
ID complex-i-deficiency; dna mutations; common-cause; disease; encephalopathy; disorders; children; adults; muscle
AB Leigh syndrome is a severe neurodegenerative disease with heterogeneous genetic etiology. We report a novel m.4296G>A variant in the mitochondrial tRNA isoleucine gene in a child with Leigh syndrome, mitochondrial proliferation, lactic acidosis, and abnormal respiratory chain enzymology. The variant is present at >75% heteroplasmy in blood and cultured fibroblasts from the proband, <5% in asymptomatic maternal relatives, and is absent in 3000 controls. It is located in the highly conserved anticodon region of tRNA(Ile) where three other pathogenic changes have been described. We conclude that there is strong evidence to classify m.4296G>A as a pathogenic mutation causing Leigh syndrome. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Cox, Rachel; Platt, Julia; Enns, Gregory M.] Lucile Packard Childrens Hosp, Div Med Genet, Dept Pediat, Stanford, CA 94305 USA.
   [Chen, Li Chieh; Tang, Sha; Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Lucile Packard Children's Hospital (LPCH); Baylor College of Medicine
RP Enns, GM (corresponding author), Lucile Packard Childrens Hosp, Div Med Genet, Dept Pediat, 300 Pasteur Dr,H-315, Stanford, CA 94305 USA.
EM greg.enns@stanford.edu
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Brautbar A, 2008, MOL GENET METAB, V94, P485, DOI 10.1016/j.ymgme.2008.04.004
   CAVANAGH JB, 1994, BRAIN, V117, P1357, DOI 10.1093/brain/117.6.1357
   Dahl HHM, 1998, AM J HUM GENET, V63, P1594, DOI 10.1086/302169
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Makino M, 2000, J HUM GENET, V45, P69, DOI 10.1007/s100380050014
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Shchelochkov OA, 2010, MOL GENET METAB, V101, P282, DOI 10.1016/j.ymgme.2010.07.012
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang J, 2011, CURR PROTOC HUM GENE, V68, P0
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Wong LJC, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.040626
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 25
TC 12
Z9 12
U1 1
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD MAR 15
PY 2012
VL 12
IS 2
BP 258
EP 261
DI 10.1016/j.mito.2011.09.006
PG 4
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 913VX
UT WOS:000301906600011
PM 21982779
DA 2024-11-01
ER

PT J
AU Jackson, CB
   Gallati, S
   Schaller, A
AF Jackson, Christopher B.
   Gallati, Sabina
   Schaller, Andre
TI qPCR-based mitochondrial DNA quantification: Influence of template DNA fragmentation on accuracy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mtDNA copy number; Real-time qPCR; DNA fragmentation; DNA degradation; Mitochondrial depletion; FFPE
ID polymerase-chain-reaction; real-time pcr; paraffin-embedded tissue; depletion syndrm; sequence; disease; rna; replication; degradation; extraction
AB Real-time PCR (qPCR) is the method of choice for quantification of mitochondrial DNA (mtDNA) by relative comparison of a nuclear to a mitochondrial locus. Quantitative abnormal mtDNA content is indicative of mitochondrial disorders and mostly confines in a tissue-specific manner. Thus handling of degradation-prone bioptic material is inevitable. We established a serial qPCR assay based on increasing amplicon size to measure degradation status of any DNA sample. Using this approach we can exclude erroneous mtDNA quantification due to degraded samples (e.g. long post-exicision time, autolytic processus, freeze-thaw cycles) and ensure abnormal DNA content measurements (e.g. depletion) in non-degraded patient material. By preparation of degraded DNA under controlled conditions using sonification and DNasel digestion we show that erroneous quantification is due to the different preservation qualities of the nuclear and the mitochondrial genome. This disparate degradation of the two genomes results in over- or underestimation of mtDNA copy number in degraded samples. Moreover, as analysis of defined archival tissue would allow to precise the molecular pathomechanism of mitochondrial disorders presenting with abnormal mtDNA content, we compared fresh frozen (FF) with formalin-fixed paraffin-embedded (FFPE) skeletal muscle tissue of the same sample. By extrapolation of measured decay constants for nuclear DNA (lambda(nDNA)) and mtDNA (lambda(mtDNA)) we present an approach to possibly correct measurements in degraded samples in the future. To our knowledge this is the first time different degradation impact of the two genomes is demonstrated and which evaluates systematically the impact of DNA degradation on quantification of mtDNA copy number. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Jackson, Christopher B.] Univ Bern, Inselspital, Dept Pediat, Div Human Genet, CH-3010 Bern, Switzerland.
   Univ Bern, Inselspital, Dept Clin Res, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern
RP Jackson, CB (corresponding author), Univ Bern, Inselspital, Dept Pediat, Div Human Genet, Freiburgstr, CH-3010 Bern, Switzerland.
EM Christopher.jackson@insel.ch; sabina.gallati@insel.ch; andre.schaller@insel.ch
FU Novartis Foundation for medical biological research; Vinetum Foundation; Gottfried and Julia Bangerter Foundation
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 2009, MITOCHONDRION, V9, P242, DOI 10.1016/j.mito.2009.02.006
   Antonov J, 2005, LAB INVEST, V85, P1040, DOI 10.1038/labinvest.3700303
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Bender K, 2004, FORENSIC SCI INT, V139, P135, DOI 10.1016/j.forsciint.2003.10.003
   Bhat HK, 2004, J BIOCHEM MOL TOXIC, V18, P180, DOI 10.1002/jbt.20024
   Cao W, 2003, CANCER DETECT PREV, V27, P397, DOI 10.1016/S0361-090X(03)00103-X
   Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Colotte M, 2009, ANAL BIOCH, V0, P0
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Coulter-Mackie MB, 1998, CLIN BIOCHEM, V31, P627, DOI 10.1016/S0009-9120(98)00074-5
   Coura R, 2005, J CLIN PATHOL, V58, P894, DOI 10.1136/jcp.2004.021352
   Cukier HN, 2009, ANAL BIOCHEM, V386, P288, DOI 10.1016/j.ab.2008.11.040
   Deagle Bruce E, 2006, FRONT ZOOL, V3, P11, DOI 10.1186/1742-9994-3-11
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Godfrey TE, 2000, J MOL DIAGN, V2, P84, DOI 10.1016/S1525-1578(10)60621-6
   Guo W, 2009, MITOCHONDRION, V9, P261, DOI 10.1016/j.mito.2009.03.003
   Heddi B, 2010, J MOL BIOL, V395, P123, DOI 10.1016/j.jmb.2009.10.023
   Lehmann U, 2001, METHODS, V25, P409, DOI 10.1006/meth.2001.1263
   MELGAR E, 1968, J BIOL CHEM, V243, P4409
   MITOMAP, 2009, MITOMAP HUM MIT GEN, V0, P0
   NASS MMK, 1966, P NATL ACAD SCI USA, V56, P1215, DOI 10.1073/pnas.56.4.1215
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.9.e45
   Pinti M, 2006, BBA-BIOENERGETICS, V1757, P700, DOI 10.1016/j.bbabio.2006.05.001
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Rutledge RG, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng093
   Schaller A, 2011, MITOCHONDRION, V11, P488, DOI 10.1016/j.mito.2011.01.005
   Schaller A, 2011, BMC NEUROL, V11, P0, DOI 10.1186/1471-2377-11-4
   Schwarz C, 2009, NUCLEIC ACIDS RES, V37, P3215, DOI 10.1093/nar/gkp159
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Süss B, 2009, J MICROBIOL METH, V76, P316, DOI 10.1016/j.mimet.2008.12.003
   Timmermans EC, 2006, CLIN CHEM, V52, P979, DOI 10.1373/clinchem.2005.062901
   Tuppen HA, 2009, BIOCH BIOPHYS ACTA, V0, P0
   Whelan JA, 2003, J IMMUNOL METHODS, V278, P261, DOI 10.1016/S0022-1759(03)00223-0
   Wong Lee-Jun C, 2006, V335, V0, P187
NR 38
TC 18
Z9 21
U1 0
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 6
PY 2012
VL 423
IS 3
BP 441
EP 447
DI 10.1016/j.bbrc.2012.05.121
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 976ZC
UT WOS:000306624900001
PM 22683632
DA 2024-11-01
ER

PT J
AU Lamperti, C
   Fang, MY
   Invernizzi, F
   Liu, XZ
   Wang, HR
   Zhang, Q
   Carrara, F
   Moroni, I
   Zeviani, M
   Zhang, JG
   Ghezzi, D
AF Lamperti, Costanza
   Fang, Mingyan
   Invernizzi, Federica
   Liu, Xuanzhu
   Wang, Hairong
   Zhang, Qing
   Carrara, Franco
   Moroni, Isabella
   Zeviani, Massimo
   Zhang, Jianguo
   Ghezzi, Daniele
TI A novel homozygous mutation in <i>SUCLA2</i> gene identified by exome sequencing
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Mitochondrial disorder; Encephalomyopathy; Mitochondrial DNA depletion; SUCLA2; Exome-sequencing
ID mitochondrial-dna depletion; succinyl-coa synthetases; deficiency; encephalomyopathy; expression; protein; kinase
AB Mitochondrial disorders with multiple mitochondrial respiratory chain (MRC) enzyme deficiency and depletion of mitochondrial DNA (mtDNA) are autosomal recessive conditions due to mutations in several nuclear genes necessary for proper mtDNA maintenance. In this report, we describe two Italian siblings presenting with encephalomyopathy and mtDNA depletion in muscle. By whole exome-sequencing and prioritization of candidate genes, we identified a novel homozygous missense mutation in the SUCLA2 gene in a highly conserved aminoacid residue. Although a recurrent mutation in the SUCLA2 gene is relatively frequent in the Faroe Islands, mutations in other populations are extremely rare. In contrast with what has been reported in other patients, methyl-malonic aciduria, a biomarker for this genetic defect, was absent in our proband and very mildly elevated in her affected sister. This report demonstrates that next-generation technologies, particularly exome-sequencing, are user friendly, powerful means for the identification of disease genes in genetically and clinically heterogeneous inherited conditions, such as mitochondrial disorders. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lamperti, Costanza; Invernizzi, Federica; Carrara, Franco; Zeviani, Massimo; Ghezzi, Daniele] Ist Ricovero & Cura Carattere Sci, Fdn Ist Neurol Carlo Besta, Unit Mol Neurogenet, I-20126 Milan, Italy.
   [Moroni, Isabella] Ist Ricovero & Cura Carattere Sci, Fdn Ist Neurol Carlo Besta, Div Child Neurol, I-20126 Milan, Italy.
   [Fang, Mingyan; Liu, Xuanzhu; Wang, Hairong; Zhang, Qing; Zhang, Jianguo] BGI Shenzhen, Shenzhen 518083, Guangdong, Peoples R China.
   [Zhang, Jianguo] Fudan Univ, T Life Res Ctr, Shanghai 200433, Peoples R China.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione IRCCS Istituto Neurologico Carlo Besta; Fondazione IRCCS Istituto Neurologico Carlo Besta; IRCCS Ca Granda Ospedale Maggiore Policlinico; Beijing Genomics Institute (BGI); Fudan University
RP Zhang, JG (corresponding author), Main Bldg,Floor 6, Shenzhen 518083, Peoples R China.
EM zhangjg@genomics.org.cn; dghezzi@istituto-besta.it
FU Pierfranco and Luisa Mariani Foundation of Italy; Fondazione Telethon [GGP11011, GPP10005]; CARIPLO [2011/0526]; Italian Ministry of Health [GR2010 - 2316392]; Italian Association of Mitochondrial Disease Patients and Families (Mitocon)
CR Becker J, 2011, AM J HUM GENET, V88, P362, DOI 10.1016/j.ajhg.2011.01.015
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   HECKMATT JZ, 1984, MUSCLE NERVE, V7, P594
   Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580
   Lambeth DO, 2004, J BIOL CHEM, V279, P36621, DOI 10.1074/jbc.M406884200
   Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336
   Li RQ, 2009, GENOME RES, V19, P1124, DOI 10.1101/gr.088013.108
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Miller C, 2011, BBA-MOL BASIS DIS, V1812, P625, DOI 10.1016/j.bbadis.2011.01.013
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Pippucci T, 2011, HUM HERED, V72, P45, DOI 10.1159/000330164
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2009, J INTERN MED, V265, P174, DOI 10.1111/j.1365-2796.2008.02059.x
NR 24
TC 35
Z9 38
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD NOV 15
PY 2012
VL 107
IS 3
BP 403
EP 408
DI 10.1016/j.ymgme.2012.08.020
PG 6
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 032LM
UT WOS:000310720200023
PM 23010432
DA 2024-11-01
ER

PT J
AU Wortmann, SB
   Champion, MP
   van den Heuvel, L
   Barth, H
   Trutnau, B
   Craig, K
   Lammens, M
   Schreuder, MF
   Taylor, RW
   Smeitink, JAM
   Wevers, RA
   Rodenburg, RJ
   Morava, E
AF Wortmann, Saskia B.
   Champion, Michael P.
   van den Heuvel, Lambert
   Barth, H.
   Trutnau, B.
   Craig, Kate
   Lammens, Martin
   Schreuder, Michiel F.
   Taylor, Robert W.
   Smeitink, Jan A. M.
   Wevers, Ron A.
   Rodenburg, Richard J.
   Morava, Eva
TI Mitochondrial DNA m.3242G &gt; A mutation, an under diagnosed cause of hypertrophic cardiomyopathy and renal tubular dysfunction?
SO EUROPEAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE CK elevation; Lipid myopathy; 3-Methylglutaconic aciduria; Muscular hypotonia; MELAS syndrome; Mitochondriopathy
ID kearns-sayre-syndrome; diabetes-mellitus; trna(leu(uur)) gene; lactic-acidosis; disorders; involvement; features; disease; patient
AB We present two new patients with the recently described mitochondrial m. 3242G > A mutation. Although the mutation is situated next to the well known m.3243A > G mutation, the most common alteration associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome, the clinical presentation is quite different, but characteristic. All three m. 3242G > A patients presented in the neonatal period with hypertrophic and dilated cardiomyopathy, generalized muscle hypotonia and lactic acidosis. Two additionally had creatine kinase elevation, renal tubular acidosis/dysfunction and showed a mild clinical course with a favourable psychomotor development. The third patient had more neurological involvement and died in infancy. The mutation occurred de novo in the two patients where maternal investigations were performed. The combination of hypertrophic cardiomyopathy and renal tubular acidosis/renal tubular dysfunction is clinically distinctive and may represent a separate entity. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Wortmann, Saskia B.; van den Heuvel, Lambert; Smeitink, Jan A. M.; Rodenburg, Richard J.; Morava, Eva] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders NCMD, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
   [Wortmann, Saskia B.; van den Heuvel, Lambert; Smeitink, Jan A. M.; Rodenburg, Richard J.; Morava, Eva] Radboud Univ Nijmegen, Med Ctr, Inst Genet & Metab Dis IGMD, NL-6500 HB Nijmegen, Netherlands.
   [Champion, Michael P.] Kings Coll Hosp London, Dept Paediat Metab Med, London, England.
   [Trutnau, B.] Nierenzentrum Kinder & Jugendliche, Marburg, Germany.
   [Craig, Kate; Taylor, Robert W.] Newcastle Univ, Sch Med, Mitochondrial Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Lammens, Martin] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands.
   [Schreuder, Michiel F.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Nephrol, NL-6500 HB Nijmegen, Netherlands.
   [Wevers, Ron A.] Radboud Univ Nijmegen, Med Ctr, Lab Genet Endocrine & Metab Dis LGEM, Dept Lab Med, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; King's College Hospital NHS Foundation Trust; King's College Hospital; Newcastle University - UK; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen
RP Wortmann, SB (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders NCMD, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
EM s.wortmann@cukz.umcn.nl
FU UK NHS
CR Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761
   Fornuskova D, 2008, BBA-MOL BASIS DIS, V1782, P317, DOI 10.1016/j.bbadis.2008.02.001
   Gattermann N, 2004, BLOOD, V103, P1499, DOI 10.1182/blood-2003-07-2446
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1990, J PEDIATR-US, V116, P904, DOI 10.1016/S0022-3476(05)80648-1
   Iwasaki N, 2001, J HUM GENET, V46, P330, DOI 10.1007/s100380170068
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Katsanos KH, 2001, AM J NEPHROL, V21, P150, DOI 10.1159/000046239
   Kishnani PS, 1996, EUR J PEDIATR, V155, P898
   MAJANDER A, 1991, PEDIATR RES, V30, P327, DOI 10.1203/00006450-199110000-00007
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   McFarland R, 2007, NEUROLOGY, V69, P911, DOI 10.1212/01.wnl.0000267843.10977.4a
   Mimaki M, 2009, MITOCHONDRION, V9, P115, DOI 10.1016/j.mito.2009.01.005
   Miyata R, 2007, AM J MED GENET A, V143A, P189, DOI 10.1002/ajmg.a.31584
   Olpin SE, 2001, J INHERIT METAB DIS, V24, P35, DOI 10.1023/A:1005694320063
   Oppenheim MLS, 2009, J INHERIT METAB DIS, V32, P269, DOI 10.1007/s10545-009-1061-8
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PintosMorell G, 1997, PEDIATR NEPHROL, V11, P386
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   Rötig A, 2003, J AM SOC NEPHROL, V14, P2995, DOI 10.1097/01.ASN.0000095481.24091.C9
   Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531
   TULINIUS MH, 1995, EUR J PEDIATR, V154, P35, DOI 10.1007/BF01972970
   Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025
   Wortmann SB, 2007, ACTA PAEDIATR, V96, P450, DOI 10.1111/j.1651-2227.2006.00158.x
NR 25
TC 24
Z9 28
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1769-7212
EI 
J9 EUR J MED GENET
JI Eur. J. Med. Genet.
PD OCT 15
PY 2012
VL 55
IS 10
BP 552
EP 556
DI 10.1016/j.ejmg.2012.06.002
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 019MI
UT WOS:000309743500010
PM 22781753
DA 2024-11-01
ER

PT J
AU Callegari, S
   Gregory, PA
   Sykes, MJ
   Bellon, J
   Andrews, S
   McKinnon, RA
   Lopes, MAD
AF Callegari, Sylvie
   Gregory, Philip A.
   Sykes, Matthew J.
   Bellon, Jennifer
   Andrews, Stuart
   McKinnon, Ross A.
   Lopes, Miguel A. de Barros
TI Polymorphisms in the Mitochondrial Ribosome Recycling Factor EF-G2mt/MEF2 Compromise Cell Respiratory Function and Increase Atorvastatin Toxicity
SO PLOS GENETICS
LA English
DT Article
ID coa reductase inhibitors; skeletal-muscle; yeast models; translation; dna; statins; mutations; impairment; myopathy; diseases
AB Mitochondrial translation, essential for synthesis of the electron transport chain complexes in the mitochondria, is governed by nuclear encoded genes. Polymorphisms within these genes are increasingly being implicated in disease and may also trigger adverse drug reactions. Statins, a class of HMG-CoA reductase inhibitors used to treat hypercholesterolemia, are among the most widely prescribed drugs in the world. However, a significant proportion of users suffer side effects of varying severity that commonly affect skeletal muscle. The mitochondria are one of the molecular targets of statins, and these drugs have been known to uncover otherwise silent mitochondrial mutations. Based on yeast genetic studies, we identify the mitochondrial translation factor MEF2 as a mediator of atorvastatin toxicity. The human ortholog of MEF2 is the Elongation Factor Gene (EF-G) 2, which has previously been shown to play a specific role in mitochondrial ribosome recycling. Using small interfering RNA (siRNA) silencing of expression in human cell lines, we demonstrate that the EF-G2mt gene is required for cell growth on galactose medium, signifying an essential role for this gene in aerobic respiration. Furthermore, EF-G2mt silenced cell lines have increased susceptibility to cell death in the presence of atorvastatin. Using yeast as a model, conserved amino acid variants, which arise from non-synonymous single nucleotide polymorphisms (SNPs) in the EF-G2mt gene, were generated in the yeast MEF2 gene. Although these mutations do not produce an obvious growth phenotype, three mutations reveal an atorvastatin-sensitive phenotype and further analysis uncovers a decreased respiratory capacity. These findings constitute the first reported phenotype associated with SNPs in the EF-G2mt gene and implicate the human EF-G2mt gene as a pharmacogenetic candidate gene for statin toxicity in humans.
C1 [Callegari, Sylvie; Sykes, Matthew J.; Andrews, Stuart; Lopes, Miguel A. de Barros] Univ S Australia, Sch Pharm & Med Sci, Div Hlth Sci, Adelaide, SA 5001, Australia.
   [Gregory, Philip A.] SA Pathol, Ctr Canc Biol, Div Human Immunol, Adelaide, SA, Australia.
   [Gregory, Philip A.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia.
   [Sykes, Matthew J.] Univ S Australia, Sansom Inst, Div Hlth Sci, Adelaide, SA 5001, Australia.
   [Bellon, Jennifer] Australian Wine Res Inst, Glen Osmond, SA, Australia.
   [McKinnon, Ross A.] Flinders Univ S Australia, Sch Med, Flinders Ctr Innovat Canc, Bedford Pk, SA 5042, Australia.
C3 University of South Australia; SA Pathology; Centre for Cancer Biology; University of Adelaide; University of South Australia; Australian Wine Research Institute; Flinders University South Australia
RP Callegari, S (corresponding author), Univ S Australia, Sch Pharm & Med Sci, Div Hlth Sci, Adelaide, SA 5001, Australia.
EM miguel.debarroslopes@unisa.edu.au
FU University of South Australia
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Antonicka H, 2010, AM J HUM GENET, V87, P115, DOI 10.1016/j.ajhg.2010.06.004
   Araki M, 2008, BIOCHEM BIOPH RES CO, V367, P462, DOI 10.1016/j.bbrc.2007.12.166
   Barrientos A, 2003, IUBMB LIFE, V55, P83, DOI 10.1080/1521654031000098122
   Baruffini E, 2010, MITOCHONDRION, V10, P183, DOI 10.1016/j.mito.2009.10.002
   Bergman M, 2003, J MUSCLE RES CELL M, V24, P417, DOI 10.1023/A:1027367022415
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Buettner C, 2008, J GEN INTERN MED, V23, P1182, DOI 10.1007/s11606-008-0636-7
   Callegari S, 2011, FEBS LETT, V585, P1140, DOI 10.1016/j.febslet.2011.03.022
   Callegari S, 2010, FEMS YEAST RES, V10, P188, DOI 10.1111/j.1567-1364.2009.00593.x
   CHARIOT P, 1993, AM J MED, V94, P109, DOI 10.1016/0002-9343(93)90129-D
   Chong PH, 2001, AM J MED, V111, P390, DOI 10.1016/S0002-9343(01)00870-1
   Christian B, 2009, MOL CELL, V35, P400, DOI 10.1016/j.molcel.2009.08.003
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   DePinieux G, 1996, BRIT J CLIN PHARMACO, V42, P333, DOI 10.1046/j.1365-2125.1996.04178.x
   Fowler DM, 2011, MOL BIOSYST, V7, P533, DOI 10.1039/c0mb00166j
   Gao N, 2007, J MOL BIOL, V374, P1345, DOI 10.1016/j.jmb.2007.10.021
   Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100
   Hammarsund M, 2001, HUM GENET, V109, P542, DOI 10.1007/s00439-001-0610-5
   Hansson S, 2005, FEBS LETT, V579, P4492, DOI 10.1016/j.febslet.2005.07.016
   Hillenmeyer ME, 2010, GENOME BIOL, V11, P0, DOI 10.1186/gb-2010-11-3-r30
   HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D
   Kaiser J, 2008, SCIENCE, V319, P395, DOI 10.1126/science.319.5862.395
   Kaufmann P, 2006, CELL MOL LIFE SCI, V63, P2415, DOI 10.1007/s00018-006-6235-z
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Liu ZC, 2006, ANNU REV GENET, V40, P159, DOI 10.1146/annurev.genet.40.110405.090613
   Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3
   Macreadie IG, 2006, FEMS MICROBIOL LETT, V262, P9, DOI 10.1111/j.1574-6968.2006.00370.x
   Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052
   Melo F, 1998, J MOL BIOL, V277, P1141, DOI 10.1006/jmbi.1998.1665
   Nishimoto T, 2003, BIOCHEM PHARMACOL, V66, P2133, DOI 10.1016/j.bcp.2003.08.011
   Oh J, 2007, LIPIDS HEALTH DIS, V6, P0, DOI 10.1186/1476-511X-6-7
   Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009
   REITZER LJ, 1979, J BIOL CHEM, V254, P2669
   Rinaldi T, 2010, FEMS YEAST RES, V10, P1006, DOI 10.1111/j.1567-1364.2010.00685.x
   Rodríguez-Enríquez S, 2001, EUR J BIOCHEM, V268, P2512, DOI 10.1046/j.1432-1327.2001.02140.x
   Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P5787, DOI 10.1093/nar/gkn576
   Schick BA, 2007, CLIN PHARMACOL THER, V81, P650, DOI 10.1038/sj.clpt.6100124
   Schwimmer Christine, 2006, BIOTECHNOLOGY JOURNAL, V1, P270, DOI 10.1002/biot.200500053
   Sirvent P, 2005, BIOCHEM BIOPH RES CO, V338, P1426, DOI 10.1016/j.bbrc.2005.10.108
   Sirvent P, 2005, BIOCHEM BIOPH RES CO, V329, P1067, DOI 10.1016/j.bbrc.2005.02.070
   Sirvent P, 2012, TOXICOL APPL PHARM, V259, P263, DOI 10.1016/j.taap.2012.01.008
   Smits P, 2010, J BIOMED BIOTECHNOL, V0, P0, DOI DOI 10.1155/2010/737385
   Storici F, 2003, P NATL ACAD SCI USA, V100, P14994, DOI 10.1073/pnas.2036296100
   Tay SKH, 2008, PEDIATR NEUROL, V39, P426, DOI 10.1016/j.pediatrneurol.2008.09.002
   Taylor SD, 2005, MOL BIOL CELL, V16, P3010, DOI 10.1091/mbc.E05-01-0053
   Thomas JE, 2007, EUR NEUROL, V57, P232, DOI 10.1159/000101287
   Towpik J, 2005, CELL MOL BIOL LETT, V10, P571
   Tsuboi M, 2009, MOL CELL, V35, P502, DOI 10.1016/j.molcel.2009.06.028
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Vergani L, 2000, NEUROMUSCULAR DISORD, V10, P454, DOI 10.1016/S0960-8966(00)00096-1
   Vladutiu GD, 2008, CURR OPIN RHEUMATOL, V20, P648, DOI 10.1097/BOR.0b013e328314b7b4
   Vladutiu GD, 2006, MUSCLE NERVE, V34, P153, DOI 10.1002/mus.20567
   Wagner BK, 2008, NAT BIOTECHNOL, V26, P343, DOI 10.1038/nbt1387
   Westwood FR, 2008, TOXICOL PATHOL, V36, P345, DOI 10.1177/0192623307311412
   Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901
   Wittmann C, 2003, BIOTECHNOL LETT, V25, P377, DOI 10.1023/A:1022402212537
NR 58
TC 5
Z9 5
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
EI 
J9 PLOS GENET
JI PLoS Genet.
PD JUN 15
PY 2012
VL 8
IS 6
BP 
EP 
DI 10.1371/journal.pgen.1002755
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 968EW
UT WOS:000305961000022
PM 22719265
DA 2024-11-01
ER

PT J
AU Mayr, JA
   Koch, J
   Fauth, C
   Zimmermann, FA
   Rauscher, C
   Zschocke, J
   Sperl, W
AF Mayr, Johannes A.
   Koch, Johannes
   Fauth, Christine
   Zimmermann, Franz A.
   Rauscher, Christian
   Zschocke, Johannes
   Sperl, Wolfgang
TI A 1.1 Million Base Pair X-Chromosomal Deletion Covering the <i>PDHA1</i> and <i>CDKL5</i> Genes in a Female Patient with West Syndrome and Pyruvate Oxidation Deficiency
SO NEUROPEDIATRICS
LA English
DT Article
DE pyruvate dehydrogenase complex deficiency; mitochondrial disease; epilepsy; CDKL5; X-inactivation
ID somatic mosaicism; dehydrogenase; mutations; disorder
AB Mutations in the X-linked E1 alpha subunit of the pyruvate dehydrogenase complex (PHDC) are the most frequent causes of PDHC deficiency. The clinical picture is heterogeneous depending on residual enzyme activity and X-inactivation. We report on a girl who presented at an age of 3 weeks with muscular hypotonia, vomiting, hyperlactatemia, microcephaly, enlarged ventricles, partial agenesis of the corpus callosum, and seizures. PDHA1 sequencing was normal in DNA from blood. In muscle, normal PDHC activity was measured while substrate oxidation rates revealed moderately diminished pyruvate oxidation. Quantitative PCR analysis revealed hemizygosity of the whole PDHA1 gene. Homozygosity mapping and determination of the breakpoint showed a 1.1 million base pair deletion on the X-chromosome including the CDKL5 and PDHA1 genes. The difficulty in the diagnosis of PDHC deficiency is evident: (1) enzyme activity can be normal depending on the X-inactivation; (2) large deletions can be missed by routine genetic analysis; and (3) only quantification of the PDHA1 gene content revealed the mutation in our patient. We recommend to revisit patients who are clinically suspicious for a mitochondrial disorder especially for hidden PDHA1 mutations, such as large deletions.
C1 [Mayr, Johannes A.; Koch, Johannes; Zimmermann, Franz A.; Rauscher, Christian; Sperl, Wolfgang] Paracelsus Med Univ, Dept Pediat, A-5020 Salzburg, Austria.
   [Fauth, Christine; Zschocke, Johannes] Med Univ Innsbruck, Dept Human Genet, Innsbruck, Austria.
C3 Paracelsus Private Medical University; Medical University of Innsbruck
RP Sperl, W (corresponding author), Paracelsus Med Univ, Univ Hosp Salzburg, Mullner Hauptstr 48, A-5020 Salzburg, Austria.
EM w.sperl@salk.at
FU Oesterreichische Nationalbank-Jubilaums-fonds [12568]; Vereinigung zur For-derung Padiatrischer Forschung und Fortbildung Salzburg
CR Bahi-Buisson N, 2008, BRAIN, V131, P2647, DOI 10.1093/brain/awn197
   Berger A, 2003, ACTA NEUROPATHOL, V105, P245, DOI 10.1007/s00401-002-0638-1
   Brivet M, 2005, MOL GENET METAB, V86, P456, DOI 10.1016/j.ymgme.2005.08.009
   BROWN RM, 1993, J MED GENET, V30, P177, DOI 10.1136/jmg.30.3.177
   Consortium TR, 1998, HUM MOL GENET, V7, P1185
   Hendrickx J, 1999, AM J HUM GENET, V64, P1541, DOI 10.1086/302399
   Liang JS, 2011, EPILEPSIA, V52, P1835, DOI 10.1111/j.1528-1167.2011.03174.x
   Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.3.CO;2-B
   Mayr JA, 2007, AM J HUM GENET, V80, P478, DOI 10.1086/511788
   Mayr JA, 2011, MOL GENET METAB, V103, P358, DOI 10.1016/j.ymgme.2011.04.010
   Mei D, 2010, EPILEPSIA, V51, P647, DOI 10.1111/j.1528-1167.2009.02308.x
   Okajima K, 2006, MOL GENET METAB, V87, P162, DOI 10.1016/j.ymgme.2005.09.023
   Quintana E, 2010, CLIN GENET, V77, P474, DOI 10.1111/j.1399-0004.2009.01313.x
   Ridout CK, 2008, HUM GENET, V124, P187, DOI 10.1007/s00439-008-0538-0
   Singer BH, 2010, MOL GENET METAB, V101, P87, DOI 10.1016/j.ymgme.2010.05.008
   SPERL W, 1993, ENZYME PROTEIN, V47, P37, DOI 10.1159/000468654
   Strassburg HM, 2006, NEUROPEDIATRICS, V37, P137, DOI 10.1055/s-2006-924555
   Weaving LS, 2004, AM J HUM GENET, V75, P1079, DOI 10.1086/426462
NR 18
TC 3
Z9 3
U1 0
U2 6
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0174-304X
EI 1439-1899
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD JUN 15
PY 2012
VL 43
IS 3
BP 130
EP 134
DI 10.1055/s-0032-1309308
PG 5
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 961NZ
UT WOS:000305473600002
PM 22473288
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Sciacco, M
   Bordoni, A
   Raimondi, M
   Ripolone, M
   Fassone, E
   Di Fonzo, A
   Rizzuti, M
   Ciscato, P
   Cosi, A
   Servida, M
   Moggio, M
   Corti, S
   Bresolin, N
   Comi, GP
AF Ronchi, Dario
   Sciacco, Monica
   Bordoni, Andreina
   Raimondi, Monika
   Ripolone, Michela
   Fassone, Elisa
   Di Fonzo, Alessio
   Rizzuti, Mafalda
   Ciscato, Patrizia
   Cosi, Alessandra
   Servida, Maura
   Moggio, Maurizio
   Corti, Stefania
   Bresolin, Nereo
   Comi, Giacomo P.
TI The novel mitochondrial <i>tRNA<SUP>Asn</SUP></i> gene mutation m.5709T&gt;C produces ophthalmoparesis and respiratory impairment
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE progressive external ophthalmoplegia; tRNA(Asn); mitochondrial myopathy
ID transfer-rna mutations; dna mutations; myopathy; ophthalmoplegia; disorders; failure; disease; muscle
AB Although mutations in mitochondrial tRNAs constitute the most common mtDNA defect, the presence of pathological variants in mitochondrial tRNA(Asn) is extremely rare. We were able to identify a novel mtDNA tRNA(Asn) gene pathogenic mutation associated with a myopathic phenotype and a previously unreported respiratory impairment. Our proband is an adult woman with ophthalmoparesis and respiratory impairment. Her muscle biopsy presented several cytochrome c oxidase-negative (COX-) fibres and signs of mitochondrial proliferation (ragged red fibres). Sequence analysis of the muscle-derived mtDNA revealed an m.5709T>C substitution, affecting mitochondrial tRNAAsn gene. Restriction-fragment length polymorphism analysis of the mutation in isolated muscle fibres showed that a threshold of at least 91.9% mutated mtDNA results in the COX deficiency phenotype. The new phenotype further increases the clinical spectrum of mitochondrial diseases caused by mutations in the tRNAAsn gene. European Journal of Human Genetics (2012) 20, 357-360; doi:10.1038/ejhg.2011.238; published online 21 December 2011
C1 [Ronchi, Dario; Sciacco, Monica; Bordoni, Andreina; Ripolone, Michela; Fassone, Elisa; Di Fonzo, Alessio; Rizzuti, Mafalda; Ciscato, Patrizia; Cosi, Alessandra; Servida, Maura; Moggio, Maurizio; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Neurol Sci, Dino Ferrari Ctr, I-20122 Milan, Italy.
   [Raimondi, Monika] Neuroctr So Switzerland, Dept Neurol, Lugano, Switzerland.
   [Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20122 Milan, Italy.
   [Bresolin, Nereo] IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; IRCCS Eugenio Medea
RP Comi, GP (corresponding author), Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Neurol Sci, Dino Ferrari Ctr, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
FU Telethon - UILDM [GUP09004]; Associazione Amici del Centro Dino Ferrari; University of Milan; Telethon [GTB07001]; Eurobiobank [QLTR-2001-02769, RF 02.187]
CR Coulbault L, 2005, BIOCHEM BIOPH RES CO, V329, P1152, DOI 10.1016/j.bbrc.2005.02.083
   CROS D, 1992, CHEST, V101, P824, DOI 10.1378/chest.101.3.824
   Hutchinson David, 2008, PRACT NEUROL, V8, P229, DOI 10.1136/pn.2008.152611
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Spinazzola A, 2004, NEUROMUSCULAR DISORD, V14, P815, DOI 10.1016/j.nmd.2004.09.002
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 17
TC 5
Z9 5
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD MAR 15
PY 2012
VL 20
IS 3
BP 357
EP 360
DI 10.1038/ejhg.2011.238
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 896XI
UT WOS:000300604300017
PM 22189266
DA 2024-11-01
ER

PT J
AU Sasarman, F
   Shoubridge, EA
AF Sasarman, Florin
   Shoubridge, Eric A.
TI Radioactive Labeling of Mitochondrial Translation Products in Cultured Cells
SO MITOCHONDRIAL DISORDERS: BIOCHEMICAL AND MOLECULAR ANALYSIS
LA English
DT Article; Book Chapter
DE Mitochondria; Oxidative Phosphorylation (OXPHOS); Mitochondrial DNA (mtDNA); Pulse-chase labeling; Mitochondrial translation
ID protein-synthesis; lactic-acidosis; melas mutation; hela-cells; myopathy; defects; encephalopathy; respiration; termination; deficiency
AB The mammalian mitochondrial genome contains 37 genes, 13 of which encode polypeptide subunits in the enzyme complexes of the oxidative phosphorylation system. The other genes encode the rRNAs and tRNAs necessary for their translation. The mitochondrial translation machinery is located in the mitochondrial matrix, and is exclusively dedicated to the synthesis of these 13 enzyme subunits. Mitochondrial disease in humans is often associated with defects in mitochondria! translation. This can manifest as a global decrease in the rate of mitochondrial protein synthesis, a decrease in the synthesis of specific polypeptides, the synthesis of abnormal polypeptides, or in altered stability of specific translation products. All of these changes in the normal pattern of mitochondrial translation can be assessed by a straightforward technique that takes advantage of he insensitivity of the mitochondrial translation machinery to antibiotics that completely inhibit cytoplasmic translation. Thus, specific radioactive labeling of the mitochondrial translation products can be achieved in cultured cells, and the results can be visualized on gradient gels. The analysis of mitochondrial translation in cells cultured from patient biopsies is useful in the study of disease-causing mutations in both the mitochondrial and the nuclear genomes.
C1 [Sasarman, Florin; Shoubridge, Eric A.] McGill Univ, Montreal Neurol Inst, Dept Human Genet, Montreal, PQ, Canada.
C3 McGill University
RP Sasarman, F (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Human Genet, Montreal, PQ, Canada.
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Antonicka H, 2010, AM J HUM GENET, V87, P115, DOI 10.1016/j.ajhg.2010.06.004
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   COSTANTINO P, 1977, J BIOL CHEM, V252, P1702
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Fernández-Silva P, 2007, METHOD CELL BIOL, V80, P571, DOI 10.1016/S0091-679X(06)80028-2
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Kemp JP, 2011, BRAIN, V134, P183, DOI 10.1093/brain/awq320
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   MARIOTTINI P, 1986, J BIOL CHEM, V261, P3355
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Sasarman F, 2008, HUM MOL GENET, V17, P3697, DOI 10.1093/hmg/ddn265
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
NR 20
TC 47
Z9 50
U1 0
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
EI 
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PD JUN 15
PY 2012
VL 837
IS 
BP 207
EP 217
DI 10.1007/978-1-61779-504-6_14
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BAG90
UT WOS:000304125100014
PM 22215550
DA 2024-11-01
ER

PT J
AU Yatsuga, S
   Povalko, N
   Nishioka, J
   Katayama, K
   Kakimoto, N
   Matsuishi, T
   Kakuma, T
   Koga, Y
AF Yatsuga, Shuichi
   Povalko, Nataliya
   Nishioka, Junko
   Katayama, Koju
   Kakimoto, Noriko
   Matsuishi, Toyojiro
   Kakuma, Tatsuyuki
   Koga, Yasutoshi
TI MELAS: A nationwide prospective cohort study of 96 patients in Japan
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE Prevalence; MELAS; Cohort study; Natural course; Survival curve; Severity of disease
ID stroke-like episodes; mitochondrial-dna mutations; lactic-acidosis; clinical-features; a3243g mutation; prevalence; epidemiology; disorders; disease; encephalopathy
AB Background: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (OMIM 540000) is the most dominant subtype of mitochondrial myopathy. The aim of this study was to determine the prevalence, natural course, and severity of MELAS. Methods: A prospective cohort study of 96 Japanese patients with MELAS was followed between June 2003 and April 2008. Patients with MELAS were identified and enrolled based on questionnaires administered to neurologists in Japan. MELAS was defined using the Japanese diagnostic criteria for MELAS. Two follow-up questionnaires were administered to neurologists managing MELAS patients at an interval of 5 years. Results: A prevalence of at least 0.58 (95% confidential interval (CI), 0.54-0.62)/100,000 was calculated for mitochondrial myopathy, whereas the prevalence of MELAS was 0.18 (95%CI, 0.02-0.34)/100,000 in the total population. MELAS patients were divided into two sub-groups: juvenile form and adult form. Stroke-like episodes, seizure and headache were the most frequent symptoms seen in both forms of MELAS. Short stature was significantly more frequent in the juvenile form, whereas hearing loss, cortical blindness and diabetes mellitus were significantly more frequent in the adult form. According to the Japanese mitochondrial disease rating scale, MELAS patients showed rapidly increasing scores (mean +/- standard deviation, 12.8 +/- 8.7) within 5 years from onset of the disease. According to a Kaplan-Meier analysis, the juvenile form was associated with a higher risk of death than the adult form (hazard ratio, 3.29; 95%CI, 1.32-8.20; p = 0.0105). Conclusions and General Significance: We confirmed that MELAS shows a rapid degenerative progression within a 5-year interval and that this occurs in both the juvenile and the adult forms of MELAS and follows different natural courses. This article is part of a Special Issue entitled: Biochemistry of Mitochondria. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Yatsuga, Shuichi; Povalko, Nataliya; Nishioka, Junko; Katayama, Koju; Kakimoto, Noriko; Matsuishi, Toyojiro; Koga, Yasutoshi] Kurume Univ, Grad Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 300011, Japan.
   [Kakuma, Tatsuyuki] Kurume Univ, Grad Sch Med, Dept Biostat, Kurume, Fukuoka 300011, Japan.
   [Yatsuga, Shuichi] Univ Helsinki, Res Program Mol Neurol, Biomedicum Helsinki, Helsinki, Finland.
C3 Kurume University; Kurume University; University of Helsinki
RP Koga, Y (corresponding author), Kurume Univ, Sch Med, Dept Pediat & Child Hlth, 67 Asahi Machi, Kurume, Fukuoka 300011, Japan.
EM yasukoga@med.kurume-u.ac.jp
FU Ministry of Culture and Education in Japan [13670853, 16390308]; Evidence-based Medicine, Ministry of Health, Labor and Welfare in Japan [CCT-B-1803]; Academy of Finland, the Center for International Mobility in Finland; Heiwa Research Foundation in Japan; Grants-in-Aid for Scientific Research [13670853, 16390308] Funding Source: KAKEN
CR Chinnery P F, 2003, NEUROMUSCUL DISORD, V13, P757, DOI 10.1016/S0960-8966(03)00097-X
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Di Mauro S, 1993, GENE REV, V0, P0
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Kaufmann P, 2009, ARCH NEUROL-CHICAGO, V66, P85, DOI 10.1001/archneurol.2008.526
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Koga Y, 2010, ANN NY ACAD SCI, V1201, P104, DOI 10.1111/j.1749-6632.2010.05624.x
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Phoenix C, 2006, NEUROMUSCULAR DISORD, V16, P814, DOI 10.1016/j.nmd.2006.08.006
   Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Skladal D, 2003, CLIN PEDIATR, V42, P703, DOI 10.1177/000992280304200806
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Sproule DM, 2007, ARCH NEUROL-CHICAGO, V64, P1625, DOI 10.1001/archneur.64.11.1625
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196
   VANDENOUWELAND JMW, 1995, MUSCLE NERVE, V0, PS124
NR 28
TC 188
Z9 217
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD MAY 15
PY 2012
VL 1820
IS 5
BP 619
EP 624
DI 10.1016/j.bbagen.2011.03.015
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 930JO
UT WOS:000303135900011
PM 21443929
DA 2024-11-01
ER

PT J
AU McKelvie, P
   Marotta, R
   Thorburn, DR
   Chin, J
   Punchihewa, S
   Collins, S
AF McKelvie, P.
   Marotta, R.
   Thorburn, D. R.
   Chin, J.
   Punchihewa, S.
   Collins, S.
TI A case of myelopathy, myopathy, peripheral neuropathy and subcortical grey matter degeneration associated with recessive compound heterozygous POLG1 mutations
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Compound heterozygous polymerase-gamma (POLO) mutations; Spinal cord degeneration; Dorsal column and dorsal spinocerebellar tract degeneration; Multiple mitochondrial DNA deletions; Peripheral neuropathy; Mitochondrial myopathy; COX-negative fibres; Ragged-red fibres; Substantia nigra degeneration; Thalamic degeneration; SANDO
ID progressive external ophthalmoplegia; sensory ataxic neuropathy; dna-polymerase-gamma; mitochondrial; sando
AB This 54 year old woman presented with symptoms of sensory ataxic neuropathy, with cerebellar features. She developed further weakness, visual disturbances with diplopia, dysarthria and dysphasia. After her death at 66 years, she was found to have compound heterozygous mutations of POLO I gene in muscle, and Southern blot showed low levels of multiple deletions of mitochondrial DNA. Neuropathological examination showed profound dorsal column and dorsal spinocerebellar tract degeneration, degeneration of dorsal root ganglia and Clarke's nucleus in spinal cord and severe predominantly sensory peripheral neuropathy. The brain showed severe neuronal loss and gliosis in substantia nigra, medial posterior thalamus and head of caudate. Excess numbers of COX-negative fibres and "ragged-red" fibres were found in five skeletal muscles sampled. (C) 2011 Elsevier B.V. All rights reserved.
C1 [McKelvie, P.] St Vincents Hosp Melbourne, Dept Anat Pathol, Fitzroy, Vic 3065, Australia.
   [Marotta, R.; Chin, J.; Punchihewa, S.; Collins, S.] St Vincents Hosp, St Vincents Melbourne Neuromuscular Diagnost Lab, Dept Clin Neurosci, Melbourne, Vic, Australia.
   [Thorburn, D. R.] Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Parkville, Vic 3052, Australia.
   [Thorburn, D. R.] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
C3 St Vincent's Health; St Vincent's Hospital Melbourne; NSW Health; St Vincents Hospital Sydney; St Vincent's Health; St Vincent's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute
RP McKelvie, P (corresponding author), St Vincents Hosp Melbourne, Dept Anat Pathol, POB 2900, Fitzroy, Vic 3065, Australia.
EM penny.mckelvie@svhm.org.au
CR Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Cottrell DA, 2000, J NEUROPATH EXP NEUR, V59, P621, DOI 10.1093/jnen/59.7.621
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hopkins SE, 2010, J CHILD NEUROL, V25, P752, DOI 10.1177/0883073809343313
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Okun MS, 2004, AM J OPHTHALMOL, V137, P951, DOI 10.1016/j.ajo.2003.10.046
   Sato K, 2011, J NEUROL, V258, P1327, DOI 10.1007/s00415-011-5936-x
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   vanDomburg PHMF, 1996, BRAIN, V119, P997, DOI 10.1093/brain/119.3.997
   Weiss MD, 2010, MUSCLE NERVE, V41, P882, DOI 10.1002/mus.21636
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 23
TC 8
Z9 8
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAY 15
PY 2012
VL 22
IS 5
BP 401
EP 405
DI 10.1016/j.nmd.2011.10.017
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 941OV
UT WOS:000303973400005
PM 22357363
DA 2024-11-01
ER

PT J
AU Heidari, MM
   Khatami, M
   Talebi, AR
AF Heidari, Mohammad Mehdi
   Khatami, Mehri
   Talebi, Ali Reza
TI The <i>POLG</i> Gene Polymorphism in Iranian Varicocele-Associated Infertility Patients
SO IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Article
DE CAG repeats length; Infertility; Mitochondria; POLG gene; Varicocele
ID mitochondrial-dna polymerase; progressive external ophthalmoplegia; cag repeat; gamma polg; men; mutations; spermatozoa; integrity; deletions
AB Objective(s) Varicocele is associated with impaired testicular function and male infertility, but the molecular mechanisms by which fertility is affected have not been satisfactorily explained. The aim of our study was to investigate whether or not the polymerase gamma (POLG) polymorphism is associated with Iranian varicocele patients. Materials and Methods We determined the POLG CAG repeat length in DNA samples extracted from 40 varicocele patients and 30 control subjects by PCR-denature polyacrylamide gel electrophoresis and sequencing. Results The distribution of the CAG repeat length in varicocele patients showed no notable difference from that in control subjects, but we found a significant statistical inverse correlation between 10/10 and 10/#10 genotypes and varicocele grade. Conclusion These findings indicate that POLG CAG repeats may affects the varicocele grade, but the mechanisms remain to be elucidated.
C1 [Heidari, Mohammad Mehdi; Khatami, Mehri] Yazd Univ, Sch Sci, Dept Biol, Yazd, Iran.
   [Talebi, Ali Reza] Shahid Sadughi Univ Med Sci, Res Clin Ctr Infertil, Dept Anat, Yazd, Iran.
C3 University of Yazd
RP Heidari, MM (corresponding author), Yazd Univ, Sch Sci, Dept Biol, Yazd, Iran.
EM Heidarimm@yazduni.ac.ir
FU Yazd University
CR Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   Allamaneni SSR, 2004, FERTIL STERIL, V82, P1684, DOI 10.1016/j.fertnstert.2004.04.071
   [Anonymous], 2008, FERTIL STERIL, V90, P0
   [Anonymous], 1999, WHO LABORATORY MANUAL FOR THE EXAMINATION OF HUMAN SEMEN AND SPERM-CERVICAL MUCUS INTERACTION, V0, P0
   BERTAZZONI U, 1977, EUR J BIOCHEM, V81, P237, DOI 10.1111/j.1432-1033.1977.tb11945.x
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Heidari M, 2008, NEUROL SCI, V29, P489, DOI 10.1007/s10072-008-1026-y
   Jarow JP, 1996, UROLOGY, V47, P73, DOI 10.1016/S0090-4295(99)80385-9
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   Kumar R, 2009, INDIAN J BIOCHEM BIO, V46, P172
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   MIEUSSET R, 1995, INT J ANDROL, V18, P169, DOI 10.1111/j.1365-2605.1995.tb00408.x
   Moro E, 2000, MOL CELL ENDOCRINOL, V161, P67, DOI 10.1016/S0303-7207(99)00226-9
   Rani DS, 2006, FERTIL STERIL, V86, P1783, DOI 10.1016/j.fertnstert.2006.04.044
   Richens J, 2004, BRIT MED J, V328, P1251, DOI 10.1136/bmj.328.7450.1251
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio A, 1999, EUR J HUM GENET, V7, P140, DOI 10.1038/sj.ejhg.5200244
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   St John JC, 2001, MOL HUM REPROD, V7, P103, DOI 10.1093/molehr/7.1.103
   Talebi AR, 2008, ANDROLOGIA, V40, P245, DOI 10.1111/j.1439-0272.2008.00852.x
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Zini A, 2005, HUM REPROD, V20, P1018, DOI 10.1093/humrep/deh701
   Zullo SJ, 1997, CYTOGENET CELL GENET, V78, P281, DOI 10.1159/000134672
NR 25
TC 11
Z9 11
U1 0
U2 2
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN
SN 2008-3866
EI 
J9 IRAN J BASIC MED SCI
JI Iran. J. Basic Med. Sci.
PD MAR-APR 15
PY 2012
VL 15
IS 2
BP 739
EP 744
DI 
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 918OG
UT WOS:000302259000007
PM 23493802
DA 2024-11-01
ER

PT J
AU Craig, K
   Young, MJ
   Blakely, EL
   Longley, MJ
   Turnbull, DM
   Copeland, WC
   Taylor, RW
AF Craig, Kate
   Young, Matthew J.
   Blakely, Emma L.
   Longley, Matthew J.
   Turnbull, Douglass M.
   Copeland, William C.
   Taylor, Robert W.
TI A p.R369G <i>POLG2</i> mutation associated with adPEO and multiple mtDNA deletions causes decreased affinity between polymerase γ subunits
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial DNA polymerase; POLG2; adPEO; Multiple mtDNA deletions; Recombinant enzyme; Replication stalling
ID mitochondrial-dna deletions; progressive external ophthalmoplegia; real-time pcr; individual cells; optic atrophy; disease; disorder; maintenance; myopathy; patient
AB Human mitochondrial DNA (mtDNA) polymerase gamma (pol gamma) is the sole enzyme required to replicate and maintain the integrity of the mitochondrial genome. It comprises two subunits, a catalytic p140 subunit and a smaller p55 accessory subunit encoded by the POLG2 gene. We describe the molecular characterization of a potential dominant POLG2 mutation (p.R369G) in a patient with adPEO and multiple mtDNA deletions. Biochemical studies of the recombinant mutant p55 protein showed a reduced affinity to the pol gamma p140 subunit, leading to impaired processivity of the holoenzyme complex but did not show sensitivity to N-ethylmalaimide (NEM) inhibition, inferring a novel disease mechanism. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Craig, Kate; Blakely, Emma L.; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Young, Matthew J.; Longley, Matthew J.; Copeland, William C.] NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 Newcastle University - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
FU Wellcome Trust [074454/Z/04/Z]; UK NHS; NIH, National Institute of Environmental Health Sciences [ES 065078]; MRC [G0700718, MC_G0802536, G0800674] Funding Source: UKRI
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kasiviswanathan R, 2010, METHODS, V51, P379, DOI 10.1016/j.ymeth.2010.02.015
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 26
TC 21
Z9 22
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD MAR 15
PY 2012
VL 12
IS 2
BP 313
EP 319
DI 10.1016/j.mito.2011.11.006
PG 7
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 913VX
UT WOS:000301906600018
PM 22155748
DA 2024-11-01
ER

PT J
AU Tang, C
   Liang, XC
   Liu, HM
   Guo, LP
   Pi, RX
   Yang, JT
AF Tang, Chun
   Liang, Xianchun
   Liu, Hongming
   Guo, Liping
   Pi, Ruxian
   Yang, Juntao
TI Changes in mitochondrial DNA and its encoded products in alcoholic cirrhosis
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Alcoholic cirrhosis; mitochondria; mitochondrial DNA; cytochrome c oxidase 2
ID oxidative stress; liver-disease; deletion; acetaldehyde; steatosis; adducts; ethanol; number; muscle
AB The purpose of this study was to investigate hepatic mitochondrial DNA (mtDNA) damage and changes in its encoded products in patients with alcoholic cirrhosis (AC) in order to understand disease pathogenesis. We enrolled 23 patients with AC, 26 alcoholics without cirrhosis, and 25 normal subjects in this study. Hepatic mtDNA deletions were positioned using a combination of long and accurate polymerase chain reaction (LA PCR) and gene sequencing. The mtDNA copy number was measured using real-time quantitative PCR. The expression of the mtDNA-encoded cytochrome c oxidase 2 (cox2) was detected by western blotting. A large deletion of bases located at positions 749-15486 was identified in hepatic mtDNA from AC patients. Moreover, the mtDNA copy number was significantly reduced (P<0.05), and its encoded product, cox2, was significantly downregulated (P<0.05). Collectively, our results suggest that specific deletions and reduced copy numbers of hepatic mtDNA in patients with AC is an important pathogenetic factor.
C1 [Tang, Chun; Liang, Xianchun; Liu, Hongming; Guo, Liping; Pi, Ruxian; Yang, Juntao] Third Mil Med Univ, Daping Hosp, Dept Hepatobiliary Surg, Chongqing 400042, Peoples R China.
C3 Army Medical University
RP Yang, JT (corresponding author), Third Mil Med Univ, Daping Hosp, Dept Hepatobiliary Surg, Chongqing 400042, Peoples R China.
EM juntaoyang6@gmail.com
FU National Natural Science Fund of China [30801114]
CR Carling PJ, 2011, MITOCHONDRION, V11, P686, DOI 10.1016/j.mito.2011.05.004
   Castro MD, 2012, EXP GERONTOL, V47, P29, DOI 10.1016/j.exger.2011.10.002
   CHEDID A, 1991, AM J GASTROENTEROL, V86, P210
   Devi SL, 2010, AMINO ACIDS, V38, P869, DOI 10.1007/s00726-009-0293-0
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Elli L, 2009, DIGEST LIVER DIS, V41, P541, DOI 10.1016/j.dld.2008.12.095
   ERNST BP, 1994, MOL CELL PROBE, V8, P45, DOI 10.1006/mcpr.1994.1006
   Fariss MW, 2005, MOL INTERV, V5, P94, DOI 10.1124/mi.5.2.7
   FERNANDEZCHECA JC, 1993, ALCOHOL, V10, P469, DOI 10.1016/0741-8329(93)90067-X
   FROMENTY B, 1995, GASTROENTEROLOGY, V108, P193, DOI 10.1016/0016-5085(95)90024-1
   Graeber MB, 1998, J NEUROSCI RES, V52, P1
   GRIVELL LA, 1989, NATURE, V341, P569, DOI 10.1038/341569a0
   Henderson NC, 2008, TOXICOLOGY, V254, P130, DOI 10.1016/j.tox.2008.08.017
   Lieber CS, 1997, CLIN CHIM ACTA, V257, P59, DOI 10.1016/S0009-8981(96)06434-0
   Mandrekar P, 2009, J HEPATOL, V50, P1258, DOI 10.1016/j.jhep.2009.03.007
   Mariani E, 1999, CLIN EXP IMMUNOL, V116, P19
   Mello T, 2008, MOL ASPECTS MED, V29, P17, DOI 10.1016/j.mam.2007.10.001
   Miñana JB, 2002, HEPATOLOGY, V35, P1205, DOI 10.1053/jhep.2002.32969
   Niemela Onni, 1999, FRONTIERS IN BIOSCIENCE, V4, PD506, DOI 10.2741/Niemela
   Nieto N, 2007, HEPATOLOGY, V45, P1433, DOI 10.1002/hep.21659
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316
   Rolla R, 2000, HEPATOLOGY, V31, P878, DOI 10.1053/he.2000.5373
   Seitz HK, 2006, BIOL CHEM, V387, P349, DOI 10.1515/BC.2006.047
   Spahr L, 2003, MED SCI MONITOR, V9, P0
   Stickel F, 2006, ALCOHOL ALCOHOLISM, V41, P209, DOI 10.1093/alcalc/agl011
   Tatsukawa H, 2009, GASTROENTEROLOGY, V136, P1783, DOI 10.1053/j.gastro.2009.01.007
   Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev
   Tuma DJ, 2003, ALCOHOL RES HEALTH, V27, P285
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P376
NR 31
TC 7
Z9 7
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
EI 
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PD JUN 15
PY 2012
VL 5
IS 3
BP 245
EP 250
DI 
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 138RF
UT WOS:000318525400005
PM 22837799
DA 2024-11-01
ER

PT J
AU Wang, ZX
   Xiao, JX
   Xie, S
   Zhao, DH
   Liu, XW
   Zhang, J
   Yuan, Y
   Huang, YN
AF Wang, Zhaoxia
   Xiao, Jiangxi
   Xie, Sheng
   Zhao, Danhua
   Liu, Xiwei
   Zhang, Jue
   Yuan, Yun
   Huang, Yining
TI MR evaluation of cerebral oxygen metabolism and blood flow in stroke-like episodes of MELAS
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like pisodes; Magnetic resonance imaging; Oxygen extraction fraction; Cerebral blood flow
ID mitochondrial myopathy; lactic-acidosis; glucose-metabolism; encephalopathy; perfusion; mutation
AB Metabolic information is essential in the investigation of the pathophysiology of stroke-like episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). Here, we used magnetic resonance imaging to evaluate the dynamic metabolic changes before and after a stroke-like episode in two patients with MELAS caused by the mitochondrial DNA mutation A3243G. We performed functional magnetic resonance imaging, including arterial spin labeling and oxygen extraction fraction imaging, and generated cerebral blood flow and oxygen extraction fraction maps. We recruited eight healthy volunteers to define the normal range of the oxygen extraction fraction. We detected a heterogeneous reduction in the oxygen extraction fraction in the brain in the interictal period as well as at the onset of a stroke-like attack. However, the oxygen extraction fraction in the stroke-like lesions normalized in the acute stage. The stroke-like lesions showed consistent hyperperfusion in the acute phase but hypoperfusion in the chronic phase. We have demonstrated the utility of using new magnetic resonance imaging techniques in the evaluation of the pathophysiology of stroke-like lesions. The increased utilization of oxygen in an acute lesion is a novel finding in our study, which might play a role in the oxidative stress. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Xie, Sheng; Liu, Xiwei] China Japan Friendship Hosp, Dept Radiol, Beijing 100029, Peoples R China.
   [Wang, Zhaoxia; Zhao, Danhua; Yuan, Yun; Huang, Yining] Peking Univ First Hosp, Dept Neurol, Beijing 100034, Peoples R China.
   [Xiao, Jiangxi] Peking Univ First Hosp, Dept Radiol, Beijing 100034, Peoples R China.
   [Zhang, Jue] Peking Univ, Adv Acad Interdisciplinary Sci, Beijing 100083, Peoples R China.
C3 China-Japan Friendship Hospital; Peking University; Peking University; Peking University
RP Xie, S (corresponding author), China Japan Friendship Hosp, Dept Radiol, YingHuaDongJie 2, Beijing 100029, Peoples R China.
EM xs_mri@126.com
FU National Natural Science Foundation of China [30870864, 81201154]
CR An H, 2003, MAGN RESON MED, V50, P708, DOI 10.1002/mrm.10576
   An HY, 2000, J CEREBR BLOOD F MET, V20, P1225, DOI 10.1097/00004647-200008000-00008
   Gilchrist JM, 1996, STROKE, V27, P1420, DOI 10.1161/01.STR.27.8.1420
   GROPEN TI, 1994, STROKE, V25, P1873, DOI 10.1161/01.STR.25.9.1873
   Iizuka T, 2005, CURR NEUROVASC RES, V2, P29, DOI 10.2174/1567202052773544
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Iizuka T, 2007, J NEUROL SCI, V257, P126, DOI 10.1016/j.jns.2007.01.040
   Ikawa M, 2009, MITOCHONDRION, V9, P144, DOI 10.1016/j.mito.2009.01.011
   Kim JH, 2011, KOREAN J RADIOL, V12, P15, DOI 10.3348/kjr.2011.12.1.15
   Lindroos MM, 2009, BRAIN, V132, P3274, DOI 10.1093/brain/awp259
   Miyamoto A, 1997, NEURORADIOLOGY, V39, P427, DOI 10.1007/s002340050438
   Molnár MJ, 2000, NEUROLOGY, V55, P544, DOI 10.1212/WNL.55.4.544
   Nariai R, 2001, J NEUROIMAGING, V11, P325, DOI 10.1111/j.1552-6569.2001.tb00057.x
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   OOIWA Y, 1993, STROKE, V24, P304, DOI 10.1161/01.STR.24.2.304
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Sano M, 1995, ACTA NEUROL SCAND, V92, P497
   Takahashi S, 1998, J NEUROL SCI, V158, P58, DOI 10.1016/S0022-510X(98)00105-1
   Thajeb P, 2005, ANN NY ACAD SCI, V1042, P48, DOI 10.1196/annals.1338.005
   Tsujikawa T, 2010, BRAIN DEV-JPN, V32, P143, DOI 10.1016/j.braindev.2008.12.003
   Xie S, 2011, AM J NEURORADIOL, V32, P1504, DOI 10.3174/ajnr.A2523
NR 21
TC 20
Z9 24
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD DEC 15
PY 2012
VL 323
IS 1-2
BP 173
EP 177
DI 10.1016/j.jns.2012.09.011
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 037UT
UT WOS:000311132700030
PM 23062409
DA 2024-11-01
ER

PT J
AU Shi, Z
   Hayashi, YK
   Mitsuhashi, S
   Goto, K
   Kaneda, D
   Choi, YC
   Toyoda, C
   Hieda, S
   Kamiyama, T
   Sato, H
   Wada, M
   Noguchi, S
   Nonaka, I
   Nishino, I
AF Shi, Z.
   Hayashi, Y. K.
   Mitsuhashi, S.
   Goto, K.
   Kaneda, D.
   Choi, Y. -C.
   Toyoda, C.
   Hieda, S.
   Kamiyama, T.
   Sato, H.
   Wada, M.
   Noguchi, S.
   Nonaka, I.
   Nishino, I.
TI Characterization of the Asian myopathy patients with VCP mutations
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE amyotrophic lateral sclerosis; cytoplasmic inclusion; inclusion body myopathy with Paget's disease of bone and frontotemporal dementia; rimmed vacuolar myopathy; nuclear inclusion; transactivation response DNA-binding protein 43; ubiquitin; valosin-containing protein
ID valosin-containing protein; inclusion-body myopathy; frontotemporal dementia; paget-disease; gene-mutations; cell-death; tdp-43; bone; autophagy; yeast
AB Background and purpose: Mutations in the valosin-containing protein (VCP) gene are known to cause inclusion body myopathy with Pagets disease of bone and frontotemporal dementia (IBMPFD) and familial amyotrophic lateral sclerosis (ALS). Despite an increasing number of clinical reports, only one Asian family with IBMPFD has been described. Methods: To characterize patients with VCP mutations, we screened a total of 152 unrelated Asian families who were suspected to have rimmed vacuolar myopathy. Results: We identified VCP mutations in seven patients from six unrelated Asian families. Five different missense mutations were found, including a novel p. Ala439Pro substitution. All patients had adult-onset progressive muscle wasting with variable involvement of axial, proximal, and distal muscles. Two of seven patients were suggested to have mild brain involvement including cerebellar ataxia, and only one showed radiological findings indicating a change in bone. Findings from skeletal muscle indicated mixed neurogenic and myogenic changes, fibers with rimmed vacuoles, and the presence of cytoplasmic and nuclear inclusions. These inclusions were immunopositive for VCP, ubiquitin, transactivation response DNA-binding protein 43, and also histone deacetylase 6 (HDAC6), of which function is regulated by VCP. Evidence of early nuclear and mitochondrial damage was also characteristic. Conclusions: Valosin-containing protein mutations are not rare in Asian patients, and gene analysis should be considered for patients with adult-onset rimmed vacuolar myopathy with neurogenic changes. A wide variety of central and peripheral nervous system symptoms coupled with rare bone abnormalities may complicate diagnosis.
C1 [Shi, Z.; Hayashi, Y. K.; Mitsuhashi, S.; Goto, K.; Noguchi, S.; Nonaka, I.; Nishino, I.] NCNP, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan.
   [Kaneda, D.] Osaka Red Cross Hosp, Dept Neurol, Osaka, Japan.
   [Choi, Y. -C.] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Neurol, Seoul, South Korea.
   [Toyoda, C.] Jikei Med Univ, Daisan Hosp, Dept Neurol, Tokyo, Japan.
   [Hieda, S.] Showa Med Univ, Dept Neurol, Tokyo, Japan.
   [Kamiyama, T.] Jikei Med Univ, Dept Neurol, Tokyo, Japan.
   [Sato, H.; Wada, M.] Yamagata Univ, Fac Med, Dept Neurol Hematol Metab Endocrinol & Diabetol, Yamagata 990, Japan.
C3 National Center for Neurology & Psychiatry - Japan; Osaka Red Cross Hospital; Yonsei University; Yonsei University Health System; Jikei University; Showa University; Jikei University; Yamagata University
RP Hayashi, YK (corresponding author), NCNP, Natl Inst Neurosci, Dept Neuromuscular Res, 4-1-1 Ogawa Higashi, Tokyo 1878502, Japan.
EM hayasi_y@ncnp.go.jp
FU Japan Society for the Promotion of Science; Research on Psychiatric and Neurological Diseases and Mental Health; Research on Measures for Intractable Diseases; Ministry of Health, Labor, and Welfare [20B-12, 20B-13]; Neurological and Psychiatric Disorders of NCNP [23-4, 23-5, 23-6]
CR Ayala YM, 2008, P NATL ACAD SCI USA, V105, P3785, DOI 10.1073/pnas.0800546105
   Boyault C, 2006, EMBO J, V25, P3357, DOI 10.1038/sj.emboj.7601210
   Braun RJ, 2008, BBA-MOL CELL RES, V1783, P1418, DOI 10.1016/j.bbamcr.2008.01.015
   Braun RJ, 2006, J BIOL CHEM, V281, P25757, DOI 10.1074/jbc.M513699200
   Braun RJ, 2011, J BIOL CHEM, V286, P19958, DOI 10.1074/jbc.M110.194852
   Guinto JB, 2007, ACTA NEUROPATHOL, V114, P55, DOI 10.1007/s00401-007-0224-7
   Guyant-Maréchal L, 2006, NEUROLOGY, V67, P644, DOI 10.1212/01.wnl.0000225184.14578.d3
   Hashimoto Jun, 2007, NIHON RINSHO, V65 Suppl 9, P56
   Heo JM, 2010, MOL CELL, V40, P465, DOI 10.1016/j.molcel.2010.10.021
   Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086
   Johnson JO, 2010, NEURON, V68, P857, DOI 10.1016/j.neuron.2010.11.036
   Ju JS, 2010, HUM MOL GENET, V19, PR38, DOI 10.1093/hmg/ddq157
   Ju JS, 2009, J CELL BIOL, V187, P875, DOI 10.1083/jcb.200908115
   Kim EJ, 2011, ARCH NEUROL-CHICAGO, V68, P787, DOI 10.1001/archneurol.2010.376
   Kimonis VE, 2008, AM J MED GENET A, V146A, P745, DOI 10.1002/ajmg.a.31862
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Miller TM, 2005, MUSCLE NERVE, V32, P431, DOI 10.1002/mus.20341
   Miyachi K, 2004, CLIN EXP IMMUNOL, V136, P568, DOI 10.1111/j.1365-2249.2004.02456.x
   Neumann M, 2007, J NEUROPATH EXP NEUR, V66, P152, DOI 10.1097/nen.0b013e31803020b9
   Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108
   Nonaka Ikuya, 2005, CURR NEUROL NEUROSCI REP, V5, P61, DOI 10.1007/s11910-005-0025-0
   Schröder R, 2005, ANN NEUROL, V57, P457, DOI 10.1002/ana.20407
   Sivakumar K, 1996, NEUROLOGY, V47, P977, DOI 10.1212/WNL.47.4.977
   Stojkovic T, 2009, NEUROMUSCULAR DISORD, V19, P316, DOI 10.1016/j.nmd.2009.02.012
   Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332
   Weihl CC, 2008, J NEUROL NEUROSUR PS, V79, P1186, DOI 10.1136/jnnp.2007.131334
   Weihl CC, 2009, NEUROMUSCULAR DISORD, V19, P308, DOI 10.1016/j.nmd.2009.01.009
   Xu YF, 2010, J NEUROSCI, V30, P10851, DOI 10.1523/JNEUROSCI.1630-10.2010
NR 28
TC 45
Z9 47
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1351-5101
EI 
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD MAR 15
PY 2012
VL 19
IS 3
BP 501
EP 509
DI 10.1111/j.1468-1331.2011.03575.x
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 895OM
UT WOS:000300505800027
PM 22040362
DA 2024-11-01
ER

PT J
AU Tuppen, HAL
   Naess, K
   Kennaway, NG
   Al-Dosary, M
   Lesko, N
   Yarham, JW
   Bruhn, H
   Wibom, R
   Nennesmo, I
   Weleber, RG
   Blakely, EL
   Taylor, RW
   McFarland, R
AF Tuppen, Helen A. L.
   Naess, Karin
   Kennaway, Nancy G.
   Al-Dosary, Mazhor
   Lesko, Nicole
   Yarham, John W.
   Bruhn, Helene
   Wibom, Rolf
   Nennesmo, Inger
   Weleber, Richard G.
   Blakely, Emma L.
   Taylor, Robert W.
   McFarland, Robert
TI Mutations in the <i>mitochondrial tRNA<SUP>Ser(AGY)</SUP></i> gene are associated with deafness, retinal degeneration, myopathy and epilepsy
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE deafness; retinitis pigmentosa; mt-tRNA(Ser(AGY)); mutation
ID succinate-dehydrogenase; pathogenicity; defects
AB Although over 200 pathogenic mitochondrial DNA (mtDNA) mutations have been reported to date, determining the genetic aetiology of many cases of mitochondrial disease is still not straightforward. Here, we describe the investigations undertaken to uncover the underlying molecular defect(s) in two unrelated Caucasian patients with suspected mtDNA disease, who presented with similar symptoms of myopathy, deafness, neurodevelopmental delay, epilepsy, marked fatigue and, in one case, retinal degeneration. Histochemical and biochemical evidence of mitochondrial respiratory chain deficiency was observed in the patient muscle biopsies and both patients were discovered to harbour a novel heteroplasmic mitochondrial tRNA (mt-tRNA)(Ser(AGY)) (MTTS2) mutation (m.12264C > T and m.12261T > C, respectively). Clear segregation of the m.12261T > C mutation with the biochemical defect, as demonstrated by single-fibre radioactive RFLP, confirmed the pathogenicity of this novel variant in patient 2. However, unusually high levels of m.12264C > T mutation within both COX-positive (98.4 +/- 1.5%) and COX-deficient (98.2 +/- 2.1%) fibres in patient 1 necessitated further functional investigations to prove its pathogenicity. Northern blot analysis demonstrated the detrimental effect of the m.12264C > T mutation on mt-tRNA(Ser(AGY)) stability, ultimately resulting in decreased steady-state levels of fully assembled complexes I and IV, as shown by blue-native polyacrylamide gel electrophoresis. Our findings expand the spectrum of pathogenic mutations associated with the MTTS2 gene and highlight MTTS2 mutations as an important cause of retinal and syndromic auditory impairment. European Journal of Human Genetics (2012) 20, 897-904; doi:10.1038/ejhg.2012.44; published online 29 February 2012
C1 [McFarland, Robert] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Naess, Karin; Lesko, Nicole; Bruhn, Helene; Wibom, Rolf; Nennesmo, Inger] Karolinska Inst, Dept Lab Med, Stockholm, Sweden.
   [Naess, Karin] Karolinska Inst, Dept Pediat, CLINTEC, S-10401 Stockholm, Sweden.
   [Kennaway, Nancy G.; Weleber, Richard G.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA.
   [Weleber, Richard G.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA.
C3 Newcastle University - UK; Karolinska Institutet; Karolinska Institutet; Oregon Health & Science University; Oregon Health & Science University
RP McFarland, R (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.mcfarland@ncl.ac.uk
FU Wellcome Trust Programme Grant [074454/Z/04/Z]; UK NHS Specialised Services; Muscular Dystrophy Association; Foundation Fighting Blindness (Columbia, MD); Stockholm County Council; Karolinska Institutet; MRC [G0800674] Funding Source: UKRI
CR Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Bornstein B, 2005, BIOCHEM J, V387, P773, DOI 10.1042/BJ20040949
   Calvaruso MA, 2008, METHODS, V46, P281, DOI 10.1016/j.ymeth.2008.09.023
   Cardaioli E, 2011, J NEUROL SCI, V303, P142, DOI 10.1016/j.jns.2010.12.020
   Davidson MM, 2009, J MOL CELL CARDIOL, V46, P936, DOI 10.1016/j.yjmcc.2009.02.011
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Esteitie N, 2005, ANN NEUROL, V58, P544, DOI 10.1002/ana.20570
   Fischel-Ghodsian N, 2004, MITOCHONDRION, V4, P675, DOI 10.1016/j.mito.2004.07.040
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Guan MX, 2004, ANN NY ACAD SCI, V1011, P259, DOI 10.1196/annals.1293.025
   HALL RE, 1993, J CLIN INVEST, V92, P2660, DOI 10.1172/JCI116882
   Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100
   Kokotas H, 2007, CLIN GENET, V71, P379, DOI 10.1111/j.1399-0004.2007.00800.x
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Leveque M, 2007, EUR J HUM GENET, V15, P1145, DOI 10.1038/sj.ejhg.5201891
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Lu JX, 2010, MITOCHONDRION, V10, P69, DOI 10.1016/j.mito.2009.09.007
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Mansergh FC, 1999, AM J HUM GENET, V64, P971, DOI 10.1086/302344
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2004, AM J MED GENET A, V131A, P107, DOI 10.1002/ajmg.a.30318
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Perli E, 2012, HUM MOL GENET, V21, P85, DOI 10.1093/hmg/ddr440
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Stiggall D L, 1979, METHODS ENZYMOL, V55, P308
   Stiggall DL, 1979, METHOD ENZYMOL, V55, P819
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Tuppen HAL, 2008, J MED GENET, V45, P55, DOI 10.1136/jmg.2007.051185
   Tuppen HAL, 2010, BRAIN, V133, P2952, DOI 10.1093/brain/awq232
   Wibom R, 2002, ANAL BIOCHEM, V311, P139, DOI 10.1016/S0003-2697(02)00424-4
   Wong LJC, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.040626
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
NR 37
TC 10
Z9 12
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD AUG 15
PY 2012
VL 20
IS 8
BP 897
EP 904
DI 10.1038/ejhg.2012.44
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 976BX
UT WOS:000306556600017
PM 22378285
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, J.
TI Cognitive dysfunction in mitochondrial disorders
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Review
DE mitochondrial disorder; encephalopathy; cognitive impairment; dementia; central nervous system involvement; mental retardation; cognitive regression
ID mohr-tranebjaerg-syndrome; spinal-cord involvement; kearns-sayre-syndrome; melas syndrome; neurogastrointestinal encephalomyopathy; psychiatric-symptoms; clinical phenotype; lactic-acidosis; a3243g mutation; nervous-system
AB Among the various central nervous system (CNS) manifestations of mitochondrial disorders (MIDs), cognitive impairment is increasingly recognized and diagnosed (mitochondrial cognitive dysfunction). Aim of the review was to summarize recent findings concerning the aetiology, pathogenesis, diagnosis and treatment of cognitive decline in MIDs. Among syndromic MIDs due to mitochondrial DNA (mtDNA) mutations, cognitive impairment occurs in patients with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes syndrome, myoclonus epilepsy with ragged-red fibres syndrome, mitochondrial chronic progressive external ophthalmoplegia, KearnsSayre syndrome, neuropathy, ataxia and retinitis pigmentosa syndrome and maternally inherited diabetes and deafness. Among syndromic MIDs due to nuclear DNA (nDNA) mutations, cognitive decline has been reported in myo-neuro-gastro-intestinal encephalopathy, mitochondrial recessive ataxia syndrome, spinocerebellar ataxia with encephalopathy, MohrTranebjaerg syndrome, leuko-encephalopathy; brain and spinal cord involvement and lactic acidosis, CMT2, Wolfram syndrome, WolfHirschhorn syndrome and Leigh syndrome. In addition to syndromic MIDs, a large number of non-syndromic MIDs due to mtDNA as well as nDNA mutations have been reported, which present with cognitive impairment as the sole or one among several other CNS manifestations of a MID. Delineation of mitochondrial cognitive impairment from other types of cognitive impairment is essential to guide the optimal management of these patients. Treatment of mitochondrial cognitive impairment is largely limited to symptomatic and supportive measures. Cognitive impairment may be a CNS manifestation of syndromic as well as non-syndromic MIDs. Correct diagnosis of mitochondrial cognitive impairment is a prerequisite for the optimal management of these patients.
C1 [Finsterer, J.] Danube Univ Krems, Krems & Krankenanstalt Rudolfstiftung, Vienna, Austria.
C3 Rudolfstiftung Hospital; Danube University Krems
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Bahmad F, 2007, LARYNGOSCOPE, V117, P1202, DOI 10.1097/MLG.0b013e3180581944
   Berg RMG, 2011, J CEREBR BLOOD F MET, V31, P1532, DOI 10.1038/jcbfm.2011.48
   Binder J, 2003, BRAIN, V126, P1814, DOI 10.1093/brain/awg174
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   BOURGEOIS M, 1986, ANN MED-PSYCHOL, V144, P485
   Carod-Artal FJ, 2007, EUR J NEUROL, V14, P581, DOI 10.1111/j.1468-1331.2007.01720.x
   Çoku J, 2010, J NEUROL SCI, V290, P166, DOI 10.1016/j.jns.2009.12.001
   Coomans H, 2011, REV NEUROL-FRANCE, V167, P847, DOI 10.1016/j.neurol.2011.01.013
   Del Bo R, 2008, NEUROLOGY, V71, P1959, DOI 10.1212/01.wnl.0000327095.32005.a4
   Deschauer M, 2003, NEUROLOGY, V60, P1357, DOI 10.1212/01.WNL.0000055869.99975.4B
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Finsterer J, 2001, J INHERIT METAB DIS, V24, P560, DOI 10.1023/A:1012415810881
   Finsterer J, 2011, REV INVEST CLIN, V63, P100
   Finsterer J, 2010, REC ADV BIOL BIOMED, V0, P90
   Finsterer J, 2010, DRUG CHEM TOXICOL, V33, P138, DOI 10.3109/01480540903207076
   Fisch GS, 2010, AM J MED GENET C, V154C, P417, DOI 10.1002/ajmg.c.30279
   Fromont I, 2009, J NEUROL, V256, P1696, DOI 10.1007/s00415-009-5185-4
   Gelfand JM, 2011, J NEUROL, V258, P440, DOI 10.1007/s00415-010-5775-1
   Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601
   Grafakou O, 2003, EUR J PEDIATR, V162, P714, DOI 10.1007/s00431-003-1282-z
   Gramstad A, 2009, EPILEPSY BEHAV, V16, P172, DOI 10.1016/j.yebeh.2009.01.014
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Jaksch M, 2001, NEUROLOGY, V57, P1930, DOI 10.1212/WNL.57.10.1930
   Kaufman KR, 2010, EPILEPSY BEHAV, V18, P494, DOI 10.1016/j.yebeh.2010.05.020
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Koga Y, 2012, BRAIN DEV-JPN, V34, P87, DOI 10.1016/j.braindev.2011.03.003
   Lien LM, 2001, ACTA NEUROL SCAND, V103, P159, DOI 10.1034/j.1600-0404.2001.103003159.x
   Lin J, 2010, J CHILD NEUROL, V25, P1425, DOI 10.1177/0883073810370897
   Lindberg C, 2008, ACTA NEUROL SCAND, V117, P128, DOI 10.1111/j.1600-0404.2007.00913.x
   López-Fraile MIP, 2006, NEUROLOGIA, V21, P327
   Lorenzoni PJ, 2011, MITOCHONDRION, V11, P528, DOI 10.1016/j.mito.2011.01.003
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   Mayer WJ, 2011, OPHTHALMOLOGE, V108, P459, DOI 10.1007/s00347-010-2296-3
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Nickl-Jockschat T, 2009, NEUROCASE, V15, P47, DOI 10.1080/13554790802613009
   Ponjavic V, 1996, ACTA OPHTHALMOL SCAN, V74, P632
   Raspall-Chaure M, 2004, REV NEUROLOGIA, V39, P1129, DOI 10.33588/rn.3912.2004296
   Salsano E, 2011, J NEUROL SCI, V300, P165, DOI 10.1016/j.jns.2010.09.022
   Sartor H, 2002, ACTA NEUROL SCAND, V106, P309, DOI 10.1034/j.1600-0404.2002.01089.x
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Schuepbach WMM, 2007, J NEUROL, V254, P146, DOI 10.1007/s00415-006-0255-3
   Seeger J, 2010, NEUROMUSCULAR DISORD, V20, P720, DOI 10.1016/j.nmd.2010.06.017
   Sharfstein SR, 1999, ARCH NEUROL-CHICAGO, V56, P241, DOI 10.1001/archneur.56.2.241
   Sparaco M, 2003, ACTA NEUROPATHOL, V106, P202, DOI 10.1007/s00401-003-0716-z
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Stratilova L, 1999, CAS LEK CESK, V138, P401
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257
   Turconi AC, 1999, J NEUROL SCI, V170, P57, DOI 10.1016/S0022-510X(99)00199-9
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
NR 51
TC 41
Z9 42
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD JUL 15
PY 2012
VL 126
IS 1
BP 1
EP 11
DI 10.1111/j.1600-0404.2012.01649.x
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 953JB
UT WOS:000304862000002
PM 22335339
DA 2024-11-01
ER

PT J
AU Sanchez-Martinez, A
   Calleja, M
   Peralta, S
   Matsushima, Y
   Hernandez-Sierra, R
   Whitworth, AJ
   Kaguni, LS
   Garesse, R
AF Sanchez-Martinez, Alvaro
   Calleja, Manuel
   Peralta, Susana
   Matsushima, Yuichi
   Hernandez-Sierra, Rosana
   Whitworth, Alexander J.
   Kaguni, Laurie S.
   Garesse, Rafael
TI Modeling Pathogenic Mutations of Human Twinkle in <i>Drosophila</i> Suggests an Apoptosis Role in Response to Mitochondrial Defects
SO PLOS ONE
LA English
DT Article
ID progressive external ophthalmoplegia; dna-polymerase-gamma; multiple deletions; thymidine phosphorylase; linker region; helicase; mutant; replication; disorders; proteins
AB The human gene C10orf2 encodes the mitochondrial replicative DNA helicase Twinkle, mutations of which are responsible for a significant fraction of cases of autosomal dominant progressive external ophthalmoplegia (adPEO), a human mitochondrial disease caused by defects in intergenomic communication. We report the analysis of orthologous mutations in the Drosophila melanogaster mitochondrial DNA (mtDNA) helicase gene, d-mtDNA helicase. Increased expression of wild type d-mtDNA helicase using the UAS-GAL4 system leads to an increase in mtDNA copy number throughout adult life without any noteworthy phenotype, whereas overexpression of d-mtDNA helicase containing the K388A mutation in the helicase active site results in a severe depletion of mtDNA and a lethal phenotype. Overexpression of two d-mtDNA helicase variants equivalent to two human adPEO mutations shows differential effects. The A442P mutation exhibits a dominant negative effect similar to that of the active site mutant. In contrast, overexpression of d-mtDNA helicase containing the W441C mutation results in a slight decrease in mtDNA copy number during the third instar larval stage, and a moderate decrease in life span in the adult population. Overexpression of d-mtDNA helicase containing either the K388A or A442P mutations causes a mitochondrial oxidative phosphorylation (OXPHOS) defect that significantly reduces cell proliferation. The mitochondrial impairment caused by these mutations promotes apoptosis, arguing that mitochondria regulate programmed cell death in Drosophila. Our study of d-mtDNA helicase overexpression provides a tractable Drosophila model for understanding the cellular and molecular effects of human adPEO mutations.
C1 [Sanchez-Martinez, Alvaro; Peralta, Susana; Hernandez-Sierra, Rosana; Garesse, Rafael] Univ Autonoma Madrid, Fac Med, Dept Bioquim,Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Madrid, Spain.
   [Sanchez-Martinez, Alvaro; Peralta, Susana; Hernandez-Sierra, Rosana; Garesse, Rafael] Univ Autonoma Madrid, Fac Med, Ctr Invest Biomed Red Enfermedades Raras, Madrid, Spain.
   [Sanchez-Martinez, Alvaro; Peralta, Susana; Hernandez-Sierra, Rosana; Garesse, Rafael] Hosp 12 Octubre I 12, Inst Invest Santitaria, Madrid, Spain.
   [Calleja, Manuel] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cient, Madrid, Spain.
   [Matsushima, Yuichi; Kaguni, Laurie S.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
   [Matsushima, Yuichi; Kaguni, Laurie S.] Michigan State Univ, Ctr Mitochondrial Sci & Med, E Lansing, MI 48824 USA.
   [Whitworth, Alexander J.] Univ Sheffield, Dept Biomed Sci, MRC Ctr Dev & Biomed Genet, Sheffield S10 2TN, S Yorkshire, England.
C3 Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Autonomous University of Madrid; Hospital Universitario 12 de Octubre; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Michigan State University; Michigan State University; University of Sheffield
RP Sanchez-Martinez, A (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Bioquim,Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Madrid, Spain.
EM rafael.garesse@uam.es
FU Centre for Biomedical Research on Rare Diseases, Instituto de Salud Carlos III [PI 07/0167]; Comunidad de Madrid [GEN-0269/2006]; National Institutes of Health [GM45295]; MRC [MC_G1000735] Funding Source: UKRI
CR Abdelwahid E, 2007, DEV CELL, V12, P793, DOI 10.1016/j.devcel.2007.04.004
   Abdelwahid E, 2011, BBA-MOL CELL RES, V1813, P597, DOI 10.1016/j.bbamcr.2010.10.008
   Adán C, 2008, J BIOL CHEM, V283, P12333, DOI 10.1074/jbc.M801342200
   Arama E, 2006, EMBO J, V25, P232, DOI 10.1038/sj.emboj.7600920
   Clayton D A, 2000, HUM REPROD, V15 Suppl 2, P11
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   El-Khoury R, 2009, GENETICS, V183, P861, DOI 10.1534/genetics.109.107813
   Frangini M, 2009, FEBS J, V276, P1104, DOI 10.1111/j.1742-4658.2008.06853.x
   Garesse R, 2001, GENE, V263, P1, DOI 10.1016/S0378-1119(00)00582-5
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303
   Haraguchi M, 2002, MOL CELL BIOL, V22, P5212, DOI 10.1128/MCB.22.14.5212-5221.2002
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Krieser RJ, 2009, APOPTOSIS, V0, P0
   Lefai E, 2000, MOL GEN GENET, V264, P37, DOI 10.1007/s004380000301
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Martínez-Azorín F, 2008, J NEUROCHEM, V105, P165, DOI 10.1111/j.1471-4159.2007.05122.x
   Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017
   Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   Mendes CS, 2006, EMBO REP, V7, P933, DOI 10.1038/sj.embor.7400773
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2
   Owusu-Ansah E, 2008, NAT GENET, V40, P356, DOI 10.1038/ng.2007.50
   PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013
   Pickrell AM, 2009, J BIOENERG BIOMEMBR, V41, P453, DOI 10.1007/s10863-009-9245-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Umate Pavan, 2011, COMMUN INTEGR BIOL, V4, P118, DOI 10.4161/cib.4.1.13844
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Walker DW, 2004, P NATL ACAD SCI USA, V101, P10290, DOI 10.1073/pnas.0403767101
   Wanrooij S, 1900, V1797, V0, P1378
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
   Ziviani E, 1900, V6, V0, P0
   Ziviani E, 2010, AUTOPHAGY, V6, P660, DOI 10.4161/auto.6.5.12242
NR 46
TC 17
Z9 19
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD AUG 28
PY 2012
VL 7
IS 8
BP 
EP 
DI 10.1371/journal.pone.0043954
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 998CA
UT WOS:000308213600064
PM 22952820
DA 2024-11-01
ER

PT J
AU Pfeffer, G
   Mezei, MM
AF Pfeffer, Gerald
   Mezei, Michelle M.
TI CARDIAC SCREENING INVESTIGATIONS IN ADULT-ONSET PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA PATIENTS
SO MUSCLE & NERVE
LA English
DT Article
DE adult onset; asymptomatic; cardiac conduction; cardiomyopathy; echocardiogram; electrocardiogram; mitochondrial myopathy; progressive external ophthalmoplegia; screening
ID mitochondrial-dna; mutation; involvement; phenotype
AB Introduction: Patients with mitochondrial myopathies may develop cardiac complications such as cardiomyopathy and/or cardiac conduction defects. To identify these potentially life-threatening and treatable conditions, it is common practice to screen patients intermittently with electrocardiography and echocardiography. The optimal time interval for such screening investigations is unknown. We developed this study to review our screening results in adult-onset patients with progressive external ophthalmoplegia (PEO). Methods: This study was a retrospective review of PEO patients with 5 years or more of cardiac screening investigations who did not have any cardiac symptoms. Results: Fifteen patients were included, and cardiomyopathy was identified on screening echo-cardiogram in 1 patient. Four patients had other abnormalities identified, which were unrelated to their mitochondrial myopathy. Conclusions: Only 1 patient in 15 developed cardiac complications related to mitochondrial disease during 5 years of follow-up. We suggest that a screening interval of 3-5 years is probably appropriate for adult-onset PEO patients who do not have cardiac symptoms. Muscle Nerve 46: 593-596, 2012
C1 [Pfeffer, Gerald; Mezei, Michelle M.] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada.
   [Pfeffer, Gerald] Univ British Columbia, Clinician Investigator Program, Vancouver, BC V5Z 1M9, Canada.
   [Mezei, Michelle M.] Univ British Columbia, Adult Metab Dis Clin, GLDHCC, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia; University of British Columbia; University of British Columbia
RP Mezei, MM (corresponding author), Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada.
EM mezei@mail.ubc.ca
FU University of British Columbia; Canadian Institutes of Health Research
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Bau V, 2005, STRABISMUS, V13, P133, DOI 10.1080/09273970500216432
   Bhati RS, 2005, J HEART LUNG TRANSPL, V24, P2286, DOI 10.1016/j.healun.2005.05.012
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   POLAK PE, 1989, EUR HEART J, V10, P281, DOI 10.1093/oxfordjournals.eurheartj.a059477
   Stricker S, 2009, J NEUROL NEUROSUR PS, V80, P1181, DOI 10.1136/jnnp.2008.166066
   Wahbi K, 2010, NEUROLOGY, V74, P674, DOI 10.1212/WNL.0b013e3181d0ccf4
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
NR 11
TC 8
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD OCT 15
PY 2012
VL 46
IS 4
BP 593
EP 596
DI 10.1002/mus.23538
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 007FR
UT WOS:000308874700019
PM 22987704
DA 2024-11-01
ER

PT J
AU Roefs, AM
   Waters, PJ
   Moore, GRW
   Dolman, PJ
AF Roefs, Anne M.
   Waters, Paula J.
   Moore, G. R. Wayne
   Dolman, Peter J.
TI Orbicularis oculi muscle biopsies for mitochondrial DNA analysis in suspected mitochondrial myopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID progressive external ophthalmoplegia
AB Aims We wished to demonstrate the feasibility of performing diagnostic mitochondrial DNA (mtDNA) analysis on biopsies of the orbicularis oculi muscle in patients with a chronic progressive external ophthalmoplegia (CPEO) phenotype and suspicion of an underlying mitochondrial disorder. Method Case series of three patients who underwent ptosis surgery and had simultaneous biopsy of the orbicularis oculi muscle because of a suspicion of a mitochondrial disorder. Orbicularis muscle samples were divided into two pieces at the time of biopsy. The first was snap-frozen in liquid nitrogen, DNA was extracted and mtDNA deletion analysis was performed by two complementary methods (long PCR and Southern blot analysis). The second piece of muscle was assessed using routine histopathology, electron microscopy and immuno-histochemical analysis. Results Three patients with clinical features of CPEO, without any positive family history, underwent orbicularis muscle biopsies at time of eyelid ptosis surgery. All biopsies were adequate to conduct histopathological and immuno-histochemical analysis, which showed evidence of abnormal muscle structure and function. mtDNA was successfully extracted from all biopsies, and long PCR and Southern blot analysis confirmed diagnostic large single mtDNA deletions in all three cases. Conclusions Orbicularis oculi muscle biopsies are useful in patients with CPEO to perform mtDNA analysis, thus avoiding a separate biopsy of skeletal muscle elsewhere.
C1 [Roefs, Anne M.; Dolman, Peter J.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 3N9, Canada.
   [Roefs, Anne M.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Waters, Paula J.; Moore, G. R. Wayne] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 3N9, Canada.
   [Waters, Paula J.] Univ Sherbrooke, Gen Med Serv, Quebec City, PQ, Canada.
   [Moore, G. R. Wayne] Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada.
C3 University of British Columbia; Erasmus University Rotterdam; Erasmus MC; University of British Columbia; University of Sherbrooke; University of British Columbia
RP Dolman, PJ (corresponding author), Univ British Columbia, Dept Ophthalmol, Eye Care Ctr, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM peterdolman@hotmail.com
CR Almousa R, 2009, OPHTHAL PLAST RECONS, V25, P366, DOI 10.1097/IOP.0b013e3181b2fd06
   Di Mauro S, 1993, GENE REV, V0, P0
   ESHAGHIAN J, 1980, ARCH OPHTHALMOL-CHIC, V98, P1070
   FASSATI A, 1994, J NEUROL SCI, V123, P140, DOI 10.1016/0022-510X(94)90216-X
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Schoser BGH, 2006, STRABISMUS, V14, P107, DOI 10.1080/09273970600701218
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
NR 8
TC 6
Z9 7
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT 15
PY 2012
VL 96
IS 10
BP 1296
EP 1299
DI 10.1136/bjophthalmol-2012-301853
PG 4
WC Ophthalmology
SC Ophthalmology
GA 012DK
UT WOS:000309215500005
PM 22893396
DA 2024-11-01
ER

PT J
AU Henriques, M
   Diogo, L
   Garcia, P
   Pratas, J
   Simoes, M
   Grazina, M
AF Henriques, Margarida
   Diogo, Luisa
   Garcia, Paula
   Pratas, Joao
   Simoes, Marta
   Grazina, Manuela
TI Mitochondrial DNA 8993T&gt;G Mutation in a Child With Ornithine Transcarbamylase Deficiency and Leigh Syndrome: An Unexpected Association
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE mtDNA 8993T > G mutation; Leigh syndrome; ornithine transcarbamylase deficiency; mitochondrial disease; lactic acidosis
ID urea cycle disorders; gene
AB MC, female, is the third child of a nonconsanguineous Portuguese couple, born after an uneventful pregnancy and delivery. A positive family history of ornithine transcarbamylase deficiency, associated with the IVS8+1 G>A mutation in the ornithine transcarbamylase gene, prompted prenatal diagnosis with identification of the same mutation in the proband. During an episode of Klebsiella pneumoniae sepsis at 1.5 months of age, lactic acidosis and moderate hyperammonemia were noticed. After a short asymptomatic period, progressive neurologic symptoms, with normal ammonemia, persistent hyperlactacidemia, and typical lesions in brain computed tomography (CT) scan led to a diagnosis of Leigh syndrome. Mitochondrial respiratory chain complex V was reduced in the liver. The mtDNA 8993T>G mutation was identified in the liver, muscle, and blood (82%-87% heteroplasmy). She died at 6 months of age. This case represents a benign phenotype of ornithine transcarbamylase deficiency, associated with a severe mitochondrial respiratory chain disorder due to an mtDNA pathogenic mutation.
C1 [Grazina, Manuela] Univ Coimbra, Fac Med Coimbra, Lab Biochem Genet, Ctr Neurosci & Cell Biol, P-3000354 Coimbra, Portugal.
   [Henriques, Margarida; Diogo, Luisa; Garcia, Paula] CHC, Ctr Desenvolvimento Dr Luis Borges, Hosp Pediat Coimbra, Coimbra, Portugal.
   [Grazina, Manuela] Univ Coimbra, Fac Med, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra
RP Grazina, M (corresponding author), Univ Coimbra, Fac Med Coimbra, Lab Biochem Genet, Ctr Neurosci & Cell Biol, Polo 3 Subunidade i Ensino,2 Andar,Gab 2-31, P-3000354 Coimbra, Portugal.
EM mgrazina@ci.uc.pt
CR Baracca A, 2007, BBA-BIOENERGETICS, V1767, P913, DOI 10.1016/j.bbabio.2007.05.005
   Bindoff L, 2006, MITOCHONDRIAL MEDICINE, V0, P143
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   Debray FG, 2007, PEDIATRICS, V119, P722, DOI 10.1542/peds.2006-1866
   Debray FG, 2010, J CHILD NEUROL, V25, P1000, DOI 10.1177/0883073809351983
   King LS, 2005, CRIT CARE CLIN, V21, PS37, DOI 10.1016/j.ccc.2005.08.001
   Leonard J, 2000, INBORN METABOLIC DIS, V0, P215
   Makino M, 2000, J HUM GENET, V45, P69, DOI 10.1007/s100380050014
   Morava E, 2006, AM J MED GENET A, V140A, P863, DOI 10.1002/ajmg.a.31194
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   Wilcken B, 2004, MOL GENET METAB, V81, PS86, DOI 10.1016/j.ymgme.2003.10.016
NR 12
TC 6
Z9 7
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 
J9 J CHILD NEUROL
JI J. Child Neurol.
PD AUG 15
PY 2012
VL 27
IS 8
BP 1059
EP 1061
DI 10.1177/0883073811431015
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 976UC
UT WOS:000306610100015
PM 22241703
DA 2024-11-01
ER

PT J
AU Pfeffer, G
   Majamaa, K
   Turnbull, DM
   Thorburn, D
   Chinnery, PF
AF Pfeffer, Gerald
   Majamaa, Kari
   Turnbull, Douglass M.
   Thorburn, David
   Chinnery, Patrick F.
TI Treatment for mitochondrial disorders
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Creatine [therapeutic use]; Dichloroacetate [therapeutic use]; Mitochondrial Diseases [drug therapy]; Sarcosine [analogs & derivatives; therapeutic use]; Ubiquinone [therapeutic use]; Humans
ID complex-i deficiency; stroke-like episodes; progressive external ophthalmoplegia; magnetic-resonance-spectroscopy; hereditary optic neuropathy; congenital lactic-acidosis; coenzyme q(10) treatment; kearns-sayre syndrome; double-blind; dna mutations
AB Background Mitochondrial respiratory chain disorders are the most prevalent group of inherited neurometabolic diseases. They present with central and peripheral neurological features usually in association with other organ involvement including the eye, the heart, the liver, and kidneys, diabetes mellitus and sensorineural deafness. Current treatment is largely supportive and the disorders progress relentlessly causing significant morbidity and premature death. Vitamin supplements, pharmacological agents and exercise therapy have been used in isolated cases and small clinical trials, but the efficacy of these interventions is unclear. The first review was carried out in 2003, and identified six clinical trials. This major update was carried out to identify new studies and grade the original studies for potential bias in accordance with revised Cochrane Collaboration guidelines. Objectives To determine whether there is objective evidence to support the use of current treatments for mitochondrial disease. Search methods We searched the Cochrane Neuromuscular Disease Group Specialized Register (4 July 2011), CENTRAL (2011, Issue 2, MEDLINE (1966 to July 2011), and EMBASE (January 1980 to July 2011), and contacted experts in the field. Selection criteria We included randomised controlled trials (including cross-over studies). Two of the authors independently selected abstracts for further detailed review. Further review was performed independently by all five authors to decide which trials fit the inclusion criteria and graded risk of bias. Participants included males and females of any age with a confirmed diagnosis of mitochondrial disease based upon muscle histochemistry, respiratory chain complex analysis of tissues or cell lines or DNA studies. Interventions included any pharmacological agent, dietary modification, nutritional supplement, exercise therapy or other treatment. The review authors excluded studies at high risk of bias in any category. The primary outcome measures included an change in muscle strength and/or endurance, or neurological clinical features. Secondary outcome measures included quality of life assessments, biochemical markers of disease and negative outcomes. Data collection and analysis Two of the authors (GP and PFC) independently identified studies for further evaluation from all abstracts within the search period. For those studies identified for further review, all five authors then independently assessed which studies met the entry criteria. For the included studies, we extracted details of the number of randomised participants, treatment, study design, study category, allocation concealment and other risk of bias criteria, and participant characteristics. Analysis was based on intention-to-treat data. We planned to use meta-analysis, but this did not prove necessary. Main results The authors reviewed 1335 abstracts, and from these identified 21 potentially eligible abstracts. Upon detailed review, 12 studies fulfilled the entry criteria. Of these, eight were new studies that had been published since the previous version of this review. Two studies which were included in the previous version of this review were excluded because of potential for bias. The comparability of the included studies is extremely low because of differences in the specific diseases studied, differences in the therapeutic agents used, dosage, study design, and outcomes. The methodological quality of included studies was generally high, although risk of bias was unclear in random sequence generation and allocation concealment for most studies. Otherwise, the risk of bias was low for most studies in the other categories. Serious adverse events were uncommon, except for peripheral nerve toxicity in a long-term trial of dichloroacetate (DCA) in adults. One trial studied high-dose coenzyme Q10 without clinically meaningful improvement (although there were multiple biochemical, physiologic, and neuroimaging outcomes, in 30 participants). Three trials used creatine monohydrate alone, with one reporting evidence of improved measures of muscle strength and post-exercise lactate, but the other two reported no benefit (total of 38 participants). One trial studied the effects of a combination of coenzyme Q10, creatine monohydrate, and lipoic acid and reported a statistically significant improvement in biochemical markers and peak ankle dorsiflexion strength, but overall no clinical improvement in 16 participants. Five trials studied the effects of DCA: three trials in children showed a statistically significant improvement in secondary outcome measures of mitochondrial metabolism (venous lactate in three trials, and magnetic resonance spectroscopy (MRS) in one trial; total of 63 participants). One trial of short-term DCA in adults demonstrated no clinically relevant improvement (improved venous lactate but no change in physiologic, imaging, or questionnaire findings, in eight participants). One longer-term DCA trial in adults was terminated prematurely due to peripheral nerve toxicity without clinical benefit (assessments included the GATE score, venous lactate and MRS, in 30 participants). One trial using dimethylglycine showed no significant effect (measurements of venous lactate and oxygen consumption (VO2) in five participants). One trial using a whey-based supplement showed statistically significant improvement in markers of free radical reducing capacity but no clinical benefit (assessments included the Short Form 36 Health Survey (SF-36) questionnaire and UK Medical Research Council (MRC) muscle strength, in 13 participants). Authors' conclusions Despite identifying eight new trials there is currently no clear evidence supporting the use of any intervention in mitochondrial disorders. Further research is needed to establish the role of a wide range of therapeutic approaches. We suggest further research should identify novel agents to be tested in homogeneous study populations with clinically relevant primary endpoints.
C1 [Pfeffer, Gerald; Chinnery, Patrick F.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Pfeffer, Gerald] Univ British Columbia, Clinician Investigator Program, Vancouver, BC V5Z 1M9, Canada.
   [Majamaa, Kari] Univ Oulu, Inst Clin Med, Dept Neurol, Oulu, Finland.
   [Turnbull, Douglass M.] Newcastle Univ, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Thorburn, David] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
C3 Newcastle University - UK; University of British Columbia; University of Oulu; Newcastle University - UK; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne
RP Chinnery, PF (corresponding author), Newcastle Univ, Inst Med Genet, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU Medical Research Council (UK); Association Francaise contre les Myopathies; UK NIHR Biomedical Research Centre for Ageing and Age-related disease; MRC Centre for Neuromuscular Diseases; Muscular Dystrophy Campaign; Octapharma; Lundbeck; Wellcome Trust Centre for Mitochondrial Research [906919]; Newcastle University Centre for Brain Ageing and Vitality; BBSRC; EPSRC; ESRC; MRC as part of the cross-council Lifelong Health and Wellbeing Initiative [G0700718]; Wellcome Trust, UK; Muscular Dystrophy Campaign, UK; Ataxia, UK; Association Francaise contre les myopathies, France; Council for Health Research, Finland; Sigrid Juselius Foundation, Finland; Australian National Health and Medical Research Council, Australia; Muscular Dystrophy Association, USA; Parkinson's UK, UK; National Institute for Health Research (NIHR), UK; Newcastle NIHR Biomedical Research Centre in ageing and age-related disease; MRC [G0700718] Funding Source: UKRI
CR Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2
   ABE K, 1991, ACTA NEUROL SCAND, V83, P356, DOI 10.1111/j.1600-0404.1991.tb03962.x
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BARBIROLI B, 1995, J NEUROL, V242, P472, DOI 10.1007/BF00873552
   Barshop BA, 2004, MOL GENET METAB, V83, P138, DOI 10.1016/j.ymgme.2004.06.009
   BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203
   BERNSEN PLJA, 1993, J NEUROL SCI, V118, P181, DOI 10.1016/0022-510X(93)90108-B
   BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chinnery PF, 1998, AM J HUM GENET, V63, P1908, DOI 10.1086/302157
   Cortelli P, 1997, J NEUROL SCI, V148, P25, DOI 10.1016/S0022-510X(96)00311-5
   CURLESS RG, 1986, NEUROLOGY, V36, P872, DOI 10.1212/WNL.36.6.872
   DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 1998, NAT GENET, V19, P214, DOI 10.1038/883
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Duncan GE, 2004, J CLIN ENDOCR METAB, V89, P1733, DOI 10.1210/jc.2003-031684
   ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529
   Gimenes AC, 2007, EUROPEAN RESP J S51, V0, PE297
   Glover EI, 2010, MUSCLE NERVE, V42, P739, DOI 10.1002/mus.21758
   Gold R, 1996, EUR NEUROL, V36, P191, DOI 10.1159/000117246
   GUBBAY SS, 1989, MED J AUSTRALIA, V151, P100, DOI 10.5694/j.1326-5377.1989.tb101170.x
   Hassani A, 2010, CURR OPIN NEUROL, V23, P459, DOI 10.1097/WCO.0b013e32833d1096
   Higgins J, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000049
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HSU CC, 1995, ACTA NEUROL SCAND, V92, P252
   IHARA Y, 1989, J NEUROL SCI, V90, P263, DOI 10.1016/0022-510X(89)90112-3
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Klopstock T, 2000, NEUROLOGY, V55, P1748, DOI 10.1212/WNL.55.11.1748
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Kornblum C, 2005, EUR J NEUROL, V12, P300, DOI 10.1111/j.1468-1331.2004.00970.x
   KURLEMANN G, 1995, EUR J PEDIATR, V154, P928, DOI 10.1007/BF01957508
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Liet JM, 2003, J PEDIATR-US, V142, P62, DOI 10.1067/mpd.2003.mpd0333
   LOU HC, 1981, ARCH NEUROL-CHICAGO, V38, P469, DOI 10.1001/archneur.1981.00510070103027
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Majamaa K, 1997, MOL CELL BIOCHEM, V174, P291, DOI 10.1023/A:1006833200371
   Mancuso M, 2010, J NEUROL, V257, P774, DOI 10.1007/s00415-009-5409-7
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mashima Y, 2000, J NEURO-OPHTHALMOL, V20, P166, DOI 10.1097/00041327-200020030-00006
   MASHIMA Y, 1992, LANCET, V340, P368, DOI 10.1016/0140-6736(92)91442-B
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   Mitsui T, 2002, ACTA NEUROPATHOL, V104, P260, DOI 10.1007/s00401-002-0553-5
   Montini G, 2008, NEW ENGL J MED, V358, P2849, DOI 10.1056/NEJMc0800582
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Mori M, 2004, BRAIN DEV-JPN, V26, P453, DOI 10.1016/j.braindev.2003.12.009
   Mowat D, 1999, J PEDIATR-US, V134, P352, DOI 10.1016/S0022-3476(99)70463-4
   Muller W, 1990, NEUROLOGICAL SCI S, V9 8, P442
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   NISHIKAWA Y, 1989, NEUROLOGY, V39, P399, DOI 10.1212/WNL.39.3.399
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OGASAHARA S, 1986, NEUROLOGY, V36, P45, DOI 10.1212/WNL.36.1.45
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Oguro H, 2004, INTERNAL MED, V43, P427, DOI 10.2169/internalmedicine.43.427
   Panetta J, 2004, J INHERIT METAB DIS, V27, P487, DOI 10.1023/B:BOLI.0000037354.66587.38
   Papadimitriou A, 1996, NEUROMUSCULAR DISORD, V6, P49, DOI 10.1016/0960-8966(95)00020-8
   PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147
   Remes AM, 2002, NEUROLOGY, V59, P1275, DOI 10.1212/WNL.59.8.1275
   Rodriguez MC, 2007, MUSCLE NERVE, V35, P235, DOI 10.1002/mus.20688
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2009, ADV EXP MED BIOL, V652, P69, DOI 10.1007/978-90-481-2813-6_6
   Stacpoole PW, 2008, PEDIATRICS, V121, PE1223, DOI 10.1542/peds.2007-2062
   Stacpoole PW, 2006, PEDIATRICS, V117, P1519, DOI 10.1542/peds.2005-1226
   Suzuki S, 1998, DIABETOLOGIA, V41, P584, DOI 10.1007/s001250050950
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Tarnopolsky M, 1999, NEUROLOGY, V52, P854, DOI 10.1212/WNL.52.4.854
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Tucker EJ, 2010, CURR NEUROL NEUROSCI, V10, P277, DOI 10.1007/s11910-010-0112-8
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
   WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zhu XY, 2009, ACTA BIOCH BIOPH SIN, V41, P179, DOI 10.1093/abbs/gmn021
NR 93
TC 240
Z9 256
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2012
VL 0
IS 4
BP 
EP 
DI 10.1002/14651858.CD004426.pub3
PG 44
WC Medicine, General & Internal
SC General & Internal Medicine
GA 928US
UT WOS:000303012500026
PM 22513923
DA 2024-11-01
ER

PT J
AU Bannwarth, S
   Figueroa, A
   Fragaki, K
   Destroismaisons, L
   Lacas-Gervais, S
   Lespinasse, F
   Vandenbos, F
   Pradelli, LA
   Ricci, JE
   Rötig, A
   Michiels, JF
   Vande Velde, C
   Paquis-Flucklinger, V
AF Bannwarth, Sylvie
   Figueroa, Alexia
   Fragaki, Konstantina
   Destroismaisons, Laurie
   Lacas-Gervais, Sandra
   Lespinasse, Francoise
   Vandenbos, Fanny
   Pradelli, Ludivine A.
   Ricci, Jean-Ehrland
   Roetig, Agnes
   Michiels, Jean-Francois
   Vande Velde, Christine
   Paquis-Flucklinger, Veronique
TI The human MSH5 (MutS Homolog 5) protein localizes to mitochondria and protects the mitochondrial genome from oxidative damage
SO MITOCHONDRION
LA English
DT Article
DE mtDNA instability; DNA polymerase gamma; Twinkle helicase; Mitochondrial diseases
ID mismatch-repair system; saccharomyces-cerevisiae; mammalian mitochondria; dna-damage; human-cells; gene; mtdna; deletions; meiosis; hmsh5
AB MutS homologs play a central role in maintaining genetic stability. We show that MSH5 (MutS Homolog 5) is localized into the mitochondria of germ and somatic cells. This protein binds to mtDNA and interacts with the Twinkle helicase and the DNA polymerase gamma. hMSH5 stimulates mtDNA repair in response to DNA damage induced by oxidative stress. Furthermore, we observed a subsarcolemmal accumulation of hMSH5 in COX negative muscle fibers of patients presenting a mitochondrial myopathy. We report a novel localization for hMSH5 suggesting that this protein may have functions other than those known in meiotic recombination. (C) 2012 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Bannwarth, Sylvie; Figueroa, Alexia; Fragaki, Konstantina; Lespinasse, Francoise; Paquis-Flucklinger, Veronique] Fac Med Nice, IRCAN, CNRS UMR 7284, UNS,Inserm U1081, F-06107 Nice 2, France.
   [Bannwarth, Sylvie; Figueroa, Alexia; Fragaki, Konstantina; Paquis-Flucklinger, Veronique] CHU Nice, Hop Archet 2, Serv Genet Med, Nice, France.
   [Destroismaisons, Laurie; Vande Velde, Christine] Univ Montreal, CHUM, Ctr Rech, Ctr Excellence Neurom, Montreal, PQ H2L 4M1, Canada.
   [Destroismaisons, Laurie; Vande Velde, Christine] Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada.
   [Lacas-Gervais, Sandra] Univ Nice Sophia Antipolis, Fac Sci, Ctr Commun Microscopie Elect Appl, Nice, France.
   [Vandenbos, Fanny; Michiels, Jean-Francois] CHU Nice, Hop Louis Pasteur, Serv Neuropathol, Nice, France.
   [Pradelli, Ludivine A.; Ricci, Jean-Ehrland] Equipe 3 AVENIR, C3M, INSERM, U895, F-06204 Nice 3, France.
   [Roetig, Agnes] Univ Paris 05, Hop Necker Enfants Malad, INSERM, U781, F-75015 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Cote d'Azur; CHU Nice; Universite de Montreal; Universite de Montreal; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Paquis-Flucklinger, V (corresponding author), Fac Med Nice, IRCAN, CNRS UMR 7284, UNS,Inserm U1081, 28 Av Valombrose, F-06107 Nice 2, France.
EM paquis@hermes.unice.fr
FU Association Francaise contre les Myopathies (AFM) [12885]; Fond de Recherche en Sante du Quebec [14015]; Canadian Institutes of Health Research [JNM-85074]
CR Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Guda C, 2004, NUCLEIC ACIDS RES, V32, PW372, DOI 10.1093/nar/gkh374
   Her C, 1998, GENOMICS, V52, P50, DOI 10.1006/geno.1998.5374
   Hori A, 2009, NUCLEIC ACIDS RES, V37, P749, DOI 10.1093/nar/gkn993
   Hyvärinen AK, 2007, NUCLEIC ACIDS RES, V35, P6458, DOI 10.1093/nar/gkm676
   Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794
   Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907
   Jun SH, 2006, FEBS J, V273, P1609, DOI 10.1111/j.1742-4658.2006.05190.x
   Kaniak A, 2009, DNA REPAIR, V8, P318, DOI 10.1016/j.dnarep.2008.11.004
   Kato T, 2007, CANCER RES, V67, P8544, DOI 10.1158/0008-5472.CAN-07-1307
   Lahaye F, 2010, NUCLEIC ACIDS RES, V38, P3655, DOI 10.1093/nar/gkq098
   Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425
   Lee HC, 2005, ANN NY ACAD SCI, V1042, P109, DOI 10.1196/annals.1338.011
   Liu PF, 2010, ENVIRON MOL MUTAGEN, V51, P417, DOI 10.1002/em.20576
   Mason PA, 2003, NUCLEIC ACIDS RES, V31, P1052, DOI 10.1093/nar/gkg167
   Mookerjee SA, 2006, MUTAT RES-FUND MOL M, V595, P91, DOI 10.1016/j.mrfmmm.2005.10.006
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Neyton S, 2004, MOL HUM REPROD, V10, P917, DOI 10.1093/molehr/gah123
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857
   Park CB, 2007, CELL, V130, P273, DOI 10.1016/j.cell.2007.05.046
   Paul R, 2000, EUR J HUM GENET, V8, P331, DOI 10.1038/sj.ejhg.5200463
   Pogorzala L, 2009, GENETICS, V182, P699, DOI 10.1534/genetics.109.103796
   REENAN RAG, 1992, GENETICS, V132, P963
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Sage JM, 2010, J BIOL CHEM, V285, P18984, DOI 10.1074/jbc.M109.099846
   Santos Janine H, 2006, METHODS MOL BIOL, V314, P183
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   Santucci-Darmanin S, 2000, FASEB J, V14, P1539, DOI 10.1096/fj.14.11.1539
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHULL S, 1991, J BIOL CHEM, V266, P24398
   Snowden T, 2004, MOL CELL, V15, P437, DOI 10.1016/j.molcel.2004.06.040
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536
   TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551
   Tompkins JD, 2009, EXP CELL RES, V315, P2420, DOI 10.1016/j.yexcr.2009.05.004
   VandeVelde C, 2008, P NATL ACAD SCI USA, V105, P4022, DOI 10.1073/PNAS.0712209105
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Xu YZ, 2011, PLANT CELL, V23, P3428, DOI 10.1105/tpc.111.089136
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yi W, 2006, CANCER RES, V66, P151, DOI 10.1158/0008-5472.CAN-05-3019
   Yi W, 2005, BIOCHEM BIOPH RES CO, V332, P524, DOI 10.1016/j.bbrc.2005.04.154
NR 48
TC 18
Z9 19
U1 1
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD NOV 15
PY 2012
VL 12
IS 6
BP 654
EP 665
DI 10.1016/j.mito.2012.07.111
PG 12
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 046IQ
UT WOS:000311759100009
PM 22917773
DA 2024-11-01
ER

PT J
AU Dillon, LM
   Rebelo, AP
   Moraes, CT
AF Dillon, Lloye M.
   Rebelo, Adriana P.
   Moraes, Carlos T.
TI The role of PGC-1 coactivators in aging skeletal muscle and heart
SO IUBMB LIFE
LA English
DT Review
DE aging; mitochondria; mitochondrial biogenesis; PGC-1; skeletal muscle; heart
ID dna-deletion mutations; mitochondrial biogenesis; oxidative-phosphorylation; caloric restriction; endurance exercise; respiratory-chain; energy-metabolism; receptor-alpha; pgc-1-alpha; cardiomyopathy
AB Aging is the progressive decline in cellular, tissue, and organ function. This complex process often manifests as loss of muscular strength, cardiovascular function, and cognitive ability. Mitochondrial dysfunction and decreased mitochondrial biogenesis are believed to participate in metabolic abnormalities and loss of organ function, which will eventually contribute to aging and decreased lifespan. In this review, we discuss what is currently known about mitochondrial dysfunction in the aging skeletal muscle and heart. We focused our discussion on the role of PGC-1 coactivators in the regulation of mitochondrial biogenesis and function and possible therapeutic benefits of increased mitochondrial biogenesis in compensating for mitochondrial dysfunction and circumventing aging and aging-related diseases. (c) 2012 IUBMB IUBMB Life, 2012
C1 [Dillon, Lloye M.; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   [Rebelo, Adriana P.; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
C3 University of Miami; University of Miami
RP Moraes, CT (corresponding author), 1420 NW 9th Ave,Rm 229, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU National Institutes of Health [1R01AG036871, 5R01CA085700, R56NS041777, 5R01EY010804]; Muscular Dystrophy Association
CR Adhihetty PJ, 2009, AM J PHYSIOL-CELL PH, V297, PC217, DOI 10.1152/ajpcell.00070.2009
   Anderson R, 2009, BBA-GEN SUBJECTS, V1790, P1059, DOI 10.1016/j.bbagen.2009.04.005
   Aquilano K, 2010, J BIOL CHEM, V285, P21590, DOI 10.1074/jbc.M109.070169
   Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002
   Arany Z, 2008, CURR OPIN GENET DEV, V18, P426, DOI 10.1016/j.gde.2008.07.018
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003
   Bastin J, 2008, J CLIN ENDOCR METAB, V93, P1433, DOI 10.1210/jc.2007-1701
   Brault JJ, 2010, J BIOL CHEM, V285, P19460, DOI 10.1074/jbc.M110.113092
   Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Chinsomboon J, 2009, P NATL ACAD SCI USA, V106, P21401, DOI 10.1073/pnas.0909131106
   Combaret L, 2009, CURR OPIN CLIN NUTR, V12, P37, DOI 10.1097/MCO.0b013e32831b9c31
   Conley KE, 2007, CURR OPIN CLIN NUTR, V10, P688, DOI 10.1097/MCO.0b013e3282f0dbfb
   Dai DF, 2010, AGING CELL, V9, P536, DOI 10.1111/j.1474-9726.2010.00581.x
   Drew B, 2003, AM J PHYSIOL-REG I, V284, PR474, DOI 10.1152/ajpregu.00455.2002
   Eisele JC, 2008, BASIC RES CARDIOL, V103, P12, DOI 10.1007/s00395-007-0684-x
   Fagard RH, 2011, PROG CARDIOVASC DIS, V53, P404, DOI 10.1016/j.pcad.2011.03.006
   Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508
   Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794
   Haemmerle G, 2011, NAT MED, V17, P1076, DOI 10.1038/nm.2439
   Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785
   Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Handschin C, 2009, TRENDS PHARMACOL SCI, V30, P322, DOI 10.1016/j.tips.2009.03.006
   Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235
   Hiona A, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0011468
   Hoeks J, 2012, J CELL PHYSIOL, V227, P1026, DOI 10.1002/jcp.22812
   Iversen N, 2011, EXP GERONTOL, V46, P670, DOI 10.1016/j.exger.2011.03.004
   Jackson JR, 1900, V66, V0, P751
   Kelly DP, 2011, NATURE, V470, P342, DOI 10.1038/nature09896
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lai L, 2008, GENE DEV, V22, P1948, DOI 10.1101/gad.1661708
   Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Lehman JJ, 2008, AM J PHYSIOL-HEART C, V295, PH185, DOI 10.1152/ajpheart.00081.2008
   Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369
   Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Li L, 2011, BASIC RES CARDIOL, V106, P1221, DOI 10.1007/s00395-011-0213-9
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200
   Lira VA, 2010, AM J PHYSIOL-ENDOC M, V299, PE145, DOI 10.1152/ajpendo.00755.2009
   Madrazo JA, 2008, J MOL CELL CARDIOL, V44, P968, DOI 10.1016/j.yjmcc.2008.03.021
   Mansouri A, 2006, MECH AGEING DEV, V127, P298, DOI 10.1016/j.mad.2005.11.004
   Melov S, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000465
   Mirebeau-Prunier D, 2010, FEBS J, V277, P713, DOI 10.1111/j.1742-4658.2009.07516.x
   MONK JP, 1987, DRUGS, V33, P539, DOI 10.2165/00003495-198733060-00002
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Murase T, 2009, BIOGERONTOLOGY, V10, P423, DOI 10.1007/s10522-008-9177-z
   Narkar VA, 2011, CELL METAB, V13, P283, DOI 10.1016/j.cmet.2011.01.019
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Philp A, 2011, AM J PHYSIOL-REG I, V301, PR864, DOI 10.1152/ajpregu.00232.2011
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Puigserver P, 2005, INT J OBESITY, V29, PS5, DOI 10.1038/sj.ijo.0802905
   Rasbach KA, 2010, P NATL ACAD SCI USA, V107, P21866, DOI 10.1073/pnas.1016089107
   Rasmussen UF, 2003, EXP GERONTOL, V38, P877, DOI 10.1016/S0531-5565(03)00092-5
   Rebelo AP, 2011, J INHERIT METAB DIS, V34, P941, DOI 10.1007/s10545-011-9330-8
   Ren J, 1900, V88, V0, P993
   Rowe GC, 2011, AM J PHYSIOL-ENDOC M, V301, PE155, DOI 10.1152/ajpendo.00681.2010
   Rowe GC, 2010, CIRC RES, V107, P825, DOI 10.1161/CIRCRESAHA.110.223818
   Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB
   Ryall JG, 2008, BIOGERONTOLOGY, V9, P213, DOI 10.1007/s10522-008-9131-0
   Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com
   Safdar A, 1900, V5, V0, P0
   Safdar A, 2011, J BIOL CHEM, V286, P10605, DOI 10.1074/jbc.M110.211466
   Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Sihag S, 2009, J MOL CELL CARDIOL, V46, P201, DOI 10.1016/j.yjmcc.2008.10.025
   Sonoda J, 2007, P NATL ACAD SCI USA, V104, P5223, DOI 10.1073/pnas.0611623104
   Srivastava S, 2007, HUM MOL GENET, V16, P993, DOI 10.1093/hmg/ddm045
   Srivastava S, 2009, HUM MOL GENET, V18, P1805, DOI 10.1093/hmg/ddp093
   St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200
   Tatarková Z, 2011, PHYSIOL RES, V60, P281, DOI 10.33549/physiolres.932019
   Tenenbaum A, 2005, CARDIOVASC DIABETOL, V4, P0, DOI 10.1186/1475-2840-4-14
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Vianna CR, 2006, CELL METAB, V4, P453, DOI 10.1016/j.cmet.2006.11.003
   Viña J, 2009, ADV DRUG DELIVER REV, V61, P1369, DOI 10.1016/j.addr.2009.06.006
   VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431
   VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380
   Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011
   Volkova M, 2005, CARDIOVASC RES, V66, P194, DOI 10.1016/j.cardiores.2004.11.016
   Wallace DC, 2000, AM HEART J, V139, PS70, DOI 10.1067/mhj.2000.103934
   Wang X, 2011, MOL ONCOL, V5, P399, DOI 10.1016/j.molonc.2011.07.008
   Wareski P, 2009, J BIOL CHEM, V284, P21379, DOI 10.1074/jbc.M109.018911
   Wende AR, 2007, J BIOL CHEM, V282, P36642, DOI 10.1074/jbc.M707006200
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106
   Wenz T, 2009, J APPL PHYSIOL, V106, P1712, DOI 10.1152/japplphysiol.91571.2008
   Wu J, 2011, CELL METAB, V13, P160, DOI 10.1016/j.cmet.2011.01.003
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Yatsuga S, 2012, HUM MOL GENET, V21, P526, DOI 10.1093/hmg/ddr482
   Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115
   Zechner C, 2010, CELL METAB, V12, P633, DOI 10.1016/j.cmet.2010.11.008
NR 100
TC 97
Z9 105
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD MAR 15
PY 2012
VL 64
IS 3
BP 231
EP 241
DI 10.1002/iub.608
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 897QF
UT WOS:000300668200004
PM 22279035
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Malfatti, E
   Battisti, C
   Da Pozzo, P
   Rubegni, A
   Gallus, GN
   Malandrini, A
   Federico, A
AF Cardaioli, Elena
   Malfatti, Edoardo
   Battisti, Carla
   Da Pozzo, Paola
   Rubegni, Anna
   Gallus, Gian Nicola
   Malandrini, Alessandro
   Federico, Antonio
TI Sporadic myopathy, myoclonus, leukoencephalopathy, neurosensory deafness, hypertrophic cardiomyopathy and insulin resistance associated with the mitochondrial 8306 T&gt;C <i>MTTK</i> mutation
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Encephalomyopathies; Mitochondrial DNA; MTTK; Heteroplasmy; Single fibre studies; Pathogenicity; Muscle biochemical analysis
ID transfer-rna mutations; diseases; genes
AB We report a new T8306C transition in the D-stem of the MTTK gene of a 67-year-old man who manifested severe adult onset myopathy, myoclonus, leukoencephalopathy, neurosensory hypoacusis, hypertrophic cardiomyopathy and insulin resistance. No other family member was affected, suggesting that our patient was a sporadic case. The T8306C mutation was heteroplasmic in several tissues of the proband, while it was absent from his asymptomatic siblings. Single fibre analysis confirmed the segregation of higher mutational load in cytochrome c oxidase-deficient fibres. The mutation T8306C is predicted to disrupt a highly conserved base pair and was not found in more than 120 controls. This finding broadens the phenotypic and molecular spectrum of mitochondrial tRNA(Lys) associated disorders. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Cardaioli, Elena; Malfatti, Edoardo; Battisti, Carla; Da Pozzo, Paola; Rubegni, Anna; Gallus, Gian Nicola; Malandrini, Alessandro; Federico, Antonio] Univ Siena, Dept Neurol Neurosurg & Behav Sci, I-53100 Siena, Italy.
   [Malfatti, Edoardo] GH Pitie Salpetriere, Inst Myol, Unite Morphol Neuromusculaire, Paris, France.
C3 University of Siena; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite
RP Federico, A (corresponding author), Univ Siena, Dept Neurol Neurosurg & Behav Sci, Viale Bracci 2, I-53100 Siena, Italy.
EM federico@unisi.it
FU University of Siena
CR Di Mauro S, 2008, MOL GENETIC BASIS NE, V0, P169
   HOLME E, 1995, BBA-MOL BASIS DIS, V1271, P249, DOI 10.1016/0925-4439(95)00035-3
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Zeviani M, 1996, J INHERIT METAB DIS, V19, P504, DOI 10.1007/BF01799111
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 10
TC 5
Z9 5
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD OCT 15
PY 2012
VL 321
IS 1-2
BP 92
EP 95
DI 10.1016/j.jns.2012.07.027
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 017DJ
UT WOS:000309570000017
PM 22925535
DA 2024-11-01
ER

PT J
AU Viikov, K
   Jasnovidova, O
   Tamm, T
   Sedman, J
AF Viikov, Katrin
   Jasnovidova, Olga
   Tamm, Tiina
   Sedman, Juhan
TI C-Terminal Extension of the Yeast Mitochondrial DNA Polymerase Determines the Balance between Synthesis and Degradation
SO PLOS ONE
LA English
DT Article
ID progressive external ophthalmoplegia; strand displacement synthesis; saccharomyces-cerevisiae; accessory subunit; gamma mutations; excision-repair; human-disease; active-site; replication; protein
AB Saccharomyces cerevisiae mitochondrial DNA polymerase (Mip1) contains a C-terminal extension (CTE) of 279 amino acid residues. The CTE is required for mitochondrial DNA maintenance in yeast but is absent in higher eukaryotes. Here we use recombinant Mip1 C-terminal deletion mutants to investigate functional importance of the CTE. We show that partial removal of the CTE in Mip1 Delta 216 results in strong preference for exonucleolytic degradation rather than DNA polymerization. This disbalance in exonuclease and polymerase activities is prominent at suboptimal dNTP concentrations and in the absence of correctly pairing nucleotide. Mip1 Delta 216 also displays reduced ability to synthesize DNA through double-stranded regions. Full removal of the CTE in Mip1 Delta 279 results in complete loss of Mip1 polymerase activity, however the mutant retains its exonuclease activity. These results allow us to propose that CTE functions as a part of Mip1 polymerase domain that stabilizes the substrate primer end at the polymerase active site, and is therefore required for efficient mitochondrial DNA replication in vivo.
C1 [Viikov, Katrin; Jasnovidova, Olga; Tamm, Tiina; Sedman, Juhan] Univ Tartu, Dept Biochem, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia.
C3 University of Tartu
RP Viikov, K (corresponding author), Univ Tartu, Dept Biochem, Inst Mol & Cell Biol, Ulikooli 18, EE-50090 Tartu, Estonia.
EM jsedman@ebc.ee
FU Estonian Science Foundation [7013, 8845]
CR Andraos N, 2004, J BIOL CHEM, V279, P50609, DOI 10.1074/jbc.M408428200
   Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Baruffini E, 2011, MITOCHONDRION, V11, P182, DOI 10.1016/j.mito.2010.09.007
   BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0
   BLANCO L, 1989, J BIOL CHEM, V264, P8935
   Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039
   ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Foury F, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0027847
   GENGA A, 1986, J BIOL CHEM, V261, P9328
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Imoto S, 2008, BIOCHEMISTRY-US, V47, P4306, DOI 10.1021/bi7021427
   ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716
   Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kamtekar S, 2004, MOL CELL, V16, P609, DOI 10.1016/j.molcel.2004.10.019
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Lucas P, 2004, MITOCHONDRION, V4, P13, DOI 10.1016/j.mito.2004.04.001
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198
   PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120
   Pérez-Arnaiz P, 2006, NUCLEIC ACIDS RES, V34, P3107, DOI 10.1093/nar/gkl402
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460
   Sedman T, 2000, MOL CELL BIOL, V20, P1816, DOI 10.1128/MCB.20.5.1816-1824.2000
   Simossis VA, 2005, NUCLEIC ACIDS RES, V33, PW289, DOI 10.1093/nar/gki390
   Singh K, 2007, J BIOL CHEM, V282, P10594, DOI 10.1074/jbc.M611242200
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Viikov K, 2011, MITOCHONDRION, V11, P119, DOI 10.1016/j.mito.2010.08.007
   WERNETTE CM, 1986, J BIOL CHEM, V261, P4764
   Young MJ, 2006, YEAST, V23, P101, DOI 10.1002/yea.1344
   Zhu YL, 2003, J VIROL, V77, P10147, DOI 10.1128/JVI.77.18.10147-10153.2003
NR 42
TC 11
Z9 12
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2012
VL 7
IS 3
BP 
EP 
DI 10.1371/journal.pone.0033482
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 931EO
UT WOS:000303198600071
PM 22432028
DA 2024-11-01
ER

PT J
AU Ding, Y
   Leng, JH
AF Ding, Yu
   Leng, Jianhang
TI Is mitochondrial tRNA<SUP>Leu(UUR)</SUP> 3291T&gt;C mutation pathogenic?
SO MITOCHONDRIAL DNA
LA English
DT Article
DE Mitochondrial tRNA(Leu(UUR)); 3291T > C mutation; phylogenetic analysis; minimum free energy
ID dna
AB According to a recent report by Sunami et al., a maternally inherited Japanese family with variable phenotypes including mitochondrial myopathy, recurrent headache, and myoclonus and epilepsy had been described to be associated with mitochondrial tRNA(Leu(UUR)) 3291T > C mutation. In order to verify this association, we reanalyzed the clinical and molecular datasets obtained from Sunami's work; in addition, a phylogenetic approach was employed to evaluate the conservation index of this mutation among different species. We further utilized RNA Fold Web Server to predict the minimum free energy (MFE) of tRNA(Leu(UUR)) gene with and without this mutation. Most strikingly, a low level of conservation was found regarding 3291T > C mutation and a slight change in MFE had been observed between the wild type and the mutant. Our negative results gave no support for an active role for this mutation on the clinical expression of mitochondrial disorders.
C1 [Ding, Yu; Leng, Jianhang] Nanjing Med Univ, Cent Lab, Hangzhou Peoples Hosp 1, Hangzhou, Zhejiang, Peoples R China.
   [Ding, Yu; Leng, Jianhang] Nanjing Med Univ, Affiliated Hangzhou Hosp, Hangzhou, Zhejiang, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Leng, JH (corresponding author), Nanjing Med Univ, Cent Lab, Hangzhou Peoples Hosp 1, Hangzhou, Zhejiang, Peoples R China.
EM lengjh5@gmail.com
FU Nanjing Medical University [2010NJMU011]; Ministry of Science and Technology of Zhejiang Province [2008R40G2090027]
CR Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Freyhult E, 2005, BMC BIOINFORMATICS, V6, P0, DOI 10.1186/1471-2105-6-241
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Gruber AR, 2008, NUCLEIC ACIDS RES, V36, PW70, DOI 10.1093/nar/gkn188
   Park CB, 2011, J CELL BIOL, V5, P809
   Salsano E, 2011, J NEUROL SCI, V300, P165, DOI 10.1016/j.jns.2010.09.022
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Sunami Y, 2011, NEUROL SCI, V32, P861, DOI 10.1007/s10072-011-0719-9
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   Woischnik M, 2002, GENOME RES, V12, P885, DOI 10.1101/gr.227202
   Yao YG, 2008, J MED GENET, V45, P769, DOI 10.1136/jmg.2008.059782
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
   ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133
NR 14
TC 12
Z9 12
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1940-1736
EI 1940-1744
J9 MITOCHONDR DNA
JI Mitochondrial DNA
PD AUG 15
PY 2012
VL 23
IS 4
BP 323
EP 326
DI 10.3109/19401736.2012.674119
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA 967JX
UT WOS:000305904700023
PM 22471645
DA 2024-11-01
ER

PT J
AU Vedrenne, V
   Galmiche, L
   Chretien, D
   de Lonlay, P
   Munnich, A
   Rötig, A
AF Vedrenne, Vanessa
   Galmiche, Louise
   Chretien, Dominique
   de Lonlay, Pascale
   Munnich, Arnold
   Roetig, Agnes
TI Mutation in the mitochondrial translation elongation factor EFTs results in severe infantile liver failure
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Mitochondria; Liver failure; Respiratory chain; Mitochondrial translation; TSFM
ID dna depletion; deficiency; protein; gene
AB Background & Aims: Multiple respiratory chain deficiencies represent a common cause of mitochondrial diseases and often result in hepatic failure. A significant fraction of patients present mitochondrial DNA depletion but a number of cases remain unexplained. The aim of our study was to identify the disease causing gene in a kindred with intrauterine growth retardation, neonatal lactic acidosis, liver dysfunction and multiple respiratory chain deficiency in muscle. Methods: Homozygosity mapping was performed by 50K SNP genotyping and candidate genes were successively analyzed by direct sequencing on genomic DNA of the family members. Results: SNP genotyping detected several regions of homozygosity in which we focused our attention to genes involved in mitochondrial translation. We sequenced the TSFM gene, encoding the mitochondrial translation factor EFTs and identified a homozygous mutation changing a highly conserved arginine into a tryptophan (R312W). Conclusions: This mutation has been previously reported in two unrelated kindred presenting two distinct syndromes (fatal mitochondrial encephalomyopathy and hypertrophic cardiomyopathy respectively). The description of a third syndrome associated with a same TSFM mutation gives support to the broad clinical and genetic heterogeneity of mitochondrial translation deficiencies in human. It suggests that mitochondrial translation deficiency represents a growing cause of hepatic failure of mitochondrial origin in infants. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 [Roetig, Agnes] Univ Paris 05, Hop Necker Enfants Malad, Dept Genet, F-75015 Paris, France.
   INSERM, U781, F-75015 Paris, France.
C3 Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Rötig, A (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, Dept Genet, 149 Rue Sevres, F-75015 Paris, France.
EM agnes.rotig@inserm.fr
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Smits P, 2011, EUR J HUM GENET, V19, P275, DOI 10.1038/ejhg.2010.208
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
NR 11
TC 30
Z9 34
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 
J9 J HEPATOL
JI J. Hepatol.
PD JAN 15
PY 2012
VL 56
IS 1
BP 294
EP 297
DI 10.1016/j.jhep.2011.06.014
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 867WC
UT WOS:000298484500048
PM 21741925
DA 2024-11-01
ER

PT J
AU Góth, L
   Nagy, T
AF Goth, Laszlo
   Nagy, Terez
TI Acatalasemia and diabetes mellitus
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Review
DE Acatalasemia; Diabetes; Reactive oxygen species; Catalase; Hydrogen peroxide
ID protein-tyrosine phosphatases; inherited catalase deficiency; beta-thalassemic erythrocytes; chronic oxidative stress; hydrogen-peroxide; reversible inactivation; hungarian acatalasemia; mitochondrial-function; superoxide-dismutase; glucose toxicity
AB The enzyme catalase catalyzes the breakdown of hydrogen peroxide into oxygen and water. It is the main regulator of hydrogen peroxide metabolism. Hydrogen peroxide is a highly reactive small molecule formed as a natural byproducts of energy metabolism. Excessive concentrations may cause significant damages to protein, DNA, RNA and lipids. Low levels in muscle cells, facilitate insulin signaling. Acatalasemia is a result of the homozygous mutations in the catalase gene, has a worldwide distribution with 12 known mutations. Increased hydrogen peroxide, due to catalase deficiency, plays a role in the pathogenesis of several diseases such as diabetes mellitus. Diabetes mellitus is a disorder caused by multiple genetic and environmental factors. Examination of Hungarian diabetic and acatalasemic patients showed that an increased frequency of catalase gene mutations exists among diabetes patients. Inherited catalase deficiency may increase the risk of type 2 diabetes mellitus, especially for females. Early onset of type 2 diabetes occurs with inherited catalase deficiency. Low levels of SOD and glutathione peroxidase could contribute to complications caused by increased oxidative stress. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Goth, Laszlo; Nagy, Terez] Univ Debrecen, Med & Hlth Sci Ctr, Dept Med Lab Analyt, H-4012 Debrecen, Hungary.
C3 University of Debrecen
RP Góth, L (corresponding author), Univ Debrecen, Med & Hlth Sci Ctr, Fac Med, Dept Biomed Lab & Imaging Sci, POB 55, H-4012 Debrecen, Hungary.
EM goth@dote.hu
FU Hungarian Scientific Research Fund (OTKA) [T 71902]
CR Ahlqvist E, 2011, CLIN CHEM, V57, P241, DOI 10.1373/clinchem.2010.157016
   ARONOFF S, 1965, SCIENCE, V150, P72, DOI 10.1126/science.150.3692.72
   Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v
   Bashan N, 2009, PHYSIOL REV, V89, P27, DOI 10.1152/physrev.00014.2008
   Baumann K, 2010, NAT REV MOL CELL BIO, V11, P0, DOI 10.1038/nrm2878
   Cappellini MD, 1999, BRIT J HAEMATOL, V104, P504, DOI 10.1046/j.1365-2141.1999.01217.x
   Casci T, 2011, NAT REV GENET, V12, P667, DOI 10.1038/nrg3071
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Cheng ML, 2005, BRIT J HAEMATOL, V128, P119, DOI 10.1111/j.1365-2141.2004.05257.x
   Concannon P, 2009, NEW ENGL J MED, V360, P1646, DOI 10.1056/NEJMra0808284
   CRAWFORD DR, 1988, BIOCHEM BIOPH RES CO, V153, P59, DOI 10.1016/S0006-291X(88)81189-6
   da Silva RL, 2011, INT J CLIN PHARM-NET, V33, P471, DOI 10.1007/s11096-011-9511-4
   Denu JM, 2002, METHOD ENZYMOL, V348, P297, DOI 10.1016/S0076-6879(02)48648-X
   Eaton JW, 1900, V2, V0, P2731
   Elsner M, 2011, DIABETES, V60, P200, DOI 10.2337/db09-1401
   Giorgio M, 2007, NAT REV MOL CELL BIO, V8, P0
   Góth L, 2000, LANCET, V356, P1820, DOI 10.1016/S0140-6736(00)03238-4
   Góth L, 2000, BLOOD CELL MOL DIS, V26, P151, DOI 10.1006/bcmd.2000.0288
   Góth L, 2005, CLIN CHEM, V51, P2401, DOI 10.1373/clinchem.2005.055517
   Góth L, 2005, ELECTROPHORESIS, V26, P1646, DOI 10.1002/elps.200410384
   GOTH L, 1992, CLIN CHIM ACTA, V207, P155, DOI 10.1016/0009-8981(92)90160-R
   Góth L, 2000, CLIN CHEM, V46, P564
   Góth L, 2003, FREE RADICAL BIO MED, V35, P882, DOI 10.1016/S0891-5849(03)00435-0
   GOTH L, 1992, ENZYME, V46, P252, DOI 10.1159/000468797
   Góth L, 2001, CLIN CHIM ACTA, V311, P161, DOI 10.1016/S0009-8981(01)00609-X
   Góth L, 2001, ELECTROPHORESIS, V22, P49, DOI 10.1002/1522-2683(200101)22:1<49::AID-ELPS49>3.0.CO;2-W
   Goth L, 2009, HDB TYPE 2 DIABETES, V0, P511
   Góth L, 2007, FREE RADICAL RES, V41, P953, DOI 10.1080/10715760701482451
   Goth Laszlo, 2004, MOL DIAGN, V8, P141
   Goth Laszlo, 2008, DIABETES CARE, V31, Pe93, DOI 10.2337/dc08-1607
   GUY GR, 1993, J BIOL CHEM, V268, P2141
   Hamada Y, 2004, ANESTHESIOLOGY, V101, P247, DOI 10.1097/00000542-200407000-00038
   Heales SJR, 2001, LANCET, V357, P314, DOI 10.1016/S0140-6736(05)71763-3
   Hirono A, 1995, BLOOD CELL MOL DIS, V21, P232, DOI 10.1006/bcmd.1995.0026
   Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634
   Hu FB, 2011, CLIN CHEM, V57, P1224, DOI 10.1373/clinchem.2011.167056
   Hur J, 2010, BMC MED GENOMICS, V3, P0, DOI 10.1186/1755-8794-3-49
   Ivashchenko O, 2011, MOL BIOL CELL, V22, P1440, DOI 10.1091/mbc.E10-11-0919
   Kirkman HN, 2007, TRENDS BIOCHEM SCI, V32, P44, DOI 10.1016/j.tibs.2006.11.003
   KISHIMOTO Y, 1992, HUM GENET, V88, P487, DOI 10.1007/BF00219333
   Kósa Z, 2012, MOL BIOL REP, V39, P4787, DOI 10.1007/s11033-011-1272-6
   Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366
   Lei XG, 2011, ANTIOXID REDOX SIGN, V14, P489, DOI 10.1089/ars.2010.3416
   Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125-007-0886-7
   Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200
   Maresca V, 2006, J INVEST DERMATOL, V126, P182, DOI 10.1038/sj.jid.5700021
   Mehmeti I, 2011, BBA-MOL CELL RES, V1813, P1827, DOI 10.1016/j.bbamcr.2011.06.022
   Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8
   Mueller S, 1997, BLOOD, V90, P4973, DOI 10.1182/blood.V90.12.4973.4973_4973_4978
   Ogata M, 2008, ACTA MED OKAYAMA, V62, P345
   PARBOOSINGH JS, 1995, ARCH NEUROL-CHICAGO, V52, P1160, DOI 10.1001/archneur.1995.00540360038013
   Pi J, 2007, DIABETES, V56, P1873
   Rains JL, 2011, FREE RADICAL BIO MED, V50, P567, DOI 10.1016/j.freeradbiomed.2010.12.006
   Ramakrishna V, 2008, ACTA DIABETOL, V45, P41, DOI 10.1007/s00592-007-0018-3
   Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481
   Robertson RP, 2007, CELL BIOCHEM BIOPHYS, V48, P139, DOI 10.1007/s12013-007-0026-5
   Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200
   Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003
   Roma LP, 2009, FREE RADICAL BIO MED, V47, P1386, DOI 10.1016/j.freeradbiomed.2009.08.010
   Sampson SR, 2010, APOPTOSIS, V15, P1165, DOI 10.1007/s10495-010-0517-5
   Scott MD, 2006, FREE RADICAL BIO MED, V40, P1264, DOI 10.1016/j.freeradbiomed.2005.11.017
   SCOTT MD, 1993, J CLIN INVEST, V91, P1706, DOI 10.1172/JCI116380
   Sindhu RK, 2004, CLIN EXP HYPERTENS, V26, P43, DOI 10.1081/CEH-120027330
   Steck AK, 2011, CLIN CHEM, V57, P176, DOI 10.1373/clinchem.2010.148221
   TAKAHARA S, 1952, LANCET, V263, P1101
   Takemoto K, 2009, CLIN CHIM ACTA, V407, P43, DOI 10.1016/j.cca.2009.06.028
   Tirosh A, 2005, NEW ENGL J MED, V353, P1454, DOI 10.1056/NEJMoa050080
   Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004
   Vally V, 2004, J INVEST DERMATOL, V122, P0
   Veal E, 2011, ANTIOXID REDOX SIGN, V15, P147, DOI 10.1089/ars.2011.3968
   Vitai M, 2005, CLIN CHEM LAB MED, V43, P1346, DOI 10.1515/CCLM.2005.230
   Vitai M, 1997, CLIN CHIM ACTA, V261, P35, DOI 10.1016/S0009-8981(97)06514-5
   WEN JK, 1990, J MOL BIOL, V211, P383, DOI 10.1016/0022-2836(90)90359-T
   West IC, 2000, DIABETIC MED, V17, P171, DOI 10.1046/j.1464-5491.2000.00259.x
   Woo HA, 2010, CELL, V140, P517, DOI 10.1016/j.cell.2010.01.009
   Wood JM, 2006, J INVEST DERMATOL, V126, P13, DOI 10.1038/sj.jid.5700051
NR 76
TC 51
Z9 57
U1 1
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD SEP 15
PY 2012
VL 525
IS 2
BP 195
EP 200
DI 10.1016/j.abb.2012.02.005
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 990DY
UT WOS:000307612400011
PM 22365890
DA 2024-11-01
ER

PT J
AU Dunn, DA
   Pinkert, CA
AF Dunn, David A.
   Pinkert, Carl A.
TI Nuclear Expression of a Mitochondrial DNA Gene: Mitochondrial Targeting of Allotopically Expressed Mutant ATP6 in TransgenicMice
SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
ID mutation; disease; system; cells; bioenergetics; organelle; therapy; subunit; product; genome
AB Nuclear encoding of mitochondrial DNA transgenes followed by mitochondrial targeting of the expressed proteins (allotopic expression; AE) represents a potentially powerful strategy for creating animal models of mtDNA disease. Mice were created that allotopically express either a mutant (A6M) or wildtype (A6W) mt-Atp6 transgene. Compared to non-transgenic controls, A6M mice displayed neuromuscular and motor deficiencies (wire hang, pole, and balance beam analyses; P < 0.05), no locomotor differences (gait analysis; P < 0.05) and enhanced endurance in Rota-Rod evaluations (P < 0.05). A6W mice exhibited inferior muscle strength (wire hang test; P < 0.05), no difference in balance beam footsteps, accelerating Rota-Rod, pole test and gait analyses; (P < 0.05) and superior performance in balance beam time-to-cross and constant velocity Rota-Rod analyses (P < 0.05) in comparison to non-transgenic control mice. Mice of both transgenic lines did not differ from non-transgenic controls in a number of bioenergetic and biochemical tests including measurements of serum lactate and mitochondrial MnSOD protein levels, ATP synthesis rate, and oxygen consumption (P > 0.05). This study illustrates a mouse model capable of circumventing in vivo mitochondrial mutations. Moreover, it provides evidence supporting AE as a tool for mtDNA disease research with implications in development of DNA-based therapeutics.
C1 [Dunn, David A.; Pinkert, Carl A.] Auburn Univ, Coll Vet Med, Dept Pathobiol, Auburn, AL 36849 USA.
C3 Auburn University System; Auburn University
RP Pinkert, CA (corresponding author), Auburn Univ, Coll Vet Med, Dept Pathobiol, 212 Samford Hall, Auburn, AL 36849 USA.
EM cap@auburn.edu
FU MitoCure Foundation, National Institutes of Health (NIH) [HD053037, RR16286]; National Science Foundation (NSF) [EPS-0447675]; Alabama Agricultural Experiment Station; Auburn University
CR Carter RJ, 1999, J NEUROSCI, V19, P3248
   Cwerman-Thibault H, 2011, J INHERIT METAB DIS, V34, P327, DOI 10.1007/s10545-010-9131-5
   DAurelio M, 2010, HUM MOL GENET, V19, P374, DOI 10.1093/hmg/ddp503
   DiMauro S, 2007, BIOSCIENCE REP, V27, P125, DOI 10.1007/s10540-007-9041-4
   Dunn DA, 2011, BIOCHIM BIOPHYS ACTA, V1820, P601
   EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610
   GEARING DP, 1986, EMBO J, V5, P3651, DOI 10.1002/j.1460-2075.1986.tb04695.x
   Guy J, 2009, INVEST OPHTH VIS SCI, V50, P4205, DOI 10.1167/iovs.08-3214
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301
   KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5
   Kyriakouli DS, 2008, GENE THER, V15, P1017, DOI 10.1038/gt.2008.91
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Pinkert CA, 2002, TRANSGENIC ANIMAL TE, V0, P0
   Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P1, DOI 10.1167/iovs.06-0789
   RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012
   Timmis JN, 2004, NAT REV GENET, V5, P123, DOI 10.1038/nrg1271
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Vives-Bauza C, 2007, METHOD CELL BIOL, V80, P155, DOI 10.1016/S0091-679X(06)80007-5
   Wallace DC, 2010, DEV DISABIL RES REV, V16, P114, DOI 10.1002/ddrr.113
   Will Y, 2006, NAT PROTOC, V1, P2563, DOI 10.1038/nprot.2006.351
   Young L, 2004, NUCLEIC ACIDS RES, V32, P0, DOI 10.1093/nar/gnh058
   Zullo SJ, 2005, REJUV RES, V8, P18, DOI 10.1089/rej.2005.8.18
NR 26
TC 17
Z9 19
U1 0
U2 6
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1110-7243
EI 
J9 J BIOMED BIOTECHNOL
JI J. Biomed. Biotechnol.
PD JUN 15
PY 2012
VL 0
IS 
BP 
EP 
DI 10.1155/2012/541245
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 968TH
UT WOS:000306007200001
PM 22778551
DA 2024-11-01
ER

PT J
AU Sekino, Y
   Inamori, M
   Yamada, E
   Ohkubo, H
   Sakai, E
   Higurashi, T
   Iida, H
   Hosono, K
   Endo, H
   Nonaka, T
   Takahashi, H
   Koide, T
   Abe, Y
   Gotoh, E
   Koyano, S
   Kuroiwa, Y
   Maeda, S
   Nakajima, A
AF Sekino, Yusuke
   Inamori, Masahiko
   Yamada, Eiji
   Ohkubo, Hidenori
   Sakai, Eiji
   Higurashi, Takuma
   Iida, Hiroshi
   Hosono, Kunihiro
   Endo, Hiroki
   Nonaka, Takashi
   Takahashi, Hirokazu
   Koide, Tomoko
   Abe, Yasunobu
   Gotoh, Eiji
   Koyano, Shigeru
   Kuroiwa, Yoshiyuki
   Maeda, Shin
   Nakajima, Atsushi
TI Characteristics of intestinal pseudo-obstruction in patients with mitochondrial diseases
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Chronic intestinal pseudo-obstruction; Criteria; Mitochondrial disease; Mitochondrial encephalopathy; Lactic acidosis; Stroke-like episodes; Chronic progressive external ophthalmoplegia
ID neurogastrointestinal encephalomyopathy mngie; phosphorylase gene-mutations; respiratory-chain diseases; dna mutation; constipation; diagnosis; diltiazem
AB AIM: To reveal the frequency, characteristics and prognosis of chronic intestinal pseudo-obstruction (CIP) in mitochondrial disease patients. METHODS: Between January 2000 and December 2010, 31 patients (13 males and 18 females) were diagnosed with mitochondrial diseases at our hospital. We conducted a retrospective review of the patients' sex, subclass of mitochondrial disease, age at onset of mitochondrial disease, frequency of CIP and the age at its onset, and the duration of survival. The age at onset or at the first diagnosis of the disorder that led to the clinical suspicion of mitochondrial disease was also examined. RESULTS: Twenty patients were sub-classified with mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), 8 with chronic progressive external ophthalmoplegia (CPEO), and 3 with myoclonus epilepsy associated with ragged-red fibers (MERRF). Nine patients were diagnosed with CIP, 8 of the 20 (40.0%) patients with MELAS, 0 of the 8 (0.0%) patients with CPEO, and 1 of the 3 (33.3%) patients with MERRF. The median age (range) at the diagnosis and the median age at onset of mitochondrial disease were 40 (17-69) and 25 (12-63) years in patients with CIP, and 49 (17-81) and 40 (11-71) years in patients without CIP. During the survey period, 5 patients (4 patients with MELAS and 1 with CPEO) died. The cause of death was cardiomyopathy in 2 patients with MELAS, cerebral infarction in 1 patient with MELAS, epilepsy and aspiration pneumonia in 1 patient with MELAS, and multiple metastases from gastric cancer and aspiration pneumonia in 1 patient with CPEO. CONCLUSION: Patients with CIP tend to have disorders that are suspected to be related to mitochondrial diseases at younger ages than are patients without CIP. (C) 2012 Baishideng. All rights reserved.
C1 [Inamori, Masahiko] Yokohama City Univ, Sch Med, Div Gastroenterol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan.
   [Gotoh, Eiji] Yokohama City Univ, Sch Med, Dept Med Educ, Yokohama, Kanagawa 2360004, Japan.
   [Koyano, Shigeru; Kuroiwa, Yoshiyuki] Yokohama City Univ, Sch Med, Dept Neurol, Yokohama, Kanagawa 2360004, Japan.
C3 Yokohama City University; Yokohama City University; Yokohama City University
RP Inamori, M (corresponding author), Yokohama City Univ, Sch Med, Div Gastroenterol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM inamorim@med.yokohama-cu.ac.jp
FU Ministry of Health, Labour and Welfare of Japan
CR Amiot A, 2009, GASTROENTEROLOGY, V137, P101, DOI 10.1053/j.gastro.2009.03.054
   ANURAS S, 1988, ANNU REV MED, V39, P1, DOI 10.1146/annurev.me.39.020188.000245
   Baris Z, 2010, EUR J PEDIATR, V169, P1375, DOI 10.1007/s00431-010-1237-0
   Betts J, 2008, NEUROLOGY, V70, P1290, DOI 10.1212/01.wnl.0000308940.38092.74
   Camarero-Temiño V, 2012, NEFROLOGIA, V32, P129, DOI 10.3265/Nefrologia.pre2011.Nov.11191
   Chinnery PF, 1997, QJM-INT J MED, V90, P657, DOI 10.1093/qjmed/90.11.657
   Chiyonobu T, 2008, BRAIN DEV-JPN, V30, P430, DOI 10.1016/j.braindev.2007.12.006
   Connor FL, 2006, GASTROENTEROLOGY, V130, PS29, DOI 10.1053/j.gastro.2005.06.081
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DUDLEY H A, 1958, J R COLL SURG EDINB, V3, P206
   FAUVILLE JP, 1995, J TOXICOL-CLIN TOXIC, V33, P273, DOI 10.3109/15563659509017999
   Fayssoil Abdallah, 2009, CONGEST HEART FAIL, V15, P284, DOI 10.1111/j.1751-7133.2009.00108.x
   Garone C, 2011, BRAIN, V134, P3326, DOI 10.1093/brain/awr245
   Gilbert J, 2005, MED HYPOTHESES, V64, P586, DOI 10.1016/j.mehy.2004.07.032
   Giordano C, 2011, METHODS MOL BIOL, V755, P223, DOI 10.1007/978-1-61779-163-5_18
   Glia A, 2004, DIS COLON RECTUM, V47, P96, DOI 10.1007/s10350-003-0016-7
   Granero Castro Pablo, 2010, INT ARCH MED, V3, P35, DOI 10.1186/1755-7682-3-35
   Hanna MG, 1999, CELL MOL LIFE SCI, V55, P691, DOI 10.1007/s000180050327
   Hirano M, 2006, INTERNAL MED, V45, P1103, DOI 10.2169/internalmedicine.45.6064
   Hokama A, 2011, WORLD J GASTRO ENDOS, V3, P157, DOI 10.4253/wjge.v3.i8.157
   Iida H, 2011, CLIN J GASTROENTEROL, V4, P141, DOI 10.1007/s12328-011-0219-8
   Kim J, 2011, J NEUROGASTROENTEROL, V17, P423, DOI 10.5056/jnm.2011.17.4.423
   Makino M, 1999, ANN REV SHINKEI, V0, P406
   Masaki T, 2012, SURG TODAY, V42, P264, DOI 10.1007/s00595-011-0115-3
   OGILVIE H, 1948, BRIT MED J, V2, P671, DOI 10.1136/bmj.2.4579.671
   Oztas E, 2010, J GASTROINTEST LIVER, V19, P195
   Park JS, 2012, MOD RHEUMATOL, V0, P0
   Parsons T, 2010, ARCH NEUROL-CHICAGO, V67, P976, DOI 10.1001/archneurol.2010.174
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   Rudolph CD, 1997, J PEDIATR GASTR NUTR, V24, P102, DOI 10.1097/00005176-199701000-00021
   Sharma A, 2011, J POSTGRAD MED, V57, P218, DOI 10.4103/0022-3859.85212
   Slama A, 2005, MOL GENET METAB, V84, P326, DOI 10.1016/j.ymgme.2004.12.004
   Sutton Dwight H, 2006, NUTR CLIN PRACT, V21, P16, DOI 10.1177/011542650602100116
   Yamanaka Y, 2006, J NEUROL NEUROSUR PS, V77, P800, DOI 10.1136/jnnp.2005.079905
   Young RP, 2005, ANN PHARMACOTHER, V39, P1749, DOI 10.1345/aph.1G133
   Zhang J, 2011, LUPUS, V20, P1324, DOI 10.1177/0961203311405702
NR 36
TC 19
Z9 20
U1 0
U2 5
PU BAISHIDENG PUBL GRP CO LTD
PI BEIJING
PA RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU, BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA
SN 1007-9327
EI 
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD SEP 7
PY 2012
VL 18
IS 33
BP 4557
EP 4562
DI 10.3748/wjg.v18.i33.4557
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 005WA
UT WOS:000308779600015
PM 22969229
DA 2024-11-01
ER

PT J
AU Jang, YO
   Quan, XL
   Das, R
   Xu, SH
   Chung, CH
   Ahn, CM
   Baik, SK
   Kong, ID
   Park, KS
   Kim, MY
AF Jang, Yoon-Ok
   Quan, Xianglan
   Das, Ranjan
   Xu, Shanhua
   Chung, Choon-Hee
   Ahn, Chan Mug
   Baik, Soon-Koo
   Kong, In Deok
   Park, Kyu-Sang
   Kim, Moon Young
TI High-dose clevudine impairs mitochondrial function and glucose-stimulated insulin secretion in INS-1E cells
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE clevudine; mitochondrial DNA; mitochondrial dysfunction; glucose-stimulated insulin secretion
ID chronic hepatitis-b; dna-polymerase-gamma; reverse-transcriptase inhibitors; in-vivo; nucleoside; depletion; myopathy; therapy; hepatocytes; oxidation
AB Background: Clevudine is a nucleoside analog reverse transcriptase inhibitor that exhibits potent antiviral activity against hepatitis B virus (HBV) without serious side effects. However, mitochondrial myopathy has been observed in patients with chronic HBV infection taking clevudine. Moreover, the development of diabetes was recently reported in patients receiving long-term treatment with clevudine. In this study, we investigated the effects of clevudine on mitochondrial function and insulin release in a rat clonal beta-cell line, INS-1E. Methods: The mitochondrial DNA (mtDNA) copy number and the mRNA levels were measured by using quantitative PCR. MTT analysis, ATP/lactate measurements, and insulin assay were performed. Results: Both INS-1E cells and HepG2 cells, which originated from human hepatoma, showed dose-dependent decreases in mtDNA copy number and cytochrome c oxidase-1 (Cox-1) mRNA level following culture with clevudine (10 mu M-1 mM) for 4 weeks. INS-1E cells treated with clevudine had reduced total mitochondrial activities, lower cytosolic ATP contents, enhanced lactate production, and more lipid accumulation. Insulin release in response to glucose application was markedly decreased in clevudine-treated INS-1E cells, which might be a consequence of mitochondrial dysfunction. Conclusions: Our data suggest that high-dose treatment with clevudine induces mitochondrial defects associated with mtDNA depletion and impairs glucose-stimulated insulin secretion in insulin-releasing cells. These findings partly explain the development of diabetes in patients receiving clevudine who might have a high susceptibility to mitochondrial toxicity.
C1 [Quan, Xianglan; Das, Ranjan; Xu, Shanhua; Kong, In Deok; Park, Kyu-Sang] Yonsei Univ, Wonju Coll Med, Dept Physiol, Wonju 220701, South Korea.
   [Jang, Yoon-Ok; Chung, Choon-Hee; Baik, Soon-Koo; Kim, Moon Young] Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju 220701, South Korea.
   [Ahn, Chan Mug] Yonsei Univ, Wonju Coll Med, Dept Basic Sci, Wonju 220701, South Korea.
   [Chung, Choon-Hee; Ahn, Chan Mug; Baik, Soon-Koo; Kong, In Deok; Park, Kyu-Sang; Kim, Moon Young] Yonsei Univ, Wonju Coll Med, Inst Lifestyle Med, Wonju 220701, South Korea.
C3 Yonsei University; Yonsei University; Yonsei University; Yonsei University
RP Park, KS (corresponding author), Yonsei Univ, Wonju Coll Med, Dept Physiol, Wonju 220701, South Korea.
EM qsang@yonsei.ac.kr; drkimmy@yonsei.ac.kr
FU Korean National Research Foundation [2010-0014617]; Yonsei University, Wonju College of Medicine [YUWCM-2009-19]
CR Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Cunha DA, 2008, J CELL SCI, V121, P2308, DOI 10.1242/jcs.026062
   Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624
   Fleischer RD, 2009, J HEPATOL, V51, P787, DOI 10.1016/j.jhep.2009.06.011
   FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6
   Goto M, 2003, J MED VIROL, V70, P497, DOI 10.1002/jmv.10423
   Igoudjil A, 2008, TOXICOL IN VITRO, V22, P887, DOI 10.1016/j.tiv.2008.01.011
   Jang JH, 2011, J VIRAL HEPATITIS, V18, P84, DOI 10.1111/j.1365-2893.2010.01281.x
   Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374
   Kim HJ, 2010, LIVER INT, V30, P834, DOI 10.1111/j.1478-3231.2010.02245.x
   Kwon SY, 2010, J VIROL, V84, P4494, DOI 10.1128/JVI.02066-09
   Lebrecht D, 2008, ARTHRITIS RHEUM-US, V58, P318, DOI 10.1002/art.23235
   Lebrecht D, 2007, HEPATOLOGY, V45, P72, DOI 10.1002/hep.21490
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Maassen JA, 2005, ANN MED, V37, P213, DOI 10.1080/07853890510007188
   Mallon PWG, 2005, J INFECT DIS, V191, P1686, DOI 10.1086/429697
   Miró O, 1998, J NEUROSCI METH, V80, P107, DOI 10.1016/S0165-0270(97)00204-5
   Niu C, 2008, ANTIVIR THER, V13, P263
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   Pai SB, 1996, ANTIMICROB AGENTS CH, V40, P380, DOI 10.1128/AAC.40.2.380
   Pan-Zhou XR, 2000, ANTIMICROB AGENTS CH, V44, P496, DOI 10.1128/AAC.44.3.496-503.2000
   Park KS, 2008, J BIOL CHEM, V283, P33347, DOI 10.1074/jbc.M806251200
   Pinti M, 2006, BBA-BIOENERGETICS, V1757, P700, DOI 10.1016/j.bbabio.2006.05.001
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Seok JI, 2009, HEPATOLOGY, V49, P2080, DOI 10.1002/hep.22959
   Sorrell MF, 2009, ANN INTERN MED, V150, P104, DOI 10.7326/0003-4819-150-2-200901200-00100
   Stankov MV, 2007, ANTIVIR THER, V12, P205
   Tak WY, 2010, J HEPATOL, V53, P261, DOI 10.1016/j.jhep.2010.03.006
   Tak WY, 2009, HEPATOL RES, V39, P944, DOI 10.1111/j.1872-034X.2009.00515.x
   Wang CH, 2010, ANN NY ACAD SCI, V1201, P157, DOI 10.1111/j.1749-6632.2010.05625.x
   Wiederkehr A, 2006, ENDOCRINOLOGY, V147, P2643, DOI 10.1210/en.2006-0057
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
   Yao GQ, 1996, BIOCHEM PHARMACOL, V51, P941, DOI 10.1016/0006-2952(96)00049-4
   김건우, 2010, THE KOREAN JOURNAL OF MEDICINE 대한내과학회지, V79, P569
NR 36
TC 6
Z9 6
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-230X
EI 
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD JAN 10
PY 2012
VL 12
IS 
BP 
EP 
DI 10.1186/1471-230X-12-4
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 902MC
UT WOS:000301041400001
PM 22230186
DA 2024-11-01
ER

PT J
AU Lamperti, C
   Diodato, D
   Lamantea, E
   Carrara, F
   Ghezzi, D
   Mereghetti, P
   Rizzi, R
   Zeviani, M
AF Lamperti, Costanza
   Diodato, Daria
   Lamantea, Eleonora
   Carrara, Franco
   Ghezzi, Daniele
   Mereghetti, Paolo
   Rizzi, Romana
   Zeviani, Massimo
TI MELAS-like encephalomyopathy caused by a new pathogenic mutation in the mitochondrial DNA encoded cytochrome c oxidase subunit I
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA; Mutation; MELAS; Cytochrome c oxidase; COX; Ragged-red fibers; SDH; Stroke-like episode; MTCOI; Mitochondrial disorder; Respiratory chain
ID deficiency; electrophoresis; cells; mtdna; gene
AB We report a 35-year-old woman presenting a stroke-like episode with transitory aphasia followed by generalized tonic-clonic seizures. She had severe hearing loss and suffered from frequent episodes of migraine. Although a brain MRI disclosed a T2-hyperintense lesion in the left parietal lobe, she had hardly any long-term sequela. Exercise intolerance, myalgias and limb-girdle muscle weakness indicated a slowly progressive myopathy. Extra-neurological features included short stature, and secondary amenorrhea with low gonadotropin levels, indicating secondary hypogonadism. However, she had three mutation-free, healthy children by ovarian stimulation. A muscle biopsy showed ragged-red, cytochrome c oxidase-negative fibers, and an isolated defect of cytochrome c oxidase activity in muscle mitochondria. Sequence analysis of muscle mtDNA revealed a previously unreported heteroplasmic m.6597C>A transversion in the MTCOI gene, encoding subunit I of cytochrome c oxidase, corresponding to p.Q232K aminoacid change. Analysis on transmitochondrial cybrids demonstrated that the mutation is indeed associated with COX deficiency, i.e. pathogenic. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Lamperti, Costanza; Diodato, Daria; Lamantea, Eleonora; Carrara, Franco; Ghezzi, Daniele; Zeviani, Massimo] Fdn Ist Neurol Carlo Besta IRCCS, Unit Mol Neurogenet, I-20126 Milan, Italy.
   [Mereghetti, Paolo] EML Res gGmbH, Mol & Cellular Modeling Grp, D-69118 Heidelberg, Germany.
   [Rizzi, Romana] Publ Hosp Santa Maria Nuova, Div Neurol, I-42123 Reggio Emilia, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Zeviani, M (corresponding author), Fdn Ist Neurol Carlo Besta IRCCS, Unit Mol Neurogenet, Via Temolo 4, I-20126 Milan, Italy.
EM Massimo.Zeviani@istituto-besta.it
FU Fondazione Pierfranco e Luisa Mariani; Fondazione Telethon [GGP11011, GPP10005]; Fondazione CARIPLO [2011/0526]; Italian Association of Mitochondrial Disease Patients and Families (Mitocon)
CR Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   Dubowitz V, 1985, MUSCLE BIOPSY PRATIC, V0, P0
   Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   Kaila VRI, 2011, BBA-BIOENERGETICS, V1807, P769, DOI 10.1016/j.bbabio.2010.12.016
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Tam EWY, 2008, NEUROPEDIATRICS, V39, P328, DOI 10.1055/s-0029-1202287
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
NR 18
TC 19
Z9 21
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD NOV 15
PY 2012
VL 22
IS 11
BP 990
EP 994
DI 10.1016/j.nmd.2012.06.003
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 047CU
UT WOS:000311816100010
PM 22832341
DA 2024-11-01
ER

PT J
AU Massie, R
   Wang, J
   Chen, LC
   Zhang, VW
   Collins, MP
   Wong, LJC
   Milone, M
AF Massie, Rami
   Wang, Jing
   Chen, Li-Chieh
   Zhang, Victor W.
   Collins, Michael P.
   Wong, Lee-Jun C.
   Milone, Margherita
TI Mitochondrial myopathy due to novel missense mutation in the <i>cytochrome</i> <i>c oxidase 1</i> gene
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial myopathy; Muscle inflammation; Cytochrome c oxidase; COX; MTCO1
ID oxidase subunit-ii; c-oxidase; nonsense mutation; lactic-acidosis; human mtdna; recurrent myoglobinuria; dna; deficiency; encephalomyopathy; patient
AB We report a novel heteroplasmic mutation p.Y440C in the mitochondrial DNA-encoded subunit! of the cytochrome c oxidase (COX) gene in a patient with late onset progressive painless weakness. Her muscle biopsy showed scattered COX-negative fibers and several small collections of inflammatory cells. The mutation was detected in the patient's muscle but not in her blood. The low mutant load in muscle could explain the patient's late onset of the myopathy and milder phenotype when compared to the previously published cases with MTCO1 mutations. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Wang, Jing; Chen, Li-Chieh; Zhang, Victor W.; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Massie, Rami; Milone, Margherita] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
   [Collins, Michael P.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.
C3 Baylor College of Medicine; Mayo Clinic; Medical College of Wisconsin
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
FU Mayo Clinic CTSA through NIH/NCRR [UL1 RR024150]
CR Abu-Amero Khaled K, 2005, OPHTHALMIC GENET, V26, P31, DOI 10.1080/13816810590918235
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Brautbar A, 2008, MOL GENET METAB, V94, P485, DOI 10.1016/j.ymgme.2008.04.004
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Brzezinski P, 2008, J BIOENERG BIOMEMBR, V40, P521, DOI 10.1007/s10863-008-9181-7
   Campos Y, 2001, ANN NEUROL, V50, P409, DOI 10.1002/ana.1141
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X
   DEMARCHI JM, 1994, HUM MUTAT, V4, P281, DOI 10.1002/humu.1380040409
   FITZSIMONS RB, 1994, LANCET, V344, P902, DOI 10.1016/S0140-6736(94)92263-2
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Herrero-Martin Maria D, 2008, HUM MUTAT, V29, PE112, DOI 10.1002/humu.20800
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Horváth R, 2002, J MED GENET, V39, P812, DOI 10.1136/jmg.39.11.812
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Lucioli S, 2006, NEUROGENETICS, V7, P51, DOI 10.1007/s10048-005-0015-z
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   Shanske S, 2004, MITOCHONDRION, V4, P403, DOI 10.1016/j.mito.2004.07.026
   Tam EWY, 2008, NEUROPEDIATRICS, V39, P328, DOI 10.1055/s-0029-1202287
   Temiz P, 2009, J NEUROL SCI, V278, P25, DOI 10.1016/j.jns.2008.11.010
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   Tsukihara T, 2003, P NATL ACAD SCI USA, V100, P15304, DOI 10.1073/pnas.2635097100
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Wang J, 2009, MOL GENET METAB, V96, P59, DOI 10.1016/j.ymgme.2008.10.006
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
NR 36
TC 6
Z9 7
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD AUG 15
PY 2012
VL 319
IS 1-2
BP 158
EP 163
DI 10.1016/j.jns.2012.05.003
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 971ZS
UT WOS:000306246900032
PM 22632780
DA 2024-11-01
ER

PT J
AU Honzik, T
   Tesarova, M
   Magner, M
   Mayr, J
   Jesina, P
   Vesela, K
   Wenchich, L
   Szentivanyi, K
   Hansikova, H
   Sperl, W
   Zeman, J
AF Honzik, Tomas
   Tesarova, Marketa
   Magner, Martin
   Mayr, Johannes
   Jesina, Pavel
   Vesela, Katerina
   Wenchich, Laszlo
   Szentivanyi, Karol
   Hansikova, Hana
   Sperl, Wolfgang
   Zeman, Jiri
TI Neonatal onset of mitochondrial disorders in 129 patients: clinical and laboratory characteristics and a new approach to diagnosis
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID cytochrome-c-oxidase; pyruvate-dehydrogenase deficiency; respiratory-chain deficiency; acute metabolic decompensation; blue-native-electrophoresis; pediatric-patients; barth-syndrome; muscle mitochondria; skeletal-muscle; dna depletion
AB Mitochondrial disorders (MD) may manifest in neonates, but early diagnosis is difficult. In this study, clinical and laboratory data were analyzed in 129 patients with neonatal onset of MD to identify any association between specific mitochondrial diseases and their symptoms with the aim of optimizing diagnosis. Retrospective clinical and laboratory data were evaluated in 461 patients (331 families) with confirmed MD. The neonatal onset of MD was reported in 28% of the patients. Prematurity, intrauterine growth retardation and hypotonia necessitating ventilatory support were present in one-third, cardiomyopathy in 40%, neonatal seizures in 16%, Leigh syndrome in 15%, and elevated lactate level in 87%. Hyperammonemia was observed in 22 out of 52 neonates. Complex I deficiency was identified in 15, complex III in one, complex IV in 23, complex V in 31, combined deficiency of several complexes in 53, and PDH complex deficiency was identified in six patients. Molecular diagnosis was confirmed in 49 cases, including a newborn with a 9134A > G mutation in the MTATP6 gene, which has not been described previously. The most significant finding is the high incidence of neonatal cardiomyopathy and hyperammonemia. Based on our experience, we propose a diagnostic flowchart applicable to critically ill neonates suspicious for MD. This tool will allow for the use of direct molecular genetic analyses without the need for muscle biopsies in neonates with Alpers, Barth, MILS and Pearson syndromes, SCO1, SCO2, TMEM70, ATP5E, SUCLG1 gene mutations and PDH complex deficiency.
C1 [Honzik, Tomas; Tesarova, Marketa; Magner, Martin; Jesina, Pavel; Vesela, Katerina; Wenchich, Laszlo; Szentivanyi, Karol; Hansikova, Hana; Zeman, Jiri] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague 12000 2, Czech Republic.
   [Honzik, Tomas; Tesarova, Marketa; Magner, Martin; Jesina, Pavel; Vesela, Katerina; Wenchich, Laszlo; Szentivanyi, Karol; Hansikova, Hana; Zeman, Jiri] Gen Univ Hosp Prague, Prague 12000 2, Czech Republic.
   [Mayr, Johannes; Sperl, Wolfgang] Paracelsus Med Univ Salzburg, Dept Pediat, A-5020 Salzburg, Austria.
C3 Charles University Prague; General University Hospital Prague; Paracelsus Private Medical University
RP Zeman, J (corresponding author), Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Ke Karlovu 2, Prague 12000 2, Czech Republic.
EM jzem@lf1.cuni.cz
FU Ministry of Health of Czech Republic [IGA MZ NS 10561-3/2009, IGA MZ NS 9782-4/2008, IGA MZ NT 11186-5/2010]; Center of Applied Genomics from Ministry of Education, Youth and Sports of Czech Republic [1 M520]; Vereinigung zur Forschung und Fortbildung, Univ. Kinderklinik Salzburg, Austria
CR Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Barnerias C, 2010, DEV MED CHILD NEUROL, V52, Pe1, DOI 10.1111/j.1469-8749.2009.03541.x
   Barth PG, 2004, AM J MED GENET A, V126A, P349, DOI 10.1002/ajmg.a.20660
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Cameron JM, 2011, MITOCHONDRION, V11, P191, DOI 10.1016/j.mito.2010.09.008
   Capkova M, 2002, CAS LEK CESK, V141, P636
   Cerna L, 2001, MED SCI MONIT, V7, P1319
   CONSTANTINTEODOSIU D, 1991, ANAL BIOCHEM, V198, P347, DOI 10.1016/0003-2697(91)90437-X
   Debray FG, 2007, PEDIATRICS, V119, P722, DOI 10.1542/peds.2006-1866
   Donati MA, 2006, J INHERIT METAB DIS, V29, P684, DOI 10.1007/s10545-006-0388-7
   Fragaki K, 2009, MITOCHONDRION, V9, P346, DOI 10.1016/j.mito.2009.06.002
   García-Cazorla A, 2005, PEDIATRICS, V116, P1170, DOI 10.1542/peds.2004-2407
   Gibson K, 2008, PEDIATRICS, V122, P1003, DOI 10.1542/peds.2007-3502
   Honzik T, 2008, EARLY HUM DEV, V84, P269, DOI 10.1016/j.earlhumdev.2006.07.008
   Honzík T, 2010, ARCH DIS CHILD, V95, P296, DOI 10.1136/adc.2009.168096
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523
   Leshinsky-Silver E, 2005, BIOCHEM BIOPH RES CO, V334, P582, DOI 10.1016/j.bbrc.2005.06.134
   Lui K, 2006, PEDIATRICS, V118, P2076, DOI 10.1542/peds.2006-1540
   Magner M, 2011, EUR J PAEDIATR NEURO, V15, P101, DOI 10.1016/j.ejpn.2010.10.001
   Mayr JA, 2004, PEDIATR RES, V55, P988, DOI 10.1203/01.pdr.0000127016.67809.6b
   Mayr JA, 2010, HUM MOL GENET, V19, P3430, DOI 10.1093/hmg/ddq254
   Morava E, 2006, NEUROLOGY, V67, P1823, DOI 10.1212/01.wnl.0000244435.27645.54
   Morel AS, 2009, EUR J PEDIATR, V168, P311, DOI 10.1007/s00431-008-0756-4
   Moslemi AR, 2008, NEUROPEDIATRICS, V39, P24, DOI 10.1055/s-2008-1076739
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pejznochova M, 2010, MITOCHONDRION, V10, P321, DOI 10.1016/j.mito.2010.01.006
   Pontes Azevedo Luciano Cesar, 2010, ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, V10, P214
   Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   SCHAGGER H, 1995, EUR J BIOCHEM, V230, P235, DOI 10.1111/j.1432-1033.1995.0235i.x
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Schiff M, 2011, SEMIN FETAL NEONAT M, V16, P216, DOI 10.1016/j.siny.2011.04.002
   Shchelochkov OA, 2010, MOL GENET METAB, V101, P282, DOI 10.1016/j.ymgme.2010.07.012
   Skladal D, 2003, CLIN PEDIATR, V42, P703, DOI 10.1177/000992280304200806
   Smits P, 2010, EUR J HUM GENET, V18, P324, DOI 10.1038/ejhg.2009.169
   Soares-Fernandes JP, 2008, PEDIATR RADIOL, V38, P559, DOI 10.1007/s00247-007-0721-9
   SPERL W, 1992, ANN CLIN BIOCHEM, V29, P638, DOI 10.1177/000456329202900604
   Spiegel R, 2011, J MED GENET, V48, P177, DOI 10.1136/jmg.2010.084608
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stiburek L, 2009, AM J PHYSIOL-CELL PH, V296, PC1218, DOI 10.1152/ajpcell.00564.2008
   Strassburg HM, 2006, NEUROPEDIATRICS, V37, P137, DOI 10.1055/s-2006-924555
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Suomalainen A, 2011, J INHERIT METAB DIS, V34, P277, DOI 10.1007/s10545-010-9222-3
   Taylor GP, 2004, PEDIATR DEVEL PATHOL, V7, P620, DOI 10.1007/s10024-004-5050-5
   Tesarova M, 2002, CAS LEK CESK, V141, P551
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Vary TC, 1999, MOL CELL BIOCHEM, V198, P113, DOI 10.1023/A:1006993910781
   Verdijk RM, 2008, AM J MED GENET A, V146A, P2822, DOI 10.1002/ajmg.a.32523
   Vesela K, 2004, ACTA PAEDIATR, V93, P1312, DOI 10.1080/08035250410031341
   von Kleist-Retzow JC, 2003, J PEDIATR-US, V143, P208, DOI 10.1067/S0022-3476(03)00130-6
   Wexler ID, 1997, NEUROLOGY, V49, P1655, DOI 10.1212/WNL.49.6.1655
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   Wortmann SB, 2007, ACTA PAEDIATR, V96, P450, DOI 10.1111/j.1651-2227.2006.00158.x
   Yen TY, 2008, EUR J PEDIATR, V167, P941, DOI 10.1007/s00431-007-0592-y
   Zand DJ, 2003, AM J NEURORADIOL, V24, P1471
NR 63
TC 59
Z9 65
U1 0
U2 19
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD SEP 15
PY 2012
VL 35
IS 5
BP 749
EP 759
DI 10.1007/s10545-011-9440-3
PG 11
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 998NO
UT WOS:000308247000002
PM 22231385
DA 2024-11-01
ER

PT J
AU Saito, K
   Kimura, N
   Oda, N
   Shimomura, H
   Kumada, T
   Miyajima, T
   Murayama, K
   Tanaka, M
   Fujii, T
AF Saito, Keiko
   Kimura, Nobusuke
   Oda, Nozomi
   Shimomura, Hideki
   Kumada, Tomohiro
   Miyajima, Tomoko
   Murayama, Kei
   Tanaka, Masashi
   Fujii, Tatsuya
TI Pyruvate therapy for mitochondrial DNA depletion syndrome
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE Pyruvate therapy; Mitochondrial DNA depletion syndrome; Mitochondrial diseases; Treatment; Lactate-to-pyruvate ratio; NAD(+)
ID mtdna; deficiency; diseases; mngie; cells
AB Background: Mitochondrial DNA depletion syndromes are a group of heterogeneous autosomal recessive disorders associated with a severe reduction in mitochondrial DNA in the affected tissues. Sodium pyruvate has been reported to have a therapeutic effect in mitochondrial diseases. Methods: We analyzed the effects of 0.5 g/kg of sodium pyruvate administered through a nasogastric tube in a one-year-old patient with myopathic mitochondrial DNA depletion syndrome. To evaluate the improvement, we used the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) and manual muscle testing. As the improvement of motor functions in this severely disabled infant could not be comprehensively detected by NPMDS, we also observed the infant's ability to perform several tasks such as pouting, winking, and number of times she could tap a toy xylophone with a stick. Blood lactate and pyruvate levels were also monitored. Results: After one month's treatment, the NPMDS score in section IV, the domain for the quality of life, improved from 17 to 13. The infant became capable of raising her forearm, lower leg and wrist against gravity. The maximum number of times she could repeat each task increased and the movements became brisker and stronger. No significant change of the blood lactate level or lactate-to-pyruvate ratio, both of which were mildly increased at the initiation of the therapy, was observed despite the clinical improvement. Conclusion: Sodium pyruvate administered at 0.5 g/kg improved the muscle strength and the NPMDS score of an infant with myopathic mitochondrial DNA depletion syndrome. General significance: Sodium pyruvate may be effective for ameliorating the clinical manifestations of mitochondrial diseases. This article is part of a Special Issue entitled: Biochemistry of Mitochondria. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Saito, Keiko; Kimura, Nobusuke; Oda, Nozomi; Shimomura, Hideki; Kumada, Tomohiro; Miyajima, Tomoko; Fujii, Tatsuya] Shiga Med Ctr Children, Dept Pediat, Moriyama, Shiga 5240022, Japan.
   [Murayama, Kei] Chiba Childrens Hosp, Dept Metab, Chiba 2660007, Japan.
   [Tanaka, Masashi] Tokyo Metropolitan Inst Gerontol, Dept Genom Longev & Hlth, Itabashi Ku, Tokyo 1730015, Japan.
C3 Chiba Children's Hospital; Tokyo Metropolitan Institute of Gerontology
RP Saito, K (corresponding author), 5-7-30 Moriyama, Moriyama, Shiga 5240022, Japan.
EM ksaitou-kyt@umin.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology; Takeda Science Foundation;  [A-22240072]
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Komaki H, 2010, BBA-GEN SUBJECTS, V1800, P313, DOI 10.1016/j.bbagen.2009.07.008
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Murayama K, 2009, EUR J PEDIATR, V168, P297, DOI 10.1007/s00431-008-0753-7
   Phoenix C, 2006, NEUROMUSCULAR DISORD, V16, P814, DOI 10.1016/j.nmd.2006.08.006
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tanaka M, 2007, MITOCHONDRION, V7, P399, DOI 10.1016/j.mito.2007.07.002
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Yavuz H, 2007, ARCH NEUROL-CHICAGO, V64, P435, DOI 10.1001/archneur.64.3.435
NR 15
TC 18
Z9 24
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD MAY 15
PY 2012
VL 1820
IS 5
BP 632
EP 636
DI 10.1016/j.bbagen.2011.08.006
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 930JO
UT WOS:000303135900013
PM 21855607
DA 2024-11-01
ER

PT J
AU Kosowska, B
   Strzala, T
   Brzezinska, K
   Grabowski, K
   Moska, M
   Dobosz, T
   Lebioda, A
AF Kosowska, Barbara
   Strzala, Tomasz
   Brzezinska, Katarzyna
   Grabowski, Krzysztof
   Moska, Magdalena
   Dobosz, Tadeusz
   Lebioda, Arleta
TI Phylogenetic analysis of steroid 21-hydroxylase (CYP21) of the wolf and selected breeds of dogs in connection with the role of this enzyme in the pathogenesis of many diseases in the Canidae family
SO MEDYCYNA WETERYNARYJNA-VETERINARY MEDICINE-SCIENCE AND PRACTICE
LA English
DT Article
DE canis lupus familiaris; 21steroid hydroxylase; pathogenesis; phylogenetics; CYP21
ID congenital adrenal-hyperplasia; alopecia-x; autoimmune-disease; mitochondrial-dna; gene-expression; candidate gene; sequence; genome; organization; pomeranians
AB The aim of this study was to determine the nucleotide sequence of the CYP21 gene in the wolf and representatives of five breeds of dogs (selected according to a classification by Parker et al, 2004) in connection with the key role of the product of this gene in the genesis of many diseases in dogs. Nuclear DNA of dogs was obtained from peripheral blood, and the wolf's DNA was isolated from muscle tissue. The amplification of the 21HS gene was carried out in 10 fragments under standardized PCR conditions. The reaction products were sequenced. The sequence of amino acids in the protein was determined on the basis of the nucleotide sequence. The sequences obtained in our study and those retrieved from the GeneBank database were compared with the Mafft program (15) and subjected to phylogenetic analysis with the MrBayes 3.2 program (35). We detected a total of nine SNP mutations in introns and exons. Furthermore, a deletion of two nucleotides, that differentiates the breeds, was detected in the promoter region. Only two differences between the dogs and the wolf were found in SNP: one in an exon and one in an intron. Genetic distance was determined between the selected breeds of dogs and between the wolf and the dogs of each breed. In addition, we estimated the evolutionary distances between amino acid sequences of the dog/wolf and homologous 21HS sequences of eight different vertebrate species obtained from GeneBank. It was shown that, among mammals, the amino acid sequence of the dog/wolf is the most similar to the sequence of the pig, and the least similar to that of the human. The sequences determined in this study may provide a reference point for the research on the CYP21 gene structure and expression in various tissues of dogs for therapeutic purposes.
C1 [Kosowska, Barbara; Strzala, Tomasz; Brzezinska, Katarzyna; Grabowski, Krzysztof; Moska, Magdalena] Wroclaw Univ Environm & Life Sci, Dept Genet, PL-51631 Wroclaw, Poland.
   [Dobosz, Tadeusz; Lebioda, Arleta] Wroclaw Med Univ, Dept Forens Med, Inst Mol Tech, PL-50369 Wroclaw, Poland.
C3 Wroclaw University of Environmental & Life Sciences; Wroclaw Medical University
RP Kosowska, B (corresponding author), Ul Kozuchowska 7, PL-51631 Wroclaw, Poland.
EM barbara.kosowska@up.wroc.pl
CR [Anonymous], 2004, MRMODELTEST V2, V0, P0, DOI DOI 10.1093/SYSBIO/SYS029
   Barg E, 2003, ADV CLIN EXP MED, V12, P507
   CAMERON PU, 1990, IMMUNOGENETICS, V31, P253, DOI 10.1007/BF00204897
   Cerundolo R, 2007, VET REC, V160, P393, DOI 10.1136/vr.160.12.393
   Corneli Patrice Showers, 2002, JOURNAL OF MAMMALIAN EVOLUTION, V9, P281, DOI 10.1023/A:1023926013667
   CRAWFORD RJ, 1992, J BIOL CHEM, V267, P16212
   Darriba D, 2011, BIOINFORMATICS, V27, P1164, DOI 10.1093/bioinformatics/btr088
   Frank LA, 2005, JAVMA-J AM VET MED A, V226, P1494, DOI 10.2460/javma.2005.226.1494
   Frank LA, 2004, VET DERMATOL, V15, P278, DOI 10.1111/j.1365-3164.2004.00372.x
   Galac S, 2010, DOMEST ANIM ENDOCRIN, V39, P259, DOI 10.1016/j.domaniend.2010.07.001
   GarciaMoreno J, 1996, CONSERV BIOL, V10, P376, DOI 10.1046/j.1523-1739.1996.10020376.x
   Hall TA, 1900, V41, V0, P95
   HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841
   Katoh K, 2010, BIOINFORMATICS, V26, P1899, DOI 10.1093/bioinformatics/btq224
   KAWAGUCHI H, 1990, EUR J IMMUNOL, V20, P739, DOI 10.1002/eji.1830200405
   KAWAGUCHI H, 1992, HUM IMMUNOL, V33, P153, DOI 10.1016/0198-8859(92)90067-W
   Kayes-Wandover KM, 2000, J CLIN ENDOCR METAB, V85, P2519, DOI 10.1210/jc.85.7.2519
   Klein SC, 2010, CAN VET J, V51, P63
   LAJIC S, 1995, J STEROID BIOCHEM, V52, P181, DOI 10.1016/0960-0760(94)00158-I
   Lessard CJ, 2012, AUTOIMMUN REV, V11, P267, DOI 10.1016/j.autrev.2011.10.003
   Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338
   Mausberg EM, 2007, ANIM BIOTECHNOL, V18, P391, DOI 10.1080/10495390701547461
   Mausberg EM, 2007, DEUT TIERARZTL WOCH, V114, P129, DOI 10.2377/0341-6593-114-129
   Mausberg EM, 2008, VET REC, V163, P121, DOI 10.1136/vr.163.4.121
   Miller WL, 1986, P NATL ACAD SCI USA, V4, P211
   Mitchell AL, 2012, NAT REV ENDOCRINOL, V8, P306, DOI 10.1038/nrendo.2012.200
   Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   Novartis Animal Health, 2003, J VET MED S, V50, P0
   PANG S, 1992, ENDOCRINOLOGY, V131, P181, DOI 10.1210/en.131.1.181
   Parker HG, 2004, SCIENCE, V304, P1160, DOI 10.1126/science.1097406
   Rajpitt N, 2009, J VET PHARM TOX, V8, P0
   Rogoff D, 2001, J STEROID BIOCHEM, V78, P77, DOI 10.1016/S0960-0760(01)00076-0
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Schaer M, 2005, P 30 WORLD C WORLD S, V0, P0
   Schmeitzel LP, 1995, KIRKS CURRENT VET TH, V0, P600
   SPEISER PW, 1985, AM J HUM GENET, V37, P650
   Stafford D, 1999, VET TECH, V20, P490
   Takada K, 2002, RES VET SCI, V73, P159, DOI 10.1016/S0034-5288(02)00070-X
   Tsuda K, 1997, GENES GENET SYST, V72, P229, DOI 10.1266/ggs.72.229
   Vilà C, 1999, MOL ECOL, V8, P2089, DOI 10.1046/j.1365-294x.1999.00825.x
   WAYNE RK, 1993, TRENDS GENET, V9, P218, DOI 10.1016/0168-9525(93)90122-X
   WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111
   Wiebolt J, 2010, EUR J CLIN INVEST, V40, P1144, DOI 10.1111/j.1365-2362.2010.02366.x
   Yu L, 2002, MOL CELL ENDOCRINOL, V190, P9, DOI 10.1016/S0303-7207(02)00041-2
   Zhou MY, 1997, J STEROID BIOCHEM, V62, P277, DOI 10.1016/S0960-0760(97)00040-X
   Ziaja J, 2008, ENDOKRYNOL POL, V59, P0
NR 48
TC 1
Z9 1
U1 0
U2 17
PU POLISH SOC VETERINARY SCIENCES EDITORIAL OFFICE
PI LUBLIN
PA AKADEMICKA 12, 20-950 LUBLIN, POLAND
SN 0025-8628
EI 
J9 MED WETER
JI Med. Weter.
PD SEP 15
PY 2012
VL 68
IS 9
BP 550
EP 556
DI 
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA 000IZ
UT WOS:000308381300008
DA 2024-11-01
ER

PT J
AU Blakely, EL
   Butterworth, A
   Hadden, RDM
   Bodi, I
   He, LP
   McFarland, R
   Taylor, RW
AF Blakely, Emma L.
   Butterworth, Anna
   Hadden, Robert D. M.
   Bodi, Istvan
   He, Langping
   McFarland, Robert
   Taylor, Robert W.
TI <i>MPV17</i> mutation causes neuropathy and leukoencephalopathy with multiple mtDNA deletions in muscle
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial DNA; mtDNA maintenance; Multiple mtDNA deletions; Neuropathy; COX-deficient fibres
ID mitochondrial-dna depletion; progressive external ophthalmoplegia; thymidine kinase; gene; protein; myopathy; twinkle; disease; cells; form
AB Disorders of mitochondrial DNA (mtDNA) maintenance are clinically and genetically heterogeneous, embracing recessive mtDNA depletion syndromes affecting children and adult-onset multiple mtDNA deletion disorders. Here we show that mutation of MPV17 - a gene implicated in severe, infantile hepatocerebral mtDNA depletion disorders characterised by a loss of mtDNA - copies can also cause clonally-expanded mtDNA deletion and focal cytochrome c oxidase (COX) deficiency in skeletal muscle associated with an adult presentation of neuropathy and leukoencephalopathy. The mpv17 protein is therefore intimately involved in both the mtDNA replication and repair processes and associated with both quantitative and qualitative mtDNA abnormalities. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Blakely, Emma L.; Butterworth, Anna; He, Langping; McFarland, Robert; Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Hadden, Robert D. M.] Kings Coll Hosp, Dept Neurol, London SE5 9RS, England.
C3 Newcastle University - UK; King's College Hospital NHS Foundation Trust; King's College Hospital
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
FU Wellcome Trust Centre for Mitochondrial Research [906919]; UK NHS Specialised Services "Rare Mitochondrial Disorders of Adults and Children" Diagnostic Service; MRC [G0800674] Funding Source: UKRI
CR Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Dallabona C, 2010, HUM MOL GENET, V19, P1098, DOI 10.1093/hmg/ddp581
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Navarro-Sastre A, 2008, MOL GENET METAB, V94, P234, DOI 10.1016/j.ymgme.2008.01.012
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65, P1108, DOI 10.1001/archneur.65.8.1108
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Viscomi C, 2009, HUM MOL GENET, V18, P12, DOI 10.1093/hmg/ddn309
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
NR 22
TC 48
Z9 50
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUL 15
PY 2012
VL 22
IS 7
BP 587
EP 591
DI 10.1016/j.nmd.2012.03.006
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 975VH
UT WOS:000306539100002
PM 22508010
DA 2024-11-01
ER

PT J
AU Buchaklian, AH
   Helbling, D
   Ware, SM
   Dimmock, DP
AF Buchaklian, Adam H.
   Helbling, Daniel
   Ware, Stephanie M.
   Dimmock, David P.
TI Recessive deoxyguanosine kinase deficiency causes juvenile onset mitochondrial myopathy
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Mitochondrial DNA depletion; DGUOK deficiency; Hepatocerebral, cardiomyopathy
ID dna depletion syndrome; mtdna depletion; molecular-features; fibroblasts; mutations; liver; supplementation; expression; genes
AB Deoxyguanosine kinase (DGUOK) (MIM#601465) deficiency was originally described as the cause of an infantile onset hepatocerebral mitochondrial disease [1]. The classic features of this disorder include significant hepatic failure with nystagmus and hypotonia. Mitochondrial DNA studies reveal significant mitochondrial DNA depletion in the affected tissues. Subsequently it has been shown that the same mutations in this gene may present with isolated acute liver failure without cerebral involvement. In this paper we studied the mitochondrial DNA depletion in cells from a patient presenting with mitochondrial myopathy caused by a novel mutation in DGUOK. Subsequently we developed the method to diagnose this condition using MyoD induced fibroblasts to study the muscle specific phenotype. In addition, supplementation of MyoD induced fibroblasts with dAMP and dGMP resulted in a restoration of mtDNA quantity. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Buchaklian, Adam H.; Helbling, Daniel; Dimmock, David P.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53221 USA.
   [Buchaklian, Adam H.; Helbling, Daniel; Dimmock, David P.] Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53221 USA.
   [Ware, Stephanie M.] Cincinnati Childrens Hosp, Dept Pediat, Div Human Genet, Cincinnati, OH USA.
   [Ware, Stephanie M.] Cincinnati Childrens Hosp, Dept Pediat, Inst Heart, Cincinnati, OH USA.
C3 Medical College of Wisconsin; Medical College of Wisconsin; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center
RP Dimmock, DP (corresponding author), Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53221 USA.
EM ddimmock@mcw.edu
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   AMAYA Y, 1988, J BIOCHEM, V103, P177, DOI 10.1093/oxfordjournals.jbchem.a122227
   Bulst S, 2009, HUM MOL GENET, V18, P1590, DOI 10.1093/hmg/ddp074
   Cameron JM, 2004, MITOCHONDRION, V4, P387, DOI 10.1016/j.mito.2004.07.039
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock D, 2007, PEDIATRICS, V119, PE773, DOI 10.1542/peds.2006-1950
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Dimmock DP, 2008, LIVER TRANSPLANT, V14, P1480, DOI 10.1002/lt.21556
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   van den Heuvel LP, 2004, MITOCHONDRION, V4, P395, DOI 10.1016/j.mito.2004.07.005
   Viscomi C, 2009, HUM MOL GENET, V18, P12, DOI 10.1093/hmg/ddn309
   WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434
NR 20
TC 20
Z9 24
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD SEP-OCT 15
PY 2012
VL 107
IS 1-2
BP 92
EP 94
DI 10.1016/j.ymgme.2012.04.019
PG 3
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 014KI
UT WOS:000309374200014
PM 22622127
DA 2024-11-01
ER

PT J
AU Nomura, Y
AF Nomura, Yasutomo
TI Direct Quantification of Mitochondria and Mitochondrial DNA Dynamics
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Review
DE Mitochondria; mtDNA; image correlation spectroscopy; fusion; fission; cytoskeleton; fluorescence microscopy
ID axonal-transport; correlation spectroscopy; skeletal-muscle; living cells; protein; morphology; reticulum; fission; gene; mutations
AB Mitochondria are known to be one of major organelles within a cell and to play a crucial role in many cellular functions. These organelles show the dynamic behaviors such as fusion, fission and the movement along cytoskeletal tracks. Besides mitochondria, mitochondrial DNA is also highly motile. Molecular analysis revealed that several proteins are involved in mitochondria and mitochondrial DNA dynamics. In addition to the degeneration of specific nerves with high energy requirement, mutation of genes coding these proteins results in metabolic diseases. During the last few years, a significant amount of relevant data has been obtained on molecular basis of these diseases but mitochondrial dynamics in cells derived from the patients is poorly understood. So far time-lapse fluorescence microscopy, fluorescence recovery after photo bleaching and image correlation methods have been used to study organellar motion. Especially, image correlation method has possibility to evaluate diffusion coefficient of mitochondria and mitochondrial DNA simultaneously and directly. When we search candidates for compounds that modulate mitochondrial dynamics by high throughput screening, image correlation method may be useful although the careful interpretation is required for crowded and heterogeneous environment within a cell.
C1 Maebashi Inst Technol, Dept Syst Life Engn, Maebashi, Gunma, Japan.
RP Nomura, Y (corresponding author), Maebashi Inst Technol, Dept Syst Life Engn, 460-1 Kamisadori, Maebashi, Gunma, Japan.
EM ynomura@maebashi-it.ac.jp
FU Ministry of Education, Science, Sports and Culture of Japan [17500299]; Japan Science and Technology Agency [02-297]; Grants-in-Aid for Scientific Research [17500299] Funding Source: KAKEN
CR Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013
   Bach D, 2005, DIABETES, V54, P2685, DOI 10.2337/diabetes.54.9.2685
   Baumann G, 2010, CURR PHARM BIOTECHNO, V11, P527, DOI 10.2174/138920110791591454
   Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200
   Camoes F, 2009, J INHERIT METAB DIS, V32, P163, DOI 10.1007/s10545-008-1018-3
   Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019
   Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161
   De Vos KJ, 2008, ANNU REV NEUROSCI, V31, P151, DOI 10.1146/annurev.neuro.31.061307.090711
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034
   Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001
   HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269
   Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0
   Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.02745
   Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111
   KENNEDY EP, 1949, J BIOL CHEM, V179, P957
   Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034
   Knowles MK, 2002, P NATL ACAD SCI USA, V99, P14772, DOI 10.1073/pnas.232346999
   Kolin DL, 2007, CELL BIOCHEM BIOPHYS, V49, P141, DOI 10.1007/s12013-007-9000-5
   Koopman WJH, 2006, CYTOM PART A, V69A, P1, DOI 10.1002/cyto.a.20198
   Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003
   Maier D, 2001, MOL BIOL CELL, V12, P821, DOI 10.1091/mbc.12.4.821
   Margineantu D, 2000, BIOPHYS J, V79, P1833, DOI 10.1016/S0006-3495(00)76433-2
   Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130
   MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315
   NASS S, 1963, J CELL BIOL, V19, P613, DOI 10.1083/jcb.19.3.613
   Nomura Y, 2006, EXP MOL PATHOL, V80, P275, DOI 10.1016/j.yexmp.2005.11.006
   Nomura Y, 2006, ANAL BIOCHEM, V350, P196, DOI 10.1016/j.ab.2006.01.010
   Nomura Y, 2009, LETT DRUG DES DISCOV, V6, P319, DOI 10.2174/1570180810906050319
   Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019
   Park J, 2009, BIOCHEM BIOPH RES CO, V378, P518, DOI 10.1016/j.bbrc.2008.11.086
   Pizzo P, 2007, TRENDS CELL BIOL, V17, P511, DOI 10.1016/j.tcb.2007.07.011
   Poole AC, 2008, P NATL ACAD SCI USA, V105, P1638, DOI 10.1073/pnas.0709336105
   Santel A, 2001, J CELL SCI, V114, P867
   Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351
   Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245
   Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tavi P, 2010, J CELL PHYSIOL, V223, P376, DOI 10.1002/jcp.22044
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Laar VS, 2009, EXP NEUROL, V218, P247, DOI 10.1016/j.expneurol.2009.03.019
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Weiss M, 2008, ANN NY ACAD SCI, V1130, P21, DOI 10.1196/annals.1430.002
   YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443
   Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 52
TC 1
Z9 1
U1 0
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PD NOV 15
PY 2012
VL 13
IS 14
BP 2617
EP 2622
DI 10.2174/138920101314151120122752
PG 6
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 064AE
UT WOS:000313042500011
PM 22039812
DA 2024-11-01
ER

PT J
AU Williams, TB
   Daniels, M
   Puthenveetil, G
   Chang, R
   Wang, RY
   Abdenur, JE
AF Williams, T. B.
   Daniels, M.
   Puthenveetil, G.
   Chang, R.
   Wang, R. Y.
   Abdenur, J. E.
TI Pearson syndrome: Unique endocrine manifestations including Neonatal Diabetes and adrenal insufficiency
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Pearson syndrome; Mitochondrial disease; Neonatal diabetes; Adrenal insufficiency; Mitochondrial DNA deletion; Anemia
ID marrow-pancreas syndrome; mitochondrial-dna deletion; kearns-sayre-syndrome; dysfunction; anemia; duplication; disorders; childhood
AB Purpose: Pearson syndrome is a very rare metabolic disorder that is usually present in infancy with transfusion dependent macrocytic anemia and multiorgan involvement including exocrine pancreas, liver and renal tubular defects. The disease is secondary to a mitochondrial DNA deletion that is variable in size and location. Endocrine abnormalities can develop, but are usually not part of the initial presentation. We report two patients who presented with unusual endocrine manifestations, neonatal diabetes and adrenal insufficiency, who were both later diagnosed with Pearson syndrome. Methods: Medical records were reviewed. Confirmatory testing included: mitochondrial DNA deletion testing and sequencing of the breakpoints, muscle biopsy, and bone marrow studies. Results: Case 1 presented with hyperglycemia requiring insulin at birth. She had several episodes of ketoacidosis triggered by stress and labile blood glucose control. Workup for genetic causes of neonatal diabetes was negative. She had transfusion dependent anemia and died at 24 months due to multisystem organ failure. Case 2 presented with adrenal insufficiency and anemia during inturcurrent illness, requiring steroid replacement since 37 months of age. He is currently 4 years old and has mild anemia. Mitochondrial DNA studies confirmed a 4.9 kb deletion in patient 1 and a 5.1 kb deletion in patient 2. Conclusion: The patients reported highlight the importance of considering mitochondrial DNA disorders in patients with early onset endocrine dysfunction, and expand the knowledge about this rare mitochondria! disease. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Williams, T. B.; Chang, R.; Wang, R. Y.; Abdenur, J. E.] CHOC Childrens, Div Metab Disorders, Orange, CA 92868 USA.
   [Daniels, M.] CHOC Childrens, Div Endocrinol, Orange, CA 92868 USA.
   [Puthenveetil, G.] CHOC Childrens, Div Hematol, Orange, CA 92868 USA.
RP Abdenur, JE (corresponding author), CHOC Childrens, Div Metab Disorders, 455 S Main St, Orange, CA 92868 USA.
EM jabdenur@choc.org
FU Commission for Families and Children of Orange County
CR BADERMEUNIER B, 1994, BRIT J HAEMATOL, V87, P381, DOI 10.1111/j.1365-2141.1994.tb04926.x
   Bruno C, 1998, J INHERIT METAB DIS, V21, P155, DOI 10.1023/A:1005347826664
   DAnnunzio G, 2008, DIABETES CARE, V31, P1743, DOI 10.2337/dc08-0178
   de Andrade PBM, 2006, DIABETOLOGIA, V49, P1816, DOI 10.1007/s00125-006-0301-9
   FAVARETO F, 1989, HAEMATOLOGICA, V74, P591
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kerr DS, 2010, MOL GENET METAB, V99, P246, DOI 10.1016/j.ymgme.2009.11.005
   MAJANDER A, 1991, PEDIATR RES, V30, P327, DOI 10.1203/00006450-199110000-00007
   Manea EM, 2009, J PEDIAT HEMATOL ONC, V31, P947, DOI 10.1097/MPH.0b013e3181bbc4ef
   MORIKAWA Y, 1993, VIRCHOWS ARCH A, V423, P227, DOI 10.1007/BF01614775
   Morris AAM, 1997, ARCH DIS CHILD, V77, P56, DOI 10.1136/adc.77.1.56
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   RIBES A, 1993, J INHERIT METAB DIS, V16, P537, DOI 10.1007/BF00711675
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   Seneca S, 1997, CLIN GENET, V51, P338
   Simaan EM, 1999, PEDIATR NEUROL, V21, P830, DOI 10.1016/S0887-8994(99)00084-3
   SMITH OP, 1995, BRIT J HAEMATOL, V90, P469, DOI 10.1111/j.1365-2141.1995.tb05178.x
   SUPERTIFURGA A, 1993, EUR J PEDIATR, V152, P44, DOI 10.1007/BF02072515
   Wong LJC, 2010, DEV DISABIL RES REV, V16, P154, DOI 10.1002/ddrr.104
NR 21
TC 29
Z9 33
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD MAY 15
PY 2012
VL 106
IS 1
BP 104
EP 107
DI 10.1016/j.ymgme.2012.01.018
PG 4
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 936YG
UT WOS:000303625300016
PM 22424738
DA 2024-11-01
ER

PT J
AU DiMauro, S
   Tanji, K
   Schon, EA
AF DiMauro, Salvatore
   Tanji, Kurenai
   Schon, Eric A.
TI The Many Clinical Faces of Cytochrome <i>c</i> Oxidase Deficiency
SO MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION: NUCLEAR-ENCODED GENES, ENZYME REGULATION, AND PATHOPHYSIOLOGY
LA English
DT Article; Book Chapter
ID infantile mitochondrial myopathy; respiratory-chain deficiency; copper-binding protein; leigh-syndrome; hypertrophic cardiomyopathy; nonsense mutation; lactic-acidosis; renal dysfunction; assembly genes; cox deficiency
AB Cytochrome c oxidase (COX) catalyzes the last step in respiration, transferring electrons from cytochrome c to molecular oxygen and coupling electron transfer with proton translocation from the mitochondrial matrix to the intermembrane space. COX is composed of 13 subunits, three larger catalytic subunits encoded by mitochondrial DNA (mtDNA) and ten subunits encoded by nuclear DNA. Clinically heterogeneous human diseases were attributed to COX deficiency since the 1970s, mostly based on histochemical or biochemical data in muscle biopsies. Here, we revisit the COX deficiencies described before the molecular era, assess the value of COX histochemistry in conjunction with succinate dehydrogenase (SDH) stain, and review the clinical presentations of primary COX deficiencies defined at the molecular level. In general, mutations in mtDNA COX genes are associated with milder and later onset clinical syndromes, probably due to heteroplasmy. Mutations affecting nuclear-encoded COX subunits ("direct hits") are extremely rare whereas mutations affecting assembly proteins ("indirect hits") account for most COX deficiencies and the list keeps growing. Onset is generally in infancy and survival into adolescence or adult life is infrequent. The most common neurological disorder is Leigh syndrome, either alone or associated with cardiopathy, hepatopathy, or nephropathy.
C1 [DiMauro, Salvatore] Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai; Schon, Eric A.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Schon, Eric A.] Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia University
RP DiMauro, S (corresponding author), Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, New York, NY 10032 USA.
EM sd12@columbia.edu; kt8@columbia.edu; eas3@columbia.edu
FU PHS HHS [P01-H23062] Funding Source: Medline
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   Betts J, 2008, NEUROLOGY, V70, P1290, DOI 10.1212/01.wnl.0000308940.38092.74
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8
   BOUSTANY RN, 1983, ANN NEUROL, V14, P462, DOI 10.1002/ana.410140411
   BRESOLIN N, 1985, NEUROLOGY, V35, P802, DOI 10.1212/WNL.35.6.802
   Brosel S, 2010, AM J PATHOL, V177, P2541, DOI 10.2353/ajpath.2010.100229
   Bugiani M, 2005, J MED GENET, V42, P0, DOI 10.1136/jmg.2004.029926
   Chrzanowska-Lightowlers Z M A, 2011, NEUROMUSCUL DISORD, V21, P142, DOI 10.1016/j.nmd.2010.10.005
   Coenen MJH, 2006, J CHILD NEUROL, V21, P508, DOI 10.1177/08830738060210062501
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795
   DIMAURO S, 1986, ANN NY ACAD SCI, V488, P19
   DIMAURO S, 1990, PEDIATR RES, V28, P536, DOI 10.1203/00006450-199011000-00025
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Fontanesi F, 2008, IUBMB LIFE, V60, P557, DOI 10.1002/iub.86
   Fontanesi F, 2006, AM J PHYSIOL-CELL PH, V291, PC1129, DOI 10.1152/ajpcell.00233.2006
   Freisinger P, 2004, J INHERIT METAB DIS, V27, P67, DOI 10.1023/B:BOLI.0000016614.47380.2f
   Ghezzi D, 2008, AM J HUM GENET, V83, P415, DOI 10.1016/j.ajhg.2008.08.009
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   HEIMANPATTERSON TD, 1982, NEUROLOGY, V32, P898, DOI 10.1212/WNL.32.8.898
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   Horvath R, 2000, BIOCHEM BIOPH RES CO, V276, P530, DOI 10.1006/bbrc.2000.3495
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Huigsloot M, 2011, AM J HUM GENET, V88, P488, DOI 10.1016/j.ajhg.2011.03.002
   Hüttemann M, 2003, GENE, V312, P95, DOI 10.1016/S0378-1119(03)00604-8
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Jaksch M, 2001, NEUROLOGY, V57, P1440, DOI 10.1212/WNL.57.8.1440
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   KENNAWAY NG, 1990, PEDIATR RES, V28, P529
   Knuf M, 2007, ACTA PAEDIATR, V96, P130, DOI 10.1111/j.1651-2227.2007.00008.x
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Leary SC, 2006, MOL GENET METAB, V89, P129, DOI 10.1016/j.ymgme.2006.04.016
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Menkes JH, 2008, MOL GENETIC BASIS NE, V0, P721
   Mimaki M, 2010, ANN NEUROL, V68, P845, DOI 10.1002/ana.22111
   MINCHOM PE, 1983, J NEUROL SCI, V60, P453, DOI 10.1016/0022-510X(83)90156-9
   Mkaouar-Rebai E, 2011, J CHILD NEUROL, V26, P12, DOI 10.1177/0883073810371227
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORIN C, 1993, AM J HUM GENET, V53, P488
   Oquendo CE, 2004, J MED GENET, V41, P540, DOI 10.1136/jmg.2003.017426
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Péquignot MO, 2001, HUM MUTAT, V17, P374, DOI 10.1002/humu.1112.abs
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   Sacconi S, 2003, PEDIATR RES, V53, P224, DOI 10.1203/01.PDR.0000048100.91730.6A
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Salviati L, 2001, MITOCHONDRION, V1, P0
   Schara U, 2011, J INHERIT METAB DIS, V34, P197, DOI 10.1007/s10545-010-9250-z
   Seeger J, 2010, NEUROMUSCULAR DISORD, V20, P720, DOI 10.1016/j.nmd.2010.06.017
   SERVIDEI S, 1987, NEUROLOGY, V37, P58, DOI 10.1212/WNL.37.1.58
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   Tarnopolsky MA, 2004, AM J MED GENET A, V125A, P310, DOI 10.1002/ajmg.a.20466
   Tay SKH, 2004, ARCH NEUROL-CHICAGO, V61, P950, DOI 10.1001/archneur.61.6.950
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Tiranti V, 2009, NAT MED, V15, P200, DOI 10.1038/nm.1907
   Uusimaa J, 2011, J MED GENET, V48, P660, DOI 10.1136/jmg.2011.089995
   Uusimaa J, 2003, PEDIATRICS, V111, P0, DOI 10.1542/peds.111.3.e262
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   VANBIERVLIET JPGM, 1977, PEDIATR RES, V11, P1088, DOI 10.1203/00006450-197711100-00005
   VANCOSTER R, 1991, J NEUROL SCI, V104, P97, DOI 10.1016/0022-510X(91)90222-S
   Vesela K, 2008, APMIS, V116, P41, DOI 10.1111/j.1600-0463.2008.00772.x
   Weraarpachai W, 2012, AM J HUM GENET, V90, P142, DOI 10.1016/j.ajhg.2011.11.027
   Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
   Xu FH, 2004, BIOCHEM J, V382, P331, DOI 10.1042/BJ20040469
   ZEVIANI M, 1985, ANN NEUROL, V17, P414, DOI 10.1002/ana.410170422
   ZEVIANI M, 1986, ARCH NEUROL-CHICAGO, V43, P1198, DOI 10.1001/archneur.1986.00520110084025
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 82
TC 49
Z9 51
U1 1
U2 6
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 2214-8019
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PD JUN 15
PY 2012
VL 748
IS 
BP 341
EP 357
DI 10.1007/978-1-4614-3573-0_14
PG 17
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA BA2SD
UT WOS:000333845500015
PM 22729865
DA 2024-11-01
ER

PT J
AU Wolf, J
   Obermaier-Kusser, B
   Jacobs, M
   Milles, C
   Mörl, M
   von Pein, HD
   Grau, AJ
   Bauer, MF
AF Wolf, Joachim
   Obermaier-Kusser, Bert
   Jacobs, Martina
   Milles, Cornelia
   Moerl, Mario
   von Pein, Harald D.
   Grau, Armin J.
   Bauer, Matthias F.
TI A new mitochondrial point mutation in the transfer RNA<SUP>LYs</SUP> gene associated with progressive external ophthalmoplegia with impaired respiratory regulation
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Progressive external ophthalmoplegia; Mitochondrial disorders; Mitochondrial tRNA; Mitochondrial DNA mutation; Respiratory insufficiency
ID cca-adding enzyme; transfer-rna; trna(lys); cardiomyopathy
AB We report a novel heteroplasmic point mutation G8299A in the gene for mitochondrial tRNA(LYs) in a patient with progressive external ophthalmoplegia complicated by recurrent respiratory insufficiency. Biochemical analysis of respiratory chain complexes in muscle homogenate showed a combined complex I and IV deficiency. The transition does not represent a known neutral polymorphism and affects a position in the tRNA acceptor stem which is conserved in primates, leading to a destabilization of this functionally important domain. In vitro analysis of an essential maturation step of the tRNA transcript indicates the probable pathogenicity of this mutation. We hypothesize that there is a causal relationship between the novel G8299A transition and progressive external ophthalmoplegia with recurrent respiratory failure due to a depressed respiratory drive. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Wolf, Joachim; Grau, Armin J.] Klinikum Ludwigshafen, Dept Neurol, Ludwigshafen, Germany.
   [Obermaier-Kusser, Bert; Jacobs, Martina; Bauer, Matthias F.] Klinikum Ludwigshafen, Inst Clin Chem & Mol Diagnost, Ludwigshafen, Germany.
   [Milles, Cornelia; Moerl, Mario] Univ Leipzig, Inst Biochem, Leipzig, Germany.
   [von Pein, Harald D.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Neuropathol, D-6500 Mainz, Germany.
C3 Ludwigshafen Hospital; Ludwigshafen Hospital; Leipzig University; Johannes Gutenberg University of Mainz
RP Wolf, J (corresponding author), Klinikum Stadt Ludwigshafen, Dept Neurol, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM wolfj@klilu.de
FU Fritz Thyssen-Stiftung [Az 10.08.1.175]
CR Akita Y, 2000, HUM MUTAT, V15, P382, DOI 10.1002/(SICI)1098-1004(200004)15:4<382::AID-HUMU15>3.0.CO;2-B
   Augustin MA, 2003, J MOL BIOL, V328, P985, DOI 10.1016/S0022-2836(03)00381-4
   BAROHN RJ, 1990, NEUROLOGY, V40, P103, DOI 10.1212/WNL.40.1.103
   Bornstein B, 2002, HUM MUTAT, V19, P234, DOI 10.1002/humu.10050
   Cho HDD, 2002, J BIOL CHEM, V277, P3447, DOI 10.1074/jbc.M109559200
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Gambello MJ, 2006, MUSCLE NERVE, V34, P437, DOI 10.1002/mus.20605
   Helm M, 1999, BIOCHEMISTRY-US, V38, P13338, DOI 10.1021/bi991061g
   Kameoka K, 1998, BIOCHEM BIOPH RES CO, V245, P523, DOI 10.1006/bbrc.1998.8437
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7
   Lizano E, 2008, BIOCHIMIE, V90, P762, DOI 10.1016/j.biochi.2007.12.007
   MANNI R, 1991, EUR NEUROL, V31, P12, DOI 10.1159/000116627
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   Ozawa M, 1997, MUSCLE NERVE, V20, P271, DOI 10.1002/(SICI)1097-4598(199703)20:3<271::AID-MUS2>3.0.CO;2-8
   Pütz J, 2007, RNA, V13, P1184, DOI 10.1261/rna.588407
   Rossmanith W, 2003, ANN NEUROL, V54, P820, DOI 10.1002/ana.10753
   Sakuta R, 2002, PEDIATR NEUROL, V27, P397, DOI 10.1016/S0887-8994(02)00456-3
   Sanaker PS, 2007, ACTA NEUROL SCAND, V115, P64, DOI 10.1111/j.1600-0404.2007.00850.x
   Santorelli FM, 1996, AM J HUM GENET, V58, P933
   Scheibe M, 2007, BMC MOL BIOL, V8, P0, DOI 10.1186/1471-2199-8-92
   Shtilbans A, 2000, J CHILD NEUROL, V15, P759, DOI 10.1177/088307380001501109
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Toh Y, 2009, EMBO J, V28, P3353, DOI 10.1038/emboj.2009.260
   Tomari Y, 2003, J BIOL CHEM, V278, P16828, DOI 10.1074/jbc.M213216200
   Tomita K, 2004, NATURE, V430, P700, DOI 10.1038/nature02712
   Wilusz JE, 2011, SCIENCE, V334, P817, DOI 10.1126/science.1213671
NR 30
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAY 15
PY 2012
VL 316
IS 1-2
BP 108
EP 111
DI 10.1016/j.jns.2012.01.013
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 930XK
UT WOS:000303177900020
PM 22326363
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Vissing, J
   González-Alonso, J
AF Jeppesen, Tina D.
   Vissing, John
   Gonzalez-Alonso, Jose
TI Influence of erythrocyte oxygenation and intravascular ATP on resting and exercising skeletal muscle blood flow in humans with mitochondrial myopathy
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial myopathy; ATP; Erythrocyte signaling
ID forearm exercise; release; cells; vasoconstriction; metabolism; activation; diagnosis; delivery; mutation
AB Oxygen (O-2) extraction is impaired in exercising skeletal muscle of humans with mutations of mitochondria( DNA (mtDNA), but the muscle hemodynamic response to exercise has never been directly investigated. This study sought to examine the extent to which human skeletal muscle perfusion can increase without reductions in blood oxygenation and to determine whether erythrocyte O-2 off-loading and related ATP vascular mechanisms are impaired in humans with mutations of mtDNA. Leg vascular hemodynamic, oxygenation and ATP were investigated in ten patients with mtDNA mutations and ten matched healthy control subjects: 1) at rest during normoxia, hypoxia, hyperoxia and intra-femoral artery ATP infusion, and 2) during passive and dynamic one-legged knee-extensor exercises. At rest, blood flow (LBF), femoral arterial and venous blood oxygenation and plasma ATP were similar in the two groups. During dynamic exercise, LBF and vascular conductance increased 9-10 fold in the patients despite erythrocyte oxygenation and leg O-2 extraction remained unchanged (p<0.01). In the patients, workload-adjusted LBF was 28% to 62% higher during submaximal- and maximal exercises and was associated with augmented plasma ATP. The appropriate hemodynamic adjustments during severe hypoxia and ATP infusion suggest that erythrocyte O-2 off-loading and related ATP vascular mechanisms are intact in patients with mtDNA mutations. Furthermore, greater increase in plasma ATP and LBF at a given metabolic demand in the patients, in concert with unchanged oxyhemoglobin, suggest that erythrocyte O-2 off-loading is not obligatory for the exercise-induced increase in blood flow and intravascular ATP concentration. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Jeppesen, Tina D.] Univ Copenhagen, Rigshosp, Neuromuscular Res Unit, Sect 3342,Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark.
   [Gonzalez-Alonso, Jose] Brunel Univ, Ctr Sports Med & Human Performance, London, England.
C3 University of Copenhagen; Rigshospitalet; Brunel University
RP Jeppesen, TD (corresponding author), Univ Copenhagen, Rigshosp, Neuromuscular Res Unit, Sect 3342,Copenhagen Muscle Res Ctr, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM tina@dysgaard.dk
FU Copenhagen Hospital System; Sara and Ludvig Elsa's Foundation; Danish Medical Research Council; NOVO Nordic Foundation; University of Copenhagen
CR Abe K, 1997, NEUROLOGY, V49, P837, DOI 10.1212/WNL.49.3.837
   ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794
   Bank W, 1997, MOL CELL BIOCHEM, V174, P7, DOI 10.1023/A:1006887319200
   BANK W, 1994, ANN NEUROL, V36, P830, DOI 10.1002/ana.410360606
   Beigi R, 1999, AM J PHYSIOL, V276, P267
   BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40
   Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x
   Carroll J, 2006, MOL BIOSYST, V2, P305, DOI 10.1039/b604362n
   Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954
   Despas F, 2009, J HYPERTENS, V27, P1849, DOI 10.1097/HJH.0b013e32832e8d0f
   Di Giovanni S, 2001, MOL CELL NEUROSCI, V17, P696, DOI 10.1006/mcne.2001.0970
   Ellsworth ML, 2009, PHYSIOLOGY, V24, P107, DOI 10.1152/physiol.00038.2008
   Ellsworth ML, 1995, AM J PHYSIOL-HEART C, V269, PH2155, DOI 10.1152/ajpheart.1995.269.6.H2155
   FUJII T, 1995, BRAIN DEV-JPN, V17, P89, DOI 10.1016/0387-7604(94)00115-E
   González-Alonso J, 2006, J PHYSIOL-LONDON, V572, P295, DOI 10.1113/jphysiol.2005.101121
   González-Alonso J, 2002, CIRC RES, V91, P1046, DOI 10.1161/01.RES.0000044939.73286.E2
   González-Alonso J, 2008, J PHYSIOL-LONDON, V586, P4033, DOI 10.1113/jphysiol.2008.160358
   GROPEN TI, 1994, STROKE, V25, P1873, DOI 10.1161/01.STR.25.9.1873
   HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135
   Jagger JE, 2001, AM J PHYSIOL-HEART C, V280, PH2833, DOI 10.1152/ajpheart.2001.280.6.H2833
   Jensen TD, 2002, NEUROLOGY, V58, P1533, DOI 10.1212/WNL.58.10.1533
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Kalsi KK, 2010, CIRCULATION, V122, P0
   Kirby BS, 2008, J PHYSIOL-LONDON, V586, P4305, DOI 10.1113/jphysiol.2008.154252
   MATSUKAWA T, 1993, J CLIN INVEST, V92, P25, DOI 10.1172/JCI116558
   Mortensen SP, 2009, AM J PHYSIOL-REG I, V296, PR1140, DOI 10.1152/ajpregu.90822.2008
   Nishioka J, 2008, BRAIN DEV-JPN, V30, P100, DOI 10.1016/j.braindev.2007.06.008
   Notarius CF, 2001, AM J PHYSIOL-HEART C, V280, PH969, DOI 10.1152/ajpheart.2001.280.3.H969
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   OZAWA T, 1995, BIOCHEM BIOPH RES CO, V213, P432, DOI 10.1006/bbrc.1995.2150
   Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560
   Radegran G, 1997, J APPL PHYSIOL, V83, P1383, DOI 10.1152/jappl.1997.83.4.1383
   Rosenmeier JB, 2008, J PHYSIOL-LONDON, V586, P4993, DOI 10.1113/jphysiol.2008.155432
   Rosenmeier JB, 2004, J PHYSIOL-LONDON, V558, P351, DOI 10.1113/jphysiol.2004.063107
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, PH1726, DOI 10.1152/ajpheart.1998.275.5.H1726
   Strehler B, 1957, ASSAY ADENOSINE TRIP, V0, P871
   Sumi Y, 2010, AM J PHYSIOL-CELL PH, V299, PC1118, DOI 10.1152/ajpcell.00122.2010
   Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Vissing J, 1996, ANN NEUROL, V40, P655, DOI 10.1002/ana.410400416
   Zhang ZQ, 2010, NEUROL RES, V32, P403, DOI 10.1179/016164110X12670144526345
NR 44
TC 7
Z9 7
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAY 15
PY 2012
VL 12
IS 3
BP 414
EP 422
DI 10.1016/j.mito.2011.11.003
PG 9
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 956RA
UT WOS:000305105600007
PM 22155147
DA 2024-11-01
ER

PT J
AU Bacman, SR
   Williams, SL
   Duan, D
   Moraes, CT
AF Bacman, S. R.
   Williams, S. L.
   Duan, D.
   Moraes, C. T.
TI Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease
SO GENE THERAPY
LA English
DT Article
DE mtDNA; heteroplasmy; AAV9; myopathy; mouse model
ID adenoassociated virus; dna heteroplasmy; gene-expression; transduction; mutation; disease; selection; vectors; therapy; route
AB Mitochondrial diseases are frequently caused by heteroplasmic mitochondrial DNA (mtDNA) mutations. As these mutations express themselves only at high relative ratios, any approach able to manipulate mtDNA heteroplasmy can potentially be curative. In this study, we developed a system to manipulate mtDNA heteroplasmy in all skeletal muscles from neonate mice. We selected muscle because it is one of the most clinically affected tissues in mitochondrial disorders. A mitochondria-targeted restriction endonuclease (mito-ApaLI) expressed from AAV9 particles was delivered either by intraperitoneal or intravenous injection in neonate mice harboring two mtDNA haplotypes, only one of which was susceptible to ApaLI digestion. A single injection was able to elicit a predictable and marked change in mtDNA heteroplasmy in all striated muscles analyzed, including heart. No health problems or reduction in mtDNA levels were observed in treated mice, suggesting that this approach could have clinical applications for mitochondrial myopathies.
C1 [Bacman, S. R.; Williams, S. L.; Moraes, C. T.] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Duan, D.] Univ Missouri, Sch Med, Dept Mol Biol & Immunol, Columbia, MO USA.
   [Moraes, C. T.] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
C3 University of Miami; University of Missouri System; University of Missouri Columbia; University of Miami
RP Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1420 NW 9th Ave, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU NIH [EY010804, AG036871]; Muscular Dystrophy Association
CR Alexeyev MF, 2008, GENE THER, V15, P516, DOI 10.1038/sj.gt.2008.11
   Bacman SR, 2007, GENE THER, V14, P1309, DOI 10.1038/sj.gt.3302981
   Bacman SR, 2010, GENE THER, V17, P713, DOI 10.1038/gt.2010.25
   Bacman SR, 2009, NUCLEIC ACIDS RES, V37, P4218, DOI 10.1093/nar/gkp348
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   Blankinship MJ, 2004, MOL THER, V10, P671, DOI 10.1016/j.ymthe.2004.07.016
   Bostick B, 2007, GENE THER, V14, P1605, DOI 10.1038/sj.gt.3303029
   Chiaratti MR, 2011, MITOCHONDRION, V11, P820, DOI 10.1016/j.mito.2010.11.004
   Cwerman-Thibault H, 2011, J INHERIT METAB DIS, V34, P327, DOI 10.1007/s10545-010-9131-5
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515
   Ghosh A, 2007, MOL THER, V15, P750, DOI 10.1038/sj.mt.6300081
   Händel EM, 2011, CURR GENE THER, V11, P28, DOI 10.2174/156652311794520120
   Inagaki K, 2006, MOL THER, V14, P45, DOI 10.1016/j.ymthe.2006.03.014
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Kyriakouli DS, 2008, GENE THER, V15, P1017, DOI 10.1038/gt.2008.91
   Lai Y, 2005, NAT BIOTECHNOL, V23, P1435, DOI 10.1038/nbt1153
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Minczuk M, 2010, METHODS MOL BIOL, V649, P257, DOI 10.1007/978-1-60761-753-2_16
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Ogura T, 2006, J GENE MED, V8, P990, DOI 10.1002/jgm.916
   Pacak CA, 2006, CIRC RES, V99, PE3, DOI 10.1161/01.RES.0000237661.18885.f6
   Pettman R, 2007, J INHERIT METAB DIS, V30, P404, DOI 10.1007/s10545-007-0460-y
   Poulton J, 2000, NEUROMUSCUL DISORD, V10, P460, DOI 10.1016/S0960-8966(00)00101-2
   Pruchnic R, 2000, HUM GENE THER, V11, P521, DOI 10.1089/10430340050015716
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Tsao CY, 2001, J CHILD NEUROL, V16, P533, DOI 10.1177/088307380101600716
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   Wenz T, 2010, DEV DISABIL RES REV, V16, P219, DOI 10.1002/ddrr.109
   Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76
NR 37
TC 60
Z9 65
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD NOV 15
PY 2012
VL 19
IS 11
BP 1101
EP 1106
DI 10.1038/gt.2011.196
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine
GA 034AA
UT WOS:000310841300008
PM 22130448
DA 2024-11-01
ER

PT J
AU Sofou, K
   Moslemi, AR
   Kollberg, G
   Bjarnadóttir, I
   Oldfors, A
   Nennesmo, I
   Holme, E
   Tulinius, M
   Darin, N
AF Sofou, Kalliopi
   Moslemi, Ali-Reza
   Kollberg, Gittan
   Bjarnadottir, Ingibjorg
   Oldfors, Anders
   Nennesmo, Inger
   Holme, Elisabeth
   Tulinius, Mar
   Darin, Niklas
TI Phenotypic and genotypic variability in Alpers syndrome
SO EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
LA English
DT Article
DE Alpers; Mitochondrial encephalomyopathy; POLG1; OXPHOS; mtDNA
ID progressive external ophthalmoplegia; diffuse cerebral degeneration; mitochondrial-dna depletion; polymerase-gamma-a; polg mutations; leigh-syndrome; autosomal-dominant; clinical-features; mtdna depletion; common-cause
AB Background: Alpers syndrome is one of the most common phenotypes of mitochondrial disorders in early childhood and has been associated with pathogenic mutations in POLG1. Aims: To investigate the phenotypic genotypic correlations in Alpers syndrome and to identify potential differences among patients with Alpers syndrome with or without pathogenic POLG1 mutations. Methods: Patients with the phenotype of Alpers syndrome who were referred to our pediatric hospital during 1984-2007 and were diagnosed with mitochondrial encephalomyopathy underwent further biochemical, morphological and genetic investigations. Results: A total of 19 patients were included in the study, of whom six had pathogenic POLG1 mutations including a novel mutation (c.907 G > A, p.Gly303Arg). Complete mtDNA sequencing in the subgroup without POLG1 mutations showed 5 novel and 5 very rare mtDNA variants considered as rare polymorphisms. Compared to POLG1(-) patients, the POLG1(+) patients more frequently had seizures at onset, which often became refractory. Ataxia and stroke-like episodes were much more common, while microcephaly and spasticity were encountered almost solely in the POLG1(-) group. Hepatic and ophthalmological involvement developed in 79% and 88% of patients, respectively. Most of the patients in both groups had predominant deficiency of complex I. In addition to the major degenerative changes in the cerebral cortex, the basal ganglia, thalamus and white matter were also involved to variable extent. Conclusion: Alpers syndrome is a heterogeneous syndrome that should be considered in patients with early-onset progressive cortical encephalopathy regardless of liver involvement. The phenotype is different depending on the presence or absence of POLG1 mutations. (C) 2012 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
C1 [Sofou, Kalliopi; Bjarnadottir, Ingibjorg; Tulinius, Mar; Darin, Niklas] Univ Gothenburg, Dept Pediat, Queen Silvias Children Hosp, S-41685 Gothenburg, Sweden.
   [Moslemi, Ali-Reza; Oldfors, Anders] Univ Gothenburg, Dept Pathol, Sahlgrenska Univ Hosp, S-41345 Gothenburg, Sweden.
   [Kollberg, Gittan; Holme, Elisabeth] Univ Gothenburg, Dept Clin Chem, Sahlgrenska Univ Hosp, S-41345 Gothenburg, Sweden.
   [Nennesmo, Inger] Karolinska Univ Hosp, Dept Pathol, S-14186 Huddinge, Stockholm, Sweden.
C3 Queen Silvia Children's Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; University of Gothenburg; Sahlgrenska University Hospital; Karolinska Institutet; Karolinska University Hospital
RP Sofou, K (corresponding author), Univ Gothenburg, Dept Pediat, Queen Silvias Children Hosp, S-41685 Gothenburg, Sweden.
EM kalliopi.sofou@vgregion.se
CR Absalon MJ, 2001, PEDIATR NEUROL, V24, P60, DOI 10.1016/S0887-8994(00)00226-5
   Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   BLACKWOOD W, 1963, ARCH DIS CHILD, V38, P193, DOI 10.1136/adc.38.199.193
   BULLARD WN, 1890, J NERV MENT DIS, V15, P699
   CHRISTENSEN E, 1949, ARCH NEURO PSYCHIATR, V61, P28, DOI 10.1001/archneurpsyc.1949.02310070034003
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   COURVILLE C B, 1960, BULL LOS ANGEL NEURO SOC, V25, P72
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   DREIFUSS FE, 1964, AM J DIS CHILD, V107, P649, DOI 10.1001/archpedi.1964.02080060651018
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   GABREELS FJM, 1984, ACTA NEUROL SCAND, V70, P145
   GREENHOUSE AH, 1964, ARCH NEUROL-CHICAGO, V10, P47, DOI 10.1001/archneur.1964.00460130051008
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   HARDING BN, 1986, BRAIN, V109, P181, DOI 10.1093/brain/109.1.181
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   JELLINGER K, 1970, ACTA NEUROPATHOL, V16, P125, DOI 10.1007/BF00687667
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   MONTINE TJ, 1995, CLIN NEUROPATHOL, V14, P322
   Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107
   Moslemi AR, 2007, MITOCHONDRION, V7, P241, DOI 10.1016/j.mito.2007.02.002
   Moslemi AR, 2003, NEUROLOGY, V61, P991, DOI 10.1212/01.WNL.0000082391.98672.0A
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033
   PRICK MJJ, 1981, ARCH NEUROL-CHICAGO, V38, P767, DOI 10.1001/archneur.1981.00510120067011
   PRICK MJJ, 1983, CLIN NEUROL NEUROSUR, V85, P57, DOI 10.1016/0303-8467(83)90024-0
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Tulinius M, 2005, EUR J PEDIATR, V164, P99, DOI 10.1007/s00431-004-1570-2
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Visser NA, 2010, NEUROLOGY, V74, P1231, DOI 10.1212/WNL.0b013e3181d90005
   Wiltshire E, 2008, ARCH NEUROL-CHICAGO, V65, P121, DOI 10.1001/archneurol.2007.14
   WOLF A, 1955, RES PUBL ASSOC RES NERV MENT DIS, V34, P199
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 46
TC 19
Z9 20
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090-3798
EI 
J9 EUR J PAEDIATR NEURO
JI Eur. J. Paediatr. Neurol.
PD JUL 15
PY 2012
VL 16
IS 4
BP 379
EP 389
DI 10.1016/j.ejpn.2011.12.006
PG 11
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 971LB
UT WOS:000306204300009
PM 22237560
DA 2024-11-01
ER

PT J
AU Béhin, A
   Jardel, C
   Claeys, KG
   Fagart, J
   Louha, M
   Romero, NB
   Laforêt, P
   Eymard, B
   Lombès, A
AF Behin, A.
   Jardel, C.
   Claeys, K. G.
   Fagart, J.
   Louha, M.
   Romero, N. B.
   Laforet, P.
   Eymard, B.
   Lombes, A.
TI Adult cases of mitochondrial DNA depletion due to <i>TK2</i> defect An expanding spectrum
SO NEUROLOGY
LA English
DT Article
ID thymidine kinase-2 gene; mtdna depletion; mutations; myopathy; patient; diseases
AB Objective: In this study we aim to demonstrate the occurrence of adult forms of TK2 mutations causing progressive mitochondrial myopathy with significant muscle mitochondrial DNA (mtDNA) depletion. Methods: Patients' investigations included serum creatine kinase, blood lactate, electromyographic, echocardiographic, and functional respiratory analyses as well as TK2 gene sequencing and TK2 activity measurement. Mitochondrial activities and mtDNA were analyzed in the patients' muscle biopsy. Results: The 3 adult patients with TK2 mutations presented with slowly progressive myopathy compatible with a fairly normal life during decades. Apart from its much slower progression, these patients' phenotype closely resembled that of pediatric cases including early onset, absence of CNS symptoms, generalized muscle weakness predominating on axial and proximal muscles but affecting facial, ocular, and respiratory muscles, typical mitochondrial myopathy with a mosaic pattern of COX-negative and ragged-red fibers, combined mtDNA-dependent respiratory complexes deficiency and mtDNA depletion. In accordance with the disease's relatively slow progression, the residual mtDNA content was higher than that observed in pediatric cases. That difference was not explained by the type of the TK2 mutations or by the residual TK2 activity. Conclusion: TK2 mutations can cause mitochondrial myopathy with a slow progression. Comparison of patients with similar mutations but different disease progression might address potential mechanisms of mtDNA maintenance modulation. Neurology (R) 2012;78:644-648
C1 [Jardel, C.; Louha, M.; Lombes, A.] GH Pitie Salpetriere, APHP, Unite Cardiogenet & Myogenet Mol & Cellulaire, Paris, France.
   [Behin, A.; Laforet, P.; Eymard, B.] GH Pitie Salpetriere, APHP, Ctr Reference Pathol Neuromusculaire Paris Est, Inst Myol, Paris, France.
   [Claeys, K. G.; Romero, N. B.] GH Pitie Salpetriere, APHP, Lab Pathol Musculaire Risler, Inst Myol, Paris, France.
   [Jardel, C.; Lombes, A.] Hop La Pitie Salpetriere, INSERM, UMRS 975, Paris, France.
   [Jardel, C.; Lombes, A.] Hop La Pitie Salpetriere, CNRS, UMR 7225, Paris, France.
   [Eymard, B.; Lombes, A.] Hop La Pitie Salpetriere, UPMC, Paris, France.
   [Claeys, K. G.] RWTH Univ Hosp Aachen, Inst Neuropathol, Aachen, Germany.
   [Claeys, K. G.] RWTH Univ Hosp Aachen, Neurol Klin, Aachen, Germany.
   [Fagart, J.] Fac Med Paris Sud, INSERM, UMRS 693, Le Kremlin Bicetre, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Hotel-Dieu - APHP; Sorbonne Universite; Hopital Universitaire Pitie-Salpetriere - APHP; Hopital Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay
RP Lombès, A (corresponding author), GH Pitie Salpetriere, APHP, Unite Cardiogenet & Myogenet Mol & Cellulaire, Paris, France.
EM anne.lombes@inserm.fr
FU AFM (Association Francaise contre les Myopathies); Genzyme Corporation; INSERM; ANR (Agence Nationale pour la Recherche) [ANR-08-MNPS-020-01]
CR ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Dubowitz V, 1973, MUSCLE BIOPSY MODERN, V0, P0
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Kim MJ, 2008, ANTIMICROB AGENTS CH, V52, P1670, DOI 10.1128/AAC.01449-07
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Martí R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294
   Medja F, 2009, MITOCHONDRION, V9, P331, DOI 10.1016/j.mito.2009.05.001
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 28
TC 37
Z9 42
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 
J9 NEUROLOGY
JI Neurology
PD FEB 15
PY 2012
VL 78
IS 9
BP 644
EP 648
DI 10.1212/WNL.0b013e318248df2b
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 901FP
UT WOS:000300948400014
PM 22345218
DA 2024-11-01
ER

PT J
AU Jones, AWE
   Yao, Z
   Vicencio, JM
   Karkucinska-Wieckowska, A
   Szabadkai, G
AF Jones, Aleck W. E.
   Yao, Zhi
   Vicencio, Jose Miguel
   Karkucinska-Wieckowska, Agnieszka
   Szabadkai, Gyorgy
TI PGC-1 family coactivators and cell fate: Roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling
SO MITOCHONDRION
LA English
DT Review
DE Mitochondrial biogenesis; Pgc-1; Retrograde signalling; Cancer; Apoptosis; Neurodegeneration; Cellular stress response
ID ppar-gamma coactivator; human breast-cancer; gene-expression; skeletal-muscle; dna mutations; huntingtons-disease; pgc-1-related coactivator; saccharomyces-cerevisiae; parkinsons-disease; oxidative stress
AB Over the past two decades, a complex nuclear transcriptional machinery controlling mitochondrial biogenesis and function has been described. Central to this network are the PGC-1 family coactivators, characterised as master regulators of mitochondrial biogenesis. Recent literature has identified a broader role for PGC-1 coactivators in both cell death and cellular adaptation under conditions of stress, here reviewed in the context of the pathology associated with cancer, neurodegeneration and cardiovascular disease. Moreover, we propose that these studies also imply a novel conceptual framework on the general role of mitochondrial dysfunction in disease. It is now well established that the complex nuclear transcriptional control of mitochondrial biogenesis allows for adaptation of mitochondrial mass and function to environmental conditions. On the other hand, it has also been suggested that mitochondria alter their function according to prevailing cellular energetic requirements and thus function as sensors that generate signals to adjust fundamental cellular processes through a retrograde mitochondria-nucleus signalling pathway. Therefore, altered mitochondrial function can affect cell fate not only directly by modifying cellular energy levels or redox state, but also indirectly, by altering nuclear transcriptional patterns. The current literature on such retrograde signalling in both yeast and mammalian cells is thus reviewed, with an outlook on its potential contribution to disease through the regulation of PGC-1 family coactivators. We propose that further investigation of these pathways will lead to the identification of novel pharmacological targets and treatment strategies to combat disease. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Jones, Aleck W. E.; Yao, Zhi; Vicencio, Jose Miguel; Szabadkai, Gyorgy] UCL, Consortium Mitochondrial Res, Dept Cell & Dev Biol, London, England.
   [Karkucinska-Wieckowska, Agnieszka] Childrens Mem Hlth Inst, Dept Pathol, Warsaw, Poland.
C3 University of London; University College London; Children's Memorial Health Institute
RP Szabadkai, G (corresponding author), UCL, Consortium Mitochondrial Res, Dept Cell & Dev Biol, London, England.
EM g.szabadkai@ucl.ac.uk
FU Parkinson's UK [G-0905]; Polish Ministry of Science and Higher Education [NN 407 075 137]; Childrens' Memorial Health Institute [117/09, 119/09]; Becas Chile; MRC
CR Acin-Perez R, 2009, EMBO MOL MED, V1, P392, DOI 10.1002/emmm.200900046
   Adhihetty PJ, 2007, AM J PHYSIOL-ENDOC M, V293, PE672, DOI 10.1152/ajpendo.00043.2007
   Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910
   Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001
   Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Arany Z, 2006, P NATL ACAD SCI USA, V103, P10086, DOI 10.1073/pnas.0603615103
   Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53
   Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983
   Bai RK, 2007, CANCER RES, V67, P4687, DOI 10.1158/0008-5472.CAN-06-3554
   Baker BM, 2011, TRENDS BIOCHEM SCI, V36, P254, DOI 10.1016/j.tibs.2011.01.004
   Baker MJ, 2011, COLD SPRING HARBOR P, V3, P0
   Basu A, 1997, J BIOL CHEM, V272, P5899, DOI 10.1074/jbc.272.9.5899
   Bianchi K, 2006, CELL DEATH DIFFER, V13, P586, DOI 10.1038/sj.cdd.4401784
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553
   Biswas G, 2008, J BIOL CHEM, V283, P12586, DOI 10.1074/jbc.M710481200
   Booker LM, 2006, J UROLOGY, V175, P468, DOI 10.1016/S0022-5347(05)00163-1
   Borniquel S, 2006, FASEB J, V20, P1889, DOI 10.1096/fj.05-5189fje
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Broadley SA, 2008, TRENDS CELL BIOL, V18, P1, DOI 10.1016/j.tcb.2007.11.003
   Burchard J, 2010, MOL SYST BIOL, V6, P0, DOI 10.1038/msb.2010.58
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   BUTOW RA, 1988, PHILOS T R SOC B, V319, P127
   Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720
   Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037
   Chandra D, 2010, BIOCHIM BIOPHYS ACTA, V1807, P620
   Chandra D, 2011, BBA-BIOENERGETICS, V1807, P620, DOI 10.1016/j.bbabio.2010.10.023
   Chaturvedi RK, 2009, HUM MOL GENET, V18, P3048, DOI 10.1093/hmg/ddp243
   Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141
   Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391
   Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025
   Clark J, 2011, BMC MED GENET, V12, P0, DOI 10.1186/1471-2350-12-69
   Connaughton S, 2010, MOL CELL ENDOCRINOL, V315, P159, DOI 10.1016/j.mce.2009.08.011
   Cowell RM, 2009, BIOCHEM BIOPH RES CO, V379, P578, DOI 10.1016/j.bbrc.2008.12.109
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015
   Czarnecka AM, 2010, FRONT BIOSCI-LANDMRK, V15, P437, DOI 10.2741/3629
   Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Duchen MR, 2008, CELL CALCIUM, V44, P1, DOI 10.1016/j.ceca.2008.02.001
   Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI 10.1042/bse0470115
   Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297
   Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977
   Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x
   Feilchenfeldt J, 2004, CANCER LETT, V203, P25, DOI 10.1016/j.canlet.2003.08.024
   Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077
   Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100
   Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148
   Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104
   Gasparre G, 2011, BBA-BIOENERGETICS, V1807, P633, DOI 10.1016/j.bbabio.2010.08.006
   Gohil VM, 2009, J CELL BIOL, V184, P468, DOI 10.1083/jcb.200901127
   GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105
   Guerra F, 2011, HUM MOL GENET, V20, P2394, DOI 10.1093/hmg/ddr146
   Guha M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M611693200
   Guha M, 2010, MOL BIOL CELL, V21, P3578, DOI 10.1091/mbc.E10-03-0192
   Guha M, 2009, MOL BIOL CELL, V20, P4107, DOI 10.1091/mbc.E09-04-0296
   Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021
   Han SW, 2009, AM J RESP CELL MOL, V40, P325, DOI 10.1165/rcmb.2008-0197OC
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Handschin C, 2005, CELL, V122, P505, DOI 10.1016/j.cell.2005.06.040
   Handschin C, 2009, TRENDS PHARMACOL SCI, V30, P322, DOI 10.1016/j.tips.2009.03.006
   Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119
   Holt IJ, 2010, TRENDS GENET, V26, P103, DOI 10.1016/j.tig.2009.12.011
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horibata Y, 2010, J BIOL CHEM, V285, P7358, DOI 10.1074/jbc.M109.056960
   Horibe T, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000835
   Huss JM, 2004, CIRC RES, V95, P568, DOI 10.1161/01.RES.0000141774.29937.e3
   Irrcher I, 2009, AM J PHYSIOL-CELL PH, V296, PC116, DOI 10.1152/ajpcell.00267.2007
   Ishikawa K, 2008, MITOCHONDRION, V8, P339, DOI 10.1016/j.mito.2008.07.006
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jeninga EH, 2010, ONCOGENE, V29, P4617, DOI 10.1038/onc.2010.206
   Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302
   Jones DP, 2008, AM J PHYSIOL-CELL PH, V295, PC849, DOI 10.1152/ajpcell.00283.2008
   Joseph AM, 2004, AM J PHYSIOL-CELL PH, V286, PC867, DOI 10.1152/ajpcell.00191.2003
   Kaipparettu BA, 2010, ANN NY ACAD SCI, V1201, P137, DOI 10.1111/j.1749-6632.2010.05621.x
   Kajimura S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108
   Kajimura S, 2010, CELL METAB, V11, P257, DOI 10.1016/j.cmet.2010.03.005
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   Klinge CM, 2008, J CELL BIOCHEM, V105, P1342, DOI 10.1002/jcb.21936
   Kong XX, 2009, MOL PHARMACOL, V76, P854, DOI 10.1124/mol.109.056424
   Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kulawiec M, 2010, ENVIRON MOL MUTAGEN, V51, P427, DOI 10.1002/em.20582
   Kulawiec M, 2009, CANCER BIOL THER, V8, P1378, DOI 10.4161/cbt.8.14.8751
   Kulawiec M, 2008, CANCER BIOL THER, V7, P1732, DOI 10.4161/cbt.7.11.6729
   Lai L, 2008, GENE DEV, V22, P1948, DOI 10.1101/gad.1661708
   Le Pennec S, 2011, J BIOL CHEM, V286, P18229, DOI 10.1074/jbc.M110.217521
   Lee CH, 2011, AM J PATHOL, V178, P2066, DOI 10.1016/j.ajpath.2011.01.056
   Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369
   Lenka N, 1996, J BIOL CHEM, V271, P30281, DOI 10.1074/jbc.271.47.30281
   Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101
   LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38
   Liao XM, 2010, BRIT J PHARMACOL, V161, P771, DOI 10.1111/j.1476-5381.2010.00900.x
   Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043
   Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200
   Lin JD, 2009, MOL ENDOCRINOL, V23, P2, DOI 10.1210/me.2008-0344
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Ling C, 2004, J CLIN INVEST, V114, P1518, DOI 10.1172/JCI200421889
   Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209
   Liu ZC, 2006, ANNU REV GENET, V40, P159, DOI 10.1146/annurev.genet.40.110405.090613
   LOMBES A, 1989, ANN NEUROL, V26, P20, DOI 10.1002/ana.410260104
   Luce K, 2010, ADV EXP MED BIOL, V694, P108
   Luo Y, 1997, P NATL ACAD SCI USA, V94, P9705, DOI 10.1073/pnas.94.18.9705
   Luo Y, 2001, J ALZHEIMERS DIS, V3, P593, DOI 10.3233/JAD-2001-3610
   Luo Y, 2009, J MOL NEUROSCI, V39, P262, DOI 10.1007/s12031-009-9196-5
   Lynn EG, 2010, J MOL CELL CARDIOL, V49, P693, DOI 10.1016/j.yjmcc.2010.06.008
   Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mandal S, 2011, STEM CELLS, V29, P486, DOI 10.1002/stem.590
   Marín-García J, 2010, VASC PHARMACOL, V52, P120, DOI 10.1016/j.vph.2009.10.008
   Martin E, 2011, HUM MOL GENET, V20, P2422, DOI 10.1093/hmg/ddr148
   Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   Maruszak A, 2011, J ALZHEIMERS DIS, V27, P197, DOI 10.3233/JAD-2011-110710
   McCammon MT, 2003, MOL BIOL CELL, V14, P958, DOI 10.1091/mbc.E02-07-0422
   Menzies KJ, 2009, AM J PHYSIOL-CELL PH, V296, PC355, DOI 10.1152/ajpcell.00415.2007
   Mercy L, 2005, FEBS J, V272, P5031, DOI 10.1111/j.1742-4658.2005.04913.x
   Miglio G, 2009, NEUROCHEM INT, V55, P496, DOI 10.1016/j.neuint.2009.05.001
   Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580
   Mirebeau-Prunier D, 2010, FEBS J, V277, P713, DOI 10.1111/j.1742-4658.2009.07516.x
   Miwa S, 2008, AGING CELL, V7, P920, DOI 10.1111/j.1474-9726.2008.00426.x
   Moisoi N, 2009, CELL DEATH DIFFER, V16, P449, DOI 10.1038/cdd.2008.166
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368
   OMalley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223
   Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150
   Owusu-Ansah E, 2008, NAT GENET, V40, P356, DOI 10.1038/ng.2007.50
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892
   Piantadosi CA, 2006, J BIOL CHEM, V281, P324, DOI 10.1074/jbc.M508805200
   Potting C, 2010, EMBO J, V29, P2888, DOI 10.1038/emboj.2010.169
   Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Qin WP, 2010, BIOCHEM BIOPH RES CO, V403, P473, DOI 10.1016/j.bbrc.2010.11.061
   Qin WP, 2009, ARCH NEUROL-CHICAGO, V66, P352, DOI 10.1001/archneurol.2008.588
   Ranganathan S, 2009, HUM MOL GENET, V18, P27, DOI 10.1093/hmg/ddn310
   Rasbach KA, 2010, P NATL ACAD SCI USA, V107, P21866, DOI 10.1073/pnas.1016089107
   Reeve AK, 2008, ANN NY ACAD SCI, V1147, P21, DOI 10.1196/annals.1427.016
   Rhodes MA, 2009, AM J PHYSIOL-HEART C, V297, PH392, DOI 10.1152/ajpheart.00164.2009
   Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770
   Rohas LM, 2007, P NATL ACAD SCI USA, V104, P7933, DOI 10.1073/pnas.0702683104
   Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB
   Sano M, 2004, EMBO J, V23, P3559, DOI 10.1038/sj.emboj.7600351
   Savagner F, 2003, BIOCHEM BIOPH RES CO, V310, P779, DOI 10.1016/j.bbrc.2003.09.076
   Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006
   Schmidt O, 2010, NAT REV MOL CELL BIO, V11, P655, DOI 10.1038/nrm2959
   Shin JH, 2011, CELL, V144, P689, DOI 10.1016/j.cell.2011.02.010
   Shiota M, 2010, MOL ENDOCRINOL, V24, P114, DOI 10.1210/me.2009-0302
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Shutt TE, 2010, ENVIRON MOL MUTAGEN, V51, P360, DOI 10.1002/em.20571
   Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100
   Siegelin MD, 2011, J CLIN INVEST, V121, P1349, DOI 10.1172/JCI44855
   Simon DK, 2004, NEUROBIOL AGING, V25, P71, DOI 10.1016/S0197-4580(03)00037-X
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Spiegelman BM, 2000, INT J OBESITY, V24, PS8, DOI 10.1038/sj.ijo.0801492
   Srinivasan V, 2010, AGING CELL, V9, P933, DOI 10.1111/j.1474-9726.2010.00622.x
   Srivastava S, 2007, HUM MOL GENET, V16, P993, DOI 10.1093/hmg/ddm045
   St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Suzuki H, 1998, BIOCHEM BIOPH RES CO, V249, P542, DOI 10.1006/bbrc.1998.9181
   Swerdlow RH, 2009, J ALZHEIMERS DIS, V17, P737, DOI 10.3233/JAD-2009-1095
   Taherzadeh-Fard E, 2011, MOL NEURODEGENER, V6, P0, DOI 10.1186/1750-1326-6-32
   Tamura Y, 2009, J CELL BIOL, V185, P1029, DOI 10.1083/jcb.200812018
   Tatsuta T, 2008, EMBO J, V27, P306, DOI 10.1038/sj.emboj.7601972
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Twig G, 2008, BBA-BIOENERGETICS, V1777, P1092, DOI 10.1016/j.bbabio.2008.05.001
   Valle I, 2005, CARDIOVASC RES, V66, P562, DOI 10.1016/j.cardiores.2005.01.026
   Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073
   Vercauteren K, 2006, MOL CELL BIOL, V26, P7409, DOI 10.1128/MCB.00585-06
   Vercauteren K, 2009, J BIOL CHEM, V284, P2307, DOI 10.1074/jbc.M806434200
   Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05
   Wada T, 2009, TRENDS ENDOCRIN MET, V20, P273, DOI 10.1016/j.tem.2009.03.003
   Wallace DC, 2007, ANNU REV BIOCHEM, V76, P781, DOI 10.1146/annurev.biochem.76.081205.150955
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   WAN B, 1995, J BIOL CHEM, V270, P26433, DOI 10.1074/jbc.270.44.26433
   Wang H, 1997, BBA-GENE STRUCT EXPR, V1352, P325, DOI 10.1016/S0167-4781(97)00035-3
   Wang X, 2011, MOL ONCOL, V5, P399, DOI 10.1016/j.molonc.2011.07.008
   Watkins G, 2004, ONCOL REP, V12, P483
   Wenz T, 2010, J CELL MOL MED, V0, P0
   Wenz Tina, 2011, J AGING RES, V2011, P810619, DOI 10.4061/2011/810619
   Wenz T, 2009, IUBMB LIFE, V61, P1051, DOI 10.1002/iub.261
   Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004
   Weydt P, 2009, MOL NEURODEGENER, V4, P0, DOI 10.1186/1750-1326-4-3
   WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514
   Wojewoda M, 2011, INT J BIOCHEM CELL B, V43, P1178, DOI 10.1016/j.biocel.2011.04.011
   Won JC, 2010, ARTERIOSCL THROM VAS, V30, P290, DOI 10.1161/ATVBAHA.109.198721
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Xiang ZM, 2011, J NEUROSCI, V31, P9544, DOI 10.1523/JNEUROSCI.1291-11.2011
   Xiong SQ, 2010, J BIOL CHEM, V285, P2474, DOI 10.1074/jbc.M109.065235
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Zechner C, 2010, CELL METAB, V12, P633, DOI 10.1016/j.cmet.2010.11.008
   Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104
   Zhang XT, 2001, J BIOL CHEM, V276, P47844, DOI 10.1074/jbc.M106285200
   Zhang Y, 2007, CELL RES, V17, P363, DOI 10.1038/cr.2007.11
   Zhang YQ, 2004, GENE DEV, V18, P157, DOI 10.1101/gad.1138104
   Zhang YB, 2009, J BIOL CHEM, V284, P32813, DOI 10.1074/jbc.M109.037556
   Zhao W, 2011, MOL NEURODEGENER, V6, P0, DOI 10.1186/1750-1326-6-51
   Zheng B, 2010, SCI TRANSL MED, V2, P0, DOI 10.1126/scitranslmed.3001059
   Zorzano A, 2010, BBA-BIOENERGETICS, V1797, P1028, DOI 10.1016/j.bbabio.2010.02.017
NR 213
TC 107
Z9 125
U1 1
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN 15
PY 2012
VL 12
IS 1
BP 86
EP 99
DI 10.1016/j.mito.2011.09.009
PG 14
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 895FS
UT WOS:000300482200011
PM 21983689
DA 2024-11-01
ER

PT J
AU Yamada, T
   Ivarsson, N
   Hernández, A
   Fahlström, A
   Cheng, AJ
   Zhang, SJ
   Bruton, JD
   Ulfhake, B
   Westerblad, H
AF Yamada, Takashi
   Ivarsson, Niklas
   Hernandez, Andres
   Fahlstrom, Andreas
   Cheng, Arthur J.
   Zhang, Shi-Jin
   Bruton, Joseph D.
   Ulfhake, Brun
   Westerblad, Hakan
TI Impaired mitochondrial respiration and decreased fatigue resistance followed by severe muscle weakness in skeletal muscle of mitochondrial DNA mutator mice
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID endurance exercise; sarcoplasmic-reticulum; calcium-concentration; superoxide-dismutase; oxidative stress; mouse muscle; fibers; mutations; myopathy; disease
AB Key points Defective mitochondrial function has been shown to cause muscle weakness and exercise intolerance. We used a mouse model of premature ageing with defective proofreading of mitochondrial DNA (mtDNA): the mtDNA mutator mouse. Muscles of young (35 months) mtDNA mutator mice showed reduced endurance, which was caused by decreased mitochondrial ATP production accompanied by decreased levels of factors stimulating mitochondrial biogenesis. The dominant defect in muscles of old (11 months) mtDNA mutator mice was severe weakness, which was caused by decreased intracellular Ca2+ stores. These results underline two important aspects of mitochondria-to-nucleus signalling in skeletal muscle: (1) it fails to respond adequately to decreased mitochondrial ATP production in sedentary animals; and (2) it can induce decreased intracellular Ca2+ stores and hence muscle weakness. These results have implication for normal ageing and suggest that the decreased mitochondrial function induced by a sedentary lifestyle may predispose to muscle weakness later in life. Abstract Mitochondrial dysfunction can drastically impair muscle function, with weakness and exercise intolerance as key symptoms. Here we examine the time course of development of muscle dysfunction in a mouse model of premature ageing induced by defective proofreading function of mitochondrial DNA (mtDNA) polymerase (mtDNA mutator mouse). Isolated fast-twitch muscles and single muscle fibres from young (35 months) and end-stage (11 months) mtDNA mutator mice were compared to age-matched control mice. Force and free myoplasmic [Ca2+] ([Ca2+]i) were measured under resting conditions and during fatigue induced by repeated tetani. Muscles of young mtDNA mutator mice displayed no weakness in the rested state, but had lower force and [Ca2+]i than control mice during induction of fatigue. Muscles of young mtDNA mutator mice showed decreased activities of citrate synthase and beta-hydroxyacyl-coenzyme A dehydrogenase, reduced expression of cytochrome c oxidase, and decreased expression of triggers of mitochondrial biogenesis (PGC-1 alpha, PPAR alpha, AMPK). Muscles from end-stage mtDNA mutator mice showed weakness under resting conditions with markedly decreased tetanic [Ca2+]i, force per cross-sectional area and protein expression of the sarcoplasmic reticulum Ca2+ pump (SERCA1). In conclusion, fast-twitch muscles of prematurely ageing mtDNA mutator mice display a sequence of deleterious mitochondrial-to-nucleus signalling with an initial decrease in oxidative capacity, which was not counteracted by activation of signalling to increase mitochondrial biogenesis. This was followed by severe muscle weakness in the end stage. These results have implication for normal ageing and suggest that decreased mitochondrial oxidative capacity due to a sedentary lifestyle may predispose towards muscle weakness developing later in life.
C1 [Yamada, Takashi; Ivarsson, Niklas; Hernandez, Andres; Cheng, Arthur J.; Zhang, Shi-Jin; Bruton, Joseph D.; Westerblad, Hakan] Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden.
   [Fahlstrom, Andreas; Ulfhake, Brun] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet
RP Westerblad, H (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden.
EM hakan.westerblad@ki.se
FU Swedish Research Council; Swedish National Center for Sports Research, Association Francaise Contre les Myopathies (AFM); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [1F32AR057619]; Grants-in-Aid for Scientific Research [24700541] Funding Source: KAKEN
CR Allen DG, 2008, PHYSIOL REV, V88, P287, DOI 10.1152/physrev.00015.2007
   Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x
   Arany Z, 2008, CURR OPIN GENET DEV, V18, P426, DOI 10.1016/j.gde.2008.07.018
   Aydin J, 2009, HUM MOL GENET, V18, P278, DOI 10.1093/hmg/ddn355
   Barclay CJ, 2005, J MUSCLE RES CELL M, V26, P225, DOI 10.1007/s10974-005-9013-x
   BASS A, 1969, EUR J BIOCHEM, V10, P198, DOI 10.1111/j.1432-1033.1969.tb00674.x
   Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018
   Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, PC817, DOI 10.1152/ajpcell.00139.2004
   Bruton JD, 2010, J PHYSIOL-LONDON, V588, P4275, DOI 10.1113/jphysiol.2010.198598
   Drummond GB, 2009, J PHYSIOL-LONDON, V587, P713, DOI 10.1113/jphysiol.2008.167387
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Hardie DG, 2011, P NUTR SOC, V70, P92, DOI 10.1017/S0029665110003915
   Hearn AS, 1999, J BIOL CHEM, V274, P24457, DOI 10.1074/jbc.274.35.24457
   Hiona A, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0011468
   HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831
   KLEIN MG, 1991, J PHYSIOL-LONDON, V441, P639, DOI 10.1113/jphysiol.1991.sp018771
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LANNERGREN J, 1991, J PHYSIOL-LONDON, V434, P307
   LANNERGREN J, 1987, J PHYSIOL-LONDON, V390, P285
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   MCADAM ME, 1977, BIOCHEM J, V165, P81, DOI 10.1042/bj1650081
   Reisch AS, 2007, METHOD CELL BIOL, V80, P199, DOI 10.1016/S0091-679X(06)80010-5
   Ríos E, 2010, J PHYSIOL SCI, V60, P81, DOI 10.1007/s12576-009-0069-z
   Ristow M, 2009, P NATL ACAD SCI USA, V106, P8665, DOI 10.1073/pnas.0903485106
   Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108
   Tarnopolsky MA, 2005, MED SCI SPORT EXER, V37, P2086, DOI 10.1249/01.mss.0000177341.89478.06
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wenz T, 2009, J APPL PHYSIOL, V106, P1712, DOI 10.1152/japplphysiol.91571.2008
   WESTERBLAD H, 1994, J PHYSIOL-LONDON, V474, P291, DOI 10.1113/jphysiol.1994.sp020022
   WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Wright DC, 2007, J BIOL CHEM, V282, P18793, DOI 10.1074/jbc.M611252200
   Zhang SJ, 2006, J PHYSIOL-LONDON, V572, P551, DOI 10.1113/jphysiol.2005.104521
NR 39
TC 25
Z9 30
U1 0
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD DEC 15
PY 2012
VL 590
IS 23
BP 6187
EP 6197
DI 10.1113/jphysiol.2012.240077
PG 11
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 045LK
UT WOS:000311697100023
PM 22988144
DA 2024-11-01
ER

PT J
AU Dündar, H
   Özgül, RK
   Yalnizoglu, D
   Erdem, S
   Oguz, KK
   Tuncel, D
   Temuçin, ÇM
   Dursun, A
AF Dundar, Hall
   Ozgul, Riza Koksal
   Yalnizoglu, Dilek
   Erdem, Sevim
   Oguz, Kader Karli
   Tuncel, Deniz
   Temucin, Cagri Mesut
   Dursun, Ali
TI Identification of a Novel Twinkle Mutation in a Family With Infantile Onset Spinocerebellar Ataxia by Whole Exome Sequencing
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; mitochondrial-dna; gene mutation; sensory neuropathy; multiple deletions; mtdna deletions; polg; features; defects; disease
AB Whole exome sequencing combined with homozygosity mapping comprises a genetic diagnostic tool to identify genetic defects in families with multiple affected members, compatible with presumed autosomal recessively inherited neurometabolic/neurogenetic disease. These tools were applied to a family with two individuals manifesting ataxia, associated with peripheral sensory neuropathy, athetosis, seizures, deafness, and ophthalmoplegia. A novel homozygous missense mutation c.1366C>G (L456V) in C10orf2 (the Twinkle gene) was identified, confirming infantile onset spinocerebellar ataxia in the probands. Signs in infantile onset spinocerebellar ataxia follow a fairly distinct pattern, affecting early development, followed by ataxia and loss of skills. However, this very rare disease was previously reported only in Finland. We suggest that infantile onset spinocerebellar ataxia should be more frequently considered in the differential diagnosis of neurometabolic diseases in childhood. Next-generation sequencing and its use along with homozygosity mapping offer highly promising techniques for molecular diagnosis, especially in small families affected with very rare neurometabolic disorders such as infantile onset spinocerebellar ataxia. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Dundar, Hall; Ozgul, Riza Koksal; Dursun, Ali] Hacettepe Univ, Fac Med, Metab Unit, Dept Pediat, TR-06100 Ankara, Turkey.
   [Ozgul, Riza Koksal] Hacettepe Univ, Inst Child Hlth, TR-06100 Ankara, Turkey.
   [Yalnizoglu, Dilek] Hacettepe Univ, Fac Med, Dept Child Neurol, TR-06100 Ankara, Turkey.
   [Erdem, Sevim; Temucin, Cagri Mesut] Hacettepe Univ, Fac Med, Dept Neurol, TR-06100 Ankara, Turkey.
   [Oguz, Kader Karli] Hacettepe Univ, Fac Med, Dept Radiol, TR-06100 Ankara, Turkey.
   [Tuncel, Deniz] Sutcu Imam Univ, Fac Med, Dept Neurol, Kahramanmaras, Turkey.
C3 Hacettepe University; Hacettepe University; Hacettepe University; Hacettepe University; Hacettepe University; Kahramanmaras Sutcu Imam University
RP Dursun, A (corresponding author), Hacettepe Univ, Fac Med, Metab Unit, Dept Pediat, TR-06100 Ankara, Turkey.
EM adursun@hacettepe.edu.tr
FU Scientific and Technology Research Council of Turkey [TUBITAK-SBAG-108S259]
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Echaniz-Laguna A, 2010, NEUROGENETICS, V11, P21, DOI 10.1007/s10048-009-0202-4
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Houshmand M, 2006, NEUROL INDIA, V54, P182
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Kallio A K, 1985, ADV AUDIOL, V3, P84
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   KOSKINEN T, 1995, AM J NEURORADIOL, V16, P1427
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   Martin-Negrier ML, 2011, EUR J NEUROL, V18, P436, DOI 10.1111/j.1468-1331.2010.03171.x
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   NIKALI K, 1995, AM J HUM GENET, V56, P1088
   NIKALI K, 1994, PEDIATR RES, V36, P607, DOI 10.1203/00006450-199411000-00012
   Rehman AU, 2010, AM J HUM GENET, V86, P378, DOI 10.1016/j.ajhg.2010.01.030
   Rivera H, 2007, NEUROMUSCULAR DISORD, V17, P677, DOI 10.1016/j.nmd.2007.05.006
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wang JL, 2010, BRAIN, V133, P3510, DOI 10.1093/brain/awq323
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
NR 34
TC 16
Z9 19
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD MAR 15
PY 2012
VL 46
IS 3
BP 172
EP 177
DI 10.1016/j.pediatrneurol.2011.12.006
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 902JU
UT WOS:000301035200007
PM 22353293
DA 2024-11-01
ER

PT J
AU de Laat, P
   Koene, S
   van den Heuvel, LPWJ
   Rodenburg, RJT
   Janssen, MCH
   Smeitink, JAM
AF de Laat, Paul
   Koene, Saskia
   van den Heuvel, Lambert P. W. J.
   Rodenburg, Richard J. T.
   Janssen, Mirian C. H.
   Smeitink, Jan A. M.
TI Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A &gt; G mutation
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID transfer rnaleu(uur) gene; stroke-like episodes; mtdna mutation; lactic-acidosis; a3243g mutation; mitochondrial myopathy; monitor progression; melas; disease; epidemiology
AB The m.3243A > G mutation has become known as the MELAS mutation. However, many other clinical phenotypes associated with this mutation have been described, most frequently being maternally inherited diabetes and deafness (MIDD). The m.3243A > G mutation, can be detected in virtually all tissues, however heteroplasmy differs between samples. Recent reports indicate, a preference to perform mutation analysis in urinary epithelial cells (UEC). To test this, and to study a correlation between the mutational load in different tissues with two mitochondrial scoring systems (NMDAS and NPMDS) we investigated 34 families carrying the m.3243A > G mutation. Heteroplasmy was determined in three non-invasively collected samples, namely leucocytes, UEC and buccal mucosa. We included 127 patients, of which 82 carried the m.3243A > G mutation. None of the children (n = 11) had specific complaints. In adults (n = 71), a median NMDAS score of 15 (IQR 10-24) was found. The most prevalent symptoms were hearing loss(48%), gastro-intestinal problems(42%), exercise intolerance(38%) and glucose intolerance(37%). Ten patients had neurologic involvement. Buccal mucosa had the best correlation with the NMDAS in all adults (r = 0.437,p < 0.001), whereas UEC had the strongest correlation with the NMDAS in severely affected patients (r = 0.593,p = 0.002). Heteroplasmy declined significantly with increasing age in all three samples (leucocytes r = -0.705 (p < 0.001), UEC r = -0.374(p = 0.001), buccal mucosa r = -0.460(p < 0.001). In our cohort of 82 patients, the m.3243A > G mutation causes a wide variety of signs and symptoms, MIDD being far more prevalent than MELAS. Looking at the characteristics of the three non-invasively available tissues for testing heteroplasmy we confirm that UEC are the preferred sample to test.
C1 [de Laat, Paul; Koene, Saskia; van den Heuvel, Lambert P. W. J.; Rodenburg, Richard J. T.; Smeitink, Jan A. M.] Radboud Univ Nijmegen, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, Med Ctr, NL-6500 HB Nijmegen, Netherlands.
   [Janssen, Mirian C. H.] Radboud Univ Nijmegen, Dept Internal Med, Nijmegen Ctr Mitochondrial Disorders, Med Ctr, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP de Laat, P (corresponding author), Radboud Univ Nijmegen, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, Med Ctr, Huispost 804,Geert Grootepl 10,POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM p.laat@cukz.umcn.nl
FU Energy4All foundation; ZonMW
CR Bergamin CS, 2008, ARQ BRAS ENDOCRINOL, V52, P1345, DOI 10.1590/S0004-27302008000800023
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Cree LM, 2009, BBA-MOL BASIS DIS, V1792, P1097, DOI 10.1016/j.bbadis.2009.03.002
   Durand-Dubief F, 2004, REV NEUROL-FRANCE, V160, P824, DOI 10.1016/S0035-3787(04)71038-3
   Fayssoil Abdallah, 2009, CONGEST HEART FAIL, V15, P284, DOI 10.1111/j.1751-7133.2009.00108.x
   Frederiksen AL, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.039339
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   Löwik MM, 2005, NEPHROL DIAL TRANSPL, V20, P336, DOI 10.1093/ndt/gfh546
   Ma YN, 2010, J NEUROL SCI, V291, P17, DOI 10.1016/j.jns.2010.01.012
   Ma YN, 2009, MITOCHONDRION, V9, P139, DOI 10.1016/j.mito.2009.01.004
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Marotta R, 2009, J CLIN NEUROSCI, V16, P1223, DOI 10.1016/j.jocn.2008.11.012
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   Michaelides M, 2008, ARCH OPHTHALMOL-CHIC, V126, P320, DOI 10.1001/archopht.126.3.320
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Phoenix C, 2006, NEUROMUSCULAR DISORD, V16, P814, DOI 10.1016/j.nmd.2006.08.006
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Verny C, 2008, DIABETES METAB, V34, P620, DOI 10.1016/j.diabet.2008.06.001
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wortmann SB, 2007, ACTA PAEDIATR, V96, P450, DOI 10.1111/j.1651-2227.2006.00158.x
NR 28
TC 96
Z9 99
U1 0
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD NOV 15
PY 2012
VL 35
IS 6
BP 1059
EP 1069
DI 10.1007/s10545-012-9465-2
PG 11
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 021GT
UT WOS:000309874000015
PM 22403016
DA 2024-11-01
ER

PT J
AU Katsuno, M
   Banno, H
   Suzuki, K
   Adachi, H
   Tanaka, F
   Sobue, G
AF Katsuno, Masahisa
   Banno, Haruhiko
   Suzuki, Keisuke
   Adachi, Hiroaki
   Tanaka, Fumiaki
   Sobue, Gen
TI Molecular Pathophysiology and Disease-Modifying Therapies for Spinal and Bulbar Muscular Atrophy
SO ARCHIVES OF NEUROLOGY
LA English
DT Review
ID transgenic mouse model; motor-neuron degeneration; expanded androgen receptor; axonal-transport; phenotypic-expression; kennedy-disease; sbma; overexpression; neurodegeneration; pathogenesis
AB Spinal and bulbar muscular atrophy (SBMA), or Kennedy disease, is an adult-onset lower motor neuron disease characterized by slowly progressive muscle weakness and atrophy. The disease is caused by the expansion of a trinucleotide CAG repeat encoding a polyglutamine tract within the first exon of the androgen receptor (AR) gene. During the 2 decades since the discovery of the AR gene mutation in SBMA, basic and clinical research have deepened our understanding of the disease phenotype and pathophysiology. Spinal and bulbar muscular atrophy exclusively affects men, whereas women homozygous for the AR mutation do not fully develop the disease. The ligand-dependent nuclear accumulation of pathogenic AR protein is central to the pathogenesis, although additional steps, eg, DNA binding and interdomain interactions of AR, are required for toxicity. Downstream molecular events, eg, transcriptional dysregulation, axonal transport disruption, and mitochondrial dysfunction, are implicated in the neurodegeneration in SBMA. Pathogenic AR-induced myopathy also contributes to the degeneration of motor neurons. Several potential therapies, including hormonal manipulation, have emerged from animal studies, some of which have been tested in clinical trials. Arch Neurol. 2012;69(4):436-440. Published online December 12, 2011. doi:10.1001/archneurol.2011.2308
C1 [Sobue, Gen] Nagoya Univ, Dept Neurol, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Banno, Haruhiko] Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University; Nagoya University
RP Sobue, G (corresponding author), Nagoya Univ, Dept Neurol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM sobueg@med.nagoya-u.ac.jp
FU Center of Excellence; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Ministry of Health, Labor, and Welfare of Japan; Japan Science and Technology Agency; Grants-in-Aid for Scientific Research [21229011, 22110005, 23790986, 24659428, 23390230] Funding Source: KAKEN
CR Adachi H, 2005, BRAIN, V128, P659, DOI 10.1093/brain/awh381
   Adachi H, 2007, J NEUROSCI, V27, P5115, DOI 10.1523/JNEUROSCI.1242-07.2007
   Atsuta N, 2006, BRAIN, V129, P1446, DOI 10.1093/brain/awl096
   Banno H, 2009, ANN NEUROL, V65, P140, DOI 10.1002/ana.21540
   Chevalier-Larsen ES, 2004, J NEUROSCI, V24, P4778, DOI 10.1523/JNEUROSCI.0808-04.2004
   Fernández-Rhodes LE, 2011, LANCET NEUROL, V10, P140, DOI 10.1016/S1474-4422(10)70321-5
   Finsterer J, 2010, J NEUROL SCI, V298, P1, DOI 10.1016/j.jns.2010.08.025
   Katsuno M, 2005, P NATL ACAD SCI USA, V102, P16801, DOI 10.1073/pnas.0506249102
   Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878
   Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6
   Katsuno M, 2006, J NEUROSCI, V26, P12106, DOI 10.1523/JNEUROSCI.3032-06.2006
   Katsuno M, 2006, EXP NEUROL, V200, P8, DOI 10.1016/j.expneurol.2006.01.021
   Katsuno M, 2010, LANCET NEUROL, V9, P875, DOI 10.1016/S1474-4422(10)70182-4
   Katsuno M, 2010, J NEUROSCI, V30, P5702, DOI 10.1523/JNEUROSCI.0388-10.2010
   Kemp MQ, 2011, HUM MOL GENET, V20, P4475, DOI 10.1093/hmg/ddr380
   KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671
   LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0
   Malik B, 2011, HUM MOL GENET, V20, P1776, DOI 10.1093/hmg/ddr061
   Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131
   Monks DA, 2007, P NATL ACAD SCI USA, V104, P18259, DOI 10.1073/pnas.0705501104
   Montie HL, 2009, HUM MOL GENET, V18, P1937, DOI 10.1093/hmg/ddp115
   Morfini G, 2006, NAT NEUROSCI, V9, P907, DOI 10.1038/nn1717
   Nedelsky NB, 2010, NEURON, V67, P936, DOI 10.1016/j.neuron.2010.08.034
   Orr CR, 2010, J BIOL CHEM, V285, P35567, DOI 10.1074/jbc.M110.146845
   Palazzolo I, 2009, NEURON, V63, P316, DOI 10.1016/j.neuron.2009.07.019
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Parodi S, 2011, FRONT NEUROENDOCRIN, V32, P416, DOI 10.1016/j.yfrne.2011.06.003
   Poletti A, 2004, FRONT NEUROENDOCRIN, V25, P1, DOI 10.1016/j.yfrne.2004.03.001
   Ranganathan S, 2009, HUM MOL GENET, V18, P27, DOI 10.1093/hmg/ddn310
   Schmidt BJ, 2002, NEUROLOGY, V59, P770, DOI 10.1212/WNL.59.5.770
   SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209
   Sopher BL, 2004, NEURON, V41, P687, DOI 10.1016/S0896-6273(04)00082-0
   Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9
   Tokui K, 2009, HUM MOL GENET, V18, P898, DOI 10.1093/hmg/ddn419
   Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298
   Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547
   Young JE, 2009, J NEUROSCI, V29, P1987, DOI 10.1523/JNEUROSCI.4072-08.2009
   Yu Z, 2006, J CLIN INVEST, V116, P2663, DOI 10.1172/JCI28773
NR 38
TC 15
Z9 17
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD APR 15
PY 2012
VL 69
IS 4
BP 436
EP 440
DI 10.1001/archneurol.2011.2308
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 921TB
UT WOS:000302499400002
PM 22158719
DA 2024-11-01
ER

PT J
AU Avital, G
   Buchshtav, M
   Zhidkov, I
   Tuval, J
   Dadon, S
   Rubin, E
   Glass, D
   Spector, TD
   Mishmar, D
AF Avital, Gal
   Buchshtav, Mor
   Zhidkov, Ilia
   Tuval (Feder), Jeanette
   Dadon, Sarah
   Rubin, Eitan
   Glass, Dan
   Spector, Timothy D.
   Mishmar, Dan
TI Mitochondrial DNA heteroplasmy in diabetes and normal adults: role of acquired and inherited mutational patterns in twins
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID paternal inheritance; mtdna mutation; association; resistance; selection; disease; tool
AB Heteroplasmy, the mixture of mitochondrial genomes (mtDNA), varies among individuals and cells. Heteroplasmy levels alter the penetrance of pathological mtDNA mutations, and the susceptibility to age-related diseases such as Parkinsons disease. Although mitochondrial dysfunction occurs in age-related type 2 diabetes mellitus (T2DM), the involvement of heteroplasmy in diabetes is unclear. We hypothesized that the heteroplasmic mutational (HM) pattern may change in T2DM. To test this, we used next-generation sequencing, i.e. massive parallel sequencing (MPS), along with PCRcloningSanger sequencing to analyze HM in blood and skeletal muscle DNA samples from monozygotic (MZ) twins either concordant or discordant for T2DM. Great variability was identified in the repertoires and amounts of HMs among individuals, with a tendency towards more mutations in skeletal muscle than in blood. Whereas many HMs were unique, many were either shared among twin pairs or among tissues of the same individual, regardless of their prevalence. This suggested a heritable influence on even low abundance HMs. We found no clear differences between T2DM and controls. However, we found approximate to 5-fold increase of HMs in non-coding sequences implying the influence of negative selection (P 0.001). This negative selection was evident both in moderate to highly abundant heteroplasmy (5 of the molecules per sample) and in low abundance heteroplasmy (5 of the molecules). Although our study found no evidence supporting the involvement of HMs in the etiology of T2DM, the twin study found clear evidence of a heritable influence on the accumulation of HMs as well as the signatures of selection in heteroplasmic mutations.
C1 [Avital, Gal; Buchshtav, Mor; Zhidkov, Ilia; Tuval (Feder), Jeanette; Dadon, Sarah; Mishmar, Dan] Ben Gurion Univ Negev, Dept Life Sci, Fac Nat Sci, IL-84105 Beer Sheva, Israel.
   [Zhidkov, Ilia; Rubin, Eitan] Ben Gurion Univ Negev, NIBN, Fac Hlth Sci, IL-84105 Beer Sheva, Israel.
   [Rubin, Eitan] Ben Gurion Univ Negev, Dept Microbiol & Immunol, Fac Hlth Sci, IL-84105 Beer Sheva, Israel.
   [Glass, Dan; Spector, Timothy D.] Kings Coll London, Div Genet & Mol Med, Dept Twin Res & Genet Epidemiol, London SE1 7EH, England.
C3 Ben Gurion University; Ben Gurion University; Ben Gurion University; University of London; King's College London
RP Mishmar, D (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, Bldg 40,Room 005, IL-84105 Beer Sheva, Israel.
EM dmishmar@bgu.ac.il
FU Israeli Science Foundation [387/08]; National Institute of Biotechnology in the Negev (NIBN); Wellcome Trust; NIHR Biomedical Resource Centre; MRC
CR Ameur A, 2011, PLOS GENET, V7, P0, DOI 10.1371/journal.pgen.1002028
   Andrew T, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0022332
   Belle EMS, 2005, GENE, V355, P58, DOI 10.1016/j.gene.2005.05.019
   Budowle B, 2003, ANNU REV GENOM HUM G, V4, P119, DOI 10.1146/annurev.genom.4.070802.110352
   Cao LQ, 2009, PLOS GENET, V5, P0, DOI 10.1371/journal.pgen.1000756
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Clark J, 2011, PARKINSONS DIS, V2011, P659
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Craven L, 2011, HUM MOL GENET, V20, PR168, DOI 10.1093/hmg/ddr373
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786
   Feder J, 2009, BMC MED GENET, V10, P0, DOI 10.1186/1471-2350-10-60
   Fuku N, 2007, AM J HUM GENET, V80, P407, DOI 10.1086/512202
   Goto H, 2011, GENOME BIOL, V12, P0, DOI 10.1186/gb-2011-12-6-r59
   Graur D, 2000, FUNDAMENTALS OF MOLECULAR EVOLUTION, V2nd, P0
   GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Homer N, 2009, PLOS ONE, V4, PA95, DOI 10.1371/journal.pone.0007767
   Keller I, 2007, PLOS GENET, V3, P185, DOI 10.1371/journal.pgen.0030022
   Kloss-Brandstätter A, 2011, HUM MUTAT, V32, P25, DOI 10.1002/humu.21382
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Lehtovirta M, 2010, DIABETOLOGIA, V53, P1314, DOI 10.1007/s00125-010-1746-4
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   Lim S, 2001, MITOCHONDRION, V1, P71, DOI 10.1016/S1567-7249(01)00003-4
   Lutz-Bonengel S, 2008, INT J LEGAL MED, V122, P315, DOI 10.1007/s00414-008-0240-8
   Moayyeri A, 2013, INT J EPIDEMIOL, V42, P76, DOI 10.1093/ije/dyr207
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Olsson C, 1998, HUM MUTAT, V12, P52, DOI 10.1002/(SICI)1098-1004(1998)12:1<52::AID-HUMU8>3.0.CO;2-K
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Saxena R, 2006, AM J HUM GENET, V79, P54, DOI 10.1086/504926
   Schwartz M, 2004, J NEUROL SCI, V218, P99, DOI 10.1016/j.jns.2003.11.008
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shoubridge EA, 2007, CURR TOP DEV BIOL, V77, P87, DOI 10.1016/S0070-2153(06)77004-1
   Sondheimer N, 2011, HUM MOL GENET, V20, P1653, DOI 10.1093/hmg/ddr043
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   Wang CH, 2010, ANN NY ACAD SCI, V1201, P157, DOI 10.1111/j.1749-6632.2010.05625.x
   White DJ, 2008, MOL ECOL, V17, P4925, DOI 10.1111/j.1365-294X.2008.03982.x
   Zhidkov I, 2011, MITOCHONDRION, V11, P924, DOI 10.1016/j.mito.2011.08.005
   Zhidkov I, 2009, GENOME RES, V19, P576, DOI 10.1101/gr.086462.108
NR 41
TC 69
Z9 76
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 1
PY 2012
VL 21
IS 19
BP 4214
EP 4224
DI 10.1093/hmg/dds245
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 007KV
UT WOS:000308888100007
PM 22736028
DA 2024-11-01
ER

PT J
AU Yoshii, Y
   Yoneda, M
   Ikawa, M
   Furukawa, T
   Kiyono, Y
   Mori, T
   Yoshii, H
   Oyama, N
   Okazawa, H
   Saga, T
   Fujibayashi, Y
AF Yoshii, Yukie
   Yoneda, Makoto
   Ikawa, Masamichi
   Furukawa, Takako
   Kiyono, Yasushi
   Mori, Tetsuya
   Yoshii, Hiroshi
   Oyama, Nobuyuki
   Okazawa, Hidehiko
   Saga, Tsuneo
   Fujibayashi, Yasuhisa
TI Radio labeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ<SUP>0</SUP> cells and cybnds carrying MELAS mitochondnal DNA mutation
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Article
DE Cu-ATSM; MELAS; Mitochondrial dysfunction; Overreduced state; PET; rho(0) cell
ID positron-emission-tomography; transfer rnaleu(uur) gene; assessing tumor hypoxia; in-vitro; oxidative stress; lactic-acidosis; cervical-cancer; point mutation; pimonidazole; cu-64-atsm
AB Objectives: Radiolabeled Cu-diacetyl-bis (N-4-methylthiosemicarbazone) (*Cu-ATSM), including Cu-60/62/64-ATSM, is a potential imaging agent of hypoxic tumors for positron emission tomography (PET). We have reported that *Cu-ATSM is trapped in tumor cells under intracellular overreduced states, e.g., hypoxia. Here we evaluated *Cu-ATSM as an indicator of intracellular overreduced states in mitochondrial disorders using cell lines with mitochondrial dysfunction. Methods: Mitochondrial DNA-less rho(0)206 cells; the parental 143B human osteosarcoma cells; the cybrids carrying mutated mitochondria from a patient of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) (2SD); and that carrying wildtype one (2SA) were used. Cells were treated under normoxia or hypoxia, and Cu-64-ATSM uptake was examined to compare it with levels of biological reductant NADH and NADPH. Results: rho(0)206 cells showed higher Cu-64-ATSM uptake than control 143B cells under normoxia, whereas Cu-64-ATSM uptake was not significantly increased under hypoxia in rho(0)206 cells. Additionally, Cu-64-ATSM uptake showed correlate change to the NADH and NADPH levels, but not oxygenic conditions. 2SD cells showed increased Cu-64-ATSM uptake under normoxia as compared with the control 2SA, and Cu-64-ATSM uptake followed NADH and NADPH levels, but not oxygenic conditions. Conclusions: Cu-64-ATSM accumulated in cells with overreduced states due to mitochondrial dysfunction, even under normoxia. We recently reported that Cu-62-ATSM-PET can visualize stroke-like episodes maintaining oxygen supply in MELAS patients. Taken together, our data indicate that *Cu-ATSM uptake reflects overreduced intracellular states, despite oxygenic conditions; thus, *Cu-ATSM would be a promising marker of intracellular overreduced states for disorders with mitochondrial dysfunction, such as MELAS, Parkinson's disease and Alzheimer's disease. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Yoshii, Yukie; Furukawa, Takako; Saga, Tsuneo; Fujibayashi, Yasuhisa] Natl Inst Radiol Sci, Mol Imaging Ctr, Chiba 2638555, Japan.
   [Yoshii, Yukie; Furukawa, Takako; Kiyono, Yasushi; Mori, Tetsuya; Okazawa, Hidehiko; Fujibayashi, Yasuhisa] Univ Fukui, Biomed Imaging Res Ctr, Fukui 9101193, Japan.
   [Yoneda, Makoto; Ikawa, Masamichi] Univ Fukui, Dept Neurol, Fac Med Sci, Fukui 9101193, Japan.
   [Yoshii, Hiroshi] Natl Inst Radiol Sci, Emergency Radiat Exposure Med Care Res Ctr, Chiba 2638555, Japan.
   [Oyama, Nobuyuki] Univ Fukui, Dept Urol, Fac Med Sci, Fukui 9101193, Japan.
C3 National Institutes for Quantum Science & Technology; University of Fukui; University of Fukui; National Institutes for Quantum Science & Technology; University of Fukui
RP Yoshii, Y (corresponding author), Natl Inst Radiol Sci, Mol Imaging Ctr, Chiba 2638555, Japan.
EM yukiey@nirs.go.jp
FU Japan Society for the Promotion of Science, Japan (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan
CR Arteel GE, 1998, EUR J BIOCHEM, V253, P743, DOI 10.1046/j.1432-1327.1998.2530743.x
   ARTEEL GE, 1995, BRIT J CANCER, V72, P889, DOI 10.1038/bjc.1995.429
   BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Dearling JLJ, 2010, NUCL MED BIOL, V37, P237, DOI 10.1016/j.nucmedbio.2009.11.004
   Dearling JLJ, 2002, J BIOL INORG CHEM, V7, P249, DOI 10.1007/s007750100291
   Dehdashti F, 2003, INT J RADIAT ONCOL, V55, P1233, DOI 10.1016/S0360-3016(02)04477-2
   Dehdashti F, 2008, J NUCL MED, V49, P201, DOI 10.2967/jnumed.107.048520
   Dence CS, 2008, NUCL MED BIOL, V35, P713, DOI 10.1016/j.nucmedbio.2008.06.001
   Dietz DW, 2008, DIS COLON RECTUM, V51, P1641, DOI 10.1007/s10350-008-9420-3
   Fujibayashi Y, 1997, J NUCL MED, V38, P1155
   Fukuyama R, 2002, J BIOL CHEM, V277, P41455, DOI 10.1074/jbc.M204176200
   Gao L, 2004, FEBS LETT, V569, P256, DOI 10.1016/j.febslet.2004.06.004
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Greco O, 2003, J CELL PHYSIOL, V197, P312, DOI 10.1002/jcp.10374
   Grigoryan R, 2005, METH MOLEC MED, V110, P87
   Grigsby PW, 2007, MOL IMAGING BIOL, V9, P278, DOI 10.1007/s11307-007-0095-2
   Guo SH, 2009, J NEUROCHEM, V108, P1309, DOI 10.1111/j.1471-4159.2009.05877.x
   Höckel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266
   Ikawa M, 2009, MITOCHONDRION, V9, P144, DOI 10.1016/j.mito.2009.01.011
   Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Lewis JS, 2001, J NUCL MED, V42, P655
   Lewis JS, 1999, J NUCL MED, V40, P177
   Lezza AMS, 1999, FASEB J, V13, P1083, DOI 10.1096/fasebj.13.9.1083
   Lohith TG, 2009, J NUCL MED, V50, P1948, DOI 10.2967/jnumed.109.069021
   Matsumoto KI, 2007, INT J ONCOL, V30, P873
   Mawrin C, 2004, NEUROSCI LETT, V357, P111, DOI 10.1016/j.neulet.2003.11.073
   McCarthy DW, 1997, NUCL MED BIOL, V24, P35, DOI 10.1016/S0969-8051(96)00157-6
   MORENO SNJ, 1983, J BIOL CHEM, V258, P4051
   ODonoghue JA, 2005, INT J RADIAT ONCOL, V61, P1493, DOI 10.1016/j.ijrobp.2004.12.057
   Obata A, 2001, ANN NUCL MED, V15, P499, DOI 10.1007/BF02988502
   Obata A, 2003, NUCL MED BIOL, V30, P535, DOI 10.1016/S0969-8051(03)00024-6
   Obata A, 2003, NUCL MED BIOL, V30, P529, DOI 10.1016/S0969-8051(03)00047-7
   OBITABOT ET, 1993, J SURG RES, V55, P575, DOI 10.1006/jsre.1993.1187
   Oh M, 2009, NUCL MED BIOL, V36, P419, DOI 10.1016/j.nucmedbio.2009.01.016
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rosenberger Christian, 2009, V466, V0, PP161, DOI 10.1007/978-1-59745-352-3_12
   Takahashi N, 2000, ANN NUCL MED, V14, P323, DOI 10.1007/BF02988690
   Tanaka T, 2006, NUCL MED BIOL, V33, P743, DOI 10.1016/j.nucmedbio.2006.05.005
   Watabe M, 2008, MOL PHARMACOL, V74, P933, DOI 10.1124/mol.108.048546
   Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   Yoshii Y, 2011, NUCL MED BIOL, V38, P151, DOI 10.1016/j.nucmedbio.2010.08.009
   Yoshii Y, 2010, NUCL MED BIOL, V37, P395, DOI 10.1016/j.nucmedbio.2009.12.011
NR 48
TC 55
Z9 57
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0969-8051
EI 1872-9614
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD FEB 15
PY 2012
VL 39
IS 2
BP 177
EP 185
DI 10.1016/j.nucmedbio.2011.08.008
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 890BY
UT WOS:000300121300002
PM 22033022
DA 2024-11-01
ER

PT J
AU Desquiret-Dumas, V
   Gueguen, N
   Barth, M
   Chevrollier, A
   Hancock, S
   Wallace, DC
   Amati-Bonneau, P
   Henrion, D
   Bonneau, D
   Reynier, P
   Procaccio, V
AF Desquiret-Dumas, Valerie
   Gueguen, Naig
   Barth, Magalie
   Chevrollier, Arnaud
   Hancock, Saege
   Wallace, Douglas C.
   Amati-Bonneau, Patrizia
   Henrion, Daniel
   Bonneau, Dominique
   Reynier, Pascal
   Procaccio, Vincent
TI Metabolically induced heteroplasmy shifting and l-arginine treatment reduce the energetic defect in a neuronal-like model of MELAS
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Mitochondria; Mitochondrial disorder; mtDNA; MELAS; Neuronal cell; L-arginine
ID stroke-like episodes; mitochondrial-dna mutation; a3243g mutation; lactic-acidosis; protein-synthesis; oxidative stress; human-cells; myopathy; encephalopathy; dysfunction
AB The m.3243A>G variant in the mitochondrial tRNA(Leu(UUR)) gene is a common mitochondrial DNA (mtDNA) mutation. Phenotypic manifestations depend mainly on the heteroplasmy, i.e. the ratio of mutant to normal mtDNA copies. A high percentage of mutant mtDNA is associated with a severe, life-threatening neurological syndrome known as MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes). MELAS is described as a neurovascular disorder primarily affecting the brain and blood vessels, but the pathophysiology of the disease is poorly understood. We developed a series of cybrid cell lines at two different mutant loads: 70% and 100% in the nuclear background of a neuroblastoma cell line (SH-SY5Y). We investigated the impact of the mutation on the metabolism and mitochondrial respiratory chain activity of the cybrids. The m.3243A>G mitochondrial mutation induced a metabolic switch towards glycolysis in the neuronal cells and produced severe defects in respiratory chain assembly and activity. We used two strategies to compensate for the biochemical defects in the mutant cells: one consisted of lowering the glucose content in the culture medium, and the other involved the addition of L-arginine. The reduction of glucose significantly shifted the 100% mutant cells towards the wild-type, reaching a 90% mutant level and restoring respiratory chain complex assembly. The addition of L-arginine, a nitric oxide (NO) donor, improved complex I activity in the mutant cells in which the defective NO metabolism had led to a relative shortage of NO. Thus, metabolically induced heteroplasmy shifting and L-arginine therapy may constitute promising therapeutic strategies against MELAS. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Desquiret-Dumas, Valerie; Gueguen, Naig; Barth, Magalie; Chevrollier, Arnaud; Amati-Bonneau, Patrizia; Bonneau, Dominique; Reynier, Pascal; Procaccio, Vincent] Angers Univ Hosp, Dept Biochem & Genet, Sch Med, F-49000 Angers, France.
   [Desquiret-Dumas, Valerie; Gueguen, Naig; Chevrollier, Arnaud; Amati-Bonneau, Patrizia; Henrion, Daniel; Bonneau, Dominique; Reynier, Pascal; Procaccio, Vincent] Univ Angers, UMR INSERM U1083 CNRS 6214, F-49000 Angers, France.
   [Hancock, Saege; Wallace, Douglas C.] Univ Penn, Ctr Mitochondrial & Epigen Med, Philadelphia, PA 19104 USA.
C3 Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Pennsylvania
RP Procaccio, V (corresponding author), CHU Angers, Biochem & Genet Lab, Natl Ctr Neurodegenerat & Mitochondrial Dis, 4 Rue Larrey, F-49933 Angers, France.
EM ViProcaccio@chu-angers.fr
FU University Hospital of Angers; Association contre les Maladies Mitochondriales (AMMi); Union Nationale des Aveugles et Deficients Visuels (UNADEV); National Institutes of Health [NS21328, AG24373, DK73691]
CR Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Davidson MM, 2009, MITOCHONDRION, V9, P463, DOI 10.1016/j.mito.2009.08.006
   Desquiret V, 2008, INT J BIOCHEM CELL B, V40, P1629, DOI 10.1016/j.biocel.2007.12.010
   El Meziane A, 1998, NAT GENET, V18, P350
   Fernández-Vizarra E, 2009, BBA-MOL CELL RES, V1793, P200, DOI 10.1016/j.bbamcr.2008.05.028
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gu Z, 1900, V41, V0, P55
   Han D, 2005, BIOCHEMISTRY-US, V44, P11986, DOI 10.1021/bi0509393
   Ishikawa K, 2009, METHOD ENZYMOL, V457, P335, DOI 10.1016/S0076-6879(09)05019-8
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   Jarrett SG, 2008, J NEUROCHEM, V106, P1044, DOI 10.1111/j.1471-4159.2008.05460.x
   Katayama Y, 2009, MITOCHONDRION, V9, P306, DOI 10.1016/j.mito.2009.04.002
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Koga Y, 2006, NEUROLOGY, V66, P1766, DOI 10.1212/01.wnl.0000220197.36849.1e
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koga Y, 2007, MITOCHONDRION, V7, P133, DOI 10.1016/j.mito.2006.11.006
   Koga Y, 2010, ANN NY ACAD SCI, V1201, P104, DOI 10.1111/j.1749-6632.2010.05624.x
   Lazarou M, 2009, BBA-MOL CELL RES, V1793, P78, DOI 10.1016/j.bbamcr.2008.04.015
   Lenaz G, 2010, BBA-BIOENERGETICS, V1797, P633, DOI 10.1016/j.bbabio.2010.01.025
   Li R, 2010, MOL CELL BIOL, V30, P2147
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Nochez Y, 2009, MOL VIS, V15, P598
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
   Pang CY, 2001, DIABETES RES CLIN PR, V54, PS45, DOI 10.1016/S0168-8227(01)00335-7
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Park JS, 2009, HUM MOL GENET, V18, P1578, DOI 10.1093/hmg/ddp069
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   Sawada N, 2009, EXPERT REV NEUROTHER, V9, P1171, DOI 10.1586/ern.09.70
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Shigemi R, 2010, BRAIN DEV, V0, P0
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Swerdlow RH, 2011, ANTIOXID REDOX SIGNA, V0, P0
   Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314
   Wu YT, 2010, ANN NY ACAD SCI, V1201, P147, DOI 10.1111/j.1749-6632.2010.05631.x
NR 43
TC 35
Z9 39
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD JUN 15
PY 2012
VL 1822
IS 6
BP 1019
EP 1029
DI 10.1016/j.bbadis.2012.01.010
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 941KE
UT WOS:000303961300020
PM 22306605
DA 2024-11-01
ER

PT J
AU Katsuno, M
   Tanaka, F
   Adachi, H
   Banno, H
   Suzuki, K
   Watanabe, H
   Sobue, G
AF Katsuno, Masahisa
   Tanaka, Fumiaki
   Adachi, Hiroaki
   Banno, Haruhiko
   Suzuki, Keisuke
   Watanabe, Hirohisa
   Sobue, Gen
TI Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA)
SO PROGRESS IN NEUROBIOLOGY
LA English
DT Review
DE Spinal and bulbar muscular atrophy; Androgen receptor; Polyglutamine; Motor neuron; Neurodegeneration; Luteinizing hormone-releasing hormone analog; Ubiquitin-proteasome; Molecular chaperone; Autophagy; Animal model; Clinical trial
ID recessive bulbospinal neuronopathy; transgenic mouse model; mutant androgen receptor; amyotrophic-lateral-sclerosis; histone deacetylase inhibitors; elongated polyglutamine tract; skeletal-muscle pathology; fast axonal-transport; heat-shock proteins; cag-repeat length
AB Spinal and bulbar muscular atrophy (SBMA) is a late-onset motor neuron disease characterized by slowly progressive muscle weakness and atrophy. During the last two decades, basic and clinical research has provided important insights into the disease phenotype and pathophysiology. The cause of SBMA is the expansion of a trinucleotide CAG repeat encoding a polyglutamine tract within the first exon of the androgen receptor (AR) gene. SBMA exclusively affects adult males, whereas females homozygous for the AR mutation do not manifest neurological symptoms. The ligand-dependent nuclear accumulation of the polyglutamine-expanded AR protein is central to the gender-specific pathogenesis of SBMA, although additional steps, e.g., DNA binding, inter-domain interactions, and post-translational modification of AR, modify toxicity. The interactions with co-regulators are another requisite for the toxic properties of the polyglutamine-expanded AR. It is also shown that the polyglutamine-expanded AR induces diverse molecular events, such as transcriptional dysregulation, axonal transport disruption, and mitochondrial dysfunction, which play causative roles in the neurodegeneration in SBMA. The pathogenic AR-induced myopathy also contributes to the non-cell autonomous degeneration of motor neurons. Pre-clinical studies using animal models show that the pathogenic AR-mediated neurodegeneration is suppressed by androgen inactivation, the efficacy of which has been tested in clinical trials. Pharmacological activation of cellular defense machineries, such as molecular chaperones, ubiquitin proteasome system, and autophagy, also exerts neuroprotective effects in experimental models of SBMA. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Katsuno, Masahisa; Tanaka, Fumiaki; Adachi, Hiroaki; Banno, Haruhiko; Suzuki, Keisuke; Watanabe, Hirohisa; Sobue, Gen] Nagoya Univ, Dept Neurol, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Banno, Haruhiko] Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan.
C3 Nagoya University; Nagoya University
RP Sobue, G (corresponding author), Nagoya Univ, Dept Neurol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM ka2no@med.nagoya-u.ac.jp; sobueg@med.nagoya-u.ac.jp
FU Kennedy Disease Association; Center-of-Excellence (COE) grant; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST); Grants-in-Aid for Scientific Research [21229011, 24659428, 23390230, 23790986] Funding Source: KAKEN
CR Adachi H, 2005, BRAIN, V128, P659, DOI 10.1093/brain/awh381
   Adachi H, 2003, J NEUROSCI, V23, P2203
   Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039
   Adachi H, 2007, J NEUROSCI, V27, P5115, DOI 10.1523/JNEUROSCI.1242-07.2007
   Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005
   Atsuta N, 2006, BRAIN, V129, P1446, DOI 10.1093/brain/awl096
   Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515
   Banno H, 2006, ANN NEUROL, V59, P520, DOI 10.1002/ana.20735
   Banno H, 2009, ANN NEUROL, V65, P140, DOI 10.1002/ana.21540
   Battaglia F, 2003, J CLIN NEUROMUSCUL DIS, V4, P165, DOI 10.1097/00131402-200306000-00001
   Bauer PO, 2009, J NEUROCHEM, V110, P1737, DOI 10.1111/j.1471-4159.2009.06302.x
   Brinkmann AO, 2001, EUR J DERMATOL, V11, P301
   Butler R, 2006, NAT REV NEUROSCI, V7, P784, DOI 10.1038/nrn1989
   Chahin N, 2009, MUSCLE NERVE, V40, P126, DOI 10.1002/mus.21310
   CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10
   Chevalier-Larsen ES, 2004, J NEUROSCI, V24, P4778, DOI 10.1523/JNEUROSCI.0808-04.2004
   Clark Peter E, 2003, METHODS MOL MED, V81, P255
   Custer SK, 2006, NAT NEUROSCI, V9, P1302, DOI 10.1038/nn1750
   Davis-Dao C, 2012, J CLIN ENDOCR METAB, V97, PE393, DOI 10.1210/jc.2011-2439
   Dejager S, 2002, J CLIN ENDOCR METAB, V87, P3893, DOI 10.1210/jc.87.8.3893
   DOYU M, 1992, ANN NEUROL, V32, P707, DOI 10.1002/ana.410320517
   Fernández-Rhodes LE, 2011, LANCET NEUROL, V10, P140, DOI 10.1016/S1474-4422(10)70321-5
   Finsterer J, 2010, J NEUROL SCI, V298, P1, DOI 10.1016/j.jns.2010.08.025
   Fischbeck KH, 1997, J INHERIT METAB DIS, V20, P152, DOI 10.1023/A:1005344403603
   FISCHBECK KH, 1986, NEUROLOGY, V36, P1595, DOI 10.1212/WNL.36.12.1595
   Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018
   Guidetti D, 1996, J NEUROL SCI, V135, P140, DOI 10.1016/0022-510X(95)00283-8
   Guidetti D, 2001, EUR J EPIDEMIOL, V17, P587, DOI 10.1023/A:1014580219761
   Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129
   Hama T, 2012, MUSCLE NERVE, V45, P169, DOI 10.1002/mus.22291
   Hanajima R, 2009, MOVEMENT DISORD, V24, P2063, DOI 10.1002/mds.22566
   HARDING AE, 1982, J NEUROL NEUROSUR PS, V45, P1012, DOI 10.1136/jnnp.45.11.1012
   Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144
   Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070
   Higashihara M, 2011, MUSCLE NERVE, V44, P539, DOI 10.1002/mus.22119
   IGARASHI S, 1992, NEUROLOGY, V42, P2300, DOI 10.1212/WNL.42.12.2300
   Inoue K, 2009, EUR J NEUROL, V16, P76, DOI 10.1111/j.1468-1331.2008.02349.x
   Ishihara H, 2001, J NEUROL, V248, P856, DOI 10.1007/s004150170069
   JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341
   Jochum T, 2012, BBA-MOL BASIS DIS, V1822, P1070, DOI 10.1016/j.bbadis.2012.02.006
   Johansen JA, 2009, NEUROBIOL DIS, V34, P113, DOI 10.1016/j.nbd.2008.12.009
   KACHI T, 1992, J NEUROL NEUROSUR PS, V55, P394, DOI 10.1136/jnnp.55.5.394
   Karitzky J, 1999, ARCH NEUROL-CHICAGO, V56, P1465, DOI 10.1001/archneur.56.12.1465
   Kassubek J, 2007, J NEUROL NEUROSUR PS, V78, P1209, DOI 10.1136/jnnp.2006.112532
   Katsuno M, 2005, P NATL ACAD SCI USA, V102, P16801, DOI 10.1073/pnas.0506249102
   Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878
   Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6
   Katsuno M, 2006, J NEUROSCI, V26, P12106, DOI 10.1523/JNEUROSCI.3032-06.2006
   Katsuno M, 2006, EXP NEUROL, V200, P8, DOI 10.1016/j.expneurol.2006.01.021
   Katsuno M, 2010, LANCET NEUROL, V9, P875, DOI 10.1016/S1474-4422(10)70182-4
   Katsuno M, 2010, J NEUROSCI, V30, P5702, DOI 10.1523/JNEUROSCI.0388-10.2010
   Kawahara H, 1897, AICHIMEDJ, V16, P3
   Kemp MQ, 2011, HUM MOL GENET, V20, P4475, DOI 10.1093/hmg/ddr380
   KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671
   Kinirons P, 2008, J NEUROL NEUROSUR PS, V79, P106, DOI 10.1136/jnnp.2006.101899
   Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X
   Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772
   La Spada AR, 2010, NAT REV GENET, V11, P247, DOI 10.1038/nrg2748
   Lafevre-Bernt MA, 2003, J BIOL CHEM, V278, P34918, DOI 10.1074/jbc.M302841200
   LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0
   Lehky TJ, 2009, MUSCLE NERVE, V40, P809, DOI 10.1002/mus.21399
   Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X
   Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216
   LI M, 1995, MUSCLE NERVE, V18, P301, DOI 10.1002/mus.880180306
   Li M, 2007, J BIOL CHEM, V282, P3157, DOI 10.1074/jbc.M609972200
   Lund A, 2001, EUR J HUM GENET, V9, P431, DOI 10.1038/sj.ejhg.5200656
   Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259
   Malik B, 2011, HUM MOL GENET, V20, P1776, DOI 10.1093/hmg/ddr061
   Meriggioli MN, 2003, MUSCLE NERVE, V27, P249, DOI 10.1002/mus.10295
   Miller J, 2011, NAT CHEM BIOL, V7, P925, DOI 10.1038/NCHEMBIO.694
   Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131
   Mirowska-Guzel D, 2009, NEUROCASE, V15, P332, DOI 10.1080/13554790902842003
   Mo KG, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0012922
   Monks DA, 2007, P NATL ACAD SCI USA, V104, P18259, DOI 10.1073/pnas.0705501104
   Montie HL, 2011, J NEUROSCI, V31, P17425, DOI 10.1523/JNEUROSCI.3958-11.2011
   Montie HL, 2009, HUM MOL GENET, V18, P1937, DOI 10.1093/hmg/ddp115
   Morfini G, 2006, NAT NEUROSCI, V9, P907, DOI 10.1038/nn1717
   Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587
   Mukherjee S, 2009, J BIOL CHEM, V284, P21296, DOI 10.1074/jbc.M109.011494
   Nagai Y, 2007, NAT STRUCT MOL BIOL, V14, P332, DOI 10.1038/nsmb1215
   Nagai Y, 2010, CURR PHARM BIOTECHNO, V11, P188, DOI 10.2174/138920110790909650
   NAGASHIMA T, 1988, J NEUROL SCI, V87, P141, DOI 10.1016/0022-510X(88)90240-7
   Nedelsky NB, 2010, NEURON, V67, P936, DOI 10.1016/j.neuron.2010.08.034
   Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784
   Orr CR, 2010, J BIOL CHEM, V285, P35567, DOI 10.1074/jbc.M110.146845
   Orr HT, 2007, ANNU REV NEUROSCI, V30, P575, DOI 10.1146/annurev.neuro.29.051605.113042
   Pachatz C, 2007, CLIN NEUROPHYSIOL, V118, P262, DOI 10.1016/j.clinph.2006.10.006
   Palazzolo I, 2008, J STEROID BIOCHEM, V108, P245, DOI 10.1016/j.jsbmb.2007.09.016
   Palazzolo I, 2007, HUM MOL GENET, V16, P1593, DOI 10.1093/hmg/ddm109
   Palazzolo I, 2009, NEURON, V63, P316, DOI 10.1016/j.neuron.2009.07.019
   Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853
   Parboosingh JS, 1997, NEUROLOGY, V49, P568, DOI 10.1212/WNL.49.2.568
   Parodi S, 2011, FRONT NEUROENDOCRIN, V32, P416, DOI 10.1016/j.yfrne.2011.06.003
   Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773
   Piccioni F, 2002, FASEB J, V16, P1418, DOI 10.1096/fj.01-1035fje
   Poletti A, 2004, FRONT NEUROENDOCRIN, V25, P1, DOI 10.1016/j.yfrne.2004.03.001
   Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123
   Ranganathan S, 2010, TRENDS PHARMACOL SCI, V31, P523, DOI 10.1016/j.tips.2010.08.005
   Ranganathan S, 2009, HUM MOL GENET, V18, P27, DOI 10.1093/hmg/ddn310
   Rhodes LE, 2009, BRAIN, V132, P3242, DOI 10.1093/brain/awp258
   Rocchi C, 2011, MUSCLE NERVE, V44, P737, DOI 10.1002/mus.22159
   Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3
   Rusmini P, 2011, NEUROBIOL DIS, V41, P83, DOI 10.1016/j.nbd.2010.08.023
   Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1
   Schmidt BJ, 2002, NEUROLOGY, V59, P770, DOI 10.1212/WNL.59.5.770
   Simeoni S, 2000, HUM MOL GENET, V9, P133, DOI 10.1093/hmg/9.1.133
   Sinclair R, 2007, BRIT J DERMATOL, V157, P290, DOI 10.1111/j.1365-2133.2007.08026.x
   SOBUE G, 1993, J NEUROL SCI, V117, P74, DOI 10.1016/0022-510X(93)90157-T
   SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209
   SOBUE G, 1990, ACTA NEUROPATHOL, V79, P402, DOI 10.1007/BF00308716
   Sopher BL, 2004, NEURON, V41, P687, DOI 10.1016/S0896-6273(04)00082-0
   Sorarù G, 2008, J NEUROL SCI, V264, P100, DOI 10.1016/j.jns.2007.08.012
   Sperfeld AD, 2005, NEUROLOGY, V64, P753, DOI 10.1212/01.WNL.0000151978.74467.E7
   Sperfeld AD, 2002, ARCH NEUROL-CHICAGO, V59, P1921, DOI 10.1001/archneur.59.12.1921
   Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568
   Suzuki E, 2009, P NATL ACAD SCI USA, V106, P3818, DOI 10.1073/pnas.0809819106
   Suzuki K, 2008, BRAIN, V131, P229, DOI 10.1093/brain/awm289
   Suzuki K, 2010, J NEUROL NEUROSUR PS, V81, P567, DOI 10.1136/jnnp.2009.190462
   Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5
   Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9
   Tanaka F, 1996, HUM MOL GENET, V5, P1253, DOI 10.1093/hmg/5.9.1253
   Tanaka F, 1999, AM J HUM GENET, V65, P966, DOI 10.1086/302578
   Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074
   Thomas M, 2004, J BIOL CHEM, V279, P8389, DOI 10.1074/jbc.M311761200
   Tokui K, 2009, HUM MOL GENET, V18, P898, DOI 10.1093/hmg/ddn419
   Udd B, 1998, ACTA NEUROL SCAND, V98, P128
   Unrath A, 2010, HUM BRAIN MAPP, V31, P1727, DOI 10.1002/hbm.20971
   Verhovshek T, 2010, ENDOCRINOLOGY, V151, P253, DOI 10.1210/en.2009-1036
   Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298
   Wyttenbach A, 2004, J MOL NEUROSCI, V23, P69, DOI 10.1385/JMN:23:1-2:069
   Yamada M, 1997, J NEUROL SCI, V146, P183, DOI 10.1016/S0022-510X(96)00303-6
   Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547
   Young JE, 2009, J NEUROSCI, V29, P1987, DOI 10.1523/JNEUROSCI.4072-08.2009
   Yu Z, 2006, J CLIN INVEST, V116, P2663, DOI 10.1172/JCI28773
   Yu ZG, 2011, PLOS GENET, V7, P0, DOI 10.1371/journal.pgen.1002321
   Yu ZG, 2009, DIS MODEL MECH, V2, P500, DOI 10.1242/dmm.003301
NR 136
TC 84
Z9 92
U1 0
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-0082
EI 1873-5118
J9 PROG NEUROBIOL
JI Prog. Neurobiol.
PD DEC 15
PY 2012
VL 99
IS 3
BP 246
EP 256
DI 10.1016/j.pneurobio.2012.05.007
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 052BJ
UT WOS:000312172400005
PM 22609045
DA 2024-11-01
ER

PT J
AU Malik, Q
   Herbert, KE
AF Malik, Qudsia
   Herbert, Karl E.
TI Oxidative and non-oxidative DNA damage and cardiovascular disease
SO FREE RADICAL RESEARCH
LA English
DT Review
DE atherosclerosis; reactive oxygen species; mitochondria; coronary artery disease; ApoE(-/-)
ID coronary-artery-disease; human atherosclerotic lesions; smooth-muscle-cells; 4977 bp deletion; e-deficient mice; mitochondrial-dna; endothelial-cells; atrial-fibrillation; metabolic syndrome; elevated levels
AB Evidence for the association of DNA damage with cardiovascular disease has been obtained from in vitro cell culture models, experimental cardiovascular disease and analysis of samples obtained from humans with disease. There is general acceptance that several factors associated with the risk of developing cardiovascular disease cause oxidative damage to DNA in cell culture models with both nuclear and mitochondrial DNA as targets. Moreover, evidence obtained over the past 10 years points to a possible mechanistic role for DNA damage in experimental atherosclerosis culminating in recent studies challenging the assumption that DNA damage is merely a biomarker of the disease process. This kind of mechanistic insight provides a renewed impetus for further studies in this area.
C1 [Malik, Qudsia; Herbert, Karl E.] Univ Leicester, Dept Cardiovasc Sci, Glenfield Hosp, Leicester LE3 9QP, Leics, England.
C3 University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital
RP Herbert, KE (corresponding author), Univ Leicester, Dept Cardiovasc Sci, Glenfield Hosp, Leicester LE3 9QP, Leics, England.
EM keh3@le.ac.uk
FU MRC
CR Andreassi MG, 2008, J MOL MED, V86, P1033, DOI 10.1007/s00109-008-0358-7
   Andreassi MG, 2003, HUM GENET, V112, P171, DOI 10.1007/s00439-002-0859-3
   Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89
   Bhatnagar A, 2006, CIRC RES, V99, P692, DOI 10.1161/01.RES.0000243586.99701.cf
   Binková B, 2002, MUTAT RES-FUND MOL M, V501, P115, DOI 10.1016/S0027-5107(02)00019-2
   Bogliolo M, 1999, MUTAGENESIS, V14, P77, DOI 10.1093/mutage/14.1.77
   Botto N, 2005, MUTAT RES-FUND MOL M, V570, P81, DOI 10.1016/j.mrfmmm.2004.10.003
   Botto N, 2002, CORONARY ARTERY DIS, V13, P269, DOI 10.1097/00019501-200208000-00004
   Botto N, 2001, MUTAT RES-GEN TOX EN, V493, P23, DOI 10.1016/S1383-5718(01)00162-0
   Cakir Y, 2007, FREE RADICAL BIO MED, V43, P1279, DOI 10.1016/j.freeradbiomed.2007.07.015
   Chuang GC, 2009, AM J PHYSIOL-LUNG C, V297, PL209, DOI 10.1152/ajplung.00102.2009
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G
   Costa RAP, 2011, J BIOENERG BIOMEMBR, V43, P25, DOI 10.1007/s10863-011-9329-8
   Costopouzos C, 2008, BIOCHEM PHARMACOL, V75, P1251, DOI 10.1016/j.bcp.2007.10.006
   Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409
   DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155
   DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7
   Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI200111235
   Farhangkhoee H, 2005, DIABETOLOGIA, V48, P1401, DOI 10.1007/s00125-005-1801-8
   Folkmann JK, 2007, MUTAGENESIS, V22, P105, DOI 10.1093/mutage/gel059
   Godschalk RWL, 2007, MUTAT RES-FUND MOL M, V621, P87, DOI 10.1016/j.mrfmmm.2007.02.012
   Gredilla R, 2010, EXP GERONTOL, V45, P478, DOI 10.1016/j.exger.2010.01.017
   Gur M, 2007, MUTAT RES-FUND MOL M, V617, P111, DOI 10.1016/j.mrfmmm.2007.01.011
   Herbert KE, 2008, CIRC RES, V102, P201, DOI 10.1161/CIRCRESAHA.107.158626
   HOUTMAN JPW, 1993, SCI TOTAL ENVIRON, V138, P31, DOI 10.1016/0048-9697(93)90402-R
   Izzotti A, 2001, FASEB J, V15, P752, DOI 10.1096/fj.00-0312com
   IZZOTTI A, 1995, CANCER EPIDEM BIOMAR, V4, P105
   Izzotti A, 2007, MUTAT RES-FUND MOL M, V621, P119, DOI 10.1016/j.mrfmmm.2006.12.012
   Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855
   Kang GS, 2011, ENVIRON HEALTH PERSP, V119, P176, DOI 10.1289/ehp.1002508
   Khan SJ, 2010, AM J PHYSIOL-HEART C, V298, PH66, DOI 10.1152/ajpheart.00501.2009
   Lai LP, 2003, CHEST, V123, P539, DOI 10.1378/chest.123.2.539
   LEADON SA, 1988, P NATL ACAD SCI USA, V85, P4365, DOI 10.1073/pnas.85.12.4365
   Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553
   Lin PH, 2003, FREE RADICAL BIO MED, V35, P1310, DOI 10.1016/j.freeradbiomed.2003.07.002
   Liu F, 2000, FREE RADICAL BIO MED, V28, P55, DOI 10.1016/S0891-5849(99)00196-3
   Liu QJ, 2009, TOXICOL LETT, V191, P314, DOI 10.1016/j.toxlet.2009.09.015
   Lynn S, 2000, CIRC RES, V86, P514, DOI 10.1161/01.RES.86.5.514
   Madsen-Bouterse SA, 2010, FREE RADICAL RES, V44, P313, DOI 10.3109/10715760903494168
   Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21
   Martinet W, 2004, EUR J CLIN INVEST, V34, P323, DOI 10.1111/j.1365-2362.2004.01343.x
   Martinet W, 2001, CIRC RES, V88, P733, DOI 10.1161/hh0701.088684
   Masetti S, 2003, J MOL MED, V81, P488, DOI 10.1007/s00109-003-0448-5
   Mazza F, 2003, EXP BIOL MED, V228, P576, DOI 10.1177/15353702-0322805-31
   Medikayala S, 2011, AM J PHYSIOL-CELL PH, V300, PC338, DOI 10.1152/ajpcell.00248.2010
   Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, PC82, DOI 10.1152/ajpcell.00287.2006
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   Melvin T, 1996, PHOTOCHEM PHOTOBIOL, V64, P769, DOI 10.1111/j.1751-1097.1996.tb01833.x
   Mercer JR, 2010, CIRC RES, V107, P1021, DOI 10.1161/CIRCRESAHA.110.218966
   Messner B, 2009, ARTERIOSCL THROM VAS, V29, P1392, DOI 10.1161/ATVBAHA.109.190082
   Naira J, 2007, MUTAT RES-FUND MOL M, V621, P95, DOI 10.1016/j.mrfmmm.2007.02.013
   Oumouna-Benachour K, 2007, CIRCULATION, V115, P2442, DOI 10.1161/CIRCULATIONAHA.106.668756
   Pathak N, 2008, BIOMETALS, V21, P179, DOI 10.1007/s10534-007-9106-7
   Pernice F, 2006, EUR J PHARMACOL, V532, P223, DOI 10.1016/j.ejphar.2006.01.003
   Quagliaro L, 2005, ATHEROSCLEROSIS, V183, P259, DOI 10.1016/j.atherosclerosis.2005.03.015
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Satoh M, 2008, ATHEROSCLEROSIS, V198, P347, DOI 10.1016/j.atherosclerosis.2007.09.040
   Schupp N, 2007, AM J PHYSIOL-RENAL, V292, PF1427, DOI 10.1152/ajprenal.00458.2006
   Shall S, 1994, MOL CELL BIOCHEM, V138, P7175
   Shen YH, 2004, CIRC RES, V94, P1310, DOI 10.1161/01.RES.0000129180.13992.43
   Spelbrink JN, 2010, IUBMB LIFE, V62, P19, DOI 10.1002/iub.282
   Suematsu N, 2003, CIRCULATION, V107, P1418, DOI 10.1161/01.CIR.0000055318.09997.1F
   Sun JZ, 2010, MOL CELL BIOCHEM, V343, P27, DOI 10.1007/s11010-010-0495-5
   Tellez-Plaza M, 2008, ENVIRON HEALTH PERSP, V116, P51, DOI 10.1289/ehp.10764
   TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B
   Trapp C, 2007, MUTAT RES-FUND MOL M, V625, P155, DOI 10.1016/j.mrfmmm.2007.06.006
   von Sonntag C, 1987, FREE RADIC RES COMMUN, V2, P217, DOI 10.3109/10715768709065286
   WEI YH, 1992, MUTAT RES, V275, P145, DOI 10.1016/0921-8734(92)90019-L
   Yang MS, 2008, TOXICOLOGY, V247, P6, DOI 10.1016/j.tox.2008.01.021
   Zhang YJ, 1998, ATHEROSCLEROSIS, V140, P325, DOI 10.1016/S0021-9150(98)00136-1
NR 72
TC 24
Z9 30
U1 0
U2 17
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1071-5762
EI 
J9 FREE RADICAL RES
JI Free Radic. Res.
PD APR 15
PY 2012
VL 46
IS 4
BP 554
EP 564
DI 10.3109/10715762.2012.663913
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 907ZA
UT WOS:000301458200012
PM 22303808
DA 2024-11-01
ER

PT J
AU Koga, Y
   Povalko, N
   Nishioka, J
   Katayama, K
   Yatsuga, S
   Matsuishi, T
AF Koga, Yasutoshi
   Povalko, Nataliya
   Nishioka, Junko
   Katayama, Koujyu
   Yatsuga, Shuichi
   Matsuishi, Toyojiro
TI Molecular pathology of MELAS and L-arginine effects
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Review
DE Mitochondrial cytopathy; Translation; RNA 19; Angiopathy; Endothelial dysfunction; L-arginine
ID stroke-like episodes; anticodon wobble nucleotide; mitochondrial-dna mutation; cerebral-blood-flow; lactic-acidosis; transfer-rna; point mutation; transcription termination; modification defect; respiratory-chain
AB Background: The pathogenic mechanism of stroke-like episodes seen in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) has not been clarified yet. About 80% of MELAS patients have an A3243G mutation in the mitochondrial tRNA(LeU(UUR)) gene, which is the base change at position 14 in the consensus structure of tRNA(LeU(UUR)) gene. Scope of review: This review aims to give an overview on the actual knowledge about the pathogenic mechanism of mitochondrial cytopathy at the molecular levels, the possible pathogenic mechanism of mitochondrial angiopathy to cause stroke-like episodes at the clinical and pathophysiological levels, and the proposed site of action of L-arginine therapy on MELAS. Major conclusions: Molecular pathogenesis is mainly demonstrated using rho degrees cybrid system. The mutation creates the protein synthesis defects caused by 1) decreased life span of steady state amount of tRNA(Leu(UUR)) molecules; 2) decreased ratio of aminoacyl-tRNA(Leu(UUR))) versus uncharged tRNA(Leu(UUR))) molecules; 3) the accumulation of aminoacylation with leucine without any misacylation; 4) accumulation of processing intermediates such as RNA 19.5) wobble modification defects. All of these loss of function abnormalities are created by the threshold effects of cell or organ to the mitochondrial energy requirement when they establish the phenotype. Mitochondrial angiopathy demonstrated by muscle or brain pathology, as SW (SDH strongly stained vessels), and by vascular physiology using FMD (flow mediated dilation). MELAS patients show decreased capacity of NO dependent vasodilation because of the low plasma levels of L-arginine and/or of respiratory chain dysfunction. Although the underlying mechanisms are not completely understood in stroke-like episodes in MELAS, L-arginine therapy improved endothelial dysfunction. General significance: Though the molecular pathogenesis of an A3243G or T3271C mutation of mitochondrial tRNA(Leu(UUR)) gene has been clarified as a mitochondrial cytopathy, the underlying mechanisms of stroke-like episodes in MELAS are not completely understood. At this point, L-arginine therapy showed promise in treating of the stroke-like episodes in MELAS. This article is part of a Special Issue entitled Biochemistry of Mitochondria. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Koga, Yasutoshi; Povalko, Nataliya; Nishioka, Junko; Katayama, Koujyu; Yatsuga, Shuichi; Matsuishi, Toyojiro] Kurume Univ, Grad Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 300011, Japan.
   [Yatsuga, Shuichi] Univ Helsinki, Res Program Mol Neurol, Biomedicum Helsinki, Helsinki, Finland.
C3 Kurume University; University of Helsinki
RP Koga, Y (corresponding author), Kurume Univ, Sch Med, Dept Pediat & Child Hlth, 67 Asahi Machi, Kurume, Fukuoka 300011, Japan.
EM yasukoga@med.kurume-u.ac.jp
FU Ministry of Culture and Education in Japan [13670853, 16390308]; Evidence-based Medicine, Ministry of Health, Labor and Welfare in Japan [CCT-B-1803]; Academy of Finland, the Center for International Mobility in Finland; Grants-in-Aid for Scientific Research [13670853, 16390308] Funding Source: KAKEN
CR BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Di Mauro S, 1993, GENE REV, V0, P0
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   Finsterer J, 2007, ACTA NEUROL SCAND, V116, P1, DOI 10.1111/j.1600-0404.2007.00836.x
   Flierl H, 1997, BIOL CHEM, V272, P27189
   GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497
   Gerriets T, 2004, BRAIN RES PROTOC, V12, P137, DOI 10.1016/j.brainresprot.2003.08.006
   GODDARD JP, 1977, PROG BIOPHYS MOL BIO, V32, P233
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hao R, 2004, FEBS LETT, V578, P135, DOI 10.1016/j.febslet.2004.11.004
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   Iizuka T, 2007, J NEUROL SCI, V257, P126, DOI 10.1016/j.jns.2007.01.040
   Iizuka T, 2010, FUTUR NEUROL, V5, P61, DOI 10.2217/FNL.09.71
   Iizuka T, 2009, J NEUROL SCI, V278, P35, DOI 10.1016/j.jns.2008.11.016
   Ikawa M, 2009, MITOCHONDRION, V9, P144, DOI 10.1016/j.mito.2009.01.011
   Ito H, 2008, BRAIN DEV-JPN, V30, P483, DOI 10.1016/j.braindev.2008.01.003
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2006, HUM MOL GENET, V15, P897, DOI 10.1093/hmg/ddl007
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   KISHI M, 1988, J NEUROL SCI, V86, P31, DOI 10.1016/0022-510X(88)90005-6
   Koga A, 2003, NEUROMUSCULAR DISORD, V13, P259, DOI 10.1016/S0960-8966(02)00267-5
   Koga Y, 2006, NEUROLOGY, V66, P1766, DOI 10.1212/01.wnl.0000220197.36849.1e
   KOGA Y, 1993, NUCLEIC ACIDS RES, V21, P657, DOI 10.1093/nar/21.3.657
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koga Y, 2002, NEUROLOGY, V58, P827, DOI 10.1212/WNL.58.5.827
   KOGA Y, 1995, MUSCLE NERVE, V0, PS119
   KOGA Y, 1988, ANN NEUROL, V24, P749, DOI 10.1002/ana.410240609
   Koge Y, 1998, ANN NEUROL, V43, P835, DOI 10.1002/ana.410430620
   KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2
   Kubota M, 2004, BRAIN DEV-JPN, V26, P481, DOI 10.1016/j.braindev.2004.01.006
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Molnár MJ, 2000, NEUROLOGY, V55, P544, DOI 10.1212/WNL.55.4.544
   MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9
   Moro MA, 2005, FREE RADICAL BIO MED, V39, P1291, DOI 10.1016/j.freeradbiomed.2005.07.010
   Naini A, 2005, J NEUROL SCI, V229, P187, DOI 10.1016/j.jns.2004.11.026
   Nariai R, 2001, J NEUROIMAGING, V11, P325, DOI 10.1111/j.1552-6569.2001.tb00057.x
   Nishioka J, 2008, BRAIN DEV-JPN, V30, P100, DOI 10.1016/j.braindev.2007.06.008
   Noguchi A, 2005, PEDIATR NEUROL, V33, P70, DOI 10.1016/j.pediatrneurol.2005.01.013
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ohshita T, 2000, NEURORADIOLOGY, V42, P651, DOI 10.1007/s002340000335
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Roy MD, 2005, RNA, V11, P254, DOI 10.1261/rna.7143305
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Stoquart-ElSankari S, 2008, J NEUROL, V255, P1593, DOI 10.1007/s00415-008-0968-6
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Tanahashi C, 2000, ACTA NEUROPATHOL, V99, P31, DOI 10.1007/PL00007403
   WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347
   Wang XL, 1996, NAT MED, V2, P41, DOI 10.1038/nm0196-41
   Wang XY, 2003, NEURORADIOLOGY, V45, P640, DOI 10.1007/s00234-003-1029-6
   Wilichowski E, 1999, NEUROPEDIATRICS, V30, P256, DOI 10.1055/s-2007-973500
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
NR 67
TC 50
Z9 54
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD MAY 15
PY 2012
VL 1820
IS 5
BP 608
EP 614
DI 10.1016/j.bbagen.2011.09.005
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 930JO
UT WOS:000303135900009
PM 21944974
DA 2024-11-01
ER

PT J
AU Graham, BH
AF Graham, Brett H.
TI Diagnostic Challenges of Mitochondrial Disorders: Complexities of Two Genomes
SO MITOCHONDRIAL DISORDERS: BIOCHEMICAL AND MOLECULAR ANALYSIS
LA English
DT Article; Book Chapter
DE Mitochondria; Respiratory chain disorders; Heteroplasmy; mtDNA; Gene testing
ID respiratory-chain disorders; c-oxidase deficiency; dna depletion; clinical spectrum; sucla2 mutations; gene-mutations; disease; children; encephalomyopathy; deletions
AB Mitochondrial disorders causing respiratory chain dysfunction comprise a group of genetically and clinically heterogeneous diseases. This heterogeneity reflects both the biochemical complexity of oxidative phosphorylation and the genetic contribution of both the nuclear and mitochondrial genomes to the respiratory chain. Current approaches to diagnose and classify mitochondrial disorders incorporate clinical, biochemical, and histological criteria, as well as DNA-based molecular diagnostic testing. While the identification of pathogenic mutations is generally accepted as definitive, the large number of candidate nuclear genes, the involvement of two genomes, and potential heteroplasmy of pathogenic mitochondrial DNA (mtDNA) frequently complicate successful molecular diagnostic confirmation. The strategy for pursuing a diagnosis derives from the integration of family history, clinical findings, biochemical evaluations, histopathological analyses, neuroradiological results, and the availability of different tissues for analyses. Screening for common point mutations and large deletions in mtDNA is usually the first step. Specific subsets of known nuclear disease genes can be screened by direct sequencing for cases of recognizable patterns of respiratory chain deficiencies or clinically identifiable syndromic presentations. Measurement of mtDNA content in affected tissues such as muscle and liver allows screening for mtDNA depletion syndromes. The growing list of known disease-causing genes and the promise of next generation sequencing technologies will undoubtedly improve diagnostic accuracy and genetic counseling for this challenging group of disorders.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Graham, BH (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Jaksch M, 1998, J MED GENET, V35, P895, DOI 10.1136/jmg.35.11.895
   Jaksch M, 2001, J MED GENET, V38, P665, DOI 10.1136/jmg.38.10.665
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Marotta R, 2004, INTERN MED J, V34, P10, DOI 10.1111/j.1444-0903.2004.t01-3-.x
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Quinzii CM, 2010, DEV DISABIL RES REV, V16, P183, DOI 10.1002/ddrr.108
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Wong LJC, 2004, MUSCLE NERVE, V30, P118, DOI 10.1002/mus.20045
   Wong LJC, 2003, J MED GENET, V40, P0
NR 38
TC 18
Z9 28
U1 0
U2 3
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
EI 
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PD JUN 15
PY 2012
VL 837
IS 
BP 35
EP 46
DI 10.1007/978-1-61779-504-6_3
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BAG90
UT WOS:000304125100003
PM 22215539
DA 2024-11-01
ER

PT J
AU Correa, CC
   Aw, W
   Melvin, RG
   Pichaud, N
   Ballard, JWO
AF Correa, C. C.
   Aw, Wc
   Melvin, R. G.
   Pichaud, N.
   Ballard, J. W. O.
TI Mitochondrial DNA variants influence mitochondrial bioenergetics in <i>Drosophila melanogaster</i>
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial bioenergetics; Reactive oxygen species; mtDNA copy number
ID organismal phenotype; acid deletion; simulans; cells; oxidase; life; respiration; dysfunction; metabolism; mutations
AB The influence of mitochondrial DNA (mtDNA) mutations on human disease has been extensively studied, but the impact of mutations within the adaptive range is debated. We studied males from lines of Drosophila melanogaster that have a highly standardized nuclear genome but different mtDNA, at two ages. We measured mitochondrial respiration on permeabilized muscle fibers, hydrogen peroxide production of isolated mitochondria and mtDNA copy number of whole individuals. The results show that a small set of naturally occurring mtDNA mutations can have a significant influence on mitochondrial bioenergetics that may change as the organism ages. (C) 2012 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Correa, C. C.; Aw, Wc; Pichaud, N.; Ballard, J. W. O.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia.
   [Melvin, R. G.] Univ Helsinki, Inst Biotechnol, Bioctr 3, FIN-00014 Helsinki, Finland.
C3 University of New South Wales Sydney; University of Helsinki
RP Ballard, JWO (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia.
EM w.ballard@unsw.edu.au
FU University of New South Wales; ARC [DP110104542]
CR AKASHI H, 1994, GENETICS, V136, P927
   Amo T, 2008, GENE, V411, P69, DOI 10.1016/j.gene.2008.01.007
   Amo T, 2007, BIOCHEM J, V404, P345, DOI 10.1042/BJ20061609
   Aoyagi N, 2000, J CELL BIOL, V150, PF45, DOI 10.1083/jcb.150.2.F45
   Aragonés J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62
   Aw WC, 2011, MITOCHONDRION, V11, P756, DOI 10.1016/j.mito.2011.06.012
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Ballard JWO, 2010, MOL ECOL, V19, P1523, DOI 10.1111/j.1365-294X.2010.04594.x
   Ballard JWO, 2011, EVOLUTION, V65, P1400, DOI 10.1111/j.1558-5646.2010.01209.x
   Ballard JWO, 2010, AM NAT, V176, PE98, DOI 10.1086/656263
   Boushel R, 2007, DIABETOLOGIA, V50, P790, DOI 10.1007/s00125-007-0594-3
   Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162
   Clancy DJ, 2008, AGING CELL, V7, P795, DOI 10.1111/j.1474-9726.2008.00428.x
   Dean MD, 2005, MOL PHYLOGENET EVOL, V36, P328, DOI 10.1016/j.ympev.2005.02.016
   Dowling DK, 2008, TRENDS ECOL EVOL, V23, P546, DOI 10.1016/j.tree.2008.05.011
   Estabrook RW, 1967, METHODS ENZYMOL, V6, P0
   Gemmell NJ, 2004, TRENDS ECOL EVOL, V19, P238, DOI 10.1016/j.tree.2004.02.002
   Giulivi C, 2010, JAMA-J AM MED ASSOC, V304, P2389, DOI 10.1001/jama.2010.1706
   Gnaiger E, 2003, ADV EXP MED BIOL, V543, P39
   Gnaiger E, 2009, INT J BIOCHEM CELL B, V41, P1837, DOI 10.1016/j.biocel.2009.03.013
   Innocenti P, 2011, SCIENCE, V332, P845, DOI 10.1126/science.1201157
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   Katewa SD, 2007, INSECT BIOCHEM MOLEC, V37, P923, DOI 10.1016/j.ibmb.2007.04.008
   Kidd P M, 2000, ALTERN MED REV, V5, P502
   Kidd PM, 2005, ALTERN MED REV, V10, P268
   Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61
   Lee HC, 2000, J BIOMED SCI, V7, P2, DOI 10.1159/000025424
   Melvin RG, 2006, AGING CELL, V5, P225, DOI 10.1111/j.1474-9726.2006.00211.x
   Mithani SK, 2008, MELANOMA RES, V18, P214, DOI 10.1097/CMR.0b013e3282f88a56
   Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7
   Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Moreno-Loshuertos R, 2011, PLOS GENET, V7, P0, DOI 10.1371/journal.pgen.1001379
   Passes JF, 2007, BIOESSAYS, V29, P908, DOI 10.1002/bies.20634
   Pesta D, 2012, METHODS MOL BIOL, V810, P25, DOI 10.1007/978-1-61779-382-0_3
   Pichaud N, 2011, AM J PHYSIOL, V301, P30
   Rasmussen HN, 2003, ANAL BIOCHEM, V319, P105, DOI 10.1016/S0003-2697(03)00274-4
   THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048
   Tucker EJ, 2011, IUBMB LIFE, V63, P669, DOI 10.1002/iub.495
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391
NR 43
TC 43
Z9 48
U1 1
U2 38
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD JUL 15
PY 2012
VL 12
IS 4
BP 459
EP 464
DI 10.1016/j.mito.2012.06.005
PG 6
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 988ZM
UT WOS:000307530000006
PM 22735574
DA 2024-11-01
ER

PT J
AU Vantyghem, MC
   Dobbelaere, D
   Mention, K
   Wemeau, JL
   Saudubray, JM
   Douillard, C
AF Vantyghem, Marie-Christine
   Dobbelaere, Dries
   Mention, Karine
   Wemeau, Jean-Louis
   Saudubray, Jean-Marie
   Douillard, Claire
TI Endocrine manifestations related to inherited metabolic diseases in adults
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Review
DE Inborn errors of metabolism; endocrine dysfunction; hypogonadism; diabetes mellitus; thyroid dysfunction; hypopituitarism; adrenal failure; hypoparathyroidism
ID progressive external ophthalmoplegia; x-linked adrenoleukodystrophy; mitochondrial-dna deletions; cause ovarian dysgenesis; onset cerebellar-ataxia; kearns-sayre-syndrome; diabetes-mellitus; congenital disorders; hearing-loss; carbohydrate-metabolism
AB Most inborn errors of metabolism (IEM) are recessive, genetically transmitted diseases and are classified into 3 main groups according to their mechanisms: cellular intoxication, energy deficiency, and defects of complex molecules. They can be associated with endocrine manifestations, which may be complications from a previously diagnosed IEM of childhood onset. More rarely, endocrinopathies can signal an IEM in adulthood, which should be suspected when an endocrine disorder is associated with multisystemic involvement (neurological, muscular, hepatic features, etc.). IEM can affect all glands, but diabetes mellitus, thyroid dysfunction and hypogonadism are the most frequent disorders. A single IEM can present with multiple endocrine dysfunctions, especially those involving energy deficiency (respiratory chain defects), and metal (hemochromatosis) and storage disorders (cystinosis). Non-autoimmune diabetes mellitus, thyroid dysfunction and/or goiter and sometimes hypoparathyroidism should steer the diagnosis towards a respiratory chain defect. Hypogonadotropic hypogonadism is frequent in haemochromatosis (often associated with diabetes), whereas primary hypogonadism is reported in Alstrom disease and cystinosis (both associated with diabetes, the latter also with thyroid dysfunction) and galactosemia. Hypogonadism is also frequent in X-linked adrenoleukodystrophy (with adrenal failure), congenital disorders of glycosylation, and Fabry and glycogen storage diseases (along with thyroid dysfunction in the first 3 and diabetes in the last). This is a new and growing field and is not yet very well recognized in adulthood despite its consequences on growth, bone metabolism and fertility. For this reason, physicians managing adult patients should be aware of these diagnoses.
C1 [Vantyghem, Marie-Christine; Wemeau, Jean-Louis; Douillard, Claire] Ctr Hosp Reg & Univ Lille, Hop C Huriez, Serv Endocrinol & Malad Metab, F-59037 Lille, France.
   [Dobbelaere, Dries; Mention, Karine; Douillard, Claire] Ctr Hosp Reg & Univ Lille, Hop Jeanne de Flandres, Ctr Reference Erreurs Innees Metab, F-59037 Lille, France.
   [Saudubray, Jean-Marie] Hop La Pitie Salpetriere, AP HP, Dept Malad Metab, Paris, France.
   [Saudubray, Jean-Marie] Univ Paris 06, F-75252 Paris 05, France.
C3 Universite de Lille; CHU Lille; Universite de Lille; CHU Lille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite
RP Vantyghem, MC (corresponding author), Ctr Hosp Reg & Univ Lille, Hop C Huriez, Serv Endocrinol & Malad Metab, 1 Rue Polonovski, F-59037 Lille, France.
EM mcvantyghem@gmail.com
CR Achouitar S, 2011, J INHERIT METAB DIS, V34, P923, DOI 10.1007/s10545-011-9325-5
   ALTER CA, 1993, AM J DIS CHILD, V147, P97, DOI 10.1001/archpedi.1993.02160250099030
   Alzahrani AS, 2006, EUR J ENDOCRINOL, V155, P787, DOI 10.1530/eje.1.02305
   Assies J, 1997, INT J ANDROL, V20, P315, DOI 10.1046/j.1365-2605.1997.00066.x
   Aversa A, 1998, HUM REPROD, V13, P2474, DOI 10.1093/humrep/13.9.2474
   Bacchetta J, 2010, PEDIATR NEPHROL, V25, P1081, DOI 10.1007/s00467-010-1453-x
   Balestri P, 2000, J CHILD NEUROL, V15, P755, DOI 10.1177/088307380001501108
   Barton JC, 2008, THYROID, V18, P831, DOI 10.1089/thy.2008.0091
   Baruteau J, 2009, J PEDIATR ENDOCR MET, V22, P1175
   Benelli E, 2008, THYROID, V18, P1001, DOI 10.1089/thy.2007.0228
   Besouw M, 2010, MINERVA PEDIATR, V62, P307
   Bettini V, 2012, PEDIATR DIABETES, V13, P59, DOI 10.1111/j.1399-5448.2011.00789.x
   Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902
   Borgna-Pignatti C, 2009, J PEDIATR-US, V155, P295, DOI 10.1016/j.jpeds.2009.01.062
   Bouyahia O, 2009, ANN ENDOCRINOL-PARIS, V70, P477, DOI 10.1016/j.ando.2009.09.001
   Brissot P, 2010, EXPERT REV MOL DIAGN, V10, P755, DOI 10.1586/erm.10.55
   Bruno C, 1998, J INHERIT METAB DIS, V21, P155, DOI 10.1023/A:1005347826664
   Buretic-Tomljanovic A, 2009, FERTIL STERIL, V91, P1793, DOI 10.1016/j.fertnstert.2008.02.129
   Carod-Artal FJ, 2007, EUR J NEUROL, V14, P581, DOI 10.1111/j.1468-1331.2007.01720.x
   Coman D, 2007, J CLIN NEUROSCI, V14, P668, DOI 10.1016/j.jocn.2006.04.008
   COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0
   Cryns K, 2003, HUM MUTAT, V22, P275, DOI 10.1002/humu.10258
   Dahl R, 2011, J MED CHEM, V54, P3661, DOI 10.1021/jm101401a
   DEZEGHER F, 1995, PEDIATR RES, V37, P395
   Dumitrescu AM, 2011, ANN ENDOCRINOL-PARIS, V72, P95, DOI 10.1016/j.ando.2011.03.011
   Ebberink MS, 2011, HUM MUTAT, V32, P59, DOI 10.1002/humu.21388
   Erdem E, 2010, J PEDIATR ENDOCR MET, V23, P503, DOI 10.1515/jpem.2010.082
   Faggiano A, 2006, J CLIN ENDOCR METAB, V91, P4319, DOI 10.1210/jc.2006-0858
   Faggiano A, 2011, MINERVA ENDOCRINOL, V36, P1
   Farahani H, 2010, HORM METAB RES, V42, P792, DOI 10.1055/s-0030-1262826
   Fasano A, 2008, MOVEMENT DISORD, V23, P751, DOI 10.1002/mds.21938
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Filler G, 1998, EUR J PEDIATR, V157, P738, DOI 10.1007/s004310050926
   Forges T, 2006, HUM REPROD UPDATE, V12, P573, DOI 10.1093/humupd/dml031
   Frints SGM, 2008, EUR J HUM GENET, V16, P1029, DOI 10.1038/ejhg.2008.66
   Frishberg Y, 2000, J PEDIATR-US, V136, P255, DOI 10.1016/S0022-3476(00)70112-0
   Gahl WA, 2007, ANN INTERN MED, V147, P242, DOI 10.7326/0003-4819-147-4-200708210-00006
   GAMA R, 1995, POSTGRAD MED J, V71, P297, DOI 10.1136/pgmj.71.835.297
   Gamberini Maria Rita, 2008, PEDIATR ENDOCRINOL REV, V6 Suppl 1, P158
   Giannitrapani L, 2006, ANN NY ACAD SCI, V1089, P228, DOI 10.1196/annals.1386.044
   Girard D, 2011, NAT REV ENDOCRINOL, V7, P77, DOI 10.1038/nrendo.2010.210
   Gironi M, 2004, NEUROLOGY, V62, P818, DOI 10.1212/01.WNL.0000113719.67643.B7
   Glinoer D, 2000, THYROID, V10, P871, DOI 10.1089/thy.2000.10.871
   Gubbels CS, 2008, OBSTET GYNECOL SURV, V63, P334, DOI 10.1097/OGX.0b013e31816ff6c5
   Gubbels CS, 2011, J INHERIT METAB DIS, V34, P387, DOI 10.1007/s10545-010-9180-9
   Harambat J, 2010, KIDNEY INT, V77, P443, DOI 10.1038/ki.2009.435
   Hartemann-Heurtier A, 2009, DIABETES METAB, V35, P233, DOI 10.1016/j.diabet.2009.01.003
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   Hauser AC, 2005, J INHERIT METAB DIS, V28, P715, DOI 10.1007/s10545-005-0003-3
   Hopkins SE, 2010, J CHILD NEUROL, V25, P752, DOI 10.1177/0883073809343313
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   Hudec M, 2008, THYROID, V18, P255, DOI 10.1089/thy.2007.0140
   Irimia JM, 2010, J BIOL CHEM, V285, P12851, DOI 10.1074/jbc.M110.106534
   Vega AI, 2011, J INHERIT METAB DIS, V34, P929, DOI 10.1007/s10545-011-9328-2
   Ismail Heba, 2009, CASES J, V2, P6891, DOI 10.4076/1757-1627-2-6891
   Isotani H, 1996, CLIN ENDOCRINOL, V45, P637, DOI 10.1046/j.1365-2265.1996.00856.x
   Jaeken J, 2011, J INHERIT METAB DIS, V34, P853, DOI 10.1007/s10545-011-9299-3
   Kapoor RR, 2011, DIABETOLOGIA, V54, P2575, DOI 10.1007/s00125-011-2207-4
   Karicheva OZ, 2011, NUCLEIC ACIDS RES, V39, P8173, DOI 10.1093/nar/gkr546
   Kleefstra T, 2011, EUR J HUM GENET, V19, P138, DOI 10.1038/ejhg.2010.171
   Klupa T, 2009, CLIN ENDOCRINOL, V71, P358, DOI 10.1111/j.1365-2265.2008.03478.x
   Kobayashi T, 1997, DIABETES, V46, P1567, DOI 10.2337/diabetes.46.10.1567
   Koç E, 2006, NEPHROLOGY, V11, P81, DOI 10.1111/j.1440-1797.2006.00443.x
   Koyama C, 2005, J HEPATOL, V43, P740, DOI 10.1016/j.jhep.2005.06.024
   Krasnewich D, 2007, AM J MED GENET C, V145C, P302, DOI 10.1002/ajmg.c.30143
   Krassas GE, 2010, ENDOCR REV, V31, P702, DOI 10.1210/er.2009-0041
   KRISTIANSSON B, 1995, ACTA PAEDIATR, V84, P655, DOI 10.1111/j.1651-2227.1995.tb13720.x
   Lacombe D, 2010, REV MED INTERNE, V31, PS214, DOI 10.1016/S0248-8663(10)70014-X
   Laloi-Michelin M, 2009, J CLIN ENDOCR METAB, V94, P3025, DOI 10.1210/jc.2008-2680
   Lanes R, 2000, J PEDIATR ENDOCR MET, V13, P325
   Lecca MR, 2011, J CELL MOL MED, V15, P1788, DOI 10.1111/j.1582-4934.2010.01187.x
   LEE PJ, 1995, CLIN ENDOCRINOL, V42, P601, DOI 10.1111/j.1365-2265.1995.tb02686.x
   Liang W C, 2010, ACTA MYOL, V29, P351
   Lightfoot YL, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0020617
   Lindroos MM, 2009, DIABETES, V58, P543, DOI 10.2337/db08-0981
   Lopez-Erauskin J, 2011, ANN NEUROL, V70, P84, DOI 10.1002/ana.22363
   Maffei P, 2007, CLIN ENDOCRINOL, V66, P269, DOI 10.1111/j.1365-2265.2007.02721.x
   Marquard J, 2011, EUR J PEDIATR, V170, P241, DOI 10.1007/s00431-010-1313-5
   Marshall JD, 2005, ARCH INTERN MED, V165, P675, DOI 10.1001/archinte.165.6.675
   Massin P, 2008, DIABETOLOGIA, V51, P1664, DOI 10.1007/s00125-008-1073-1
   McDermott JH, 2005, J CLIN ENDOCR METAB, V90, P2451, DOI 10.1210/jc.2004-0980
   Melis D, 2007, J PEDIATR-US, V150, P300, DOI 10.1016/j.jpeds.2006.11.056
   Mezghani N, 2011, BIOCHEM BIOPH RES CO, V411, P247, DOI 10.1016/j.bbrc.2011.06.106
   Miller BS, 2011, MOL GENET METAB, V103, P101, DOI 10.1016/j.ymgme.2011.01.016
   Miller BS, 2003, REV ENDOCR METAB DIS, V4, P103, DOI 10.1023/A:1021883605280
   Misery L, 2002, ANN MED INTERNE, V153, P283
   Mokashi A, 2011, PEDIATR DIABETES, V12, P270, DOI 10.1111/j.1399-5448.2010.00698.x
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MOSEWICH RK, 1993, ARCH NEUROL-CHICAGO, V50, P275, DOI 10.1001/archneur.1993.00540030041012
   Nicolino M, 1997, J CLIN ENDOCR METAB, V82, P3063, DOI 10.1210/jc.82.9.3063
   Noormets K, 2011, EXP CLIN ENDOCR DIAB, V119, P271, DOI 10.1055/s-0030-1265163
   Ogimoto M, 2011, INTERNAL MED, V50, P1415, DOI 10.2169/internalmedicine.50.5108
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   Okada M, 1998, NIHON SHOKAKIBYO GAKKAI ZASSHI, V95, P445
   Oki Y, 2000, DIABETIC MED, V17, P810, DOI 10.1046/j.1464-5491.2000.00378.x
   Panis B, 2007, EUR J PEDIATR, V166, P443, DOI 10.1007/s00431-006-0255-4
   Papadimitriou A, 1996, NEUROMUSCULAR DISORD, V6, P49, DOI 10.1016/0960-8966(95)00020-8
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   Pierce SB, 2011, P NATL ACAD SCI USA, V108, P6543, DOI 10.1073/pnas.1103471108
   Pierce SB, 2010, AM J HUM GENET, V87, P282, DOI 10.1016/j.ajhg.2010.07.007
   Polgreen LE, 2011, EUR J PEDIATR, V170, P1049, DOI 10.1007/s00431-011-1401-1
   QUADE A, 1992, CLIN INVESTIGATOR, V70, P396
   Ramos HE, 2011, EUR J ENDOCRINOL, V164, P309, DOI 10.1530/EJE-10-0679
   Rangwala SM, 2010, J BIOL CHEM, V285, P22619, DOI 10.1074/jbc.M110.125401
   Rubio-Gozalbo ME, 2010, HUM REPROD UPDATE, V16, P177, DOI 10.1093/humupd/dmp038
   Rubio-Gozalbo ME, 2006, MOL GENET METAB, V89, P316, DOI 10.1016/j.ymgme.2006.07.005
   Sadikovic B, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0015687
   Sansanwal P, 2010, J INHERIT METAB DIS, V33, P775, DOI 10.1007/s10545-010-9203-6
   Saudubray JM, 2009, ANN ENDOCRINOL-PARIS, V70, P14, DOI 10.1016/j.ando.2008.12.004
   Schiff M, 2009, J INHERIT METAB DIS, V32, P684, DOI 10.1007/s10545-009-1263-0
   Schoenmakers E, 2010, J CLIN INVEST, V120, P4220, DOI 10.1172/JCI43653
   Schoffer KL, 2006, MOVEMENT DISORD, V21, P869, DOI 10.1002/mds.20804
   Schomburg L, 2009, THYROID, V19, P277, DOI 10.1089/thy.2008.0397
   Schweitzer-Krantz S, 2003, EUR J PEDIATR, V162, PS50, DOI 10.1007/s00431-003-1352-2
   Sevin C, 2011, ORPHANET J RARE DIS, V6, P0, DOI 10.1186/1750-1172-6-8
   Shimizu J, 2008, CLIN NEPHROL, V70, P348
   Spiegel R, 2005, J PEDIATR ENDOCR MET, V18, P617
   STRISCIUGLIO P, 1987, EUR J PEDIATR, V146, P431, DOI 10.1007/BF00444957
   SUZUKI S, 1994, DIABETOLOGIA, V37, P818, DOI 10.1007/s001250050183
   Tengan CH, 1998, J CLIN ENDOCR METAB, V83, P125, DOI 10.1210/jc.83.1.125
   Tintillier M, 2004, CLIN NEPHROL, V62, P155
   Tyni T, 1997, J PEDIATR-US, V131, P766, DOI 10.1016/S0022-3476(97)70111-2
   Valenti L, 2009, OSTEOPOROSIS INT, V20, P549, DOI 10.1007/s00198-008-0701-4
   Vantyghem MC, 2006, EUR J ENDOCRINOL, V154, P835, DOI 10.1530/eje.1.02152
   Wang Y, 2011, MOL GENET METAB, V104, P160, DOI 10.1016/j.ymgme.2011.05.016
   Watanabe M, 2010, INTERNAL MED, V49, P1581, DOI 10.2169/internalmedicine.49.3508
   Wémeau JL, 2008, J CLIN ENDOCR METAB, V93, P2084, DOI 10.1210/jc.2007-2719
   WINKLER L, 1993, EUR J PEDIATR, V152, P244, DOI 10.1007/BF01956154
   Wirth EK, 2011, EUR J ENDOCRINOL, V165, P555, DOI 10.1530/EJE-11-0369
   Yamasaki Ryo, 2004, RINSHO SHINKEIGAKU, V44, P291
NR 132
TC 29
Z9 31
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1750-1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD JAN 28
PY 2012
VL 7
IS 
BP 
EP 
DI 10.1186/1750-1172-7-11
PG 19
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 940GF
UT WOS:000303877300001
PM 22284844
DA 2024-11-01
ER

PT J
AU Sarzi, E
   Angebault, C
   Seveno, M
   Gueguen, N
   Chaix, B
   Bielicki, G
   Boddaert, N
   Mausset-Bonnefont, AL
   Cazevieille, C
   Rigau, V
   Renou, JP
   Wang, J
   Delettre, C
   Brabet, P
   Puel, JL
   Hamel, CP
   Reynier, P
   Lenaers, G
AF Sarzi, Emmanuelle
   Angebault, Claire
   Seveno, Marie
   Gueguen, Naig
   Chaix, Benjamin
   Bielicki, Guy
   Boddaert, Nathalie
   Mausset-Bonnefont, Anne-Laure
   Cazevieille, Chantal
   Rigau, Valerie
   Renou, Jean-Pierre
   Wang, Jing
   Delettre, Cecile
   Brabet, Philippe
   Puel, Jean-Luc
   Hamel, Christian P.
   Reynier, Pascal
   Lenaers, Guy
TI The human <i>OPA1<SUP>delTTAG</SUP></i> mutation induces premature age-related systemic neurodegeneration in mouse
SO BRAIN
LA English
DT Article
DE dominant optic atrophy; neurodegeneration; mitochondria; respiratory chain complexes; mouse model
ID dominant optic atrophy; mitochondrial-dna instability; opa1 mutations; alzheimers-disease; in-vitro; cardiolipin; model; deficiency; fusion; defects
AB Dominant optic atrophy is a rare inherited optic nerve degeneration caused by mutations in the mitochondrial fusion gene OPA1. Recently, the clinical spectrum of dominant optic atrophy has been extended to frequent syndromic forms, exhibiting various degrees of neurological and muscle impairments frequently found in mitochondrial diseases. Although characterized by a specific loss of retinal ganglion cells, the pathophysiology of dominant optic atrophy is still poorly understood. We generated an Opa1 mouse model carrying the recurrent Opa1(delTTAG) mutation, which is found in 30% of all patients with dominant optic atrophy. We show that this mouse displays a multi-systemic poly-degenerative phenotype, with a presentation associating signs of visual failure, deafness, encephalomyopathy, peripheral neuropathy, ataxia and cardiomyopathy. Moreover, we found premature age-related axonal and myelin degenerations, increased autophagy and mitophagy and mitochondrial supercomplex instability preceding degeneration and cell death. Thus, these results support the concept that Opa1 protects against neuronal degeneration and opens new perspectives for the exploration and the treatment of mitochondrial diseases.
C1 [Sarzi, Emmanuelle; Seveno, Marie; Chaix, Benjamin; Wang, Jing; Delettre, Cecile; Brabet, Philippe; Puel, Jean-Luc; Hamel, Christian P.; Lenaers, Guy] Univ Montpellier I & II, Inst Neurosci Montpellier, INSERM, U1051, F-34091 Montpellier 5, France.
   [Angebault, Claire; Gueguen, Naig; Reynier, Pascal] CHU Angers, Dept Biochim & Genet, CNRS, UMR 6214,INSERM,U1083, F-49000 Angers, France.
   [Bielicki, Guy; Renou, Jean-Pierre] INRA, UR370, F-63122 St Genes Champanelle, France.
   [Boddaert, Nathalie] Hop Necker Enfants Malad, Serv Radiol Pediat, F-75743 Paris, France.
   [Mausset-Bonnefont, Anne-Laure] Univ Montpellier I & II, Inst Neurosci Montpellier, INSERM, U844, F-34091 Montpellier, France.
   [Cazevieille, Chantal] Univ Montpellier I, Ctr Ressources Imagerie Cellulaire, F-34093 Montpellier, France.
   [Rigau, Valerie] CHU Guy de Chauliac, Serv Anat & Cytol Pathol, F-34295 Montpellier, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre National de la Recherche Scientifique (CNRS); INRAE; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier
RP Lenaers, G (corresponding author), Univ Montpellier I & II, CHU St Eloi, Inst Neurosci Montpellier, INSERM,U1051, 80 Rue Auguste Fliche, F-34091 Montpellier 5, France.
EM guy.lenaers@inserm.fr
FU Association Francaise contre les Myopathies; Retina France; Union Nationale des Aveugles et Deficients Visuels; Ouvrir Les Yeux; European E-RARE program ERMION
CR Acehan D, 2011, J BIOL CHEM, V286, P899, DOI 10.1074/jbc.M110.171439
   Acin-Pérez R, 2008, MOL CELL, V32, P529, DOI 10.1016/j.molcel.2008.10.021
   Akepati VR, 2008, J NEUROCHEM, V106, P372, DOI 10.1111/j.1471-4159.2008.05401.x
   Alavi MV, 2007, BRAIN, V130, P1029, DOI 10.1093/brain/awm005
   Alavi MV, 2009, EXP NEUROL, V220, P404, DOI 10.1016/j.expneurol.2009.09.026
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2005, CLIN GENET, V67, P102, DOI 10.1111/j.1399-0004.2004.00358.x
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Baker MR, 2011, NEUROLOGY, V77, P1309, DOI 10.1212/WNL.0b013e318230a15a
   Ban T, 2010, HUM MOL GENET, V19, P2113, DOI 10.1093/hmg/ddq088
   BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61
   Boddaert N, 2008, MOL GENET METAB, V93, P85, DOI 10.1016/j.ymgme.2007.09.003
   Bürklen TS, 2006, J BIOMED BIOTECHNOL, V0, P0, DOI DOI 10.1155/JBB/2006/35936
   Chekroud K, 2011, OPHTHALMIC RES, V45, P174, DOI 10.1159/000321118
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Chen HC, 2009, HUM MOL GENET, V18, PR169, DOI 10.1093/hmg/ddp326
   Chen YF, 2009, GENE DEV, V23, P1183, DOI 10.1101/gad.1779509
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Cloonan SM, 2012, CURR OPIN IMMUNOL, V24, P32, DOI 10.1016/j.coi.2011.11.001
   dYdewalle C, 2011, NAT MED, V17, P968, DOI 10.1038/nm.2396
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Dorn GW, 2011, CIRC RES, V108, P12, DOI 10.1161/CIRCRESAHA.110.236745
   Elachouri G, 2011, GENOME RES, V21, P12, DOI 10.1101/gr.108696.110
   Ferdinandusse S, 2008, P NATL ACAD SCI USA, V105, P17712, DOI 10.1073/pnas.0806066105
   Forster DM, 2012, NMR BIOMED, V25, P52, DOI 10.1002/nbm.1712
   Frenzel M, 2010, EXP GERONTOL, V45, P563, DOI 10.1016/j.exger.2010.02.003
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Gohil VM, 2004, J BIOL CHEM, V279, P42612, DOI 10.1074/jbc.M402545200
   Gómez LA, 2009, ARCH BIOCHEM BIOPHYS, V490, P30, DOI 10.1016/j.abb.2009.08.002
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Hoffmann MH, 2010, ARTHRITIS RES THER, V12, P0, DOI 10.1186/ar2950
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kiebish MA, 2008, J LIPID RES, V49, P2545, DOI 10.1194/jlr.M800319-JLR200
   Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278
   Martin LJ, 2010, PHARMACEUTICALS, V3, P839, DOI 10.3390/ph3040839
   Medja F, 2009, MITOCHONDRION, V9, P331, DOI 10.1016/j.mito.2009.05.001
   Mochel F, 2012, J BIOL CHEM, V287, P1361, DOI 10.1074/jbc.M111.309849
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2006, BBA-MOL CELL RES, V1763, P500, DOI 10.1016/j.bbamcr.2006.04.003
   Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200
   Piquereau J, 2012, CARDIOVASC RES, V94, P408, DOI 10.1093/cvr/cvs117
   ROBINSON DW, 1979, AUDIOLOGY, V18, P320
   Saneto RP, 2008, MITOCHONDRION, V8, P396, DOI 10.1016/j.mito.2008.05.003
   Schapira AHV, 2012, LANCET, V379, P1825, DOI 10.1016/S0140-6736(11)61305-6
   Schlame M, 2005, CHEM PHYS LIPIDS, V138, P38, DOI 10.1016/j.chemphyslip.2005.08.002
   Van Eyken E, 2007, AUDIOL NEURO-OTOL, V12, P345, DOI 10.1159/000106478
   Vancová O, 2010, J CELL MOL MED, V14, P2667, DOI 10.1111/j.1582-4934.2009.00879.x
   Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2
   White KE, 2009, INVEST OPHTH VIS SCI, V50, P2567, DOI 10.1167/iovs.08-2913
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2011, BRAIN, V134, P0, DOI 10.1093/brain/awq288
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   Zhong Q, 2004, J BIOL CHEM, V279, P32294, DOI 10.1074/jbc.M403275200
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 55
TC 81
Z9 87
U1 0
U2 31
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD DEC 15
PY 2012
VL 135
IS 
BP 3599
EP 3613
DI 10.1093/brain/aws303
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 058SU
UT WOS:000312655100013
PM 23250881
DA 2024-11-01
ER

PT J
AU Navarro-Sastre, A
   Tort, F
   Garcia-Villoria, J
   Pons, MR
   Nascimento, A
   Colomer, J
   Campistol, J
   Yoldi, ME
   López-Gallardo, E
   Montoya, J
   Unceta, M
   Martinez, MJ
   Briones, P
   Ribes, A
AF Navarro-Sastre, Aleix
   Tort, Frederic
   Garcia-Villoria, Judit
   Ruiz Pons, Monica
   Nascimento, Andres
   Colomer, Jaume
   Campistol, Jaume
   Eugenia Yoldi, Maria
   Lopez-Gallardo, Ester
   Montoya, Julio
   Unceta, Maria
   Jesus Martinez, Maria
   Briones, Paz
   Ribes, Antonia
TI Mitochondrial DNA depletion syndrome: New descriptions and the use of citrate synthase as a helpful tool to better characterise the patients
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE mtDNA depletion; SUCLA2; SUCLG1; DGUOK; MPV17; POLG
ID methylmalonic aciduria; thymidine kinase; lactic-acidosis; mtdna content; mpv17 gene; mutations; deficiency; encephalomyopathy; succinate; diagnosis
AB Mitochondrial DNA depletion syndrome (MDS) is a clinically heterogeneous group of mitochondrial disorders characterised by a quantitative reduction of the mitochondrial DNA copy number. Three main clinical forms of MDS: myopathic, encephalomyopathic and hepatocerebral have been defined, although patients may present with other MDS associated clinical symptoms and signs that cover a wide spectrum of onset age and disease. We studied 52 paediatric individuals suspected to have MDS. These patients have been divided into three different groups, and the appropriate MDS genes have been screened according to their clinical and biochemical phenotypes. Mutational study of DGUOK, MPV17, SUCLA2, SUCLG1 and POLG allowed us to identify 3 novel mutations (c.1048G>A and c.1049G>T in SUCLA2 and c.531 + 4A>T in SUCLG1) and 7 already known mutations in 10 patients (8 families). Seventeen patients presented with mtDNA depletion in liver or muscle, but the cause of mtDNA depletion still remains unknown in 8 of them. When possible, we quantified mtDNA/nDNA and CS activity in the same tissue sample, providing an additional tool for the study of MDS. The ratio (mtDNA/nDNA)/CS has shed some light in the discrepant results between the mtDNA copy number and the enzymatic respiratory chain activities of some cases. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Ribes, Antonia] Hosp Clin Barcelona, Serv Bioquim & Genet Mol, Secc Errores Congenitos Metab IBC,Inst Invest Bio, Div Inborn Errors Metab,Dept Biochem & Mol Genet, Barcelona 08028, Spain.
   [Ruiz Pons, Monica] Hosp Univ NS de la Candelaria, Dept Pediat Nutr & Metab, Tenerife, Islas Canarias, Spain.
   [Nascimento, Andres; Colomer, Jaume; Campistol, Jaume] Hosp St Joan de Deu, Dept Neurol, Barcelona, Spain.
   [Eugenia Yoldi, Maria] Hosp Virgen Camino, Dept Pediat, Pamplona, Spain.
   [Lopez-Gallardo, Ester; Montoya, Julio] Univ Zaragoza, Biochem & Mol & Cellular Biol Dept, Inst Aragones Ciencias Salud, Zaragoza, Spain.
   [Unceta, Maria] Hosp Univ Cruces, Dept Biochem, Bizkaia, Spain.
   [Jesus Martinez, Maria] Hosp Univ Cruces, Neuropediat Dept, Bizkaia, Spain.
   [Briones, Paz] CSIC, E-08028 Barcelona, Spain.
   [Navarro-Sastre, Aleix; Tort, Frederic; Garcia-Villoria, Judit; Lopez-Gallardo, Ester; Montoya, Julio; Briones, Paz; Ribes, Antonia] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Servicio Navarro de Salud - Osasunbidea; Hospital Virgen del Camino; University of Zaragoza; Hospital Universitario Cruces; Hospital Universitario Cruces; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERER
RP Ribes, A (corresponding author), Hosp Clin Barcelona, Serv Bioquim & Genet Mol, Secc Errores Congenitos Metab IBC,Inst Invest Bio, Div Inborn Errors Metab,Dept Biochem & Mol Genet, Edificio Helios 3,Planta Baja,C Mejia Lequerica S, Barcelona 08028, Spain.
EM aribes@clinic.ub.es
FU Instituto de Salud Carlos III [FIS-PI08/90348, FIS-PI10/00662]
CR Andreu AL, 2009, MITOCHONDRION, V9, P242, DOI 10.1016/j.mito.2009.02.006
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Fellman V, 2011, SEMIN FETAL NEONAT M, V16, P222, DOI 10.1016/j.siny.2011.05.002
   Font A, 2011, JIMD REP, V1, P125, DOI 10.1007/8904_2011_27
   Fowler B, 2008, J INHERIT METAB DIS, V31, P350, DOI 10.1007/s10545-008-0839-4
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2000, BRAIN PATHOL, V10, P451
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Montero R, 2005, BIOFACTORS, V25, P109, DOI 10.1002/biof.5520250112
   Morten KJ, 2007, MITOCHONDRION, V7, P386, DOI 10.1016/j.mito.2007.09.001
   Navarro-Sastre A, 2010, J INHERIT METAB DIS, V0, P0
   Navarro-Sastre A, 2008, MOL GENET METAB, V94, P234, DOI 10.1016/j.ymgme.2008.01.012
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2008, J INHERIT METAB DIS, V31, P226, DOI 10.1007/s10545-008-0828-7
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Ostergaard E, 2010, EUR J PEDIATR, V169, P201, DOI 10.1007/s00431-009-1007-z
   Rivera H, 2010, MITOCHONDRION, V10, P362, DOI 10.1016/j.mito.2010.03.003
   Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sakamoto O, 2011, PEDIATR INT, V53, P921, DOI 10.1111/j.1442-200X.2011.03412.x
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Scaglia F, 1993, HEPATOCEREBRAL FORM, V0, P0
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Srere PA, 1969, CITRATE SYNTHASE, V13, P3
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Valayannopoulos V, 2010, MITOCHONDRION, V10, P335, DOI 10.1016/j.mito.2010.02.006
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VILASECA MA, 1991, J INHERIT METAB DIS, V14, P285, DOI 10.1007/BF01811683
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang WY, 2011, NUCLEIC ACIDS RES, V39, P44, DOI 10.1093/nar/gkq750
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 52
TC 31
Z9 37
U1 0
U2 26
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD NOV 15
PY 2012
VL 107
IS 3
BP 409
EP 415
DI 10.1016/j.ymgme.2012.08.018
PG 7
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 032LM
UT WOS:000310720200024
PM 22980518
DA 2024-11-01
ER

PT J
AU Papa, S
   De Rasmo, D
   Technikova-Dobrova, Z
   Panelli, D
   Signorile, A
   Scacco, S
   Petruzzella, V
   Papa, F
   Palmisano, G
   Gnoni, A
   Micelli, L
   Sardanelli, AM
AF Papa, Sergio
   De Rasmo, Domenico
   Technikova-Dobrova, Zuzana
   Panelli, Damiano
   Signorile, Anna
   Scacco, Salvatore
   Petruzzella, Vittoria
   Papa, Francesco
   Palmisano, Giuseppe
   Gnoni, Antonio
   Micelli, Loris
   Sardanelli, Anna Maria
TI Respiratory chain complex I, a main regulatory target of the cAMP/PKA pathway is defective in different human diseases
SO FEBS LETTERS
LA English
DT Review
DE Complex I; cAMP/PKA pathway; NDUFS4; Mitochondrial diseases
ID dependent protein-kinase; mitochondrial-dna mutations; element-binding protein; nadh-quinone oxidoreductase; human ndufs4 gene; bovine heart; oxidative-phosphorylation; skeletal-muscle; aqdq subunit; pgc-1-alpha transcription
AB In mammals, complex I (NADH-ubiquinone oxidoreductase) of the mitochondrial respiratory chain has 31 supernumerary subunits in addition to the 14 conserved from prokaryotes to humans. Multiplicity of structural protein components, as well as of biogenesis factors, makes complex I a sensible pace-maker of mitochondrial respiration. The work reviewed here shows that the cAMP/PKA pathway regulates the biogenesis, assembly and catalytic activity of complex I and mitochondrial oxygen superoxide production. The structural, functional and regulatory complexity of complex I, renders it particularly vulnerable to genetic and sporadic pathological factors. Complex I dysfunction has, indeed, been found, to be associated with several human diseases. Knowledge of the pathogenetic mechanisms of these diseases can help to develop new therapeutic strategies. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
C1 [Papa, Sergio; De Rasmo, Domenico; Panelli, Damiano; Signorile, Anna; Scacco, Salvatore; Petruzzella, Vittoria; Gnoni, Antonio; Micelli, Loris; Sardanelli, Anna Maria] Univ Bari Aldo Moro, Dept Basic Med Sci, Sect Med Biochem, Bari, Italy.
   [Papa, Sergio] Inst Biomembranes & Bioenerget IBBE, Bari, Italy.
   [Technikova-Dobrova, Zuzana] Czech Acad Sci, Inst Microbiol, Prague, Czech Republic.
   [Papa, Francesco] Univ Bari Aldo Moro, Dept Odontostomatol & Surg, Bari, Italy.
   [Palmisano, Giuseppe] Univ So Denmark, Dept Biochem & Mol Biol, Odense M, Denmark.
C3 Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Universita degli Studi di Bari Aldo Moro; University of Southern Denmark
RP Papa, S (corresponding author), Univ Bari Aldo Moro, Dept Basic Med Sci, Sect Med Biochem, Bari, Italy.
EM s.papa@biochem.uniba.it
FU Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) [RBRN07BMCT_014, RBFR0813Z5]; National Project, "Progetto FIRB Rete Nazionale per lo Studio della Proteomica Umana (Italian Human ProteomeNet)"; Progetto Strategico Ric.002 [POR 2000/06]
CR Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105
   Anderson SL, 2008, J INHERIT METAB 1226, V0, P0
   Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200
   Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200
   Aquilano K, 2010, J BIOL CHEM, V285, P21590, DOI 10.1074/jbc.M109.070169
   Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112
   Baillie GS, 2005, FEBS LETT, V579, P3264, DOI 10.1016/j.febslet.2005.03.089
   Baracca A, 2010, BBA-BIOENERGETICS, V1797, P314, DOI 10.1016/j.bbabio.2009.11.006
   Barrès R, 2009, CELL METAB, V10, P189, DOI 10.1016/j.cmet.2009.07.011
   Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911
   Bénit P, 2003, HUM GENET, V112, P563, DOI 10.1007/s00439-002-0884-2
   BOYER PD, 1977, ANNU REV BIOCHEM, V46, P955, DOI 10.1146/annurev.bi.46.070177.004515
   Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539
   Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Cammarota M, 1999, J NEUROCHEM, V72, P2272, DOI 10.1046/j.1471-4159.1999.0722272.x
   Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200
   Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200
   Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200
   Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604
   Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247
   Chen RM, 2004, J BIOL CHEM, V279, P26036, DOI 10.1074/jbc.M402710200
   Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625
   De Rasmo D, 2008, CELL SIGNAL, V20, P989, DOI 10.1016/j.cellsig.2008.01.017
   De Rasmo D, 2011, EUR J PHARMACOL, V652, P15, DOI 10.1016/j.ejphar.2010.11.016
   De Rasmo D, 2010, MITOCHONDRION, V10, P464, DOI 10.1016/j.mito.2010.04.005
   De Rasmo D, 2009, FEBS J, V276, P4325, DOI 10.1111/j.1742-4658.2009.07133.x
   Efremov RG, 2010, NATURE, V465, P441, DOI 10.1038/nature09066
   ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   Fato R, 2008, NEUROCHEM RES, V33, P2487, DOI 10.1007/s11064-008-9747-0
   Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200
   Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585
   Fernández-Vizarra E, 2009, BBA-MOL CELL RES, V1793, P200, DOI 10.1016/j.bbamcr.2008.05.028
   Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350
   Franko A, 2008, MOL CELL BIOL, V28, P2446, DOI 10.1128/MCB.00980-07
   Gadaleta MN, 1998, BIOCHIMIE, V80, P863, DOI 10.1016/S0300-9084(00)88881-1
   Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633
   Grivennikova VG, 2006, BBA-BIOENERGETICS, V1757, P553, DOI 10.1016/j.bbabio.2006.03.013
   Hao JJ, 2010, J NUTR BIOCHEM, V21, P634, DOI 10.1016/j.jnutbio.2009.03.012
   Hardie DG, 2011, AM J CLIN NUTR, V93, P891S, DOI 10.3945/ajcn.110.001925
   HELD W, 1990, P NATL ACAD SCI USA, V87, P2239, DOI 10.1073/pnas.87.6.2239
   Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8
   Hirst J, 2010, BIOCHEM J, V425, P327, DOI 10.1042/BJ20091382
   Hurd TR, 2008, J BIOL CHEM, V283, P24801, DOI 10.1074/jbc.M803432200
   Huttemann M, 2007, BBA-MOL CELL RES, V1773, P1701, DOI 10.1016/j.bbamcr.2007.10.001
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Iuso A, 2006, J BIOL CHEM, V281, P10374, DOI 10.1074/jbc.M513387200
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   Koopman Werner J H, 2010, ANTIOXID REDOX SIGNAL, V12, P1431, DOI 10.1089/ars.2009.2743
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lazarou M, 2007, MOL CELL BIOL, V27, P4228, DOI 10.1128/MCB.00074-07
   Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861
   Lieberman J, 2010, IMMUNOL REV, V235, P93, DOI 10.1111/j.0105-2896.2010.00902.x
   Lill R, 2008, ANNU REV BIOCHEM, V77, P669, DOI 10.1146/annurev.biochem.76.052705.162653
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   Mckenzie M, 2010, IUBMB LIFE, V62, P497, DOI 10.1002/iub.335
   Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878
   Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Panelli D, 2008, BIOCHIMIE, V90, P1452, DOI 10.1016/j.biochi.2008.04.017
   Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1
   Papa S, 1996, FEBS LETT, V379, P299, DOI 10.1016/0014-5793(95)01532-9
   Papa S, 2001, FEBS LETT, V489, P259, DOI 10.1016/S0014-5793(00)02334-6
   Papa S, 2007, HDB NEUROCHEMISTRY M, V0, P93
   Papa S, 2009, J BIOENERG BIOMEMBR, V41, P509, DOI 10.1007/s10863-009-9252-4
   Papa S, 2009, BBA-BIOENERGETICS, V1787, P502, DOI 10.1016/j.bbabio.2008.12.018
   Petruzzella V, 2005, FEBS LETT, V579, P3770, DOI 10.1016/j.febslet.2005.05.035
   Petruzzella V, 2002, GENE, V286, P149, DOI 10.1016/S0378-1119(01)00810-1
   Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529
   Piccoli C, 2006, FEBS LETT, V580, P4539, DOI 10.1016/j.febslet.2006.06.085
   Pocsfalvi G, 2007, MOL CELL PROTEOMICS, V6, P231, DOI 10.1074/mcp.M600268-MCP200
   Potluri P, 2004, EUR J BIOCHEM, V271, P3265, DOI 10.1111/j.1432-1033.2004.04260.x
   Remacle C, 2008, MOL GENET GENOMICS, V280, P93, DOI 10.1007/s00438-008-0350-5
   Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4
   Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354
   Rötig A, 2004, BBA-BIOENERGETICS, V1659, P129, DOI 10.1016/j.bbabio.2004.07.007
   Ryu H, 2005, P NATL ACAD SCI USA, V102, P13915, DOI 10.1073/pnas.0502878102
   Sardanelli AM, 1995, FEBS LETT, V377, P470, DOI 10.1016/0014-5793(95)01407-1
   Sardanelli AM, 1996, FEBS LETT, V396, P276, DOI 10.1016/0014-5793(96)01112-X
   Sardanelli AM, 2006, FEBS LETT, V580, P5690, DOI 10.1016/j.febslet.2006.09.020
   Scacco S, 2000, J BIOL CHEM, V275, P17578, DOI 10.1074/jbc.M001174200
   Scacco S, 2003, J BIOL CHEM, V278, P44161, DOI 10.1074/jbc.M307615200
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Scheffler IE, 2004, BBA-BIOENERGETICS, V1659, P160, DOI 10.1016/j.bbabio.2004.08.002
   Schilling B, 2005, FEBS LETT, V579, P2485, DOI 10.1016/j.febslet.2005.03.061
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Signorile A, 2002, FEBS LETT, V512, P91, DOI 10.1016/S0014-5793(02)02226-3
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Steen H, 2006, MOL CELL PROTEOMICS, V5, P172, DOI 10.1074/mcp.M500135-MCP200
   TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971
   Technikova-Dobrova Z, 2001, BIOCHEMISTRY-US, V40, P13941, DOI 10.1021/bi011066p
   TECHNIKOVADOBROVA Z, 1993, FEBS LETT, V322, P51, DOI 10.1016/0014-5793(93)81109-D
   TECHNIKOVADOBROVA Z, 1994, FEBS LETT, V350, P187, DOI 10.1016/0014-5793(94)00760-8
   Thomas HE, 2010, CELL DEATH DIFFER, V17, P577, DOI 10.1038/cdd.2009.165
   Valenti D, 2011, BIOCHEM J, V435, P679, DOI 10.1042/BJ20101908
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   VARDANIS A, 1977, J BIOL CHEM, V252, P807
   Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8
   WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X
   Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103
   Yadava N, 2008, INT J BIOCHEM CELL B, V40, P447, DOI 10.1016/j.biocel.2007.08.015
   Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b
   Yuzefovych L, 2010, AM J PHYSIOL-ENDOC M, V299, PE1096, DOI 10.1152/ajpendo.00238.2010
   Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982
   Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102
   Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
NR 115
TC 61
Z9 65
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD MAR 9
PY 2012
VL 586
IS 5
BP 568
EP 577
DI 10.1016/j.febslet.2011.09.019
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 904UH
UT WOS:000301222900015
PM 21945319
DA 2024-11-01
ER

PT J
AU Schon, EA
   DiMauro, S
   Hirano, M
AF Schon, Eric A.
   DiMauro, Salvatore
   Hirano, Michio
TI Human mitochondrial DNA: roles of inherited and somatic mutations
SO NATURE REVIEWS GENETICS
LA English
DT Review
ID cytochrome-c-oxidase; hereditary optic neuropathy; progressive external ophthalmoplegia; deficient muscle-fibers; kearns-sayre syndrome; human skeletal-muscle; nitric-oxide; 1555a-greater-than-g mutation; point mutations; mtdna deletions
AB Mutations in the human mitochondrial genome are known to cause an array of diverse disorders, most of which are maternally inherited, and all of which are associated with defects in oxidative energy metabolism. It is now emerging that somatic mutations in mitochondrial DNA (mtDNA) are also linked to other complex traits, including neurodegenerative diseases, ageing and cancer. Here we discuss insights into the roles of mtDNA mutations in a wide variety of diseases, highlighting the interesting genetic characteristics of the mitochondrial genome and challenges in studying its contribution to pathogenesis.
C1 [Schon, Eric A.; DiMauro, Salvatore; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Schon, Eric A.] Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Schon, EA (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 630 W 168th St, New York, NY 10032 USA.
EM eas3@columbia.edu
FU US National Institutes of Health [HD32062]; US Department of Defense [W911NF-12-1-0159]; Muscular Dystrophy Association; Ellison Medical Foundation; Alzheimer Drug Discovery Foundation; Marriott Mitochondrial Disorder Clinical Research Fund
CR Amo T, 2007, BIOCHEM J, V404, P345, DOI 10.1042/BJ20061609
   Anderson CD, 2011, ANN NEUROL, V69, P471, DOI 10.1002/ana.22108
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Arning L, 2010, J MOL MED, V88, P431, DOI 10.1007/s00109-010-0589-2
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   Bai RK, 2011, J ONCOL, V2011, P0, DOI 10.1155/2011/496189
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bitner-Glindzicz M, 2009, NEW ENGL J MED, V360, P640, DOI 10.1056/NEJMc0806396
   Bodyak ND, 2001, HUM MOL GENET, V10, P17, DOI 10.1093/hmg/10.1.17
   BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Calvo SE, 2012, SCI TRANSL MED, V4, P0, DOI 10.1126/scitranslmed.3003310
   CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0
   Carelli V, 2006, AM J HUM GENET, V78, P564, DOI 10.1086/501236
   Caro P, 2010, MITOCHONDRION, V10, P479, DOI 10.1016/j.mito.2010.05.004
   Cheng X, 2010, AGING CELL, V9, P919, DOI 10.1111/j.1474-9726.2010.00607.x
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Chong P Siao Tick, 2003, J CLIN NEUROMUSCUL DIS, V5, P1, DOI 10.1097/00131402-200309000-00001
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Damas J, 2012, NUCLEIC ACIDS RES, V40, P7606, DOI 10.1093/nar/gks500
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Ellinger J, 2012, UROL ONCOL-SEMIN ORI, V30, P509, DOI 10.1016/j.urolonc.2010.03.004
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Elson JL, 2007, AM J HUM GENET, V80, P378, DOI 10.1086/511652
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   Ericson NG, 2012, PLOS GENET, V8, P0, DOI 10.1371/journal.pgen.1002689
   Garcia-Rodriguez Luis J, 2007, METHODS CELL BIOL, V80, P809, DOI 10.1016/S0091-679X(06)80040-3
   Ghelli A, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0007922
   Gilkerson RW, 2008, J CELL BIOL, V181, P1117, DOI 10.1083/jcb.200712101
   Gilkerson RW, 2012, HUM MOL GENET, V21, P978, DOI 10.1093/hmg/ddr529
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006
   Goldin E, 2004, HUM MUTAT, V24, P460, DOI 10.1002/humu.20094
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   HASEGAWA H, 1993, ACTA NEUROPATHOL, V85, P280
   HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159
   Hazkani-Covo E, 2010, PLOS GENET, V6, P0, DOI 10.1371/journal.pgen.1000834
   Hiona A, 2008, EXP GERONTOL, V43, P24, DOI 10.1016/j.exger.2007.10.001
   Hirano T, 1999, MUTAT RES-FUND MOL M, V425, P195, DOI 10.1016/S0027-5107(99)00037-8
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Ingram CJE, 2012, AMYOTROPH LATERAL SC, V13, P341, DOI 10.3109/17482968.2012.654394
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kaufmann P, 2011, NEUROLOGY, V77, P1965, DOI 10.1212/WNL.0b013e31823a0c7f
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001
   Kiebish MA, 2005, BMC CANCER, V5, P0, DOI 10.1186/1471-2407-5-102
   King M P, 1996, METHODS ENZYMOL, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koopman WJH, 2012, NEW ENGL J MED, V366, P1132, DOI 10.1056/NEJMra1012478
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Lang M, 2012, HUM GENET, V131, P757, DOI 10.1007/s00439-011-1125-3
   Lee JH, 2011, PATHOL ONCOL RES, V17, P201, DOI 10.1007/s12253-010-9297-z
   Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006
   LESTIENNE P, 1988, LANCET, V1, P885
   LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F
   Madan E, 2011, ONCOTARGET, V2, P948
   Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004
   Maki J, 2008, AM J CLIN PATHOL, V129, P57, DOI 10.1309/UJJTH4HFEPWAQ78Q
   Mancuso Michelangelo, 2008, HUMAN GENOMICS, V3, P71
   McRae AF, 2008, GENOME RES, V18, P911, DOI 10.1101/gr.074872.107
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   MELNICK PJ, 1965, ANN NY ACAD SCI, V125, P689, DOI 10.1111/j.1749-6632.1965.tb45422.x
   MILLER RW, 1971, ARCH BIOCHEM BIOPHYS, V146, P256, DOI 10.1016/S0003-9861(71)80063-2
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORAES CT, 1995, MUSCLE NERVE, V0, PS150
   MORAIS R, 1994, CANCER RES, V54, P3889
   Mourier T, 2001, MOL BIOL EVOL, V18, P1833, DOI 10.1093/oxfordjournals.molbev.a003971
   Naini A, 2005, J NEUROL SCI, V229, P187, DOI 10.1016/j.jns.2004.11.026
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishigaki Y, 2010, GERIATR GERONTOL INT, V10, PS221, DOI 10.1111/j.1447-0594.2010.00599.x
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   Pallotti F, 1996, AM J HUM GENET, V59, P591
   Parr RL, 2006, BMC GENOMICS, V7, P0, DOI 10.1186/1471-2164-7-185
   Parr RL, 2006, J MOL DIAGN, V8, P312, DOI 10.2353/jmoldx.2006.050112
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100
   PETERS GJ, 1990, CANCER RES, V50, P4644
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Quinzii CM, 2010, FASEB J, V24, P3733, DOI 10.1096/fj.09-152728
   Raimundo N, 2012, CELL, V148, P716, DOI 10.1016/j.cell.2011.12.027
   Ramos A, 2011, MITOCHONDRION, V11, P946, DOI 10.1016/j.mito.2011.08.009
   Rodríguez-Juárez F, 2007, BIOCHEM J, V405, P223, DOI 10.1042/BJ20070033
   Rose G, 2008, EUR J NEUROL, V15, P1006, DOI 10.1111/j.1468-1331.2008.02222.x
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   SAGAN L, 1967, J THEOR BIOL, V14, P225, DOI 10.1016/0022-5193(67)90079-3
   Sánchez-Ferrero E, 2012, J NEUROL, V259, P246, DOI 10.1007/s00415-011-6155-1
   SanGiovanni JP, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0005508
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   Santoro A, 2012, PLOS ONE, V5, P0
   Saxena R, 2006, AM J HUM GENET, V79, P54, DOI 10.1086/504926
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schon EA, 2011, NEURON, V70, P1033, DOI 10.1016/j.neuron.2011.06.003
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022
   Sequeira Adolfo, 2012, FRONTIERS IN GENETICS, V3, P103, DOI 10.3389/fgene.2012.00103
   Sgarbi G, 2006, BIOCHEM J, V395, P493, DOI 10.1042/BJ20051748
   Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Storlazzi CT, 2010, GENOME RES, V20, P1198, DOI 10.1101/gr.106252.110
   Suzuki T, 2011, WIRES RNA, V2, P376, DOI 10.1002/wrna.65
   Tay SHK, 2006, ARCH NEUROL-CHICAGO, V63, P281, DOI 10.1001/archneur.63.2.281
   Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849
   TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169
   Tranah GJ, 2011, AGEING RES REV, V10, P238, DOI 10.1016/j.arr.2010.06.003
   Turner C, 2003, HUM GENET, V112, P303, DOI 10.1007/s00439-002-0892-2
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200
   Uusimaa J, 2011, J MED GENET, V48, P660, DOI 10.1136/jmg.2011.089995
   Valsesia A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0018369
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   van Nederveen FH, 2009, LANCET ONCOL, V10, P764, DOI 10.1016/S1470-2045(09)70164-0
   Vandebona H, 2009, NEW ENGL J MED, V360, P642, DOI 10.1056/NEJMc0806397
   Vives-Bauza C, 2010, PROG BRAIN RES, V183, P99, DOI 10.1016/S0079-6123(10)83006-7
   Vu TH, 2000, MUSCLE NERVE, V23, P80, DOI 10.1002/(SICI)1097-4598(200001)23:1<80::AID-MUS10>3.0.CO;2-V
   Wang D, 2012, P NATL ACAD SCI USA, V109, P2444, DOI 10.1073/pnas.1117890109
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   Willett-Brozick JE, 2001, HUM GENET, V109, P216, DOI 10.1007/s004390100564
   Yan QF, 2006, BIOCHEM BIOPH RES CO, V342, P1130, DOI 10.1016/j.bbrc.2006.02.078
   Ylikallio E, 2012, ANN MED, V44, P41, DOI 10.3109/07853890.2011.598547
   YONEDA M, 1995, MUSCLE NERVE, V0, PS95
   Yu M, 2007, IUBMB LIFE, V59, P450, DOI 10.1080/15216540701509955
   Yu M, 2011, LIFE SCI, V89, P65, DOI 10.1016/j.lfs.2011.05.010
NR 149
TC 545
Z9 615
U1 0
U2 121
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-0056
EI 1471-0064
J9 NAT REV GENET
JI Nat. Rev. Genet.
PD DEC 15
PY 2012
VL 13
IS 12
BP 878
EP 890
DI 10.1038/nrg3275
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 038ZL
UT WOS:000311212500010
PM 23154810
DA 2024-11-01
ER

PT J
AU Gamba, J
   Kiyomoto, BH
   de Oliveira, ASB
   Gabbai, AA
   Schmidt, B
   Tengan, CH
AF Gamba, Juliana
   Kiyomoto, Beatriz Hitomi
   Bulle de Oliveira, Acary Souza
   Gabbai, Alberto Alain
   Schmidt, Beny
   Tengan, Celia Harumi
TI The mutations m.5628T&gt;C and m18348A&gt;G in single muscle fibers of a patient with chronic progressive external ophthalmoplegia
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mtDNA; tRNA; CPEO; Mitochondria; Mitochondrial diseases; Mutation; Polymorphism
ID mitochondrial-dna mutations; trna(lys) gene; transfer-rnas; hearing-loss; disease; disorder; sequence; genome
AB We identified a double mutation in a patient with chronic progressive external ophthalmoplegia, located in the tRNA(Ala) (m.5628T > C) and tRNA(LYs) (m.8348A > G) genes. Both mutations were previously described separately and considered pathogenic, however the same mutations were also reported as polymorphisms or phenotype modulator. We analyzed the proportion of each mutation in isolated muscle fibers by single fiber-polymerase chain reaction to investigate the contribution of each mutation to mitochondrial deficiency. Our findings demonstrated that the mutations were heteroplasmic in skeletal muscle and both mutations were present in all single muscle fibers. The proportions of the m.5628T > C mutation were not significantly different between normal and cytochrome-c-oxidase (COX) deficient fibers. However, a significant higher proportion of the m.8348A > G mutation was observed in COX deficient fibers. Homoplasmic m.8348A > G was only observed in COX negative fibers. In conclusion, we provide a piece of evidence toward the pathogenicity of the m.8348A > G mutation and suggest that m.5628T > C is probably a neutral polymorphism. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Gamba, Juliana; Kiyomoto, Beatriz Hitomi; Bulle de Oliveira, Acary Souza; Gabbai, Alberto Alain; Tengan, Celia Harumi] Univ Fed Sao Paulo, Dept Neurol & Neurosurg, Escola Paulista Med, BR-04039032 Sao Paulo, Brazil.
   [Schmidt, Beny] Univ Fed Sao Paulo, Dept Pathol, Escola Paulista Med, BR-04039032 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)
RP Tengan, CH (corresponding author), Univ Fed Sao Paulo, Dept Neurol & Neurosurg, Escola Paulista Med, Rua Pedro Toledo 781,7th Floor, BR-04039032 Sao Paulo, Brazil.
EM chtengan@unifesp.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Arenas J, 1999, NEUROLOGY, V52, P377, DOI 10.1212/WNL.52.2.377
   Bertolin C, 2011, J HUM GENET, V56, P869, DOI 10.1038/jhg.2011.111
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   Bortot B, 2009, MITOCHONDRION, V9, P123, DOI 10.1016/j.mito.2009.01.006
   Crispim D, 2008, ARQ BRAS ENDOCRINOL, V52, P1228, DOI 10.1590/S0004-27302008000800005
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Finsterer J, 2010, ACTA NEUROL BELG, V110, P110
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   Han DY, 2007, BIOCHEM BIOPH RES CO, V357, P554, DOI 10.1016/j.bbrc.2007.03.199
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Kato T, 2010, J HUM GENET, V55, P147, DOI 10.1038/jhg.2009.143
   Mamit-tRNA, 2007, COMP MAMM MIT TRNA G, V0, P0
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Moraes C T, 1996, METHODS ENZYMOL, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Sissler M, 2004, RNA, V10, P841, DOI 10.1261/rna.5267604
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Terasaki F, 2001, JPN CIRC J, V65, P691, DOI 10.1253/jcj.65.691
   Ueki I, 2006, MITOCHONDRION, V6, P29, DOI 10.1016/j.mito.2005.10.003
   Zhu Y, 2009, MITOCHONDRION, V9, P418, DOI 10.1016/j.mito.2009.07.006
NR 27
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD SEP 15
PY 2012
VL 320
IS 1-2
BP 131
EP 135
DI 10.1016/j.jns.2012.05.037
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 000JC
UT WOS:000308381600025
PM 22743145
DA 2024-11-01
ER

PT J
AU Sun, R
   Eriksson, S
   Wang, LY
AF Sun, Ren
   Eriksson, Staffan
   Wang, Liya
TI Oxidative Stress Induced <i>S</i>-glutathionylation and Proteolytic Degradation of Mitochondrial Thymidine Kinase 2
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID dna depletion myopathy; protein glutathionylation; mutations; mechanism; dysfunction; cancer; damage
AB Protein glutathionylation in response to oxidative stress can affect both the stability and activity of target proteins. Mitochondrial thymidine kinase 2 (TK2) is a key enzyme in mitochondrial DNA precursor synthesis. Using an antibody specific for glutathione (GSH), S-glutathionylated TK2 was detected after the addition of glutathione disulfide (GSSG) but not GSH. This was reversed by the addition of dithiothreitol, suggesting that S-glutathionylation of TK2 is reversible. Site-directed mutagenesis of the cysteine residues and subsequent analysis of mutant enzymes demonstrated that Cys-189 and Cys-264 were specifically glutathionylated by GSSG. These cysteine residues do not appear to be part of the active site, as demonstrated by kinetic studies of the mutant enzymes. Treatment of isolated rat mitochondria with hydrogen peroxide resulted in S-glutathionylation of added recombinant TK2. Treatment of intact cells with hydrogen peroxide led to reduction of mitochondrial TK2 activity and protein levels, as well as S-glutathionylation of TK2. Furthermore, the addition of S-glutathionylated recombinant TK2 to mitochondria isolated from hydrogen peroxide-treated cells led to degradation of the S-glutathionylated TK2, which was not observed with unmodified TK2. S-Glutathionylation on Cys-189 was responsible for the observed selective degradation of TK2 in mitochondria. These results strongly suggest that oxidative damage-induced S-glutathionylation and degradation of TK2 have significant impact on mitochondrial DNA precursor synthesis.
C1 [Sun, Ren; Eriksson, Staffan; Wang, Liya] Swedish Univ Agr Sci, Biomed Ctr, Dept Anat Physiol & Biochem, SE-75123 Uppsala, Sweden.
C3 Swedish University of Agricultural Sciences
RP Wang, LY (corresponding author), Swedish Univ Agr Sci, Biomed Ctr, Dept Anat Physiol & Biochem, Box 575, SE-75123 Uppsala, Sweden.
EM liya.wang@slu.se
FU Swedish Research Council; Swedish Research Council for Environment, Agricultural Sciences, and Spatial Planning
CR Anathy V, 2012, ANTIOXID REDOX SIGN, V16, P496, DOI 10.1089/ars.2011.4281
   Ayer A, 2010, FREE RADICAL BIO MED, V49, P1956, DOI 10.1016/j.freeradbiomed.2010.09.023
   Baker BM, 2011, TRENDS BIOCHEM SCI, V36, P254, DOI 10.1016/j.tibs.2011.01.004
   Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836
   Bulteau AL, 2012, BBA-MOL BASIS DIS, V1822, P212, DOI 10.1016/j.bbadis.2011.11.003
   Bulteau AL, 2006, EXP GERONTOL, V41, P653, DOI 10.1016/j.exger.2006.03.013
   Cooper AJL, 2011, EXPERT OPIN DRUG MET, V7, P891, DOI 10.1517/17425255.2011.577738
   Fariss MW, 2005, MOL INTERV, V5, P94, DOI 10.1124/mi.5.2.7
   Garcia J, 2010, J BIOL CHEM, V285, P39646, DOI 10.1074/jbc.M110.164160
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Graham JC, 1999, CURRENT PROTOCOLS CE, V0, P331
   Hurd TR, 2005, BIOCHEM SOC T, V33, P1390, DOI 10.1042/BST0331390
   Hurd TR, 2005, ANTIOXID REDOX SIGN, V7, P999, DOI 10.1089/ars.2005.7.999
   JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   Kil IS, 2005, J BIOL CHEM, V280, P10846, DOI 10.1074/jbc.M411306200
   Kline ER, 2009, CARDIOVASC TOXICOL, V9, P1, DOI 10.1007/s12012-008-9029-8
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Liedhegner EAS, 2012, ANTIOXID REDOX SIGN, V16, P543, DOI 10.1089/ars.2011.4119
   MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sun R, 2010, NUCLEOS NUCLEOT NUCL, V29, P382, DOI 10.1080/15257771003741018
   Tatsuta T, 2008, EMBO J, V27, P306, DOI 10.1038/sj.emboj.7601972
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Ugarte N, 2010, ANTIOXID REDOX SIGN, V13, P539, DOI 10.1089/ars.2009.2998
   Verschoor ML, 2010, CAN J PHYSIOL PHARM, V88, P204, DOI 10.1139/Y09-135
   Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6
   Wang L, 2011, ANTIMICROB AGENTS CH, V55, P2552, DOI 10.1128/AAC.00109-11
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   Yusuf MA, 2010, FREE RADICAL BIO MED, V49, P908, DOI 10.1016/j.freeradbiomed.2010.06.020
NR 35
TC 36
Z9 41
U1 1
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 13
PY 2012
VL 287
IS 29
BP 24304
EP 24312
DI 10.1074/jbc.M112.381996
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 977IQ
UT WOS:000306651100024
PM 22661713
DA 2024-11-01
ER

PT J
AU Chamkha, I
   Alila-Fersi, O
   Mkaouar-Rebai, E
   Aloulou, H
   Kifagi, C
   Hachicha, M
   Fakhfakh, F
AF Chamkha, Imen
   Alila-Fersi, Olfa
   Mkaouar-Rebai, Emna
   Aloulou, Hajer
   Kifagi, Chamseddine
   Hachicha, Mongia
   Fakhfakh, Faiza
TI A novel m.12908T&gt;A mutation in the mitochondrial <i>ND5</i> gene in patient with infantile-onset Pompe disease
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Pompe disease; MT-ND5; m.12908T > A; Mitochondrial mutation; Cardiomyopathy
ID complex-i deficiency; wolfram-syndrome; nadh dehydrogenase; clinical-features; encoded subunits; skeletal-muscle; optic atrophy; dna; sequence; cells
AB Pompe disease is a progressive metabolic myopathy caused by deficiency in lysosomal acid a-glucosidase and results in cellular lysosomal and cytoplasmic glycogen accumulation. A wide spectrum of clinical phenotypes exists from hypotonia and severe cardiac hypertrophy in the first few months of life to a milder form with the onset of symptoms in adulthood. The disease is typically due to severe mutations in GM gene. In the present study, we described a newborn boy with clinical features of Pompe disease particularly with hypertrophic cardiomyopathy, hypotonia and hepatomegaly. This case was at first mis-diagnosed as mitochondrial disorder. Accordingly, we performed a mitochondrial mutational analysis that revealed a novel mutation m.12908T>A in the ND5 gene. Secondary structure analysis of the ND5 protein further supported the deleterious role of the m.12908T>A mutation, as it was found to involve an extended imbalance in its hydrophobicity and affect its function. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Chamkha, Imen; Alila-Fersi, Olfa; Mkaouar-Rebai, Emna; Fakhfakh, Faiza] Univ Sfax, Human Mol Genet Lab, Fac Med Sfax, Sfax 3029, Tunisia.
   [Aloulou, Hajer; Hachicha, Mongia] CHU Hedi Chaker Sfax, Serv Pediat, Sfax, Tunisia.
   [Kifagi, Chamseddine] Univ Montpellier 2, CNRS, UMR5535, Inst Genet Mol Montpellier, F-34095 Montpellier 5, France.
C3 Universite de Sfax; Universite de Sfax; Hopital Hedi Chaker; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)
RP Chamkha, I (corresponding author), Univ Sfax, Human Mol Genet Lab, Fac Med Sfax, Ave Magida Boulila, Sfax 3029, Tunisia.
EM imen.chamkha@gmail.com; faiza.fakhfakh@gmail.com
FU Ministry of the Higher Education and the Scientific Research in Tunisia
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000
   Barrientos A, 1996, AM J HUM GENET, V58, P963
   Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256
   BUNDEY S, 1992, J INHERIT METAB DIS, V15, P315, DOI 10.1007/BF02435965
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961
   Downham E, 2008, NEUROMUSCULAR DISORD, V18, P310, DOI 10.1016/j.nmd.2008.01.003
   Fan L, 2011, MITOCHONDRION, V11, P351, DOI 10.1016/j.mito.2010.09.013
   Fernández R, 1999, NEUROMUSCULAR DISORD, V9, P136, DOI 10.1016/S0960-8966(98)00117-5
   HOFHAUS G, 1995, MOL CELL BIOL, V15, P964
   Huang HP, 2011, HUM MOL GENET, V20, P4851, DOI 10.1093/hmg/ddr424
   Kishnani PS, 2006, GENET MED, V8, P267, DOI 10.1097/01.gim.0000218152.87434.f3
   Kroos MA, 2007, NEUROLOGY, V68, P110, DOI 10.1212/01.wnl.0000252798.25690.76
   Kroos M, 2012, AM J MED GENET C, V160C, P59, DOI 10.1002/ajmc.31318
   Lewandowska E, 2008, FOLIA NEUROPATHOL, V46, P123
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   Martí-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Mezghani N, 2011, BIOCHEM BIOPH RES CO, V411, P247, DOI 10.1016/j.bbrc.2011.06.106
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267
   Ruiter EM, 2007, EUR J HUM GENET, V15, P155, DOI 10.1038/sj.ejhg.5201735
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thurberg BL, 2006, LAB INVEST, V86, P1208, DOI 10.1038/labinvest.3700484
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Valentino ML, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.037507
   van der Ploeg AT, 2008, LANCET, V372, P1342, DOI 10.1016/S0140-6736(08)61555-X
   Weidberg H, 2011, ANNU REV BIOCHEM, V80, P125, DOI 10.1146/annurev-biochem-052709-094552
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, PW407, DOI 10.1093/nar/gkm290
   Winkel LPF, 2005, J NEUROL, V252, P875, DOI 10.1007/s00415-005-0922-9
   Wokke JHJ, 2008, MUSCLE NERVE, V38, P1236, DOI 10.1002/mus.21025
   Wu JJ, 2009, AGING-US, V1, P425, DOI 10.18632/aging.100038
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Zhadanov SI, 2007, MITOCHONDRION, V7, P260, DOI 10.1016/j.mito.2007.01.003
   Zickermann V, 2009, BBA-BIOENERGETICS, V1787, P574, DOI 10.1016/j.bbabio.2009.01.012
NR 41
TC 6
Z9 8
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 7
PY 2012
VL 429
IS 1-2
BP 31
EP 38
DI 10.1016/j.bbrc.2012.10.105
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 056TG
UT WOS:000312513700006
PM 23131568
DA 2024-11-01
ER

PT J
AU Sen, D
   Nandakumar, D
   Tang, GQ
   Patel, SS
AF Sen, Doyel
   Nandakumar, Divya
   Tang, Guo-Qing
   Patel, Smita S.
TI Human Mitochondrial DNA Helicase TWINKLE Is Both an Unwinding and Annealing Helicase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID progressive external ophthalmoplegia; single-stranded-dna; structure-function defects; nucleotide hydrolysis; central channel; gene-4 protein; replication; binding; bacteriophage-t7; primase
AB TWINKLE is a nucleus-encoded human mitochondrial (mt) DNA helicase. Point mutations in TWINKLE are associated with heritable neuromuscular diseases characterized by deletions in the mtDNA. To understand the biochemical basis of these diseases, it is important to define the roles of TWINKLE in mtDNA metabolism by studying its enzymatic activities. To this end, we purified native TWINKLE from Escherichia coli. The recombinant TWINKLE assembles into hexamers and higher oligomers, and addition of MgUTP stabilizes hexamers over higher oligomers. Probing into the DNA unwinding activity, we discovered that the efficiency of unwinding is greatly enhanced in the presence of a heterologous single strand-binding protein or a single-stranded (ss) DNA that is complementary to the unwound strand. We show that TWINKLE, although a helicase, has an antagonistic activity of annealing two complementary ssDNAs that interferes with unwinding in the absence of gp2.5 or ssDNA trap. Furthermore, only ssDNA and not double-stranded (ds)DNA competitively inhibits the annealing activity, although both DNAs bind with high affinities. This implies that dsDNA binds to a site that is distinct from the ssDNA-binding site that promotes annealing. Fluorescence anisotropy competition binding experiments suggest that TWINKLE has more than one ssDNA-binding sites, and we speculate that a surface-exposed ssDNA-specific site is involved in catalyzing DNA annealing. We propose that the strand annealing activity of TWINKLE may play a role in recombination-mediated replication initiation found in the mitochondria of mammalian brain and heart or in replication fork regression during repair of damaged DNA replication forks.
C1 [Sen, Doyel; Nandakumar, Divya; Tang, Guo-Qing; Patel, Smita S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences
RP Patel, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.
EM patelss@umdnj.edu
FU National Institutes of Health [GM55310]
CR Ahnert P, 2000, EMBO J, V19, P3418, DOI 10.1093/emboj/19.13.3418
   Cheok CF, 2005, NUCLEIC ACIDS RES, V33, P3932, DOI 10.1093/nar/gki712
   Costa A, 2006, J STRUCT BIOL, V156, P210, DOI 10.1016/j.jsb.2006.04.001
   Crampton DJ, 2006, J MOL BIOL, V360, P667, DOI 10.1016/j.jmb.2006.05.037
   Delagoutte E, 2011, BIOCHEMISTRY-US, V50, P932, DOI 10.1021/bi101583e
   Farge G, 2008, NUCLEIC ACIDS RES, V36, P393, DOI 10.1093/nar/gkm1025
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   HALLER I, 1974, P NATL ACAD SCI USA, V71, P2018, DOI 10.1073/pnas.71.5.2018
   HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028
   Holmlund T, 2009, BBA-MOL BASIS DIS, V1792, P132, DOI 10.1016/j.bbadis.2008.11.009
   Jemt E, 2011, NUCLEIC ACIDS RES, V39, P9238, DOI 10.1093/nar/gkr653
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Longley MJ, 2010, J BIOL CHEM, V285, P29690, DOI 10.1074/jbc.M110.151795
   Machwe A, 2005, J BIOL CHEM, V280, P23397, DOI 10.1074/jbc.M414130200
   Mao Chih-Chieh, 2009, CHANG GUNG MED J, V32, P354
   MATSON SW, 1985, J BIOL CHEM, V260, P2281
   MATSON SW, 1983, J BIOL CHEM, V258, P4017
   Matsushima Y, 2008, J BIOL CHEM, V283, P23964, DOI 10.1074/jbc.M803674200
   Oliveira MT, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0015379
   PATEL SS, 1992, J BIOL CHEM, V267, P15013
   PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029
   Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651
   Picha KM, 2000, BIOCHEMISTRY-US, V39, P6401, DOI 10.1021/bi992857i
   Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315
   Pohjoismäki JLO, 2009, J BIOL CHEM, V284, P21446, DOI 10.1074/jbc.M109.016600
   Rasnik I, 2008, EMBO J, V27, P1727, DOI 10.1038/emboj.2008.106
   Remus D, 2009, CURR OPIN CELL BIOL, V21, P771, DOI 10.1016/j.ceb.2009.08.002
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tang GQ, 2006, BIOCHEMISTRY-US, V45, P4936, DOI 10.1021/bi0522910
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
   Xu XH, 2009, EMBO J, V28, P568, DOI 10.1038/emboj.2009.13
   Yakovchuk P, 2006, NUCLEIC ACIDS RES, V34, P564, DOI 10.1093/nar/gkj454
   Ziebarth TD, 2007, J MOL BIOL, V367, P1382, DOI 10.1016/j.jmb.2007.01.079
   Ziebarth TD, 2010, J BIOL CHEM, V285, P14639, DOI 10.1074/jbc.M109.099663
NR 38
TC 49
Z9 59
U1 2
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 27
PY 2012
VL 287
IS 18
BP 14545
EP 14556
DI 10.1074/jbc.M111.309468
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 941XU
UT WOS:000304003200021
PM 22383523
DA 2024-11-01
ER

PT J
AU Sarnat, HB
   Flores-Sarnat, L
   Casey, R
   Scott, P
   Khan, A
AF Sarnat, Harvey B.
   Flores-Sarnat, Laura
   Casey, Robin
   Scott, Patrick
   Khan, Aneal
TI Endothelial ultrastructural alterations of intramuscular capillaries in infantile mitochondrial cytopathies: "Mitochondrial angiopathy"
SO NEUROPATHOLOGY
LA English
DT Article
DE electron microscopy; endoplasmic reticulum; endothelium; microvilli; mitochondrial cytopathy; paracrystallin structures
ID central-nervous-system; electron-microscopy; disorders; encephalomyopathy; myopathy; muscle; brain; encephalopathy; diagnosis; pathology
AB Electron microscopy (EM) is a reliable method for diagnosing mitochondrial diseases in striated muscle biopsy in infancy. Ultrastructural alterations in mitochondria of myofibers are well documented, but there are few studies of endothelial involvement in intramuscular capillaries. Quadriceps femoris biopsies of five representative infants and toddlers, ages neonate to 3.5 years, were performed because of clinical and laboratory data consistent with mitochondrial disease without mitochondrial DNA (mtDNA) mutations and likely with nuclear DNA mutations. Pathological studies included histochemistry, EM, respiratory chain enzymatic assay and mtDNA sequencing and deletion/duplication analysis. EM demonstrated frequent and severe alterations of mitochondria in capillary endothelium. The most constant changes included: either too few or fragmented cristae; stacked and whorled cristae; paracrystallin structures that often were large and spheroid with stress fractures; closely apposed membranes of granular endoplasmic reticulum surrounding mitochondria with loss of the normal intervening layer of cytoplasm; long narrow, thin looped microvilli extending into the lumen; and thick microvilli containing large, abnormal mitochondria. We conclude that mitochondrial cytopathies in early life exhibit more severe ultrastructural alterations in the endothelium than in myofibers and that paracrystallin body structure differs, perhaps due to less rigid surrounding structures. This distribution may explain the frequent lack of prominent histochemical and biochemical abnormalities in muscle biopsies of young patients. Endothelial changes do not distinguish the genetic defects. Vascular involvement in brain contributes to cerebral lesions and neuronal death by impairment of molecular and nutrient transport and ischemia; endothelium in muscle may reflect similar changes.
C1 [Sarnat, Harvey B.; Flores-Sarnat, Laura; Khan, Aneal] Univ Calgary, Fac Med, Dept Paediat, Edmonton, AB, Canada.
   [Sarnat, Harvey B.] Univ Calgary, Fac Med, Dept Pathol & Lab Med Neuropathol, Edmonton, AB, Canada.
   [Sarnat, Harvey B.; Flores-Sarnat, Laura] Univ Calgary, Fac Med, Dept Clin Neurosci, Edmonton, AB, Canada.
   [Casey, Robin; Khan, Aneal] Univ Calgary, Fac Med, Dept Med Genet, Edmonton, AB, Canada.
   [Sarnat, Harvey B.] Alberta Childrens Prov Gen Hosp, Edmonton, AB, Canada.
   [Scott, Patrick] Univ Alberta, Dept Med Genet, Edmonton, AB, Canada.
C3 University of Calgary; University of Calgary; University of Calgary; University of Calgary; Alberta Childrens Hospital; University of Calgary; University of Alberta
RP Sarnat, HB (corresponding author), Alberta Childrens Prov Gen Hosp, Dept Pathol & Lab Med, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.
EM harvey.sarnat@albertahealthservices.ca
CR Agamanolis DP, 2005, FDN DIAGNOSTIC PATHO, V0, P385
   ASMUSSEN I, 1984, ATHEROSCLEROSIS, V50, P203, DOI 10.1016/0021-9150(84)90023-6
   Bauserman SC, 1984, CONT ISSUES SURG PAT, V3, P109
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Carpenter S, 2001, PATHOLOGY SKELETAL M, V0, P453
   Castejón OJ, 2011, FOLIA NEUROPATHOL, V49, P162
   Chinnery PF, 2008, GREENFIELDS NEUROPAT, V0, P601
   COQUET M, 1990, ANN PATHOL, V10, P181
   DIAS MJM, 1984, NEUROPEDIATRICS, V15, P18, DOI 10.1055/s-2008-1052334
   Dubowitz V, 2007, MUSCLE BIOPSY PRACTI, V0, P169
   HAMMERSEN F, 1982, INT J MICROCIRC, V1, P135
   Hays AP, 2006, MITOCHONDRIAL MEDICINE, V0, P45
   Hilton-Jones D, 1995, MAJOR PROBLEMS NEURO, V29, P136
   Hunter MF, 2011, PEDIATR NEUROL, V45, P311, DOI 10.1016/j.pediatrneurol.2011.07.008
   KARIMU AL, 1995, PLACENTA, V16, P93, DOI 10.1016/0143-4004(95)90085-3
   Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829
   Lindl KA, 2007, NEUROPATH APPL NEURO, V33, P658, DOI 10.1111/j.1365-2990.2007.00866.x
   Marín-García J, 2003, PEDIATR NEUROL, V29, P26, DOI 10.1016/S0887-8994(03)00013-4
   Mierau GW, 2004, PEDIATR DEVEL PATHOL, V7, P637, DOI 10.1007/s10024-004-5048-z
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   MOLNAR M, 1995, NEUROPATH APPL NEURO, V21, P432, DOI 10.1111/j.1365-2990.1995.tb01080.x
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   OLDENDORF WH, 1975, P SOC EXP BIOL MED, V149, P736
   Rodenburg RJT, 2011, J INHERIT METAB DIS, V34, P283, DOI 10.1007/s10545-010-9081-y
   Sarnat HB, 2005, CAN J NEUROL SCI, V32, P152, DOI 10.1017/S0317167100003929
   Sarnat HB, 1984, MUSCLE PATHOLOGY HIS, V0, P76
   SATO W, 1994, AM HEART J, V128, P733, DOI 10.1016/0002-8703(94)90272-0
   SCHOCHET SS, 1981, INTRO DIAGNOSTIC ELE, V0, P131
   SCHRODER JM, 1993, BRAIN PATHOL, V3, P177, DOI 10.1111/j.1750-3639.1993.tb00742.x
   Selim LAM, 2009, RES. J. MED. MED. SCI, V4, P369
   Shoubridge EA, 2002, STRUCTURAL MOL BASIS, V0, P202
   SMITH U, 1971, SCIENCE, V173, P925, DOI 10.1126/science.173.4000.925
   STADHOUDERS AM, 1981, MITOCHONDRIA MUSCULA, V0, P113
   Sulbaran TA, 2002, JOURNAL OF SUBMICROSCOPIC CYTOLOGY AND PATHOLOGY, V34, P389
   Wada H, 1996, BRAIN DEV-JPN, V18, P263, DOI 10.1016/0387-7604(96)00017-4
NR 35
TC 16
Z9 17
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-6544
EI 
J9 NEUROPATHOLOGY
JI Neuropathology
PD DEC 15
PY 2012
VL 32
IS 6
BP 617
EP 627
DI 10.1111/j.1440-1789.2012.01308.x
PG 11
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 041JN
UT WOS:000311398200005
PM 23174091
DA 2024-11-01
ER

PT J
AU Elstner, M
   Turnbull, DM
AF Elstner, Matthias
   Turnbull, Douglass M.
TI Transcriptome analysis in mitochondrial disorders
SO BRAIN RESEARCH BULLETIN
LA English
DT Review
DE Mitochondrial disease; Gene expression; Microarray; OXPHOS; Mitochondrial biogenesis; PGC-1 alpha; Cell cycle; Epigenetics
ID focused cdna microarray; gene-expression changes; respiratory-chain; skeletal-muscle; cells lacking; degenerative diseases; oxidative stress; mtdna mutations; nuclear genes; dna
AB The spectrum of genetic disorders associated with primary mitochondrial dysfunction ranges from isolated hearing loss to lethal neonatal syndromes. Mitochondrial biogenesis and function relies on the enigmatic interplay of the mitochondrial and nuclear genome and allows for adjustment of energy consumption to substrate availability and adaption to genetic and toxic stressors. Whole transcriptome studies permit a global perspective on these events and promise deeper insight into mitochondrial physiology and dysfunction. Data coming from microarray studies has revealed the activation of an intricate signaling network that promotes bioenergetic adaption through autophagy and enhanced mitochondrial biogenesis. The effectors of this network are currently under much investigation for their therapeutic potential. Microarray data also implicate a profound impact of mitochondrial dysfunction on global nuclear transcription activity through alteration of genomic stability, cell cycle progression and epigenetic regulation. In this review, results of gene expression studies performed on human and animal tissue as well as cell culture models with mitochondrial dysfunction are summarized and discussed. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Elstner, Matthias] Univ Munich, Friedrich Baur Inst, Dept Neurol, D-81377 Munich, Germany.
   [Turnbull, Douglass M.] Newcastle Univ, Inst Ageing & Hlth, Ctr Brain Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Turnbull, Douglass M.] Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 University of Munich; Newcastle University - UK; Newcastle University - UK
RP Elstner, M (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurol, Marchioninistr 15, D-81377 Munich, Germany.
EM melstner@med.uni-muenchen.de
FU MRC [G0601943, G1100540, G0400074, G0502157, G0700718, G0900652] Funding Source: UKRI; Medical Research Council [G0601943, G0900652, G0400074, G0502157, G1100540, G0700718] Funding Source: Medline; Wellcome Trust [096919] Funding Source: Medline
CR Abramov AY, 2010, BRAIN, V133, P797, DOI 10.1093/brain/awq015
   Abramov AY, 2010, BBA-GEN SUBJECTS, V1800, P297, DOI 10.1016/j.bbagen.2009.08.002
   Alemi M, 2007, FREE RADICAL BIO MED, V42, P32, DOI 10.1016/j.freeradbiomed.2006.09.014
   Alesci S, 2006, PHARMACOGENOMICS J, V6, P333, DOI 10.1038/sj.tpj.6500377
   Aragonés J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62
   Arduíno DM, 2010, CNS NEUROL DISORD-DR, V9, P105, DOI 10.2174/187152710790966687
   Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   Bai XY, 2007, BIOTECHNIQUES, V42, P365, DOI 10.2144/000112388
   Bastin J, 2008, J CLIN ENDOCR METAB, V93, P1433, DOI 10.1210/jc.2007-1701
   Behan A, 2005, MITOCHONDRION, V5, P173, DOI 10.1016/j.mito.2005.03.002
   Benard G, 2010, BBA-BIOENERGETICS, V1797, P698, DOI 10.1016/j.bbabio.2010.02.030
   Bonod-Bidaud C, 1999, EXP CELL RES, V246, P91, DOI 10.1006/excr.1998.4302
   Buesa C, 2004, J NEUROPATH EXP NEUR, V63, P1003, DOI 10.1093/jnen/63.10.1003
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009
   Chaturvedi RK, 2008, J NEUROCHEM, V106, P506, DOI 10.1111/j.1471-4159.2008.05388.x
   Chinnery P, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub2
   Chinnery PF, 2001, NEUROLOGY, V56, P1101, DOI 10.1212/WNL.56.8.1101
   Cízková A, 2008, BMC GENOMICS, V9, P0, DOI 10.1186/1471-2164-9-38
   Cortopassi G, 2006, MITOCHONDRION, V6, P161, DOI 10.1016/j.mito.2006.05.002
   Craven L, 2010, NATURE, V465, P82, DOI 10.1038/nature08958
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Danielson SR, 2005, BRAIN, V128, P1026, DOI 10.1093/brain/awh447
   Delsite Robert, 2002, MOL CANCER, V1, P6, DOI 10.1186/1476-4598-1-6
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Elstner M, 2008, MOL BIOTECHNOL, V40, P306, DOI 10.1007/s12033-008-9100-5
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Finley LWS, 2009, AGEING RES REV, V8, P173, DOI 10.1016/j.arr.2009.03.003
   Fujita Y, 2007, MITOCHONDRION, V7, P80, DOI 10.1016/j.mito.2006.11.003
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gibson GE, 2010, BBA-MOL BASIS DIS, V1802, P122, DOI 10.1016/j.bbadis.2009.08.010
   Graeber MB, 2008, ACTA NEUROPATHOL, V115, P493, DOI 10.1007/s00401-008-0363-5
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Haack TB, 2010, NAT GENET, V42, P1131, DOI 10.1038/ng.706
   HEDDI A, 1994, BBA-MOL BASIS DIS, V1226, P206, DOI 10.1016/0925-4439(94)90030-2
   HEDDI A, 1993, J BIOL CHEM, V268, P12156
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Kemp JP, 2011, BRAIN, V134, P183, DOI 10.1093/brain/awq320
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirby DM, 2009, CELL PROLIFERAT, V42, P413, DOI 10.1111/j.1365-2184.2009.00612.x
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Krishnan KJ, 2007, NUCLEIC ACIDS RES, V35, P7399, DOI 10.1093/nar/gkm635
   Kyriakouli DS, 2008, GENE THER, V15, P1017, DOI 10.1038/gt.2008.91
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   Narendra DP, 2010, PLOS BIOL, V8, P0, DOI 10.1371/journal.pbio.1000298
   Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409
   Ogasawara E, 2010, HUM MOL GENET, V19, P3179, DOI 10.1093/hmg/ddq228
   Onyango IG, 2010, BBA-MOL BASIS DIS, V1802, P228, DOI 10.1016/j.bbadis.2009.07.014
   Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x
   Pecina P, 2004, PHYSIOL RES, V53, PS213, DOI 10.33549/physiolres.930000.53.S213
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Shoubridge EA, 2001, SEMIN NEUROL, V21, P261, DOI 10.1055/s-2001-17943
   Simmen T, 2010, BBA-BIOMEMBRANES, V1798, P1465, DOI 10.1016/j.bbamem.2010.04.009
   Smits P, 2010, J BIOMED BIOTECHNOL, V0, P0, DOI DOI 10.1155/2010/737385
   Srivastava S, 2009, HUM MOL GENET, V18, P1805, DOI 10.1093/hmg/ddp093
   Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015
   Subrarnaniam V, 2008, BBA-BIOENERGETICS, V1777, P666, DOI 10.1016/j.bbabio.2008.03.015
   Swalwell H, 2008, EUR J HUM GENET, V16, P1265, DOI 10.1038/ejhg.2008.65
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200
   van der Westhuizen FH, 2003, NEUROPEDIATRICS, V34, P14, DOI 10.1055/s-2003-38618
   van Waveren C, 2008, BMC GENOMICS, V9, P0, DOI 10.1186/1471-2164-9-18
   Vawter MP, 2006, MOL PSYCHIATR, V11, P663, DOI 10.1038/sj.mp.4001830
   Veatch JR, 2009, CELL, V137, P1247, DOI 10.1016/j.cell.2009.04.014
   Vesce S, 2005, J BIOL CHEM, V280, P38720, DOI 10.1074/jbc.M506575200
   Voss JG, 2008, BIOL RES NURS, V9, P272, DOI 10.1177/1099800408315160
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wallace DC, 2010, DEV DISABIL RES REV, V16, P114, DOI 10.1002/ddrr.113
   Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wenz T, 2010, DEV DISABIL RES REV, V16, P219, DOI 10.1002/ddrr.109
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zheng B, 2010, SCI TRANSL MED, V2, P0, DOI 10.1126/scitranslmed.3001059
NR 91
TC 14
Z9 15
U1 1
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD JUL 1
PY 2012
VL 88
IS 4
BP 285
EP 293
DI 10.1016/j.brainresbull.2011.07.018
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 981RW
UT WOS:000306988400001
PM 21856382
DA 2024-11-01
ER

PT J
AU Lee, S
   Han, MJ
   Lee, KS
   Back, SC
   Hwang, D
   Kim, HY
   Shin, JH
   Suh, SP
   Ryang, DW
   Kim, HR
   Shin, MG
AF Lee, Soong
   Han, Moon-Jong
   Lee, Ki-Sang
   Back, Seung-Chul
   Hwang, David
   Kim, Hwan-Young
   Shin, Jong-Hee
   Suh, Soon-Pal
   Ryang, Dong-Wook
   Kim, Hye-Ran
   Shin, Myung-Geun
TI Frequent Occurrence of Mitochondrial DNA Mutations in Barrett's Metaplasia without the Presence of Dysplasia
SO PLOS ONE
LA English
DT Article
ID esophageal adenocarcinoma; atrial-fibrillation; cancer; progression; tissue; muscle
AB Background: Barrett's esophagus (BE) is one of the most common premalignant lesions and can progress to esophageal adenocarcinoma (EA). The numerous molecular events may play a role in the neoplastic transformation of Barrett's mucosa such as the change of DNA ploidy, p53 mutation and alteration of adhesion molecules. However, the molecular mechanism of the progression of BE to EA remains unclear and most studies of mitochondrial DNA (mtDNA) mutations in BE have performed on BE with the presence of dysplasia. Methods/Findings: Thus, the current study is to investigate new molecular events (Barrett's esophageal tissue-specific-mtDNA alterations/instabilities) in mitochondrial genome and causative factors for their alterations using the corresponding adjacent normal mucosal tissue (NT) and tissue (BT) from 34 patients having Barrett's metaplasia without the presence of dysplasia. Eighteen patients (53%) exhibited mtDNA mutations which were not found in adjacent NT. mtDNA copy number was about 3 times higher in BT than in adjacent NT. The activity of the mitochondrial respiratory chain enzyme complexes in tissues from Barrett's metaplasia without the presence of dysplasia was impaired. Reactive oxygen species (ROS) level in BT was significantly higher than those in corresponding samples. Conclusion/Significance: High ROS level in BT may contribute to the development of mtDNA mutations, which may play a crucial role in disease progression and tumorigenesis in BE.
C1 [Lee, Soong; Han, Moon-Jong; Lee, Ki-Sang; Back, Seung-Chul; Hwang, David] Seonam Univ, Coll Med, Dept Internal Med, Namwon, South Korea.
   [Kim, Hwan-Young; Shin, Jong-Hee; Suh, Soon-Pal; Ryang, Dong-Wook; Shin, Myung-Geun] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea.
   [Kim, Hwan-Young; Shin, Jong-Hee; Suh, Soon-Pal; Ryang, Dong-Wook; Shin, Myung-Geun] Chonnam Natl Univ, Dept Lab Med, Hwasun, South Korea.
   [Kim, Hye-Ran] Chonnam Natl Univ, Ctr Biomed Human Resources, Brain Korea Project 21, Kwangju, South Korea.
   [Kim, Hye-Ran; Shin, Myung-Geun] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea.
   [Kim, Hye-Ran; Shin, Myung-Geun] Chonnam Natl Univ, Sch Med, Environm Hlth Ctr Childhood Leukemia & Canc, Hwasun, South Korea.
C3 Seonam University; Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University
RP Lee, S (corresponding author), Seonam Univ, Coll Med, Dept Internal Med, Namwon, South Korea.
EM KimHR@chonnam.ac.kr; mgshin@chonnam.ac.kr
FU Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2010-0024326]
CR Baumann S, 2006, INT J CANCER, V119, P264, DOI 10.1002/ijc.21848
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   Fléjou JF, 2005, GUT, V54, PI6, DOI 10.1136/gut.2004.041525
   HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jankowski JA, 2002, GASTROENTEROLOGY, V122, P588, DOI 10.1053/gast.2002.31599
   Lee JS, 2001, MUTAT RES-FUND MOL M, V480, P189, DOI 10.1016/S0027-5107(01)00199-3
   Lee S, 2007, CLIN CHEM, V53, P1390, DOI 10.1373/clinchem.2007.088047
   Lin PH, 2003, FREE RADICAL BIO MED, V35, P1310, DOI 10.1016/j.freeradbiomed.2003.07.002
   Nishikawa M, 2005, BRIT J CANCER, V93, P331, DOI 10.1038/sj.bjc.6602664
   Park HW, 2007, J CLIN PATHOL, V60, P948, DOI 10.1136/jcp.2007.047134
   Park SY, 2009, MITOCHONDRION, V9, P318, DOI 10.1016/j.mito.2009.04.006
   PERA M, 1993, ANN THORAC SURG, V56, P1191, DOI 10.1016/0003-4975(95)90050-0
   Sharma P, 2006, ENDOSCOPY, V38, P1206, DOI 10.1055/s-2006-944974
   Shin MG, 2007, LEUKEMIA, V21, P369, DOI 10.1038/sj.leu.2404502
   Shin MG, 2006, ELECTROPHORESIS, V27, P1331, DOI 10.1002/elps.200500551
   Shin MG, 2004, BLOOD, V103, P553, DOI 10.1182/blood-2003-05-1724
   Sommerer F, 2004, ONCOGENE, V23, P554, DOI 10.1038/sj.onc.1207189
   Sui GP, 2006, MOL CANCER, V5, P0, DOI 10.1186/1476-4598-5-73
   Tan BHL, 2009, EUR J CANCER, V45, P736, DOI 10.1016/j.ejca.2009.01.013
   Tischoff Iris, 2008, EXPERT REV GASTROENTEROL HEPATOL, V2, P653, DOI 10.1586/17474124.2.5.653
   Zagorowicz E, 2007, POSTGRAD MED J, V83, P529, DOI 10.1136/pgmj.2006.052910
NR 23
TC 12
Z9 12
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2012
VL 7
IS 5
BP 
EP 
DI 10.1371/journal.pone.0037571
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959VQ
UT WOS:000305345300053
PM 22629421
DA 2024-11-01
ER

PT J
AU Venegas, V
   Halberg, MC
AF Venegas, Victor
   Halberg, Michelle C.
TI Measurement of Mitochondrial DNA Copy Number
SO MITOCHONDRIAL DISORDERS: BIOCHEMICAL AND MOLECULAR ANALYSIS
LA English
DT Article; Book Chapter
DE mtDNA copy number; mtDNA content; mtDNA qPCR; Quantification of mtDNA content; mtDNA depletion
ID comparative genomic hybridization; sucla2 mutations; depletion; gene; encephalomyopathy; disorders; encephalopathy; deficiency; rrm2b
AB Mitochondrial disorders are complex and heterogeneous diseases that may be caused by molecular defects in either the nuclear or Mitochondrial genome. The biosynthesis and maintenance of the integrity of the mitochondrial genome is solely dependent on a number of nuclear proteins. Defects in these nuclear genes can lead to mitochondria! DNA (mrDNA) depletion (Spinazzola et al. Biosci Rep 27:39-51, 2007). The mitochondria! DNA (mtDNA) depletion syndromes (MDDSs) arc autosomal recessive disorders characterized by a significant reduction in mtDNA content. These genes include POLG, DGUOK, TK2, MPV17, SUCLA2, SUCLG1, RRM2B, and C10orf2, all nine genes have mutations reported to cause various forms of MDDSs. In this chapter, we outline the real-time quantitative polymerase chain reaction (qPCR) analysis of mtDNA content in muscle or liver tissues.
C1 [Venegas, Victor; Halberg, Michelle C.] Baylor Coll Med, Dept Mol & Human Genet, Med Genet Labs, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Venegas, V (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Med Genet Labs, Houston, TX 77030 USA.
CR Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Lee NC, 2009, ARCH DIS CHILD, V94, P55, DOI 10.1136/adc.2008.139584
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Shanske S, 2004, MITOCHONDRION, V4, P403, DOI 10.1016/j.mito.2004.07.026
   Spinazzola A, 2009, J INTERN MED, V265, P174, DOI 10.1111/j.1365-2796.2008.02059.x
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Tay SKH, 2004, ARCH NEUROL-CHICAGO, V61, P950, DOI 10.1001/archneur.61.6.950
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 22
TC 120
Z9 134
U1 0
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
EI 
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PD JUN 15
PY 2012
VL 837
IS 
BP 327
EP 335
DI 10.1007/978-1-61779-504-6_22
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BAG90
UT WOS:000304125100022
PM 22215558
DA 2024-11-01
ER

PT J
AU Read, JL
   Whittaker, RG
   Miller, N
   Clark, S
   Taylor, R
   McFarland, R
   Turnbull, D
AF Read, Jennifer L.
   Whittaker, Roger G.
   Miller, Nick
   Clark, Sue
   Taylor, Robert
   McFarland, Robert
   Turnbull, Douglass
TI Prevalence and severity of voice and swallowing difficulties in mitochondrial disease
SO INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS
LA English
DT Article
DE Mitochondrial disease; voice; swallowing
ID handicap index; dna mutations; patient; epidemiology
AB Background| Mutations of mitochondrial DNA(mtDNA) cause a broad spectrum of clinical phenotypes. Anecdotal evidence suggests that voice and swallow problems are a common feature of these diseases. Aims: To characterize accurately the prevalence and severity of voice and swallow problems in a large cohort of patients with mitochondrial disease. Methods & Procedures: Patients with proven mitochondrial disease were sent validated questionnaires to assess both voice and swallow function. The presence of voice and swallow symptoms was correlated with other clinical features of mitochondrial disease in affected patients. Outcomes & Results: From the original 177 patients contacted, 98 swallowing status questionnaires and 96 Voice Handicap Index questionnaires were returned, response rates of 55% and 54%, respectively. Swallow: 48% of patients reported more difficulties with swallowing than control participants. Patients with single mtDNA deletions were most likely to report problems (65.2%), with patients with an m. 8344A>G point mutation least likely (33.3%). All genotypes had a mean severity score in excess of the normal range, the highest mean score being found in the single large-scale mtDNA deletion group (10.12), the lowest in the m. 3243A>G group (5.56) Voice; 48% of patients reported some difficulty with voice. Patients with single large-scale deletions showed the highest prevalence (65.2%), patients with the m. 3243A>G mutation the lowest (33%). The most severe voice difficulties were reported by patients with an m. 8344A>G point mutation. Patients with an m. 3243A>G point mutation had the mildest and lowest incidence of voice problems. All genotypes scored outside of the normal range expected on the VHI overall (>= 11.5 in control trials). Patients with an m. 8344A>G point mutation reported a significantly higher degree of physical voice handicap than m. 3243A>G patients (13.13 versus 4.40, p = 0.02). In patients with either single or multiple mtDNA deletions the likely pathophysiological mechanism is of proximal muscle weakness, whereas in patients with the m. 8344A>G mutation cerebellar ataxia is the likely cause. Conclusions & Implications: Dysphagia and dysarthria have been identified as symptoms in previous research, however the prevalence and pathophysiology of these symptoms have not been explored. This paper indicates that voice and swallow problems are a common, though predominantly mild feature of mitochondrial disease and that there is a core group of pathophysiological symptoms linked to the presence of voice and swallowing problems. This paper recommends early referral to speech and language therapists to identify emerging dysphonia and dysphagia and to provide appropriate intervention.
C1 [Read, Jennifer L.] Manchester Metropolitan Univ, Dept Hlth Profess, Manchester M13 OJA, Lancs, England.
   [Whittaker, Roger G.; Clark, Sue; Taylor, Robert; McFarland, Robert; Turnbull, Douglass] Newcastle Univ, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Miller, Nick] Newcastle Univ, Inst Hlth & Soc Speech & Language Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Manchester Metropolitan University; Newcastle University - UK; Newcastle University - UK
RP Read, JL (corresponding author), Manchester Metropolitan Univ, Dept Hlth Profess, Elizabeth Gaskell Site, Manchester M13 OJA, Lancs, England.
EM j.read@mmu.ac.uk
FU EUMITOCOMBAT; MRC [G0700718, G0800674] Funding Source: UKRI
CR Amir O, 2006, J VOICE, V20, P318, DOI 10.1016/j.jvoice.2005.08.006
   Behrman A, 2008, J SPEECH LANG HEAR R, V51, P350, DOI 10.1044/1092-4388(2008/026)
   CHINNERY PF, 1999, AM J MED GENET, V106, P94
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1999, LANCET, V354, P0
   Helidoni ME, 2010, J VOICE, V24, P221, DOI 10.1016/j.jvoice.2008.06.005
   Jacobson BH, 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0603.66
   Malki KH, 2010, EUR ARCH OTO-RHINO-L, V267, P1743, DOI 10.1007/s00405-010-1296-x
   Nagashima T, 2001, NEUROMUSCULAR DISORD, V11, P470, DOI 10.1016/S0960-8966(01)00190-0
   Okun MS, 2004, AM J OPHTHALMOL, V137, P951, DOI 10.1016/j.ajo.2003.10.046
   Peeters AJGE, 2004, EUR ARCH OTO-RHINO-L, V261, P534, DOI 10.1007/s00405-003-0697-5
   Peng Y, 2003, MOVEMENT DISORD, V18, P716, DOI 10.1002/mds.10428
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Wallace AL, 2000, GASTROENTEROLOGY, V118, P678, DOI 10.1016/S0016-5085(00)70137-5
NR 16
TC 9
Z9 10
U1 0
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-2822
EI 1460-6984
J9 INT J LANG COMM DIS
JI Int. J. Lang. Commun. Disord.
PD JAN-FEB 15
PY 2012
VL 47
IS 1
BP 106
EP 111
DI 10.1111/j.1460-6984.2011.00072.x
PG 6
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 892KI
UT WOS:000300284700010
PM 22268906
DA 2024-11-01
ER

PT J
AU Menezes, MP
   Ouvrier, RA
AF Menezes, Manoj P.
   Ouvrier, Robert A.
TI Peripheral neuropathy associated with mitochondrial disease in children
SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
LA English
DT Review
ID marie-tooth-disease; progressive external ophthalmoplegia; pyruvate-dehydrogenase deficiency; onset spinocerebellar ataxia; recessive twinkle mutations; hereditary optic neuropathy; spinal-cord involvement; kearns-sayre syndrome; c-oxidase deficiency; dna-polymerase-gamma
AB Mitochondrial diseases in children are often associated with a peripheral neuropathy but the presence of the neuropathy is under-recognized because of the overwhelming involvement of the central nervous system (CNS). These mitochondrial neuropathies are heterogeneous in their clinical, neurophysiological, and histopathological characteristics. In this article, we provide a comprehensive review of childhood mitochondrial neuropathy. Early recognition of neuropathy may help with the identification of the mitochondrial syndrome. While it is not definite that the characteristics of the neuropathy would help in directing genetic testing without the requirement for invasive skin, muscle or liver biopsies, there appears to be some evidence for this hypothesis in Leigh syndrome, in which nuclear SURF1 mutations cause a demyelinating neuropathy and mitochondrial DNA MTATP6 mutations cause an axonal neuropathy. POLG1 mutations, especially when associated with late-onset phenotypes, appear to cause a predominantly sensory neuropathy with prominent ataxia. The identification of the peripheral neuropathy also helps to target genetic testing in the mitochondrial optic neuropathies. Although often subclinical, the peripheral neuropathy may occasionally be symptomatic and cause significant disability. Where it is symptomatic, recognition of the neuropathy will help the early institution of rehabilitative therapy. We therefore suggest that nerve conduction studies should be a part of the early evaluation of children with suspected mitochondrial disease.
C1 [Menezes, Manoj P.; Ouvrier, Robert A.] Childrens Hosp Westmead, Inst Neurosci & Muscle Res, Sydney, NSW 2145, Australia.
C3 University of Sydney; NSW Health; The Children's Hospital at Westmead
RP Menezes, MP (corresponding author), Childrens Hosp Westmead, Inst Neurosci & Muscle Res, Sydney, NSW 2145, Australia.
EM drmanojpm@yahoo.co.in
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   APPENZELLER O, 1976, ARCH NEUROL-CHICAGO, V33, P733, DOI 10.1001/archneur.1976.00500110001001
   Barkovich AJ, 2007, J NEURORADIOLOGY, V34, P75, DOI 10.1016/j.neurad.2007.01.125
   Bedlack RS, 2004, MUSCLE NERVE, V29, P364, DOI 10.1002/mus.10546
   BONNE G, 1993, PEDIATR RES, V33, P284, DOI 10.1203/00006450-199303000-00016
   Bouillot S, 2002, J PERIPHER NERV SYST, V7, P213, DOI 10.1046/j.1529-8027.2002.02027.x
   Bruno C, 2002, J CHILD NEUROL, V17, P233, DOI 10.1177/088307380201700318
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Cassereau J, 2009, NEUROGENETICS, V10, P145, DOI 10.1007/s10048-008-0166-9
   Castagna AE, 2007, AM J MED GENET A, V143A, P808, DOI 10.1002/ajmg.a.31637
   CHABROL B, 1994, J CHILD NEUROL, V9, P52, DOI 10.1177/088307389400900113
   Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   Childs AM, 2007, NEUROPEDIATRICS, V38, P313, DOI 10.1055/s-2008-1065355
   Claramunt R, 2005, J MED GENET, V42, P358, DOI 10.1136/jmg.2004.022178
   Colomer J, 2000, REV NEUROLOGIA, V30, P1117, DOI 10.33588/rn.3012.2000079
   Craig K, 2007, J MED GENET, V44, P797, DOI 10.1136/jmg.2007.052902
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   den Boer MEJ, 2003, J PEDIATR-US, V142, P684, DOI 10.1067/mpd.2003.231
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Di Rocco M, 2000, EUR J PAEDIATR NEUROL, V4, P115, DOI 10.1053/ejpn.2000.0278
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Erol I, 2009, NEUROMUSCULAR DISORD, V19, P275, DOI 10.1016/j.nmd.2009.01.012
   EYMARD B, 1991, REV NEUROL, V147, P508
   FEDERICO A, 1990, EUR NEUROL, V30, P123
   Távora DGF, 2007, ARQ NEURO-PSIQUIAT, V65, P506, DOI 10.1590/S0004-282X2007000300028
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   Finsterer J, 2011, J NEUROL SCI, V304, P9, DOI 10.1016/j.jns.2011.02.012
   Fujii T, 1998, PEDIATR NEUROL, V18, P275, DOI 10.1016/S0887-8994(97)00187-2
   Funalot B, 2009, REV NEUROL-FRANCE, V165, P1118, DOI 10.1016/j.neurol.2009.10.001
   Gilhuis HJ, 2006, NEUROMUSCULAR DISORD, V16, P394, DOI 10.1016/j.nmd.2006.03.006
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Halter J, 2011, BONE MARROW TRANSPL, V46, P330, DOI 10.1038/bmt.2010.100
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Isohanni P, 2010, J MED GENET, V47, P66, DOI 10.1136/jmg.2009.068221
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Marsac C, 1997, HUM GENET, V99, P785, DOI 10.1007/s004390050449
   McDonald DGM, 2002, AM J MED GENET, V111, P191, DOI 10.1002/ajmg.10522
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   McLaughlin HM, 2010, AM J HUM GENET, V87, P560, DOI 10.1016/j.ajhg.2010.09.008
   Miyake N, 2011, CLIN GENET, V80, P293, DOI 10.1111/j.1399-0004.2011.01644.x
   MOLNAR M, 1995, NEUROPATH APPL NEURO, V21, P432, DOI 10.1111/j.1365-2990.1995.tb01080.x
   Morava E, 2009, MITOCHONDRION, V9, P438, DOI 10.1016/j.mito.2009.08.003
   Nelis E, 2002, NEUROLOGY, V59, P1865, DOI 10.1212/01.WNL.0000036272.36047.54
   Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2008, J INHERIT METAB DIS, V31, P226, DOI 10.1007/s10545-008-0828-7
   OUVRIER RA, 1982, J NEUROL SCI, V55, P137, DOI 10.1016/0022-510X(82)90095-8
   Pandolfo M, 2009, J NEUROL, V256, P9, DOI 10.1007/s00415-009-1003-2
   Pandolfo M, 2009, J NEUROL, V256, P3, DOI 10.1007/s00415-009-1002-3
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   Patel KP, 2012, MOL GENET METAB, V105, P34, DOI 10.1016/j.ymgme.2011.09.032
   Perez-Atayde AR, 1998, AM J SURG PATHOL, V22, P1141, DOI 10.1097/00000478-199809000-00014
   Rojo A, 2006, ACTA NEUROPATHOL, V111, P610, DOI 10.1007/s00401-006-0040-5
   Saneto RP, 2008, MITOCHONDRION, V8, P396, DOI 10.1016/j.mito.2008.05.003
   Santoro L, 2000, NEUROMUSCULAR DISORD, V10, P450, DOI 10.1016/S0960-8966(99)00122-4
   Santoro L, 1999, J NEUROL NEUROSUR PS, V66, P93, DOI 10.1136/jnnp.66.1.93
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   SCHRODER JM, 1993, BRAIN PATHOL, V3, P177, DOI 10.1111/j.1750-3639.1993.tb00742.x
   Sedel F, 2008, J NEUROL NEUROSUR PS, V79, P846, DOI 10.1136/jnnp.2007.136630
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Song ZY, 2009, MOL BIOL CELL, V20, P3525, DOI 10.1091/mbc.E09-03-0252
   Spiekerkoetter U, 2004, MUSCLE NERVE, V29, P66, DOI 10.1002/mus.10500
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65, P1108, DOI 10.1001/archneur.65.8.1108
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Stickler DE, 2006, PEDIATR NEUROL, V34, P127, DOI 10.1016/j.pediatrneurol.2005.08.006
   Stickler DE, 2003, J CHILD NEUROL, V18, P574, DOI 10.1177/08830738030180081101
   Thorburn DR, 2003, GENE REV, V0, P0
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Vallat JM, 2008, J NEUROPATH EXP NEUR, V67, P1097, DOI 10.1097/NEN.0b013e31818b6cbc
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VANERVEN PMM, 1987, J NEUROL, V234, P215
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2009, J MED GENET, V46, P145, DOI 10.1136/jmg.2007.054270
   Zanssen S, 1998, CLIN NEUROPATHOL, V17, P291
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 95
TC 25
Z9 27
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1622
EI 
J9 DEV MED CHILD NEUROL
JI Dev. Med. Child Neurol.
PD MAY 15
PY 2012
VL 54
IS 5
BP 407
EP 414
DI 10.1111/j.1469-8749.2012.04271.x
PG 8
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 922KP
UT WOS:000302546100011
PM 22435634
DA 2024-11-01
ER

PT J
AU Garone, C
   Rubio, JC
   Calvo, SE
   Naini, A
   Tanji, K
   DiMauro, S
   Mootha, VK
   Hirano, M
AF Garone, Caterina
   Carlos Rubio, Juan
   Calvo, Sarah E.
   Naini, Ali
   Tanji, Kurenai
   DiMauro, Salvatore
   Mootha, Vamsi K.
   Hirano, Michio
TI <i>MPV17</i> Mutations Causing Adult-Onset Multisystemic Disorder With Multiple Mitochondrial DNA Deletions
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; depletion syndrome; polg mutations; navajo neurohepatopathy; gene; protein; parkinsonism; disease
AB Objective: To identify the cause of an adult-onset multisystemic disease with multiple deletions of mitochondrial DNA (mtDNA). Design: Case report. Setting: University hospitals. Patient: A 65-year-old man with axonal sensorimotor peripheral neuropathy, ptosis, ophthalmoparesis, diabetes mellitus, exercise intolerance, steatohepatopathy, depression, parkinsonism, and gastrointestinal dysmotility. Results: Skeletal muscle biopsy revealed ragged-red and cytochrome-c oxidase-deficient fibers, and Southern blot analysis showed multiple mtDNA deletions. No deletions were detected in fibroblasts, and the results of quantitative polymerase chain reaction showed that the amount of mtDNA was normal in both muscle and fibroblasts. Exome sequencing using a mitochondrial library revealed compound heterozygous MPV17 mutations (p.LysMet88-89MetLeu and p.Leu143*), a novel cause of mtDNA multiple deletions. Conclusions: In addition to causing juvenile-onset disorders with mtDNA depletion, MPV17 mutations can cause adult-onset multisystemic disease with multiple mtDNA deletions. Arch Neurol. 2012; 69(12): 1648-1651. Published online September 10, 2012. doi:10.1001/archneurol.2012.405
C1 [Garone, Caterina; Carlos Rubio, Juan; Naini, Ali; DiMauro, Salvatore; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] MIT, Cambridge, MA 02139 USA.
   [Garone, Caterina] Univ Turin, Joint PhD Program, I-10124 Turin, Italy.
   [Garone, Caterina] Univ Bologna, Joint PhD Program, I-40126 Bologna, Italy.
   [Carlos Rubio, Juan] Hosp 12 Octubre, Unidad Genom, Ctr Invest, E-28041 Madrid, Spain.
C3 Columbia University; Columbia University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); University of Turin; University of Bologna; Hospital Universitario 12 de Octubre
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 630 W 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@columbia.edu
FU Associazione Malattie Metaboliche Congenite ereditarie; National Institutes of Health [R01HD056103, 1R01HD057543, U54NS078059]; Muscular Dystrophy Association; Marriott Mitochondrial Disorder Clinical Research Fund
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Calvo SE, 2012, SCI TRANSL MED, V4, P0, DOI 10.1126/scitranslmed.3003310
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Holve S, 1999, J PEDIATR-US, V135, P482, DOI 10.1016/S0022-3476(99)70172-1
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   KARASAWA M, 1993, HUM MOL GENET, V2, P1829, DOI 10.1093/hmg/2.11.1829
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65, P1108, DOI 10.1001/archneur.65.8.1108
   Spinazzola A, 2009, ADV EXP MED BIOL, V652, P69, DOI 10.1007/978-90-481-2813-6_6
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Vu TH, 2001, HEPATOLOGY, V34, P116, DOI 10.1053/jhep.2001.25921
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
NR 21
TC 59
Z9 61
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD DEC 15
PY 2012
VL 69
IS 12
BP 1648
EP 1651
DI 10.1001/archneurol.2012.405
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 052KI
UT WOS:000312196100018
PM 22964873
DA 2024-11-01
ER

PT J
AU Vafai, SB
   Mootha, VK
AF Vafai, Scott B.
   Mootha, Vamsi K.
TI Mitochondrial disorders as windows into an ancient organelle
SO NATURE
LA English
DT Review
ID skeletal-muscle mitochondria; oxidative-phosphorylation; membrane-protein; inner membrane; mutation; dna; disease; cells; ca2+; complexes
AB Much of our current knowledge about mitochondria has come from studying patients who have respiratory chain disorders. These disorders comprise a large collection of individually rare syndromes, each presenting in a unique and often devastating way. In recent years, there has been great progress in defining their genetic basis, but we still know little about the cascade of events that gives rise to such diverse pathology. Here, we review these disorders and explore them in the context of a contemporary understanding of mitochondrial evolution, biochemistry and genetics. Fully deciphering their pathogenesis is a challenging next step that will inspire the development of drug treatments for rare and common diseases.
C1 [Vafai, Scott B.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Vafai, Scott B.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Med, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Vafai, Scott B.; Mootha, Vamsi K.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02142 USA.
   [Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School
RP Mootha, VK (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Ctr Human Genet Res, Boston, MA 02114 USA.
EM vamsi@hms.harvard.edu
FU National Institutes of Health
CR Allen JF, 2003, PHILOS T R SOC B, V358, P19, DOI 10.1098/rstb.2002.1191
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094
   Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53
   BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638
   Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Bitner-Glindzicz M, 2009, NEW ENGL J MED, V360, P640, DOI 10.1056/NEJMc0806396
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Calvo SE, 2012, SCI TRANSL MED, V4, P0, DOI 10.1126/scitranslmed.3003310
   Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720
   Chan DC, 2012, ANN REV GENET, V0, P0
   CHANCE B, 1955, NATURE, V176, P250, DOI 10.1038/176250a0
   CHANCE B, 1955, J BIOL CHEM, V217, P409
   COGSWELL AM, 1993, AM J PHYSIOL, V264, PC383, DOI 10.1152/ajpcell.1993.264.2.C383
   Copeland JM, 2009, CURR BIOL, V19, P1591, DOI 10.1016/j.cub.2009.08.016
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200
   De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   Efremov RG, 2010, NATURE, V465, P441, DOI 10.1038/nature09066
   ERNSTER L, 1959, NATURE, V184, P1851, DOI 10.1038/1841851a0
   Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508
   Glancy B, 2012, BIOCHEMISTRY-US, V51, P2959, DOI 10.1021/bi2018909
   Gohil VM, 2010, NAT BIOTECHNOL, V28, P249, DOI 10.1038/nbt.1606
   GROEN AK, 1982, J BIOL CHEM, V257, P2754
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010
   Hartwell L, 2004, SCIENCE, V303, P774, DOI 10.1126/science.1094731
   Haynes CM, 2010, J CELL SCI, V123, P3849, DOI 10.1242/jcs.075119
   HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x
   Hobbs AEA, 2001, J CELL BIOL, V152, P401, DOI 10.1083/jcb.152.2.401
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hoppins S, 2011, J CELL BIOL, V195, P323, DOI 10.1083/jcb.201107053
   Hunte C, 2010, SCIENCE, V329, P448, DOI 10.1126/science.1191046
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   Johnson DT, 2007, AM J PHYSIOL-CELL PH, V292, PC698, DOI 10.1152/ajpcell.00109.2006
   Kacser H, 1973, SYMP SOC EXP BIOL, V27, P65
   Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200
   Kirby DM, 2008, TWIN RES HUM GENET, V11, P395, DOI 10.1375/twin.11.4.395
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Koopman WJH, 2012, NEW ENGL J MED, V366, P1132, DOI 10.1056/NEJMra1012478
   Kornmann B, 2009, SCIENCE, V325, P477, DOI 10.1126/science.1175088
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056
   Lieber DS, 2012, BMC MED GENET, V13, P0, DOI 10.1186/1471-2350-13-3
   MacAskill AF, 2010, TRENDS CELL BIOL, V20, P102, DOI 10.1016/j.tcb.2009.11.002
   Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006
   MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702
   Miceli Michael V, 2012, FRONTIERS IN GENETICS, V2, P102, DOI 10.3389/fgene.2011.00102
   Michelakis ED, 2010, SCI TRANSL MED, V2, P0, DOI 10.1126/scitranslmed.3000677
   Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1
   MORAIS R, 1982, CAN J BIOCHEM CELL B, V60, P290, DOI 10.1139/o82-035
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Munnich A, 2006, SCRIVERS ONLINE META, V0, P0
   Nilsson R, 2009, CELL METAB, V10, P119, DOI 10.1016/j.cmet.2009.06.012
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nouws J, 2010, CELL METAB, V12, P283, DOI 10.1016/j.cmet.2010.08.002
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607
   Owusu-Ansah E, 2008, NAT GENET, V40, P356, DOI 10.1038/ng.2007.50
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Park SG, 2008, P NATL ACAD SCI USA, V105, P11043, DOI 10.1073/pnas.0802862105
   Perocchi F, 2010, NATURE, V467, P291, DOI 10.1038/nature09358
   Pfeffer G, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub3
   Pierron D, 2012, BBA-BIOENERGETICS, V1817, P590, DOI 10.1016/j.bbabio.2011.07.007
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Reeves MB, 2007, SCIENCE, V316, P1345, DOI 10.1126/science.1142984
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Rugarli EI, 2012, EMBO J, V31, P1336, DOI 10.1038/emboj.2012.38
   RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3
   Sadun A, 1998, TRANS AM OPHTHALMOL SOC, V96, P881
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   Schägger H, 2001, J BIOL CHEM, V276, P37861
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Shaham O, 2010, P NATL ACAD SCI USA, V107, P1571, DOI 10.1073/pnas.0906039107
   Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1
   Shoffner J, 2006, SCRIVERS ONLINE META, V0, P0
   Shoubridge EA, 2012, CELL METAB, V15, P271, DOI 10.1016/j.cmet.2012.02.009
   Shutt TE, 2006, TRENDS GENET, V22, P90, DOI 10.1016/j.tig.2005.11.007
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Spiegelman Bruce M, 2007, NOVARTIS FOUND SYMP, V287, P60
   Stacpoole PW, 2011, MITOCHONDRION, V11, P679, DOI 10.1016/j.mito.2011.05.002
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Szklarczyk R, 2010, PROTEOMICS, V10, P4012, DOI 10.1002/pmic.201000329
   Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Vasta V, 2012, PEDIATR INT, V54, P585, DOI 10.1111/j.1442-200X.2012.03644.x
   Viscomi C, 2010, NAT MED, V16, P869, DOI 10.1038/nm.2188
   Vockley J, 2000, MOL GENET METAB, V71, P10, DOI 10.1006/mgme.2000.3066
   von Kleist-Retzow JC, 2007, EXP CELL RES, V313, P3076, DOI 10.1016/j.yexcr.2007.04.015
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Ward SM, 2000, J PHYSIOL-LONDON, V525, P355, DOI 10.1111/j.1469-7793.2000.t01-1-00355.x
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
   Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
NR 98
TC 547
Z9 624
U1 0
U2 121
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 15
PY 2012
VL 491
IS 7424
BP 374
EP 383
DI 10.1038/nature11707
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 036MY
UT WOS:000311031600034
PM 23151580
DA 2024-11-01
ER

PT J
AU Picard, M
   Jung, B
   Liang, F
   Azuelos, I
   Hussain, S
   Goldberg, P
   Godin, R
   Danialou, G
   Chaturvedi, R
   Rygiel, K
   Matecki, S
   Jaber, S
   Des Rosiers, C
   Karpati, G
   Ferri, L
   Burelle, Y
   Turnbull, DM
   Taivassalo, T
   Petrof, BJ
AF Picard, Martin
   Jung, Boris
   Liang, Feng
   Azuelos, Ilan
   Hussain, Sabah
   Goldberg, Peter
   Godin, Richard
   Danialou, Gawiyou
   Chaturvedi, Rakesh
   Rygiel, Karolina
   Matecki, Stefan
   Jaber, Samir
   Des Rosiers, Christine
   Karpati, George
   Ferri, Lorenzo
   Burelle, Yan
   Turnbull, Douglass M.
   Taivassalo, Tanja
   Petrof, Basil J.
TI Mitochondrial Dysfunction and Lipid Accumulation in the Human Diaphragm during Mechanical Ventilation
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE ventilator-induced diaphragmatic dysfunction; oxidative stress; mitochondrial DNA; metabolic oversupply; diaphragmatic fatigue
ID insulin-resistance; oxidative stress; dna deletions; muscle; failure; activation; exercise; sirt1; ampk; myopathy
AB Rationale: Mechanical ventilation (MV) is associated with adverse effects on the diaphragm, but the cellular basis for this phenomenon, referred to as ventilator-induced diaphragmatic dysfunction (VIDD), is poorly understood. Objectives: To determine whether mitochondrial function and cellular energy status are disrupted in human diaphragms after MV, and the role of mitochondria-derived oxidative stress in the development of VIDD. Methods: Diaphragm and biceps specimens obtained from brain-dead organ donors who underwent MV (15-176 h) and age-matched control subjects were compared regarding mitochondrial enzymatic function, mitochondrial DNA integrity, lipid content, and metabolic gene and protein expression. In addition, diaphragmatic force and oxidative stress after exposure to MV for 6 hours were evaluated in mice under different conditions. Measurements and Main Results: In human MV diaphragms, mitochondrial biogenesis and content were down-regulated, with a more specific defect of respiratory chain cytochrome-c oxidase. Laser capture microdissection of cytochrome-c oxidase deficient fibers revealed mitochondrial DNA deletions, consistent with damage from oxidative stress. Diaphragmatic lipid accumulation and responses of master cellular metabolic sensors (AMP-activated protein kinase and sirtuins) were consistent with energy substrate excess as a possible stimulus for these changes. In mice, induction of hyper-lipidemia worsened diaphragmatic oxidative stress during MV, whereas transgenic overexpression of a mitochondria-localized antioxidant (peroxiredoxin-3) was protective against VIDD. Conclusions: Our data suggest that mitochondrial dysfunction lies at the nexus between oxidative stress and the impaired diaphragmatic contractility that develops during MV. Energy substrate oversupply relative to demand, resulting from diaphragmatic inactivity during MV, could play an important role in this process.
C1 [Picard, Martin; Jung, Boris; Liang, Feng; Azuelos, Ilan; Hussain, Sabah; Goldberg, Peter; Danialou, Gawiyou; Petrof, Basil J.] McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada.
   [Picard, Martin; Taivassalo, Tanja] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ H2X 2P2, Canada.
   [Picard, Martin; Taivassalo, Tanja] McGill Univ, Resp Epidemiol & Clin Res Unit, Montreal, PQ H2X 2P2, Canada.
   [Karpati, George; Taivassalo, Tanja] McGill Univ, Montreal Neurol Inst, Montreal, PQ H2X 2P2, Canada.
   [Jung, Boris; Jaber, Samir] St Eloi Hosp, Anesthesiol & Crit Care Dept, Montpellier, France.
   [Jung, Boris; Matecki, Stefan; Jaber, Samir] Ctr Hosp Univ, Arnaud de Villeneuve Hosp, INSERM, U1046, Montpellier, France.
   [Hussain, Sabah; Goldberg, Peter; Chaturvedi, Rakesh] McGill Univ Hlth Ctr, Crit Care Div, Montreal, PQ, Canada.
   [Hussain, Sabah; Goldberg, Peter; Chaturvedi, Rakesh] McGill Univ Hlth Ctr, Div Resp, Montreal, PQ, Canada.
   [Ferri, Lorenzo] McGill Univ Hlth Ctr, Dept Thorac Surg, Montreal, PQ, Canada.
   [Godin, Richard; Burelle, Yan] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada.
   [Des Rosiers, Christine] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
   Res Inst, Montreal, PQ, Canada.
   [Rygiel, Karolina; Turnbull, Douglass M.] Newcastle Univ, Ctr Brain Ageing & Vital, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 McGill University; McGill University; McGill University; McGill University; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal; Newcastle University - UK
RP Petrof, BJ (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.
EM basil.petrof@mcgill.ca
FU McGill University Health Centre Research Institute; Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Fonds de Recherche en Sante du Quebec; INSERM; Societe Francaise d'Anesthesie Reanimation; Association Pour l'Assistance et la Rehabilitation a Domicile; Newcastle University Centre for Brain Ageing and Vitality; MRC [G0700718] Funding Source: UKRI
CR Anderson EJ, 2009, J CLIN INVEST, V119, P573, DOI 10.1172/JCI37048
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bugger H, 2008, CLIN SCI, V114, P195, DOI 10.1042/CS20070166
   Camara AKS, 2010, ANTIOXID REDOX SIGN, V13, P279, DOI 10.1089/ars.2009.2788
   Cantó C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cantó C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   Cholette J, 2009, CRIT CARE MED, V37, PA434, DOI 10.1097/CCM.0b013e3181b6e760
   Divangahi M, 2009, PLOS GENET, V5, P0, DOI 10.1371/journal.pgen.1000586
   Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC
   Handschin C, 2008, NATURE, V454, P463, DOI 10.1038/nature07206
   Hermans G, 2007, AM J RESP CRIT CARE, V175, P480, DOI 10.1164/rccm.200605-665OC
   Hermans G, 2010, CRIT CARE, V14, P0, DOI 10.1186/cc9094
   Hoehn KL, 2009, P NATL ACAD SCI USA, V106, P17787, DOI 10.1073/pnas.0902380106
   Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634
   Hussain SNA, 2010, AM J RESP CRIT CARE, V182, P1377, DOI 10.1164/rccm.201002-0234OC
   Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026
   Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC
   Johnston TP, 2004, J CARDIOVASC PHARM, V43, P595, DOI 10.1097/00005344-200404000-00016
   Jung B, 2011, AM J RESP CRIT CARE, V183, P0
   Jung B, 2012, AM J RESP CRIT CARE, V185, P0
   Kane DA, 2010, FREE RADICAL BIO MED, V49, P1082, DOI 10.1016/j.freeradbiomed.2010.06.022
   Kavazis AN, 2009, FREE RADIC BIOL MED, V46, P842
   Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Kukidome D, 2006, DIABETES, V55, P120, DOI 10.2337/diabetes.55.1.120
   Lee HY, 2010, CELL METAB, V12, P668, DOI 10.1016/j.cmet.2010.11.004
   Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447
   Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804
   Matsushima S, 2006, CIRCULATION, V113, P1779, DOI 10.1161/CIRCULATIONAHA.105.582239
   Medikayala S, 2011, AM J PHYSIOL-CELL PH, V300, PC338, DOI 10.1152/ajpcell.00248.2010
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   Muoio DM, 2008, NAT REV MOL CELL BIO, V9, P193, DOI 10.1038/nrm2327
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Palmeira CM, 2007, TOXICOL APPL PHARM, V225, P214, DOI 10.1016/j.taap.2007.07.015
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petrof BJ, 2010, CURR OPIN CRIT CARE, V16, P19, DOI 10.1097/MCC.0b013e328334b166
   Picard M, 2011, AM J RESP CRIT CARE, V183, P0
   Powers SK, 2011, CRIT CARE MED, V39, P1749, DOI 10.1097/CCM.0b013e3182190b62
   Rachek LI, 2007, ENDOCRINOLOGY, V148, P293, DOI 10.1210/en.2006-0998
   Schrauwen P, 2010, BBA-MOL CELL BIOL L, V1801, P266, DOI 10.1016/j.bbalip.2009.09.011
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Tang HB, 2011, FASEB J, V25, P2921, DOI 10.1096/fj.11-183798
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002
   Tobin MJ, 2009, J APPL PHYSIOL, V107, P962, DOI 10.1152/japplphysiol.00165.2009
   Vassilakopoulos T, 1998, AM J RESP CRIT CARE, V158, P378, DOI 10.1164/ajrccm.158.2.9710084
   Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP
   Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011
   Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010
   Whidden MA, 2009, J APPL PHYSIOL, V106, P385, DOI 10.1152/japplphysiol.91106.2008
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yu TZ, 2008, CARDIOVASC RES, V79, P341, DOI 10.1093/cvr/cvn104
   ZALOGA GP, 1987, J CLIN ENDOCR METAB, V64, P1010, DOI 10.1210/jcem-64-5-1010
   Zergeroglu MA, 2003, J APPL PHYSIOL, V95, P1116, DOI 10.1152/japplphysiol.00824.2002
NR 61
TC 157
Z9 174
U1 0
U2 17
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD DEC 1
PY 2012
VL 186
IS 11
BP 1140
EP 1149
DI 10.1164/rccm.201206-0982OC
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 050GG
UT WOS:000312040600019
PM 23024021
DA 2024-11-01
ER

PT J
AU Lax, NZ
   Pienaar, IS
   Reeve, AK
   Hepplewhite, PD
   Jaros, E
   Taylor, RW
   Kalaria, RN
   Turnbull, DM
AF Lax, Nichola Z.
   Pienaar, Ilse S.
   Reeve, Amy K.
   Hepplewhite, Philippa D.
   Jaros, Evelyn
   Taylor, Robert W.
   Kalaria, Raj N.
   Turnbull, Doug M.
TI Microangiopathy in the cerebellum of patients with mitochondrial DNA disease
SO BRAIN
LA English
DT Article
DE mitochondrial diseases; mitochondrial DNA; microangiopathy; cerebellum; blood-brain barrier
ID stroke-like episodes; blood-brain-barrier; polymerase-gamma mutations; kearns-sayre-syndrome; lactic-acidosis; vascular involvement; alzheimers-disease; serum-protein; melas; cells
AB Neuropathological findings in mitochondrial DNA disease vary and are often dependent on the type of mitochondrial DNA defect. Many reports document neuronal cell loss, demyelination, gliosis and necrotic lesions in post-mortem material. However, previous studies highlight vascular abnormalities in patients harbouring mitochondrial DNA defects, particularly in those with the m.3243A > G mutation in whom stroke-like events are part of the mitochondrial encephalopathy lactic acidosis and stroke-like episodes syndrome. We investigated microangiopathic changes in the cerebellum of 16 genetically and clinically well-defined patients. Respiratory chain deficiency, high levels of mutated mitochondrial DNA and increased mitochondrial mass were present within the smooth muscle cells and endothelial cells comprising the vessel wall in patients. These changes were not limited to those harbouring the m.3243A > G mutation frequently associated with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, but were documented in patients harbouring m.8344A > G and autosomal recessive polymerase (DNA directed), gamma (POLG) mutations. In 8 of the 16 patients, multiple ischaemic-like lesions occurred in the cerebellar cortex suggestive of vascular smooth muscle cell dysfunction. Indeed, changes in vascular smooth muscle and endothelium distribution and cell size are indicative of vascular cell loss. We found evidence of blood-brain barrier breakdown characterized by plasma protein extravasation following fibrinogen and IgG immunohistochemistry. Reduced immunofluorescence was also observed using markers for endothelial tight junctions providing further evidence in support of blood-brain barrier breakdown. Understanding the structural and functional changes occurring in central nervous system microvessels in patients harbouring mitochondrial DNA defects will provide an important insight into mechanisms of neurodegeneration in mitochondrial DNA disease. Since therapeutic strategies targeting the central nervous system are limited, modulating vascular function presents an exciting opportunity to lessen the burden of disease in these patients.
C1 [Lax, Nichola Z.; Pienaar, Ilse S.; Reeve, Amy K.; Hepplewhite, Philippa D.; Taylor, Robert W.; Turnbull, Doug M.] Newcastle Univ, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Lax, Nichola Z.; Pienaar, Ilse S.; Reeve, Amy K.; Kalaria, Raj N.; Turnbull, Doug M.] Newcastle Univ, Inst Ageing & Hlth, Ctr Brain Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Jaros, Evelyn] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Jaros, Evelyn] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
   [Jaros, Evelyn] Newcastle Tyne Hosp NHS Fdn Trust, UK NIHR Biomed Res Ctr Ageing & Age Related Dis a, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust
RP Turnbull, DM (corresponding author), Newcastle Univ, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM doug.turnbull@newcastle.ac.uk
FU UK Medical Research Council [G0400074]; Wellcome Trust Centre for Mitochondrial Research [906919]; BBSRC; EPSRC; ESRC; MRC; Wellbeing Initiative [G0700718]; UK NIHR Biomedical Research Centre for Ageing and Age-related disease; UK NHS; MRC [G0500247, G1100540, G0400074, G0502157, G0900652, G0700718] Funding Source: UKRI
CR Alston CL, 2010, J NEUROL SCI, V298, P140, DOI 10.1016/j.jns.2010.08.014
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betts J, 2008, NEUROLOGY, V70, P1290, DOI 10.1212/01.wnl.0000308940.38092.74
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Betts-Henderson J, 2009, NEUROPATH APPL NEURO, V35, P120, DOI 10.1111/j.1365-2990.2008.00981.x
   BRADBURY MWB, 1993, EXP PHYSIOL, V78, P453, DOI 10.1113/expphysiol.1993.sp003698
   Clatterbuck RE, 2001, J NEUROL NEUROSUR PS, V71, P188, DOI 10.1136/jnnp.71.2.188
   Cortes-Canteli M, 2010, NEURON, V66, P695, DOI 10.1016/j.neuron.2010.05.014
   Davidson MM, 2009, MITOCHONDRION, V9, P463, DOI 10.1016/j.mito.2009.08.006
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Fuseler JW, 2006, MICROSC MICROANAL, V12, P269, DOI 10.1017/S1431927606060260
   Fuseler JW, 2010, MICROSC MICROANAL, V16, P73, DOI 10.1017/S143192760999119X
   Gilchrist JM, 1996, STROKE, V27, P1420, DOI 10.1161/01.STR.27.8.1420
   Glading A, 2007, J CELL BIOL, V179, P247, DOI 10.1083/jcb.200705175
   Guan YF, 2011, AM J PHYSIOL-CELL PH, V300, PC1404, DOI 10.1152/ajpcell.00270.2010
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Iizuka T, 2005, CURR NEUROVASC RES, V2, P29, DOI 10.2174/1567202052773544
   Iizuka T, 2003, NEUROLOGY, V61, P1238, DOI 10.1212/01.WNL.0000091888.26232.FE
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Iizuka T, 2007, J NEUROL SCI, V257, P126, DOI 10.1016/j.jns.2007.01.040
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koga Y, 2010, ANN NY ACAD SCI, V1201, P104, DOI 10.1111/j.1749-6632.2010.05624.x
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Lax NZ, 2012, BRAIN, V135, P62, DOI 10.1093/brain/awr326
   Lax NZ, 2012, J NEUROPATH EXP NEUR, V71, P148, DOI 10.1097/NEN.0b013e318244477d
   Love S, 1996, J PATHOL, V178, P182, DOI 10.1002/(SICI)1096-9896(199602)178:2<182::AID-PATH434>3.0.CO;2-6
   Matz PG, 2001, J CEREBR BLOOD F MET, V21, P921, DOI 10.1097/00004647-200108000-00004
   MORI S, 1991, LAB INVEST, V64, P345
   Munoz DG, 1997, ANN NY ACAD SCI, V826, P173, DOI 10.1111/j.1749-6632.1997.tb48469.x
   Ohama E, 1988, NO TO SHINKEI, V40, P109
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Östling S, 2003, INT J GERIATR PSYCH, V18, P983, DOI 10.1002/gps.997
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Szigeti K, 2004, ANN NEUROL, V56, P881, DOI 10.1002/ana.20302
   Tanji K, 1999, ANN NEUROL, V45, P377, DOI 10.1002/1531-8249(199903)45:3<377::AID-ANA14>3.0.CO;2-M
   Tanji K, 1999, J NEUROL SCI, V166, P64, DOI 10.1016/S0022-510X(99)00114-8
   Tanji K, 2003, ACTA NEUROPATHOL, V105, P69, DOI 10.1007/s00401-002-0604-y
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   TOKUNAGA M, 1993, ANN NEUROL, V33, P275, DOI 10.1002/ana.410330308
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Tzoulis C, 2010, BRAIN, V133, P1428, DOI 10.1093/brain/awq067
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yamamoto Y, 2009, STROKE, V40, P2004, DOI 10.1161/STROKEAHA.108.528299
NR 50
TC 37
Z9 39
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD JUN 15
PY 2012
VL 135
IS 
BP 1736
EP 1750
DI 10.1093/brain/aws110
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 948YC
UT WOS:000304538900009
PM 22577219
DA 2024-11-01
ER

PT J
AU Vital, A
   Vital, C
AF Vital, Anne
   Vital, Claude
TI Mitochondria and Peripheral Neuropathies
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Review
DE Ganglioside-induced differentiation-associated protein 1; Mitochondria; Mitofusin 2; Peripheral neuropathy; Peripheral nerve biopsy; Polymerase gamma 1
ID charcot-marie-tooth; progressive external ophthalmoplegia; mitofusin 2 mutations; neurogastrointestinal encephalomyopathy mngie; sensory ataxic neuropathy; kearns-sayre syndrome; sural nerve biopsy; cytochrome-c-oxidase; stroke-like episodes; gdap1 mutations
AB There has been considerable progress during the past 24 years in the molecular genetics of mitochondrial DNA and related nuclear DNA mutations, and more than 100 nerve biopsies from hereditary neuropathies related to mitochondrial cytopathy have been accurately examined. Neuropathies were first reported in diseases related to point mutations of mitochondrial DNA, but they proved to be a prominent feature of the phenotype in mitochondrial disorders caused by defects in nuclear DNA, particularly in 3 genes: polymerase gamma 1 (POLG1), mitofusin 2 (MFN2), and ganglioside-induced differentiation-associated protein 1 (GDAP1). Most patients have sensory-motor neuropathy, sometimes associated with ophthalmoplegia, ataxia, seizures, parkinsonism, myopathy, or visceral disorders. Some cases are caused by consanguinity, but most are sporadic with various phenotypes mimicking a wide range of other etiologies. Histochemistry on muscle biopsy, as well as identification of crystalloid inclusions at electron microscopy, may provide a diagnostic clue to mitochondriopathy, but nerve biopsy is often less informative. Nevertheless, enlarged mitochondria containing distorted or amputated cristae are highly suggestive, particularly when located in the Schwann cell cytoplasm. Also noticeable are clusters of regenerating myelinated fibers surrounded by concentric Schwann cell processes, and such onion bulb-like formations are frequently observed in neuropathies caused by GDAP1 mutations.
C1 [Vital, Anne; Vital, Claude] Univ Bordeaux, CNRS, Inst Malad Neurodegenerat, Bordeaux, France.
   [Vital, Anne] CHU Bordeaux, Dept Pathol, Bordeaux, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Bordeaux; Universite de Bordeaux; CHU Bordeaux
RP Vital, A (corresponding author), Univ Bordeaux 2, Neuropathol Lab, 146 Rue Leo Saignat,BP 42, F-33076 Bordeaux, France.
EM anne.vital@chu-bordeaux.fr
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Ammar N, 2003, NEUROMUSCULAR DISORD, V13, P720, DOI 10.1016/S0960-8966(03)00093-2
   Angelini C, 2009, ACTA MYOL, V28, P16
   [Anonymous], 2001, PATHOLOGY PERIPHERAL, V0, P0
   [Anonymous], 1975, PERIPHERAL NEUROPATHY, V0, P0
   Asbury AK, 1978, PATHOLOGY PERIPHERAL, V0, P0
   Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007
   BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   Bedlack RS, 2004, MUSCLE NERVE, V29, P364, DOI 10.1002/mus.10546
   Benard G, 2008, ANTIOXID REDOX SIGN, V10, P1313, DOI 10.1089/ars.2007.2000
   Benedetti S, 2010, ARCH NEUROL-CHICAGO, V67, P1498, DOI 10.1001/archneurol.2010.303
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Biancheri R, 2006, J NEUROL, V253, P1234, DOI 10.1007/s00415-006-0149-4
   Birouk N, 2003, ARCH NEUROL-CHICAGO, V60, P598, DOI 10.1001/archneur.60.4.598
   Boerkoel CF, 2003, ANN NEUROL, V53, P400, DOI 10.1002/ana.10505
   Bouillot S, 2002, J PERIPHER NERV SYST, V7, P213, DOI 10.1046/j.1529-8027.2002.02027.x
   Calvo J, 2009, ARCH NEUROL-CHICAGO, V66, P1511, DOI 10.1001/archneurol.2009.284
   Cartoni R, 2009, EXP NEUROL, V218, P268, DOI 10.1016/j.expneurol.2009.05.003
   Carvalho AAS, 2005, J PERIPHER NERV SYST, V10, P85, DOI 10.1111/j.1085-9489.2005.10112.x
   Cassereau J, 2011, NEUROLOGY, V76, P1524, DOI 10.1212/WNL.0b013e318217e77d
   Cassereau J, 2011, EXP NEUROL, V227, P31, DOI 10.1016/j.expneurol.2010.09.006
   Chen HC, 2006, CURR OPIN CELL BIOL, V18, P453, DOI 10.1016/j.ceb.2006.06.004
   Chinnery PF, 2008, GREENFIELDS NEUROPAT, V0, P601
   Chu CC, 1997, EUR NEUROL, V37, P110, DOI 10.1159/000117420
   Chung KW, 2006, BRAIN, V129, P2103, DOI 10.1093/brain/awl174
   Chung KW, 2008, J HUM GENET, V53, P360, DOI 10.1007/s10038-008-0249-3
   CIAFALONI E, 1991, NEUROLOGY, V41, P1663, DOI 10.1212/WNL.41.10.1663
   Claramunt R, 2005, J MED GENET, V42, P358, DOI 10.1136/jmg.2004.022178
   Copeland WC, 2012, CRIT REV BIOCHEM MOL, V47, P64, DOI 10.3109/10409238.2011.632763
   Cottrell DA, 2000, J NEUROPATH EXP NEUR, V59, P621, DOI 10.1093/jnen/59.7.621
   Dashe JF, 1998, NEW ENGL J MED, V339, P1914, DOI 10.1056/NEJM199812243392608
   Debouverie M, 1997, REV NEUROL, V153, P547
   Del Bo R, 2008, NEUROLOGY, V71, P1959, DOI 10.1212/01.wnl.0000327095.32005.a4
   Di Maria E, 2004, J NEUROL NEUROSUR PS, V75, P1495, DOI 10.1136/jnnp.2003.028100
   DiMauro S, 2010, ACTA MYOL, V29, P333
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   FARDEAU M, 1969, J NEUROPATH EXP NEUR, V28, P278
   Filosto M, 2011, J INHERIT METAB DIS, V34, P1199, DOI 10.1007/s10545-011-9332-6
   Finsterer J, 2011, J NEUROL SCI, V304, P9, DOI 10.1016/j.jns.2011.02.012
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Genari AB, 2011, NEUROMUSCULAR DISORD, V21, P428, DOI 10.1016/j.nmd.2011.03.008
   HAHN AF, 1993, BRAIN PATHOL, V3, P147, DOI 10.1111/j.1750-3639.1993.tb00739.x
   HANNA MG, 2005, PERIPHERAL NEUROPATH, V0, P1937
   HARA H, 1994, J NEUROL NEUROSUR PS, V57, P1545, DOI 10.1136/jnnp.57.12.1545-a
   Harrower T, 2008, ARCH NEUROL-CHICAGO, V65, P133, DOI 10.1001/archneurol.2007.4
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Houlden H, 2009, NEUROMUSCULAR DISORD, V19, P264, DOI 10.1016/j.nmd.2009.01.006
   Huang CC, 1999, ACTA NEUROL SCAND, V99, P125, DOI 10.1111/j.1600-0404.1999.tb00670.x
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kabzinska D, 2007, ACTA MYOL, V26, P108
   Kabzinska D, 2006, J NEUROL SCI, V241, P7, DOI 10.1016/j.jns.2005.10.002
   Kabzinska D, 2006, ACTA MYOL, V25, P34
   Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2
   King MD, 1996, NEUROLOGY, V46, P1495, DOI 10.1212/WNL.46.5.1495
   King RHM, 1999, ATLAS OF PERIPHERAL NERVE PATHOLOGY, V0, P0
   Klein CJ, 2011, ARCH NEUROL-CHICAGO, V68, P1295, DOI 10.1001/archneurol.2011.225
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Koopman WJH, 2012, NEW ENGL J MED, V366, P1132, DOI 10.1056/NEJMra1012478
   KORTHALS JK, 1978, ANN NEUROL, V4, P487, DOI 10.1002/ana.410040603
   Lamperti C, 2009, ACTA MYOL, V28, P2
   Lax NZ, 2012, BRAIN, V135, P62, DOI 10.1093/brain/awr326
   Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294
   Luigetti M, 2011, J NEUROL SCI, V307, P168, DOI 10.1016/j.jns.2011.04.025
   MADRID R, 1977, J NEUROL SCI, V32, P91, DOI 10.1016/0022-510X(77)90042-9
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Martin-Negrier ML, 2011, EUR J NEUROL, V18, P436, DOI 10.1111/j.1468-1331.2010.03171.x
   MIDRONI G, 1995, BIOPSY DIAGNOSIS PER, V0, P0
   Milone M, 2012, NEUROLOGY, V78, P1612, DOI 10.1212/WNL.0b013e3182563c46
   Milone M, 2011, NEUROLOGY, V77, P1847, DOI 10.1212/WNL.0b013e318238863a
   MOLNAR M, 1995, NEUROPATH APPL NEURO, V21, P432, DOI 10.1111/j.1365-2990.1995.tb01080.x
   Molnar M, 1996, ACTA NEUROPATHOL, V91, P654, DOI 10.1007/s004010050480
   Moroni I, 2009, NEUROMUSCULAR DISORD, V19, P476, DOI 10.1016/j.nmd.2009.04.014
   Nagashima T, 2001, NEUROMUSCULAR DISORD, V11, P470, DOI 10.1016/S0960-8966(01)00190-0
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Naumann M, 1997, MUSCLE NERVE, V20, P833, DOI 10.1002/(SICI)1097-4598(199707)20:7<833::AID-MUS7>3.0.CO;2-8
   Nelis E, 2002, NEUROLOGY, V59, P1865, DOI 10.1212/01.WNL.0000036272.36047.54
   Nicholson G, 2002, NEUROLOGY, V59, P1835, DOI 10.1212/WNL.59.12.1835
   Nicholson GA, 2008, NEUROLOGY, V70, P1678, DOI 10.1212/01.wnl.0000311275.89032.22
   NICOLL JAR, 1993, CLIN NEUROPATHOL, V12, P38
   Niemann A, 2006, NEUROMOL MED, V8, P217, DOI 10.1385/NMM:8:1:217
   Niemann A, 2009, NEUROBIOL DIS, V36, P509, DOI 10.1016/j.nbd.2009.09.011
   Nishino I, 2000, ANN NEUROL, V47, P792
   Ouvrier R, 2010, DEV MED CHILD NEUROL, V52, P328, DOI 10.1111/j.1469-8749.2010.03613.x
   Pedrola L, 2008, J CELL MOL MED, V12, P679, DOI 10.1111/j.1582-4934.2007.00158.x
   Picard M, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0018317
   Posada IJ, 2010, MED CLIN-BARCELONA, V135, P452, DOI 10.1016/j.medcli.2010.03.031
   Rahman S, 2009, J NEUROL NEUROSUR PS, V80, P943, DOI 10.1136/jnnp.2008.158279
   Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x
   Said G, 2005, J NEUROL, V252, P655, DOI 10.1007/s00415-005-0712-4
   Sander S, 1998, MUSCLE NERVE, V21, P217, DOI 10.1002/(SICI)1097-4598(199802)21:2<217::AID-MUS9>3.0.CO;2-E
   Santoro L, 2000, NEUROMUSCULAR DISORD, V10, P450, DOI 10.1016/S0960-8966(99)00122-4
   Santoro L, 2006, J NEUROL, V253, P869, DOI 10.1007/s00415-006-0082-6
   SASAKI H, 1983, NEUROLOGY, V33, P1288, DOI 10.1212/WNL.33.10.1288
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Schapira AHV, 2012, LANCET, V379, P1825, DOI 10.1016/S0140-6736(11)61305-6
   SCHRODER JM, 1991, ACTA NEUROPATHOL, V82, P471, DOI 10.1007/BF00293381
   Senderek J, 2003, BRAIN, V126, P642, DOI 10.1093/brain/awg068
   Sevilla T, 2003, BRAIN, V126, P2023, DOI 10.1093/brain/awg202
   Sevilla T, 2008, BRAIN, V131, P3051, DOI 10.1093/brain/awn228
   Sheng ZH, 2012, NAT REV NEUROSCI, V13, P77, DOI 10.1038/nrn3156
   Sivera R, 2010, J PERIPHER NERV SYST, V15, P334, DOI 10.1111/j.1529-8027.2010.00286.x
   Sole G, 2009, J PERIPHER NERV SYST, V14, P206, DOI 10.1111/j.1529-8027.2009.00234.x
   SOMMER C, 1989, ARCH NEUROL-CHICAGO, V46, P973, DOI 10.1001/archneur.1989.00520450043017
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Stickler DE, 2006, PEDIATR NEUROL, V34, P127, DOI 10.1016/j.pediatrneurol.2005.08.006
   Stickler DE, 2003, J CHILD NEUROL, V18, P574, DOI 10.1177/08830738030180081101
   Tang S, 2012, J NEUROL, V259, P862, DOI 10.1007/s00415-011-6268-6
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   UNCINI A, 1994, MUSCLE NERVE, V17, P667, DOI 10.1002/mus.880170616
   Valentijn KM, 2011, BLOOD, V117, P5033, DOI 10.1182/blood-2010-09-267492
   Vallat JM, 2008, J NEUROPATH EXP NEUR, V67, P1097, DOI 10.1097/NEN.0b013e31818b6cbc
   Vallat JM, 2009, J NEUROPATH EXP NEUR, V68, P833, DOI 10.1097/NEN.0b013e3181af2b9c
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126
   Viader A, 2011, J NEUROSCI, V31, P10128, DOI 10.1523/JNEUROSCI.0884-11.2011
   VITAL A, 1985, ACTA NEUROPATHOL, V67, P136, DOI 10.1007/BF00688134
   Vital A, 2001, J PERIPHER NERV SYST, V6, P79, DOI 10.1046/j.1529-8027.2001.01011.x
   Vital A, 2012, NEUROMUSCULAR DISORD, V22, P735, DOI 10.1016/j.nmd.2012.04.001
   Vital C, 2006, J PERIPHER NERV SYST, V11, P20, DOI 10.1111/j.1085-9489.2006.00060.x
   VITAL C, 1983, ACTA NEUROPATHOL, V61, P225, DOI 10.1007/BF00691990
   Vital C, 2002, ULTRASTRUCT PATHOL, V26, P9, DOI 10.1080/01913120252934279
   Vital C, 1987, ULTRASTRUCTURAL STUD, V0, P0
   Vital C, 2008, J PERIPHER NERV SYST, V13, P103, DOI 10.1111/j.1529-8027.2008.00163.x
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
   Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314
   Wang XN, 2009, CELL, V136, P163, DOI 10.1016/j.cell.2008.11.046
   Weis J, 2012, CLIN NEUROPATHOL, V31, P7, DOI 10.5414/NP300468
   Weiss MD, 2010, MUSCLE NERVE, V41, P882, DOI 10.1002/mus.21636
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   YIANNIKAS C, 1986, ANN NEUROL, V20, P249, DOI 10.1002/ana.410200211
   Zanssen S, 1998, CLIN NEUROPATHOL, V17, P291
   Zeviani M, 2008, BRAIN, V131, P314, DOI 10.1093/brain/awm339
   Zeviani M, 2007, CURR OPIN NEUROL, V20, P564, DOI 10.1097/WCO.0b013e3282ef58cd
   Zimón M, 2011, NEUROLOGY, V77, P540, DOI 10.1212/WNL.0b013e318228fc70
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 143
TC 35
Z9 38
U1 1
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-3069
EI 1554-6578
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD DEC 15
PY 2012
VL 71
IS 12
BP 1036
EP 1046
DI 10.1097/NEN.0b013e3182764d47
PG 11
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 047OS
UT WOS:000311850900001
PM 23147504
DA 2024-11-01
ER

PT J
AU Mao, PZ
   Gallagher, P
   Nedungadi, S
   Manczak, M
   Shirendeb, UP
   Kohama, SG
   Ferguson, B
   Park, BS
   Reddy, PH
AF Mao, Peizhong
   Gallagher, Patience
   Nedungadi, Samira
   Manczak, Maria
   Shirendeb, Ulziibat P.
   Kohama, Steven G.
   Ferguson, Betsy
   Park, Byung S.
   Reddy, P. Hemachandra
TI Mitochondrial DNA deletions and differential mitochondrial DNA content in Rhesus monkeys: Implications for aging
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Rhesus monkeys; Mitochondrial DNA; Aging; Real-time RT-PCR; Mitochondrial DNA deletion; Mitochondrial-encoded DNA
ID skeletal-muscle; alzheimers-disease; gene-expression; life-span; common deletion; amyloid-beta; mutations; dysfunction; damage; abnormality
AB The purpose of this study was to determine the relationship between mitochondria! DNA (mtDNA) deletions, mtDNA content and aging in rhesus monkeys. Using 2 sets of specific primers, we amplified an 8 kb mtDNA fragment covering a common 5.7 kb deletion and the entire 16.5 kb mitochondrial genome in the brain and buffy-coats of young and aged monkeys. We studied a total of 66 DNA samples: 39 were prepared from a buffy-coat and 27 were prepared from occipital cortex tissues. The mtDNA data were assessed using a permutation test to identify differences in mtDNA, in the different monkey groups. Using real-time RT-PCR strategy, we also assessed both mtDNA and nuclear DNA levels for young, aged and male and female monkeys. We found a 5.7 kb mtDNA deletion in 81.8% (54 of 66) of the total tested samples. In the young group of buffy-coat DNA, we found 5.7 kb deletions in 7 of 17 (41%), and in the aged group, we found 5.7 kb deletions in 12 of 22 (54%), suggesting that the prevalence of mtDNA deletions is related to age. We found decreased mRNA levels of mtDNA in aged monkeys relative to young monkeys. The increases in mtDNA deletions and mtDNA levels in aged rhesus monkeys suggest that damaged DNA accumulates as rhesus monkeys age and these altered mtDNA changes may have physiological relevance to compensate decreased mitochondrial function. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Reddy, P. Hemachandra] Oregon Hlth & Sci Univ, Neurogenet Lab, Div Neurosci, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA.
   [Park, Byung S.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97239 USA.
   [Reddy, P. Hemachandra] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University
RP Reddy, PH (corresponding author), Oregon Hlth & Sci Univ, Neurogenet Lab, Div Neurosci, Oregon Natl Primate Res Ctr, West Campus,505 NW 185th Ave, Beaverton, OR 97006 USA.
EM reddyh@ohsu.edu
FU NIH [AG028072, RR00163]; Alzheimer Association IIRG [IIRG-09-92429]
CR Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x
   de Carvalho CV, 2000, BIOGERONTOLOGY, V1, P357, DOI 10.1023/A:1026542618182
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Fernandes A, 2003, INVEST OPHTH VIS SCI, V44, P2373, DOI 10.1167/iovs.02-0944
   Fu YJ, 2009, CELL MOL NEUROBIOL, V29, P649, DOI 10.1007/s10571-009-9359-5
   Gibson TC, 2005, MOL HUM REPROD, V11, P785, DOI 10.1093/molehr/gah227
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   Gutala RV, 2004, J NEUROSCI METH, V132, P101, DOI 10.1016/j.jneumeth.2003.09.005
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X
   Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Krishnan KJ, 2004, J INVEST DERMATOL, V123, P1020, DOI 10.1111/j.0022-202X.2004.23457.x
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LeDoux SP, 2007, NEUROSCIENCE, V145, P1249, DOI 10.1016/j.neuroscience.2006.10.002
   Lim PS, 2000, FREE RADICAL BIO MED, V29, P454, DOI 10.1016/S0891-5849(00)00334-8
   Lopez ME, 2000, MUTAT RES-FUND MOL M, V452, P123, DOI 10.1016/S0027-5107(00)00059-2
   Manczak M, 2004, NEUROMOL MED, V5, P147, DOI 10.1385/NMM:5:2:147
   Manczak M, 2009, HUM MOL GENET, V18, P3876, DOI 10.1093/hmg/ddp331
   Mao PZ, 2010, BBA-MOL BASIS DIS, V1802, P66, DOI 10.1016/j.bbadis.2009.07.002
   Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7
   Mehmet D, 2001, MOL HUM REPROD, V7, P301, DOI 10.1093/molehr/7.3.301
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   Peng TI, 2006, BBA-MOL BASIS DIS, V1762, P241, DOI 10.1016/j.bbadis.2005.10.008
   Perry G, 2002, FREE RADICAL BIO MED, V33, P1475, DOI 10.1016/S0891-5849(02)01113-9
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Reddy PH, 2008, TRENDS MOL MED, V14, P45, DOI 10.1016/j.molmed.2007.12.002
   Reddy PH, 2007, ANTIOXID REDOX SIGN, V9, P1647, DOI 10.1089/ars.2007.1754
   Reddy PH, 2008, NEUROMOL MED, V10, P291, DOI 10.1007/s12017-008-8044-z
   Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140
   Roth GS, 2004, SCIENCE, V305, P1423, DOI 10.1126/science.1102541
   Sastre J, 2002, ANN NY ACAD SCI, V959, P448, DOI 10.1111/j.1749-6632.2002.tb02114.x
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Sedensky MM, 2006, EXP GERONTOL, V41, P237, DOI 10.1016/j.exger.2006.01.004
   Swerdlow RH, 2009, J ALZHEIMERS DIS, V17, P737, DOI 10.3233/JAD-2009-1095
   Tonska K, 2009, J APPL GENET, V50, P55, DOI 10.1007/BF03195653
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Vijg J, 2000, MUTAT RES-FUND MOL M, V447, P117, DOI 10.1016/S0027-5107(99)00202-X
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
NR 43
TC 14
Z9 16
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD FEB 15
PY 2012
VL 1822
IS 2
BP 111
EP 119
DI 10.1016/j.bbadis.2011.10.014
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 888EM
UT WOS:000299986600002
PM 22056405
DA 2024-11-01
ER

PT J
AU Kami, K
   Fujita, Y
   Igarashi, S
   Koike, S
   Sugawara, S
   Ikeda, S
   Sato, N
   Ito, M
   Tanaka, M
   Tomita, M
   Soga, T
AF Kami, Kenjiro
   Fujita, Yasunori
   Igarashi, Saori
   Koike, Sayaka
   Sugawara, Shoko
   Ikeda, Satsuki
   Sato, Naomi
   Ito, Masafumi
   Tanaka, Masashi
   Tomita, Masaru
   Soga, Tomoyoshi
TI Metabolomic profiling rationalized pyruvate efficacy in cybrid cells harboring MELAS mitochondrial DNA mutations
SO MITOCHONDRION
LA English
DT Article
DE MELAS; Pyruvate; Cybrid; Energy metabolism; Metabolome; CE-MS
ID stroke-like episodes; electrophoresis-mass-spectrometry; lactic-acidosis; escherichia-coli; mtdna mutation; leigh-syndrome; encephalopathy; therapy; myopathy; encephalomyopathy
AB Pyruvate treatment was found to alleviate clinical symptoms of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome and is highly promising therapeutic. Using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS), we measured time-changes of 161 intracellular and 85 medium metabolites to elucidate metabolic effects of pyruvate treatment on cybrid human 143B osteosarcoma cells harboring normal (2SA) and MELAS mutant (2SD) mitochondria. The results demonstrated dramatic and sustainable effects of pyruvate administration on the energy metabolism of 2SD cells, corroborating pyruvate as a metabolically rational treatment regimen for improving symptoms associated with MELAS and possibly other mitochondrial diseases. (C) 2012 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Tanaka, Masashi] Tokyo Metropolitan Inst Gerontol, Dept Genom Longev & Hlth, Itabashi Ku, Tokyo 1730015, Japan.
   [Kami, Kenjiro; Igarashi, Saori; Koike, Sayaka; Sugawara, Shoko; Ikeda, Satsuki; Sato, Naomi; Tomita, Masaru; Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata 9970017, Japan.
   [Kami, Kenjiro; Tomita, Masaru; Soga, Tomoyoshi] Keio Univ, Grad Sch Media & Governance, Syst Biol Program, Fujisawa, Kanagawa 2528520, Japan.
   [Fujita, Yasunori; Ito, Masafumi] Tokyo Metropolitan Inst Gerontol, Res Team Mech Aging, Itabashi Ku, Tokyo 1730015, Japan.
   [Tomita, Masaru; Soga, Tomoyoshi] Human Metabolome Technol Inc, Tsuruoka, Yamagata 9970052, Japan.
C3 Tokyo Metropolitan Institute of Gerontology; Keio University; Keio University; Tokyo Metropolitan Institute of Gerontology
RP Tanaka, M (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Genom Longev & Hlth, Itabashi Ku, 35-2 Sake Cho, Tokyo 1730015, Japan.
EM mtanaka@tmig.or.jp
FU Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan [A-22240072, B-21390459, 180 73004, 18GS0314, F-3]; Ministry of Health, Labour and Welfare (MHLW) of Japan [H23-016, H23-119, H24-005]; Takeda Science Foundation; Gifu Prefecture, Japan; Government of Yamagata Prefecture; Tsuruoka City, Japan; Grants-in-Aid for Scientific Research [22300244] Funding Source: KAKEN
CR CASTILLO M, 1995, AM J NEURORADIOL, V16, P233
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Desagher S, 1997, J NEUROSCI, V17, P9060
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Fujita Y, 2007, MITOCHONDRION, V7, P80, DOI 10.1016/j.mito.2006.11.003
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806
   Hussein Ahmed, 2009, EUR J INTERN MED, V20, Pe114, DOI 10.1016/j.ejim.2008.09.018
   ICHIKI T, 1989, PEDIATR RES, V25, P194, DOI 10.1203/00006450-198902000-00023
   Iizuka T, 2005, CURR NEUROVASC RES, V2, P29, DOI 10.2174/1567202052773544
   Ishii N, 2007, SCIENCE, V316, P593, DOI 10.1126/science.1132067
   Junker BH, 2006, BMC BIOINFORMATICS, V7, P0, DOI 10.1186/1471-2105-7-109
   Koga Y, 2012, BBA-GEN SUBJECTS, V1820, P608, DOI 10.1016/j.bbagen.2011.09.005
   Koga Y, 2012, BRAIN DEV-JPN, V34, P87, DOI 10.1016/j.braindev.2011.03.003
   Komaki H, 2010, BBA-GEN SUBJECTS, V1800, P313, DOI 10.1016/j.bbagen.2009.07.008
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   NATH KA, 1995, AM J PHYSIOL-CELL PH, V268, PC227, DOI 10.1152/ajpcell.1995.268.1.C227
   Ohashi Y, 2008, MOL BIOSYST, V4, P135, DOI 10.1039/b714176a
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Saito K, 2012, BBA-GEN SUBJECTS, V1820, P632, DOI 10.1016/j.bbagen.2011.08.006
   Sandhu JK, 2005, BIOCHEM J, V391, P191, DOI 10.1042/BJ20050272
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m
   Soga T, 2007, J CHROMATOGR A, V1159, P125, DOI 10.1016/j.chroma.2007.05.054
   Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Sugimoto M, 2010, METABOLOMICS, V6, P78, DOI 10.1007/s11306-009-0178-y
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tanaka M, 2007, MITOCHONDRION, V7, P399, DOI 10.1016/j.mito.2007.07.002
   van Winden WA, 2002, BIOTECHNOL BIOENG, V80, P477, DOI 10.1002/bit.10393
   Voet D, 1995, BIOCHEMISTRY, V2, P0
   Wilichowski E, 1998, J NEUROL SCI, V157, P206, DOI 10.1016/S0022-510X(98)00068-9
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
   YONEDA M, 1989, J NEUROL SCI, V92, P143, DOI 10.1016/0022-510X(89)90132-9
   Zhang J, 1998, BIOCHEM MOL BIOL INT, V46, P71
NR 39
TC 16
Z9 19
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD NOV 15
PY 2012
VL 12
IS 6
BP 644
EP 653
DI 10.1016/j.mito.2012.07.113
PG 10
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 046IQ
UT WOS:000311759100008
PM 22884939
DA 2024-11-01
ER

PT J
AU Echaniz-Laguna, A
   Chassagne, M
   Ceresuela, J
   Rouvet, I
   Padet, S
   Acquaviva, C
   Nataf, S
   Vinzio, S
   Bozon, D
   de Camaret, BM
AF Echaniz-Laguna, Andoni
   Chassagne, Maite
   Ceresuela, Jennifer
   Rouvet, Isabelle
   Padet, Sylvie
   Acquaviva, Cecile
   Nataf, Serge
   Vinzio, Stephane
   Bozon, Dominique
   de Camaret, Benedicte Mousson
TI Complete loss of expression of the <i>ANT1</i> gene causing cardiomyopathy and myopathy
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID adenine-nucleotide translocator; mitochondrial adp/atp carrier; congenital cataract; lactic-acidosis; deficiency; muscle; mouse; antioxidant; skeletal; isoform
AB Background The ANT1 gene, encoding ADP/ATP translocase 1, was investigated in an adult patient with an autosomal recessive mitochondrial disorder characterised by congenital cataracts, hypertrophic cardiomyopathy, myopathy and lactic acidosis. Methods and results ANT1 sequencing showed that the patient was homozygous for a new nucleotide variation, c.111+1G -> A, abolishing the invariant GT splice donor site of intron 1. The ANT1 transcript was undetectable in both muscle and skin fibroblasts. A markedly abnormal metabolic profile was found, and skeletal muscle showed a dramatic proliferation of abnormal mitochondria, increased mitochondrial mass, and multiple mitochondrial DNA deletions. No compensating increase in the transcript level of the ANT3 gene, which encodes the human ubiquitous isoform of the ADP/ATP translocase, was observed. The patient's heterozygous mother had normal clinical, biochemical and pathological features. Conclusions Complete loss of expression of the ANT1 gene causes a clinical syndrome mainly characterised by cardiomyopathy and myopathy. This report expands the clinical spectrum of ANT1-related human diseases, and emphasises the crucial role of the mitochondrial ADP/ATP carriers in muscle function and pathophysiology of human myopathies.
C1 [Echaniz-Laguna, Andoni] Hop Hautepierre, Hop Univ, Dept Neurol, F-67098 Strasbourg, France.
   [Echaniz-Laguna, Andoni] Univ Strasbourg, INSERM U692, Strasbourg, France.
   [Chassagne, Maite; Ceresuela, Jennifer; Padet, Sylvie; Acquaviva, Cecile; de Camaret, Benedicte Mousson] CHU Lyon, Serv Malad Hereditaires Metab, Ctr Biol & Pathol Est, Bron, France.
   [Rouvet, Isabelle; Nataf, Serge] CHU Lyon, Ctr Biotechnol Cellulaire, Ctr Biol & Pathol Est, Bron, France.
   [Vinzio, Stephane] Hop Univ, Dept Med Interne, Strasbourg, France.
   [Bozon, Dominique] CHU Lyon, Unite Cardiogenet Mol, Ctr Biol & Pathol Est, Bron, France.
C3 Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Lyon; CHU Lyon; CHU Strasbourg; CHU Lyon
RP Echaniz-Laguna, A (corresponding author), Hop Hautepierre, Hop Univ, Dept Neurol, F-67098 Strasbourg, France.
EM andoni.echaniz-laguna@chru-strasbourg.fr
CR Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309
   CRUYSBERG JRM, 1986, AM J OPHTHALMOL, V102, P740, DOI 10.1016/0002-9394(86)90402-2
   Dahout-Gonzalez C, 2006, PHYSIOLOGY, V21, P242, DOI 10.1152/physiol.00005.2006
   de Camaret BM, 2011, MITOCHONDRION, V11, P223, DOI 10.1016/j.mito.2010.07.011
   Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Markova NG, 2009, FREE RADICAL BIO MED, V46, P1168, DOI 10.1016/j.freeradbiomed.2009.01.021
   Narula N, 2011, JACC-CARDIOVASC IMAG, V4, P1, DOI 10.1016/j.jcmg.2010.06.018
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   SENGERS RCA, 1975, J PEDIATR-US, V86, P873, DOI 10.1016/S0022-3476(75)80217-4
   SMEITINK JAM, 1989, EUR J PEDIATR, V148, P656, DOI 10.1007/BF00441527
   STEPIEN G, 1992, J BIOL CHEM, V267, P14592
   Subrarnaniam V, 2008, BBA-BIOENERGETICS, V1777, P666, DOI 10.1016/j.bbabio.2008.03.015
   VALSSON J, 1988, AM J CARDIOL, V61, P193, DOI 10.1016/0002-9149(88)91331-8
   Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314
   Yin H, 2005, INVEST OPHTH VIS SCI, V46, P4555, DOI 10.1167/iovs.05-0695
NR 20
TC 53
Z9 59
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 
J9 J MED GENET
JI J. Med. Genet.
PD FEB 15
PY 2012
VL 49
IS 2
BP 146
EP 150
DI 10.1136/jmedgenet-2011-100504
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 879DC
UT WOS:000299308900012
PM 22187496
DA 2024-11-01
ER

PT J
AU Hill, BG
   Benavides, GA
   Lancaster, JR
   Ballinger, S
   Dell'Italia, L
   Zhang, JH
   Darley-Usmar, VM
AF Hill, Bradford G.
   Benavides, Gloria A.
   Lancaster, Jack R., Jr.
   Ballinger, Scott
   Dell'Italia, Lou
   Zhang, Jianhua
   Darley-Usmar, Victor M.
TI Integration of cellular bioenergetics with mitochondrial quality control and autophagy
SO BIOLOGICAL CHEMISTRY
LA English
DT Review
DE cardiovascular disease; haplotypes; mitophagy; neurodegenerative disease; spare respiratory capacity; xanthine oxidase
ID spare respiratory capacity; oxidative stress; nitric-oxide; reactive oxygen; skeletal-muscle; tobacco-smoke; proton leak; vascular dysfunction; protein-degradation; cytochrome-oxidase
AB Bioenergetic dysfunction is emerging as a cornerstone for establishing a framework for understanding the pathophysiology of cardiovascular disease, diabetes, cancer and neurodegeneration. Recent advances in cellular bioenergetics have shown that many cells maintain a substantial bioenergetic reserve capacity, which is a prospective index of 'healthy' mitochondrial populations. The bioenergetics of the cell are likely regulated by energy requirements and substrate availability. Additionally, the overall quality of the mitochondrial population and the relative abundance of mitochondria in cells and tissues also impinge on overall bioenergetic capacity and resistance to stress. Because mitochondria are susceptible to damage mediated by reactive oxygen/nitrogen and lipid species, maintaining a 'healthy' population of mitochondria through quality control mechanisms appears to be essential for cell survival under conditions of pathological stress. Accumulating evidence suggest that mitophagy is particularly important for preventing amplification of initial oxidative insults, which otherwise would further impair the respiratory chain or promote mutations in mitochondrial DNA (mtDNA). The processes underlying the regulation of mitophagy depend on several factors, including the integrity of mtDNA, electron transport chain activity, and the interaction and regulation of the autophagic machinery. The integration and interpretation of cellular bioenergetics in the context of mitochondrial quality control and genetics is the theme of this review.
C1 [Benavides, Gloria A.; Ballinger, Scott; Zhang, Jianhua; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Hill, Bradford G.] Univ Louisville, Diabet & Obes Ctr, Inst Mol Cardiol, Louisville, KY 40292 USA.
   [Hill, Bradford G.] Univ Louisville, Dept Med, Louisville, KY 40292 USA.
   [Hill, Bradford G.] Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.
   [Hill, Bradford G.; Lancaster, Jack R., Jr.] Univ Louisville, Dept Physiol & Biophys, Louisville, KY 40292 USA.
   [Benavides, Gloria A.; Lancaster, Jack R., Jr.; Ballinger, Scott; Dell'Italia, Lou; Zhang, Jianhua; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
   [Lancaster, Jack R., Jr.] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35294 USA.
   [Lancaster, Jack R., Jr.; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Dept Environm Hlth Sci, Dept Med, Birmingham, AL 35294 USA.
   [Ballinger, Scott; Dell'Italia, Lou; Darley-Usmar, Victor M.] Univ Alabama Birmingham, Ctr Heart Failure Res, Birmingham, AL 35294 USA.
   [Dell'Italia, Lou; Zhang, Jianhua] Dept Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham; University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham
RP Darley-Usmar, VM (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM Darley@uab.edu
FU NIH-NCRR [P20 RR024489]; NIH [CA131653, HL94518, HL103859, HL097176, HL109785, ES10167, AA 13395, DK 75865]; VA merit award;  [NIHR01-NS064090]
CR Affourtit C, 2008, BIOCHEM J, V409, P199, DOI 10.1042/BJ20070954
   Ahmed MI, 2010, J AM COLL CARDIOL, V55, P671, DOI 10.1016/j.jacc.2009.08.074
   Amo T, 2008, GENE, V411, P69, DOI 10.1016/j.gene.2008.01.007
   Amo T, 2007, BIOCHEM J, V404, P345, DOI 10.1042/BJ20061609
   Apostolova N, 2011, CURR PHARM DESIGN, V17, P4047, DOI 10.2174/138161211798764924
   Arteel G, 2003, BEST PRACT RES CL GA, V17, P625, DOI 10.1016/S1521-6918(03)00053-2
   ASHFORD TP, 1962, J CELL BIOL, V12, P198, DOI 10.1083/jcb.12.1.198
   Bailey SM, 2002, FREE RADICAL BIO MED, V32, P11, DOI 10.1016/S0891-5849(01)00769-9
   Bailey SM, 2003, FREE RADICAL RES, V37, P585, DOI 10.1080/1071576031000091711
   Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Band M, 2009, FASEB J, V23, P2327, DOI 10.1096/fj.08-122978
   Bayot A, 2008, BIOCHIMIE, V90, P260, DOI 10.1016/j.biochi.2007.10.010
   Befroy DE, 2008, P NATL ACAD SCI USA, V105, P16701, DOI 10.1073/pnas.0808889105
   Bhopal RS, 2009, INT J EPIDEMIOL, V38, P1072, DOI 10.1093/ije/dyp202
   Bordicchia M, 2012, J CLIN INVEST, V122, P1022, DOI 10.1172/JCI59701
   Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836
   Bota DA, 2001, MITOCHONDRION, V1, P33, DOI 10.1016/S1567-7249(01)00005-8
   BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707
   BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617
   Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162
   BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S
   Briefel RR, 2004, ANNU REV NUTR, V24, P401, DOI 10.1146/annurev.nutr.23.011702.073349
   Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, PC817, DOI 10.1152/ajpcell.00139.2004
   BROWN GC, 1990, EUR J BIOCHEM, V192, P355, DOI 10.1111/j.1432-1033.1990.tb19234.x
   BROWN GC, 1992, FASEB J, V6, P2961, DOI 10.1096/fasebj.6.11.1644259
   Bruce-Keller AJ, 2009, BBA-MOL BASIS DIS, V1792, P395, DOI 10.1016/j.bbadis.2008.10.004
   Brunengraber H, 2006, J INHERIT METAB DIS, V29, P327, DOI 10.1007/s10545-006-0320-1
   Cakir Y, 2007, FREE RADICAL BIO MED, V43, P1279, DOI 10.1016/j.freeradbiomed.2007.07.015
   Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200
   Carreira RS, 2011, CURR PHARM DESIGN, V17, P2017
   Chacko BK, 2011, HEPATOLOGY, V54, P153, DOI 10.1002/hep.24377
   Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638
   Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048
   CHANCE B, 1958, BIOCHEM J, V68, P283, DOI 10.1042/bj0680283
   CHANCE B, 1958, J BIOL CHEM, V233, P736
   Choi SW, 2009, J NEUROCHEM, V109, P1179, DOI 10.1111/j.1471-4159.2009.06055.x
   Chu CT, 2010, HUM MOL GENET, V19, PR28, DOI 10.1093/hmg/ddq143
   Chuang GC, 2009, AM J PHYSIOL-LUNG C, V297, PL209, DOI 10.1152/ajplung.00102.2009
   Cooper CE, 2007, AM J PHYSIOL-CELL PH, V292, PC1993, DOI 10.1152/ajpcell.00310.2006
   Cordain L, 2000, AM J CLIN NUTR, V71, P682, DOI 10.1093/ajcn/71.3.682
   Coskun P, 2012, BBA-GEN SUBJECTS, V1820, P553, DOI 10.1016/j.bbagen.2011.08.008
   Cotán D, 2011, FASEB J, V25, P2669, DOI 10.1096/fj.10-165340
   Cutting WLT, 1933, JAMA-J AM MED ASSOC, V101, P1472
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   Díaz-Ruiz R, 2008, J BIOL CHEM, V283, P26948, DOI 10.1074/jbc.M800408200
   Diers AR, 2012, BIOCHEM J, V444, P561, DOI 10.1042/BJ20120294
   Ding WX, 2011, AUTOPHAGY, V7, P248, DOI 10.4161/auto.7.2.14347
   Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537
   Divakaruni AS, 2011, PHYSIOLOGY, V26, P192, DOI 10.1152/physiol.00046.2010
   Donohue TM, 2009, WORLD J GASTROENTERO, V15, P1178, DOI 10.3748/wjg.15.1178
   Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005
   Dranka BP, 2010, FREE RADICAL BIO MED, V48, P905, DOI 10.1016/j.freeradbiomed.2010.01.015
   Duffey KJ, 2007, OBESITY, V15, P2739, DOI 10.1038/oby.2007.326
   Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008
   Finck BN, 2007, CIRCULATION, V115, P2540, DOI 10.1161/CIRCULATIONAHA.107.670588
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047
   Garedew A, 2012, CELL METAB, V15, P466, DOI 10.1016/j.cmet.2012.03.003
   Gegg ME, 2010, HUM MOL GENET, V19, P4861, DOI 10.1093/hmg/ddq419
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gerencser AA, 2009, ANAL CHEM, V81, P6868, DOI 10.1021/ac900881z
   Gladden JD, 2011, FREE RADICAL BIO MED, V51, P1975, DOI 10.1016/j.freeradbiomed.2011.08.022
   Gladden JD, 2011, AM J MED SCI, V342, P114, DOI 10.1097/MAJ.0b013e318224ab93
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Gong GR, 2003, AM J PHYSIOL-HEART C, V285, PH541, DOI 10.1152/ajpheart.01142.2002
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Gutierrez J, 2006, CIRC RES, V99, P924, DOI 10.1161/01.RES.0000248212.86638.e9
   HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x
   Hao LY, 2010, P NATL ACAD SCI USA, V107, P9747, DOI 10.1073/pnas.0911175107
   Harper ME, 2008, ANNU REV NUTR, V28, P13, DOI 10.1146/annurev.nutr.28.061807.155357
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
   He CC, 2012, NATURE, V481, P511, DOI 10.1038/nature10758
   Higdon AN, 2012, AM J PHYSIOL-HEART C, V302, PH1394, DOI 10.1152/ajpheart.00584.2011
   Hill BG, 2009, BIOCHEM J, V424, P99, DOI 10.1042/BJ20090934
   Hirsch GA, 2012, J AM COLL CARDIOL, V59, P802, DOI 10.1016/j.jacc.2011.10.895
   Hori O, 2002, J CELL BIOL, V157, P1151, DOI 10.1083/jcb.200108103
   Hu FB, 2003, JAMA-J AM MED ASSOC, V289, P1785, DOI 10.1001/jama.289.14.1785
   Ingwall JS, 2009, CARDIOVASC RES, V81, P412, DOI 10.1093/cvr/cvn301
   Irwin JA, 2009, J MOL EVOL, V68, P516, DOI 10.1007/s00239-009-9227-4
   Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109
   Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166
   James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401
   Jenner P, 2003, ANN NEUROL, V53, PS26, DOI 10.1002/ana.10483
   Jia W, 2011, J IMMUNOL, V186, P5313, DOI 10.4049/jimmunol.1002404
   Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849
   Johnson-Cadwell LI, 2007, J NEUROCHEM, V101, P1619, DOI 10.1111/j.1471-4159.2007.04516.x
   Kant AK, 2004, PREV MED, V38, P243, DOI 10.1016/j.ypmed.2003.10.004
   Kant AK, 2006, AM J CLIN NUTR, V84, P1215, DOI 10.1093/ajcn/84.5.1215
   Karbowski M, 2012, ACTA NEUROPATHOL, V123, P157, DOI 10.1007/s00401-011-0921-0
   KAUPPINEN RA, 1986, EUR J BIOCHEM, V158, P159, DOI 10.1111/j.1432-1033.1986.tb09733.x
   Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034
   Kim I, 2011, AM J PHYSIOL-CELL PH, V300, PC308, DOI 10.1152/ajpcell.00056.2010
   Kim KY, 2011, J CLIN INVEST, V121, P3701, DOI 10.1172/JCI44736
   Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, PE776, DOI 10.1152/ajpendo.1996.270.5.E776
   KORZENIEWSKI B, 1995, BBA-BIOENERGETICS, V1229, P315, DOI 10.1016/0005-2728(95)00008-7
   Kovsan J, 2011, J CLIN ENDOCR METAB, V96, PE268, DOI 10.1210/jc.2010-1681
   Krebiehl G, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0009367
   Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005
   Krzywanski DM, 2011, LAB INVEST, V91, P1122, DOI 10.1038/labinvest.2011.95
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Lemasters JJ, 2007, J GASTROEN HEPATOL, V22, PS31, DOI 10.1111/j.1440-1746.2006.04643.x
   Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009
   Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450
   Liao RL, 1996, CIRC RES, V78, P893, DOI 10.1161/01.RES.78.5.893
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Marcil M, 2006, J MOL CELL CARDIOL, V41, P998, DOI 10.1016/j.yjmcc.2006.08.117
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   MENZIES RA, 1971, J BIOL CHEM, V246, P2425
   Michel S, 2012, J CELL PHYSIOL, V227, P2297, DOI 10.1002/jcp.23021
   Mitra Kasturi, 2010, CURR PROTOC CELL BIOL, VChapter 4, P0, DOI 10.1002/0471143030.cb0425s46
   Mitra K, 2009, P NATL ACAD SCI USA, V106, P11960, DOI 10.1073/pnas.0904875106
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nair KS, 2008, DIABETES, V57, P1166, DOI 10.2337/db07-1556
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799
   Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426
   Narendra DP, 2010, PLOS BIOL, V8, P0, DOI 10.1371/journal.pbio.1000298
   Nascimben L, 2004, HYPERTENSION, V44, P662, DOI 10.1161/01.HYP.0000144292.69599.0c
   Nicholls David G, 2010, J VIS EXP, V0, P0, DOI DOI 10.3791/2511
   Nielsen AJ, 2003, JAMA-J AM MED ASSOC, V289, P450
   Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368
   NOBES CD, 1990, J BIOL CHEM, V265, P12910
   NOBES CD, 1989, BIOCHIM BIOPHYS ACTA, V976, P241, DOI 10.1016/S0005-2728(89)80236-1
   Okamoto K, 2012, BBA-GEN SUBJECTS, V1820, P595, DOI 10.1016/j.bbagen.2011.08.001
   Okatsu K, 2010, GENES CELLS, V15, P887, DOI 10.1111/j.1365-2443.2010.01426.x
   Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504
   Osiewacz HD, 2011, BIOCHEM SOC T, V39, P1488, DOI 10.1042/BST0391488
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Pan-Zhou XR, 2000, ANTIMICROB AGENTS CH, V44, P496, DOI 10.1128/AAC.44.3.496-503.2000
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Piantadosi CA, 2012, BBA-GEN SUBJECTS, V1820, P532, DOI 10.1016/j.bbagen.2012.01.003
   Pilsl A, 2012, ACTA NEUROPATHOL, V123, P173, DOI 10.1007/s00401-011-0902-3
   Popkin BM, 2006, AM J CLIN NUTR, V83, P529, DOI 10.1093/ajcn.83.3.529
   Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143
   Rakovic A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0016746
   Ramachandran A, 2004, P NATL ACAD SCI USA, V101, P384, DOI 10.1073/pnas.0304653101
   Rautou PE, 2010, J HEPATOL, V53, P1123, DOI 10.1016/j.jhep.2010.07.006
   Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561
   Roger VL, 2012, CIRCULATION, V125, PE2, DOI 10.1161/CIR.0b013e3182456d46
   Rose G, 2001, EUR J HUM GENET, V9, P701, DOI 10.1038/sj.ejhg.5200703
   ROTHWELL NJ, 1983, CLIN SCI, V64, P19, DOI 10.1042/cs0640019
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   SAKO EY, 1988, J BIOL CHEM, V263, P10600
   Sansbury BE, 2011, BIOCHEM J, V435, P519, DOI 10.1042/BJ20101390
   Sansbury BE, 2011, CHEM-BIOL INTERACT, V191, P288, DOI 10.1016/j.cbi.2010.12.002
   Sarti P, 2003, FREE RADICAL BIO MED, V34, P509, DOI 10.1016/S0891-5849(02)01326-6
   Sato M, 2011, SCIENCE, V334, P1141, DOI 10.1126/science.1210333
   Scaglioni F, 2011, DIGEST DIS, V29, P202, DOI 10.1159/000323886
   Schapira AHV, 2011, PARKINSONS DIS-US, V2011, P0, DOI 10.4061/2011/159160
   Schneider L, 2011, FREE RADICAL BIO MED, V51, P2007, DOI 10.1016/j.freeradbiomed.2011.08.030
   Schrauwen-Hinderling VB, 2006, INT J SPORTS MED, V27, P786, DOI 10.1055/s-2005-873020
   Schrauwen-Hinderling VB, 2005, OBES RES, V13, P2088, DOI 10.1038/oby.2005.259
   Shiva S, 2005, FREE RADICAL BIO MED, V38, P297, DOI 10.1016/j.freeradbiomed.2004.10.037
   Singh R, 2009, J CLIN INVEST, V119, P3329, DOI 10.1172/JCI39228
   SMITH DE, 1994, JAMA-J AM MED ASSOC, V271, P1747, DOI 10.1001/jama.271.22.1747
   Speakman JR, 2008, INT J OBESITY, V32, P1611, DOI 10.1038/ijo.2008.161
   Sridharan V, 2008, AM J PHYSIOL-CELL PH, V295, PC29, DOI 10.1152/ajpcell.00466.2007
   STRAUER BE, 1987, BASIC RES CARDIOL, V82, P389
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   Sun FZ, 2003, AM J HUM GENET, V72, P1515, DOI 10.1086/375656
   Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013
   THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418
   THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0
   Tseng YH, 2010, NAT REV DRUG DISCOV, V9, P465, DOI 10.1038/nrd3138
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Twig G, 2008, BBA-BIOENERGETICS, V1777, P1092, DOI 10.1016/j.bbabio.2008.05.001
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Ugarte N, 2010, ANTIOXID REDOX SIGN, V13, P539, DOI 10.1089/ars.2009.2998
   Ulasova E, 2011, J MOL CELL CARDIOL, V50, P147, DOI 10.1016/j.yjmcc.2010.10.034
   van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007
   Van Humbeeck C, 2011, J NEUROSCI, V31, P10249, DOI 10.1523/JNEUROSCI.1917-11.2011
   Venkatraman A, 2004, HEPATOLOGY, V40, P565, DOI 10.1002/hep.20326
   Venkatraman A, 2004, J BIOL CHEM, V279, P22092, DOI 10.1074/jbc.M402245200
   Venkatraman A, 2004, AM J PHYSIOL-GASTR L, V286, PG521, DOI 10.1152/ajpgi.00399.2003
   Wallace DC, 2011, COLD SH Q B, V76, P1, DOI 10.1101/sqb.2011.76.010462
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   Wang YC, 2008, PEDIATRICS, V121, PE1604, DOI 10.1542/peds.2007-2834
   Wasko MCM, 2007, JAMA-J AM MED ASSOC, V298, P187, DOI 10.1001/jama.298.2.187
   Westbrook DG, 2010, CARDIOVASC TOXICOL, V10, P216, DOI 10.1007/s12012-010-9085-8
   WILLIAMSON DF, 1993, INT J OBESITY, V17, P279
   WILLIAMSON JR, 1980, FEBS LETT, V117, PK73, DOI 10.1016/0014-5793(80)80572-2
   Wu DF, 2010, BIOCHEM BIOPH RES CO, V402, P116, DOI 10.1016/j.bbrc.2010.09.127
   Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163
   Wu M, 2007, AM J PHYSIOL-CELL PH, V292, PC125, DOI 10.1152/ajpcell.00247.2006
   Xu YN, 2011, J REPROD DEVELOP, V57, P143, DOI 10.1262/jrd.10-110H
   Yadava N, 2007, J NEUROSCI, V27, P7310, DOI 10.1523/JNEUROSCI.0212-07.2007
   Yang Z, 2007, MUTAT RES-FUND MOL M, V621, P61, DOI 10.1016/j.mrfmmm.2007.02.010
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   YUN KL, 1992, J THORAC CARDIOV SUR, V104, P26
   Zakhari S, 2007, HEPATOLOGY, V46, P2032, DOI 10.1002/hep.22010
   Zatloukal K, 2007, EXP CELL RES, V313, P2033, DOI 10.1016/j.yexcr.2007.04.024
   Zelickson BR, 2011, BBA-BIOENERGETICS, V1807, P1573, DOI 10.1016/j.bbabio.2011.09.011
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhang Y, 2009, P NATL ACAD SCI USA, V106, P19860, DOI 10.1073/pnas.0906048106
NR 202
TC 360
Z9 410
U1 1
U2 58
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1431-6730
EI 1437-4315
J9 BIOL CHEM
JI Biol. Chem.
PD DEC 15
PY 2012
VL 393
IS 12
BP 1485
EP 1512
DI 10.1515/hsz-2012-0198
PG 28
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 036SQ
UT WOS:000311051400012
PM 23092819
DA 2024-11-01
ER

PT J
AU Carra, S
   Crippa, V
   Rusmini, P
   Boncoraglio, A
   Minoia, M
   Giorgetti, E
   Kampinga, HH
   Poletti, A
AF Carra, Serena
   Crippa, Valeria
   Rusmini, Paola
   Boncoraglio, Alessandra
   Minoia, Melania
   Giorgetti, Elisa
   Kampinga, Harm H.
   Poletti, Angelo
TI Alteration of protein folding and degradation in motor neuron diseases: Implications and protective functions of small heat shock proteins
SO PROGRESS IN NEUROBIOLOGY
LA English
DT Review
DE Neurodegeneration; Motor neuron diseases; Spinal and bulbar muscular atrophy; Amyotrophic lateral sclerosis; Small heat shock proteins; Autophagy; HSPB8; Protein misfolding; Protein aggregation; SBMA; ALS
ID amyotrophic-lateral-sclerosis; bulbar muscular-atrophy; marie-tooth-disease; aggregate-prone proteins; ubiquitin-proteasome system; androgen receptor protein; transgenic mouse model; rat spinal-cord; expansion neurodegenerative disease; elongated polyglutamine tract
AB Motor neuron diseases (MNDs) are neurodegenerative disorders that specifically affect the survival and function of upper and/or lower motor neurons. Since motor neurons are responsible for the control of voluntary muscular movement, MNDs are characterized by muscle spasticity, weakness and atrophy. Different susceptibility genes associated with an increased risk to develop MNDs have been reported and several mutated genes have been linked to hereditary forms of MNDs. However, most cases of MNDs occur in sporadic forms and very little is known on their causes. Interestingly, several molecular mechanisms seem to participate in the progression of both the inherited and sporadic forms of MNDs. These include cytoskeleton organization, mitochondrial functions, DNA repair and RNA synthesis/processing, vesicle trafficking, endolysosomal trafficking and fusion, as well as protein folding and protein degradation. In particular, accumulation of aggregate-prone proteins is a hallmark of MNDs, suggesting that the protein quality control system (molecular chaperones and the degradative systems: ubiquitin-proteasome-system and autophagy) are saturated or not sufficient to allow the clearance of these altered proteins. In this review we mainly focus on the MNDs associated with disturbances in protein folding and protein degradation and on the potential implication of a specific class of molecular chaperones, the small heat shock proteins (sHSPs/HSPBs), in motor neuron function and survival. How boosting of specific HSPBs may be a potential useful therapeutic approach in MNDs and how mutations in specific HSPBs can directly cause motor neuron degeneration is discussed. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Carra, Serena; Boncoraglio, Alessandra; Minoia, Melania; Kampinga, Harm H.] Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, NL-9713 AV Groningen, Netherlands.
   [Carra, Serena] Univ Modena & Reggio Emilia, Dipartimento Sci Biomed, I-41125 Modena, Italy.
   [Crippa, Valeria; Rusmini, Paola; Boncoraglio, Alessandra; Giorgetti, Elisa; Poletti, Angelo] Univ Milan, Ctr Eccellenza Studio Malattie Neurodegenerat CEN, Dipartimento Endocrinol Fisiopatol & Biol Applica, I-20133 Milan, Italy.
   [Crippa, Valeria; Rusmini, Paola; Giorgetti, Elisa; Poletti, Angelo] Univ Florence, InterUniv Ctr Neurodegenerat Dis, Genoa, Italy.
   [Crippa, Valeria; Rusmini, Paola; Giorgetti, Elisa; Poletti, Angelo] Univ Florence, InterUniv Ctr Neurodegenerat Dis, Milan, Italy.
C3 University of Groningen; Universita di Modena e Reggio Emilia; University of Milan; University of Florence; University of Florence
RP Poletti, A (corresponding author), Dipartimento Endocrinol Fisiopatol & Biol Applica, Via Balzaretti 9, I-20133 Milan, Italy.
EM angelo.poletti@unimi.it
FU Fondation Thierry Latran, France; Marie Curie International Reintegration Grant [PIRG-03-GA-2008-230908]; Association Francaise contre les Myopathies; Fondazione Telethon Funding Source: Custom
CR Abel A, 2001, HUM MOL GENET, V10, P107, DOI 10.1093/hmg/10.2.107
   Ackerley S, 2006, HUM MOL GENET, V15, P347, DOI 10.1093/hmg/ddi452
   Adachi H, 2007, NEUROPATH APPL NEURO, V33, P135, DOI 10.1111/j.1365-2990.2007.00830.x
   Adachi H, 2005, BRAIN, V128, P659, DOI 10.1093/brain/awh381
   Adachi H, 2003, J NEUROSCI, V23, P2203
   Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039
   Aguzzi A, 2010, NAT REV DRUG DISCOV, V9, P237, DOI 10.1038/nrd3050
   Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200
   An JJ, 2009, BMB REP, V42, P136, DOI 10.5483/BMBRep.2009.42.3.136
   Arndt V, 2010, CURR BIOL, V20, P143, DOI 10.1016/j.cub.2009.11.022
   Arrigo AP, 2001, IUBMB LIFE, V52, P303, DOI 10.1080/152165401317291156
   Arrigo AP, 2005, M S-MED SCI, V21, P619, DOI 10.1051/medsci/2005216-7619
   Arrigo AP, 2005, ANTIOXID REDOX SIGN, V7, P414, DOI 10.1089/ars.2005.7.414
   Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515
   Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158
   Bhagyalaxmi SG, 2009, BBA-MOL BASIS DIS, V1792, P974, DOI 10.1016/j.bbadis.2009.06.011
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405
   Bosco DA, 2010, NAT NEUROSCI, V13, P1396, DOI 10.1038/nn.2660
   Bossy-Wetzel E, 2004, NAT MED, V10, PS2, DOI 10.1038/nm1067
   BREEDLOVE SM, 1980, SCIENCE, V210, P564, DOI 10.1126/science.7423210
   Brooks BP, 1998, J NEUROCHEM, V70, P1054
   BROOKS BP, 1995, TRENDS NEUROSCI, V18, P459, DOI 10.1016/0166-2236(95)94497-S
   Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595
   Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467
   Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a
   Buratti E, 2008, FRONT BIOSCI-LANDMRK, V13, P867, DOI 10.2741/2727
   Cappelletti G, 2007, J NEUROSCI RES, V85, P2702, DOI 10.1002/jnr.21235
   Carra S, 2005, HUM MOL GENET, V14, P1659, DOI 10.1093/hmg/ddi174
   Carra S, 2006, BOOK REV HEAT SHOCK, V0, P331
   Carra S, 2008, J BIOL CHEM, V283, P1437, DOI 10.1074/jbc.M706304200
   Carra S, 2010, J BIOL CHEM, V285, P37811, DOI 10.1074/jbc.M110.127498
   Chai YH, 1999, J NEUROSCI, V19, P10338
   Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000
   Chen Q, 2009, MOL VIS, V15, P1359
   Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8
   CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4
   Cogli L, 2009, BIOCHEM SOC T, V37, P1027, DOI 10.1042/BST0371027
   Copped F, 2007, NEUROSCI LETT, V420, P163, DOI 10.1016/j.neulet.2007.04.067
   Cozzolino M, 2008, ANTIOXID REDOX SIGN, V10, P405, DOI 10.1089/ars.2007.1760
   Cozzolino M, 2009, ANTIOXID REDOX SIGN, V11, P1547, DOI 10.1089/ARS.2009.2545
   Cozzolino M, 2012, PROG NEUROBIOL, V97, P54, DOI 10.1016/j.pneurobio.2011.06.003
   Crippa V, 2010, AUTOPHAGY, V6, P958, DOI 10.4161/auto.6.7.13042
   Crippa V, 2010, HUM MOL GENET, V19, P3440, DOI 10.1093/hmg/ddq257
   Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511
   De Jonghe P, 2001, ANN NEUROL, V49, P245, DOI 10.1002/1531-8249(20010201)49:2<245::AID-ANA45>3.0.CO;2-A
   Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0
   den Engelsman J, 2009, J MOL BIOL, V393, P1022, DOI 10.1016/j.jmb.2009.08.052
   Deng HX, 2011, NATURE, V477, P211, DOI 10.1038/nature10353
   Dobrowolny G, 2008, CELL METAB, V8, P425, DOI 10.1016/j.cmet.2008.09.002
   Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261
   Dondi D, 2010, ENDOCR-RELAT CANCER, V17, P731, DOI 10.1677/ERC-10-0032
   Drengler SM, 1996, MOL BRAIN RES, V41, P8, DOI 10.1016/0169-328X(96)00060-5
   Elden AC, 2010, NATURE, V466, P1069, DOI 10.1038/nature09320
   Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354
   Fabrizi GM, 2007, BRAIN, V130, P394, DOI 10.1093/brain/awl284
   Fauconneau B, 2002, J NEUROCHEM, V83, P1338, DOI 10.1046/j.1471-4159.2002.01230.x
   Fernández-Rhodes LE, 2011, LANCET NEUROL, V10, P140, DOI 10.1016/S1474-4422(10)70321-5
   Ferri A, 2006, P NATL ACAD SCI USA, V103, P13860, DOI 10.1073/pnas.0605814103
   Ferri A, 2010, HUM MOL GENET, V19, P4529, DOI 10.1093/hmg/ddq383
   Figlewicz DA, 2003, AMYOTROPH LATERAL SC, V4, P225, DOI 10.1080/14660820310011287
   Fischbeck KH, 2001, BRAIN RES BULL, V56, P161, DOI 10.1016/S0361-9230(01)00577-9
   Fischbeck KH, 1997, J INHERIT METAB DIS, V20, P152, DOI 10.1023/A:1005344403603
   Fontaine JM, 2006, FASEB J, V20, P2168, DOI 10.1096/fj.06-5911fje
   FREEMAN LM, 1995, J NEUROBIOL, V27, P51, DOI 10.1002/neu.480270106
   Fuchs M, 2010, BIOCHEM J, V425, P245, DOI 10.1042/BJ20090907
   Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021
   Fukada Y, 2007, BRAIN RES, V1160, P1, DOI 10.1016/j.brainres.2007.05.044
   Gamerdinger M, 2009, EMBO J, V28, P889, DOI 10.1038/emboj.2009.29
   Garrido C, 2002, CELL DEATH DIFFER, V9, P483, DOI 10.1038/sj.cdd.4401005
   Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448
   Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018
   Graw J, 2006, GRAEF ARCH CLIN EXP, V244, P912, DOI 10.1007/s00417-005-0234-x
   Guerini V, 2005, CANCER RES, V65, P5445, DOI 10.1158/0008-5472.CAN-04-1941
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Haapasalo A, 2010, BIOCHEM SOC T, V38, P150, DOI 10.1042/BST0380150
   Hageman J, 2010, MOL CELL, V37, P355, DOI 10.1016/j.molcel.2010.01.001
   Hamson DK, 2010, NEURON, V66, P167, DOI 10.1016/j.neuron.2010.04.025
   Houlden H, 2008, NEUROLOGY, V71, P1660, DOI 10.1212/01.wnl.0000319696.14225.67
   Ikeda Y, 2009, J NEUROL SCI, V277, P9, DOI 10.1016/j.jns.2008.09.031
   Inagaki N, 2006, BIOCHEM BIOPH RES CO, V342, P379, DOI 10.1016/j.bbrc.2006.01.154
   Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328
   Irobi J, 2010, HUM MOL GENET, V19, P3254, DOI 10.1093/hmg/ddq234
   Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102
   Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200
   James PA, 2008, J NEUROL NEUROSUR PS, V79, P461, DOI 10.1136/jnnp.2007.125179
   JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015
   Jordanova A, 2006, NAT GENET, V38, P197, DOI 10.1038/ng1727
   Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132
   Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941
   Kanning KC, 2010, ANNU REV NEUROSCI, V33, P409, DOI 10.1146/annurev.neuro.051508.135722
   Kappé G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2
   Katsuno M, 2005, P NATL ACAD SCI USA, V102, P16801, DOI 10.1073/pnas.0506249102
   Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878
   Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6
   KAZEMIESFARJANI P, 1995, HUM MOL GENET, V4, P523, DOI 10.1093/hmg/4.4.523
   Khan AO, 2007, AM J OPHTHALMOL, V144, P949, DOI 10.1016/j.ajo.2007.08.005
   Khan AO, 2010, OPHTHALMIC GENET, V31, P30, DOI 10.3109/13816810903452047
   Khanova HA, 2007, BIOPHYS CHEM, V125, P521, DOI 10.1016/j.bpc.2006.11.002
   Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7
   Kijima K, 2005, J HUM GENET, V50, P473, DOI 10.1007/s10038-005-0280-6
   Kim SH, 2010, J BIOL CHEM, V285, P34097, DOI 10.1074/jbc.M110.154831
   Kim SH, 2009, J BIOL CHEM, V284, P8083, DOI 10.1074/jbc.M808064200
   Kirbach BB, 2011, J NEUROSCI RES, V89, P162, DOI 10.1002/jnr.22536
   Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772
   Kobayashi Z, 2010, J NEUROL SCI, V298, P70, DOI 10.1016/j.jns.2010.08.013
   Kolb SJ, 2010, NEUROLOGY, V74, P502, DOI 10.1212/WNL.0b013e3181cef84a
   Kolb SJ, 2010, MUSCLE NERVE, V41, P5, DOI 10.1002/mus.21428
   Korolchuk VI, 2010, FEBS LETT, V584, P1393, DOI 10.1016/j.febslet.2009.12.047
   Korolchuk VI, 2009, AUTOPHAGY, V5, P862, DOI 10.4161/auto.8840
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Koyama S, 2006, BIOCHEM BIOPH RES CO, V343, P719, DOI 10.1016/j.bbrc.2006.02.170
   Krishnan J, 2006, EXP NEUROL, V200, P301, DOI 10.1016/j.expneurol.2006.02.135
   Krishnan J, 2008, J NEUROCHEM, V106, P2170, DOI 10.1111/j.1471-4159.2008.05545.x
   KUJAWA KA, 1993, J NEUROSCI RES, V35, P268, DOI 10.1002/jnr.490350306
   Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066
   Lafevre-Bernt MA, 2003, J BIOL CHEM, V278, P34918, DOI 10.1074/jbc.M302841200
   Lagier-Tourenne C, 2010, HUM MOL GENET, V19, PR46, DOI 10.1093/hmg/ddq137
   Lagier-Tourenne C, 2009, CELL, V136, P1001, DOI 10.1016/j.cell.2009.03.006
   Larkowski TD, 2000, J NEUROBIOL, V45, P207, DOI 10.1002/1097-4695(200012)45:4<207::AID-NEU2>3.0.CO;2-V
   LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0
   LAVOIE JN, 1993, J BIOL CHEM, V268, P24210
   LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X
   Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216
   LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215
   LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443
   Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471
   Liu YZ, 2006, INVEST OPHTH VIS SCI, V47, P1069, DOI 10.1167/iovs.05-1004
   Luigetti M, 2010, J NEUROL SCI, V298, P114, DOI 10.1016/j.jns.2010.09.008
   Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046
   Mackenzie IRA, 2011, ACTA NEUROPATHOL, V121, P207, DOI 10.1007/s00401-010-0764-0
   Mackenzie IRA, 2010, LANCET NEUROL, V9, P995, DOI 10.1016/S1474-4422(10)70195-2
   Mandich P, 2010, J CHILD NEUROL, V25, P107, DOI 10.1177/0883073809334387
   Marron TU, 2005, J NEUROCHEM, V92, P10, DOI 10.1111/j.1471-4159.2004.02836.x
   Maruyama H, 2010, NATURE, V465, P223, DOI 10.1038/nature08971
   Matkovich SJ, 2010, J CLIN INVEST, V120, P280, DOI 10.1172/JCI39085
   MATSUMOTO A, 1988, J NEUROSCI, V8, P4168
   Matsumoto A, 1997, BRAIN RES BULL, V44, P539, DOI 10.1016/S0361-9230(97)00240-2
   McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197
   MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184
   Mitchell J, 2010, P NATL ACAD SCI USA, V107, P7556, DOI 10.1073/pnas.0914128107
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Morimoto RI, 2006, NEW ENGL J MED, V355, P2254, DOI 10.1056/NEJMcibr065573
   Musaro Antonio, 2010, WORLD J BIOL CHEM, V1, P62, DOI 10.4331/wjbc.v1.i5.62
   Nedelsky NB, 2008, BBA-MOL BASIS DIS, V1782, P691, DOI 10.1016/j.bbadis.2008.10.002
   NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0
   Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108
   OReilly AM, 2010, MOL NEUROBIOL, V42, P124, DOI 10.1007/s12035-010-8143-3
   Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399
   Onesto E, 2011, J NEUROCHEM, V118, P266, DOI 10.1111/j.1471-4159.2011.07298.x
   Palazzolo I, 2008, J STEROID BIOCHEM, V108, P245, DOI 10.1016/j.jsbmb.2007.09.016
   Palazzolo I, 2007, HUM MOL GENET, V16, P1593, DOI 10.1093/hmg/ddm109
   Palazzolo I, 2009, NEURON, V63, P316, DOI 10.1016/j.neuron.2009.07.019
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pareyson D, 2009, CURR OPIN NEUROL, V22, P451, DOI 10.1097/WCO.0b013e3283311dfd
   Pareyson D, 2009, LANCET NEUROL, V8, P654, DOI 10.1016/S1474-4422(09)70110-3
   Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971
   Patel YJK, 2005, MOL BRAIN RES, V134, P256, DOI 10.1016/j.molbrainres.2004.10.028
   Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002
   Paul C, 2010, EXP CELL RES, V316, P1535, DOI 10.1016/j.yexcr.2010.03.006
   Pennuto M, 2009, HUM MOL GENET, V18, PR40, DOI 10.1093/hmg/ddn412
   Perlson E, 2010, TRENDS NEUROSCI, V33, P335, DOI 10.1016/j.tins.2010.03.006
   PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002
   Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399
   PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355
   Piccioni F, 2002, FASEB J, V16, P1418, DOI 10.1096/fj.01-1035fje
   Poletti A, 2005, ENDOCRINE, V28, P243, DOI 10.1385/ENDO:28:3:243
   Poletti A, 2004, FRONT NEUROENDOCRIN, V25, P1, DOI 10.1016/j.yfrne.2004.03.001
   POLETTI A, 1994, ENDOCRINOLOGY, V135, P2623, DOI 10.1210/en.135.6.2623
   Poletti A, 2001, J NEUROENDOCRINOL, V13, P353, DOI 10.1046/j.1365-2826.2001.00635.x
   Pozzi P, 2003, J NEUROENDOCRINOL, V15, P882, DOI 10.1046/j.1365-2826.2003.01074.x
   Pras E, 2000, INVEST OPHTH VIS SCI, V41, P3511
   Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123
   Ravikumar B, 2005, NAT GENET, V37, P771, DOI 10.1038/ng1591
   Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036
   Ravikumar B, 2004, NEUROREPORT, V15, P2443, DOI 10.1097/00001756-200411150-00001
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107
   Ravikumar Brinda, 2006, MOLECULAR ASPECTS OF MEDICINE, V27, P520, DOI 10.1016/j.mam.2006.08.008
   Reilich P, 2010, NEUROMUSCULAR DISORD, V20, P255, DOI 10.1016/j.nmd.2010.01.012
   Richter L, 2008, AM J MED GENET A, V146A, P833, DOI 10.1002/ajmg.a.32236
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Rusmini P, 2011, NEUROBIOL DIS, V41, P83, DOI 10.1016/j.nbd.2010.08.023
   Rusmini P, 2010, NEUROBIOL DIS, V40, P361, DOI 10.1016/j.nbd.2010.06.016
   Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003
   Salinthone S, 2007, AM J PHYSIOL-LUNG C, V293, PL1194, DOI 10.1152/ajplung.00453.2006
   Santhiya S, 2006, MOL VIS, V12, P768
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Sau D, 2007, HUM MOL GENET, V16, P1604, DOI 10.1093/hmg/ddm110
   Sau D, 2011, BIOL CELL, V103, P87, DOI 10.1042/BC20100093
   Schmidt BJ, 2002, NEUROLOGY, V59, P770, DOI 10.1212/WNL.59.5.770
   Seidel K, 2012, NEUROPATH APPL NEURO, V38, P39, DOI 10.1111/j.1365-2990.2011.01198.x
   Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767
   Sharp PS, 2008, NEUROBIOL DIS, V30, P42, DOI 10.1016/j.nbd.2007.12.002
   Shefner JM, 1999, NEUROLOGY, V53, P1239, DOI 10.1212/WNL.53.6.1239
   Shemetov AA, 2011, ARCH BIOCHEM BIOPHYS, V513, P1, DOI 10.1016/j.abb.2011.06.014
   Simeoni S, 2000, HUM MOL GENET, V9, P133, DOI 10.1093/hmg/9.1.133
   SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209
   Song TF, 2009, J INT MED RES, V37, P1375, DOI 10.1177/147323000903700512
   Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584
   Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731
   Street VA, 2003, NEUROLOGY, V60, P22, DOI 10.1212/WNL.60.1.22
   Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095
   Sun X, 2010, CELL STRESS CHAPERON, V15, P567, DOI 10.1007/s12192-010-0169-y
   Takayama S, 2001, NATURE, V411, P1016, DOI 10.1038/35082637
   Takayama S, 2001, NAT CELL BIOL, V3, PE237, DOI 10.1038/ncb1001-e237
   Tang BS, 2005, HUM GENET, V116, P222, DOI 10.1007/s00439-004-1218-3
   Thomas M, 2006, HUM MOL GENET, V15, P1876, DOI 10.1093/hmg/ddl110
   Ticozzi N, 2010, CNS NEUROL DISORD-DR, V9, P285, DOI 10.2174/187152710791292585
   Tokui K, 2009, HUM MOL GENET, V18, P898, DOI 10.1093/hmg/ddn419
   Tradewell ML, 2009, J NEUROPATH EXP NEUR, V68, P642, DOI 10.1097/NEN.0b013e3181a5deeb
   Traub R, 2011, CURR NEUROL NEUROSCI, V11, P67, DOI 10.1007/s11910-010-0160-0
   Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x
   Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942
   Verhoeven K, 2003, AM J HUM GENET, V72, P722, DOI 10.1086/367847
   Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9
   Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765
   Vismara G, 2009, NEUROBIOL DIS, V33, P395, DOI 10.1016/j.nbd.2008.11.007
   Vleminckx V, 2002, J NEUROPATH EXP NEUR, V61, P968, DOI 10.1093/jnen/61.11.968
   Vos MJ, 2010, HUM MOL GENET, V19, P4677, DOI 10.1093/hmg/ddq398
   Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532
   Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298
   Waza M, 2006, J MOL MED, V84, P635, DOI 10.1007/s00109-006-0066-0
   Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200
   WEIGEL NL, 1995, J STEROID BIOCHEM, V53, P509, DOI 10.1016/0960-0760(95)00098-K
   Williams AJ, 2008, TRENDS NEUROSCI, V31, P521, DOI 10.1016/j.tins.2008.07.004
   Williams A, 2006, CURR TOP DEV BIOL, V76, P89, DOI 10.1016/S0070-2153(06)76003-3
   Wong M, 2010, HUM MOL GENET, V19, P2284, DOI 10.1093/hmg/ddq106
   Woulfe J, 2010, BRAIN PATHOL, V20, P589, DOI 10.1111/j.1750-3639.2009.00337.x
   Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137
   Xie R, 2010, BMC CELL BIOL, V11, P0, DOI 10.1186/1471-2121-11-89
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yamashita H, 2007, J NEUROCHEM, V102, P1497, DOI 10.1111/j.1471-4159.2007.04534.x
   YU WHA, 1989, J NEUROSCI, V9, P3908
   Zhai JB, 2007, HUM MOL GENET, V16, P3103, DOI 10.1093/hmg/ddm272
   Zhang HL, 2010, J MOL CELL CARDIOL, V49, P918, DOI 10.1016/j.yjmcc.2010.09.004
NR 239
TC 56
Z9 57
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-0082
EI 1873-5118
J9 PROG NEUROBIOL
JI Prog. Neurobiol.
PD MAY 15
PY 2012
VL 97
IS 2
BP 83
EP 100
DI 10.1016/j.pneurobio.2011.09.009
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA 952MH
UT WOS:000304796100004
PM 21971574
DA 2024-11-01
ER

PT J
AU Arredondo, JJ
   Gallardo, ME
   García-Pavía, P
   Domingo, V
   Bretón, B
   García-Silva, MT
   Sedano, MJ
   Martín, MA
   Arenas, J
   Cervera, M
   Garesse, R
   Bornstein, B
AF Arredondo, Juan J.
   Esther Gallardo, M.
   Garcia-Pavia, Pablo
   Domingo, Veronica
   Breton, Begona
   Teresa Garcia-Silva, M.
   Jesus Sedano, M.
   Martin, Miguel A.
   Arenas, Joaquin
   Cervera, Margarita
   Garesse, Rafael
   Bornstein, Belen
TI Mitochondrial tRNA valine as a recurrent target for mutations involved in mitochondrial cardiomyopathies
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial DNA; m.1628C > T; m.1644G > A; Mitochondrial tRNA quantification; Mitochondrial diseases; Mitochondrial cardiomyopathies
ID lactic-acidosis; dna; gene; trna(lys); sequence; aminoacylation; pathogenicity; myopathy; history
AB The aim of this study was to identify the genetic defect in two patients having cardiac dysfunction accompanied by neurological symptoms, and in one case MRI evidence of cortical and cerebellar atrophy with hyper-intensities in the basal ganglia. Muscle biopsies from each patient revealed single and combined mitochondrial respiratory chain deficiency. The complete mtDNA sequencing of both patients revealed two transitions in the mitochondrial tRNA(Val) gene (MT-TV) (m.1628C>T in Patient 1, and m.1644G>A in Patient 2). The functional and molecular analyses reported here suggest that the MT-TV gene should be routinely considered in the diagnosis of mitochondrial cardiomyopathies. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Arredondo, Juan J.; Esther Gallardo, M.; Domingo, Veronica; Breton, Begona; Cervera, Margarita; Garesse, Rafael; Bornstein, Belen] Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim,Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.
   [Esther Gallardo, M.; Martin, Miguel A.; Arenas, Joaquin; Garesse, Rafael; Bornstein, Belen] CIBERER, Madrid, Spain.
   [Garcia-Pavia, Pablo] Hosp Univ Puerta de Hierro, Serv Cardiol, Madrid, Spain.
   [Garcia-Pavia, Pablo] Red Invest Clin & Basica Insuficiencia Cardiaca R, Madrid, Spain.
   [Teresa Garcia-Silva, M.] Hosp Univ 12 Octubre, Serv Pediat, Madrid, Spain.
   [Jesus Sedano, M.] Hosp Gen Yague, Serv Neurol, Burgos, Spain.
   [Martin, Miguel A.; Arenas, Joaquin] Hosp Univ 12 Octubre, Ctr Invest, Lab Enfermedades Mitocondriales, Madrid, Spain.
   [Bornstein, Belen] Hosp Univ Puerta de Hierro, Serv Bioquim, Madrid, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Puerta de Hierro-Majadahonda; Hospital Universitario 12 de Octubre; Hospital General Yague; Hospital Universitario 12 de Octubre; Hospital Puerta de Hierro-Majadahonda
RP Bornstein, B (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim,Inst Invest Biomed Alberto Sols, C Arzobispo Morcillo 4, E-28029 Madrid, Spain.
EM belen.bornstein@uam.es
FU Instituto de Salud Carlos III (ISCIII), Ministry of Science and Innovation (MICIN) [PI060205, PI070167, PI060547]; Comunidad de Madrid (CM) [GEN-0269/2006]; Center for Biomedical Research on Rare Diseases (CIBERER); ISCIII-MICIN; Agencia Lain Entralgo (CM)
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 2009, MITOCHONDRION, V9, P242, DOI 10.1016/j.mito.2009.02.006
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bacman SR, 2003, BIOCHEM J, V374, P131, DOI 10.1042/BJ20030222
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Blakely EL, 2004, J NEUROL SCI, V225, P99, DOI 10.1016/j.jns.2004.07.007
   Bornstein B, 2005, BIOCHEM J, V387, P773, DOI 10.1042/BJ20040949
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Da Pozzo P, 2009, EUR J HUM GENET, V17, P1092, DOI 10.1038/ejhg.2009.12
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   DiMauro S, 2011, ACTA MYOL, V29, P333
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Gallardo ME, 2006, HUM MUTAT, V27, P575, DOI 10.1002/humu.20338
   García-Velasco A, 2003, J INTERN MED, V253, P381, DOI 10.1046/j.1365-2796.2003.01095.x
   Hirano M, 2001, CURR OPIN CARDIOL, V16, P201, DOI 10.1097/00001573-200105000-00008
   Horvath R, 2009, J NEUROL, V256, P810, DOI 10.1007/s00415-009-5023-8
   Ingman M, 2003, GENOME RES, V13, P1600, DOI 10.1101/gr.686603
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   Limongelli G, 2010, EUR J HEART FAIL, V12, P114, DOI 10.1093/eurjhf/hfp186
   Marín-García J, 2002, PEDIATR NEUROL, V27, P213, DOI 10.1016/S0887-8994(02)00426-5
   Marin-Garcia J, 2000, J CARD FAIL, V6, P321, DOI 10.1054/jcaf.2000.19232
   Martinez B, 2001, J NEUROCHEM, V78, P1054, DOI 10.1046/j.1471-4159.2001.00487.x
   MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P3065, DOI 10.1093/nar/gkn147
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Shimotake T, 1998, J PEDIATR SURG, V33, P1837, DOI 10.1016/S0022-3468(98)90301-3
   SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, PR1, DOI 10.1093/nar/17.1.1
   Tanji K, 2008, J NEUROL SCI, V270, P23, DOI 10.1016/j.jns.2008.01.016
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Tucker EJ, 2010, CURR NEUROL NEUROSCI, V10, P277, DOI 10.1007/s11910-010-0112-8
   Wahbi K, 2010, NEUROLOGY, V74, P674, DOI 10.1212/WNL.0b013e3181d0ccf4
   Yan NH, 2010, MOL VIS, V16, P1736
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 46
TC 13
Z9 13
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAR 15
PY 2012
VL 12
IS 2
BP 357
EP 362
DI 10.1016/j.mito.2011.09.010
PG 6
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 913VX
UT WOS:000301906600024
PM 21986556
DA 2024-11-01
ER

PT J
AU Levinger, L
   Serjanov, D
AF Levinger, Louis
   Serjanov, Dmitri
TI Pathogenesis-related mutations in the T-loops of human mitochondrial tRNAs affect 3′ end processing and tRNA structure
SO RNA BIOLOGY
LA English
DT Article
ID trnase-z; crystal-structure; flexible arm; gene; substrate; dna; substitutions; precursor; cleavage; identification
AB Numerous mutations in the mitochondrial genome are associated with maternally transmitted diseases and syndromes that affect muscle and other high energy-demand tissues. The mitochondrial genome encodes 13 polypeptides, 2 rRNAs and 22 interspersed tRNAs via long bidirectional polycistronic primary transcripts, requiring precise excision of the tRNAs. Despite making up only similar to 10% of the mitochondrial genome, tRNA genes harbor most of the pathogenesis-related mutations. tRNase Z endonucleolytically removes the pre-tRNA 3' trailer. The flexible arm of tRNase Z recognizes and binds the elbow (including the T-loop) of pre-tRNA. Pathogenesis-related T-loop mutations in mitochondrial tRNAs could thus affect tRNA structure, reduce tRNase Z binding and 3' processing, and consequently slow mitochondrial protein synthesis. Here we inspect the effects of pathogenesis-related mutations in the T-loops of mitochondrial tRNAs on pre-tRNA structure and tRNase Z processing. Increases in K-M arising from 59A > G substitutions in mitochondrial tRNA(Gly) and tRNA(Ile) accompany changes in T-loop structure, suggesting impaired substrate binding to enzyme.
C1 [Levinger, Louis; Serjanov, Dmitri] CUNY York Coll, Jamaica, NY 11451 USA.
C3 City University of New York (CUNY) System; York College NY (CUNY)
RP Levinger, L (corresponding author), CUNY York Coll, Jamaica, NY 11451 USA.
EM llevinger@york.cuny.edu
FU National Institutes of Health [SC3GM08153, R15CA120072]
CR AEBI M, 1990, J BIOL CHEM, V265, P16216
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009
   Brzezniak LK, 2011, RNA BIOL, V8, P616, DOI 10.4161/rna.8.4.15393
   Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470
   de la Sierra-Gallay IL, 2006, NAT STRUCT MOL BIOL, V13, P376, DOI 10.1038/nsmb1066
   de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284
   Dominski Z, 2007, CRIT REV BIOCHEM MOL, V42, P67, DOI 10.1080/10409230701279118
   Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182
   Fan LJ, 2011, BMC EVOL BIOL, V11, P0, DOI 10.1186/1471-2148-11-219
   Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   Gan XH, 2011, BIOCHEM J, V435, P103, DOI 10.1042/BJ20101619
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Hadjigeorgiou GM, 1999, J NEUROL SCI, V164, P153, DOI 10.1016/S0022-510X(99)00062-3
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Holzmann J, 2008, CELL, V135, P462, DOI 10.1016/j.cell.2008.09.013
   Hopkinson A, 2008, RNA BIOL, V5, P104, DOI 10.4161/rna.5.2.6086
   Ishii R, 2005, J BIOL CHEM, V280, P14138, DOI 10.1074/jbc.M500355200
   Ishii R, 2007, ACTA CRYSTALLOGR F, V63, P637, DOI 10.1107/S1744309107033623
   Karkashon S, 2007, BIOCHEMISTRY-US, V46, P9380, DOI 10.1021/bi700578v
   Kostelecky B, 2006, J BACTERIOL, V188, P1607, DOI 10.1128/JB.188.4.1607-1614.2006
   Leontis NB, 2002, NUCLEIC ACIDS RES, V30, P3497, DOI 10.1093/nar/gkf481
   Levinger L, 1998, J BIOL CHEM, V273, P1015, DOI 10.1074/jbc.273.2.1015
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   Levinger L, 2001, NUCLEIC ACIDS RES, V29, P4334, DOI 10.1093/nar/29.21.4334
   Levinger L, 2009, J BIOL CHEM, V284, P15685, DOI 10.1074/jbc.M900745200
   Maizels N, 1999, BIOL BULL, V196, P331, DOI 10.2307/1542963
   Mandel CR, 2006, NATURE, V444, P953, DOI 10.1038/nature05363
   MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980
   Mimaki M, 2003, J HUM GENET, V48, P47, DOI 10.1007/s100380300005
   Mineri R, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0005713
   MITOMAP, 2008, HUM MIT GEN, V0, P0
   MONTOYA J, 1981, NATURE, V290, P465, DOI 10.1038/290465a0
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   Pütz J, 2007, RNA, V13, P1184, DOI 10.1261/rna.588407
   Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h
   Rossmanith W, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0019152
   Santorelli FM, 1996, PEDIATR NEUROL, V15, P145, DOI 10.1016/0887-8994(96)00163-4
   Schaller A, 2011, MITOCHONDRION, V11, P488, DOI 10.1016/j.mito.2011.01.005
   Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769
   Schilling O, 2005, J BIOL CHEM, V280, P17857, DOI 10.1074/jbc.M500591200
   Shi PY, 1998, RNA, V4, P276
   Shin WS, 2000, AM J HUM GENET, V67, P1617, DOI 10.1086/316896
   TANAKA M, 1995, MUSCLE NERVE, V0, PS165
   Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808
   Toompuu M, 2004, BIOCHEM BIOPH RES CO, V322, P803, DOI 10.1016/j.bbrc.2004.07.181
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Xie X, 2011, INSECT BIOCHEM MOLEC, V41, P167, DOI 10.1016/j.ibmb.2010.12.001
   Yan H, 2006, J BIOL CHEM, V281, P3926, DOI 10.1074/jbc.M509822200
   Zhao W, 2010, BMC EVOL BIOL, V10, P0, DOI 10.1186/1471-2148-10-272
NR 55
TC 10
Z9 12
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
PD MAR 15
PY 2012
VL 9
IS 3
BP 283
EP 291
DI 10.4161/rna.19025
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 943BV
UT WOS:000304096300008
PM 22336717
DA 2024-11-01
ER

PT J
AU Garrido-Maraver, J
   Cordero, MD
   Moñino, ID
   Pereira-Arenas, S
   Lechuga-Vieco, AV
   Cotán, D
   De la Mata, M
   Oropesa-Avila, M
   De Miguel, M
   Lorite, JB
   Infante, ER
   Alvarez-Dolado, M
   Navas, P
   Jackson, S
   Francisci, S
   Sánchez-Alcázar, JA
AF Garrido-Maraver, Juan
   Cordero, Mario D.
   Dominguez Monino, Irene
   Pereira-Arenas, Sheila
   Lechuga-Vieco, Ana V.
   Cotan, David
   De la Mata, Mario
   Oropesa-Avila, Manuel
   De Miguel, Manuel
   Bautista Lorite, Juan
   Rivas Infante, Eloy
   Alvarez-Dolado, Manuel
   Navas, Placido
   Jackson, Sandra
   Francisci, Silvia
   Sanchez-Alcazar, Jose A.
TI Screening of effective pharmacological treatments for MELAS syndrome using yeasts, fibroblasts and cybrid models of the disease
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE coenzyme Q10; riboflavin; mitochondrial disease; MELAS; mitophagy
ID transfer rnaleu(uur) gene; mitochondrial-dna; lactic-acidosis; transfer-rna; coenzyme q(10); protein-synthesis; mutation; encephalopathy; myopathy; riboflavin
AB BACKGROUND AND PURPOSE MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) is a mitochondrial disease most usually caused by point mutations in tRNA genes encoded by mitochondrial DNA (mtDNA). Approximately 80% of cases of MELAS syndrome are associated with a m.3243A > G mutation in the MT-TL1 gene, which encodes the mitochondrial tRNALeu (UUR). Currently, no effective treatments are available for this chronic progressive disorder. Treatment strategies in MELAS and other mitochondrial diseases consist of several drugs that diminish the deleterious effects of the abnormal respiratory chain function, reduce the presence of toxic agents or correct deficiencies in essential cofactors. EXPERIMENTAL APPROACH We evaluated the effectiveness of some common pharmacological agents that have been utilized in the treatment of MELAS, in yeast, fibroblast and cybrid models of the disease. The yeast model harbouring the A14G mutation in the mitochondrial tRNALeu(UUR) gene, which is equivalent to the A3243G mutation in humans, was used in the initial screening. Next, the most effective drugs that were able to rescue the respiratory deficiency in MELAS yeast mutants were tested in fibroblasts and cybrid models of MELAS disease. KEY RESULTS According to our results, supplementation with riboflavin or coenzyme Q10 effectively reversed the respiratory defect in MELAS yeast and improved the pathologic alterations in MELAS fibroblast and cybrid cell models. CONCLUSIONS AND IMPLICATIONS Our results indicate that cell models have great potential for screening and validating the effects of novel drug candidates for MELAS treatment and presumably also for other diseases with mitochondrial impairment.
C1 [Garrido-Maraver, Juan; Cordero, Mario D.; Dominguez Monino, Irene; Pereira-Arenas, Sheila; Lechuga-Vieco, Ana V.; Cotan, David; De la Mata, Mario; Oropesa-Avila, Manuel; Navas, Placido; Sanchez-Alcazar, Jose A.] Univ Pablo Olavide, Consejo Super Invest Cient Junta de Andalucia, Inst Salud Carlos III, CABD, Seville 41013, Spain.
   [Garrido-Maraver, Juan; Cordero, Mario D.; Dominguez Monino, Irene; Pereira-Arenas, Sheila; Lechuga-Vieco, Ana V.; Cotan, David; De la Mata, Mario; Oropesa-Avila, Manuel; Navas, Placido; Sanchez-Alcazar, Jose A.] Univ Pablo Olavide, Consejo Super Invest Cient Junta de Andalucia, Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Seville 41013, Spain.
   [Rivas Infante, Eloy] Hosp Virgen del Rocio, Dept Anat Patol, Seville, Spain.
   [De Miguel, Manuel] Univ Seville, Fac Med, Dept Citol & Histol Normal & Patol, Seville, Spain.
   [Bautista Lorite, Juan] Hosp Sagrado Corazon, Seville, Spain.
   [Alvarez-Dolado, Manuel] Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Seville, Spain.
   [Jackson, Sandra] Uniklinikum CG Carus, Dresden, Germany.
   [Francisci, Silvia] Univ Roma La Sapienza, Dept Biol & Biotechnol, Rome, Italy.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); Instituto de Salud Carlos III; Universidad Pablo de Olavide; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Virgen del Rocio University Hospital; University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Technische Universitat Dresden; Sapienza University Rome
RP Sánchez-Alcázar, JA (corresponding author), Univ Pablo Olavide, Consejo Super Invest Cient Junta de Andalucia, Inst Salud Carlos III, CABD, Carretera Utrera Km 1, Seville 41013, Spain.
EM jasanalc@upo.es
FU Ministerio de Sanidad, Spain [FIS PI10/00543, FIS EC08/00076]; Fondo Europeo de Desarrollo Regional (FEDER-Union Europea) [SAS 111242]; Servicio Andaluz de Salud-Junta de Andalucia, Proyecto de Investigacion de Excelencia de la Junta de Andalucia [CTS-5725]; AEPMI (Asociacion de Enfermos de Patologia Mitocondrial); FEEL (Fundacion Espanola de Enfermedades Lisosomales); Federacion Andaluza de Fibromialgia y Fatiga Cronica (ALBA Andalucia); Colegio Oficial de Farmaceuticos de Sevilla
CR ADDISON R, 1978, BIOCHEM BIOPH RES CO, V81, P133, DOI 10.1016/0006-291X(78)91640-6
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Barrientos A, 2003, IUBMB LIFE, V55, P83, DOI 10.1080/1521654031000098122
   BODNAR AG, 1995, BIOCHEM J, V305, P817, DOI 10.1042/bj3050817
   Chinnery P, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub2
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Cotán D, 2011, FASEB J, V25, P2669, DOI 10.1096/fj.10-165340
   Crestanello JA, 2002, J SURG RES, V102, P221, DOI 10.1006/jsre.2001.6324
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   de Andrade PBM, 2006, DIABETOLOGIA, V49, P1816, DOI 10.1007/s00125-006-0301-9
   Depeint F, 2006, CHEM-BIOL INTERACT, V163, P94, DOI 10.1016/j.cbi.2006.04.014
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3
   FATO R, 1984, FEBS LETT, V172, P6, DOI 10.1016/0014-5793(84)80861-3
   Feuermann M, 2003, EMBO REP, V4, P53, DOI 10.1038/sj.embor.embor713
   Finsterer J, 2007, ACTA NEUROL SCAND, V116, P1, DOI 10.1111/j.1600-0404.2007.00836.x
   FOX TD, 1991, METHOD ENZYMOL, V194, P149
   Gajewski CD, 2003, MOL BIOL CELL, V14, P3628, DOI 10.1091/mbc.E02-12-0796
   Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546
   Gold DR, 2001, SEMIN NEUROL, V21, P309, DOI 10.1055/s-2001-17948
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Herbert V, 1996, J NUTR, V126, PS1197, DOI 10.1093/jn/126.suppl_4.1197S
   Higashi-Okai Kiyoka, 2006, JOURNAL OF UOEH, V28, P359
   Hilton G, 1995, J NEUROSCI NURS, V27, P278
   Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169
   Jacobson J, 2002, J NEUROCHEM, V82, P224, DOI 10.1046/j.1471-4159.2002.00945.x
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401
   Kerr DS, 2010, MOL GENET METAB, V99, P246, DOI 10.1016/j.ymgme.2009.11.005
   Khan SM, 2007, AM J PHYSIOL-CELL PH, V292, PC658, DOI 10.1152/ajpcell.00224.2006
   Kim G, 2002, MUTAGENESIS, V17, P375, DOI 10.1093/mutage/17.5.375
   Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Koga Y, 2010, ANN NY ACAD SCI, V1201, P104, DOI 10.1111/j.1749-6632.2010.05624.x
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Ma D, 2001, PROG DRUG RES, V57, P117
   Marriage B, 2003, J AM DIET ASSOC, V103, P1029, DOI 10.1016/S0002-8223(03)00476-0
   MATTHEWS PM, 1993, NEUROLOGY, V43, P884, DOI 10.1212/WNL.43.5.884
   Montanari A, 2008, RNA, V14, P275, DOI 10.1261/rna.740108
   Montini G, 2008, NEW ENGL J MED, V358, P2849, DOI 10.1056/NEJMc0800582
   Powers HJ, 1999, P NUTR SOC, V58, P435, DOI 10.1017/S0029665199000579
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Quinzii CM, 2007, NEUROCHEM RES, V32, P723, DOI 10.1007/s11064-006-9190-z
   Quinzii CM, 2010, DEV DISABIL RES REV, V16, P183, DOI 10.1002/ddrr.108
   Rinaldi T, 2010, FEMS YEAST RES, V10, P1006, DOI 10.1111/j.1567-1364.2010.00685.x
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2011, MOL GENET METAB, V104, P39, DOI 10.1016/j.ymgme.2011.07.016
   Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014
   Santa KM, 2010, PHARMACOTHERAPY, V30, P1179, DOI 10.1592/phco.30.11.1179
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   Smith MG, 2006, CURRENT PROTOCOLS IN HUMAN GENETICS, V0, P0
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Tafrechi RSJ, 2005, MUTAT RES-FUND MOL M, V578, P43, DOI 10.1016/j.mrfmmm.2005.02.002
   Thambisetty M, 2002, NEUROLOGIST, V8, P302, DOI 10.1097/00127893-200209000-00003
   Vergani L, 1999, BRAIN, V122, P2401, DOI 10.1093/brain/122.12.2401
   Zeviani M, 2007, CURR OPIN NEUROL, V20, P564, DOI 10.1097/WCO.0b013e3282ef58cd
NR 65
TC 32
Z9 35
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV 15
PY 2012
VL 167
IS 6
BP 1311
EP 1328
DI 10.1111/j.1476-5381.2012.02086.x
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 024AR
UT WOS:000310080300012
PM 22747838
DA 2024-11-01
ER

PT J
AU Finsterer, J
   Höftberger, R
   Stöllberger, C
   Rolinski, B
AF Finsterer, Josef
   Hoeftberger, Romana
   Stoellberger, Claudia
   Rolinski, Boris
TI Mimicry between mitochondrial disorder and multiple sclerosis
SO METABOLIC BRAIN DISEASE
LA English
DT Article
DE Multiple sclerosis; Metabolic defect; Respiratory chain; Mitochondrial dysfunction; Metabolic myopathy; Leucencephalopathy
ID respiratory-chain defects; optic neuropathy; imaging findings; dna; deficiency; mutation; illness
AB Under certain conditions or at certain stages of the disease course, multiple sclerosis (MS) and mitochondrial disorder (MID) may be differential diagnoses and thus may be confused with each other. In a 30 years old female MS was diagnosed at age 16 year upon recurrent sensory disturbances of the right lower leg, an "inflammatory" cerebrospinal fluid, and a cerebral MRI with multiple non-enhancing white matter lesions. Steroids were repeatedly given but because of rapid deterioration treatment was switched to interferon and mitoxantrone, without improvement. Fourteen years after onset the patient additionally presented with a history of rhabdomyolysis, hypothyroidism, ophthalmoparesis, anarthria, tetraspasticity, tetraparesis, and joint contractures. After MID had been diagnosed in her mother she was re-evaluated and elevated resting lactate, axonal polyneuropathy, and empty sella were additionally found. Muscle biopsy revealed myophagy, fat deposition, and type-II predominance, and biochemical investigations showed a deficiency of complex I and IV of the respiratory chain. MID was diagnosed also in the index patient. It is concluded that even if CSF investigations or imaging studies suggest MS, differentials such as MIDs need to be excluded before prescribing medication possibly toxic to a MID. An "inflammatory CSF" may also occur in MIDs.
C1 [Finsterer, Josef] Danube Univ Krems, Krems, Austria.
   [Hoeftberger, Romana] Med Univ Vienna, Clin Inst Neurol, Vienna, Austria.
   [Stoellberger, Claudia] Krankenanstaltung Rudolfstiftung, Dept Med 2, Vienna, Austria.
   [Rolinski, Boris] Acad Hosp Munchen Schwabing, Inst Clin Chem, Munich, Germany.
C3 Danube University Krems; Medical University of Vienna; Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Postfach 20 Europe, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Ahlbeck K, 2009, ACTA ANAESTH SCAND, V53, P717, DOI 10.1111/j.1399-6576.2009.01952.x
   Bargalló N, 2000, AM J NEURORADIOL, V21, P479
   Barragán-Campos HM, 2005, ARCH NEUROL-CHICAGO, V62, P737, DOI 10.1001/archneur.62.5.737
   Castro-Gago M, 1999, REV NEUROLOGIA, V29, P912, DOI 10.33588/rn.2910.99062
   Chinnery PF, 1999, LANCET, V354, P0
   DAguanno S, 2008, J NEUROIMMUNOL, V193, P156, DOI 10.1016/j.jneuroim.2007.10.004
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Geldof K, 2007, JBR-BTR, V90, P288
   HARDING AE, 1992, BRAIN, V115, P979, DOI 10.1093/brain/115.4.979
   Hasselmann O, 2010, MOL GENET METAB, V99, P58, DOI 10.1016/j.ymgme.2009.08.005
   Isohanni P, 2010, J MED GENET, V47, P66, DOI 10.1136/jmg.2009.068221
   Kihira Tameko, 2004, RINSHO SHINKEIGAKU, V44, P187
   Kim J, 2008, EUR RADIOL, V18, P1741, DOI 10.1007/s00330-008-0921-1
   Kumleh HH, 2006, J NEUROL SCI, V243, P65, DOI 10.1016/j.jns.2005.11.030
   Marie SKN, 1999, ARQ NEURO-PSIQUIAT, V57, P1017, DOI 10.1590/S0004-282X1999000600020
   Marrie RA, 2001, EPILEPSIA, V42, P430, DOI 10.1046/j.1528-1157.2001.15800.x
   Maruyama S, 1998, RINSHO SHINKEIGAKU, V38, P641
   OLSEN NK, 1995, ACTA NEUROL SCAND, V91, P326, DOI 10.1111/j.1600-0404.1995.tb07016.x
   Palace J, 2009, J NEUROL SCI, V286, P24, DOI 10.1016/j.jns.2009.09.009
   Parry-Jones A R, 2008, PRACT NEUROL, V8, P118, DOI 10.1136/jnnp.2007.139360
   Pato-Pato A, 2006, REV NEUROLOGIA, V42, P22, DOI 10.33588/rn.4201.2005404
   RESZKA K, 1986, JOURNAL OF FREE RADICALS IN BIOLOGY AND MEDICINE, V2, P25, DOI 10.1016/0748-5514(86)90120-0
   Robeck S, 1996, NERVENARZT, V67, P465
   Scaglia F, 2005, AM J NEURORADIOL, V26, P1675
   Yis U, 2009, EUR J PAEDIATR NEURO, V13, P550, DOI 10.1016/j.ejpn.2008.10.009
NR 25
TC 4
Z9 6
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
EI 
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD JUN 15
PY 2012
VL 27
IS 2
BP 217
EP 220
DI 10.1007/s11011-012-9277-y
PG 4
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 940BO
UT WOS:000303865200014
PM 22311611
DA 2024-11-01
ER

PT J
AU Pitceathly, RDS
   Smith, C
   Fratter, C
   Alston, CL
   He, LP
   Craig, K
   Blakely, EL
   Evans, JC
   Taylor, J
   Shabbir, Z
   Deschauer, M
   Pohl, U
   Roberts, ME
   Jackson, MC
   Halfpenny, CA
   Turnpenny, PD
   Lunt, PW
   Hanna, MG
   Schaefer, AM
   McFarland, R
   Horvath, R
   Chinnery, PF
   Turnbull, DM
   Poulton, J
   Taylor, RW
   Gorman, GS
AF Pitceathly, Robert D. S.
   Smith, Conrad
   Fratter, Carl
   Alston, Charlotte L.
   He, Langping
   Craig, Kate
   Blakely, Emma L.
   Evans, Julie C.
   Taylor, John
   Shabbir, Zarfishan
   Deschauer, Marcus
   Pohl, Ute
   Roberts, Mark E.
   Jackson, Matthew C.
   Halfpenny, Christopher A.
   Turnpenny, Peter D.
   Lunt, Peter W.
   Hanna, Michael G.
   Schaefer, Andrew M.
   McFarland, Robert
   Horvath, Rita
   Chinnery, Patrick F.
   Turnbull, Douglass M.
   Poulton, Joanna
   Taylor, Robert W.
   Gorman, Grainne S.
TI Adults with <i>RRM2B</i>-related mitochondrial disease have distinct clinical and molecular characteristics
SO BRAIN
LA English
DT Article
DE mitochondrial DNA; mtDNA maintenance; mtDNA depletion; multiple mitochondrial DNA deletions; RRM2B
ID progressive external ophthalmoplegia; dna depletion syndrm; real-time pcr; polymerase gamma; individual cells; mtdna deletions; mutations; gene; rrm2b; diagnosis
AB Mutations in the nuclear-encoded mitochondrial maintenance gene RRM2B are an important cause of familial mitochondrial disease in both adults and children and represent the third most common cause of multiple mitochondrial DNA deletions in adults, following POLG [polymerase (DNA directed), gamma] and PEO1 (now called C10ORF2, encoding the Twinkle helicase) mutations. However, the clinico-pathological and molecular features of adults with RRM2B-related disease have not been clearly defined. In this multicentre study of 26 adult patients from 22 independent families, including five additional cases published in the literature, we show that extra-ocular neurological complications are common in adults with genetically confirmed RRM2B mutations. We also demonstrate a clear correlation between the clinical phenotype and the underlying genetic defect. Myopathy was a prominent manifestation, followed by bulbar dysfunction and fatigue. Sensorineural hearing loss and gastrointestinal disturbance were also important findings. Severe multisystem neurological disease was associated with recessively inherited compound heterozygous mutations with a mean age of disease onset at 7 years. Dominantly inherited heterozygous mutations were associated with a milder predominantly myopathic phenotype with a later mean age of disease onset at 46 years. Skeletal muscle biopsies revealed subsarcolemmal accumulation of mitochondria and/or cytochrome c oxidase-deficient fibres. Multiple mitochondrial DNA deletions were universally present in patients who underwent a muscle biopsy. We identified 18 different heterozygous RRM2B mutations within our cohort of patients, including five novel mutations that have not previously been reported. Despite marked clinical overlap between the mitochondrial maintenance genes, key clinical features such as bulbar dysfunction, hearing loss and gastrointestinal disturbance should help prioritize genetic testing towards RRM2B analysis, and sequencing of the gene may preclude performance of a muscle biopsy.
C1 [Gorman, Grainne S.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Pitceathly, Robert D. S.; Hanna, Michael G.] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England.
   [Pitceathly, Robert D. S.; Hanna, Michael G.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.
   [Smith, Conrad; Fratter, Carl; Evans, Julie C.; Taylor, John] Churchill Hosp, Oxford Med Genet Labs, Oxford OX3 7LE, England.
   [Deschauer, Marcus] Univ Halle Wittenberg, Dept Neurol, D-06097 Halle, Germany.
   [Pohl, Ute] Queens Hosp, Dept Cellular Pathol, Romford RM7 0AG, Essex, England.
   [Roberts, Mark E.] Salford Royal NHS Fdn Trust, Dept Neurol, Salford M6 8HD, Lancs, England.
   [Jackson, Matthew C.] Wycombe Gen Hosp, Dept Neurol, High Wycombe HP11 2TT, Bucks, England.
   [Halfpenny, Christopher A.] Queen Alexandra Hosp, Dept Neurol, Portsmouth PO6 3LY, Hants, England.
   [Turnpenny, Peter D.] Royal Devon & Exeter Hosp, Dept Clin Genet, Exeter EX2 5DW, Devon, England.
   [Lunt, Peter W.] Gloucester Royal Hosp, Dept Clin Genet, Gloucester GL1 3NN, England.
   [Horvath, Rita; Chinnery, Patrick F.] Newcastle Univ, Inst Genet Med, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Poulton, Joanna] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
C3 Newcastle University - UK; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Oxford; Martin Luther University Halle Wittenberg; Salford Royal NHS Foundation Trust; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Exeter; Newcastle University - UK; University of Oxford
RP Gorman, GS (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM grainne.gorman@ncl.ac.uk
FU MRC Centre for Translational Research in Neuromuscular Disease Mitochondrial Disease Patient Cohort (UK) [G0800674]; Wellcome Trust Centre for Mitochondrial Research [906919]; MRC Centre for Neuromuscular Diseases [G0601943]; Newcastle University Centre for Brain Ageing and Vitality; BBSRC; EPSRC; ESRC; MRC [G0700718]; Wellcome Trust [074454/Z/04/Z]; UK NIHR Biomedical Research Centre for Ageing and Age-related disease award; German Federal Ministry of Education and Research (BMBF); MRC [G1000848, G0700718, G0800674, G0601943] Funding Source: UKRI
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pitceathly RDS, 2011, J MED GENET, V48, P610, DOI 10.1136/jmg.2010.088328
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Smith P, 2009, BIOCHEMISTRY-US, V48, P11134, DOI 10.1021/bi9001425
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Takata A, 2011, GENOME BIOL, V12, P0, DOI 10.1186/gb-2011-12-9-r92
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Zhang KQ, 2011, MOL CANCER THER, V10, P269, DOI 10.1158/1535-7163.MCT-10-0728
NR 28
TC 60
Z9 62
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD NOV 15
PY 2012
VL 135
IS 
BP 3392
EP 3403
DI 10.1093/brain/aws231
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 044SV
UT WOS:000311644800024
PM 23107649
DA 2024-11-01
ER

PT J
AU Sangatsuda, Y
   Nakamura, M
   Tomiyasu, A
   Deguchi, A
   Toyota, Y
   Goto, Y
   Nishino, I
   Ueno, S
   Sano, A
AF Sangatsuda, Yoko
   Nakamura, Masayuki
   Tomiyasu, Akiyuki
   Deguchi, Akiko
   Toyota, Yasutaka
   Goto, Yu-ichi
   Nishino, Ichizo
   Ueno, Shu-ichi
   Sano, Akira
TI Heteroplasmic m.1624C&gt;T mutation of the mitochondrial tRNA<SUP>Val</SUP> gene in a proband and his mother with repeated consciousness disturbances
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial DNA mutation; m.1624C > T; Mitochondrial tRNA(Val) gene; Heteroplasmy; Neuropsychiatric symptoms
ID bipolar disorder; dna mutation; melas; encephalomyopathy; diseases; deafness; muscle; load
AB Homoplasmic m.1624C>T mutation of the mitochondrial tRNA(Val) gene was previously demonstrated to cause fatal neonatal Leigh syndrome. Here, we report the clinical phenotypes of a Japanese male and his mother with heteroplasmic m.1624C>T mutation. The 36-year-old male presented with repeated episodes of consciousness disturbance since the age of 25, cognitive decline, and personality change. Cerebrospinal fluid levels of lactate and pyruvate were elevated. His mother showed similar symptoms and course. The mutation m.1624C>T was identified heteroplasmically in the proband's muscle and leukocytes and in the mother's leukocytes. The heteroplasmy load decreased with age. (C) 2012 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Sangatsuda, Yoko; Nakamura, Masayuki; Tomiyasu, Akiyuki; Deguchi, Akiko; Sano, Akira] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Psychiat, Kagoshima 8908520, Japan.
   [Toyota, Yasutaka; Ueno, Shu-ichi] Ehime Univ, Grad Sch Med, Dept Neuropsychiat, Shitsukawa, Toon Ehime 7910295, Japan.
   [Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Kodaira, Tokyo 1878502, Japan.
   [Nishino, Ichizo] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Tokyo 1878502, Japan.
C3 Kagoshima University; Ehime University; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan
RP Sano, A (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Psychiat, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM yoko38@m2.kufm.kagoshima-u.ac.jp; nakamu36@m.kufm.kagoshima-u.ac.jp; aki-tomy@m2.kufm.kagoshima-u.ac.jp; akiko48@m2.kufm.kagoshima-u.ac.jp; yatoyota@m.ehime-u.ac.jp; goto@ncnp.go.jp; nishino@ncnp.go.jp; ueno@m.ehime-u.acjp; sano@m3.lufm.kagoshima-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan; Research Committee of CNS Degenerative Diseases; Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research [23390291] Funding Source: KAKEN
CR [Anonymous], 1997, ADMINISTRATION AND SCORING GUIDE, V0, P0
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Choi BO, 2010, EXP MOL MED, V42, P446, DOI 10.3858/emm.2010.42.6.046
   CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Fattal O, 2006, PSYCHOSOMATICS, V47, P1, DOI 10.1176/appi.psy.47.1.1
   Genasetti A, 2007, J MOL DIAGN, V9, P538, DOI 10.2353/jmoldx.2007.060183
   Ichiba M, 2007, J NEUROL SCI, V263, P124, DOI 10.1016/j.jns.2007.07.011
   Jeppesen TD, 2006, ARCH NEUROL-CHICAGO, V63, P1701, DOI 10.1001/archneur.63.12.1701
   Kato M, 2011, NEUROSCI RES, V69, P331, DOI 10.1016/j.neures.2010.12.013
   Laloi-Michelin M, 2009, J CLIN ENDOCR METAB, V94, P3025, DOI 10.1210/jc.2008-2680
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Munakata K, 2007, MUTAT RES-FUND MOL M, V617, P119, DOI 10.1016/j.mrfmmm.2007.01.006
   NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   Nomiyama T, 2004, ANN NY ACAD SCI, V1011, P193, DOI 10.1196/annals.1293.020
   Olsson C, 2001, EUR J HUM GENET, V9, P917, DOI 10.1038/sj.ejhg.5200742
   Rollins B, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0004913
   Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P3065, DOI 10.1093/nar/gkn147
   Rossignol DA, 2012, MOL PSYCHIATR, V17, P290, DOI 10.1038/mp.2010.136
   Sakiyama Y, 2011, ACTA NEUROPATHOL, V121, P775, DOI 10.1007/s00401-011-0818-y
   SHIRAIWA N, 1993, J NEUROL SCI, V120, P174, DOI 10.1016/0022-510X(93)90270-9
   tHart LM, 1996, HUM MUTAT, V7, P193
   Wechsler D, 1981, WAIS R MANUAL, V0, P0
   Zhang CF, 1998, HUM MUTAT, V11, P360
NR 28
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD NOV 15
PY 2012
VL 12
IS 6
BP 617
EP 622
DI 10.1016/j.mito.2012.10.002
PG 6
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 046IQ
UT WOS:000311759100004
PM 23063709
DA 2024-11-01
ER

PT J
AU Lenaers, G
   Hamel, C
   Delettre, C
   Amati-Bonneau, P
   Procaccio, V
   Bonneau, D
   Reynier, P
   Milea, D
AF Lenaers, Guy
   Hamel, Christian
   Delettre, Cecile
   Amati-Bonneau, Patrizia
   Procaccio, Vincent
   Bonneau, Dominique
   Reynier, Pascal
   Milea, Dan
TI Dominant optic atrophy
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Review
ID mitochondrial-dna instability; sensorineural hearing-loss; dynamin-related protein; retinal ganglion-cells; chromosome 3q region; mouse model; opa1 mutations; missense mutation; genetic-heterogeneity; clinical-features
AB Definition of the disease: Dominant Optic Atrophy (DOA) is a neuro-ophthalmic condition characterized by a bilateral degeneration of the optic nerves, causing insidious visual loss, typically starting during the first decade of life. The disease affects primary the retinal ganglion cells (RGC) and their axons forming the optic nerve, which transfer the visual information from the photoreceptors to the lateral geniculus in the brain. Epidemiology: The prevalence of the disease varies from 1/10000 in Denmark due to a founder effect, to 1/30000 in the rest of the world. Clinical description: DOA patients usually suffer of moderate visual loss, associated with central or paracentral visual field deficits and color vision defects. The severity of the disease is highly variable, the visual acuity ranging from normal to legal blindness. The ophthalmic examination discloses on fundoscopy isolated optic disc pallor or atrophy, related to the RGC death. About 20% of DOA patients harbour extraocular multi-systemic features, including neurosensory hearing loss, or less commonly chronic progressive external ophthalmoplegia, myopathy, peripheral neuropathy, multiple sclerosis-like illness, spastic paraplegia or cataracts. Aetiology: Two genes (OPA1, OPA3) encoding inner mitochondrial membrane proteins and three loci (OPA4, OPA5, OPA8) are currently known for DOA. Additional loci and genes (OPA2, OPA6 and OPA7) are responsible for X-linked or recessive optic atrophy. All OPA genes yet identified encode mitochondrial proteins embedded in the inner membrane and ubiquitously expressed, as are the proteins mutated in the Leber Hereditary Optic Neuropathy. OPA1 mutations affect mitochondrial fusion, energy metabolism, control of apoptosis, calcium clearance and maintenance of mitochondrial genome integrity. OPA3 mutations only affect the energy metabolism and the control of apoptosis. Diagnosis: Patients are usually diagnosed during their early childhood, because of bilateral, mild, otherwise unexplained visual loss related to optic discs pallor or atrophy, and typically occurring in the context of a family history of DOA. Optical Coherence Tomography further discloses non-specific thinning of retinal nerve fiber layer, but a normal morphology of the photoreceptors layers. Abnormal visual evoked potentials and pattern ERG may also reflect the dysfunction of the RGCs and their axons. Molecular diagnosis is provided by the identification of a mutation in the OPA1 gene (75% of DOA patients) or in the OPA3 gene (1% of patients). Prognosis: Visual loss in DOA may progress during puberty until adulthood, with very slow subsequent chronic progression in most of the cases. On the opposite, in DOA patients with associated extra-ocular features, the visual loss may be more severe over time. Management: To date, there is no preventative or curative treatment in DOA; severely visually impaired patients may benefit from low vision aids. Genetic counseling is commonly offered and patients are advised to avoid alcohol and tobacco consumption, as well as the use of medications that may interfere with mitochondrial metabolism. Gene and pharmacological therapies for DOA are currently under investigation.
C1 [Lenaers, Guy; Hamel, Christian; Delettre, Cecile] Univ Montpellier I & II, Inst Neurosci Montpellier, U1051, INSERM, F-34091 Montpellier 05, France.
   [Hamel, Christian] Hop Gui De Chauliac, CHRU Montpellier, Ctr Reference Malad Sensorielles Genet, F-34295 Montpellier, France.
   [Amati-Bonneau, Patrizia; Procaccio, Vincent; Bonneau, Dominique; Reynier, Pascal; Milea, Dan] INSERM, U1083, F-49000 Angers, France.
   [Amati-Bonneau, Patrizia; Procaccio, Vincent; Bonneau, Dominique; Reynier, Pascal; Milea, Dan] CNRS 6214, F-49000 Angers, France.
   [Amati-Bonneau, Patrizia; Procaccio, Vincent; Bonneau, Dominique; Reynier, Pascal; Milea, Dan] CHU Angers, F-49000 Angers, France.
   [Milea, Dan] Glostrup Univ Hosp, Copenhagen, Denmark.
C3 Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre National de la Recherche Scientifique (CNRS); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; University of Copenhagen
RP Lenaers, G (corresponding author), Univ Montpellier I & II, Inst Neurosci Montpellier, U1051, INSERM, BP 74103, F-34091 Montpellier 05, France.
EM guy.lenaers@inserm.fr
FU INSERM; CNRS, Universite Montpellier I et II, France; University of Angers, France; European E-Rare program
CR Alavi MV, 2007, BRAIN, V130, P1029, DOI 10.1093/brain/awm005
   Alavi MV, 2009, EXP NEUROL, V220, P404, DOI 10.1016/j.expneurol.2009.09.026
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Almind GJ, 2011, BMC MED GENET, V12, P0, DOI 10.1186/1471-2350-12-49
   Alward WLM, 2003, BRIT J OPHTHALMOL, V87, P2, DOI 10.1136/bjo.87.1.2
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2003, AM J OPHTHALMOL, V136, P1170, DOI 10.1016/S0002-9394(03)00665-2
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Amati-Bonneau P, 2009, INT J BIOCHEM CELL B, V41, P1855, DOI 10.1016/j.biocel.2009.04.012
   Andrews RM, 1999, BRIT J OPHTHALMOL, V83, P231, DOI 10.1136/bjo.83.2.231
   Anikster Y, 2001, AM J HUM GENET, V69, P1218, DOI 10.1086/324651
   Assink JJM, 1997, AM J HUM GENET, V61, P934, DOI 10.1086/514884
   Barbet F, 2005, J MED GENET, V42, P0, DOI 10.1136/jmg.2004.025502
   Barbet F, 2003, EUR J HUM GENET, V11, P966, DOI 10.1038/sj.ejhg.5201070
   Barboni P, 2010, OPHTHALMOLOGY, V117, P1547, DOI 10.1016/j.ophtha.2009.12.042
   Barnard AR, 2011, EXP EYE RES, V93, P771, DOI 10.1016/j.exer.2011.07.004
   Barrett TG, 1997, J MED GENET, V34, P838, DOI 10.1136/jmg.34.10.838
   Barrett TG, 1997, EYE, V11, P882, DOI 10.1038/eye.1997.226
   Batten B, 1896, TRANS OPHTHALMOL SOC UK, V16, P125
   BONNEAU D, 1995, J MED GENET, V32, P951, DOI 10.1136/jmg.32.12.951
   Bremner FD, 2001, INVEST OPHTH VIS SCI, V42, P675
   Bristow EA, 2002, ARCH OPHTHALMOL-CHIC, V120, P791
   Carelli V, 2007, BIOSCIENCE REP, V27, P173, DOI 10.1007/s10540-007-9045-0
   Carelli V, 2011, HUM MOL GENET, V20, P1893, DOI 10.1093/hmg/ddr071
   Chevrollier A, 2008, ANN NEUROL, V63, P794, DOI 10.1002/ana.21385
   Cohn AC, 2008, BRIT J OPHTHALMOL, V92, P1333, DOI 10.1136/bjo.2007.134726
   Cornille K, 2008, ANN NEUROL, V63, P667, DOI 10.1002/ana.21376
   Da Cruz S, 2003, J BIOL CHEM, V278, P41566, DOI 10.1074/jbc.M304940200
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   Dayanithi G, 2010, OPHTHALMIC GENET, V31, P53, DOI 10.3109/13816811003698117
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278
   Eiberg H, 2006, J MED GENET, V43, P435, DOI 10.1136/jmg.2005.034892
   EIBERG H, 1994, HUM MOL GENET, V3, P977, DOI 10.1093/hmg/3.6.977
   Elachouri G, 2011, GENOME RES, V21, P12, DOI 10.1101/gr.108696.110
   Ferré M, 2009, HUM MUTAT, V30, PE692, DOI 10.1002/humu.21025
   Fuhrmann N, 2009, J MED GENET, V46, P136, DOI 10.1136/jmg.2008.062570
   Fuhrmann N, 2010, MOL NEURODEGENER, V5, P0, DOI 10.1186/1750-1326-5-25
   Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200
   Griscom J, 1921, AM J OPHTHALMOL, V5, P347
   Hanein S, 2009, AM J HUM GENET, V84, P493, DOI 10.1016/j.ajhg.2009.03.003
   Heiduschka P, 2010, INVEST OPHTH VIS SCI, V51, P1424, DOI 10.1167/iovs.09-3606
   Holder GE, 1998, DOC OPHTHALMOL, V95, P217, DOI 10.1023/A:1001844021014
   Huang TS, 2009, BRAIN RES, V1300, P97, DOI 10.1016/j.brainres.2009.08.083
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177
   Katz BJ, 2006, AM J MED GENET A, V140A, P2207, DOI 10.1002/ajmg.a.31455
   Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805
   Kjer B, 1996, ACTA OPHTHALMOL SCAN, V74, P3
   KJER P, 1959, ACTA OPHTHALMOL SUPPL, V164, P1
   Kleta R, 2002, MOL GENET METAB, V76, P201, DOI 10.1016/S1096-7192(02)00047-1
   La Morgia C, 2010, BRAIN, V133, P2426, DOI 10.1093/brain/awq155
   Lenaers G, 2009, INT J BIOCHEM CELL B, V41, P1866, DOI 10.1016/j.biocel.2009.04.013
   Li CM, 2005, AM J MED GENET A, V138A, P208, DOI 10.1002/ajmg.a.30794
   Man CYYW, 2005, MED HYPOTHESES, V65, P1038, DOI 10.1016/j.mehy.2004.10.021
   Marelli C, 2011, BRAIN, V134, P0, DOI 10.1093/brain/awq306
   Milea D, 2010, ACTA OPHTHALMOL, V88, P342, DOI 10.1111/j.1755-3768.2008.01469.x
   Milea D, 2010, CURR OPIN NEUROL, V23, P24, DOI 10.1097/WCO.0b013e3283347b27
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   Nettleship E, 1909, T OPHTHAL SOC UK, V29, P116
   Nochez Y, 2009, MOL VIS, V15, P598
   Olichon A, 2007, CELL DEATH DIFFER, V14, P682, DOI 10.1038/sj.cdd.4402048
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X
   Olichow A, 2007, J CELL PHYSIOL, V211, P423, DOI 10.1002/jcp.20950
   Osborne NN, 2008, J NEUROCHEM, V105, P2013, DOI 10.1111/j.1471-4159.2008.05320.x
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Pierron D, 2009, BMC MED GENET, V10, P0, DOI 10.1186/1471-2350-10-70
   Pretegiani E, 2011, BRAIN, V134, P0, DOI 10.1093/brain/awr101
   Puomila A, 2005, ACTA OPHTHALMOL SCAN, V83, P337, DOI 10.1111/j.1600-0420.2005.00448.x
   Rendtorff ND, 2011, AM J MED GENET A, V155A, P1298, DOI 10.1002/ajmg.a.33970
   Reynier P, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.016576
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Schaaf CP, 2011, MOL GENET METAB, V103, P383, DOI 10.1016/j.ymgme.2011.04.018
   SMITH DP, 1972, AMER J OPT ARCH AM A, V49, P183
   Snell S, 1897, TRANS OPHTHALMOL SOC UK, V17, P66
   Spinazzi M, 2008, HUM MOL GENET, V17, P3291, DOI 10.1093/hmg/ddn225
   Taban M, 2006, J CHILD NEUROL, V21, P956, DOI 10.1177/08830738060210111601
   Thiselton DL, 2002, INVEST OPHTH VIS SCI, V43, P1715
   Toomes C, 2001, HUM MOL GENET, V10, P1369, DOI 10.1093/hmg/10.13.1369
   TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257
   Verny C, 2008, NEUROLOGY, V70, P1152, DOI 10.1212/01.wnl.0000289194.89359.a1
   Voisin J, 1949, B SOC OPHT FRANCE, V2, P0
   Volker-Dieben H J, 1974, MOD PROBL OPHTHALMOL, V13, P277
   Voo I, 2003, AM J OPHTHALMOL, V136, P670, DOI 10.1016/S0002-9394(03)00390-8
   Votruba M, 1998, J MED GENET, V35, P793, DOI 10.1136/jmg.35.10.793
   Votruba M, 2003, BRIT J OPHTHALMOL, V87, P48, DOI 10.1136/bjo.87.1.48
   Votruba M, 1998, ARCH OPHTHALMOL-CHIC, V116, P351, DOI 10.1001/archopht.116.3.351
   Wang L, 2003, INVEST OPHTH VIS SCI, V44, P2, DOI 10.1167/iovs.02-0333
   WENT LN, 1975, J MED GENET, V12, P94, DOI 10.1136/jmg.12.1.94
   White KE, 2009, INVEST OPHTH VIS SCI, V50, P2567, DOI 10.1167/iovs.08-2913
   Williams PA, 2010, BRAIN, V133, P2942, DOI 10.1093/brain/awq218
   Yu-Wai-Man P, 2011, EYE, V25, P597, DOI 10.1038/eye.2011.2
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2010, J MED GENET, V47, P120, DOI 10.1136/jmg.2009.067512
   Yu-Wai-Man P, 2009, J MED GENET, V46, P145, DOI 10.1136/jmg.2007.054270
   Yu-Wai-Man P, 2010, BRAIN, V0, P0
   Yu-Wai-Man P, 2010, OPHTHALMOLOGY, V117, P1538, DOI 10.1016/j.ophtha.2009.12.038
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 101
TC 189
Z9 203
U1 0
U2 41
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1750-1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD JUL 9
PY 2012
VL 7
IS 
BP 
EP 
DI 10.1186/1750-1172-7-46
PG 12
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 066RG
UT WOS:000313237300001
PM 22776096
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Garone, C
   Bordoni, A
   Rios, PG
   Calvo, SE
   Ripolone, M
   Ranieri, M
   Rizzuti, M
   Villa, L
   Magri, F
   Corti, S
   Bresolin, N
   Mootha, VK
   Moggio, M
   DiMauro, S
   Comi, GP
   Sciacco, M
AF Ronchi, Dario
   Garone, Caterina
   Bordoni, Andreina
   Rios, Purificacion Gutierrez
   Calvo, Sarah E.
   Ripolone, Michela
   Ranieri, Michela
   Rizzuti, Mafalda
   Villa, Luisa
   Magri, Francesca
   Corti, Stefania
   Bresolin, Nereo
   Mootha, Vamsi K.
   Moggio, Maurizio
   DiMauro, Salvatore
   Comi, Giacomo P.
   Sciacco, Monica
TI Next-generation sequencing reveals <i>DGUOK</i> mutations in adult patients with mitochondrial DNA multiple deletions
SO BRAIN
LA English
DT Article
DE DGUOK; mitochondrial DNA instability; autosomal recessive progressive external ophthalmoplegia; multiple mitochondrial DNA deletions
ID progressive external ophthalmoplegia; human deoxyguanosine kinase; thymidine kinase; mtdna deletions; optic atrophy; neurogastrointestinal encephalomyopathy; molecular-features; gene-mutations; human-cells; depletion
AB The molecular diagnosis of mitochondrial disorders still remains elusive in a large proportion of patients, but advances in next generation sequencing are significantly improving our chances to detect mutations even in sporadic patients. Syndromes associated with mitochondrial DNA multiple deletions are caused by different molecular defects resulting in a wide spectrum of predominantly adult-onset clinical presentations, ranging from progressive external ophthalmoplegia to multi-systemic disorders of variable severity. The mutations underlying these conditions remain undisclosed in half of the affected subjects. We applied next-generation sequencing of known mitochondrial targets (MitoExome) to probands presenting with adult-onset mitochondrial myopathy and harbouring mitochondrial DNA multiple deletions in skeletal muscle. We identified autosomal recessive mutations in the DGUOK gene (encoding mitochondrial deoxyguanosine kinase), which has previously been associated with an infantile hepatocerebral form of mitochondrial DNA depletion. Mutations in DGUOK occurred in five independent subjects, representing 5.6% of our cohort of patients with mitochondrial DNA multiple deletions, and impaired both muscle DGUOK activity and protein stability. Clinical presentations were variable, including mitochondrial myopathy with or without progressive external ophthalmoplegia, recurrent rhabdomyolysis in a young female who had received a liver transplant at 9 months of age and adult-onset lower motor neuron syndrome with mild cognitive impairment. These findings reinforce the concept that mutations in genes involved in deoxyribonucleotide metabolism can cause diverse clinical phenotypes and suggest that DGUOK should be screened in patients harbouring mitochondrial DNA deletions in skeletal muscle.
C1 [Ronchi, Dario; Bordoni, Andreina; Ranieri, Michela; Rizzuti, Mafalda; Magri, Francesca; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat DEPT, Dino Ferrari Ctr,Neurosci Sect,Neurol Unit, I-20122 Milan, Italy.
   [Garone, Caterina; Rios, Purificacion Gutierrez; DiMauro, Salvatore] Columbia Univ Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Garone, Caterina] Univ Turin, Human Genet Joint PhD Programme, I-10125 Turin, Italy.
   [Garone, Caterina] Univ Bologna, I-40125 Bologna, Italy.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Broad Inst Harvard & MIT, Seven Cambridge Ctr, Broad Metab Initiat, Cambridge, MA 02142 USA.
   [Ripolone, Michela; Villa, Luisa; Moggio, Maurizio; Sciacco, Monica] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, Neuromuscular Unit, I-20122 Milan, Italy.
   [Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20122 Milan, Italy.
   [Bresolin, Nereo] IRCCS Eugenio Medea, I-23842 Bosisio Parini, Lecco, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Columbia University; University of Turin; University of Bologna; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; IRCCS Eugenio Medea
RP Ronchi, D (corresponding author), Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Neurosci Sect, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM dario.ronchi@unimi.it
FU National Institutes of Health [GM077465, GM097136, HD32062]; Marriott Mitochondrial Disorder Clinical Research Fund; Italian Telethon [GUP09004]; Associazione Amici del Centro Dino Ferrari, University of Milan; Telethon project [GTB07001ER]; Eurobiobank project [QLTR-2001-02769]; Criobanca Automatizzata di Materiale Biologico [02.187]
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517
   Bergmeyer HU, 1974, METHODS ENZYMATIC AN, V1, P0
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Buchaklian AH, 2012, MOL GENET METAB, V0, P0
   Calvo SE, 2012, SCI TRANSL MED, V4, P0, DOI 10.1126/scitranslmed.3003310
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock DP, 2008, LIVER TRANSPLANT, V14, P1480, DOI 10.1002/lt.21556
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Garone C, 2011, BRAIN, V134, P3326, DOI 10.1093/brain/awr245
   Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 2008, ARCH NEUROL-CHICAGO, V65, P403, DOI 10.1001/archneurol.2007.65
   Houdayer C, 2011, METHODS MOL BIOL, V760, P269, DOI 10.1007/978-1-61779-176-5_17
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258
   Jüllig M, 2000, EUR J BIOCHEM, V267, P5466, DOI 10.1046/j.1432-1327.2000.01607.x
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Rötig A, 2009, BBA-MOL BASIS DIS, V1792, P1103, DOI 10.1016/j.bbadis.2009.06.009
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Slama A, 2005, MOL GENET METAB, V86, P462, DOI 10.1016/j.ymgme.2005.09.006
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
   Yu-Wai-Man P, 2012, BRAIN, V135, P9, DOI 10.1093/brain/awr352
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 57
TC 74
Z9 81
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD NOV 15
PY 2012
VL 135
IS 
BP 3404
EP 3415
DI 10.1093/brain/aws258
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 044SV
UT WOS:000311644800025
PM 23043144
DA 2024-11-01
ER

PT J
AU Frank, M
   Finsterer, J
AF Frank, Marlies
   Finsterer, Josef
TI CREATINE KINASE ELEVATION, LACTACIDEMIA, AND METABOLIC MYOPATHY IN ADULT PATIENTS WITH DIABETES MELLITUS
SO ENDOCRINE PRACTICE
LA English
DT Article
ID myotonic-dystrophy type-2; muscular-dystrophy; mitochondrial-dna; mtdna mutation; renal-failure; rhabdomyolysis; phenotype; disease; rosiglitazone; spectrum
AB Objective: To determine the frequency of elevated creatine kinase (CK) levels among patients with diabetes mellitus and to determine how often elevated CK is attributable to primary myopathy. Methods: In this prospective study, we investigated how often CK, aspartate aminotransferase, alanine aminotransferase, and resting lactate were elevated among consecutive diabetic patients attending our clinic. Those with elevated CK values were offered a neurologic workup. Results: Ninety-nine patients with diabetes mellitus, aged 19 to 87 years, were assessed between May 2008 and April 2010. Seven patients had type 1 diabetes and 92 patients had type 2 diabetes. CK, aspartate aminotransferase, alanine aminotransferase, and resting lactate were elevated in 19 of 99, 25 of 99, 22 of 99, and 24 of 98 patients, respectively. Eleven of 19 patients with increased CK were self-injecting insulin. Ten of 24 patients with elevated serum lactate took metformin. Seven of 19 patients with elevated CK consented to neurologic workup. Two of the 7 had elevated resting lactate. In all 7 patients, the findings from neurologic investigation were indicative of a metabolic defect and further diagnostic evaluation was recommended. Conclusions: In diabetic patients attending our clinic, elevated CK levels occur in one-fifth and lactacidemia occurs in one-quarter. Elevated CK levels are attributable to a primary metabolic myopathy in most cases. Elevated CK levels in the setting of diabetes mellitus require further neurologic evaluation. (Endocr Pract. 2012;18:387-393)
C1 [Frank, Marlies] First Med Dept, Vienna, Austria.
   [Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
   [Finsterer, Josef] Danube Univ Krems, Vienna, Austria.
C3 Rudolfstiftung Hospital; Danube University Krems
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Berardo A, 2010, NEUROMUSCULAR DISORD, V20, P204, DOI 10.1016/j.nmd.2010.01.006
   Bertipaglia I, 2007, V45, V0, P29
   Bhattacharjee M, 2006, ULTRASTRUCT PATHOL, V30, P481, DOI 10.1080/01913120600689624
   Bird TD, 1993, GENEREVIEWS INTERNET, V0, P0
   BRAITHWAITE SS, 1987, DIABETES CARE, V10, P540, DOI 10.2337/diacare.10.4.540
   Casteels Kristina, 2003, PEDIATR DIABETES, V4, P29, DOI 10.1034/j.1399-5448.2003.00026.x
   Corona P, 2002, ANN NEUROL, V51, P118, DOI 10.1002/ana.10059
   Day JW, 2003, NEUROLOGY, V60, P657, DOI 10.1212/01.WNL.0000054481.84978.F9
   De Block CEM, 2004, EXP CLIN ENDOCR DIAB, V112, P80, DOI 10.1055/s-2004-815754
   Debray FG, 2006, AM J MED GENET A, V140A, P2330, DOI 10.1002/ajmg.a.31457
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   DiGregorio RV, 2009, PHARMACOTHERAPY, V29, P352, DOI 10.1592/phco.29.3.352
   Emery AEH, 2000, NEUROMUSCULAR DISORD, V10, P228, DOI 10.1016/S0960-8966(00)00105-X
   Engelmann G, 2008, J INHERIT METAB DIS, V31, P540, DOI 10.1007/s10545-008-0867-0
   Faubert P F, 1987, ANN INTERN MED, V107, P785
   Finsterer J, 2001, J INHERIT METAB DIS, V24, P560, DOI 10.1023/A:1012415810881
   Fromont I, 2009, J NEUROL, V256, P1696, DOI 10.1007/s00415-009-5185-4
   Galtrey Clare M, 2008, J MED CASE REP, V2, P159, DOI 10.1186/1752-1947-2-159
   Gangopadhyay KK, 2006, J ROY SOC MED, V99, P200, DOI 10.1258/jrsm.99.4.200
   Goksen D, 2006, PEDIATR DIABETES, V7, P279, DOI 10.1111/j.1399-5448.2006.00201.x
   Higa EMS, 1997, RENAL FAILURE, V19, P289, DOI 10.3109/08860229709026291
   Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   Huang BK, 2010, AM J ROENTGENOL, V195, P198, DOI 10.2214/AJR.09.2494
   Kelley DE, 2004, DIABETES CARE, V27, P33, DOI 10.2337/diacare.27.1.33
   Kennie N, 2007, ANN PHARMACOTHER, V41, P521, DOI 10.1345/aph.1H609
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Kilbane BJ, 2006, PEDIATR CRIT CARE ME, V7, P169, DOI 10.1097/01.PCC.0000192340.09136.82
   Kim MS, 2009, J PEDIATR ENDOCR MET, V22, P565
   Komulainen T, 2010, BMC NEUROL, V10, P0, DOI 10.1186/1471-2377-10-29
   Layne RD, 2004, ANN PHARMACOTHER, V38, P232, DOI 10.1345/aph.1D282
   Ledl M, 2005, DIABETOLOGIA, V48, P1996, DOI 10.1007/s00125-005-1919-8
   Ling JQ, 2007, P NATL ACAD SCI USA, V104, P15299, DOI 10.1073/pnas.0704441104
   Liu SM, 2007, DIABETES RES CLIN PR, V76, P425, DOI 10.1016/j.diabres.2006.09.032
   Makovi Helga, 2002, ORV HETIL, V143, P2489
   Malfatti E, 2010, J NEUROL SCI, V297, P105, DOI 10.1016/j.jns.2010.06.009
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   McNab Tammy L, 2005, ENDOCR PRACT, V11, P18
   Mitani S, 2000, HEART VESSELS, V15, P23, DOI 10.1007/s003800070044
   Muschke P, 2007, AM J MED GENET A, V143A, P2810, DOI 10.1002/ajmg.a.32046
   Nagashima T, 1999, ACTA NEUROPATHOL, V97, P416, DOI 10.1007/s004010051007
   Oishi M, 2008, INTERNAL MED, V47, P441, DOI 10.2169/internalmedicine.47.0579
   Ranjbar SH, 2008, J PEDIATR ENDOCR MET, V21, P1185
   Saccone V, 2008, HUM MUTAT, V29, P240, DOI 10.1002/humu.20633
   Savkur RS, 2004, AM J HUM GENET, V74, P1309, DOI 10.1086/421528
   Swalwell H, 2008, EUR J HUM GENET, V16, P1265, DOI 10.1038/ejhg.2008.65
   TRUMP D, 1994, POSTGRAD MED J, V70, P44, DOI 10.1136/pgmj.70.819.44
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   van Rossum Ineke A, 2010, NED TIJDSCHR GENEESKD, V154, P0
   WANG LM, 1994, DIABETES RES CLIN PR, V26, P209, DOI 10.1016/0168-8227(94)90062-0
   Yamauchi A, 1996, INTERNAL MED, V35, P403, DOI 10.2169/internalmedicine.35.403
   Yokoyama M, 2000, DIABETES CARE, V23, P421, DOI 10.2337/diacare.23.3.421
NR 52
TC 11
Z9 12
U1 12
U2 17
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
EI 
J9 ENDOCR PRACT
JI Endocr. Pract.
PD MAY-JUN 15
PY 2012
VL 18
IS 3
BP 387
EP 393
DI 10.4158/EP11316.OR
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 944WI
UT WOS:000304234100012
PM 22297056
DA 2024-11-01
ER

PT J
AU Vasta, V
   Merritt, JL
   Saneto, RP
   Hahn, SH
AF Vasta, Valeria
   Merritt, J. Lawrence, II
   Saneto, Russell P.
   Hahn, Si Houn
TI Next-generation sequencing for mitochondrial diseases: A wide diagnostic spectrum
SO PEDIATRICS INTERNATIONAL
LA English
DT Article
DE mitochondrial disorders; mitochondrial respiratory chain complex enzyme deficiency; next-generation sequencing
ID polymerase-gamma; neurogastrointestinal encephalomyopathy; dehydrogenase-deficiency; mutation analysis; polg1 mutations; point mutations; dna; identification; heterozygosity; disorders
AB Background: The current diagnostic approach for mitochondrial disorders requires invasive procedures such as muscle biopsy and multiple biochemical testing but the results are often inconclusive. Clinical sequencing tests are available only for a limited number of genes. Recently, massively parallel sequencing has become a powerful tool for testing genetically heterogeneous conditions such as mitochondrial disorders. Methods: Targeted next-generation sequencing was performed on 26 patients with known or suspected mitochondrial disorders using in-solution capture for the exons of 908 known and candidate nuclear genes and an Illumina genome analyzer. Results: None of the 18 patients with various abnormal respiratory chain complex (RCC) activities had molecular defects in either subunits or assembly factors of mitochondrial RCC enzymes except a reference control sample with known mutations in SURF1. Instead, several variants in known pathogenic genes including CPT2, POLG, PDSS1, UBE3A, SDHD, and a few potentially pathogenic variants in candidate genes such as MTO1 or SCL7A13 were identified. Conclusions: Sequencing only nuclear genes for RCC subunits and assembly factors may not provide the diagnostic answers for suspected patients with mitochondrial disorders. The present findings indicate that the diagnostic spectrum of mitochondrial disorders is much broader than previously thought, which could potentially lead to misdiagnosis and/or inappropriate treatment. Overall analytic sensitivity and precision appear acceptable for clinical testing. Despite the limitations in finding mutations in all patients, the present findings underscore the considerable clinical benefits of targeted next-generation sequencing and serve as a prototype for extending the clinical evaluation in this clinically heterogeneous patient group.
C1 [Vasta, Valeria; Hahn, Si Houn] Univ Washington, Sch Med, Seattle Childrens Hosp, Seattle Childrens Hosp Res Inst, Seattle, WA 98101 USA.
   [Merritt, J. Lawrence, II; Hahn, Si Houn] Univ Washington, Sch Med, Seattle Childrens Hosp, Dept Pediat,Div Genet Med, Seattle, WA 98101 USA.
   [Saneto, Russell P.] Univ Washington, Sch Med, Seattle Childrens Hosp, Dept Neurol,Div Pediat Neurol, Seattle, WA 98101 USA.
C3 Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Seattle Children's Hospital; University of Washington; University of Washington Seattle
RP Hahn, SH (corresponding author), Univ Washington, Sch Med, Seattle Childrens Res Inst, Dept Pediat, C9S,1900 9th Ave, Seattle, WA 98101 USA.
EM sihahn@uw.edu
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Albers CA, 2011, GENOME RES, V21, P961, DOI 10.1101/gr.112326.110
   Amstutz U, 2011, CLIN CHEM, V57, P102, DOI 10.1373/clinchem.2010.150706
   Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Bell CJ, 2011, SCI TRANSL MED, V3, P0, DOI 10.1126/scitranslmed.3001756
   Bennett RR, 2009, BMC GENET, V10, P0, DOI 10.1186/1471-2156-10-66
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Biery BJ, 1996, AM J HUM GENET, V59, P1006
   Biesecker LG, 2009, GENOME RES, V19, P1665, DOI 10.1101/gr.092841.109
   Blish KR, 2005, MED HYPOTHESES, V64, P96, DOI 10.1016/j.mehy.2004.06.005
   Braathen GJ, 2010, BMC MED GENET, V11, P0, DOI 10.1186/1471-2350-11-48
   Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chen XL, 2011, GENET MED, V13, P794, DOI 10.1097/GIM.0b013e31821afca5
   Colby G, 1998, J BIOL CHEM, V273, P27945, DOI 10.1074/jbc.273.43.27945
   Coughlin EM, 1998, MOL GENET METAB, V63, P254, DOI 10.1006/mgme.1998.2684
   Cruz DN, 2001, KIDNEY INT, V59, P710, DOI 10.1046/j.1523-1755.2001.059002710.x
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Dursun A, 2002, J INHERIT METAB DIS, V25, P89, DOI 10.1023/A:1015668425004
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Engelfried K, 2006, BMC MED GENET, V7, P0, DOI 10.1186/1471-2350-7-53
   Foroud T, 2003, NEUROLOGY, V60, P796, DOI 10.1212/01.WNL.0000049470.00180.07
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Gellerich FN, 2004, MITOCHONDRION, V4, P427, DOI 10.1016/j.mito.2004.07.007
   Gobin S, 2003, J BIOL CHEM, V278, P50428, DOI 10.1074/jbc.M310130200
   Hsiao P, 2007, J HEPATOL, V47, P303, DOI 10.1016/j.jhep.2007.04.014
   IJLST L, 1994, BBA-LIPID LIPID MET, V1215, P347, DOI 10.1016/0005-2760(94)90064-7
   Kay DM, 2007, ANN NEUROL, V61, P47, DOI 10.1002/ana.21039
   Kocaefe YÇ, 2003, EUR J HUM GENET, V11, P102, DOI 10.1038/sj.ejhg.5200908
   Lossin C, 2009, BRAIN DEV-JPN, V31, P114, DOI 10.1016/j.braindev.2008.07.011
   Loudianos G, 1999, J MED GENET, V36, P833
   MATSUDA J, 1995, J INHERIT METAB DIS, V18, P534, DOI 10.1007/BF02435998
   McCorquodale DS, 2011, J NEUROL, V258, P1234, DOI 10.1007/s00415-011-5910-7
   McKinney JT, 2004, MOL GENET METAB, V82, P112, DOI 10.1016/j.ymgme.2004.04.004
   Meder B, 2011, CIRC-CARDIOVASC GENE, V4, P110, DOI 10.1161/CIRCGENETICS.110.958322
   Molinari F, 2010, J BIOENERG BIOMEMBR, V42, P467, DOI 10.1007/s10863-010-9323-6
   Musunuru K, 2010, NEW ENGL J MED, V363, P2220, DOI 10.1056/NEJMoa1002926
   Ng SB, 2010, HUM MOL GENET, V19, PR119, DOI 10.1093/hmg/ddq390
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ni Y, 2008, AM J HUM GENET, V83, P261, DOI 10.1016/j.ajhg.2008.07.011
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nouws J, 2012, BRAIN, V135, P12, DOI 10.1093/brain/awr261
   Oberkanins C, 2000, GENET TEST, V4, P121, DOI 10.1089/10906570050114812
   Oglesbee D, 2007, GENET MED, V9, P108, DOI 10.1097/GIM.0b013e31802f78d6
   Oglesbee D, 2006, PEDIATR NEUROL, V35, P289, DOI 10.1016/j.pediatrneurol.2006.05.007
   Park WD, 2003, HUM MUTAT, V22, P313, DOI 10.1002/humu.10255
   Perren A, 2002, ONCOGENE, V21, P7605, DOI 10.1038/sj.onc.1205812
   PURDUE PE, 1990, J CELL BIOL, V111, P2341, DOI 10.1083/jcb.111.6.2341
   Quinzii CM, 2008, BIOFACTORS, V32, P113, DOI 10.1002/biof.5520320113
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Scharfe C, 2009, PLOS COMPUT BIOL, V5, P0, DOI 10.1371/journal.pcbi.1000374
   Schimmenti LA, 2007, MOL GENET METAB, V90, P441, DOI 10.1016/j.ymgme.2006.10.003
   Sibbing D, 2011, EUR HEART J, V32, P1121, DOI 10.1093/eurheartj/ehq507
   Spiekerkoetter U, 2003, J PEDIATR-US, V143, P335, DOI 10.1067/S0022-3476(03)00292-0
   Stenson PD, 2009, GENOME MED, V1, P0, DOI 10.1186/gm13
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Su HL, 2011, NEUROSCI LETT, V487, P129, DOI 10.1016/j.neulet.2009.06.079
   Tarnopolsky MA, 2008, ADV DRUG DELIVER REV, V60, P1561, DOI 10.1016/j.addr.2008.05.001
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Traverso M, 2008, LAB INVEST, V88, P275, DOI 10.1038/labinvest.3700713
   Tsurusaki Y, 2011, J MED GENET, V48, P606, DOI 10.1136/jmg.2010.083535
   Tucker EJ, 2012, HUM MUTAT, V33, P411, DOI 10.1002/humu.21654
   Vasta V, 2009, GENOME MED, V1, P0, DOI 10.1186/gm100
   Vatta M, 2006, CIRCULATION, V114, P2104, DOI 10.1161/CIRCULATIONAHA.106.635268
   Vladutiu GD, 1999, MUSCLE NERVE, V22, P949, DOI 10.1002/(SICI)1097-4598(199907)22:7<949::AID-MUS23>3.3.CO;2-9
   Vladutiu GD, 2000, MOL GENET METAB, V70, P134, DOI 10.1006/mgme.2000.3009
   Wang WY, 2011, NUCLEIC ACIDS RES, V39, P44, DOI 10.1093/nar/gkq750
   Wang XJ, 2009, MITOCHONDRION, V9, P180, DOI 10.1016/j.mito.2009.01.010
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 70
TC 56
Z9 64
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1328-8067
EI 1442-200X
J9 PEDIATR INT
JI Pediatr. Int.
PD OCT 15
PY 2012
VL 54
IS 5
BP 585
EP 601
DI 10.1111/j.1442-200X.2012.03644.x
PG 17
WC Pediatrics
SC Pediatrics
GA 012KI
UT WOS:000309234600001
PM 22494076
DA 2024-11-01
ER

PT J
AU Rahman, S
AF Rahman, Shamima
TI Mitochondrial disease and epilepsy
SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
LA English
DT Review
ID c-oxidase deficiency; complex-i deficiency; alpers-huttenlocher syndrome; coenzyme q(10) deficiency; respiratory-chain defects; leigh-syndrome; dna depletion; myoclonic epilepsy; ketogenic diet; gene-mutations
AB Mitochondrial respiratory chain disorders are relatively common inborn errors of energy metabolism, with a combined prevalence of one in 5000. These disorders typically affect tissues with high energy requirements, and cerebral involvement occurs frequently in childhood, often manifesting in seizures. Mitochondrial diseases are genetically heterogeneous; to date, mutations have been reported in all 37 mitochondrially encoded genes and more than 80 nuclear genes. The major genetic causes of mitochondrial epilepsy are mitochondrial DNA mutations (including those typically associated with the mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS] and myoclonic epilepsy with ragged red fibres [MERRF] syndromes); mutations in POLG (classically associated with Alpers syndrome but also presenting as the mitochondrial recessive ataxia syndrome [MIRAS], spinocerebellar ataxia with epilepsy [SCAE], and myoclonus, epilepsy, myopathy, sensory ataxia [MEMSA] syndromes in older individuals) and other disorders of mitochondrial DNA maintenance; complex I deficiency; disorders of coenzyme Q10 biosynthesis; and disorders of mitochondrial translation such as RARS2 mutations. It is not clear why some genetic defects, but not others, are particularly associated with seizures. Epilepsy may be the presenting feature of mitochondrial disease but is often part of a multisystem clinical presentation. Mitochondrial epilepsy may be very difficult to manage, and is often a poor prognostic feature. At present there are no curative treatments for mitochondrial disease. Individuals with mitochondrial epilepsy are frequently prescribed multiple anticonvulsants, and the role of vitamins and other nutritional supplements and the ketogenic diet remain unproven.
C1 UCL Inst Child Hlth, Mitochondrial Res Grp, Clin & Mol Genet Unit, London WC1N 1EH, England.
C3 University of London; University College London
RP Rahman, S (corresponding author), UCL Inst Child Hlth, Mitochondrial Res Grp, Clin & Mol Genet Unit, 30 Guilford St, London WC1N 1EH, England.
EM s.rahman@ich.ucl.ac.uk
FU Great Ormond Street Hospital Children's Charity, Ataxia UK; Child Health Research Appeal Trust; Children's Liver Disease Foundation, Climb; Medical Research Council
CR Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Arpin S, 2009, METAB BRAIN DIS, V24, P453, DOI 10.1007/s11011-009-9144-7
   Barghuti F, 2008, MOL GENET METAB, V94, P78, DOI 10.1016/j.ymgme.2007.11.013
   Bitner-Glindzicz M, 2009, NEW ENGL J MED, V360, P640, DOI 10.1056/NEJMc0806396
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Canafoglia L, 2001, NEUROLOGY, V56, P1340, DOI 10.1212/WNL.56.10.1340
   CHABROL B, 1994, EUR J PEDIATR, V153, P133, DOI 10.1007/BF01959226
   Chinnery P, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub2
   Chrzanowska-Lightowlers Z M A, 2011, NEUROMUSCUL DISORD, V21, P142, DOI 10.1016/j.nmd.2010.10.005
   Cohen BH, 1993, GENEREVIEWS((R)), V0, P0
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   Debray FG, 2007, PEDIATRICS, V119, P722, DOI 10.1542/peds.2006-1866
   Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   El Sabbagh S, 2010, EPILEPSIA, V51, P1225, DOI 10.1111/j.1528-1167.2009.02504.x
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Fassone E, 2010, HUM MOL GENET, V19, P4837, DOI 10.1093/hmg/ddq414
   Fernandez-Moreira D, 2007, ANN NEUROL, V61, P73, DOI 10.1002/ana.21036
   Fernandez-Vizarra E, 2007, HUM MOL GENET, V16, P1241, DOI 10.1093/hmg/ddm072
   Galimberti CA, 2006, NEUROLOGY, V67, P1715, DOI 10.1212/01.wnl.0000242882.58086.9a
   Ghezzi D, 2008, AM J HUM GENET, V83, P415, DOI 10.1016/j.ajhg.2008.08.009
   Ghezzi D, 2010, AM J HUM GENET, V86, P639, DOI 10.1016/j.ajhg.2010.03.002
   Glamuzina E, 2011, J INHERIT METAB 1116, V0, P0
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   Harris MO, 2010, ARCH NEUROL-CHICAGO, V67, P493, DOI 10.1001/archneurol.2010.36
   Heeringa SF, 2011, J CLIN INVEST, V121, P2013, DOI 10.1172/JCI45693
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horváth R, 2006, J NEUROL NEUROSUR PS, V77, P74, DOI 10.1136/jnnp.2005.067041
   Huigsloot M, 2011, AM J HUM GENET, V88, P488, DOI 10.1016/j.ajhg.2011.03.002
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Joshi CN, 2009, PEDIATR NEUROL, V40, P314, DOI 10.1016/j.pediatrneurol.2008.10.023
   Kang HC, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2006.00906.x
   Khurana DS, 2008, NEUROPEDIATRICS, V39, P8, DOI 10.1055/s-2008-1076737
   Koga Y, 2007, MITOCHONDRION, V7, P133, DOI 10.1016/j.mito.2006.11.006
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Kunz WS, 2002, CURR OPIN NEUROL, V15, P179, DOI 10.1097/00019052-200204000-00009
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Lam CW, 1997, EUR J PEDIATR, V156, P562, DOI 10.1007/s004310050663
   Lee YM, 2008, EPILEPSIA, V49, P685, DOI 10.1111/j.1528-1167.2007.01522.x
   Lheureux PER, 2009, CLIN TOXICOL, V47, P101, DOI 10.1080/15563650902752376
   Lin CM, 2007, METAB BRAIN DIS, V22, P105, DOI 10.1007/s11011-006-9039-9
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   Mancuso M, 2006, J NEUROL SCI, V243, P97, DOI 10.1016/j.jns.2005.11.021
   Molinari F, 2005, AM J HUM GENET, V76, P334, DOI 10.1086/427564
   Molinari F, 2009, CLIN GENET, V76, P188, DOI 10.1111/j.1399-0004.2009.01236.x
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nouws J, 2010, CELL METAB, V12, P283, DOI 10.1016/j.cmet.2010.08.002
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Parikh S, 2008, PEDIATR NEUROL, V38, P191, DOI 10.1016/j.pediatrneurol.2007.10.011
   Pineda M, 2006, ANN NEUROL, V59, P394, DOI 10.1002/ana.20746
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rahman S, 2009, J NEUROL NEUROSUR PS, V80, P943, DOI 10.1136/jnnp.2008.158279
   Rahman S, 2011, NEUROMUSCUL DIS 0630, V0, P0
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Rankin J, 2010, AM J MED GENET A, V152A, P2079, DOI 10.1002/ajmg.a.33531
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Shahwan A, 2005, LANCET NEUROL, V4, P239, DOI 10.1016/S1474-4422(05)70043-0
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Spiegel R, 2011, J MED GENET, V48, P177, DOI 10.1136/jmg.2010.084608
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Tam EWY, 2008, NEUROPEDIATRICS, V39, P328, DOI 10.1055/s-0029-1202287
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Thorburn DR, 1993, GENEREVIEWS, V0, P0
   Tiranti V, 1999, ANN NEUROL, V46, P161, DOI 10.1002/1531-8249(199908)46:2<161::AID-ANA4>3.0.CO;2-O
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Urbanska EM, 1998, EUR J PHARMACOL, V359, P55, DOI 10.1016/S0014-2999(98)00648-7
   Uusimaa J, 2008, EPILEPSIA, V49, P1038, DOI 10.1111/j.1528-1167.2008.01544.x
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Wolf NI, 2009, EPILEPSIA, V50, P1596, DOI 10.1111/j.1528-1167.2008.01877.x
   Yamamoto HA, 1996, NEUROSCI LETT, V207, P89, DOI 10.1016/0304-3940(96)12493-9
   Zhang Y, 2007, J INHERIT METAB DIS, V30, P265, DOI 10.1007/s10545-006-0481-y
NR 94
TC 127
Z9 139
U1 0
U2 21
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0012-1622
EI 
J9 DEV MED CHILD NEUROL
JI Dev. Med. Child Neurol.
PD MAY 15
PY 2012
VL 54
IS 5
BP 397
EP 406
DI 10.1111/j.1469-8749.2011.04214.x
PG 10
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 922KP
UT WOS:000302546100010
PM 22283595
DA 2024-11-01
ER

PT J
AU Echaniz-Laguna, A
   Benoilid, A
   Vinzio, S
   Fornecker, LM
   Lannes, B
   Goullé, JP
   Broly, F
   de Camaret, BM
AF Echaniz-Laguna, Andoni
   Benoilid, Aurelien
   Vinzio, Stephane
   Fornecker, Luc-Matthieu
   Lannes, Beatrice
   Goulle, Jean-Pierre
   Broly, Frank
   de Camaret, Benedicte Mousson
TI Mitochondrial myopathy caused by arsenic trioxide therapy
SO BLOOD
LA English
DT Article
ID acute promyelocytic leukemia; mammalian-cells; muscle; rhabdomyolysis; metabolism; mechanisms; apoptosis; damage
AB Arsenic trioxide (ATO) has been successfully used as a treatment for acute promyelocytic leukemia (APL) for more than a decade. Here we report a patient with APL who developed a mitochondrial myopathy after treatment with ATO. Three months after ATO therapy withdrawal, the patient was unable to walk without assistance and skeletal muscle studies showed a myopathy with abundant cytoplasmic lipid droplets, decreased activities of the mitochondrial respiratory chain complexes, multiple mitochondrial DNA (mtDNA) deletions, and increased muscle arsenic content. Six months after ATO treatment was interrupted, the patient recovered normal strength, lipid droplets had decreased in size and number, respiratory chain complex activities were partially restored, but multiple mtDNA deletions and increased muscle arsenic content persisted. ATO therapy may provoke a delayed, severe, and partially reversible mitochondrial myopathy, and a long-term careful surveillance for muscle disease should be instituted when ATO is used in patients with APL. (Blood. 2012;119(18):4272-4274)
C1 [Echaniz-Laguna, Andoni; Benoilid, Aurelien] Hop Univ, Dept Neurol, Strasbourg, France.
   [Echaniz-Laguna, Andoni] Univ Strasbourg, INSERM, U692, Strasbourg, France.
   [Vinzio, Stephane] Hop Univ, Serv Med Interne, Strasbourg, France.
   [Fornecker, Luc-Matthieu] Hop Univ, Serv Oncohematol, Strasbourg, France.
   [Lannes, Beatrice] Hop Univ, Dept Pathol, Strasbourg, France.
   [Goulle, Jean-Pierre] Ctr Hosp, Toxicol Lab, Le Havre, France.
   [Broly, Frank] Ctr Hosp Reg & Univ Lille, Ctr Biol & Pathol, F-59037 Lille, France.
   [de Camaret, Benedicte Mousson] Ctr Hosp Univ Lyon, Ctr Biol Est, Serv Malad Hereditaires Metab, Bron, France.
C3 CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Lorraine; CHU Strasbourg; CHU Strasbourg; CHU Strasbourg; Universite de Lille; CHU Lille; Universite Claude Bernard Lyon 1; CHU Lyon
RP Echaniz-Laguna, A (corresponding author), Hop Hautepierre, Hop Univ Strasbourg, Dept Neurol, 1 Ave Moliere, F-67098 Strasbourg, France.
EM andoni.echaniz-laguna@chru-strasbourg.fr
CR Argos M, 2010, LANCET, V376, P252, DOI 10.1016/S0140-6736(10)60481-3
   Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953
   Carter DE, 2003, TOXICOL APPL PHARM, V193, P309, DOI 10.1016/j.taap.2003.07.009
   Chen SJ, 2011, BLOOD, V117, P6425, DOI 10.1182/blood-2010-11-283598
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Das J, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0012602
   Du L, 2007, FEMS YEAST RES, V7, P860, DOI 10.1111/j.1567-1364.2007.00274.x
   Estey E, 2006, BLOOD, V107, P3469, DOI 10.1182/blood-2005-10-4006
   Fanton L, 1999, HUM EXP TOXICOL, V18, P640, DOI 10.1191/096032799678839509
   FERNANDEZSOLA J, 1991, J TOXICOL-CLIN TOXIC, V29, P131, DOI 10.3109/15563659109038603
   HIGUCHI I, 1989, ACTA NEUROPATHOL, V79, P300, DOI 10.1007/BF00294665
   Klaassen CD, 2008, CASARETT DOULLS TOXI, V0, P936
   Krishnan KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI 10.1196/annals.1395.024
   Liu SX, 2005, CANCER RES, V65, P3236, DOI 10.1158/0008-5472.CAN-05-0424
   Mathews V, 2006, BLOOD, V107, P2627, DOI 10.1182/blood-2005-08-3532
   MIRANDA N, 1994, LANCET, V344, P1096, DOI 10.1016/S0140-6736(94)91756-6
   Partridge MA, 2007, CANCER RES, V67, P5239, DOI 10.1158/0008-5472.CAN-07-0074
   Santra A, 2007, TOXICOL APPL PHARM, V220, P146, DOI 10.1016/j.taap.2006.12.029
   Sanz MA, 2011, J CLIN ONCOL, V29, P495, DOI 10.1200/JCO.2010.32.1067
   Sanz MA, 2009, BLOOD, V113, P1875, DOI 10.1182/blood-2008-04-150250
   SANZ P, 1989, JAMA-J AM MED ASSOC, V262, P3271, DOI 10.1001/jama.1989.03430230043020
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Steinmaus C, 2007, J TOXICOL ENV HEAL A, V70, P159, DOI 10.1080/15287390600755240
   Yen YP, 2010, ENVIRON HEALTH PERSP, V118, P949, DOI 10.1289/ehp.0901525
NR 24
TC 15
Z9 18
U1 0
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 
J9 BLOOD
JI Blood
PD MAY 3
PY 2012
VL 119
IS 18
BP 4272
EP 4274
DI 10.1182/blood-2011-10-385138
PG 3
WC Hematology
SC Hematology
GA 959BL
UT WOS:000305284600024
PM 22427206
DA 2024-11-01
ER

PT J
AU Copeland, WC
AF Copeland, William C.
TI Defects in mitochondrial DNA replication and human disease
SO CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Review
DE DNA polymerase g; mitochondrial DNA replication; nucleotide pools; mitochondrial DNA depletion syndrome; progressive external ophthalmoplegia; ataxia-neuropathy
ID progressive external ophthalmoplegia; polymerase-gamma mutations; neurogastrointestinal encephalomyopathy mngie; thymidine phosphorylase-deficiency; recessive twinkle mutations; multiple mtdna deletions; p55 accessory subunit; deoxyguanosine kinase; polg mutations; saccharomyces-cerevisiae
AB Mitochondrial DNA (mtDNA) is replicated by the DNA polymerase g in concert with accessory proteins such as the mtDNA helicase, single stranded DNA binding protein, topoisomerase, and initiating factors. Nucleotide precursors for mtDNA replication arise from the mitochondrial salvage pathway originating from transport of nucleosides, or alternatively from cytoplasmic reduction of ribonucleotides. Defects in mtDNA replication or nucleotide metabolism can cause mitochondrial genetic diseases due to mtDNA deletions, point mutations, or depletion which ultimately cause loss of oxidative phosphorylation. These genetic diseases include mtDNA depletion syndromes such as Alpers or early infantile hepatocerebral syndromes, and mtDNA deletion disorders, such as progressive external ophthalmoplegia (PEO), ataxia-neuropathy, or mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). This review focuses on our current knowledge of genetic defects of mtDNA replication (POLG, POLG2, C10orf2) and nucleotide metabolism (TYMP, TK2, DGOUK, and RRM2B) that cause instability of mtDNA and mitochondrial disease.
C1 Natl Inst Environm Hlth Sci, Mol Genet Lab, Durham, NC 27709 USA.
RP Copeland, WC (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, POB 12233, Durham, NC 27709 USA.
EM copelan1@niehs.nih.gov
FU National Institute of Environmental Health Sciences, NIH [ES 065078, ES 065080]
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Baruffini E, 2011, MITOCHONDRION, V11, P182, DOI 10.1016/j.mito.2010.09.007
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Cohen BH, 2010, POLG RELATED DISORDE, V0, P0
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Eriksson S, 2008, NUCLEOS NUCLEOT NUCL, V27, P800, DOI 10.1080/15257770802146197
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Gandhi VV, 2011, PLOS COMPUT BIOL, V7, P0, DOI 10.1371/journal.pcbi.1002078
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Holmlund T, 2009, BBA-MOL BASIS DIS, V1792, P132, DOI 10.1016/j.bbadis.2008.11.009
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Kukat C, 2011, P NATL ACAD SCI USA, V108, P13534, DOI 10.1073/pnas.1109263108
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2010, J BIOL CHEM, V285, P29690, DOI 10.1074/jbc.M110.151795
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng060
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Scaglia F, 2009, DGUOK RELATED MITOCH, V0, P0
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Torres-Torronteras J, 2011, GENE THER, V18, P795, DOI 10.1038/gt.2011.24
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Tyynismaa H, 2009, EMBO REP, V10, P137, DOI 10.1038/embor.2008.242
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Valentino ML, 2007, FEBS LETT, V581, P3410, DOI 10.1016/j.febslet.2007.06.042
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 107
TC 125
Z9 149
U1 0
U2 52
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1040-9238
EI 
J9 CRIT REV BIOCHEM MOL
JI Crit. Rev. Biochem. Mol. Biol.
PD JAN 15
PY 2012
VL 47
IS 1
BP 64
EP 74
DI 10.3109/10409238.2011.632763
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 863TA
UT WOS:000298189700005
PM 22176657
DA 2024-11-01
ER

PT J
AU Dillon, LM
   Williams, SL
   Hida, A
   Peacock, JD
   Prolla, TA
   Lincoln, J
   Moraes, CT
AF Dillon, Lloye M.
   Williams, Sion L.
   Hida, Aline
   Peacock, Jacqueline D.
   Prolla, Tomas A.
   Lincoln, Joy
   Moraes, Carlos T.
TI Increased mitochondrial biogenesis in muscle improves aging phenotypes in the mtDNA mutator mouse
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID oxidative-phosphorylation; skeletal-muscle; point mutations; dna mutations; pgc-1-alpha; induction; striatum; protects; myopathy; stress
AB Aging is an intricate process that increases susceptibility to sarcopenia and cardiovascular diseases. The accumulation of mitochondrial DNA (mtDNA) mutations is believed to contribute to mitochondrial dysfunction, potentially shortening lifespan. The mtDNA mutator mouse, a mouse model with a proofreading-deficient mtDNA polymerase , was shown to develop a premature aging phenotype, including sarcopenia, cardiomyopathy and decreased lifespan. This phenotype was associated with an accumulation of mtDNA mutations and mitochondrial dysfunction. We found that increased expression of peroxisome proliferator-activated receptor coactivator-1 (PGC-1), a crucial regulator of mitochondrial biogenesis and function, in the muscle of mutator mice increased mitochondrial biogenesis and function and also improved the skeletal muscle and heart phenotypes of the mice. Deep sequencing analysis of their mtDNA showed that the increased mitochondrial biogenesis did not reduce the accumulation of mtDNA mutations but rather caused a small increase. These results indicate that increased muscle PGC-1 expression is able to improve some premature aging phenotypes in the mutator mice without reverting the accumulation of mtDNA mutations.
C1 [Dillon, Lloye M.; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   [Williams, Sion L.; Hida, Aline; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Peacock, Jacqueline D.; Lincoln, Joy] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
   [Prolla, Tomas A.] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.
C3 University of Miami; University of Miami; University of Miami; University of Wisconsin System; University of Wisconsin Madison
RP Moraes, CT (corresponding author), 1420 NW 9th Ave,Rm 229, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU National Institutes of Health [EY010804, AG036871]; Muscular Dystrophy Association; James & Esther King Biomedical Research Program
CR Ameur A, 2011, PLOS GENET, V7, P0, DOI 10.1371/journal.pgen.1002028
   Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Arnold AS, 2011, GERONTOLOGY, V57, P37, DOI 10.1159/000281883
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Biernacka A, 2011, AGING DIS, V2, P158
   Brault JJ, 2010, J BIOL CHEM, V285, P19460, DOI 10.1074/jbc.M110.113092
   Cheung MC, 2009, J SURG RES, V153, P326, DOI 10.1016/j.jss.2008.05.002
   Conley KE, 2007, EXERC SPORT SCI REV, V35, P43
   de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Figueiredo PA, 2008, BIOGERONTOLOGY, V9, P67, DOI 10.1007/s10522-007-9121-7
   Fukui H, 2008, TRENDS NEUROSCI, V31, P251, DOI 10.1016/j.tins.2008.02.008
   Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200
   Hiona A, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0011468
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Lira VA, 2010, AM J PHYSIOL-ENDOC M, V299, PE145, DOI 10.1152/ajpendo.00755.2009
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Martinez B, 2001, J NEUROCHEM, V78, P1054, DOI 10.1046/j.1471-4159.2001.00487.x
   Meissner C, 2007, Z GERONTOL GERIATR, V40, P325, DOI 10.1007/s00391-007-0481-z
   Meissner C, 2006, EXP GERONTOL, V41, P518, DOI 10.1016/j.exger.2006.03.010
   Mohamed SA, 2006, EXP GERONTOL, V41, P508, DOI 10.1016/j.exger.2006.03.014
   Peacock JD, 2010, CIRC RES, V106, P712, DOI 10.1161/CIRCRESAHA.109.213702
   Pickrell AM, 2011, J NEUROSCI, V31, P9895, DOI 10.1523/JNEUROSCI.6223-10.2011
   Polisecki EY, 2004, J FORENSIC SCI, V49, P1335
   Rebelo AP, 2011, J INHERIT METAB DIS, V34, P941, DOI 10.1007/s10545-011-9330-8
   Rowe GC, 2010, CIRC RES, V107, P825, DOI 10.1161/CIRCRESAHA.110.223818
   Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB
   Safdar A, 2011, J BIOL CHEM, V286, P10605, DOI 10.1074/jbc.M110.211466
   Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108
   Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trifunovic A, 2006, BBA-BIOENERGETICS, V1757, P611, DOI 10.1016/j.bbabio.2006.03.003
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Viña J, 2009, ADV DRUG DELIVER REV, V61, P1369, DOI 10.1016/j.addr.2009.06.006
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106
   Wiesner RJ, 2006, FREE RADICAL RES, V40, P1284, DOI 10.1080/10715760600913168
   Williams SL, 2010, CELL METAB, V12, P675, DOI 10.1016/j.cmet.2010.11.012
   Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115
NR 44
TC 74
Z9 85
U1 3
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2012
VL 21
IS 10
BP 2288
EP 2297
DI 10.1093/hmg/dds049
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 933BH
UT WOS:000303333700013
PM 22357654
DA 2024-11-01
ER

PT J
AU Yin, HZ
   Nalbandian, A
   Hsu, CI
   Li, S
   Llewellyn, KJ
   Mozaffar, T
   Kimonis, VE
   Weiss, JH
AF Yin, H. Z.
   Nalbandian, A.
   Hsu, C-I
   Li, S.
   Llewellyn, K. J.
   Mozaffar, T.
   Kimonis, V. E.
   Weiss, J. H.
TI Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice
SO CELL DEATH & DISEASE
LA English
DT Article
DE motor neuron; SOD1; TDP-43; amyotrophic lateral sclerosis; animal models
ID amyotrophic-lateral-sclerosis; dna-binding protein; motor-neurons; paget-disease; tdp-43; mutations; aggregation; degeneration; sod1; vcp
AB Pathological features of amyotrophic lateral sclerosis (ALS) include, in addition to selective motor neuron (MN) degeneration, the occurrence of protein aggregates, mitochondrial dysfunction and astrogliosis. SOD1 mutations cause rare familial forms of ALS and have provided the most widely studied animal models. Relatively recent studies implicating another protein, TDP-43, in familial and sporadic forms of ALS have led to the development of new animal models. More recently, mutations in the valosin-containing protein (VCP) gene linked to the human genetic disease, Inclusion Body Myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD), were found also to be associated with ALS in some patients. A heterozygous knock-in VCP mouse model of IBMPFD (VCPR155H/+) exhibited muscle, bone and brain pathology characteristic of the human disease. We have undertaken studies of spinal cord pathology in VCPR155H/+ mice and find age-dependent degeneration of ventral horn MNs, TDP-43-positive cytosolic inclusions, mitochondrial aggregation and progressive astrogliosis. Aged animals (similar to 24-27 months) show electromyography evidence of denervation consistent with the observed MN loss. Although these animals do not develop rapidly progressive fatal ALS-like disease during their lifespans, they recapitulate key pathological features of both human disease and other animal models of ALS, and may provide a valuable new model for studying events preceding onset of catastrophic disease. Cell Death and Disease (2012) 3, e374; doi:10.1038/cddis.2012.115; published online 16 August 2012
C1 [Yin, H. Z.; Hsu, C-I; Li, S.; Mozaffar, T.; Weiss, J. H.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA.
   [Nalbandian, A.; Llewellyn, K. J.; Kimonis, V. E.] Univ Calif Irvine, Dept Pediat, Div Genet & Metab, Irvine, CA 92697 USA.
   [Weiss, J. H.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.
   [Mozaffar, T.] Univ Calif Irvine, Dept Orthopaed Surg, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine
RP Weiss, JH (corresponding author), Univ Calif Irvine, Dept Neurol, 2101 Gillespie Bldg, Irvine, CA 92697 USA.
EM vkimonis@uci.edu; jweiss@uci.edu
FU National Institutes of Health [NS36548, AR050236]; Muscular Dystrophy Association
CR ALEXIANU ME, 1994, ANN NEUROL, V36, P846, DOI 10.1002/ana.410360608
   Ayala V, 2011, ACTA NEUROPATHOL, V122, P259, DOI 10.1007/s00401-011-0850-y
   Badadani M, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0013183
   Baloh RH, 2011, FEBS J, V278, P3539, DOI 10.1111/j.1742-4658.2011.08256.x
   Braun RJ, 2011, J BIOL CHEM, V286, P19958, DOI 10.1074/jbc.M110.194852
   Carriedo SG, 1996, J NEUROSCI, V16, P4069
   Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000
   Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18
   Colombrita C, 2009, J NEUROCHEM, V111, P1051, DOI 10.1111/j.1471-4159.2009.06383.x
   Custer SK, 2010, HUM MOL GENET, V19, P1741, DOI 10.1093/hmg/ddq050
   Deng HX, 2011, NATURE, V477, P211, DOI 10.1038/nature10353
   Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103
   Duan W, 2010, NEUROSCIENCE, V169, P1621, DOI 10.1016/j.neuroscience.2010.06.018
   Fecto F, 2011, ARCH NEUROL-CHICAGO, V68, P1440, DOI 10.1001/archneurol.2011.250
   Fecto F, 2011, J MOL NEUROSCI, V45, P663, DOI 10.1007/s12031-011-9637-9
   Ferri A, 2010, HUM MOL GENET, V19, P4529, DOI 10.1093/hmg/ddq383
   Furukawa Y, 2006, P NATL ACAD SCI USA, V103, P7148, DOI 10.1073/pnas.0602048103
   Geser F, 2010, ARCH NEUROL-CHICAGO, V67, P1238, DOI 10.1001/archneurol.2010.254
   Halawani D, 2006, MOL CELL, V22, P713, DOI 10.1016/j.molcel.2006.06.003
   Johnson JO, 2010, NEURON, V68, P857, DOI 10.1016/j.neuron.2010.11.036
   Ju JS, 2009, J CELL BIOL, V187, P875, DOI 10.1083/jcb.200908115
   Kimonis VE, 2008, AM J MED GENET A, V146A, P745, DOI 10.1002/ajmg.a.31862
   Lagier-Tourenne C, 2010, HUM MOL GENET, V19, PR46, DOI 10.1093/hmg/ddq137
   Manfredi G, 2005, MITOCHONDRION, V5, P77, DOI 10.1016/j.mito.2005.01.002
   Maruyama H, 2010, NATURE, V465, P223, DOI 10.1038/nature08971
   Nalbandian A, 2013, MUSCLE NERVE, V47, P260, DOI 10.1002/mus.23522
   Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108
   Niwa J, 2007, J BIOL CHEM, V282, P28087, DOI 10.1074/jbc.M704465200
   Philips T, 2011, LANCET NEUROL, V10, P253, DOI 10.1016/S1474-4422(11)70015-1
   Rao SD, 2004, TRENDS NEUROSCI, V27, P17, DOI 10.1016/j.tins.2003.11.001
   Rao SD, 2003, J NEUROSCI, V23, P2627
   Rothstein JD, 2009, ANN NEUROL, V65, PS3, DOI 10.1002/ana.21543
   Shan X, 2010, P NATL ACAD SCI USA, V107, P16325, DOI 10.1073/pnas.1003459107
   Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584
   Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155
   Van Den Bosch L, 2000, J NEUROL SCI, V180, P29, DOI 10.1016/S0022-510X(00)00414-7
   Vanselow BK, 2000, J PHYSIOL-LONDON, V525, P433, DOI 10.1111/j.1469-7793.2000.t01-1-00433.x
   Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332
   Wegorzewska I, 2011, NEURODEGENER DIS, V8, P262, DOI 10.1159/000321547
   Xu YF, 2010, J NEUROSCI, V30, P10851, DOI 10.1523/JNEUROSCI.1630-10.2010
   Yin HZ, 2007, EXP NEUROL, V207, P177, DOI 10.1016/j.expneurol.2007.07.011
NR 41
TC 58
Z9 61
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
EI 
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 15
PY 2012
VL 3
IS 
BP 
EP 
DI 10.1038/cddis.2012.115
PG 12
WC Cell Biology
SC Cell Biology
GA 002SC
UT WOS:000308553800015
PM 22898872
DA 2024-11-01
ER

PT J
AU van der Walt, EM
   Smuts, I
   Taylor, RW
   Elson, JL
   Turnbull, DM
   Louw, R
   van der Westhuizen, FH
AF van der Walt, Elizna M.
   Smuts, Izelle
   Taylor, Robert W.
   Elson, Joanna L.
   Turnbull, Douglass M.
   Louw, Roan
   van der Westhuizen, Francois H.
TI Characterization of mtDNA variation in a cohort of South African paediatric patients with mitochondrial disease
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; mitochondrial diseases; paediatrics; Africa; high-throughput nucleotide sequencing
ID hereditary optic neuropathy; dna mutations; respiratory-chain; complex-i; disorders; identification; increase
AB Mitochondrial disease can be attributed to both mitochondrial and nuclear gene mutations. It has a heterogeneous clinical and biochemical profile, which is compounded by the diversity of the genetic background. Disease-based epidemiological information has expanded significantly in recent decades, but little information is known that clarifies the aetiology in African patients. The aim of this study was to investigate mitochondrial DNA variation and pathogenic mutations in the muscle of diagnosed paediatric patients from South Africa. A cohort of 71 South African paediatric patients was included and a high-throughput nucleotide sequencing approach was used to sequence full-length muscle mtDNA. The average coverage of the mtDNA genome was 81 +/- 26 per position. After assigning haplogroups, it was determined that although the nature of non-haplogroup-defining variants was similar in African and non-African haplogroup patients, the number of substitutions were significantly higher in African patients. We describe previously reported disease-associated and novel variants in this cohort. We observed a general lack of commonly reported syndrome-associated mutations, which supports clinical observations and confirms general observations in African patients when using single mutation screening strategies based on (predominantly non-African) mtDNA disease-based information. It is finally concluded that this first extensive report on muscle mtDNA sequences in African paediatric patients highlights the need for a full-length mtDNA sequencing strategy, which applies to all populations where specific mutations is not present. This, in addition to nuclear DNA gene mutation and pathogenicity evaluations, will be required to better unravel the aetiology of these disorders in African patients. European Journal of Human Genetics (2012) 20, 650-656; doi:10.1038/ejhg.2011.262; published online 18 January 2012
C1 [van der Walt, Elizna M.; Louw, Roan; van der Westhuizen, Francois H.] North West Univ, Ctr Human Metabon, ZA-2520 Potchefstroom, South Africa.
   [Smuts, Izelle] Univ Pretoria, Steve Biko Acad Hosp, Dept Paediat & Child Hlth, ZA-0002 Pretoria, South Africa.
   [Taylor, Robert W.; Elson, Joanna L.; Turnbull, Douglass M.; van der Westhuizen, Francois H.] Newcastle Univ, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 North West University - South Africa; University of Pretoria; Newcastle University - UK
RP van der Westhuizen, FH (corresponding author), North West Univ, Ctr Human Metabon, Private Bag X6001, ZA-2520 Potchefstroom, South Africa.
EM Francois.vanderWesthuizen@nwu.ac.za
FU Department of Science and Technology and Medical Research Council of South Africa; Wellcome Trust [074454/Z/04/Z]; UK NHS Specialised Services 'Rare Mitochondrial Disorders of Adults and Children' Diagnostic Service; Newcastle University Research Committee Visiting Professorship bursary; MRC [G0800674, MC_G0802536, G0700718] Funding Source: UKRI
CR Alston CL, 2010, J NEUROL SCI, V298, P140, DOI 10.1016/j.jns.2010.08.014
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bandelt HJ, 2008, INT J CARDIOL, V126, P439, DOI 10.1016/j.ijcard.2007.02.049
   Bannwarth S, 2008, MITOCHONDRION, V8, P136, DOI 10.1016/j.mito.2007.10.008
   Chandrasekar A, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0007447
   Coble MD, 2004, INT J LEGAL MED, V118, P137, DOI 10.1007/s00414-004-0427-6
   De Schrijver JM, 2010, BMC BIOINFORMATICS, V11, P0, DOI 10.1186/1471-2105-11-269
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Hedges D, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0008232
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   HOWELL N, 1995, GENETICS, V140, P285
   HOWELL N, 1991, AM J HUM GENET, V48, P935
   Human H, 2010, BIOCHEM BIOPH RES CO, V393, P751, DOI 10.1016/j.bbrc.2010.02.075
   Janssen AJM, 2007, CLIN CHEM, V53, P729, DOI 10.1373/clinchem.2006.078873
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   Joyjinda Y, 2007, THESIS MAHIDOL U MAH, V0, P0
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   MACKEY DA, 1994, EYE, V8, P431, DOI 10.1038/eye.1994.102
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Pereira L, 2009, AM J HUM GENET, V84, P628, DOI 10.1016/j.ajhg.2009.04.013
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Porcelli AM, 2010, HUM MOL GENET, V19, P1019, DOI 10.1093/hmg/ddp566
   Prasad GN, 2006, INT J CARDIOL, V109, P432, DOI 10.1016/j.ijcard.2005.07.065
   Pye D, 2006, NUCLEIC ACIDS RES, V34, P0, DOI 10.1093/nar/gkl516
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Reinecke F, 2009, BBA-MOL BASIS DIS, V1792, P1113, DOI 10.1016/j.bbadis.2009.04.003
   SHEPHERD D, 1969, BIOCHEM J, V114, P597, DOI 10.1042/bj1140597
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smuts I, 2010, J INHERIT METAB DIS, V33, PS95, DOI 10.1007/s10545-009-9031-8
   Swalwell H, 2011, EUR J HUM GENET, V19, P769, DOI 10.1038/ejhg.2011.18
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Zaragoza MV, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0012295
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 39
TC 32
Z9 32
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JUN 15
PY 2012
VL 20
IS 6
BP 650
EP 656
DI 10.1038/ejhg.2011.262
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 944KK
UT WOS:000304200000014
PM 22258525
DA 2024-11-01
ER

PT J
AU Murphy, JL
   Ratnaike, TE
   Shang, ES
   Falkous, G
   Blakely, EL
   Alston, CL
   Taivassalo, T
   Haller, RG
   Taylor, RW
   Turnbull, DM
AF Murphy, Julie L.
   Ratnaike, Thiloka E.
   Shang, Ersong
   Falkous, Gavin
   Blakely, Emma L.
   Alston, Charlotte L.
   Taivassalo, Tanja
   Haller, Ronald G.
   Taylor, Robert W.
   Turnbull, Doug M.
TI Cytochrome <i>c</i> oxidase-intermediate fibres: Importance in understanding the pathogenesis and treatment of mitochondrial myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial myopathy; mtDNA; cytochrome c oxidase; enzyme histochemistry
ID real-time pcr; dna mutations; individual cells; muscle-fibers; deletions; disease; single; deficiency; diagnosis
AB An important diagnostic muscle biopsy finding in patients with mitochondrial DNA disease is the presence of respiratory-chain deficient fibres. These fibres are detected as cytochrome c oxidase-deficient following a sequential cytochrome c oxidase-succinate dehydrogenase reaction, often in a mosaic pattern within a population of cytochrome c oxidase-normal fibres. Detailed analysis of muscle biopsies from patients with various mitochondrial DNA defects shows that a spectrum of deficiency exists, as there are a large number of fibres which do not correspond to being either completely cytochrome c oxidase-normal (brown staining) or cytochrome c oxidase-deficient (blue staining). We have used a combination of histochemical and immunocytochemical techniques to show that a population of cytochrome c oxidase-intermediate reacting fibres are a gradation between normal and deficient fibres. We show that cytochrome c oxidase-intermediate fibres also have different genetic characteristics in terms of amount of mutated and wild-type mtDNA, and as such, may represent an important transition between respiratory normal and deficient fibres. Assessing changes in intermediate fibres will be crucial to evaluating the responses to treatment and in particular to exercise training regimes in patients with mitochondrial DNA disease. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Turnbull, Doug M.] Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Taivassalo, Tanja] McGill Univ, Dept Kinesiol, Montreal, PQ, Canada.
   [Taivassalo, Tanja] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
   [Haller, Ronald G.] Texas Hlth Presbyterian Hosp, Neuromuscular Ctr, Inst Exercise & Environm Med, Dallas, TX USA.
   [Haller, Ronald G.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.
C3 Newcastle University - UK; McGill University; McGill University; University of Texas System; University of Texas Southwestern Medical Center Dallas
RP Turnbull, DM (corresponding author), Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM doug.turnbull@newcastle.ac.uk
FU Muscular Dystrophy Campaign, Newcastle University Centre for Brain Ageing and Vitality; BBSRC; EPSRC; ESRC; MRC as part of cross-council Lifelong Health; Wellbeing Initiative [G0700718]; MRC Mitochondrial Disease Cohort Study; Wellcome Trust Centre for Mitochondrial Research [906919]; UK NIHR Biomedical Research Centre for Ageing and Age-related disease; UK NHS Highly Specialised Services Commissioners; National Institutes of Health (National Institute of Arthritis, Musculoskeletal and Skin Diseases, NIAMS), USA [RO1-AR050597]; MRC [MC_G0802536, G0800674, G0700718] Funding Source: UKRI
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews H, 2006, J NEUROSCI RES, V83, P1533, DOI 10.1002/jnr.20842
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010
   Capaldi RA, 2004, MITOCHONDRION, V4, P417, DOI 10.1016/j.mito.2004.07.006
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Durham SE, 2007, AM J HUM GENET, V81, P189, DOI 10.1086/518901
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   Greaves LC, 2011, J PATHOL, V0, P0
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Perales-Clemente E, 2010, MOL CELL BIOL, V30, P3038, DOI 10.1128/MCB.00025-10
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
NR 23
TC 37
Z9 41
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG 15
PY 2012
VL 22
IS 8
BP 690
EP 698
DI 10.1016/j.nmd.2012.04.003
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 990GV
UT WOS:000307619900003
PM 22647770
DA 2024-11-01
ER

PT J
AU Kim, MJ
   Lee, W
   Park, EJ
   Park, SY
AF Kim, Mi-Jin
   Lee, Wan
   Park, Eun-Ju
   Park, Seung-Yoon
TI Depletion of Mitochondrial DNA Stabilizes C1qTNF-Related Protein 6 mRNA in Muscle Cells
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE DNA, Mitochondrial; CTRP6; C1qTNF-6; mRNA Stability; C2C12 Cells
ID l6 glut4myc myocytes; fatty-acid oxidation; insulin-resistance; ethidium bromide; glucose-utilization; stress; kinase; inhibition; activation; expression
AB Mutation and reduction of mitochondrial DNA (mtDNA) have been suggested as factors in the pathogenesis of several metabolic diseases. Recently, we demonstrated that C1qTNF-related protein-6 (CTRP6) is involved in fatty acid metabolism in muscle cells. In this study, we showed that expression of CTRP6 was up-regulated in mtDNA-depleted C2C12 cells, which displayed a marked decrease in cellular mtDNA and ATP content. Replacement of mtDNA normalized the expression level of CTRP6 similar to that in normal C2C12 cells, indicating that CTRP6 expression was up-regulated by mtDNA depletion. However, CTRP6 promoter activity remained unchanged in mtDNA-depleted cells. We also found that mtDNA depletion inhibited decay of CTRP6 mRNA. Taken together, mtDNA depletion induces an increase in CTRP6 expression by increasing mRNA stability.
C1 [Kim, Mi-Jin; Lee, Wan; Park, Eun-Ju; Park, Seung-Yoon] Dongguk Univ, Sch Med, Dept Biochem, Gyeongju 780714, South Korea.
C3 Dongguk University
RP Park, SY (corresponding author), Dongguk Univ, Sch Med, Dept Biochem, 87 Dongdae Ro, Gyeongju 780714, South Korea.
EM psyoon@dongguk.ac.kr
FU National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0016102, M108KM010008-08K1301-00810]
CR Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910
   Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104
   Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028
   Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005
   Choi HS, 2007, J BIOL CHEM, V282, P31217, DOI 10.1074/jbc.M705098200
   DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163
   Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297
   García-Ruiz I, 2006, HEPATOLOGY, V44, P581, DOI 10.1002/hep.21313
   Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300
   Kim MJ, 2010, MOL CELLS, V30, P59, DOI 10.1007/s10059-010-0088-x
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Koh EH, 2007, DIABETES, V56, P2973, DOI 10.2337/db07-0510
   Lee W, 2008, EXP MOL MED, V40, P109, DOI 10.3858/emm.2008.40.1.109
   Lee W, 2010, FEBS LETT, V584, P968, DOI 10.1016/j.febslet.2010.01.040
   Park SY, 2009, J BIOL CHEM, V284, P27780, DOI 10.1074/jbc.M109.005611
   Park SY, 2005, J BIOL CHEM, V280, P9855, DOI 10.1074/jbc.M409399200
   Park SY, 2006, PROTEOMICS, V6, P1210, DOI 10.1002/pmic.200500284
   Park SY, 2005, EXP MOL MED, V37, P220, DOI 10.1038/emm.2005.30
   Prigione A, 2007, AGING CELL, V6, P619, DOI 10.1111/j.1474-9726.2007.00323.x
   Ryu HS, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0017343
   Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583
   Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wong GW, 2008, BIOCHEM J, V416, P161, DOI 10.1042/BJ20081240
   Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   ZYLBER E, 1969, J MOL BIOL, V44, P195, DOI 10.1016/0022-2836(69)90414-8
NR 28
TC 7
Z9 9
U1 0
U2 5
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD MAY 15
PY 2012
VL 27
IS 5
BP 465
EP 470
DI 10.3346/jkms.2012.27.5.465
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 938TJ
UT WOS:000303755600002
PM 22563208
DA 2024-11-01
ER

PT J
AU Pontarin, G
   Ferraro, P
   Bee, L
   Reichard, P
   Bianchi, V
AF Pontarin, Giovanna
   Ferraro, Paola
   Bee, Leonardo
   Reichard, Peter
   Bianchi, Vera
TI Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
DE DNA precursors; dNTP de novo synthesis; cell cycle; mitochondrial disease
ID histone h2ax phosphorylation; nucleotide excision-repair; strand breaks; damage; gene; inhibition; mutations; depletion; rrm2b; fibroblasts
AB In postmitotic mammalian cells, protein p53R2 substitutes for protein R2 as a subunit of ribonucleotide reductase. In human patients with mutations in RRM2B, the gene for p53R2, mitochondrial (mt) DNA synthesis is defective, and skeletal muscle presents severe mtDNA depletion. Skin fibroblasts isolated from a patient with a lethal homozygous missense mutation of p53R2 grow normally in culture with an unchanged complement of mtDNA. During active growth, the four dNTP pools do not differ in size from normal controls, whereas during quiescence, the dCTP and dGTP pools decrease to 50% of the control. We investigate the ability of these mutated fibroblasts to synthesize mtDNA and repair DNA after exposure to UV irradiation. Ethidium bromide depleted both mutant and normal cells of mtDNA. On withdrawal of the drug, mtDNA recovered equally well in cycling mutant and control cells, whereas during quiescence, the mutant fibroblasts remained deficient. Addition of deoxynucleosides to the medium increased intracellular dNTP pools and normalized mtDNA synthesis. Quiescent mutant fibroblasts were also deficient in the repair of UV-induced DNA damage, as indicated by delayed recovery of dsDNA analyzed by fluorometric analysis of DNA unwinding and the more extensive and prolonged phosphorylation of histone H2AX after irradiation. Supplementation by deoxynucleosides improved DNA repair. Our results show that in nontransformed cells only during quiescence, protein p53R2 is required for maintenance of mtDNA and for optimal DNA repair after UV damage.
C1 [Pontarin, Giovanna; Ferraro, Paola; Bee, Leonardo; Reichard, Peter; Bianchi, Vera] Univ Padua, Dept Biol, I-35131 Padua, Italy.
C3 University of Padua
RP Reichard, P (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.
EM reichard@bio.unipd.it; vbianchi@bio.unipd.it
FU Italian Telethon Grant [GGP09019]; Italian Association for Cancer Research (AIRC) [1091]; University of Padova; Strategic Project "Models of Mitochondrial Diseases"; Cariparo Foundation
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Baumstark-Khan C, 2000, PHOTOCHEM PHOTOBIOL, V72, P477, DOI 10.1562/0031-8655(2000)072<0477:FAODUF>2.0.CO;2
   BIRNBOIM HC, 1981, CANCER RES, V41, P1889
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   CARSON DA, 1976, J CLIN INVEST, V57, P274, DOI 10.1172/JCI108278
   Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200
   Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100
   Chaouch S, 2009, HUM GENE THER, V20, P784, DOI 10.1089/hum.2008.163
   Cleaver JE, 2011, PHOTOCHEM PHOTOBIOL, V87, P1230, DOI 10.1111/j.1751-1097.2011.00995.x
   Devlin HL, 2008, MOL CANCER RES, V6, P808, DOI 10.1158/1541-7786.MCR-07-2027
   ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7
   Friedberg ECW, 2006, DNA REPAIR MUTAGENES, V0, P0
   Håkansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200
   HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8
   King M P, 1996, METHODS ENZYMOL, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   KRAKOFF IH, 1968, CANCER RES, V28, P1559
   Kumar D, 2011, NUCLEIC ACIDS RES, V39, P1360, DOI 10.1093/nar/gkq829
   Kunos CA, 2010, RADIAT RES, V174, P574, DOI 10.1667/RR2273.1
   Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103
   Matsumoto M, 2007, J CELL SCI, V120, P1104, DOI 10.1242/jcs.03391
   MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6
   Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774
   Niida H, 2010, CANCER SCI, V101, P2505, DOI 10.1111/j.1349-7006.2010.01719.x
   Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443
   Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2
   Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200
   Pontarin G, 2011, J BIOL CHEM, V286, P11132, DOI 10.1074/jbc.M110.202283
   Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105
   Rampazzo C, 2010, MUTAT RES-GEN TOX EN, V703, P2, DOI 10.1016/j.mrgentox.2010.06.002
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Schramm VL, 2002, BBA-MOL BASIS DIS, V1587, P107, DOI 10.1016/S0925-4439(02)00073-X
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
NR 38
TC 91
Z9 100
U1 0
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 14
PY 2012
VL 109
IS 33
BP 13302
EP 13307
DI 10.1073/pnas.1211289109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 992VC
UT WOS:000307807000040
PM 22847445
DA 2024-11-01
ER

PT J
AU Krishnan, KJ
   Ratnaike, TE
   De Gruyter, HLM
   Jaros, E
   Turnbull, DM
AF Krishnan, Kim J.
   Ratnaike, Thiloka E.
   De Gruyter, Heidi L. M.
   Jaros, Evelyn
   Turnbull, Doug M.
TI Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Mitochondrial DNA; mtDNA deletions; Alzheimer's disease; Aging; Mitochondrial dysfunction
ID human skeletal-muscle; substantia-nigra neurons; real-time pcr; individual cells; oxidase; accumulate; mutations; brain
AB Alzheimer's disease (AD) is the most common form of dementia, increasing in prevalence with age. Most patients who develop AD have an unknown cause, but characteristic neuropathological features include the deposition of extracellular amyloid beta and of intraneuronal hyperphosphorylated tau protein. Researchers have previously implicated mitochondrial dysfunction in AD. We previously showed an increase in neurons displaying a mitochondrial biochemical defect-cytochrome-c oxidase (COX) deficiency-in the hippocampus in patients with sporadic AD compared with age-matched controls. COX deficiency is well described as a marker of mitochondrial (mt) DNA dysfunction. This present study analyzed the mtDNA in single neurons from both COX normal and COX-deficient cells. Analysis of the mtDNA revealed that COX deficiency is caused by high levels of mtDNA deletions which accumulate with age. Future research is needed to clarify the role mtDNA deletions have in normal aging and investigate the relationship between mtDNA deletions and the pathogenesis of sporadic AD. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Krishnan, Kim J.] Newcastle Univ, Mitochondrial Res Grp, Sch Med, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Krishnan, Kim J.; Ratnaike, Thiloka E.; Turnbull, Doug M.] Newcastle Univ, Inst Ageing & Hlth, Ctr Brain Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Jaros, Evelyn] NHS Fdn Trust, Newcastle Upon Tyne Hosp, UK NIHR Biomed Res Ctr Ageing & Age Related Dis, Newcastle Upon Tyne, Tyne & Wear, England.
   [Jaros, Evelyn] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle University - UK
RP Krishnan, KJ (corresponding author), Newcastle Univ, Mitochondrial Res Grp, Sch Med, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM k.j.krishnan@ncl.ac.uk
FU Alzheimer's Research UK; Newcastle University Centre for Brain Ageing and Vitality; BBSRC; EPSRC; ESRC; MRC as part of the cross-council Lifelong Health and Wellbeing Initiative; MRC [G0700718, G0900652, G0800674, G0502157, MC_G0802536, G1100540, G0400074] Funding Source: UKRI
CR Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bender A, 2008, J NEUROL, V255, P1231, DOI 10.1007/s00415-008-0892-9
   Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(20)32205-4
   BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Campbell GR, 2010, ANN NEUROL, V2010, P8
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   Cottrell DA, 2001, NEUROLOGY, V57, P260, DOI 10.1212/WNL.57.2.260
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Melberg A, 2005, ACTA NEUROPATHOL, V110, P315, DOI 10.1007/s00401-005-1047-z
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090
   Petersen CAH, 2008, P NATL ACAD SCI USA, V105, P13145, DOI 10.1073/pnas.0806192105
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
NR 22
TC 75
Z9 81
U1 2
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD SEP 15
PY 2012
VL 33
IS 9
BP 2210
EP 2214
DI 10.1016/j.neurobiolaging.2011.08.009
PG 5
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 981TW
UT WOS:000306994600032
PM 21925769
DA 2024-11-01
ER

PT J
AU Hollingsworth, KG
   Gorman, GS
   Trenell, MI
   McFarland, R
   Taylor, RW
   Turnbull, DM
   MacGowan, GA
   Blamire, AM
   Chinnery, PF
AF Hollingsworth, Kieren G.
   Gorman, Grainne S.
   Trenell, Michael I.
   McFarland, Robert
   Taylor, Robert W.
   Turnbull, Douglass M.
   MacGowan, Guy A.
   Blamire, Andrew M.
   Chinnery, Patrick F.
TI Cardiomyopathy is common in patients with the mitochondrial DNA m.3243A&gt;G mutation and correlates with mutation load
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial disease; Cardiomyopathy; Tagging; MRI
ID 3243a-greater-than-g mutation; mtdna; depletion; reversal
AB Although neuromuscular clinical features often dominate the clinical presentation of mitochondrial disease due to the m.3243A>G mitochondrial DNA (mtDNA) mutation, many patients develop cardiac failure, which is often overlooked until it reaches an advanced stage. We set out to determine whether cardiac complications are sufficiently common to warrant prospective screening in all mutation carriers. Routine clinical echocardiography and 3 Tesla cardiac MRI were performed on ten m.3243A>G mutation carriers and compared to age and gender matched controls, with contemporaneous quadriceps muscle biopsies to measure respiratory chain activity and mtDNA mutation levels. Despite normal echocardiography, all ten m.3243A>G mutation carriers had evidence of abnormal cardiac function on MRI. The degree of cardiac dysfunction correlated with the percentage level of mutant mtDNA in skeletal muscle. Sub-clinical cardiac dysfunction was a universal finding in this study, adding weight to the importance of screening for cardiac complications in patients with m.3243A>G. The early detection of cardiac dysfunction with MRI opens up opportunities to prevent heart failure in these patients through early intervention. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Chinnery, Patrick F.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Hollingsworth, Kieren G.; Trenell, Michael I.; Blamire, Andrew M.] Newcastle Univ, Inst Cellular Med, Newcastle Magnet Resonance Ctr, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
   [Gorman, Grainne S.; McFarland, Robert; Taylor, Robert W.; Turnbull, Douglass M.; Chinnery, Patrick F.] Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Gorman, Grainne S.; McFarland, Robert; Taylor, Robert W.; Turnbull, Douglass M.; Chinnery, Patrick F.] Newcastle Univ, Inst Ageing & Hlth, NIHR Biomed Res Ctr Ageing & Age Related Dis, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [MacGowan, Guy A.] Freeman Rd Hosp, Dept Cardiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.
   [MacGowan, Guy A.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK; Newcastle University - UK
RP Chinnery, PF (corresponding author), Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU UK NHS; Medical Research Council (UK) Translational Muscle Centre, Parkinson's UK; Association Francaise contre les Myopathies; UK NIHR Biomedical Research Centre for Ageing and Agerelated disease; MRC [G0700718, G0900686, G0800674, MC_G0802536] Funding Source: UKRI
CR Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Colucci WS, 2007, CIRCULATION, V116, P49, DOI 10.1161/CIRCULATIONAHA.106.666016
   Durham SE, 2006, NEUROLOGY, V67, P502, DOI 10.1212/01.wnl.0000227961.55640.2f
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Hsu PC, 2008, INT J CARDIOL, V129, P441, DOI 10.1016/j.ijcard.2007.06.098
   Majamaa-Voltti K, 2008, J NEUROL NEUROSUR PS, V79, P0, DOI 10.1136/jnnp.2007.122648
   Majamaa-Voltti Kirsi, 2002, BMC CARDIOVASC DISORD, V2, P12
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   Taylor RW, 1997, ORGANELLE DIS, V0, P0
   Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196
NR 11
TC 31
Z9 32
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUL 15
PY 2012
VL 22
IS 7
BP 592
EP 596
DI 10.1016/j.nmd.2012.03.001
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 975VH
UT WOS:000306539100003
PM 22513320
DA 2024-11-01
ER

PT J
AU De Meirleir, L
AF De Meirleir, Linda
TI THE CLINICAL SPECTRUM OF MITOCHONDRIAL DISEASES IN NEONATES AND YOUNG CHILDREN AND APPROACH TO DIAGNOSIS
SO PAEDIATRIA CROATICA
LA English
DT Article
DE DNA, MITOCHONDRIAL; LEIGH DISEASE; MITOCHONDRIAL ENCEPHALOMYOPATHIES; LACTIC ACIDOSIS
ID respiratory-chain deficiency; mutations cause; dna; gene; manifestations; encephalopathy; translation; prevalence; disorders; pathology
AB Mitochondrial diseases are becoming more frequently diagnosed in neonates and small children. Different clinical presentations are possible and specific investigations need to he performed in order to get to the right molecular diagnosis necessary for further genetic counseling. MONA or nuclear genes can be investigated after biochemical work-up in the affected tissue. In the neonate, severe presentation may lead to early death, so taking the possible mitochondrial disease in consideration is essential, especially in case of severe lactic acidosis, encephalopathy, myopathy, cardiomyopathy or hepatopathy. In infancy, there are three syndromes that can occur more frequently: Pearson's syndrome due to deletion of mitochondrial DNA; Leigh's encephalopathy, a progressive neurodegenerative disorder with many different mitochondrial gene mutations; and Alpers' disease, progressive gray matter degeneration due to mutations in the POLG gene. Different organ involvement is seen in mtDNA depletion syndromes and finally one should also consider CoQ10 deficiency in certain clinical presentations.
C1 Univ Brussels, Dept Neuropediat, Brussels, Belgium.
C3 Free University of Brussels
RP De Meirleir, L (corresponding author), Univ Brussels, Dept Neuropediat, Laarbeeklaan 101, Brussels, Belgium.
EM linda.demeirleir@uz-bnissel.be
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Cizková A, 2008, NAT GENET, V40, P1288, DOI 10.1038/ng.246
   De Meirleir L, 2003, AM J MED GENET A, V121A, P126, DOI 10.1002/ajmg.a.20171
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Fellman V, 2011, SEMIN FETAL NEONAT M, V16, P222, DOI 10.1016/j.siny.2011.05.002
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Jonckheere AI, 2012, J INHERIT METAB DIS, V35, P211, DOI 10.1007/s10545-011-9382-9
   Kemp JP, 2011, BRAIN, V134, P183, DOI 10.1093/brain/awq320
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Rahman S, 2012, NEUROMUSCULAR DISORD, V22, P76, DOI 10.1016/j.nmd.2011.05.001
   Rötig A, 2010, DIABETES METAB, V36, P97, DOI 10.1016/j.diabet.2009.11.002
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Scalais E, 2012, EUR J PAEDIAT NEUROL, V17, P0
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schiff M, 2011, SEMIN FETAL NEONAT M, V16, P216, DOI 10.1016/j.siny.2011.04.002
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smet J, 2009, ELECTROPHORESIS, V30, P3565, DOI 10.1002/elps.200900213
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   von Kleist-Retzow JC, 2003, J PEDIATR-US, V143, P208, DOI 10.1067/S0022-3476(03)00130-6
   Wolf NI, 2009, EPILEPSIA, V50, P1596, DOI 10.1111/j.1528-1167.2008.01877.x
NR 26
TC 0
Z9 0
U1 0
U2 5
PU CHILDRENS HOSPITAL ZAGREB
PI ZAGREB
PA KLAICEVA 16, ZAGREB, 10000, CROATIA
SN 1330-1403
EI 
J9 PAEDIATR CROAT
JI Paediatr. Croat.
PD APR-JUN 15
PY 2012
VL 56
IS 2
BP 99
EP 103
DI 
PG 5
WC Pediatrics
SC Pediatrics
GA 986ET
UT WOS:000307324700002
DA 2024-11-01
ER

PT J
AU Pätsi, J
   Maliniemi, P
   Pakanen, S
   Hinttala, R
   Uusimaa, J
   Majamaa, K
   Nyström, T
   Kervinen, M
   Hassinen, IE
AF Patsi, Jukka
   Maliniemi, Pilvi
   Pakanen, Salla
   Hinttala, Reetta
   Uusimaa, Johanna
   Majamaa, Kari
   Nystrom, Thomas
   Kervinen, Marko
   Hassinen, Ilmo E.
TI LHON/MELAS overlap mutation in ND1 subunit of mitochondrial complex I affects ubiquinone binding as revealed by modeling in <i>Escherichia coli</i> NDH-1
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article
DE Escherichia coli; Leber hereditary optic neuropathy; MELAS; Mitochondria; NADH-ubiquinone oxidoreductase; Ubiquinone
ID hereditary optic neuropathy; membrane domain; reduction kinetics; acidic residues; 49-kda subunit; nadh; oxidoreductase; deficiency; genes; dna
AB Defects in complex 1 due to mutations in mitochondrial DNA are associated with clinical features ranging from single organ manifestation like Leber hereditary optic neuropathy (LHON) to multiorgan disorders like mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome. Specific mutations cause overlap syndromes combining several phenotypes, but the mechanisms of their biochemical effects are largely unknown. The m.3376G>A transition leading to p.E24K substitution in ND1 with LHON/MELAS phenotype was modeled here in a homologous position (NuoH-E36K) in the Escherichia coli enzyme and it almost totally abolished complex I activity. The more conservative mutation NuoH-E36Q resulted in higher apparent K-m for ubiquinone and diminished inhibitor sensitivity. A NuoH homolog of the m.3865A > G transition, which has been found concomitantly in the overlap syndrome patient with the m.3376G>A, had only a minor effect. Consequences of a primary LHON-mutation m.3460G > A affecting the same extramembrane loop as the m.3376G > A substitution were also studied in the E. coli model and were found to be mild. The results indicate that the overlap syndrome-associated m.3376G > A transition in MTND1 is the pathogenic mutation and m.3865A>G transition has minor, if any, effect on presentation of the disease. The kinetic effects of the NuoH-E36Q mutation suggest its proximity to the putative ubiquinone binding domain in 49 kD/PSST subunits. In all, m.3376G > A perturbs ubiquinone binding, a phenomenon found in LHON, and decreases the activity of fully assembled complex I as in MELAS. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Pakanen, Salla; Kervinen, Marko] Univ Oulu, Dept Ophthalmol, Inst Clin Med, FIN-90014 Oulu, Finland.
   [Patsi, Jukka; Maliniemi, Pilvi; Kervinen, Marko; Hassinen, Ilmo E.] Univ Oulu, Dept Med Biochem & Mol Biol, Inst Biomed, FIN-90014 Oulu, Finland.
   [Pakanen, Salla; Uusimaa, Johanna] Univ Oulu, Dept Paediat, Inst Clin Med, FIN-90014 Oulu, Finland.
   [Hinttala, Reetta; Majamaa, Kari] Univ Oulu, Dept Neurol, Inst Clin Med, FIN-90014 Oulu, Finland.
   [Pakanen, Salla; Hinttala, Reetta; Uusimaa, Johanna; Majamaa, Kari; Kervinen, Marko] Univ Oulu, Oulu Univ Hosp, Clin Res Ctr, FIN-90014 Oulu, Finland.
   [Nystrom, Thomas] Univ Gothenburg, Dept Cell & Mol Biol, SE-40530 Gothenburg, Sweden.
C3 University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Gothenburg
RP Kervinen, M (corresponding author), Univ Oulu, Dept Ophthalmol, Inst Clin Med, POB 5000, FIN-90014 Oulu, Finland.
EM marko.kervinen@oulu.fi; ilmo.hassinen@oulu.fi
FU Academy of Finland Council for Health and Council for Biosciences and Environment; Sigrid Juselius foundation; Academy of Finland [216378]; Eye Foundation; Evald and Hilda Nissi Foundation; Finnish Medical Foundation; Oulu University Scholarship foundation; Foundation for Paediatric Research; Alfred Kordelin Foundation; Alma and K.A. Snellman Foundation; Emil Aaltonen Foundation; Arvo and Lea Ylppo Foundation; Academy of Finland (AKA) [216378] Funding Source: Academy of Finland (AKA)
CR Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200
   Baba T, 2006, MOL SYST BIOL, V2, P0, DOI 10.1038/msb4100050
   Baranova EA, 2007, J MOL BIOL, V366, P140, DOI 10.1016/j.jmb.2006.11.026
   Björklöf K, 2000, FEBS LETT, V467, P105, DOI 10.1016/S0014-5793(00)01130-3
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200
   Cortés A, 2001, BIOCHEM J, V357, P263, DOI 10.1042/0264-6021:3570263
   Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   Efremov RG, 2011, NATURE, V476, P414, DOI 10.1038/nature10330
   Efremov RG, 2010, NATURE, V465, P441, DOI 10.1038/nature09066
   Fendel U, 2008, BBA-BIOENERGETICS, V1777, P660, DOI 10.1016/j.bbabio.2008.04.033
   FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x
   Gerencer Laszlo, 2004, ACTA BIOLOGICA SZEGEDIENSIS, V48, P25
   Ghelli A, 1997, MOL ASPECTS MED, V18, P0
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Grönlund MA, 2010, BRIT J OPHTHALMOL, V94, P121, DOI 10.1136/bjo.2008.154187
   Hinttala R, 2010, MITOCHONDRION, V10, P358, DOI 10.1016/j.mito.2010.02.002
   Horváth R, 2008, NEUROMUSCULAR DISORD, V18, P553, DOI 10.1016/j.nmd.2008.05.002
   Hunte C, 2010, SCIENCE, V329, P448, DOI 10.1126/science.1191046
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   Kakutani N, 2010, BIOCHEMISTRY-US, V49, P4794, DOI 10.1021/bi100454b
   Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200
   Kervinen M, 2004, BIOCHEMISTRY-US, V43, P773, DOI 10.1021/bi0355903
   Kervinen M, 2006, HUM MOL GENET, V15, P2543, DOI 10.1093/hmg/ddl176
   King MS, 2009, BIOCHEMISTRY-US, V48, P2053, DOI 10.1021/bi802282h
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Kurki S, 2000, BIOCHEMISTRY-US, V39, P13496, DOI 10.1021/bi001134s
   Lenaz G, 2004, BBA-BIOENERGETICS, V1658, P89, DOI 10.1016/j.bbabio.2004.03.013
   Liang M, 2009, BIOCHEM BIOPH RES CO, V383, P286, DOI 10.1016/j.bbrc.2009.03.097
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lunardi J, 1998, BBA-MOL BASIS DIS, V1407, P114, DOI 10.1016/S0925-4439(98)00036-2
   Majander A, 1996, EUR J BIOCHEM, V239, P201, DOI 10.1111/j.1432-1033.1996.0201u.x
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   Maliniemi P, 2009, MITOCHONDRION, V9, P394, DOI 10.1016/j.mito.2009.07.001
   Matsuoka R, 1999, BIOCHEM BIOPH RES CO, V257, P228, DOI 10.1006/bbrc.1999.0443
   Montoya J, 2009, BIOCHIM BIOPHYS ACTA, V1787, P470
   Moslemi AR, 2008, NEUROPEDIATRICS, V39, P24, DOI 10.1055/s-2008-1076739
   Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625
   Pätsi J, 2008, BIOCHEM J, V409, P129, DOI 10.1042/BJ20070866
   Pohl T, 2007, BIOCHEMISTRY-US, V46, P10694, DOI 10.1021/bi701057t
   Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809
   Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200
   Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6
   Sharpley MS, 2006, BIOCHEMISTRY-US, V45, P241, DOI 10.1021/bi051809x
   Sinegina L, 2005, BIOCHEMISTRY-US, V44, P8500, DOI 10.1021/bi050134v
   Sinha PK, 2009, J BIOL CHEM, V284, P9814, DOI 10.1074/jbc.M809468200
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tocilescu MA, 2007, J BIOL CHEM, V282, P29514, DOI 10.1074/jbc.M704519200
   Tocilescu MA, 2010, BBA-BIOENERGETICS, V1797, P625, DOI 10.1016/j.bbabio.2010.01.029
   Torres-Bacete J, 2007, J BIOL CHEM, V282, P36914, DOI 10.1074/jbc.M707855200
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
   Zickermann V, 1998, BIOCHEMISTRY-US, V37, P11792, DOI 10.1021/bi9810555
NR 58
TC 16
Z9 19
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 1879-2650
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD FEB 15
PY 2012
VL 1817
IS 2
BP 312
EP 318
DI 10.1016/j.bbabio.2011.10.014
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 892CW
UT WOS:000300265300007
PM 22079202
DA 2024-11-01
ER

PT J
AU Saada, A
   Edvardson, S
   Shaag, A
   Chung, WK
   Segel, R
   Miller, C
   Jalas, C
   Elpeleg, O
AF Saada, Ann
   Edvardson, Shimon
   Shaag, Avraham
   Chung, Wendy K.
   Segel, Reeval
   Miller, Chaya
   Jalas, Chaim
   Elpeleg, Orly
TI Combined OXPHOS complex I and IV defect, due to mutated complex I assembly factor C20ORF7
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID mitochondrial complex; molecular chaperone; deficiency; disease; mutations; gene; encephalopathy; prevalence; subunits; foxred1
AB Defects of the mitochondrial oxidative phosphorylation (OXPHOS) system are frequent causes of neurological disorders in children. Linkage analysis and DNA sequencing identified a new founder p.G250V substitution in the C20ORF7 complex I chaperone in five Ashkenazi Jewish patients from two families with a combined OXPHOS complex I and IV defect presenting with Leigh's syndrome in infancy. Complementation with the wild type gene restored complex I, but only partially complex IV activity. Although the pathogenic mechanism remains elusive, a C20ORF7 defect should be considered not only in isolated complex I deficiency, but also in combination with decreased complex IV. Given the significant 1:290 carrier rate for the p.G250V mutation among Ashkenazi Jews, this mutation should be screened in all Ashkenazi patients with Leigh's syndrome prior to muscle biopsy.
C1 [Saada, Ann; Shaag, Avraham; Miller, Chaya; Elpeleg, Orly] Hebrew Univ Jerusalem, Med Ctr, Monique & Jacques Roboh Dept Genet Res, IL-91120 Jerusalem, Israel.
   [Saada, Ann; Shaag, Avraham; Miller, Chaya; Elpeleg, Orly] Hebrew Univ Jerusalem, Med Ctr, Dept Genet & Metab Dis, IL-91120 Jerusalem, Israel.
   [Edvardson, Shimon] Hadassah Med Ctr, Pediat Neurol Unit, IL-91120 Jerusalem, Israel.
   [Chung, Wendy K.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA.
   [Chung, Wendy K.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA.
   [Segel, Reeval] Shaare Zedek Med Ctr, Dept Pediat, IL-91031 Jerusalem, Israel.
   [Segel, Reeval] Shaare Zedek Med Ctr, Dept Med Genet, IL-91031 Jerusalem, Israel.
   [Jalas, Chaim] Bonei Olam Ctr Rare Jewish Genet Disorders, Brooklyn, NY USA.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Columbia University; Columbia University; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center
RP Saada, A (corresponding author), Hebrew Univ Jerusalem, Med Ctr, Monique & Jacques Roboh Dept Genet Res, POB 1200, IL-91120 Jerusalem, Israel.
EM annsr@hadassah.org.il
FU Israeli Ministry of Health [5914]; Israeli Academy of Sciences [1462/09]
CR Barghuti F, 2008, MOL GENET METAB, V94, P78, DOI 10.1016/j.ymgme.2007.11.013
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Carroll J, 2005, MOL CELL PROTEOMICS, V4, P693, DOI 10.1074/mcp.M500014-MCP200
   Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200
   DiMauro S, 1998, NAT GENET, V19, P214, DOI 10.1038/883
   Dunning CJR, 2007, EMBO J, V26, P3227, DOI 10.1038/sj.emboj.7601748
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Fassone E, 2010, HUM MOL GENET, V19, P4837, DOI 10.1093/hmg/ddq414
   Gerards M, 2010, J MED GENET, V47, P507, DOI 10.1136/jmg.2009.067553
   Gerards M, 2011, BRAIN, V134, P210, DOI 10.1093/brain/awq273
   Haack TB, 2010, NAT GENET, V42, P1131, DOI 10.1038/ng.706
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   Jones CN, 2009, MITOCHONDRION, V9, P429, DOI 10.1016/j.mito.2009.08.001
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Lazarou M, 2009, BBA-MOL CELL RES, V1793, P78, DOI 10.1016/j.bbamcr.2008.04.015
   Mckenzie M, 2010, IUBMB LIFE, V62, P497, DOI 10.1002/iub.335
   Nouws J, 2010, CELL METAB, V12, P283, DOI 10.1016/j.cmet.2010.08.002
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Pogozelski WK, 2003, MITOCHONDRION, V2, P415, DOI 10.1016/S1567-7249(03)00033-3
   Saada A, 2004, ANAL BIOCHEM, V335, P66, DOI 10.1016/j.ab.2004.08.015
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Sheftel AD, 2009, MOL CELL BIOL, V29, P6059, DOI 10.1128/MCB.00817-09
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Sugiana C, 2008, AM J HUM GENET, V83, P468, DOI 10.1016/j.ajhg.2008.09.009
   Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037
NR 28
TC 44
Z9 50
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD JAN 15
PY 2012
VL 35
IS 1
BP 125
EP 131
DI 10.1007/s10545-011-9348-y
PG 7
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 870EU
UT WOS:000298652700015
PM 21607760
DA 2024-11-01
ER

PT J
AU Jash, S
   Chowdhury, T
   Adhya, S
AF Jash, Sukanta
   Chowdhury, Tapas
   Adhya, Samit
TI Modulation of mitochondrial respiratory capacity by carrier-mediated transfer of RNA in vivo
SO MITOCHONDRION
LA English
DT Article
DE Mitochondria; RNA; Gene therapy; In vivo; Muscle respiration; Aging
ID allotopic expression; mutant mitochondria; yeast mitochondria; metabolic disease; dna deletions; delivery; complex; cells; gene; mutations
AB Genetic dysfunction of mitochondria is pathological, but an effective method of nucleic acid delivery to mitochondria in vivo is lacking. Injection into rodents of tagged polycistronic RNAs (pcRNAs) encoding parts of the organelle genome and bound to a carrier complex, resulted in rapid uptake and concentration of the RNA in many tissues. The delivered RNA was localized to mitochondria. A pan-genomic cocktail of pcRNAs restored mRNA levels, stimulated mitochondrial translation and respiratory capacity of skeletal muscle of middle-aged and old rats. Thus, the carrier-based protocol may be suitable for delivery of functional RNAs to mitochondria in vivo. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Jash, Sukanta; Chowdhury, Tapas; Adhya, Samit] Indian Inst Chem Biol, Genet Engn Lab, CSIR, Kolkata 700032, W Bengal, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)
RP Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, CSIR, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.
EM nilugrandson@gmail.com
FU CSIR-IICB [SIP0007]; CSIR
CR Bacman SR, 2010, GENE THER, V17, P713, DOI 10.1038/gt.2010.25
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Cantó C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   DSouza GGM, 2003, J CONTROL RELEASE, V92, P189, DOI 10.1016/S0168-3659(03)00297-9
   Ellouze S, 2008, AM J HUM GENET, V83, P373, DOI 10.1016/j.ajhg.2008.08.013
   Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478
   Guy J, 2009, INVEST OPHTH VIS SCI, V50, P4205, DOI 10.1167/iovs.08-3214
   Hudson EK, 1998, MECH AGEING DEV, V103, P179, DOI 10.1016/S0047-6374(98)00043-8
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jash S, 2011, MITOCHONDRION, V11, P607, DOI 10.1016/j.mito.2011.03.124
   Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lane N, 2006, NATURE, V440, P600, DOI 10.1038/440600a
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   López-Lluch G, 2008, EXP GERONTOL, V43, P813, DOI 10.1016/j.exger.2008.06.014
   Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343
   Mahata B, 2005, J BIOL CHEM, V280, P5141, DOI 10.1074/jbc.C400572200
   Mahata B, 2006, SCIENCE, V314, P471, DOI 10.1126/science.1129754
   Mahato B, 2011, MITOCHONDRION, V11, P564, DOI 10.1016/j.mito.2011.03.006
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872
   Mukherjee S, 2008, HUM MOL GENET, V17, P1292, DOI 10.1093/hmg/ddn017
   Mukherjee S, 2007, EMBO REP, V8, P589, DOI 10.1038/sj.embor.7400979
   Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852
   NAGLEY P, 1988, P NATL ACAD SCI USA, V85, P2091, DOI 10.1073/pnas.85.7.2091
   Pak WJ, 2008, AGING CELL, V2, P1
   Perales-Clemente E, 2011, NUCLEIC ACIDS RES, V39, P225, DOI 10.1093/nar/gkq769
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Yamada Y, 2008, BBA-BIOMEMBRANES, V1778, P423, DOI 10.1016/j.bbamem.2007.11.002
   Zullo SJ, 2005, REJUV RES, V8, P18, DOI 10.1089/rej.2005.8.18
NR 36
TC 10
Z9 11
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAR 15
PY 2012
VL 12
IS 2
BP 262
EP 270
DI 10.1016/j.mito.2011.10.001
PG 9
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 913VX
UT WOS:000301906600012
PM 22037019
DA 2024-11-01
ER

PT J
AU Meola, G
   Bugiardini, E
   Cardani, R
AF Meola, G.
   Bugiardini, E.
   Cardani, R.
TI Muscle biopsy
SO JOURNAL OF NEUROLOGY
LA English
DT Review
DE Muscle biopsy; Neuromuscular disorders; Muscular dystrophies; Inflammatory myopathies; Toxic and drug-induced myopathies
ID myotonic-dystrophy type-2; inclusion-body myositis; (cctg)n mutation; ctg repeat; gene; diagnosis; cell; expression; expansion
AB Muscle biopsy is required to provide a definitive diagnosis in many neuromuscular disorders. It can be performed through an open or needle technique under local anesthesia. The major limitations of the needle biopsy technique are the sample size, which is smaller than that obtained with open biopsy, and the impossibility of direct visualization of the sampling site. However, needle biopsy is a less invasive procedure than open biopsy and is particularly indicated for diagnosis of neuromuscular disease in infancy and childhood. The biopsied muscle should be one affected by the disease but not be too weak or too atrophic. Usually, in case of proximal muscle involvement, the quadriceps and the biceps are biopsied, while under suspicion of mitochondrial disorder, the deltoid is preferred. The samples must be immediately frozen or fixed after excision to prevent loss of enzymatic reactivity, DNA depletion or RNA degradation. A battery of stainings is performed on muscle sections from every frozen muscle biopsy arriving in the pathology laboratory. Histological, histochemical, and histoenzymatic stainings are performed to evaluate fiber atrophy, morphological, and structural changes and metabolic disorders. Moreover, immunohistochemistry and Western blotting analysis may be used for expression analysis of muscle proteins to obtain a specific diagnosis. There are myopathies that do not need muscle biopsy since a genetic test performed on a blood sample is enough for definitive diagnosis. Muscle biopsy is a useful technique which can make an enormous contribution in the field of neuromuscular disorders but should be considered and interpreted together with the patient's family and clinical history.
C1 [Meola, G.; Bugiardini, E.] Univ Milan, Dept Neurol, IRCCS Policlin San Donato, I-20097 San Donato Milanese, Italy.
   [Cardani, R.] Univ Milan, Dept Mol Biol & Biotechnol, Milan, Italy.
   [Cardani, R.] Univ Milan, CMN Neuromuscular Dis Ctr, IRCCS Policlin San Donato, Milan, Italy.
C3 IRCCS Policlinico San Donato; University of Milan; University of Milan; IRCCS Policlinico San Donato; University of Milan
RP Meola, G (corresponding author), Univ Milan, Dept Neurol, IRCCS Policlin San Donato, Via Morandi 30, I-20097 San Donato Milanese, Italy.
EM giovanni.meola@unimi.it
CR Askanas V, 2001, J NEUROPATH EXP NEUR, V60, P1
   Bachinski LL, 2003, AM J HUM GENET, V73, P835, DOI 10.1086/378566
   Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689
   Bassez G, 2008, J NEUROPATH EXP NEUR, V67, P319, DOI 10.1097/NEN.0b013e31816b4acc
   Bergstrom J, 1962, SCAND J CLIN LAB INV, V14, P511
   BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5
   Cardani R, 2004, EUR J HISTOCHEM, V48, P437
   Connor A, 2007, JCR-J CLIN RHEUMATOL, V13, P341, DOI 10.1097/RHU.0b013e31815dca0a
   Day JW, 2003, NEUROLOGY, V60, P657, DOI 10.1212/01.WNL.0000054481.84978.F9
   Derry KL, 2009, CAN J NEUROL SCI, V36, P201, DOI 10.1017/S0317167100006569
   Dubowitz V, 2007, MUSCLE BIOPSY: A PRACTICAL APPROACH, V0, P0
   Duggan DJ, 1997, NEUROGENETICS, V1, P49, DOI 10.1007/s100480050008
   Duggan DJ, 1997, NEW ENGL J MED, V336, P618, DOI 10.1056/NEJM199702273360904
   EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   EVANS WJ, 1982, MED SCI SPORT EXER, V14, P101
   Fernandez C, 2005, ULTRASTRUCT PATHOL, V29, P437, DOI 10.1080/01913120500323175
   FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326
   GREIG PD, 1985, SURG GYNECOL OBSTET, V160, P466
   Hennessey JV, 1997, J APPL PHYSIOL, V82, P1739, DOI 10.1152/jappl.1997.82.6.1739
   HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4
   KARPATI G, 1993, BAILLIERE CLIN NEUR, V2, P527
   KARPATI G, 1988, ANN NEUROL, V23, P64, DOI 10.1002/ana.410230111
   Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125
   MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325
   MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493
   Melendez MM, 2007, J SURG RES, V142, P301, DOI 10.1016/j.jss.2007.03.043
   Meola G, 2005, EUR J HISTOCHEM, V49, P93
   Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365
   Muntoni F, 2001, NEUROLOGY, V57, P574, DOI 10.1212/WNL.57.4.574
   Needham M, 2007, LANCET NEUROL, V6, P620, DOI 10.1016/S1474-4422(07)70171-0
   OSullivan PJ, 2006, J ULTRAS MED, V25, P1
   Raheem O, 2010, ACTA NEUROPATHOL, V119, P495, DOI 10.1007/s00401-010-0643-8
   Ranum LPW, 1998, NAT GENET, V19, P196, DOI 10.1038/570
   RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2
   ROUND JM, 1980, HISTOCHEM J, V12, P707, DOI 10.1007/BF01012026
   Sallinen R, 2004, NEUROMUSCULAR DISORD, V14, P274, DOI 10.1016/j.nmd.2004.01.002
   Seale P, 2003, CELL CYCLE, V2, P418, DOI 10.4161/cc.2.5.498
   Sewry CA, 2008, J MUSCLE RES CELL M, V29, P231, DOI 10.1007/s10974-008-9155-8
   Tarnopolsky MA, 2011, MUSCLE NERVE, V43, P717, DOI 10.1002/mus.21945
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Udd B, 2003, NEUROMUSCUL DISORD, V13, P589, DOI 10.1016/S0960-8966(03)00092-0
   van der Meulen MFG, 2001, NEUROMUSCULAR DISORD, V11, P447, DOI 10.1016/S0960-8966(00)00219-4
   Vihola A, 2003, NEUROLOGY, V60, P1854, DOI 10.1212/01.WNL.0000065898.61358.09
   Vogel H, 2005, J NEUROPATH EXP NEUR, V64, P181, DOI 10.1093/jnen/64.3.181
NR 45
TC 27
Z9 30
U1 1
U2 26
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD APR 15
PY 2012
VL 259
IS 4
BP 601
EP 610
DI 10.1007/s00415-011-6193-8
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 921PL
UT WOS:000302489400001
PM 21805256
DA 2024-11-01
ER

PT J
AU Baruffini, E
   Serafini, F
   Ferrero, I
   Lodi, T
AF Baruffini, Enrico
   Serafini, Fausta
   Ferrero, Iliana
   Lodi, Tiziana
TI Overexpression of DNA Polymerase Zeta Reduces the Mitochondrial Mutability Caused by Pathological Mutations in DNA Polymerase Gamma in Yeast
SO PLOS ONE
LA English
DT Article
ID progressive external ophthalmoplegia; coli shuttle vectors; large ribosomal-rna; saccharomyces-cerevisiae; induced mutagenesis; rev1 protein; resistance mutations; depletion syndrm; complex-formation; gene-expression
AB In yeast, DNA polymerase zeta (Rev3 and Rev7) and Rev1, involved in the error-prone translesion synthesis during replication of nuclear DNA, localize also in mitochondria. We show that overexpression of Rev3 reduced the mtDNA extended mutability caused by a subclass of pathological mutations in Mip1, the yeast mitochondrial DNA polymerase orthologous to human Pol gamma. This beneficial effect was synergistic with the effect achieved by increasing the dNTPs pools. Since overexpression of Rev3 is detrimental for nuclear DNA mutability, we constructed a mutant Rev3 isoform unable to migrate into the nucleus: its overexpression reduced mtDNA mutability without increasing the nuclear one.
C1 [Baruffini, Enrico; Serafini, Fausta; Ferrero, Iliana; Lodi, Tiziana] Univ Parma, Dept Genet, I-43100 Parma, Italy.
C3 University of Parma
RP Baruffini, E (corresponding author), Univ Parma, Dept Genet, I-43100 Parma, Italy.
EM enrico.baruffini@nemo.unipr.it
FU Fondazione Telethon-Italy [GGP07019]
CR Acharya N, 2005, MOL CELL BIOL, V25, P9734, DOI 10.1128/MCB.25.21.9734-9740.2005
   Acharya N, 2006, MOL CELL BIOL, V26, P9555, DOI 10.1128/MCB.01671-06
   Atanassova N, 2011, HUM MOL GENET, V20, P1212, DOI 10.1093/hmg/ddq565
   Ausubel FM, 1994, CURR. PROTOC. MOL. BIOL, V0, P0
   Baruffini E, 2007, BIOCHIM BIOPHYS ACTA, V1772, P225
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Baruffini E, 2011, MITOCHONDRION, V11, P182, DOI 10.1016/j.mito.2010.09.007
   Baruffini E, 2010, METHODS, V51, P426, DOI 10.1016/j.ymeth.2010.02.023
   Baruffini E, 2010, MITOCHONDRION, V10, P183, DOI 10.1016/j.mito.2009.10.002
   Baruffini E, 2009, J BIOTECHNOL, V143, P247, DOI 10.1016/j.jbiotec.2009.08.007
   BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609
   Bulst S, 2009, HUM MOL GENET, V18, P1590, DOI 10.1093/hmg/ddp074
   Chiappini F, 2009, CURR HIV RES, V7, P244, DOI 10.2174/157016209787581409
   CHIT NW, 1994, J BIOL CHEM, V269, P29993
   CODON AC, 1995, APPL ENVIRON MICROB, V61, P630
   Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000
   CUI Z, 1989, CURR GENET, V16, P273, DOI 10.1007/BF00422114
   de Padula M, 2004, NUCLEIC ACIDS RES, V32, P5003, DOI 10.1093/nar/gkh831
   DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841
   Dujon B, 1981, MOL BIOL YEAST SACCH, V0, P505
   Euro L, 2011, NUCLEIC ACIDS RES, V39, P9072, DOI 10.1093/nar/gkr618
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Gibson BR, 2008, LETT APPL MICROBIOL, V46, P636, DOI 10.1111/j.1472-765X.2008.02360.x
   Gietz R Daniel, 2006, METHODS MOL BIOL, V313, P107
   GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0
   Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2004, NUCLEIC ACIDS RES, V32, P397, DOI 10.1093/nar/gkh213
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Hall BM, 2009, BIOINFORMATICS, V25, P1564, DOI 10.1093/bioinformatics/btp253
   Haracska L, 2003, MOL CELL BIOL, V23, P1453, DOI 10.1128/MCB.23.4.1453-1459.2003
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   Huang ME, 2002, GENETICS, V160, P1409
   Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026
   Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030
   Kaiser C, 1994, METHODS YEAST GENETI, V0, P0
   Kalifa L, 2007, DNA REPAIR, V6, P1732, DOI 10.1016/j.dnarep.2007.06.005
   Kaniak A, 2009, DNA REPAIR, V8, P318, DOI 10.1016/j.dnarep.2008.11.004
   Kasiviswanathan R, 2011, J BIOL CHEM, V0, P0, DOI DOI 10.1074/jbc.M111.306852jbc.M111.306852
   KUENZI MT, 1974, J BACTERIOL, V117, P80
   Lawrence CW, 2004, ADV PROTEIN CHEM, V69, P167
   Lawrence CW, 1996, CANCER SURV, V28, P21
   Lawrence CW, 2000, COLD SPRING HARB SYM, V65, P61, DOI 10.1101/sqb.2000.65.61
   LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080
   Lebedeva MA, 2007, CELL CYCLE, V6, P2048, DOI 10.4161/cc.6.16.4572
   LECRENIER N, 1995, MOL GEN GENET, V249, P1, DOI 10.1007/BF00290229
   Lee JC, 2001, FEMS YEAST RES, V1, P57
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lucas P, 2004, MITOCHONDRION, V4, P13, DOI 10.1016/j.mito.2004.04.001
   Mieczkowski PA, 1997, MOL GEN GENET, V253, P655, DOI 10.1007/s004380050369
   Mookerjee SA, 2006, MUTAT RES-FUND MOL M, V595, P91, DOI 10.1016/j.mrfmmm.2005.10.006
   MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989
   Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0
   Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646
   Northam MR, 2010, GENETICS, V184, P27, DOI 10.1534/genetics.109.107482
   PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Rajpal DK, 2000, MUTAT RES-DNA REPAIR, V461, P133, DOI 10.1016/S0921-8777(00)00047-1
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Sembongi H, 2007, HUM MOL GENET, V16, P2306, DOI 10.1093/hmg/ddm182
   Sherman F, 1986, LAB COURSE MANUAL ME, V0, P0
   Singh KK, 2009, J HUM GENET, V54, P516, DOI 10.1038/jhg.2009.71
   SINGHAL RK, 1992, MOL GEN GENET, V236, P17, DOI 10.1007/BF00279638
   SOR F, 1984, NUCLEIC ACIDS RES, V12, P8313, DOI 10.1093/nar/12.22.8313
   SOR F, 1982, NUCLEIC ACIDS RES, V10, P6571, DOI 10.1093/nar/10.21.6571
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stewart JD, 2010, HEPATOLOGY, V52, P1791, DOI 10.1002/hep.23891
   Stricker S, 2009, J NEUROL NEUROSUR PS, V80, P1181, DOI 10.1136/jnnp.2008.166066
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Taylor SD, 2005, MOL BIOL CELL, V16, P3010, DOI 10.1091/mbc.E05-01-0053
   THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9
   Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
   Zhang HS, 2006, GENETICS, V172, P2683, DOI 10.1534/genetics.105.051029
   Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4
NR 81
TC 19
Z9 20
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD MAR 28
PY 2012
VL 7
IS 3
BP 
EP 
DI 10.1371/journal.pone.0034322
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 948FM
UT WOS:000304489000096
PM 22470557
DA 2024-11-01
ER

PT J
AU Martikainen, MH
   Hinttala, R
   Röyttä, M
   Jääskeläinen, S
   Wendelin-Saarenhovi, M
   Parkkola, R
   Majamaa, K
AF Martikainen, Mika H.
   Hinttala, Reetta
   Roytta, Matias
   Jaaskelainen, Satu
   Wendelin-Saarenhovi, Maria
   Parkkola, Riitta
   Majamaa, Kari
TI Progressive External Ophthalmoplegia in Southwestern Finland: A Clinical and Genetic Study
SO NEUROEPIDEMIOLOGY
LA English
DT Article
DE Progressive external ophthalmoplegia; Epidemiology of mitochondrial diseases; POLG1; Mitochondrial DNA deletions
ID mitochondrial-dna deletions; autosomal-dominant; multiple deletions; mtdna maintenance; frequent cause; optic atrophy; mutations; opa1; twinkle; instability
AB Background: Progressive external ophthalmoplegia (PEO) is a common phenotype of mitochondrial disease. Molecular etiologies include sporadic, large-scale deletions in mitochondrial DNA (mtDNA), multiple mtDNA deletions secondary to autosomal dominant or recessive mutations and mtDNA point mutations. Methods: We studied the prevalence and clinical and genetic characteristics of PEO in a defined population in southwestern Finland. A total of 620 patients were first identified from the patient registry at the Turku University Hospital over an 18-year period. The medical records of these patients were scrutinized, and those with clinical features compatible with PEO were ascertained. Results: We identified 10 patients with possible PEO. The patients were examined clinically, and DNA was analyzed for mtDNA deletions and for the m.3243A>G and m.8344A>G mtDNA point mutations. The AND, PEO1, POLG1 and POLG2 genes were sequenced. We confirmed the clinical diagnosis of PEO in 6 patients. Large-scale mtDNA deletions were detected in 3 out of 6 PEO patients and mutations in the POLG1 gene in 1 out of 6. We did not find any mutations in the ANTI, PEO1 or POLG2 genes. Conclusions: Our results suggest that molecular investigation of patients with PEO, either sporadic or familial, should start with an analysis for mtDNA deletions, followed by an analysis of the POLG1 gene. Copyright (C) 2012 S. Karger AG, Basel
C1 [Hinttala, Reetta; Majamaa, Kari] Univ Oulu, Dept Clin Med, FI-90014 Oulu, Finland.
   [Martikainen, Mika H.] Turku Univ Hosp, Dept Neurol, FIN-20520 Turku, Finland.
   [Roytta, Matias] Turku Univ Hosp, Dept Pathol, FIN-20520 Turku, Finland.
   [Jaaskelainen, Satu] Turku Univ Hosp, Dept Clin Neurophysiol, FIN-20520 Turku, Finland.
   [Wendelin-Saarenhovi, Maria] Turku Univ Hosp, Dept Clin Physiol, FIN-20520 Turku, Finland.
   [Parkkola, Riitta] Turku Univ Hosp, Dept Radiol, FIN-20520 Turku, Finland.
   [Hinttala, Reetta] Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
C3 University of Oulu; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Oulu
RP Majamaa, K (corresponding author), Univ Oulu, Dept Clin Med, FI-90014 Oulu, Finland.
EM kari.majamaa@oulu.fi
FU Research Council for Health at the Academy of Finland; Sigrid Juselius Foundation; National Graduate School of Clinical Investigation; Emil Aaltonen Foundation; Alfred Kordelin Foundation
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   KALTON G, 1986, J ROY STAT SOC A STA, V149, P65, DOI 10.2307/2981886
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Martikainen Mika H, 2010, BMJ CASE REP, V2010, P0, DOI 10.1136/bcr.01.2010.2604
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stewart JD, 2008, NEUROLOGY, V71, P1829, DOI 10.1212/01.wnl.0000335931.54095.0a
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1991, AM J HUM GENET, V48, P203
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 31
TC 5
Z9 5
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0251-5350
EI 1423-0208
J9 NEUROEPIDEMIOLOGY
JI Neuroepidemiology
PD JUN 15
PY 2012
VL 38
IS 2
BP 114
EP 119
DI 10.1159/000336112
PG 6
WC Public, Environmental & Occupational Health; Clinical Neurology
SC Public, Environmental & Occupational Health; Neurosciences & Neurology
GA 910FK
UT WOS:000301622400007
PM 22377773
DA 2024-11-01
ER

PT J
AU Liu, HM
   Tsai, LP
   Chien, YH
   Wu, JF
   Weng, WC
   Peng, SF
   Wu, ET
   Huang, PH
   Lee, WT
   Tsai, IJ
   Hwu, WL
   Lee, NC
AF Liu, Hsin-Ming
   Tsai, Li-Ping
   Chien, Yin-Hsiu
   Wu, Jia-Feng
   Weng, Wen-Chin
   Peng, Shinn-Forng
   Wu, En-Ting
   Huang, Pei-Hsin
   Lee, Wang-Tso
   Tsai, I-Jun
   Hwu, Wuh-Liang
   Lee, Ni-Chung
TI A Novel 3670-Base Pair Mitochondrial DNA Deletion Resulting in Multi-systemic Manifestations in a Child
SO PEDIATRICS AND NEONATOLOGY
LA English
DT Article
DE Fanconi syndrome; mitochondrial DNA deletion; pancreatitis
ID complex-i-deficiency; mutation
AB Mitochondrial DNA (mtDNA) deletion is a rare occurrence that results in defects to oxidative phosphorylation. The common clinical presentations of mtDNA deletion vary but include mitochondrial myopathy, Pearson syndrome, Kearns-Sayre syndrome, and progressive external ophthalmoplegia. Here, we report the case of a 10-year-old boy who presented with progressive deterioration of his clinical status (which included hypoglycemia, short stature, sensorineural hearing loss, retinitis pigmentosa, and chronic gastrointestinal dysmotility) that progressed to acute deterioration with pancreatitis, Fanconi syndrome, lactic acidosis, and acute encephalopathy. Following treatment, the patient was stabilized and his neurological condition improved. Through a combination of histological examinations and biochemical and molecular analyses, mitochondrial disease was confirmed. A novel 3670-base pair deletion (deletion of mtDNA nt 7,628-11,297) was identified in the muscle tissue. A direct repeat of CTACT at the breakpoints was also detected. Copyright (C) 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
C1 [Liu, Hsin-Ming; Chien, Yin-Hsiu; Wu, Jia-Feng; Weng, Wen-Chin; Wu, En-Ting; Lee, Wang-Tso; Tsai, I-Jun; Hwu, Wuh-Liang; Lee, Ni-Chung] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10041, Taiwan.
   [Liu, Hsin-Ming; Chien, Yin-Hsiu; Wu, Jia-Feng; Weng, Wen-Chin; Peng, Shinn-Forng; Wu, En-Ting; Huang, Pei-Hsin; Lee, Wang-Tso; Tsai, I-Jun; Hwu, Wuh-Liang; Lee, Ni-Chung] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
   [Tsai, Li-Ping] Tzu Ji Gen Hosp, Dept Pediat, Taipei, Taiwan.
   [Chien, Yin-Hsiu; Hwu, Wuh-Liang; Lee, Ni-Chung] Natl Taiwan Univ Hosp, Dept Med Genet, Taipei 10041, Taiwan.
   [Peng, Shinn-Forng] Natl Taiwan Univ Hosp, Dept Radiol, Taipei 10041, Taiwan.
   [Huang, Pei-Hsin] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10041, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital
RP Lee, NC (corresponding author), Natl Taiwan Univ Hosp, Dept Pediat & Med Genet, Room 19005,19F,Childrens Hosp Bldg,8 Chung Shan S, Taipei 10041, Taiwan.
EM ncleentu@ntu.edu.tw
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Brautbar A, 2008, MOL GENET METAB, V94, P485, DOI 10.1016/j.ymgme.2008.04.004
   Chinnery PF, 1993, MITOCHONDRIAL DISORD, V0, P0
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   DiMauro S, 2007, MITOCHONDRIAL DNA DE, V0, P0
   Mkaouar-Rebai E, 2010, MITOCHONDRION, V10, P449, DOI 10.1016/j.mito.2010.04.003
   Ruiz-Pesini E, 2010, MITOMAP HUMAN MITOCH, V0, P0
   Sadikovic B, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0015687
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
NR 9
TC 11
Z9 12
U1 0
U2 2
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN
SN 1875-9572
EI 
J9 PEDIATR NEONATOL
JI Pediatr. Neonatol.
PD AUG 15
PY 2012
VL 53
IS 4
BP 264
EP 268
DI 10.1016/j.pedneo.2011.08.013
PG 5
WC Pediatrics
SC Pediatrics
GA 020IP
UT WOS:000309802500009
PM 22964285
DA 2024-11-01
ER

PT J
AU de Wit, HM
   Westeneng, HJ
   van Engelen, BGM
   Mudde, AH
AF de Wit, H. M.
   Westeneng, H. J.
   van Engelen, B. G. M.
   Mudde, A. H.
TI MIDD or MELAS: that's not the question MIDD evolving into MELAS: a severe phenotype of the m.3243A&gt;G mutation due to paternal co-inheritance of type 2 diabetes and a high heteroplasmy level
SO NETHERLANDS JOURNAL OF MEDICINE
LA English
DT Article
DE Insulin resistance; m.3243A > G mutation; MELAS; MIDD; heteroplasmy
ID clinical phenotype; insulin-resistance; mitochondrial; mellitus; deafness; gene; muscle; dna
AB Maternally inherited diabetes and deafness (MIDD) and mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) are different syndromes, but are caused by the same m.3243A>G mutation in mitochondrial DNA. Why some patients develop MIDD while others MELAS is unknown, but may be related to heteroplasmy level. Progression from MIDD to MELAS has not been described. Here we report a patient with MIDD who over time developed severe insulin resistance and symptoms and signs consistent with MELAS. The most likely explanation here was paternal co-inheritance of type 2 diabetes in combination with a high heteroplasmy level. The present case showing evolution of MIDD to MELAS supports the concept that both syndromes can be regarded as two phenotypes of the same disease.
C1 [de Wit, H. M.; Mudde, A. H.] Slingeland Hosp, Dept Internal Med, Doetinchem, Netherlands.
   [de Wit, H. M.] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
   [van Engelen, B. G. M.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
   [Westeneng, H. J.] St Antonius Hosp, Dept Neurol, Nieuwegein, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; St. Antonius Hospital Utrecht
RP Mudde, AH (corresponding author), Slingeland Hosp, Dept Internal Med, Doetinchem, Netherlands.
EM a.mudde@slingeland.nl
CR De Laat P, 2012, J INHERIT METAB DIS, V0, P9
   Fromont I, 2009, J NEUROL, V256, P1696, DOI 10.1007/s00415-009-5185-4
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   Hendrickx JJ, 2006, OTOL NEUROTOL, V27, P802, DOI 10.1097/01.mao.0000224091.02506.a0
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Jeppesen TD, 2006, ARCH NEUROL-CHICAGO, V63, P1701, DOI 10.1001/archneur.63.12.1701
   Laloi-Michelin M, 2009, J CLIN ENDOCR METAB, V94, P3025, DOI 10.1210/jc.2008-2680
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Suzuki S, 2003, DIABETES RES CLIN PR, V59, P207, DOI 10.1016/S0168-8227(02)00246-2
   Szendroedi J, 2009, DIABETES CARE, V32, P677, DOI 10.2337/dc08-2078
   Tack CJJ, 2000, DIABETES CARE, V23, P424, DOI 10.2337/diacare.23.3.424
   tHart LM, 1996, HUM MUTAT, V7, P193
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
NR 16
TC 17
Z9 20
U1 0
U2 2
PU VAN ZUIDEN COMMUNICATIONS
PI ALPHEN AAN DE RIJN
PA HENRY DUNANTWEG 40A, 2402 NR ALPHEN AAN DE RIJN, NETHERLANDS
SN 0300-2977
EI 
J9 NETH J MED
JI Neth. J. Med.
PD DEC 15
PY 2012
VL 70
IS 10
BP 460
EP 462
DI 
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 082PZ
UT WOS:000314405700006
PM 23230016
DA 2024-11-01
ER

PT J
AU Rouzier, C
   Bannwarth, S
   Chaussenot, A
   Chevrollier, A
   Verschueren, A
   Bonello-Palot, N
   Fragaki, K
   Cano, A
   Pouget, J
   Pellissier, JF
   Procaccio, V
   Chabrol, B
   Paquis-Flucklinger, V
AF Rouzier, Cecile
   Bannwarth, Sylvie
   Chaussenot, Annabelle
   Chevrollier, Arnaud
   Verschueren, Annie
   Bonello-Palot, Nathalie
   Fragaki, Konstantina
   Cano, Aline
   Pouget, Jean
   Pellissier, Jean-Francois
   Procaccio, Vincent
   Chabrol, Brigitte
   Paquis-Flucklinger, Veronique
TI The <i>MFN2</i> gene is responsible for mitochondrial DNA instability and optic atrophy 'plus' phenotype
SO BRAIN
LA English
DT Article
DE MFN2; mitochondrial DNA instability; dominant optic atrophy; mitochondrial fusion; Charcot-Marie-Tooth 2A
ID marie-tooth disease; opa1 mutations; external ophthalmoplegia; patient fibroblasts; coupling defect; fusion; mitofusin-2; damage; deletions; cells
AB MFN2 and OPA1 genes encode two dynamin-like GTPase proteins involved in the fusion of the mitochondrial membrane. They have been associated with Charcot-Marie-Tooth disease type 2A and autosomal dominant optic atrophy, respectively. We report a large family with optic atrophy beginning in early childhood, associated with axonal neuropathy and mitochondrial myopathy in adult life. The clinical presentation looks like the autosomal dominant optic atrophy 'plus' phenotype linked to OPA1 mutations but is associated with a novel MFN2 missense mutation (c.629A > T, p.D210V). Multiple mitochondrial DNA deletions were found in skeletal muscle and this observation makes MFN2 a novel gene associated with 'mitochondrial DNA breakage' syndrome. Contrary to previous studies in patients with Charcot-Marie-Tooth disease type 2A, fibroblasts carrying the MFN2 mutation present with a respiratory chain deficiency, a fragmentation of the mitochondrial network and a significant reduction of MFN2 protein expression. Furthermore, we show for the first time that impaired mitochondrial fusion is responsible for a deficiency to repair stress-induced mitochondrial DNA damage. It is likely that defect in mitochondrial DNA repair is due to variability in repair protein content across the mitochondrial population and is at least partially responsible for mitochondrial DNA instability.
C1 [Rouzier, Cecile; Bannwarth, Sylvie; Chaussenot, Annabelle; Fragaki, Konstantina; Paquis-Flucklinger, Veronique] Nice Teaching Hosp, Natl Ctr Mitochondrial Dis, Dept Med Genet, F-06200 Nice, France.
   [Rouzier, Cecile; Bannwarth, Sylvie; Fragaki, Konstantina; Paquis-Flucklinger, Veronique] Nice Sophia Antipolis Univ, Sch Med, INSERM, CNRS,LBPG,UMR 6267,U998,UNS, F-06100 Nice, France.
   [Chevrollier, Arnaud; Procaccio, Vincent] CNRS, INSERM, UMR 6214, U771, F-49000 Angers, France.
   [Chevrollier, Arnaud; Procaccio, Vincent] Angers Teaching Hosp, Dept Biochem & Genet, F-49000 Angers, France.
   [Verschueren, Annie; Pouget, Jean] Marseille Teaching Hosp, Timone Hosp, Dept Neurol, F-13005 Marseille, France.
   [Bonello-Palot, Nathalie] Marseille Teaching Hosp, Timone Hosp, Dept Med Genet, F-13005 Marseille, France.
   [Cano, Aline] Marseille Teaching Hosp, Timone Hosp, Dept Neuropaediat, F-13005 Marseille, France.
   [Pellissier, Jean-Francois] Marseille Teaching Hosp, Timone Hosp, Dept Neuropathol, F-13005 Marseille, France.
C3 CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille
RP Paquis-Flucklinger, V (corresponding author), Sch Med, INSERM, CNRS, LBPG,UMR 6267,U998,UNS, 28 Av Valombrose, F-06107 Nice 2, France.
EM paquis@hermes.unice.fr
FU Association Francaise contre les Myopathies (AFM)
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Amiott EA, 2008, EXP NEUROL, V211, P115, DOI 10.1016/j.expneurol.2008.01.010
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cartoni R, 2009, EXP NEUROL, V218, P268, DOI 10.1016/j.expneurol.2009.05.003
   Chen H, 2010, ANN NY ACAD SCI, V1201, P21, DOI 10.1111/j.1749-6632.2010.05615.x
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Chevrollier A, 2008, ANN NEUROL, V63, P794, DOI 10.1002/ana.21385
   Chung KW, 2006, BRAIN, V129, P2103, DOI 10.1093/brain/awl174
   Del Bo R, 2008, NEUROLOGY, V71, P1959, DOI 10.1212/01.wnl.0000327095.32005.a4
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Detmer SA, 2007, J CELL BIOL, V176, P405, DOI 10.1083/jcb.200611080
   Griffin EE, 2006, J BIOL CHEM, V281, P16599, DOI 10.1074/jbc.M601847200
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Santos JH, 2006, HUM MOL GENET, V15, P1757, DOI 10.1093/hmg/ddl098
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hunter SE, 2010, METHODS, V51, P444, DOI 10.1016/j.ymeth.2010.01.033
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793
   Lawson VH, 2005, NEUROLOGY, V65, P197, DOI 10.1212/01.wnl.0000168898.76071.70
   Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008
   Loiseau D, 2007, ANN NEUROL, V61, P315, DOI 10.1002/ana.21086
   Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Paul R, 1996, TRENDS GENET, V12, P131
   ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5
   Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P31
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   SHULL S, 1991, J BIOL CHEM, V266, P24398
   Song ZY, 2009, MOL BIOL CELL, V20, P3525, DOI 10.1091/mbc.E09-03-0252
   Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 39
TC 184
Z9 194
U1 0
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JAN 15
PY 2012
VL 135
IS 
BP 23
EP 34
DI 10.1093/brain/awr323
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 888ZX
UT WOS:000300044400012
PM 22189565
DA 2024-11-01
ER

PT J
AU Larosa, V
   Coosemans, N
   Motte, P
   Bonnefoy, N
   Remacle, C
AF Larosa, Veronique
   Coosemans, Nadine
   Motte, Patrick
   Bonnefoy, Nathalie
   Remacle, Claire
TI Reconstruction of a human mitochondrial complex I mutation in the unicellular green alga Chlamydomonas
SO PLANT JOURNAL
LA English
DT Article
DE Chlamydomonas; mutation; mitochondrial; human; heteroplasmic; homoplasmic
ID nadh-ubiquinone oxidoreductase; structural organization; subunit composition; rna genes; reinhardtii; dna; transformation; sequence; binding; enzyme
AB Defects in complex I (NADH:ubiquinone oxidoreductase (EC 1.6.5.3)) are the most frequent cause of human respiratory disorders. The pathogenicity of a given human mitochondrial mutation can be difficult to demonstrate because the mitochondrial genome harbors large numbers of polymorphic base changes that have no pathogenic significance. In addition, mitochondrial mutations are usually found in the heteroplasmic state, which may hide the biochemical effect of the mutation. We propose that the unicellular green alga Chlamydomonas could be used to study such mutations because (i) respiratory complex-deficient mutants are viable and mitochondrial mutations are found in the homoplasmic state, (ii) transformation of the mitochondrial genome is feasible, and (iii) Chlamydomonas complex I is similar to that of humans. To illustrate this proposal, we introduced a Leu157Pro substitution into the Chlamydomonas ND4 subunit of complex I in two recipient strains by biolistic transformation, demonstrating that site-directed mutagenesis of the Chlamydomonas mitochondrial genome is possible. This substitution did not lead to any respiratory enzyme defects when present in the heteroplasmic state in a patient with chronic progressive external ophthalmoplegia. When present in the homoplasmic state in the alga, the mutation does not prevent assembly of whole complex I (950 kDa) and the NADH dehydrogenase activity of the peripheral arm of the complex is mildly affected. However, the NADH:duroquinone oxidoreductase activity is strongly reduced, suggesting that the substitution could affect binding of ubiquinone to the membrane domain. The in vitro defects correlate with a decrease in dark respiration and growth rate in vivo.
C1 [Larosa, Veronique; Coosemans, Nadine; Motte, Patrick; Remacle, Claire] Univ Liege, Inst Bot, Dept Life Sci, B-4000 Liege, Belgium.
   [Bonnefoy, Nathalie] CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.
C3 University of Liege; Centre National de la Recherche Scientifique (CNRS); Universite Paris Saclay
RP Remacle, C (corresponding author), Univ Liege, Inst Bot, Dept Life Sci, B-4000 Liege, Belgium.
EM c.remacle@ulg.ac.be
FU Fonds National de la Recherche Scientifique [1.5.255.08, 2.4.601.08, 2.4567.11]; Action de la Recherche Concertee [ARC07/12-04]; FP7 [GA 245070]; University of Liege; Formation a la Recherche dans l'Industrie et l'Agriculture; Agence Nationale pour la Recherche (ANR) [JCJC06-0163]; FNRS [2.4581.10, 2.4531.09]
CR Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Baranova EA, 2007, J STRUCT BIOL, V159, P238, DOI 10.1016/j.jsb.2007.01.009
   Blakely EL, 2005, FEBS J, V272, P3583, DOI 10.1111/j.1742-4658.2005.04779.x
   BOER PH, 1988, CURR GENET, V14, P583, DOI 10.1007/BF00434084
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BUSCHGES R, 1994, YEAST, V10, P475, DOI 10.1002/yea.320100406
   Cardol P, 2004, BBA-BIOENERGETICS, V1658, P212, DOI 10.1016/j.bbabio.2004.06.001
   Cardol P, 2003, PLANT PHYSIOL, V133, P2010, DOI 10.1104/pp.103.028076
   Cardol P, 2002, J MOL BIOL, V319, P1211, DOI 10.1016/S0022-2836(02)00407-2
   Cardol P, 2008, BBA-BIOENERGETICS, V1777, P388, DOI 10.1016/j.bbabio.2008.01.001
   Cardol P, 2011, BBA-BIOENERGETICS, V1807, P1390, DOI 10.1016/j.bbabio.2011.06.015
   Clason T, 2010, J STRUCT BIOL, V169, P81, DOI 10.1016/j.jsb.2009.08.017
   Darrouzet E, 1998, FEBS LETT, V431, P34, DOI 10.1016/S0014-5793(98)00719-4
   Dauvillee D, 2004, PHOTOSYNTH RES, V79, P219, DOI 10.1023/B:PRES.0000015384.24958.a9
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DiMauro S, 2007, BIOSCIENCE REP, V27, P5, DOI 10.1007/s10540-007-9032-5
   Dröse S, 2011, PLOS BIOL, V9, P0, DOI 10.1371/journal.pbio.1001128
   Duby F, 1999, PLANT CELL, V11, P115
   Efremov RG, 2010, NATURE, V465, P441, DOI 10.1038/nature09066
   EHARA T, 1995, J CELL SCI, V108, P499
   Eubel H, 2004, PLANT PHYSIOL BIOCH, V42, P937, DOI 10.1016/j.plaphy.2004.09.010
   Fearnley Ian M, 2007, METHODS MOL BIOL, V357, P103
   Förster B, 2005, BBA-BIOENERGETICS, V1709, P45, DOI 10.1016/j.bbabio.2005.05.012
   Guénebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518
   Harris EH, 1989, CHLAMYDOMONAS SOURCE, V0, P0
   Hirst J, 2010, BIOCHEM J, V425, P327, DOI 10.1042/BJ20091382
   Hunte C, 2010, SCIENCE, V329, P448, DOI 10.1126/science.1191046
   Karpova OV, 1999, PLANT J, V17, P511, DOI 10.1046/j.1365-313X.1999.00401.x
   Khakhlova O, 2006, PLANT J, V46, P85, DOI 10.1111/j.1365-313X.2006.02673.x
   Lunardi J, 1998, BBA-MOL BASIS DIS, V1407, P114, DOI 10.1016/S0925-4439(98)00036-2
   MARIENFELD JR, 1994, GENETICS, V138, P855
   Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   NEWMAN SM, 1990, GENETICS, V126, P875
   Peters K, 2008, BBA-BIOENERGETICS, V1777, P84, DOI 10.1016/j.bbabio.2007.10.012
   Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Quiles MJ, 1996, PLANT CELL PHYSIOL, V37, P1134, DOI 10.1093/oxfordjournals.pcp.a029064
   Remacle C, 2006, P NATL ACAD SCI USA, V103, P4771, DOI 10.1073/pnas.0509501103
   Remacle C, 2001, GENETICS, V158, P1051
   Remacle C, 2001, BIOCHEM SOC T, V29, P442, DOI 10.1042/BST0290442
   Remacle C, 2010, PLANT MOL BIOL, V74, P223, DOI 10.1007/s11103-010-9668-6
   RUITERS MHJ, 1991, J INHERIT METAB DIS, V14, P45, DOI 10.1007/BF01804387
   Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809
   Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Simpson Deborah J, 2007, ENVIRONMENTAL BIOSAFETY RESEARCH, V6, P55, DOI 10.1051/ebr:2007027
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   STAUB JM, 1992, PLANT CELL, V4, P39, DOI 10.1105/tpc.4.1.39
   Tocilescu MA, 2007, J BIOL CHEM, V282, P29514, DOI 10.1074/jbc.M704519200
   Torres-Bacete J, 2007, J BIOL CHEM, V282, P36914, DOI 10.1074/jbc.M707855200
   Venegas V, 2011, CURR PROTOC HUM GENE, V68, P1971, DOI 10.1002/0471142905.HG1907S68
   Zickermann V, 2009, BBA-BIOENERGETICS, V1787, P574, DOI 10.1016/j.bbabio.2009.01.012
NR 53
TC 14
Z9 16
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7412
EI 
J9 PLANT J
JI Plant J.
PD JUN 15
PY 2012
VL 70
IS 5
BP 759
EP 768
DI 10.1111/j.1365-313X.2012.04912.x
PG 10
WC Plant Sciences
SC Plant Sciences
GA 945ZJ
UT WOS:000304316600004
PM 22268373
DA 2024-11-01
ER

PT J
AU Laing, NG
AF Laing, Nigel G.
TI Genetics of neuromuscular disorders
SO CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
LA English
DT Review
DE Carrier detection; congenital myopathies; distal myopathies; molecular diagnosis; muscular dystrophies; next generation DNA sequencing; pre-implantation diagnosis; prenatal diagnosis; pre-symptomatic diagnosis; spinal muscular atrophy
ID duchenne muscular-dystrophy; central core disease; myosin storage myopathy; ryanodine receptor gene; marie-tooth disease; recessive nemaline myopathy; polymerase chain-reaction; fiber-type disproportion; skeletal-muscle actin; myotonic-dystrophy
AB Neuromuscular disorders affect the peripheral nervous system and muscle. The principle effect of neuromuscular disorders is therefore on the ability to perform voluntary movements. Neuromuscular disorders cause significant incapacity, including, at the most extreme, almost complete paralysis. Neuromuscular diseases include some of the most devastating disorders that afflict mankind, for example motor neuron disease. Neuromuscular diseases have onset any time from in utero until old age. They are most often genetic. The last 25 years has been the golden age of genetics, with the disease genes responsible for many genetic neuromuscular disorders now identified. Neuromuscular disorders may be inherited as autosomal dominant, autosomal recessive, or X-linked traits. They may also result from mutations in mitochondrial DNA or from de novo mutations not present in the peripheral blood DNA of either parent. The high incidence of de novo mutation has been one of the surprises of the recent increase in information about the genetics of neuromuscular disorders. The disease burden imposed on families is enormous including decision making in relation to presymptomatic diagnosis for late onset neurodegenerative disorders and reproductive choices. Diagnostic molecular neurogenetics laboratories have been faced with an ever-increasing range of disease genes that could be tested for and usually a finite budget with which to perform the possible testing. Neurogenetics has moved from one known disease gene, the Duchenne muscular dystrophy gene in July 1987, to hundreds of disease genes in 2011. It can be anticipated that with the advent of next generation sequencing (NGS), most, if not all, causative genes will be identified in the next few years. Any type of mutation possible in human DNA has been shown to cause genetic neuromuscular disorders, including point mutations, small insertions and deletions, large deletions and duplications, repeat expansions or contraction and somatic mosaicism. The diagnostic laboratory therefore has to be capable of a large number of techniques in order to identify the different mutation types and requires highly skilled staff. Mutations causing neuromuscular disorders affect the largest human proteins for example titin and nebulin. Successful molecular diagnosis can make invasive and expensive diagnostic procedures such as muscle biopsy unnecessary. Molecular diagnosis is currently largely based on Sanger sequencing, which at most can sequence a small number of exons in one gene at a time. NGS techniques will facilitate molecular diagnostics, but not for all types of mutations. For example, NGS is not good at identifying repeat expansions or copy number variations. Currently, diagnostic molecular neurogenetics is focused on identifying the causative mutation(s) in a patient. In the future, the focus might move to prevention, by identifying carriers of recessive diseases before they have affected children. The pathobiology of many of the diseases remains obscure, as do factors affecting disease severity. The aim of this review is to describe molecular diagnosis of genetic neuromuscular disorders in the past, the present and speculate on the future.
C1 [Laing, Nigel G.] Univ Western Australia, Med Res Ctr, Western Australian Inst Med Res, Nedlands, WA 6009, Australia.
C3 University of Western Australia
RP Laing, NG (corresponding author), Univ Western Australia M519, Med Res Ctr, Western Australian Inst Med Res, QE Med Ctr 2, B Block,Hovea Lane, Nedlands, WA 6009, Australia.
EM nlaing@cyllene.uwa.edu.au
FU Australian National Health and Medical Research Council (NHMRC) [APP1002147]
CR ABBS S, 1990, GENOMICS, V7, P602, DOI 10.1016/0888-7543(90)90205-9
   Abbs Stephen, 2010, NEUROMUSCUL DISORD, V20, P422, DOI 10.1016/j.nmd.2010.04.005
   Agrawal PB, 2007, AM J HUM GENET, V80, P162, DOI 10.1086/510402
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0
   Baets J, 2011, BRAIN, V134, P2664, DOI 10.1093/brain/awr184
   BAKKER E, 1986, J MED GENET, V23, P573, DOI 10.1136/jmg.23.6.573
   BAKKER E, 1985, LANCET, V1, P655
   Bartoli M, 2008, HUM MOL GENET, V17, P1214, DOI 10.1093/hmg/ddn029
   BEGGS AH, 1990, HUM GENET, V86, P45
   Bell CJ, 2011, SCI TRANSL MED, V3, P0, DOI 10.1126/scitranslmed.3001756
   BRADLEY DM, 1993, BRIT MED J, V306, P357, DOI 10.1136/bmj.306.6874.357
   BROCK DJH, 1990, J MED GENET, V27, P8, DOI 10.1136/jmg.27.1.8
   BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5
   BUNDEY S, 1978, J MED GENET, V15, P249, DOI 10.1136/jmg.15.4.249
   BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0
   Campbell L, 1997, AM J HUM GENET, V61, P40, DOI 10.1086/513886
   Carmignac V, 2007, ANN NEUROL, V61, P340, DOI 10.1002/ana.21089
   Castets P, 2011, HUM MOL GENET, V20, P694, DOI 10.1093/hmg/ddq515
   Catalli C, 2010, J MOL DIAGN, V12, P601, DOI 10.2353/jmoldx.2010.090239
   CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X
   CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350
   Cirak S, 2011, LANCET, V378, P595, DOI 10.1016/S0140-6736(11)60756-3
   Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975
   Clarke NF, 2010, HUM MUTAT, V31, PE1544, DOI 10.1002/humu.21278
   COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347
   Dalakas MC, 2011, CURR OPIN NEUROL, V24, P457, DOI 10.1097/WCO.0b013e32834a9589
   Davis M, 2002, BRIT J ANAESTH, V88, P508, DOI 10.1093/bja/88.4.508
   Davis MR, 2003, NEUROMUSCULAR DISORD, V13, P151, DOI 10.1016/S0960-8966(02)00218-3
   de Visser M, 2004, MYOLOGY, V0, P655
   DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011
   Donner K, 2004, EUR J HUM GENET, V12, P744, DOI 10.1038/sj.ejhg.5201242
   DORKINS H, 1985, HUM GENET, V71, P103, DOI 10.1007/BF00283362
   Dubourg O, 2011, J NEUROL, V258, P1157, DOI 10.1007/s00415-011-5900-9
   Dubowitz V, 2007, MUSCLE BIOPSY: A PRACTICAL APPROACH, V0, P0
   Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2
   EMERY AEH, 1980, BRIT MED BULL, V36, P117, DOI 10.1093/oxfordjournals.bmb.a071624
   Emery AlanEH, 1998, NEUROMUSCULAR DISORD, V0, P1
   Fee DB, 2004, MUSCLE NERVE, V30, P375, DOI 10.1002/mus.20092
   Ferreiro A, 2002, ANN NEUROL, V51, P750, DOI 10.1002/ana.10231
   Fischer D, 2008, NEUROLOGY, V71, P758, DOI 10.1212/01.wnl.0000324927.28817.9b
   Flanigan KM, 2003, AM J HUM GENET, V72, P931, DOI 10.1086/374176
   Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815
   GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862
   Hackman P, 2002, AM J HUM GENET, V71, P492, DOI 10.1086/342380
   Haldane JBS, 1935, J GENET, V31, P317, DOI 10.1007/BF02982403
   HARPER PS, 1992, AM J HUM GENET, V51, P10
   Hildebrandt F, 2009, PLOS GENET, V5, P0, DOI 10.1371/journal.pgen.1000353
   Hoischen A, 2010, HUM MUTAT, V31, P492, DOI 10.1002/humu.21221
   Homayoun H, 2011, NEUROMUSCULAR DISORD, V21, P219, DOI 10.1016/j.nmd.2010.12.005
   HURSE P V, 1974, PROCEEDINGS OF THE AUSTRALIAN ASSOCIATION OF NEUROLOGISTS, V11, P145
   JADAYEL D, 1990, NATURE, V343, P558, DOI 10.1038/343558a0
   Johnson JO, 2010, NEURON, V68, P857, DOI 10.1016/j.neuron.2010.11.036
   Jungbluth H, 2005, NEUROLOGY, V65, P1930, DOI 10.1212/01.wnl.0000188870.37076.f2
   Jungbluth H, 2005, NEUROMUSCULAR DISORD, V15, P681
   Jungbluth H, 2004, NEUROMUSCULAR DISORD, V14, P779, DOI 10.1016/j.nmd.2004.08.005
   Jungbluth H, 2002, NEUROLOGY, V59, P284, DOI 10.1212/WNL.59.2.284
   Kaback MM, 2001, ADV GENET, V44, P253
   Kelly K F, 2002, HEALTH BULL (EDINB), V60, P83
   Klein A, 2011, ARCH NEUROL-CHICAGO, V68, P1171, DOI 10.1001/archneurol.2011.188
   KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6
   Kono S, 2010, NEUROLOGY, V75, P547, DOI 10.1212/WNL.0b013e3181ec7fbd
   Krivosic-Horber R, 2004, EUR J ANAESTH, V21, P572, DOI 10.1017/S0265021504227120
   KUNKEL LM, 1986, NATURE, V322, P73, DOI 10.1038/322073a0
   LAING NG, 1990, MED J AUSTRALIA, V152, P270, DOI 10.5694/j.1326-5377.1990.tb120926.x
   Laing NG, 2007, MYOPATHIES 3, V0, P1
   Laing NG, 2009, HUM MUTAT, V30, P1267, DOI 10.1002/humu.21059
   Laing NG, 2008, J MUSCLE RES CELL M, V29, P247, DOI 10.1007/s10974-008-9158-5
   Lalonde E, 2010, HUM MUTAT, V31, P918, DOI 10.1002/humu.21293
   Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463
   LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0
   LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3
   Lehtokari VL, 2006, HUM MUTAT, V27, P946, DOI 10.1002/humu.20370
   Lemmers RJFL, 2004, AM J HUM GENET, V75, P1124, DOI 10.1086/426035
   Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936
   Lo HP, 2008, NEUROMUSCULAR DISORD, V18, P34, DOI 10.1016/j.nmd.2007.08.009
   Lupski JR, 2010, NEW ENGL J MED, V362, P1181, DOI 10.1056/NEJMoa0908094
   LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4
   Mercuri E, 2005, CURR OPIN NEUROL, V18, P526, DOI 10.1097/01.wco.0000183947.01362.fe
   Mercuri E, 2010, DISORDERS VOLUNTARY, V0, P151
   Meredith C, 2004, AM J HUM GENET, V75, P703, DOI 10.1086/424760
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9
   MONACO AP, 1985, NATURE, V316, P842, DOI 10.1038/316842a0
   Monnier N, 2000, HUM MOL GENET, V9, P2599, DOI 10.1093/hmg/9.18.2599
   Montenegro G, 2011, ANN NEUROL, V69, P464, DOI 10.1002/ana.22235
   Muelas N, 2010, NEUROLOGY, V75, P732, DOI 10.1212/WNL.0b013e3181eee4d5
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499
   Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250
   Nowak KJ, 1999, NAT GENET, V23, P208, DOI 10.1038/13837
   Nowak KJ, 2007, ANN NEUROL, V61, P175, DOI 10.1002/ana.21035
   Ockeloen CW, 2011, NEUROMUSCULAR DISORD, V21, P696, DOI 10.1016/j.nmd.2011.06.941
   Odgerel Z, 2010, CLIN CHEM LAB MED, V48, P1409, DOI 10.1515/CCLM.2010.272
   ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8
   Ortolano S, 2011, NEUROMUSCULAR DISORD, V21, P254, DOI 10.1016/j.nmd.2010.12.011
   Peat RA, 2008, NEUROLOGY, V71, P312, DOI 10.1212/01.wnl.0000284605.27654.5a
   Pegoraro E, 2007, NEUROMUSCULAR DISORD, V17, P321, DOI 10.1016/j.nmd.2007.01.010
   Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305
   PRIOR TW, 1995, AM J HUM GENET, V57, P22
   QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51
   Radvansky J, 2011, GENET TEST MOL BIOMA, V15, P133, DOI 10.1089/gtmb.2010.0127
   Ravenscroft G, 2011, J MED GENET, V48, P793, DOI 10.1136/jmedgenet-2011-100211
   Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010
   Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54
   Robinson R, 2006, HUM MUTAT, V27, P977, DOI 10.1002/humu.20356
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   ROSES AD, 1988, ARCH NEUROL-CHICAGO, V45, P84, DOI 10.1001/archneur.1988.00520250090026
   Saillour Y, 2008, HUM MUTAT, V29, P1083, DOI 10.1002/humu.20829
   Saporta ASD, 2011, ANN NEUROL, V69, P22, DOI 10.1002/ana.22166
   Sato I, 2008, NEUROLOGY, V70, P114, DOI 10.1212/01.wnl.0000269792.63927.86
   Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221
   Scacheri PC, 2000, NEUROLOGY, V55, P1689, DOI 10.1212/WNL.55.11.1689
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf056
   Sejerson T, 2009, ADV EXP MED BIOL, V652, P13, DOI 10.1007/978-90-481-2813-6_2
   Sewry CA, 2002, NEUROMUSCULAR DISORD, V12, P930, DOI 10.1016/S0960-8966(02)00135-9
   Sewry CA, 2008, CURR OPIN NEUROL, V21, P569, DOI 10.1097/WCO.0b013e32830f93c7
   Silander K, 1996, HUM MUTAT, V8, P304, DOI 10.1002/(SICI)1098-1004(1996)8:4<304::AID-HUMU2>3.3.CO;2-6
   Simpson DA, 2011, J MED GENET, V48, P145, DOI 10.1136/jmg.2010.083568
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   Supala-Berger A, 2009, MUSCLE NERVE, V40, P657, DOI 10.1002/mus.21079
   SUTHERS G, 1994, LANCET, V344, P1773, DOI 10.1016/S0140-6736(94)92913-0
   Tabet AC, 2010, AM J MED GENET A, V152A, P1781, DOI 10.1002/ajmg.a.33433
   Tajsharghi H, 2003, ANN NEUROL, V54, P494, DOI 10.1002/ana.10693
   Tajsharghi H, 2007, NEUROLOGY, V68, P962, DOI 10.1212/01.wnl.0000257131.13438.2c
   TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192
   VALENTIJN LJ, 1995, HUM MUTAT, V5, P76, DOI 10.1002/humu.1380050110
   VANDERSTEEGE G, 1995, LANCET, V345, P985, DOI 10.1016/S0140-6736(95)90732-7
   Villard E, 2005, EUR HEART J, V26, P794, DOI 10.1093/eurheartj/ehi193
   von der Hagen M, 2006, NEUROMUSCULAR DISORD, V16, P4, DOI 10.1016/j.nmd.2005.10.001
   Wallgren-Pettersson C, 2010, DISORDERS VOLUNTARY, V0, P282
   Wallgren-Pettersson Carina, 2004, NEUROMUSCUL DISORD, V14, P56, DOI 10.1016/j.nmd.2003.09.003
   WallgrenPettersson C, 1996, NEUROMUSCULAR DISORD, V6, P389, DOI 10.1016/0960-8966(96)00354-9
   Walsh T, 2010, P NATL ACAD SCI USA, V107, P12629, DOI 10.1073/pnas.1007983107
   Warner JP, 1996, J MED GENET, V33, P1022, DOI 10.1136/jmg.33.12.1022
   Weedon MN, 2011, AM J HUM GENET, V89, P308, DOI 10.1016/j.ajhg.2011.07.002
   WIRTH B, 1995, PRENATAL DIAG, V15, P407, DOI 10.1002/pd.1970150503
   Wu SW, 2006, BRAIN, V129, P1470, DOI 10.1093/brain/awl077
   ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46
   Zlotogora J, 2009, HUM GENET, V126, P247, DOI 10.1007/s00439-009-0669-y
NR 142
TC 56
Z9 60
U1 1
U2 22
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1040-8363
EI 
J9 CRIT REV CL LAB SCI
JI Crit. Rev. Clin. Lab. Sci.
PD MAR-APR 15
PY 2012
VL 49
IS 2
BP 33
EP 48
DI 10.3109/10408363.2012.658906
PG 16
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 919JR
UT WOS:000302321500001
PM 22468856
DA 2024-11-01
ER

PT J
AU DeBrosse, S
   Parikh, S
AF DeBrosse, Suzanne
   Parikh, Sumit
TI Neurologic Disorders Due to Mitochondria! DNA Mutations
SO SEMINARS IN PEDIATRIC NEUROLOGY
LA English
DT Review
ID hereditary optic neuropathy; progressive external ophthalmoplegia; kearns-sayre syndrome; stroke-like episodes; ribosomal-rna mutation; ragged-red fibers; leigh-syndrome; hearing-loss; diabetes-mellitus; pearson-syndrome
AB The mitochondrial DNA (mtDNA) is a compact genome inherited through the maternal lineage. Mutations in mtDNA lead to many of the earliest identified syndromic mitochondrial diseases and display a diverse range of age of onset, symptoms, and outcomes-from isolated childhood onset vision or hearing loss to a multisystemic neurodegenerative disorder with strokes, neuropathy, ophthalmoparesis, and epilepsy beginning at any age. As a heterogeneous group, mitochondrial diseases represent one of the most common metabolic disorders in children and adults, frequently seen by both pediatric and adult specialists. Although the myriad of diseases can make diagnosis seems daunting, the need for extensive supportive care and treatment (the latter for at least a select few mitochondrial disorders) and a rapid and accurate recognition of these disorders is necessary. Here, we provide a review of the most common mitochondrial disease syndromes due to mtDNA mutations. Semin Pediatr Neurol 19:194-202 (C) 2012 Elsevier Inc. All rights reserved.
C1 [Parikh, Sumit] Cleveland Clin, Neurogenet Inst, Cleveland, OH 44195 USA.
   [DeBrosse, Suzanne] Univ Hosp Cleveland, Case Med Ctr, Ctr Human Genet, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; University Hospitals of Cleveland; University System of Ohio; Case Western Reserve University
RP Parikh, S (corresponding author), Cleveland Clin, Neurogenet Inst, 9500 Euclid Ave,S60, Cleveland, OH 44195 USA.
EM parikhs@ccf.org
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alexeyev MF, 2008, GENE THER, V15, P516, DOI 10.1038/sj.gt.2008.11
   Anderson CM, 2002, J NEUROSCI, V22, P9203
   [Anonymous], 2012, ARCH NEUROL, V0, P0
   [Anonymous], 2002, PEDIAT NEUROL, V0, P0
   [Anonymous], 1997, GEN DIAGN PATHOL, V0, P0
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   Bastin J, 2008, J CLIN ENDOCR METAB, V93, P1433, DOI 10.1210/jc.2007-1701
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   Beretta S, 2004, BRAIN, V127, P2183, DOI 10.1093/brain/awh258
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   Brackmann F, 2012, EUR J PEDIATR, V171, P859, DOI 10.1007/s00431-011-1662-8
   BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198
   Buchan JC, 2007, EYE, V21, P859, DOI 10.1038/sj.eye.6702729
   Carelli V, 2001, J NEUROL NEUROSUR PS, V71, P813, DOI 10.1136/jnnp.71.6.813
   Carelli V, 2007, ENVIRON HEALTH PERSP, V115, P113, DOI 10.1289/ehp.9245
   Chalmers RM, 1996, AM J HUM GENET, V59, P103
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   Chong P Siao Tick, 2003, J CLIN NEUROMUSCUL DIS, V5, P1, DOI 10.1097/00131402-200309000-00001
   Chowers I, 1999, BRIT J OPHTHALMOL, V83, P190, DOI 10.1136/bjo.83.2.190
   Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200
   de Laat P, 2012, J INHERIT METAB DIS, V0, P0
   DeVries DD, 1996, AM J HUM GENET, V58, P703
   DiMauro S, 1993, MITOCHONDRIAL DNA DE, V0, P0
   Donovan LE, 2006, J CLIN ENDOCR METAB, V91, P4737, DOI 10.1210/jc.2006-1498
   El-Hattab AW, 2012, MOL GENET METAB, V105, P607, DOI 10.1016/j.ymgme.2012.01.016
   Emma F, 2012, PEDIATR NEPHROL, V27, P539, DOI 10.1007/s00467-011-1926-6
   Emmanuele V, 2011, MUSCLE NERVE, V44, P448, DOI 10.1002/mus.22149
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   Goldenberg PC, 2003, NEUROLOGY, V60, P865, DOI 10.1212/01.WNL.0000049460.72439.7F
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horváth R, 2000, J NEUROL, V247, P65, DOI 10.1007/s004150050015
   Howell N, 2003, AM J MED GENET A, V119A, P147, DOI 10.1002/ajmg.a.20135
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Ito S, 2008, AM J NEURORADIOL, V29, P392, DOI 10.3174/ajnr.A0865
   Ji YL, 2010, MOL VIS, V16, P416
   JOHNS DR, 1992, ARCH OPHTHALMOL-CHIC, V110, P1577, DOI 10.1001/archopht.1992.01080230077025
   JOHNS DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P495, DOI 10.1001/archopht.1993.01090040087038
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   KELLARWOOD H, 1994, ANN NEUROL, V36, P109, DOI 10.1002/ana.410360121
   Kerrison JB, 2000, AM J OPHTHALMOL, V130, P803, DOI 10.1016/S0002-9394(00)00603-6
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koga Y, 2010, ANN NY ACAD SCI, V1201, P104, DOI 10.1111/j.1749-6632.2010.05624.x
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   KOTAGAL S, 1988, PEDIATR NEUROL, V4, P241, DOI 10.1016/0887-8994(88)90038-0
   Kubota M, 2004, BRAIN DEV-JPN, V26, P481, DOI 10.1016/j.braindev.2004.01.006
   Laloi-Michelin M, 2009, J CLIN ENDOCR METAB, V94, P3025, DOI 10.1210/jc.2008-2680
   Lau KK, 2007, INT UROL NEPHROL, V39, P941, DOI 10.1007/s11255-006-9172-8
   Lax NZ, 2012, ARCH NEUROL-CHICAGO, V69, P490, DOI 10.1001/archneurol.2011.2167
   Leber hereditary optic neuropathy, 1993, GENEREVIEWS, V0, P0
   Lee HF, 2007, EUR J PAEDIATR NEURO, V11, P208, DOI 10.1016/j.ejpn.2006.12.008
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Leshinsky-Silver E, 2003, MOL GENET METAB, V79, P288, DOI 10.1016/S1096-7192(03)00097-0
   Maassen JA, 2002, AM J MED GENET, V115, P66, DOI 10.1002/ajmg.10346
   Mancuso M, 2007, BIOCHEM BIOPH RES CO, V354, P1058, DOI 10.1016/j.bbrc.2007.01.099
   Mashima Y, 2000, J NEURO-OPHTHALMOL, V20, P166, DOI 10.1097/00041327-200020030-00006
   MASSIN P, 1995, AM J OPHTHALMOL, V120, P247, DOI 10.1016/S0002-9394(14)72615-7
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   Melegh B, 1997, NEUROPEDIATRICS, V28, P257, DOI 10.1055/s-2007-973710
   Mnatsakanyan L, 2011, J NEURO-OPHTHALMOL, V31, P6, DOI 10.1097/WNO.0b013e3181fab1b4
   Morimoto N, 2004, NEUROLOGY, V63, P2451, DOI 10.1212/01.WNL.0000147321.38129.ED
   Nance WE, 2002, GENET MED, V4, P162
   Negrier MLM, 1998, AM J HUM GENET, V63, P1227, DOI 10.1086/302045
   NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   NIKOSKELAINEN EK, 1994, LANCET, V344, P857, DOI 10.1016/S0140-6736(94)92830-4
   Nye JS, 2000, TERATOLOGY, V61, P165, DOI 10.1002/(SICI)1096-9926(200003)61:3<165::AID-TERA3>3.3.CO;2-5
   OGASAHARA S, 1986, NEUROLOGY, V36, P45, DOI 10.1212/WNL.36.1.45
   Olmos PR, 2011, J OTOLARYNGOL-HEAD N, V40, P93, DOI 10.2310/7070.2010.100078
   Palace J, 2009, J NEUROL SCI, V286, P24, DOI 10.1016/j.jns.2009.09.009
   Pandya A, 1993, GENEREVIEWS, V0, P0
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   Pitceathly RDS, 2011, J MED GENET, V48, P610, DOI 10.1136/jmg.2010.088328
   POULTON J, 1989, LANCET, V1, P236
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Qi XP, 2007, ARCH OPHTHALMOL-CHIC, V125, P268, DOI 10.1001/archopht.125.2.268
   Qi XP, 2004, ANN NEUROL, V56, P182, DOI 10.1002/ana.20175
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROWLAND LP, 1975, HDB CLINICAL NEUROLO, V22, P177
   Sadun AA, 2003, AM J OPHTHALMOL, V136, P231, DOI 10.1016/S0002-9394(03)00099-0
   Sadun F, 2004, AM J OPHTHALMOL, V137, P271, DOI 10.1016/j.ajo.2003.08.010
   Santorelli FM, 1997, NEUROLOGY, V49, P270, DOI 10.1212/WNL.49.1.270
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Santorelli FM, 1996, AM J HUM GENET, V58, P933
   Santorelli FM, 1996, PEDIATR RES, V39, P914, DOI 10.1203/00006450-199605000-00028
   Scalais E, 2007, EUR J NEUROL, V14, Pe3, DOI 10.1111/j.1468-1331.2007.01926.x
   Schon EA, 2003, GENETICS MITOCHONDRI, V0, P111
   SCHULZ JB, 1993, LANCET, V341, P438
   Sevior KB, 1998, AM J MED GENET, V75, P179, DOI 10.1002/(SICI)1096-8628(19980113)75:2<179::AID-AJMG11>3.0.CO;2-M
   Sgarbi G, 2009, ARCH NEUROL-CHICAGO, V66, P951, DOI 10.1001/archneurol.2009.134
   Shankar SP, 2008, OPHTHALMIC GENET, V29, P17, DOI 10.1080/13816810701867607
   Shear T, 2004, PEDIATR ANESTH, V14, P792, DOI 10.1111/j.1460-9592.2004.01289.x
   SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   Smits BW, 2011, J NEUROL, V258, P2020, DOI 10.1007/s00415-011-6060-7
   Spector Reynold, 2010, CEREBROSPINAL FLUID RES, V7, P14, DOI 10.1186/1743-8454-7-14
   Spruijt L, 2006, AM J OPHTHALMOL, V141, P676, DOI 10.1016/j.ajo.2005.11.007
   Spruijt L, 2007, ARCH NEUROL-CHICAGO, V64, P890, DOI 10.1001/archneur.64.6.890
   Stacpoole PW, 2008, PEDIATRICS, V121, PE1223, DOI 10.1542/peds.2007-2062
   Suzuki S, 1998, DIABETOLOGIA, V41, P584, DOI 10.1007/s001250050950
   Takanashi J, 1997, J NEUROL SCI, V145, P83, DOI 10.1016/S0022-510X(96)00248-1
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Thorburn DR, 1993, GENEREVIEWS, V0, P0
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   Velho G, 1996, DIABETES, V45, P478, DOI 10.2337/diabetes.45.4.478
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
   Williams TB, 2012, MOL GENET METAB, V106, P104, DOI 10.1016/j.ymgme.2012.01.018
NR 124
TC 10
Z9 10
U1 0
U2 34
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1071-9091
EI 
J9 SEMIN PEDIATR NEUROL
JI Semin. Pediatr. Neurol.
PD DEC 15
PY 2012
VL 19
IS 4
BP 194
EP 202
DI 10.1016/j.spen.2012.09.006
PG 9
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 063UB
UT WOS:000313026400006
PM 23245552
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Inherited Mitochondrial Disorders
SO ADVANCES IN MITOCHONDRIAL MEDICINE
LA English
DT Article; Book Chapter
DE Neuromuscular; Encephalomyopathy; Metabolic disease; Multisystem disease; Genetics; Mitochondrial DNA
ID hereditary optic neuropathy; c-oxidase deficiency; onset spinocerebellar ataxia; linked sideroblastic anemia; kearns-sayre-syndrome; progressive external ophthalmoplegia; polymerase-gamma mutations; surf1 gene-mutations; rna-synthetase gene; dna depletion
AB Though inherited mitochondrial disorders (MIDs) are most well known for their syndromic forms, for which widely known acronyms (MELAS, MERRF, NARP, LHON etc.) have been coined, the vast majority of inherited MIDs presents in a non-syndromic form. Since MIDs are most frequently multisystem disorders already at onset or during the disease course, a MID should be suspected if there is a combination of neurological and non-neurological abnormalities. Neurological abnormalities occurring as a part of a MID include stroke-like episodes, epilepsy, migraine-like headache, movement disorders, cerebellar ataxia, visual impairment, encephalopathy, cognitive impairment, dementia, psychosis, hypopituitarism, aneurysms, or peripheral nervous system disease, such as myopathy, neuropathy, or neuronopathy. Non-neurological manifestations concern the ears, the endocrine organs, the heart, the gastrointestinal tract, the kidneys, the bone marrow, and the skin. Whenever there is an unexplained combination of neurological and non-neurological disease in a patient or kindred, a MID should be suspected and appropriate diagnostic measures initiated. Genetic testing should be guided by the phenotype, the biopsy findings, and the biochemical results.
C1 Danube Univ Krems, A-1180 Vienna, Austria.
C3 Danube University Krems
RP Finsterer, J (corresponding author), Danube Univ Krems, Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Aguirre LA, 2008, NEUROMUSCULAR DISORD, V18, P979, DOI 10.1016/j.nmd.2008.09.009
   Ajlouni K, 2002, AM J MED GENET, V115, P61, DOI 10.1002/ajmg.10345
   Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Ances BM, 2006, J CHILD NEUROL, V21, P805, DOI 10.1177/08830738060210090901
   Barrientos A, 1996, AM J HUM GENET, V58, P963
   Barth M, 2010, J INHERIT M IN PRESS, V0, P0
   Barth PG, 2004, AM J MED GENET A, V126A, P349, DOI 10.1002/ajmg.a.20660
   Bhatti MT, 1999, J NEURO-OPHTHALMOL, V19, P28
   Binder J, 2003, BRAIN, V126, P1814, DOI 10.1093/brain/awg174
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   Bleyl SB, 1997, AM J MED GENET, V72, P257, DOI 10.1002/(SICI)1096-8628(19971031)72:3<257::AID-AJMG2>3.0.CO;2-O
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Casarin A, 2008, BIOCHEM BIOPH RES CO, V372, P35, DOI 10.1016/j.bbrc.2008.04.172
   Chen YF, 2010, ANN NY ACAD SCI, V1201, P58, DOI 10.1111/j.1749-6632.2010.05619.x
   Chen Yung-Nien, 2004, CHANG GUNG MED J, V27, P66
   Chinnery PF, 1999, LANCET, V354, P0
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   Chinnery PF, 2010, GENEREVIEWS, V0, P0
   Chowers I, 1999, BRIT J OPHTHALMOL, V83, P190, DOI 10.1136/bjo.83.2.190
   Condie J, 2010, J CHILD NEUROL, V25, P633, DOI 10.1177/0883073809342004
   Cryns K, 2003, HUM MUTAT, V22, P275, DOI 10.1002/humu.10258
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Debouverie M, 1997, REV NEUROL, V153, P547
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Di Fonzo A, 2009, AM J HUM GENET, V84, P594, DOI 10.1016/j.ajhg.2009.04.004
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Fassone E, 2010, HUM MOL GENET, V19, P4837, DOI 10.1093/hmg/ddq414
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Finsterer J, 2007, VASA-J VASCULAR DIS, V36, P229, DOI 10.1024/0301-1526.36.4.229
   Finsterer J, 2009, EUR J NEUROL, V16, P1255, DOI 10.1111/j.1468-1331.2009.02811.x
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   Finsterer J, 2009, CAN J NEUROL SCI, V36, P143, DOI 10.1017/S0317167100006508
   Fuhrmann N, 2010, MOL NEURODEGENER, V5, P0, DOI 10.1186/1750-1326-5-25
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   Ghezzi D, 2008, AM J HUM GENET, V83, P415, DOI 10.1016/j.ajhg.2008.08.009
   Ghezzi D, 2010, AM J HUM GENET, V86, P639, DOI 10.1016/j.ajhg.2010.03.002
   Giordano C, 2010, ARCH NEUROL-CHICAGO, V67, P1144, DOI 10.1001/archneurol.2010.200
   Gordon N, 2006, DEV MED CHILD NEUROL, V48, P1001, DOI 10.1017/S0012162206002209
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guan MX, 2011, MITOCHONDRION, V11, P237, DOI 10.1016/j.mito.2010.10.006
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hellier KD, 2001, J NEUROL NEUROSUR PS, V70, P65, DOI 10.1136/jnnp.70.1.65
   Hinson JT, 2007, NEW ENGL J MED, V356, P809, DOI 10.1056/NEJMoa055262
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1996, HANDBOOK OF MUSCLE DISEASE, V0, P479
   Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horváth R, 2000, J NEUROL, V247, P65, DOI 10.1007/s004150050015
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hourani RG, 2006, NEUROPEDIATRICS, V37, P110, DOI 10.1055/s-2006-924226
   HOWELL N, 1995, GENETICS, V140, P285
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   INBAL A, 1995, AM J MED GENET, V55, P372, DOI 10.1002/ajmg.1320550325
   Isohanni P, 2010, J MED GENET, V47, P66, DOI 10.1136/jmg.2009.068221
   Jansen PHP, 1996, J NEUROL SCI, V135, P176, DOI 10.1016/0022-510X(95)00287-C
   Jones CN, 2008, J BIOL CHEM, V283, P34445, DOI 10.1074/jbc.M806992200
   Kang N, 2010, J BIOL CHEM, V285, P28343, DOI 10.1074/jbc.M110.109199
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KELLARWOOD H, 1994, ANN NEUROL, V36, P109, DOI 10.1002/ana.410360121
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Lee HF, 2007, EUR J PAEDIATR NEURO, V11, P208, DOI 10.1016/j.ejpn.2006.12.008
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Leshinsky-Silver E, 2003, MOL GENET METAB, V79, P288, DOI 10.1016/S1096-7192(03)00097-0
   Liguori M, 2008, J NEUROL, V255, P127, DOI 10.1007/s00415-008-0571-x
   Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.3.CO;2-B
   Lodi R, 2011, ARCH NEUROL-CHICAGO, V68, P67, DOI 10.1001/archneurol.2010.228
   Loiseau D, 2007, ANN NEUROL, V61, P315, DOI 10.1002/ana.21086
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Maguire A, 2001, BRIT J HAEMATOL, V115, P910, DOI 10.1046/j.1365-2141.2001.03015.x
   Makino M, 1998, NEUROMUSCULAR DISORD, V8, P149, DOI 10.1016/S0960-8966(98)00017-0
   Malfatti E, 2010, J NEUROL SCI, V297, P105, DOI 10.1016/j.jns.2010.06.009
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   Marti R, 2002, MITOCHONDRION, V2, P143, DOI 10.1016/S1567-7249(02)00036-3
   Mayr JA, 2007, AM J HUM GENET, V80, P478, DOI 10.1086/511788
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   Medlej R, 2004, J CLIN ENDOCR METAB, V89, P1656, DOI 10.1210/jc.2002-030015
   Millar David S, 2010, HUM GENOMICS, V4, P384
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Misko A, 2010, J NEUROSCI, V30, P4232, DOI 10.1523/JNEUROSCI.6248-09.2010
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Montero R, 2007, CEREBELLUM, V6, P118, DOI 10.1080/14734220601021700
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Morán M, 2010, HUM MUTAT, V31, P930, DOI 10.1002/humu.21294
   Morgan NV, 2010, PLOS GENET, V6, P0, DOI 10.1371/journal.pgen.1000833
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   Namavar Y, 2011, BRAIN, V134, P143, DOI 10.1093/brain/awq287
   Naumann M, 1997, MUSCLE NERVE, V20, P833, DOI 10.1002/(SICI)1097-4598(199707)20:7<833::AID-MUS7>3.0.CO;2-8
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Nicolino M, 1997, J CLIN ENDOCR METAB, V82, P3063, DOI 10.1210/jc.82.9.3063
   Nijveldt R, 2004, LANCET, V364, P636, DOI 10.1016/S0140-6736(04)16858-X
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   NIKOSKELAINEN EK, 1994, CLIN NEUROSCI, V2, P115
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nishioka K, 2010, PARKINSONISM RELAT D, V16, P686, DOI 10.1016/j.parkreldis.2010.09.007
   ORTIZ RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1525, DOI 10.1001/archopht.1993.01090110091031
   Osman C, 2010, EMBO J, V29, P1976, DOI 10.1038/emboj.2010.98
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   Peng Y, 2003, MOVEMENT DISORD, V18, P716, DOI 10.1002/mds.10428
   Riera ARP, 2008, J ELECTROCARDIOL, V41, P675, DOI 10.1016/j.jelectrocard.2008.04.001
   Pondarre C, 2007, BLOOD, V109, P3567, DOI 10.1182/blood-2006-04-015768
   Poulton J, 1998, AM J HUM GENET, V62, P752, DOI 10.1086/301811
   Pupo Altair Cadrobbi, 2008, BRAZ J OTORHINOLARYNGOL, V74, P786, DOI 10.1016/S1808-8694(15)31392-6
   Quinzii CM, 2008, BIOFACTORS, V32, P113, DOI 10.1002/biof.5520320113
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rankin J, 2010, AM J MED GENET A, V152A, P2079, DOI 10.1002/ajmg.a.33531
   Rantamäki M, 2007, CLIN GENET, V72, P532, DOI 10.1111/j.1399-0004.2007.00908.x
   RICCI E, 1992, BRAIN PATHOL, V2, P141, DOI 10.1111/j.1750-3639.1992.tb00682.x
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   Rydzanicz M, 2010, BIOCHEM BIOPH RES CO, V395, P116, DOI 10.1016/j.bbrc.2010.03.149
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Sadun Alfredo A, 2006, TRANS AM OPHTHALMOL SOC, V104, P51
   Santorelli FM, 1997, NEUROLOGY, V49, P270, DOI 10.1212/WNL.49.1.270
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Scharfe C, 2000, J MED GENET, V37, P669, DOI 10.1136/jmg.37.9.669
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Smits P, 2011, EUR J HUM GENET, V19, P275, DOI 10.1038/ejhg.2010.208
   Spector Reynold, 2010, CEREBROSPINAL FLUID RES, V7, P14, DOI 10.1186/1743-8454-7-14
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spencer CT, 2006, PEDIATRICS, V118, PE337, DOI 10.1542/peds.2005-2667
   Spiegel R, 2009, ANN NEUROL, V66, P419, DOI 10.1002/ana.21752
   Spiegel R, 2009, EUR J HUM GENET, V17, P1200, DOI 10.1038/ejhg.2009.24
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Spruijt L, 2007, ARCH NEUROL-CHICAGO, V64, P890, DOI 10.1001/archneur.64.6.890
   Sugiana C, 2008, AM J HUM GENET, V83, P468, DOI 10.1016/j.ajhg.2008.09.009
   Tay SHK, 2006, ARCH NEUROL-CHICAGO, V63, P281, DOI 10.1001/archneur.63.2.281
   Tay SKH, 2005, J CHILD NEUROL, V20, P670, DOI 10.1177/08830738050200080701
   Teitelbaum JE, 2002, J PEDIATR GASTR NUTR, V35, P377, DOI 10.1097/00005176-200209000-00029
   Thorburn DR, 2006, GENEREVIEWS, V0, P1993
   Tranebjoerg L, 2000, ADV OTO-RHINO-LARYNG, V56, P97
   Tsao CY, 2003, J CHILD NEUROL, V18, P62, DOI 10.1177/08830738030180011401
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   van de Glind G, 2007, EUR J PAEDIATR NEURO, V11, P243, DOI 10.1016/j.ejpn.2007.01.004
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VANDENOUWELAND JMW, 1995, MUSCLE NERVE, V0, PS124
   Verny C, 2011, MITOCHONDRION, V11, P70, DOI 10.1016/j.mito.2010.07.006
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390
   Wiedemann FR, 2008, CLIN NEUROL NEUROSUR, V110, P859, DOI 10.1016/j.clineuro.2008.06.010
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Worle H, 1998, CLIN NEUROPATHOL, V17, P63
   Young TM, 2010, ARCH NEUROL-CHICAGO, V67, P1399, DOI 10.1001/archneurol.2010.283
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
   Zoccolella S, 2006, FUNCT NEUROL, V21, P39
NR 177
TC 24
Z9 26
U1 0
U2 11
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 2214-8019
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PD JUN 15
PY 2012
VL 942
IS 
BP 187
EP 213
DI 10.1007/978-94-007-2869-1_8
PG 27
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA BA2RR
UT WOS:000333840200009
PM 22399423
DA 2024-11-01
ER

PT J
AU Plotz, G
   Casper, M
   Raedle, J
   Hinrichsen, I
   Heckel, V
   Brieger, A
   Trojan, J
   Zeuzem, S
AF Plotz, Guido
   Casper, Markus
   Raedle, Jochen
   Hinrichsen, Inga
   Heckel, Verena
   Brieger, Angela
   Trojan, Joerg
   Zeuzem, Stefan
TI MUTYH gene expression and alternative splicing in controls and polyposis patients
SO HUMAN MUTATION
LA English
DT Article
DE MUTYH; alternative splicing; MUTYH-associated polyposis (MAP)
ID excision-repair gene; messenger-rna levels; colorectal-cancer risk; subcellular-localization; oxidative damage; homolog hmyh; myh; dna; mutations; identification
AB Mutational loss of the human DNA repair gene MUTYH in the germline predisposes for colorectal polyposis and cancer, a recessively heritable disease called MUTYH-associated polyposis. The MUTYH gene shows heavy alternative splicing, but the transcripts relevant for biological function and cancer prevention have not been determined. This knowledge is required to assess the consequences that germline variants of unknown functional significance may have. We therefore quantified expression and investigated patterns of alternative splicing in control individuals, tissue samples, and carriers of two frequent germline alterations. MUTYH expression differed organ dependently, correlating with proliferative activity. Alternative first exons were used tissue specifically; transcripts for mitochondrial proteins predominated in muscle tissues, while ascending colon and testes showed the highest fractions of transcripts for nuclear proteins. Colon cancer cell lines produced predominant transcripts for nuclear protein. Exon skipping was frequent and governed by splice-site quality. Five transcripts were found to encode the biologically relevant products of the MUTYH gene. Carriers of the disease-causing mutation c.1187G>A (p.Gly396Asp) showed normal transcript composition, but the frequent single-nucleotide polymorphism rs3219468:G>C largely reduced one transcript species of MUTYH. Since this alteration decreases protein production of the gene, an increased cancer risk for compound heterozygous carriers is possible. Hum Mutat 33:10671074, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Plotz, Guido; Hinrichsen, Inga; Heckel, Verena; Brieger, Angela; Trojan, Joerg; Zeuzem, Stefan] Klinikum Johann Wolfgang Goethe Univ, Med Klin 1, Biomed Forsch Lab, D-60590 Frankfurt, Germany.
   [Casper, Markus] Univ Saarlandes Kliniken, Klin Innere Med 2, D-66421 Homburg, Germany.
   [Raedle, Jochen] Westpfalz Klinikum, Med Klin 3, D-67655 Kaiserslautern, Germany.
C3 Goethe University Frankfurt; Goethe University Frankfurt Hospital; Universitatsklinikum des Saarlandes; Westpfalz-Klinikum GmbH
RP Plotz, G (corresponding author), Klinikum Johann Wolfgang Goethe Univ, Med Klin 1, Biomed Forsch Lab, Haus 11,Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM plotz@med.uni-frankfurt.de
CR Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828
   Ali M, 2008, GASTROENTEROLOGY, V135, P499, DOI 10.1053/j.gastro.2008.04.035
   Alvarez JD, 2005, J BIOL RHYTHM, V20, P111, DOI 10.1177/0748730404274078
   Arai T, 2006, ACTA NEUROPATHOL, V112, P139, DOI 10.1007/s00401-006-0081-9
   Barnetson RA, 2007, CLIN GENET, V72, P551, DOI 10.1111/j.1399-0004.2007.00900.x
   Berezin C, 2004, BIOINFORMATICS, V20, P1322, DOI 10.1093/bioinformatics/bth070
   Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Casper M, 2011, COLORECTAL DIS, V0, P0
   Cleary SP, 2009, GASTROENTEROLOGY, V136, P1251, DOI 10.1053/j.gastro.2008.12.050
   Couch FJ, 2008, HUM MUTAT, V29, P1314, DOI 10.1002/humu.20899
   DAgostino VG, 2010, DNA REPAIR, V9, P700, DOI 10.1016/j.dnarep.2010.03.008
   Desviat Lourdes R, 2003, METHODS MOL BIOL, V232, P257
   Dunlop MG, 2009, SURG ONCOL CLIN N AM, V18, P599, DOI 10.1016/j.soc.2009.08.003
   Fox-Walsh KL, 2009, P NATL ACAD SCI USA, V106, P1766, DOI 10.1073/pnas.0813128106
   Hanaoka T, 2000, CANCER EPIDEM BIOMAR, V9, P1255
   Ichinoe A, 2004, NUCLEIC ACIDS RES, V32, P477, DOI 10.1093/nar/gkh214
   Kambara T, 2004, GENE CHROMOSOME CANC, V40, P1, DOI 10.1002/gcc.20011
   Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036
   Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104
   Kosinski J, 2010, HUM MUTAT, V31, P975, DOI 10.1002/humu.21301
   Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014
   Lipton L, 2003, CANCER RES, V63, P7595
   Lynch KW, 2006, NAT STRUCT MOL BIOL, V13, P952, DOI 10.1038/nsmb1106-952
   Martin SA, 2010, CANCER CELL, V17, P235, DOI 10.1016/j.ccr.2009.12.046
   Molatore S, 2010, HUM MUTAT, V31, P159, DOI 10.1002/humu.21158
   Müller GA, 2010, FEBS J, V277, P877, DOI 10.1111/j.1742-4658.2009.07508.x
   Nakabeppu Y, 2004, ANN NY ACAD SCI, V1011, P101, DOI 10.1196/annals.1293.011
   Nielsen M, 2009, BMC CANCER, V9, P0, DOI 10.1186/1471-2407-9-184
   Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355
   Oka S, 2008, EMBO J, V27, P421, DOI 10.1038/sj.emboj.7601975
   Oka S, 2011, CANCER SCI, V102, P677, DOI 10.1111/j.1349-7006.2011.01869.x
   Out AA, 2010, HUM MUTAT, V31, P1205, DOI 10.1002/humu.21343
   Sakamoto K, 2007, CANCER RES, V67, P6599, DOI 10.1158/0008-5472.CAN-06-4802
   Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283
   Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638
   Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917
   Tao H, 2008, CANCER SCI, V99, P355, DOI 10.1111/j.1349-7006.2007.00694.x
   Theodoratou E, 2010, BRIT J CANCER, V103, P1875, DOI 10.1038/sj.bjc.6605966
   Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x
   Vogel U, 2000, MUTAT RES-DNA REPAIR, V461, P197, DOI 10.1016/S0921-8777(00)00051-3
   Vogel U, 2002, CARCINOGENESIS, V23, P1505, DOI 10.1093/carcin/23.9.1505
   Wang L, 2004, GASTROENTEROLOGY, V127, P9, DOI 10.1053/j.gastro.2004.03.070
   Win AK, 2011, FAM CANCER, V10, P1, DOI 10.1007/s10689-010-9399-5
   Yamaguchi S, 2002, GENES CELLS, V7, P461, DOI 10.1046/j.1365-2443.2002.00532.x
   Yeo G, 2004, J COMPUT BIOL, V11, P377, DOI 10.1089/1066527041410418
NR 46
TC 27
Z9 30
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD JUL 15
PY 2012
VL 33
IS 7
BP 1067
EP 1074
DI 10.1002/humu.22059
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 952TK
UT WOS:000304815100011
PM 22473953
DA 2024-11-01
ER

PT J
AU Duran, GP
   Martinez-Aguayo, A
   Poggi, H
   Lagos, M
   Gutierrez, D
   Harris, PR
AF Duran, Gloria P.
   Martinez-Aguayo, A.
   Poggi, H.
   Lagos, M.
   Gutierrez, D.
   Harris, P. R.
TI Large Mitochondrial DNA Deletion in an Infant with Addison Disease
SO JIMD REPORTS - CASE AND RESEARCH REPORTS, 2011/3
LA English
DT Article; Book Chapter
ID kearns-sayre-syndrome; growth-hormone deficiency; chronic-pancreatitis; manifestation; evolution; child
AB Background: Mitochondrial diseases are a group of disorders caused by mutations in nuclear DNA or mitochondrial DNA, usually involving multiple organ systems. Primary adrenal insufficiency due to mitochondrial disease is extremely infrequent and has been reported in association with mitochondrial DNA deletion syndromes such as Kearns-Sayre syndrome. Aim: To report a 3-year-old boy with Addison disease, congenital glaucoma, chronic pancreatitis, and mitochondrial myopathy due to large mitochondrial DNA deletion. Method: Molecular analysis of mitochondrial DNA samples obtained from peripheral blood, oral mucosa, and muscle tissue. Results: A novel large mitochondrial DNA deletion of 7,372 bp was identified involving almost all genes on the big arch of mtDNA. Conclusions: This case reaffirms the association of adrenal insufficiency and mitochondrial DNA deletions and presents new evidence that glaucoma is another manifestation of mitochondrial diseases. Due to the genetic and clinical heterogeneity of mitochondrial disorders, molecular analysis is crucial to confirm diagnosis and to allow accurate genetic counseling.
C1 [Duran, Gloria P.; Martinez-Aguayo, A.; Harris, P. R.] Pontificia Univ Catolica Chile, Dept Pediat, Sch Med, Santiago 8330074, Chile.
   [Poggi, H.; Lagos, M.; Gutierrez, D.] Pontificia Univ Catolica Chile, Dept Clin Labs, Sch Med, Santiago 8330074, Chile.
C3 Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile
RP Duran, GP (corresponding author), Pontificia Univ Catolica Chile, Dept Pediat, Sch Med, Lira 85,5 Piso, Santiago 8330074, Chile.
EM gduran@med.puc.cl
CR AMMANN RW, 1988, GASTROENTEROLOGY, V95, P1018, DOI 10.1016/0016-5085(88)90178-3
   Arlt W, 2003, LANCET, V361, P1881, DOI 10.1016/S0140-6736(03)13492-7
   Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902
   Cassandrini D, 2006, J CHILD NEUROL, V21, P983, DOI 10.1177/08830738060210111001
   Ferlin T, 1997, MOL CELL BIOCHEM, V174, P221, DOI 10.1023/A:1006860508606
   Finsterer J, 2007, MINERVA GASTROENTEROL DIETOL, V53, P285
   Finsterer J, 2007, AM J MED GENET A, V143A, P632, DOI 10.1002/ajmg.a.31629
   Gücüyener K, 1998, J INHERIT METAB DIS, V21, P173, DOI 10.1023/A:1005304015278
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   KATO S, 1990, J PEDIATR GASTR NUTR, V11, P549, DOI 10.1097/00005176-199011000-00018
   Kishnani PS, 1996, EUR J PEDIATR, V155, P898
   Kleinle S, 1997, HUM GENET, V100, P643, DOI 10.1007/s004390050567
   ROTIG A, 1993, J INHERIT METAB DIS, V16, P527, DOI 10.1007/BF00711672
   Sanaker PS, 2007, ACTA NEUROL SCAND, V115, P64, DOI 10.1111/j.1600-0404.2007.00850.x
   Schleiffer T, 2000, EXP CLIN ENDOCR DIAB, V108, P81, DOI 10.1055/s-2000-5800
   SCURO LA, 1990, INT J PANCREATOL, V6, P139
   Simaan EM, 1999, PEDIATR NEUROL, V21, P830, DOI 10.1016/S0887-8994(99)00084-3
   Toyono M, 2001, NEUROMUSCULAR DISORD, V11, P300, DOI 10.1016/S0960-8966(00)00176-0
   Tsao CY, 2000, J CHILD NEUROL, V15, P822, DOI 10.1177/088307380001501213
   Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
NR 21
TC 11
Z9 11
U1 0
U2 5
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 2192-8304
EI 
J9 JIMD REP
PD JUN 15
PY 2012
VL 3
IS 
BP 5
EP 9
DI 10.1007/8904_2011_33
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA BEB08
UT WOS:000315963200002
PM 23430867
DA 2024-11-01
ER

PT J
AU Greaves, LC
   Reeve, AK
   Taylor, RW
   Turnbull, DM
AF Greaves, Laura C.
   Reeve, Amy K.
   Taylor, Robert W.
   Turnbull, Doug M.
TI Mitochondrial DNA and disease
SO JOURNAL OF PATHOLOGY
LA English
DT Review
DE mitochondrion; oxidative phosphorylation; disease; mitochondrial DNA; mutation
ID progressive external ophthalmoplegia; cytochrome-c-oxidase; hereditary optic neuropathy; substantia-nigra neurons; kearns-sayre syndrome; complex i deficiency; red fibers merrf; stem-cells; myoclonic epilepsy; skeletal-muscle
AB Mitochondrial DNA (mtDNA) defects are a relatively common cause of inherited disease and have been implicated in both ageing and cancer. MtDNA encodes essential subunits of the mitochondrial respiratory chain and defects result in impaired oxidative phosphorylation (OXPHOS). Similar OXPHOS defects have been shown to be present in a number of neurodegenerative conditions, including Parkinson's disease, as well as in normal ageing human tissues. Additionally, a number of tumours have been shown to contain mtDNA mutations and an altered metabolic phenotype. In this review we outline the unique characteristics of mitochondrial genetics before detailing important pathological features of mtDNA diseases, focusing on adult neurological disease as well as the role of mtDNA mutations in neurodegenerative diseases, ageing and cancer. Copyright (C) 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Greaves, Laura C.; Reeve, Amy K.; Taylor, Robert W.; Turnbull, Doug M.] Newcastle Univ, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Greaves, LC (corresponding author), Newcastle Univ, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM laura.greaves@ncl.ac.uk; doug.turnbull@ncl.ac.uk
FU Newcastle University Centre for Brain Ageing and Vitality; BBSRC; EPSRC; ESRC; MRC [G0700718]; Wellcome Trust [074454/Z/04/Z]; UK NIHR Biomedical Research Centre for Ageing and Age-related Disease; UK NHS Specialist Commissioners; MRC [G0700718, G0900652, G0502157, G0400074, G1100540, G0601943] Funding Source: UKRI
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews HE, 2005, MED HYPOTHESES, V64, P669, DOI 10.1016/j.mehy.2004.09.001
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betts J, 2008, NEUROLOGY, V70, P1290, DOI 10.1212/01.wnl.0000308940.38092.74
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Betts-Henderson J, 2009, NEUROPATH APPL NEURO, V35, P120, DOI 10.1111/j.1365-2990.2008.00981.x
   Bitner-Glindzicz M, 2009, NEW ENGL J MED, V360, P640, DOI 10.1056/NEJMc0806396
   Blackwood JK, 2011, J PATHOL, V225, P181, DOI 10.1002/path.2965
   BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967
   Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720
   Campbell GR, 2011, ANN NEUROL, V69, P481, DOI 10.1002/ana.22109
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Cottrell DA, 2000, J NEUROPATH EXP NEUR, V59, P621, DOI 10.1093/jnen/59.7.621
   Cottrell DA, 2001, NEUROPATH APPL NEURO, V27, P206, DOI 10.1046/j.1365-2990.2001.00315.x
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   De Alwis N, 2009, HEPATOLOGY, V50, P992, DOI 10.1002/hep.23160
   Durham SE, 2007, AM J HUM GENET, V81, P189, DOI 10.1086/518901
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Fellous TG, 2009, STEM CELLS, V27, P1410, DOI 10.1002/stem.67
   Fellous TG, 2009, HEPATOLOGY, V49, P1655, DOI 10.1002/hep.22791
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   FUKUHARA N, 1991, REV NEUROL, V147, P476
   Gaisa NT, 2011, J PATHOL, V225, P163, DOI 10.1002/path.2945
   Gaisa NT, 2011, J PATHOL, V225, P172, DOI 10.1002/path.2959
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   He L, 2003, LEUKEMIA, V17, P2487, DOI 10.1038/sj.leu.2403146
   Heerdt BG, 2006, CANCER RES, V66, P1591, DOI 10.1158/0008-5472.CAN-05-2717
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Irrcher I, 2010, HUM MOL GENET, V0, P0
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kemp JP, 2011, BRAIN, V134, P183, DOI 10.1093/brain/awq320
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Lax NZ, 2011, ARCH NEUROL IN PRESS, V0, P0
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   Mcdonald SAC, 2008, GASTROENTEROLOGY, V134, P500, DOI 10.1053/j.gastro.2007.11.035
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MITOMAP, 2009, MITOMAP HUM MIT GEN, V0, P0
   Mokranjac D, 2005, BIOCHEM SOC T, V33, P1019, DOI 10.1042/BST0331019
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   Moraes CT, 2001, METHOD CELL BIOL, V65, P397, DOI 10.1016/S0091-679X(01)65023-4
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   NASS MMK, 1966, P NATL ACAD SCI USA, V56, P1215, DOI 10.1073/pnas.56.4.1215
   Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8
   Parrella P, 2001, CANCER RES, V61, P7623
   Pedersen P L, 1978, PROG EXP TUMOR RES, V22, P190
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Porcelli AM, 2010, HUM MOL GENET, V19, P1019, DOI 10.1093/hmg/ddp566
   Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Rahman S, 2000, BRAIN, V123, P591, DOI 10.1093/brain/123.3.591
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Rotig A, 2010, BIOCHIM BIOPHYS ACTA, V1807, P1198
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Schara U, 2011, J INHERIT METAB DIS, V34, P197, DOI 10.1007/s10545-010-9250-z
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012
   SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   SHOUBRIDGE EA, 1994, J BIOENERG BIOMEMBR, V26, P301, DOI 10.1007/BF00763101
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Tan DJ, 2006, BMC CANCER, V6, P0, DOI 10.1186/1471-2407-6-93
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   van der Giezen M, 2005, EMBO REP, V6, P525, DOI 10.1038/sj.embor.7400440
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vandebona H, 2009, NEW ENGL J MED, V360, P642, DOI 10.1056/NEJMc0806397
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WARBURG O, 1956, SCIENCE, V124, P269
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Yin PH, 2010, MITOCHONDRION, V10, P174, DOI 10.1016/j.mito.2009.12.147
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zhou L, 1997, J NEUROSCI, V17, P7746
NR 114
TC 214
Z9 233
U1 2
U2 113
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 
J9 J PATHOL
JI J. Pathol.
PD JAN 15
PY 2012
VL 226
IS 2
BP 274
EP 286
DI 10.1002/path.3028
PG 13
WC Oncology; Pathology
SC Oncology; Pathology
GA 877DQ
UT WOS:000299157600011
PM 21989606
DA 2024-11-01
ER

PT J
AU Tang, S
   Dimberg, EL
   Milone, M
   Wong, LJC
AF Tang, Sha
   Dimberg, Elliot L.
   Milone, Margherita
   Wong, Lee-Jun C.
TI Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of <i>POLG1</i> mutations
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE POLG1; MNGIE; Mitochondrial DNA; Pseudo-obstruction; Leukoencephalopathy
ID thymidine phosphorylase-deficiency; comparative genomic hybridization; dna polymerase-gamma; depletion; mngie; disorder; features; disease; gene; neuropathy
AB The aim of the study was to determine the prevalence of MNGIE-like phenotype in patients with recessive POLG1 mutations. Mutations in the POLG1 gene, which encodes for the catalytic subunit of the mitochondrial DNA polymerase gamma essential for mitochondrial DNA replication, cause a wide spectrum of mitochondrial disorders. Common phenotypes associated with POLG1 mutations include Alpers syndrome, ataxia-neuropathy syndrome, and progressive external ophthalmoplegia (PEO). Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder characterized by severe gastrointestinal dysmotility, cachexia, PEO and/or ptosis, peripheral neuropathy, and leukoencephalopathy. MNGIE is caused by TYMP mutations. Rare cases of MNGIE-like phenotype have been linked to RRM2B mutations. Recently, POLG1 mutations were identified in a family with clinical features of MNGIE but no leukoencephalopathy. The coding regions and exon-intron boundaries of POLG1 were sequence analyzed in patients suspected of POLG1 related disorders. Clinical features of 92 unrelated patients with two pathogenic POLG1 alleles were carefully reviewed. Three patients, accounting for 3.3% of all patients with two pathogenic POLG1 mutations, were found to have clinical features consistent with MNGIE but no leukoencephalopathy. Patient 1 carries p.W748S and p.R953C; patient 2 is homozygous for p.W748S, and patient 3 is homozygous for p.A467T. In addition, patient 2 has a similarly affected sibling with the same POLG1 genotype. POLG1 mutations may cause MNGIE-like syndrome, but the lack of leukoencephalopathy and the normal plasma thymidine favor POLG1 mutations as responsible molecular defect.
C1 [Milone, Margherita] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
   [Tang, Sha; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Tang, Sha; Wong, Lee-Jun C.] Baylor Coll Med, Med Genet Labs, Houston, TX 77030 USA.
   [Dimberg, Elliot L.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
C3 Mayo Clinic; Baylor College of Medicine; Baylor College of Medicine; Mayo Clinic
RP Milone, M (corresponding author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
EM Milone.Margherita@mayo.edu
CR Amiot A, 2009, GASTROENTEROLOGY, V137, P101, DOI 10.1053/j.gastro.2009.03.054
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Echaniz-Laguna A, 2010, ARCH NEUROL-CHICAGO, V67, P1140, DOI 10.1001/archneurol.2010.219
   Giordano C, 2008, AM J PATHOL, V173, P1120, DOI 10.2353/ajpath.2008.080252
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Kapur RP, 2011, AM J SURG PATHOL, V35, P714, DOI 10.1097/PAS.0b013e31821433af
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Martí R, 2005, ANN NEUROL, V58, P649, DOI 10.1002/ana.20615
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2011, ARCH NEUROL-CHICAGO, V68, P806, DOI 10.1001/archneurol.2011.124
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105
   Santoro L, 2006, J NEUROL, V253, P869, DOI 10.1007/s00415-006-0082-6
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Shanske S, 2004, MITOCHONDRION, V4, P403, DOI 10.1016/j.mito.2004.07.026
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Szigeti K, 2004, ANN NEUROL, V56, P881, DOI 10.1002/ana.20302
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Venegas Victor, 2011, CURR PROTOC HUM GENET, VChapter 19, P0, DOI 10.1002/0471142905.hg1907s68
   Vissing J, 2002, NEUROLOGY, V59, P926, DOI 10.1212/WNL.59.6.926
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 35
TC 44
Z9 48
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 
J9 J NEUROL
JI J. Neurol.
PD MAY 15
PY 2012
VL 259
IS 5
BP 862
EP 868
DI 10.1007/s00415-011-6268-6
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 947RR
UT WOS:000304447900007
PM 21993618
DA 2024-11-01
ER

PT J
AU Spiegel, K
   Pines, O
   Ta-Shma, A
   Burak, E
   Shaag, A
   Halvardson, J
   Edvardson, S
   Mahajna, M
   Zenvirt, S
   Saada, A
   Shalev, S
   Feuk, L
   Elpeleg, O
AF Spiegel, Konen
   Pines, Ophry
   Ta-Shma, Asaf
   Burak, Efrat
   Shaag, Avraham
   Halvardson, Jonatan
   Edvardson, Shimon
   Mahajna, Muhammad
   Zenvirt, Shamir
   Saada, Ann
   Shalev, Stavit
   Feuk, Lars
   Elpeleg, Orly
TI Infantile Cerebellar-Retinal Degeneration Associated with a Mutation in Mitochondrial Aconitase, <i>ACO2</i>
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID oxidative stress; dna depletion; deficiency; gene; neurodegeneration; defects; subunit; cancer
AB Degeneration of the cerebrum, cerebellum, and retina in infancy is part of the clinical spectrum of lysosomal storage disorders, mitochondrial respiratory chain defects, carbohydrate glycosylation defects, and infantile neuroaxonal dystrophy. We studied eight individuals from two unrelated families who presented at 2-6 months of age with truncal hypotonia and athetosis, seizure disorder, and ophthalmologic abnormalities. Their course was characterized by failure to acquire developmental milestones and culminated in profound psychomotor retardation and progressive visual loss, including optic nerve and retinal atrophy. Despite their debilitating state, the disease was compatible with survival of up to 18 years. Laboratory investigations were normal, but the oxidation of glutamate by muscle mitochondria was slightly reduced. Serial brain MRI displayed progressive, prominent cerebellar atrophy accompanied by thinning of the corpus callosum, dysmyelination, and frontal and temporal cortical atrophy. Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2, encoding mitochondrial aconitase, a component of the Krebs cycle. Specific aconitase activity in the individuals' lymphoblasts was severely reduced. Under restrictive conditions, the mutant human ACO2 failed to complement a yeast ACO1 deletion strain, whereas the wild-type human ACO2 succeeded, indicating that this mutation is pathogenic. Thus, a defect in mitochondrial aconitase is associated with an infantile neurodegenerative disorder affecting mainly the cerebellum and retina. In the absence of noninvasive biomarkers, determination of the ACO2 sequence or of aconitase activity in lymphoblasts are warranted in similarly affected individuals, based on clinical and neuroradiologic grounds.
C1 [Pines, Ophry; Burak, Efrat] Hebrew Univ Jerusalem, Dept Microbiol & Mol Genet, Inst Med Res Israel Canada, Fac Med, IL-91120 Jerusalem, Israel.
   [Spiegel, Konen; Shalev, Stavit] HaEmek Med Ctr, Dept Pediat A, IL-18101 Afula, Israel.
   [Spiegel, Konen; Shalev, Stavit] HaEmek Med Ctr, Genet Inst, IL-18101 Afula, Israel.
   [Spiegel, Konen; Shalev, Stavit] Technion Israel Inst Technol, Rappaport Fac Med, IL-31096 Haifa, Israel.
   [Ta-Shma, Asaf; Shaag, Avraham; Edvardson, Shimon; Zenvirt, Shamir; Saada, Ann; Elpeleg, Orly] Hebrew Univ Med Ctr, Moniques & Jacques Roboh Dept Genet Res, IL-91120 Jerusalem, Israel.
   [Halvardson, Jonatan; Feuk, Lars] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden.
   [Halvardson, Jonatan; Feuk, Lars] Uppsala Univ, Sci Life Lab, Rudbeck Lab, S-75185 Uppsala, Sweden.
   [Mahajna, Muhammad] Hillel Yaffe Med Ctr, Child Dev & Pediat Neurol Unit, IL-38101 Hadera, Israel.
C3 Hebrew University of Jerusalem; Emek Medical Center; Emek Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Uppsala University; Uppsala University
RP Pines, O (corresponding author), Hebrew Univ Jerusalem, Dept Microbiol & Mol Genet, Inst Med Res Israel Canada, Fac Med, IL-91120 Jerusalem, Israel.
EM ophryp@ekmd.huji.ac.il; elpeleg@hadassah.org.il
CR Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399
   Gregory A, 2008, NEUROLOGY, V71, P1402, DOI 10.1212/01.wnl.0000327094.67726.28
   Hartong DT, 2008, NAT GENET, V40, P1230, DOI 10.1038/ng.223
   Hinerfeld D, 2004, J NEUROCHEM, V88, P657, DOI 10.1046/j.1471-4159.2003.02195.x
   Jaeken J, 2007, ANNU REV GENOM HUM G, V8, P261, DOI 10.1146/annurev.genom.8.080706.092327
   Kil IS, 2005, J BIOL CHEM, V280, P10846, DOI 10.1074/jbc.M411306200
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   NARDOCCI N, 1995, AM J MED GENET, V57, P137, DOI 10.1002/ajmg.1320570205
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ottolenghi C, 2011, HUM MUTAT, V32, P1046, DOI 10.1002/humu.21534
   Patel M, 2004, FREE RADICAL BIO MED, V37, P1951, DOI 10.1016/j.freeradbiomed.2004.08.021
   Prensner JR, 2011, NAT MED, V17, P291, DOI 10.1038/nm0311-291
   Regev-Rudzki N, 2005, MOL BIOL CELL, V16, P4163, DOI 10.1091/mbc.e04-11-1028
   Regev-Rudzki N, 2008, J CELL SCI, V121, P2423, DOI 10.1242/jcs.029207
   SLAUGHTER CA, 1977, ANN HUM GENET, V40, P385
   Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
NR 22
TC 84
Z9 88
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAR 9
PY 2012
VL 90
IS 3
BP 518
EP 523
DI 10.1016/j.ajhg.2012.01.009
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 911ZI
UT WOS:000301762800018
PM 22405087
DA 2024-11-01
ER

PT J
AU Arzuffi, P
   Lamperti, C
   Fernandez-Vizarra, E
   Tonin, P
   Morandi, L
   Zeviani, M
AF Arzuffi, Paola
   Lamperti, Costanza
   Fernandez-Vizarra, Erika
   Tonin, Paola
   Morandi, Lucia
   Zeviani, Massimo
TI Partial tandem duplication of mtDNA-tRNA<SUP>Phe</SUP> impairs mtDNA translation in late-onset mitochondrial myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial myopathy; Oxidative phosphorylation; mtDNA; Cytochrome c oxidase; mtDNA translation; mtDNA mutation
ID inclusion-body myopathy; mutation; transcription; cells; gene; dna
AB An 80-year-old woman (PI) has been suffering of late onset progressive weakness and wasting of lower-limb muscles, accompanied by high creatine kinase levels in blood. A muscle biopsy, performed at 63 years, showed myopathic features with partial deficiency of cytochrome c oxidase. A second biopsy taken 7 years later confirmed the presence of a mitochondria' myopathy but also of vacuolar degeneration and other morphological features resembling inclusion body myopathy. Her 46-year-old daughter (PII) and 50-year-old son (PIII) are clinically normal, but the creatine kinase levels were moderately elevated and the EMG was consistently myopathic in both. Analysis of mitochondria' DNA sequence revealed in all three patients a novel, homoplasmic 15 bp tandem duplication adjacent to the 5' end of mitochondrial tRNA(Phe) gene, encompassing the first 11 nucleotides of this gene and the four terminal nucleotides of the adjacent D-loop region. Both mutant fibroblasts and cybrids showed low oxygen consumption rate, reduced mitochondria' protein synthesis, and decreased mitochondrial tRNA(Phe) amount. These findings are consistent with an unconventional pathogenic mechanism causing the tandem duplication to interfere with the maturation of the mitochondrial tRNA(Phe) transcript. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Arzuffi, Paola; Lamperti, Costanza; Zeviani, Massimo] Carlo Besta Neurol Inst Fdn IRCCS, Unit Mol Neurogenet, I-20126 Milan, Italy.
   [Fernandez-Vizarra, Erika] Hosp Univ Miguel Servet, Inst Aragones Ciencias Salud, Unidad Invest Translac, Zaragoza, Spain.
   [Tonin, Paola] Univ Verona, Dipartimento Sci Neurol Neuropsicol Morfol & Moto, I-37100 Verona, Italy.
   [Morandi, Lucia] Carlo Besta Neurol Inst Fdn IRCCS, Unit Neuromuscular & Neuroinflammatory Disorders, I-20126 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Miguel Servet University Hospital; University of Verona; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Zeviani, M (corresponding author), Carlo Besta Neurol Inst Fdn IRCCS, Unit Mol Neurogenet, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
FU Pierfranco and Luisa Mariani Foundation Italy, Ricerca; Fondazione Giuseppe Tomasello ONLUS; Fondazione MitoCon ONLUS; Fondazione Telethon-Italy [GGP07019, GPP10005]
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bersano A, 2009, NEUROBIOL AGING, V30, P752, DOI 10.1016/j.neurobiolaging.2007.08.009
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Del Bo R, 2003, MUSCLE NERVE, V28, P113, DOI 10.1002/mus.10391
   Enriquez J A, 1996, METHODS ENZYMOL, V264, P183, DOI 10.1016/S0076-6879(96)64019-1
   Enriquez JA, 1996, P NATL ACAD SCI USA, V93, P8300, DOI 10.1073/pnas.93.16.8300
   Fernández-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8
   HECKMATT JZ, 1984, MUSCLE NERVE, V7, P594
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9
   MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   OJALA D, 1980, CELL, V22, P393, DOI 10.1016/0092-8674(80)90350-5
   Oldfors A, 2006, NEUROLOGY, V66, PS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Shutt TE, 2010, ENVIRON MOL MUTAGEN, V51, P360, DOI 10.1002/em.20571
   Wu M, 2007, AM J PHYSIOL-CELL PH, V292, PC125, DOI 10.1152/ajpcell.00247.2006
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
   YOKOBORI S, 1995, P NATL ACAD SCI USA, V92, P10432, DOI 10.1073/pnas.92.22.10432
NR 20
TC 2
Z9 3
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN 15
PY 2012
VL 22
IS 1
BP 50
EP 55
DI 10.1016/j.nmd.2011.07.009
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 901ZW
UT WOS:000301009400007
PM 22227277
DA 2024-11-01
ER

PT J
AU Tyynismaa, H
   Sun, R
   Ahola-Erkkilä, S
   Almusa, H
   Pöyhönen, R
   Korpela, M
   Honkaniemi, J
   Isohanni, P
   Paetau, A
   Wang, LY
   Suomalainen, A
AF Tyynismaa, Henna
   Sun, Ren
   Ahola-Erkkila, Sofia
   Almusa, Henrikki
   Poyhonen, Rosanna
   Korpela, Mari
   Honkaniemi, Jari
   Isohanni, Pirjo
   Paetau, Anders
   Wang, Liya
   Suomalainen, Anu
TI Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID twinkle mutations; mtdna depletion; protein; gene; encephalopathy; specificity; disorder; myopathy; polg
AB Autosomal-inherited progressive external ophthalmoplegia (PEO) is an adult-onset disease characterized by the accumulation of multiple mitochondrial DNA (mtDNA) deletions in post-mitotic tissues. Mutations in six different genes have been described to cause the autosomal dominant form of the disease, but only mutations in the DNA polymerase gamma gene are known to cause autosomal recessive PEO (arPEO), leaving the genetic background of arPEO mostly unknown. Here we used whole-exome sequencing and identified compound heterozygous mutations, leading to two amino acid alterations R225W and a novel T230A in thymidine kinase 2 (TK2) in arPEO patients. TK2 is an enzyme of the mitochondrial nucleotide salvage pathway and its loss-of-function mutations have previously been shown to underlie the early-infantile myopathic form of mtDNA depletion syndrome (MDS). Our TK2 activity measurements of patient fibroblasts and mutant recombinant proteins show that the combination of the identified arPEO variants, R225W and T230A, leads to a significant reduction in TK2 activity, consistent with the late-onset phenotype, whereas homozygosity for R225W, previously associated with MDS, leads to near-total loss of activity. Our finding identifies a new genetic cause of arPEO with multiple mtDNA deletions. Furthermore, MDS and multiple mtDNA deletion disorders are manifestations of the same pathogenic pathways affecting mtDNA replication and repair, indicating that MDS-associated genes should be studied when searching for genetic background of PEO disorders.
C1 [Tyynismaa, Henna; Ahola-Erkkila, Sofia; Poyhonen, Rosanna; Isohanni, Pirjo; Suomalainen, Anu] Biomedicum Helsinki, Res Programs Unit, Mol Neurol, Helsinki 00290, Finland.
   [Almusa, Henrikki; Suomalainen, Anu] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki 00290, Finland.
   [Paetau, Anders] Univ Helsinki, Dept Pathol, Helsinki 00290, Finland.
   [Sun, Ren; Wang, Liya] Biomed Ctr, SLU, Sect Vet Med Biochem, Dept Anat Physiol & Biochem, SE-75123 Uppsala, Sweden.
   [Korpela, Mari; Suomalainen, Anu] Helsinki Univ Cent Hosp, Dept Neurol, Helsinki 00290, Finland.
   [Honkaniemi, Jari] Tampere Univ Hosp, Tampere 33520, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki; Swedish University of Agricultural Sciences; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital
RP Tyynismaa, H (corresponding author), Biomedicum Helsinki, Res Programs Unit, Mol Neurol, Haartmaninkatu 8, Helsinki 00290, Finland.
EM henna.tyynismaa@helsinki.fi
FU Academy of Finland; Helsinki Biomedical Graduate School; Sigrid Juselius Foundation; University of Helsinki; Swedish Research Council; Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning
CR Barroso JF, 2005, BIOCHEMISTRY-US, V44, P4886, DOI 10.1021/bi047766m
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   González-Vioque E, 2011, PLOS GENET, V7, P0, DOI 10.1371/journal.pgen.1002035
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Götz A, 2011, AM J HUM GENET, V88, P635, DOI 10.1016/j.ajhg.2011.04.006
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hazra S, 2010, J MED CHEM, V53, P5792, DOI 10.1021/jm1005379
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kawamata H, 2011, HUM MOL GENET, V20, P2964, DOI 10.1093/hmg/ddr200
   Knecht W, 2002, EMBO J, V21, P1873, DOI 10.1093/emboj/21.7.1873
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274
   Poulton Joanna, 2009, NEUROMUSCUL DISORD, V19, P439, DOI 10.1016/j.nmd.2009.04.009
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Tzoulis C, 2009, ACTA NEUROL SCAND, V120, P38, DOI 10.1111/j.1600-0404.2009.01212.x
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 45
TC 68
Z9 78
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 1
PY 2012
VL 21
IS 1
BP 66
EP 75
DI 10.1093/hmg/ddr438
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 859GO
UT WOS:000297865100007
PM 21937588
DA 2024-11-01
ER

PT J
AU Lax, NZ
   Whittaker, RG
   Hepplewhite, PD
   Reeve, AK
   Blakely, EL
   Jaros, E
   Ince, PG
   Taylor, RW
   Fawcett, PRW
   Turnbull, DM
AF Lax, Nichola Z.
   Whittaker, Roger G.
   Hepplewhite, Philippa D.
   Reeve, Amy K.
   Blakely, Emma L.
   Jaros, Evelyn
   Ince, Paul G.
   Taylor, Robert W.
   Fawcett, Peter R. W.
   Turnbull, Doug M.
TI Sensory neuronopathy in patients harbouring recessive polymerase γ mutations
SO BRAIN
LA English
DT Article
DE polymerase gamma; mitochondrial DNA; sensory neuronopathy; neurodegeneration
ID progressive external ophthalmoplegia; mitochondrial-dna deletions; real-time pcr; polg mutations; ataxic neuropathy; ophthalmoparesis sando; individual cells; disease; gene; involvement
AB Defects in the mitochondrial DNA replication enzyme, polymerase gamma, are an important cause of mitochondrial disease with similar to 25% of all adult diagnoses attributed to mutations in the POLG gene. Peripheral neuronopathy is often part of the clinical syndrome and can represent the most disabling feature. In spite of this, the molecular mechanisms underlying the neuronopathy remain to be elucidated and treatment strategies are limited. In the present study, we use a combined approach comprising clinical, electrophysiological, neuropathological and molecular genetic investigations to unravel the mechanisms underpinning peripheral neuronopathy in autosomal recessive polymerase gamma-related disease. Electrophysiological assessments documented a dorsal root ganglionopathy in all 11 cases. Of the 11 cases, eight also showed changes consistent with motor fibre loss. Detailed neuropathological investigation of two patients confirmed the electrophysiological findings, revealing atrophy of posterior columns and striking neuronal cell loss from the dorsal root ganglia, which was accompanied by severe mitochondrial biochemical abnormalities involving respiratory chain complexes I and IV due to clonally-expanded mitochondrial DNA deletions and a significant reduction in mitochondrial DNA copy number in affected neurons. We propose that the respiratory chain defects, secondary to mitochondrial DNA deletion and depletion, are likely to be responsible for pathology observed in the dorsal root ganglion and the sensory ganglionopathy documented electrophysiologically.
C1 [Turnbull, Doug M.] Newcastle Univ, Sch Med, Mitochondrial Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Lax, Nichola Z.; Reeve, Amy K.; Turnbull, Doug M.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Univ Ctr Brain Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Whittaker, Roger G.; Fawcett, Peter R. W.] Royal Victoria Infirm, Dept Clin Neurophysiol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Jaros, Evelyn] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
   [Ince, Paul G.] Univ Sheffield, Sheffield Inst Translat Neurosci, Dept Neurosci, Sheffield S10 2HQ, S Yorkshire, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; University of Sheffield
RP Turnbull, DM (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, Inst Ageing & Hlth, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM doug.turnbull@newcastle.ac.uk
FU UK Medical Research Council [G0400074]; Wellcome Trust [074454/Z/04/Z]; BBSRC; EPSRC; ESRC; MRC as part of the cross-council Lifelong Health and Wellbeing Initiative [G0700718]; UK NIHR Biomedical Research Centre for Ageing; UK NHS; MRC [G0502157, G0900652, G0700718, G0400074, G1100540] Funding Source: UKRI
CR Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Cottrell DA, 2000, J NEUROPATH EXP NEUR, V59, P621, DOI 10.1093/jnen/59.7.621
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hopkins SE, 2010, J CHILD NEUROL, V25, P752, DOI 10.1177/0883073809343313
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   McHugh JC, 2010, MUSCLE NERVE, V41, P265, DOI 10.1002/mus.21494
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Rantamäki M, 2001, NEUROLOGY, V57, P1043, DOI 10.1212/WNL.57.6.1043
   Schicks J, 2010, MOVEMENT DISORD, V25, P2678, DOI 10.1002/mds.23286
   Schulte C, 2009, NEUROLOGY, V73, P898, DOI 10.1212/WNL.0b013e3181b78488
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Stricker S, 2009, J NEUROL NEUROSUR PS, V80, P1181, DOI 10.1136/jnnp.2008.166066
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Weiss MD, 2010, MUSCLE NERVE, V41, P882, DOI 10.1002/mus.21636
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 26
TC 54
Z9 56
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD JAN 15
PY 2012
VL 135
IS 
BP 62
EP 71
DI 10.1093/brain/awr326
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 888ZX
UT WOS:000300044400015
PM 22189570
DA 2024-11-01
ER

PT J
AU Priego, EM
   Karlsson, A
   Gago, F
   Camarasa, MJ
   Balzarini, J
   Pérez-Pérez, MJ
AF Priego, Eva-Maria
   Karlsson, Anna
   Gago, Federico
   Camarasa, Maria-Jose
   Balzarini, Jan
   Perez-Perez, Maria-Jesus
TI Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Mitochondrial thymidine kinase 2 (TK2); nucleoside metabolism; enzymatic inhibitors; mitochondrial depletion syndrome (MDS); tumorigenesis
ID mitochondrial-dna depletion; acyclic nucleoside analogs; selective inhibitors; triphosphate pools; molecular-cloning; prognostic value; phosphorylation; mutations; substrate; design
AB Thymidine kinase 2 (TK2), encoded on chromosome 16q22 of the human genome, is a deoxynucleoside kinase (dNK) that catalyzes the phosphorylation of the pyrimidine deoxynucleosides 2'-deoxythymidine (dThd), 2'-deoxyuridine (dUrd) and 2'-deoxycytidine (dCyd) to the corresponding deoxynucleoside 5'-monophosphate derivatives. In contrast to the S-phase-specific thymidine kinase 1 (TK1), TK2 is constitutively expressed in the mitochondria and plays an important role in providing dNTPs for the replication and maintenance of mitochondrial DNA (mtDNA). The severe mitochondrial DNA depletion syndrome (MDS) has been associated with mutations in TK2, resulting in mtDNA depletion, isolated skeletal myopathy, and death of the individual at an early stage of life. Some antiviral nucleoside analogs, such as 3'-azido-dThd (AZT) that is targeting the human immunodeficiency virus (HIV)-encoded reverse transcriptase, are substrates for TK2 and it has been proposed that the mitochondrial toxicity observed after prolonged treatment with such drugs could be due to their interaction with TK2. Therefore, the design of specific TK2 inhibitors may be useful to investigate the role of TK2 in the maintenance and homeostasis of mitochondrial dNTP pools and its contribution to the mitochondrial toxicity of several antiviral and anticancer drugs. Since 2000, several potent and selective TK2 inhibitors have been described. Besides bringing together previously reported inhibitors, special attention will be paid in this review to the new families of TK2 inhibitors more recently described, together with modeling studies and biological assays. Moreover, the last section will be focused on several recent investigations that suggest that depletion of mtDNA can take place both in tumorigenesis and during cancer treatment with certain nucleoside analogues.
C1 [Priego, Eva-Maria; Camarasa, Maria-Jose; Perez-Perez, Maria-Jesus] CSIC, Inst Quim Med, E-28006 Madrid, Spain.
   [Karlsson, Anna] Karolinska Inst, Huddinge Univ Hosp, Dept Lab Med, SE-14186 Stockholm, Sweden.
   [Gago, Federico] Univ Alcala de Henares, Dept Farmacol, E-28871 Alcala De Henares, Madrid, Spain.
   [Balzarini, Jan] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG); CSIC - Instituto de Quimica Medica (IQM); Karolinska Institutet; Universidad de Alcala; KU Leuven
RP Priego, EM (corresponding author), CSIC, Inst Quim Med, C Juan de la Cierva 3, E-28006 Madrid, Spain.
EM empriego@iqm.csic.es
FU Spanish CICYT [SAF2006-12713-C02, SAF2003-07219-C02, SAF2000-0153-C02]; European Union [QLRT-2001-01004]; Comunidad de Madrid [S-BIO-0214-2006]; K.U. Leuven
CR Apostolova N, 2011, CURR PHARM DESIGN, V17, P2130, DOI 10.2174/138161211796904731
   ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Balzarini J, 2000, BIOCHEM J, V351, P167, DOI 10.1042/0264-6021:3510167
   Balzarini J, 2003, MOL PHARMACOL, V63, P263, DOI 10.1124/mol.63.2.263
   Balzarini J, 2001, BIOCHEM PHARMACOL, V61, P727, DOI 10.1016/S0006-2952(01)00529-9
   BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P2847, DOI 10.1016/0006-2952(88)90049-4
   Balzarini J, 2009, MOL PHARMACOL, V75, P1127, DOI 10.1124/mol.108.053785
   Bartesaghi S, 2010, HUM MOL GENET, V19, P1669, DOI 10.1093/hmg/ddq043
   BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316
   Chen ZH, 2008, ANTICANCER RES, V28, P3897
   Ciliberti N, 2007, BIOORGAN MED CHEM, V15, P3065, DOI 10.1016/j.bmc.2007.01.049
   Deville-Bonne D, 2010, ANTIVIR RES, V86, P101, DOI 10.1016/j.antiviral.2010.02.001
   Egeblad-Welin L, 2007, FEBS J, V274, P1542, DOI 10.1111/j.1742-4658.2007.05701.x
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9
   Frangini M, 2009, FEBS J, V276, P1104, DOI 10.1111/j.1742-4658.2008.06853.x
   Franzolin E, 2006, BIOCHEM BIOPH RES CO, V344, P30, DOI 10.1016/j.bbrc.2006.03.147
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Håkansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200
   HALLEK M, 1992, ANN HEMATOL, V65, P1, DOI 10.1007/BF01715117
   Hernández AI, 2003, BIOORG MED CHEM LETT, V13, P3027, DOI 10.1016/S0960-894X(03)00639-5
   Hernández AI, 2002, J MED CHEM, V45, P4254, DOI 10.1021/jm011128+
   Hernández AI, 2006, J MED CHEM, V49, P7766, DOI 10.1021/jm0610550
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Holm L, 2010, NUCLEIC ACIDS RES, V38, PW545, DOI 10.1093/nar/gkq366
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Kierdaszuk B, 1999, NUCLEOS NUCLEOT, V18, P1883, DOI 10.1080/07328319908044850
   Kim EY, 2001, AIDS RES HUM RETROV, V17, P401, DOI 10.1089/088922201750102445
   Lu JX, 2009, CELL RES, V19, P802, DOI 10.1038/cr.2009.69
   Lynx MD, 2006, BIOCHEM PHARMACOL, V72, P239, DOI 10.1016/j.bcp.2006.04.004
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Manfredini S, 2001, BIOORG MED CHEM LETT, V11, P1329, DOI 10.1016/S0960-894X(01)00207-4
   McGuffin LJ, 2006, BMC BIOINFORMATICS, V7, P0, DOI 10.1186/1471-2105-7-288
   Munch-Petersen B, 2010, NUCLEOS NUCLEOT NUCL, V29, P363, DOI 10.1080/15257771003729591
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Payne BAI, 2011, NAT GENET, V43, P806, DOI 10.1038/ng.863
   Pérez-Pérez MJ, 2008, MED RES REV, V28, P797, DOI 10.1002/med.20124
   Pérez-Pérez MJ, 2005, CURR TOP MED CHEM, V5, P1205, DOI 10.2174/156802605774463097
   Pontarin G, 2011, J BIOL CHEM, V286, P11132, DOI 10.1074/jbc.M110.202283
   Priego EM, 2004, BIOORGAN MED CHEM, V12, P5079, DOI 10.1016/j.bmc.2004.07.036
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   Rampazzo C, 2007, J BIOL CHEM, V282, P34758, DOI 10.1074/jbc.M705923200
   ROMAIN S, 1995, INT J CANCER, V61, P7, DOI 10.1002/ijc.2910610103
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Susan-Resiga D, 2007, ANTIMICROB AGENTS CH, V51, P1142, DOI 10.1128/AAC.01227-06
   Van Daele I, 2007, J MED CHEM, V50, P5281, DOI 10.1021/jm0706158
   Van Poecke S, 2011, ORG BIOMOL CHEM, V9, P892, DOI 10.1039/c0ob00591f
   Van Poecke S, 2010, J MED CHEM, V53, P2902, DOI 10.1021/jm901532h
   Van Rompay AR, 2003, PHARMACOL THERAPEUT, V100, P119, DOI 10.1016/j.pharmthera.2003.07.001
   Wang L, 2010, NUCLEOS NUCLEOT NUCL, V29, P370, DOI 10.1080/15257771003729732
   Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6
   Welin M, 2004, P NATL ACAD SCI USA, V101, P17970, DOI 10.1073/pnas.0406332102
   Wettin K, 1999, FEBS LETT, V460, P103, DOI 10.1016/S0014-5793(99)01325-3
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
   Zhou XS, 2010, J INHERIT METAB DIS, V33, P231, DOI 10.1007/s10545-010-9102-x
NR 57
TC 15
Z9 21
U1 1
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JUL 15
PY 2012
VL 18
IS 20
BP 2981
EP 2994
DI 10.2174/138161212800672787
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 975YK
UT WOS:000306547500014
PM 22571666
DA 2024-11-01
ER

PT J
AU Kazakos, K
   Kotsa, K
   Yavropoulou, M
   Dionyssopoulos, A
   Grabs, R
   Yovos, J
   Polychronakos, C
AF Kazakos, Kyriakos
   Kotsa, Kalliopi
   Yavropoulou, Maria
   Dionyssopoulos, Alexander
   Grabs, Rosemary
   Yovos, John
   Polychronakos, Constantin
TI Familial Clustering Strongly Suggests that the Phenotypic Variation of the 8344 A&gt;G Lys Mitochondrial tRNA Mutation is Encoded in cis
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE Diabetes; lipomatosis; lysine tRNA; mitochondrial; myopathy; MERRF
ID multiple symmetric lipomatosis; dna mutation; replication; merrf; mtdna
AB The maternally inherited 8344 A>G mutation in the mitochondrial Lys tRNA is classically associated with the myoclonic epilepsy, ragged-red muscle fiber (MERRF) syndrome. Multiple lipomatosis (Madelung's disease) is occasionally described. Here we report a large kindred with a statistically significant clustering of very unusual clinical manifestations. We have studied a Greek family that includes seven symptomatic cases of 8344 A>G. Clinical features, glucose tolerance and heteroplasmy in fat, muscle and blood were analyzed. The patients, aged 3476 at the time of assessment, all suffer from progressive proximal limb-girdle myopathy and extensive lipomatosis. Four of the seven have either impaired glucose tolerance or diabetes but none has had epilepsy, a cardinal feature of MERRF. Heteroplasmy was not higher in adipose tissue than that found in the literature. Compared to literature reports, the familial clustering of this unusual combination of manifestations (lipomatosis in all, epilepsy in none) is statistically significant. The clustering of unusual manifestations in this large kindred strongly suggests that much of the phenotypic variability of 8344 A>G is determined by mitochondrially encoded modifiers in cis.
C1 [Grabs, Rosemary; Polychronakos, Constantin] McGill Univ, Ctr Hlth, Endocrine Genet Lab, Dept Pediat, Montreal, PQ H3H 1P3, Canada.
   [Kazakos, Kyriakos; Kotsa, Kalliopi; Yavropoulou, Maria; Yovos, John] Aristotle Univ Thessaloniki, Dept Med 1, Ctr Diabet, AHEPA Hosp, GR-54006 Thessaloniki, Greece.
   [Dionyssopoulos, Alexander] Aristotle Univ Thessaloniki, Fac Med, Papageorgiou Hosp, Dept Plast Surg, GR-54006 Thessaloniki, Greece.
C3 McGill University; Aristotle University of Thessaloniki; Ahepa University Hospital; Papageorgiou Hospital; Aristotle University of Thessaloniki
RP Polychronakos, C (corresponding author), McGill Univ, Ctr Hlth, Endocrine Genet Lab, Dept Pediat, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.
EM constantin.polychronakos@mcgill.ca
FU McGill Department of Paediatrics
CR Andreu AL, 2003, J NEUROL, V250, P1403, DOI 10.1007/s00415-003-0281-3
   Auré K, 2003, REV NEUROL-FRANCE, V159, P1163
   Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Campos Y, 1996, NEUROLOGY, V47, P1012, DOI 10.1212/WNL.47.4.1012
   Gámez J, 1998, NEUROLOGY, V51, P258, DOI 10.1212/WNL.51.1.258
   KLOPSTOCK T, 1994, NEUROLOGY, V44, P862, DOI 10.1212/WNL.44.5.862
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WILSON MR, 1995, INT J LEGAL MED, V108, P68, DOI 10.1007/BF01369907
   ZEVIANI M, 1991, AM J HUM GENET, V48, P203
NR 13
TC 8
Z9 8
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
EI 
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD JUL 15
PY 2012
VL 76
IS 
BP 296
EP 300
DI 10.1111/j.1469-1809.2012.00711.x
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 956EH
UT WOS:000305072200004
PM 22681518
DA 2024-11-01
ER

PT J
AU Bindoff, LA
   Engelsen, BA
AF Bindoff, Laurence A.
   Engelsen, Bernt A.
TI Mitochondrial diseases and epilepsy
SO EPILEPSIA
LA English
DT Article
DE Mitochondrial respiratory chain; Mitochondrial myopathy encephalopathy; Lactic acidosis and stroke; Myoclonus epilepsy and ragged-red fibers; Polymerase gamma
ID dna-polymerase-gamma; stroke-like episodes; myoclonus epilepsy; status epilepticus; lactic-acidosis; energy failure; mutations; melas; encephalopathy; disorders
AB The mitochondrial respiratory chain is the final common pathway for energy production. Defects affecting this pathway can give rise to disease that presents at any age and affects any tissue. However, irrespective of genetic defect, epilepsy is common and there is a significant risk of status epilepticus. This review summarizes our current understanding of the epilepsy that occurs in mitochondrial disease, focusing on three of the most common disorders: mitochondrial myopathy encephalopathy, lactic acidosis and stroke-like episodes (MELAS), myoclonus epilepsy and ragged-red fibers (MERRF), and polymerase gamma (POLG) related disease. In addition, we review the pathogenesis and possible treatment of these disorders.
C1 [Bindoff, Laurence A.] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
   Univ Bergen, Dept Clin Med, Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of Bergen
RP Bindoff, LA (corresponding author), Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
EM laurence.bindoff@nevro.uib.no
CR Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Canafoglia L, 2001, NEUROLOGY, V56, P1340, DOI 10.1212/WNL.56.10.1340
   Copeland WC, 2012, CRIT REV BIOCHEM MOL, V47, P64, DOI 10.3109/10409238.2011.632763
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   El Sabbagh S, 2010, EPILEPSIA, V51, P1225, DOI 10.1111/j.1528-1167.2009.02504.x
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Farrar MA, 2010, PEDIATRICS, V126, PE734, DOI 10.1542/peds.2009-2930
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   Gibbs JE, 2006, EPILEPSIA, V47, P469, DOI 10.1111/j.1528-1167.2006.00454.x
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1997, EPILEPSY COMPREHENSI, V0, P2563
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Iizuka T, 2003, NEUROLOGY, V61, P1238, DOI 10.1212/01.WNL.0000091888.26232.FE
   Kann O, 2007, AM J PHYSIOL-CELL PH, V292, PC641, DOI 10.1152/ajpcell.00222.2006
   Kann O, 2011, BRAIN, V134, P345, DOI 10.1093/brain/awq333
   Khurana D, 2008, EPILEPSIA, V49, P1972, DOI 10.1111/j.1528-1167.2008.01783.x
   Kilbride SM, 2008, J NEUROCHEM, V106, P826, DOI 10.1111/j.1471-4159.2008.05441.x
   Kim DY, 2008, CURR OPIN CLIN NUTR, V11, P113, DOI 10.1097/MCO.0b013e3282f44c06
   Kunz WS, 2002, CURR OPIN NEUROL, V15, P179, DOI 10.1097/00019052-200204000-00009
   Lee HF, 2011, PEDIATR NEUROL, V45, P169, DOI 10.1016/j.pediatrneurol.2011.04.008
   Lee WT, 2000, NEUROSCIENCE, V95, P89
   Leff AP, 1998, EPILEPSIA, V39, P438, DOI 10.1111/j.1528-1157.1998.tb01397.x
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444
   Molinari F, 2009, CLIN GENET, V76, P188, DOI 10.1111/j.1399-0004.2009.01236.x
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rahman S, 2012, DEV MED CHILD NEUROL, V54, P397, DOI 10.1111/j.1469-8749.2011.04214.x
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Serra G, 1996, BRAIN DEV-JPN, V18, P185, DOI 10.1016/0387-7604(95)00147-6
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Trevelyan AJ, 2010, BRAIN, V133, P787, DOI 10.1093/brain/awq023
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Tzoulis C, 2010, BRAIN, V133, P1428, DOI 10.1093/brain/awq067
   Tzoulis C, 2009, STROKE, V40, PE15, DOI 10.1161/STROKEAHA.108.523118
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 44
TC 82
Z9 89
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD SEP 15
PY 2012
VL 53
IS 
BP 92
EP 97
DI 10.1111/j.1528-1167.2012.03618.x
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 000RG
UT WOS:000308404700012
PM 22946726
DA 2024-11-01
ER

